

=&gt; d his

(FILE 'HOME' ENTERED AT 14:08:54 ON 26 MAR 2002)

(FILE 'MEDLINE, CABA, CAPLUS, BIOTECHNO, CONFSCI, EMBASE, BIOTECHDS, WPIDS' ENTERED AT 14:09:39 ON 26 MAR 2002)

L1 2370 S MITCHELL W?/AU  
 L2 592 S STRATTON C?/AU  
 L3 32 S L1 AND L2  
 L4 40243 S ?CHLAMYDI?  
 L5 53 S L4 AND (L1 OR L2)  
 L6 55 S L3 OR L5  
 L7 30 DUP REM L6 (25 DUPLICATES REMOVED)

(=&gt; d ibib-ab-17 1-30) fil hom

L7 ANSWER 1 OF 30 MEDLINE DUPLICATE 1  
 ACCESSION NUMBER: 2001371246 MEDLINE  
 DOCUMENT NUMBER: 21241020 PubMed ID: 11342681  
 TITLE: CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens.  
 COMMENT: Comment in: Neurology. 2001 May 8;56(9):1126-7  
 Comment in: Neurology. 2001 May 8;56(9):1128-9  
 Comment in: Neurology. 2001 May 8;56(9):1130  
 AUTHOR: Yao S Y; Stratton C W; Mitchell W M; Sriram S  
 CORPORATE SOURCE: Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN, USA.  
 SOURCE: NEUROLOGY, (2001 May 8) 56 (9) 1168-76.  
 Journal code: NZ0; 0401060. ISSN: 0028-3878.  
 PUB. COUNTRY: United States  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
 ENTRY MONTH: 200106  
 ENTRY DATE: Entered STN: 20010702  
 Last Updated on STN: 20010702  
 Entered Medline: 20010628

AB BACKGROUND: Considerable evidence suggests the role of an infectious agent in MS. The presence of Chlamydophila pneumoniae in CSF from patients with MS was shown earlier; to further examine this association the reactivity of the oligoclonal antibody response in the CSF of patients with MS to C pneumoniae antigens was determined and compared with other antigens. METHODS: Seventeen patients with MS and 14 control subjects with other neurologic disease were studied. Affinity-driven immunoblot studies and solid-phase adsorption of CSF oligoclonal bands by elementary body antigens of C pneumoniae, viral antigens (measles and herpes simplex virus-1), bacterial antigen (Escherichia coli and Staphylococcus aureus), and heat shock protein-60 were performed. RESULTS: Affinity-driven immunoblot studies demonstrated reactivity of oligoclonal bands in CSF samples from 16 patients with MS against elementary body antigens of C pneumoniae. None of the control subjects showed a prominent reactivity to elementary body antigens of C pneumoniae. In 14 of 17 patients with MS examined, oligoclonal bands were adsorbed either partially or completely from the CSF by elementary body antigens of C pneumoniae, but not by myelin basic protein, heat shock protein-60, or bacterial or viral antigens. In three patients with subacute sclerosing panencephalitis, adsorption of oligoclonal bands was seen with measles virus antigens but not with elementary body antigens of C pneumoniae. CONCLUSIONS: Oligoclonal bands in CSF of patients with MS include antibodies against Chlamydophila antigens.

L7 ANSWER 2 OF 30 MEDLINE DUPLICATE 2

ACCESSION NUMBER: 2001435272 MEDLINE  
DOCUMENT NUMBER: 21229846 PubMed ID: 11331036  
TITLE: Regulation by IFN-beta of inducible nitric oxide synthase and interleukin-12/p40 in murine macrophages cultured in the presence of **Chlamydia pneumoniae** antigens.  
AUTHOR: Yao S Y; Ljunggren-Rose A; Stratton C W; Mitchell W M; Sriram S  
CORPORATE SOURCE: Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.  
SOURCE: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, (2001 Mar) 21 (3) 137-46.  
PUB. COUNTRY: Journal code: CD4; 9507088. ISSN: 1079-9907. United States  
LANGUAGE: Journal; Article; (JOURNAL ARTICLE) English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200108  
ENTRY DATE: Entered STN: 20010806  
Last Updated on STN: 20010806  
Entered Medline: 20010802

AB **Chlamydia pneumoniae** has been demonstrated in the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS). Interferon-beta (IFN-beta) has favorable effects on the clinical course of MS. We investigated whether the beneficial effects of IFN-beta in MS may involve its role in regulating nitric oxide (NO) and interleukin-12 (IL-12) in macrophages, as these immune modulators form part of the innate immune response to intracellular pathogens, such as *C. pneumoniae*. Murine macrophages in cultures exposed to elementary body antigens or recombinant major outer membrane protein (rMOMP) of *C. pneumoniae* demonstrate a significant increase in NO as well as production of IL-12/p40 in culture supernatants compared with basal levels. Addition of murine IFN-beta increased NO activity in murine macrophages cultured with **chlamydial** antigens. Addition of neutralizing anti-IFN-beta antibody prevented the NO increase. In contrast to its effect on inducible NO synthase (iNOS), IFN-beta reduced induction of IL-12/p40 following culture with either elementary body antigens or rMOMP. Inhibition was reversed with anti-IFN-beta antibody. If *C. pneumoniae* infection is responsible for the inflammatory response in the pathogenesis of MS, the beneficial effects of IFN-beta in MS may be due to its enhancing intracellular NO activity while inhibiting secretion of the proinflammatory cytokine, IL-12.

L7 ANSWER 3 OF 30 MEDLINE DUPLICATE 5  
ACCESSION NUMBER: 2000111212 MEDLINE  
DOCUMENT NUMBER: 20111212 PubMed ID: 10642692  
TITLE: Pyoderma gangrenosum and **Chlamydia pneumoniae** infection in a diabetic man: pathogenic role or coincidence?  
AUTHOR: Vannucci S A; Mitchell W M; Stratton C W ; King L E Jr  
CORPORATE SOURCE: Department of Medicine, Division of Dermatology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-5227, USA.  
SOURCE: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, (2000 Feb) 42 (2 Pt 1) 295-7.  
PUB. COUNTRY: Journal code: HVG; 7907132. ISSN: 0190-9622. United States  
LANGUAGE: Journal; Article; (JOURNAL ARTICLE) English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200002  
ENTRY DATE: Entered STN: 20000309  
Last Updated on STN: 20000309

Entered Medline: 20000224

AB **Chlamydia** Pneumoniae is not a known cause of skin infections, but unusual pathogens cause chronic infections in diabetic patients. Multiple idiopathic pyoderma gangrenosum-like (PG-like) lesions were refractory to multiple therapeutic agents in a diabetic patient who had C pneumoniae identified by serologic tests and polymerase chain reaction. Based on complete resolution by prolonged anti-**chlamydial** antibiotic therapy and concomitant decrease in serologic and titers determined by polymerase chain reactions, the PG-like lesions were presumed to be due to C pneumoniae.

L7 ANSWER 4 OF 30 MEDLINE DUPLICATE 6  
ACCESSION NUMBER: 1999206606 MEDLINE  
DOCUMENT NUMBER: 99206606 PubMed ID: 10192388  
TITLE: Comparative genomes of **Chlamydia** pneumoniae and C. trachomatis.  
AUTHOR: Kalman S; **Mitchell W**; Marathe R; Lammel C; Fan J; Hyman R W; Olinger L; Grimwood J; Davis R W; Stephens R S  
CORPORATE SOURCE: Stanford DNA Sequencing and Technology Center, Stanford University, California 94305, USA.  
SOURCE: NATURE GENETICS, (1999 Apr) 21 (4) 385-9.  
Journal code: BRO; 9216904. ISSN: 1061-4036.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
OTHER SOURCE: GENBANK-AE001273; GENBANK-AE001363  
ENTRY MONTH: 199904  
ENTRY DATE: Entered STN: 19990511  
Last Updated on STN: 19990511  
Entered Medline: 19990426

AB **Chlamydia** are obligate intracellular eubacteria that are phylogenetically separated from other bacterial divisions. C. trachomatis and C. pneumoniae are both pathogens of humans but differ in their tissue tropism and spectrum of diseases. C. pneumoniae is a newly recognized species of **Chlamydia** that is a natural pathogen of humans, and causes pneumonia and bronchitis. In the United States, approximately 10% of pneumonia cases and 5% of bronchitis cases are attributed to C. pneumoniae infection. Chronic disease may result following respiratory-acquired infection, such as reactive airway disease, adult-onset asthma and potentially lung cancer. In addition, C. pneumoniae infection has been associated with atherosclerosis. C. trachomatis infection causes trachoma, an ocular infection that leads to blindness, and sexually transmitted diseases such as pelvic inflammatory disease, chronic pelvic pain, ectopic pregnancy and epididymitis. Although relatively little is known about C. trachomatis biology, even less is known concerning C. pneumoniae. Comparison of the C. pneumoniae genome with the C. trachomatis genome will provide an understanding of the common biological processes required for infection and survival in mammalian cells. Genomic differences are implicated in the unique properties that differentiate the two species in disease spectrum. Analysis of the 1,230,230-nt C. pneumoniae genome revealed 214 protein-coding sequences not found in C. trachomatis, most without homologues to other known sequences. Prominent comparative findings include expansion of a novel family of 21 sequence-variant outer-membrane proteins, conservation of a type-III secretion virulence system, three serine/threonine protein kinases and a pair of paralogous phospholipase-D-like proteins, additional purine and biotin biosynthetic capability, a homologue for aromatic amino acid (tryptophan) hydroxylase and the loss of tryptophan biosynthesis genes.

L7 ANSWER 5 OF 30 MEDLINE DUPLICATE 7  
ACCESSION NUMBER: 1999328202 MEDLINE

DOCUMENT NUMBER: 99328202 PubMed ID: 10401775  
TITLE: **Chlamydia pneumoniae** infection of the central nervous system in multiple sclerosis.  
COMMENT: Comment in: Ann Neurol. 1999 Jul;46(1):4-5  
Comment in: Ann Neurol. 2000 Mar;47(3):408-9; discussion 409-11  
Comment in: Ann Neurol. 2000 Mar;47(3):408; discussion 409-11  
Comment in: Ann Neurol. 2000 Sep;48(3):399  
Comment in: Ann Neurol. 2000 Sep;48(3):399-400  
Comment in: Ann Neurol. 2000 Sep;48(3):400  
Comment in: Ann Neurol. 2001 Jan;49(1):135  
AUTHOR: Sriram S; **Stratton C W**; Yao S; Tharp A; Ding L; Bannan J D; **Mitchell W M**  
CORPORATE SOURCE: Department of Neurology, Vanderbilt School of Medicine, Nashville, TN, USA.  
SOURCE: ANNALS OF NEUROLOGY, (1999 Jul) 46 (1) 6-14.  
Journal code: 7707449. ISSN: 0364-5134.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199908  
ENTRY DATE: Entered STN: 19990816  
Last Updated-on-STN: 20020314  
Entered Medline: 19990802

AB Our identification of **Chlamydia pneumoniae** in the cerebrospinal fluid (CSF) of a patient with multiple sclerosis (MS) led us to examine the incidence of this organism in the CSF from 17 patients with relapsing-remitting MS, 20 patients with progressive MS, and 27 patients with other neurological diseases (OND). CSF samples were examined for C pneumoniae by culture, polymerase chain reaction assays, and CSF immunoglobulin (Ig) reactivity with C pneumoniae elementary body antigens. C pneumoniae was isolated from CSF in 64% of MS patients versus 11% of OND controls. Polymerase chain reaction assays demonstrated the presence of C pneumoniae MOMP gene in the CSF of 97% of MS patients versus 18% of OND controls. Finally, 86% of MS patients had increased CSF antibodies to C pneumoniae elementary body antigens as shown by enzyme-linked immunosorbent assay absorbance values that were 3 SD greater than those seen in OND controls. The specificity of this antibody response was confirmed by western blot assays of the CSF, using elementary body antigens. Moreover, CSF isoelectric focusing followed by western blot assays revealed cationic antibodies against C pneumoniae. Infection of the central nervous system with C pneumoniae is a frequent occurrence in MS patients. Although the organism could represent the pathogenetic agent of MS, it may simply represent a secondary infection of damaged central nervous system tissue. A therapeutic trial directed at eliminating C pneumoniae from the central nervous system may provide additional information on its role in MS.

L7 ANSWER 6 OF 30 MEDLINE DUPLICATE 10  
ACCESSION NUMBER: 1999000809 MEDLINE  
DOCUMENT NUMBER: 99000809 PubMed ID: 9784136  
TITLE: Genome sequence of an obligate intracellular pathogen of humans: **Chlamydia trachomatis**.  
COMMENT: Comment in: Science. 1998 Oct 23;282(5389):638-9  
AUTHOR: Stephens R S; Kalman S; Lammel C; Fan J; Marathe R; Aravind L; **Mitchell W**; Olinger L; Tatusov R L; Zhao Q; Koonin E V; Davis R W  
CORPORATE SOURCE: Program in Infectious Diseases, University of California, Berkeley, CA 94720, USA.. ctgenome@socrates.berkeley.edu  
CONTRACT NUMBER: AI 39258 (NIAID)  
SOURCE: SCIENCE, (1998 Oct 23) 282 (5389) 754-9.



Journal code: UJ7; 0404511. ISSN: 0036-8075.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
OTHER SOURCE: GENBANK-AE001275; GENBANK-AE001276; GENBANK-AE001277;  
GENBANK-AE001278; GENBANK-AE001279; GENBANK-AE001280;  
GENBANK-AE001281; GENBANK-AE001282; GENBANK-AE001283;  
GENBANK-AE001284; GENBANK-AE001285; GENBANK-AE001286;  
GENBANK-AE001287; GENBANK-AE001288; GENBANK-AE001289;  
GENBANK-AE001290; GENBANK-AE001291; GENBANK-AE001292;  
GENBANK-AE001293; GENBANK-AE001294; GENBANK-AE001295;  
GENBANK-AE001296; GENBANK-AE001297; GENBANK-AE001298;  
GENBANK-AE001299; GENBANK-AE001300; GENBANK-AE001301;  
GENBANK-AE001302; GENBANK-AE001303; GENBANK-AE001304  
ENTRY MONTH: 199811  
ENTRY DATE: Entered STN: 19990106  
Last Updated on STN: 20000303  
Entered Medline: 19981109  
AB Analysis of the 1,042,519-base pair **Chlamydia** trachomatis genome revealed unexpected features related to the complex biology of **chlamydiae**. Although **chlamydiae** lack many biosynthetic capabilities, they retain functions for performing key steps and interconversions of metabolites obtained from their mammalian host cells. Numerous potential virulence-associated proteins also were characterized. Several eukaryotic chromatin-associated domain proteins were identified, suggesting a eukaryotic-like mechanism for **chlamydial** nucleoid condensation and decondensation. The phylogenetic mosaic of **chlamydial** genes, including a large number of genes with phylogenetic origins from eukaryotes, implies a complex evolution for adaptation to obligate intracellular parasitism.

L7 ANSWER 7 OF 30 MEDLINE DUPLICATE 11  
ACCESSION NUMBER: 1998145402 MEDLINE  
DOCUMENT NUMBER: 98145402 PubMed ID: 9484408  
TITLE: Multiple sclerosis associated with **Chlamydia** pneumoniae infection of the CNS.  
COMMENT: Comment in: Neurology. 2001 Aug 28;57(4):746  
AUTHOR: Sriram S; Mitchell W; Stratton C  
CORPORATE SOURCE: Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37212, USA.  
SOURCE: NEUROLOGY, (1998 Feb) 50 (2) 571-2.  
Journal code: 0401060. ISSN: 0028-3878.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
OTHER SOURCE: GENBANK-AF131889  
ENTRY MONTH: 199803  
ENTRY DATE: Entered STN: 19980326  
Last Updated on STN: 20020130  
Entered Medline: 19980316

L7 ANSWER 8 OF 30 MEDLINE DUPLICATE 13  
ACCESSION NUMBER: 92346653 MEDLINE  
DOCUMENT NUMBER: 92346653 PubMed ID: 1638577  
TITLE: Fluoroquinolone antibiotics: properties of the class and individual agents.  
AUTHOR: Stratton C  
CORPORATE SOURCE: Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee.  
SOURCE: CLINICAL THERAPEUTICS, (1992 May-Jun) 14 (3) 348-75; discussion 347. Ref: 121

PUB. COUNTRY: Journal code: CPE; 7706726. ISSN: 0149-2918.  
 United States  
 Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199209  
 ENTRY DATE: Entered STN: 19920911  
 Last Updated on STN: 19920911  
 Entered Medline: 19920901

AB The broad spectrum of activity and bactericidal nature of the fluoroquinolones, together with their excellent absorption, rapid distribution, and high tissue concentration, make them excellent therapeutic agents for the management of a number of complicated community-acquired and nosocomial infections of the urinary tract, bone and soft tissue, gastrointestinal tract, and prostate, as well as some respiratory tract infections and sexually transmitted diseases. Data are presented and reviewed concerning the in vitro activity, pharmacology, and clinical use of ciprofloxacin, norfloxacin, and ofloxacin, which have been available for some time, and lomefloxacin and temafloxacin, which are recently approved agents. The comparable qualities and differences in activity and clinical applications of these agents are considered. For many infections in selected patients, quinolones are excellent substitutes for parenteral agents. In general, adverse effects have been infrequent and rarely require drug discontinuation. Significant interactions, such as with theophylline and caffeine, have occurred but are quinolone dependent. Antacids can markedly impair the absorption of all quinolones. Because emerging resistance to *Pseudomonas* and *Staphylococcus* species have been observed, the improper use of the quinolones must be avoided, and the clinician must be aware that an unfavorable response may signal resistance. The development of future agents with better gram-positive activity, improved gram-negative coverage, and activity against unusual pathogens such as *Chlamydia* species and *Mycobacterium* species, will make these oral agents invaluable. Assessing the usefulness and safety of these antibiotics in children is an ongoing challenge.

L7 ANSWER 9 OF 30 MEDLINE  
 ACCESSION NUMBER: 2001314629 MEDLINE  
 DOCUMENT NUMBER: 21244261 PubMed ID: 11346358  
 TITLE: Diabetic foot ulcers and *Chlamydia pneumoniae*:  
 innocent bystander or opportunistic pathogen?.  
 AUTHOR: King L E Jr; Bushman T; Stratton C W;  
 Mitchell W M  
 SOURCE: ARCHIVES OF DERMATOLOGY, (2001 May) 137 (5) 671-2.  
 Journal code: 6WU; 0372433. ISSN: 0003-987X.  
 PUB. COUNTRY: United States  
 Letter  
 LANGUAGE: English  
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
 ENTRY MONTH: 200106  
 ENTRY DATE: Entered STN: 20010611  
 Last Updated on STN: 20010611  
 Entered Medline: 20010607

L7 ANSWER 10 OF 30 MEDLINE  
 ACCESSION NUMBER: 2000092443 MEDLINE  
 DOCUMENT NUMBER: 20092443 PubMed ID: 10628821  
 TITLE: Does *Chlamydia pneumoniae* play a role in the  
 pathogenesis of multiple sclerosis?.  
 AUTHOR: Stratton C W; Mitchell W M; Sriram S  
 SOURCE: JOURNAL OF MEDICAL MICROBIOLOGY, (2000 Jan) 49 (1) 1-3.  
 Journal code: J2N; 0224131. ISSN: 0022-2615.

PUB. COUNTRY: ENGLAND: United Kingdom  
 Editorial  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200001  
 ENTRY DATE: Entered STN: 20000124  
 Last Updated on STN: 20000124  
 Entered Medline: 20000113

L7 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3  
 ACCESSION NUMBER: 2000:688466 CAPLUS  
 DOCUMENT NUMBER: 133:249334  
 TITLE: Methods and reagents for the diagnosis and treatment  
 of multiple sclerosis caused by **Chlamydia**  
 INVENTOR(S): **Stratton, Charles W.; Mitchell, William**  
**M.; Yao, Song-yi; Bannan, Jason D.;**  
**Ljunggren-Rose, Asa; Sriram, Subramaniam**  
 PATENT ASSIGNEE(S): Vanderbilt University, USA  
 SOURCE: PCT Int. Appl., 102 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000057187	A2	20000928	WO 2000-US7226	20000317
WO 2000057187	A3	20010419		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1166117	A2	20020102	EP 2000-916513	20000317
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRIORITY APPLN. INFO.:			US 1999-125598P	P 19990319
			US 2000-176662P	P 20000118
			US 2000-176784P	P 20000118
			US 2000-176940P	P 20000118
			WO 2000-US7226	W 20000317

AB The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that **Chlamydia** is present in patients with multiple sclerosis, and that anti-**chlamydial** agents improve or sustain neurol. function in these patients.

L7 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 4  
 ACCESSION NUMBER: 2000:335519 CAPLUS  
 DOCUMENT NUMBER: 133:1493  
 TITLE: **Chlamydia pneumoniae** genome sequence  
 INVENTOR(S): **Stephens, Richard; Mitchell, Wayne; Kalman, Sue; Davis, Ronald**  
 PATENT ASSIGNEE(S): The Regents of the University of California, USA  
 SOURCE: PCT Int. Appl., 330 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027994	A2	20000518	WO 1999-US26923	19991112
WO 2000027994	A3	20001123		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000017223	A5	20000529	AU 2000-17223	19991112
EP 1133572	A2	20010919	EP 1999-960323	19991112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.:

US 1998-108279P P 19981112  
US 1999-128606P P 19990408  
WO 1999-US26923 W 19991112

AB The *Chlamydia pneumoniae* genome sequence and anal. of the encoded polypeptides and RNAs are provided. The *C. pneumoniae* genome contains 187,711 addnl. nucleotides compared to the *C. trachomatis* genome, and the 214 coding sequences not found in *C. trachomatis* account for most of the increased genome size. The majority of these addnl. genes lack identifiable homologs to genes from other organisms, and probably are essential for specific attributes that define the differential biol., tropism, and pathogenesis of *C. trachomatis* and *C. pneumoniae*. The *C. pneumoniae* gene nucleic acid compns. find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compns. that modulate the expression or function of the protein; and in studying assocd. physiol. pathways. In addn., modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

L7 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 8  
ACCESSION NUMBER: 1998:752291 CAPLUS  
DOCUMENT NUMBER: 130:10609  
TITLE: Diagnosis and management of infection caused by *Chlamydia*  
INVENTOR(S): Mitchell, William M.; Stratton, Charles W.  
PATENT ASSIGNEE(S): Vanderbilt University, USA  
SOURCE: PCT Int. Appl., 139 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850074	A2	19981112	WO 1998-US9237	19980506
WO 9850074	A3	19990819		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
CM, GA, GN, ML, MR, NE, SN, TD, TG

US 2001002421 A1 20010531 US 1998-25176 19980218  
US 6258532 B1 20010710  
AU 9872899 A1 19981127 AU 1998-72899 19980506  
EP 981372 A2 20000301 EP 1998-920292 19980506

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

ZA 9803798 A 20000307 ZA 1998-3798 19980506  
PRIORITY APPLN. INFO.: US 1997-45689P P 19970506  
US 1997-45739P P 19970506  
US 1997-45779P P 19970506  
US 1997-45780P P 19970506  
US 1997-45784P P 19970506  
US 1997-45787P P 19970506  
US 1997-911593 A 19970814  
US 1998-25176 A2 19980218  
US 1998-25521 A2 19980218  
US 1998-25174 A 19980218  
WO 1998-US9237 W 19980506

AB A combination of agents directed toward various stages of the **chlamydial** life cycle is effective in substantially reducing infection. These include agents targeted against the cryptic phase (e.g. nitroarom. compds.), elementary body phase (e.g. disulfide reducing agents), and replicating phase, probenecid, and antiporphyrin agents. **Chlamydia**-free cell lines and animals can be obtained, and **Chlamydia** infections can be treated, by use of .gtoreq.2 such agents. **Chlamydia** infections may be diagnosed or monitored by immunoassays (e.g. ELISA or antigen capture assay) for the cysteine-rich major outer membrane protein or for specific antigenic peptides, DNA amplification assays (e.g. PCR) for **chlamydial** genes, and Western blot assays. Thus, a multiple sclerosis patient showing progressive limb impairment was diagnosed with *C. pneumoniae* infection by cerebrospinal fluid PCR and culture; treatment with rifampin (300 mg twice a day for 2 mo against the elementary body/reticulate body transition), flagyl (500 mg twice a day for 5 mo against the stationary phase reticulate body), and ofloxacin (for 2 mo) and Bactrim (double strength twice a day) and levaquin (500 mg/day) for 5 mo against the replicating reticulate body resulted in marked improvement in all aspects of neurol. function and an ability to return to work and routine athletic activities.

L7 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 9  
ACCESSION NUMBER: 1998:124043 CAPLUS  
DOCUMENT NUMBER: 128:201045  
TITLE: Compositions of **antichlamydial** agents for  
the diagnosis and management of infection caused by  
**chlamydia**  
INVENTOR(S): Mitchell, William M.; Stratton, Charles  
W.  
PATENT ASSIGNEE(S): Vanderbilt University, USA; Mitchell, William M.;  
Stratton, Charles W.  
SOURCE: PCT Int. Appl., 83 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9806435	A2	19980219	WO 1997-US14402	19970814
WO 9806435	A3	19980409		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,  
 UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,  
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,  
 GN, ML, MR, NE, SN, TD, TG

AU 9741516 A1 19980306 AU 1997-41516 19970814  
 PRIORITY APPLN. INFO.: US 1996-23921P P 19960814  
 WO 1997-US14402 W 19970814

AB The invention provides a unique approach for the diagnosis and management of infections by **Chlamydia** species, particularly *C. pneumoniae*. The invention is based, in part, on the discovery that a combination of agents directed toward the various stages of the **chlamydial** life cycle is effective in substantially reducing infection. Products comprising combination of **antichlamydial** agents, compns., and pharmaceutical packs are also described.

L7 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:65982 CAPLUS  
 DOCUMENT NUMBER: 136:133602  
 TITLE: Identification of antigenic peptide sequences  
 INVENTOR(S): Mitchell, William M.; Stratton, Charles W.  
 PATENT ASSIGNEE(S): Vanderbilt University, USA  
 SOURCE: U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 911,593, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6340463	B1	20020122	US 1998-25596	19980218
PRIORITY APPLN. INFO.:			US 1996-23921P	P 19960814
			US 1997-911593	B2 19970814

AB Identification of linear amino acid antigenic sequences for the prodn. of both polyclonal and monoclonal antibodies to defined antigenic domains is described. Also described are antigenic peptides identified by the described methods and antibodies thereto.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:397834 CAPLUS  
 DOCUMENT NUMBER: 135:2559  
 TITLE: Methods for in vitro susceptibility testing of **Chlamydia**  
 INVENTOR(S): Stratton, Charles W.; Mitchell, William M.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 911,593, abandoned.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

US 2001002421 A1 20010531 US 1998-25176 19980218  
US 6258532 B1 20010710  
US 2002009802 A1 20020124 US 1998-25174 19980218  
WO 9850074 A2 19981112 WO 1998-US9237 19980506  
WO 9850074 A3 19990819

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK,  
EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP,  
KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,  
US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9872899 A1 19981127 AU 1998-72899 19980506  
EP 981372 A2 20000301 EP 1998-920292 19980506

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

## PRIORITY APPLN. INFO.:

US 1997-911593 B2 19970814  
US 1997-45689P P 19970506  
US 1997-45739P P 19970506  
US 1997-45779P P 19970506  
US 1997-45780P P 19970506  
US 1997-45784P P 19970506  
US 1997-45787P P 19970506  
US 1998-25174 A 19980218  
US 1998-25176 A2 19980218  
US 1998-25521 A2 19980218  
WO 1998-US9237 W 19980506

AB Methods for detg. the susceptibility of intracellular pathogens, particularly **Chlamydia**, to single or combination of test agents are described. The methods can be used for in vitro or in vivo evaluation of agents that can be used as therapeutic agents in the treatment/eradication of pathogen infection in general or to target a specific infected organ. Assays which utilize nucleic amplification techniques (e.g., PCR) to det. effectiveness of the agent(s) evaluated are also described.

L7 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:607994 CAPLUS

DOCUMENT NUMBER: 136:84535

TITLE: Association of multiple sclerosis with  
**Chlamydia pneumoniae**: Demonstration of the 16S  
rRNA gene and immunoreactivity of CSF cationic  
antibodies against C. pneumoniae antigens

AUTHOR(S): Sriram, S.; Stratton, C. W.; Yao, S.;  
Bannan, J. D.; Mitchell, W. M.

CORPORATE SOURCE: Department of Neurology, Vanderbilt School of  
Medicine, Nashville, TN, USA

SOURCE: Genes and Viruses in Multiple Sclerosis (2001),  
221-229. Editor(s): Hommes, Otto R.; Clanet, Michel;  
Wekerle, Hartmut. Elsevier Science B.V.: Amsterdam,  
Neth.

CODEN: 69BRQ7

DOCUMENT TYPE: Conference

LANGUAGE: English

AB The immunoreactivity of the cationic antibodies in the CSF of multiple sclerosis (MS) patients was evaluated using affinity-driven immunoblot assays. Among the 17 CSF samples from MS patients, 88% contained DNA specific for the 16S rRNA gene of **Chlamydia pneumoniae**. MS patients had an increased Igs in the CSF, and part of the increase was represented as oligoclonal bands on isoelec. focusing gels. The development of an intrathecal immune response to C. pneumoniae was found to be a common occurrence in patients with MS. The cationic anti-EB

antibodies were present in patients with MS and might represent in part the specificity of the oligoclonal bands. The results of IEF/affinity-driven assays showed that a CNS immune response specifically to *C. pneumoniae* EB antigens was present in patients with MS.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 30 CONFSCI COPYRIGHT 2002 CSA

ACCESSION NUMBER: 85:2268 CONFSCI  
DOCUMENT NUMBER: 85002357  
TITLE: Clinical evaluation of the MicroTrak direct specimen test for the detection of *Chlamydia trachomatis* in genital specimens  
AUTHOR: Peters, T.H.; Lefkowitz, L.B.; Ratner, H.B.; Davidson, T.L.; Stratton, C.W.  
CORPORATE SOURCE: Vanderbilt Univ. Med. Cent. and Metropolitan Health Dep., Nashville-Davidson County, Nashville, TN, USA  
SOURCE: 1985, Abstracts available: American Society for Microbiology, Publication Department, 1913 I St. NW, Washington, DC 20006, USA, Paper No. C 382. Meeting Info.: 851 5000: American Society for Microbiology, 85th Annual Meeting (8515000). Las Vegas, NV (USA). 3-7 Mar 85. American Society for Microbiology.  
DOCUMENT TYPE: Conference  
FILE SEGMENT: DCCP  
LANGUAGE: UNAVAILABLE

L7 ANSWER 19 OF 30 CONFSCI COPYRIGHT 2002 CSA

ACCESSION NUMBER: 86:15890 CONFSCI  
DOCUMENT NUMBER: 86043671  
TITLE: *Chlamydia* screening of male patients with gonorrhea  
AUTHOR: Lefkowitz, L.B.; Peters, T.H.; Ratner, H.B.; Davidson, T.L.; Stratton, C.W.  
CORPORATE SOURCE: Vanderbilt Univ., Nashville, TN, USA  
SOURCE: American Society for Microbiology, 1913 I Street, N.W., Washington, DC 20006 (USA), Poster Paper No. C30. Meeting Info.: 861 0146: American Society for Microbiology 86th Annual Meeting (8610146). Washington, DC (USA). 23-28 Mar 1986. American Society for Microbiology (ASM).  
DOCUMENT TYPE: Conference  
FILE SEGMENT: DCCP  
LANGUAGE: UNAVAILABLE

L7 ANSWER 20 OF 30 CONFSCI COPYRIGHT 2002 CSA

ACCESSION NUMBER: 84:751 CONFSCI  
DOCUMENT NUMBER: 84006418  
TITLE: Comparison of immunoperoxidase staining with iodine staining for the detection of *Chlamydia trachomatis* inclusion bodies in McCoy cells  
AUTHOR: Stratton, C.W.; Judson, F.N.; Simpson, E.B.; Jones, M.R.; Kasselberg, A.G.  
CORPORATE SOURCE: Vanderbilt Univ. Hosp., Nashville, TN  
SOURCE: Abstracts available: American Society for Microbiology, Publications Department, 1913 I St. NW, Washington, DC 20006, USA, Paper No. C105. Meeting Info.: 841 0195: American Society for Microbiology 84th Annual Meeting (8410195). St. Louis, MO (USA). 4-9 Mar 84. American Society for Microbiology (ASM).  
DOCUMENT TYPE: Conference  
FILE SEGMENT: DCCP  
LANGUAGE: UNAVAILABLE



L7 ANSWER 21 OF 30 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2002091023 EMBASE

TITLE: Pharmacokinetic, pharmacodynamic and tolerability profiles of telithromycin, the first ketolide antimicrobial agent.

AUTHOR: Stratton C.W.

CORPORATE SOURCE: Dr. C.W. Stratton, Clinical Microbiology Laboratory, Vanderbilt Clinic, 21st and Edgehill, Nashville, TN 37232, United States. Charles.Stratton@mcmail.Vanderbilt.edu

SOURCE: Today's Therapeutic Trends, (2002) 20/1 (37-58).

Refs: 102

ISSN: 0741-2320 CODEN: TTTRDH

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis  
017 Public Health, Social Medicine and Epidemiology  
030 Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

AB The ketolides are the latest structural derivatives of erythromycin to be added to the macrolide family, with telithromycin being the first ketolide to undergo clinical evaluation. Telithromycin is a broad-spectrum and highly potent antimicrobial agent, which has a number of unique pharmacokinetic and pharmacodynamic properties that assure its clinical utility despite the increasing prevalence of macrolide resistance among the major respiratory tract pathogens. It appears that the most important factors in terms of structure-activity are the lack of the neutral sugar cladinose in position C3 as well as a C11/C12 carbamate group, which together markedly increase the affinity of telithromycin for its microbial target, the 23S ribosomal drug-binding pocket. This increased affinity is seen even in macrolide-resistant strains, and also results in concentration-dependent bactericidal activity and a prolonged post-antimicrobial effect against important respiratory tract pathogens. The microbiological spectrum of activity for telithromycin includes *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Legionella* species, *Mycoplasma pneumoniae*, and *Chlamydia pneumoniae*, suggesting that telithromycin will play an important clinical role in the empirical treatment of community-acquired respiratory tract infections. The pharmacokinetic profile of telithromycin demonstrates that this drug can be administered once daily without regard for meals, and requires no dosage reduction in elderly patients or those with hepatic impairment. Telithromycin is well absorbed after oral administration, with rapid penetration into respiratory tissues and fluids, and as well is highly concentrated within white blood cells. Integration of pharmacokinetic and pharmacodynamic properties reveals that telithromycin has a high AUC/MIC ratio compared with macrolide antimicrobial agents, resulting in enhanced efficacy. Finally, telithromycin is well tolerated and has a low propensity for drug interactions. In summary, telithromycin promises to be a potent agent for the treatment of community-acquired respiratory tract infections.

L7 ANSWER 22 OF 30 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2001185465 EMBASE

TITLE: Diabetic foot ulcers and *chlamydia pneumoniae*: Innocent bystander or opportunistic pathogen? [10].

AUTHOR: King L.E. Jr.; Bushman T.; Stratton C.W.; Mitchell W.M.

CORPORATE SOURCE: Dr. L.E. King Jr., Division of Dermatology, Vanderbilt Univ. Sch. of Med. 3983, Vanderbilt Clinic, Nashville, TN 37232-2556, United States. lloyd.king@amcm.vanderbilt.edu

SOURCE: Archives of Dermatology, (2001) 137/5 (671-672).

Refs: 6  
ISSN: 0003-987X CODEN: ARDEAC  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Letter  
FILE SEGMENT: 004 Microbiology  
006 Internal Medicine  
013 Dermatology and Venereology  
LANGUAGE: English

L7 ANSWER 23 OF 30 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 2001241578 EMBASE  
TITLE: Association of **Chlamydia pneumoniae** with chronic human diseases.  
AUTHOR: Stratton C.W.  
CORPORATE SOURCE: Dr. C.W. Stratton, Vanderbilt Univ. School of Medicine, Nashville, TN 37232, United States  
SOURCE: Antimicrobics and Infectious Diseases Newsletter, (2000) 18/7 (49-55).  
Refs: 141

ISSN: 1069-417X CODEN: AIDIEX  
COUNTRY: United States  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 004 Microbiology  
008 Neurology and Neurosurgery  
011 Otorhinolaryngology  
015 Chest Diseases, Thoracic Surgery and Tuberculosis  
017 Public Health, Social Medicine and Epidemiology  
LANGUAGE: English  
SUMMARY LANGUAGE: English

AB It is apparent from this review that *C. pneumoniae* has been implicated in many chronic diseases of humans. Whether the role is that of innocent bystander, cause, or perhaps something in between remains to be determined. Regardless of the role of *C. pneumoniae* in these or other chronic diseases, this microorganism is becoming a major health concern. Considerable resources will be needed to determine its role in human disease. If *C. pneumoniae* proves to play an important role in any or all of these chronic diseases, its eventual control or eradication may do much to improve the health of countless persons.

L7 ANSWER 24 OF 30 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 2000017568 EMBASE  
TITLE: Does **Chlamydia pneumoniae** play a role in the pathogenesis of multiple sclerosis?.  
AUTHOR: Stratton C.W.; Mitchell W.M.; Sriram S.  
CORPORATE SOURCE: C.W. Stratton, Department of Pathology, Vanderbilt School of Medicine, Nashville, TN 37232, United States.  
Charles.Stratton@mcmail.Vanderbilt.edu  
SOURCE: Journal of Medical Microbiology, (2000) 49/1 (1-3).  
Refs: 28  
ISSN: 0022-2615 CODEN: JMMIAV  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Editorial  
FILE SEGMENT: 004 Microbiology  
008 Neurology and Neurosurgery  
LANGUAGE: English

L7 ANSWER 25 OF 30 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 1999287545 EMBASE  
TITLE: The role of **Chlamydia** in connective tissues diseases.  
AUTHOR: Stratton C.W.  
CORPORATE SOURCE: Dr. C.W. Stratton, Vanderbilt University School of Med., Nashville, TN 37232, United States

SOURCE: Antimicrobics and Infectious Diseases Newsletter, (1998)  
17/2 (9-15).  
Refs: 129  
ISSN: 1069-417X CODEN: AIDIEX

COUNTRY: United States  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 004 Microbiology  
005 General Pathology and Pathological Anatomy  
006 Internal Medicine

LANGUAGE: English  
SUMMARY LANGUAGE: English

AB In summary, **Chlamydia** species have been shown to infect synovial tissues. The synovial infection produced can be persistent and can cause a cell-mediated inflammatory response directed at **chlamydial** HSPs. Antimicrobial therapies of arthritis syndromes to date have demonstrated some success despite not being optimized for persistent **chlamydial** infection. Clearly, additional work is both needed and warranted to firmly establish the role of **Chlamydia** species in connective tissue diseases. Included in this is the need to optimize antimicrobial therapy against persistent infections caused by **Chlamydia**.

L7 ANSWER 26 OF 30 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 97374392 EMBASE

DOCUMENT NUMBER: 1997374392

TITLE: The importance of **Chlamydia pneumoniae** as a pathogen: The 1996 consensus conference on **Chlamydia pneumoniae** infections.

AUTHOR: File T.M. Jr.; Bartlett J.G.; Cassell G.H.; Gaydos C.A.; Grayston J.T.; Hammerschlag M.R.; Jones R.B.; Kahn J.B.; Marie T.J.; Ramirez J.A.; Saikku P.; Schachter J.; Schumacher H.R.; Stamm W.E.; **Stratton C.W.**; Yu V.L.

CORPORATE SOURCE: T.M. File Jr., Infectious Disease Section, SUMMA Health System, 75 Arch Street, Akron, OH 44304-1430, United States

SOURCE: Infectious Diseases in Clinical Practice, (1997) 6/SUPPL. 2 (S28-S31).  
Refs: 26

ISSN: 1056-9103 CODEN: IDCPEY

COUNTRY: United States

DOCUMENT TYPE: Journal; (Short Survey)

FILE SEGMENT: 004 Microbiology  
015 Chest Diseases, Thoracic Surgery and Tuberculosis  
018 Cardiovascular Diseases and Cardiovascular Surgery

LANGUAGE: English

L7 ANSWER 27 OF 30 BIOTECHDS COPYRIGHT 2002 DERWENT INFO AND ISI

ACCESSION NUMBER: 1996-11724 BIOTECHDS

TITLE: Inducing mucosal immune response by administration of antigen-encoding DNA; genetic immunization against disease caused by HIV virus, herpes virus, orthomyxo virus, mumps virus, hepatitis virus, Salmonella, Shigella, **Chlamydia** or **Helicobacter** sp.

AUTHOR: **Mitchell W M**

PATENT ASSIGNEE: Univ.Vanderbilt

LOCATION: Nashville, TN, USA.

PATENT INFO: WO 9621356 18 Jul 1996

APPLICATION INFO: WO 1995-US8374 3 Jul 1995

PRIORITY INFO: US 1995-372429 13 Jan 1995

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 1996-341965 [34]

AB A new method for inducing a mucosal immune response in a subject involves

administering to the mucosa of the subject an amount of an antigen-encoding DNA effective to induce a mucosal immune response complexed to a transfection-facilitating lipospermine or lipospermidine. Preferably, administration is nasal, oral, rectal or vaginal and the lipospermine is dioctadecylamidoglycylspermine. The DNA encodes an envelope antigen or an envelope-associated antigen. Also new is a composition of the antigen-encoding DNA complexed to a transfection facilitating lipospermine or lipospermidine. The DNA induces both humoral and cellular responses and allows easy formulation of multiple sequence variants into a single genetic vaccine. The method provides the advantages of live, attenuated vaccines and lacks the threat of reversion to virulence. The antigen-encoding DNA may be cloned into a vector, e.g. plasmid pBR322-based plasmid pHenv. (82pp)

L7 ANSWER 28 OF 30 BIOTECHDS COPYRIGHT 2002 DERWENT INFO AND ISI

ACCESSION NUMBER: 2001-00586 BIOTECHDS

TITLE: Diagnosing and monitoring multiple sclerosis by assaying a test sample for **Chlamydia**, and treating multiple sclerosis by administering anti-**chlamydial** agents such as rifamycins, azalides, macrolides, ketolides; polymerase chain reaction for diagnosis and drug screening method

AUTHOR: Stratton C W; Mitchell W M; Yao S Y; Bannan J D; Ljunggren-Rose A; Sriram S

PATENT ASSIGNEE: Univ.Vanderbilt

LOCATION: Nashville, TN, USA.

PATENT INFO: WO 2000057187 28 Sep 2000

APPLICATION INFO: WO 2000-US7226 17 Mar 2000

PRIORITY INFO: US 2000-176784 18 Jan 2000; US 1999-125598 19 Mar 1999

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2000-602242 [57]

AB A new method (M1) for diagnosing or monitoring multiple sclerosis in an individual is claimed. It involves assaying a test sample (selected from blood, serum or cerebrospinal fluid) for the presence of **Chlamydia** selected from **Chlamydia pneumoniae** by contacting cultured **Chlamydia**-free indicator cells with the test sample. Also claimed are; a method (M2) for isolating elementary bodies from a receptacle by treating the receptacle with trypsin (EC-3.4.21.4)/EDTA(ethylene diamine tetraacetic acid); a method (M3) for releasing DNA from elementary bodies by incubating them under disulfide reducing conditions and digesting with a protease; a method (M4) for treating an individual with multiple sclerosis; a method (M5) for determining if a candidate compound is a potential drug for the treatment of **Chlamydial** infection-related disease by infecting a non-human animal with **Chlamydia**, administering a candidate compound to the animal, and assaying for the presence of a **chlamydial** infection. The methods are useful for diagnosing and treating multiple sclerosis and for identifying agents which may potentially be useful for treating the disease. (100pp)

L7 ANSWER 29 OF 30 BIOTECHDS COPYRIGHT 2002 DERWENT INFO AND ISI

ACCESSION NUMBER: 2000-10037 BIOTECHDS

TITLE: Isolated nucleic acid for use in diagnostic and analytical methods encodes genomic sequence of **Chlamydia pneumoniae**;

method is useful for prophylactic and therapeutic purpose

AUTHOR: Stephens R; Mitchell W; Kalman S; Davis R

PATENT ASSIGNEE: Univ.California

LOCATION: Oakland, CA, USA.

PATENT INFO: WO 2000027994 18 May 2000

APPLICATION INFO: WO 1999-US26923 12 Nov 1999

PRIORITY INFO: US 1999-128606 8 Apr 1999; US 1998-108279 12 Nov 1998

DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: WPI: 2000-376516 [32]

AB A new isolated nucleic acid (N1) encoding a **Chlamydia** pneumoniae protein (P1) is claimed. Also claimed are: a probe containing a hybridizing fragment of N1; an isolated nucleic acid (N2) that hybridizes under stringent conditions to N1; an expression cassette containing N1 under the transcriptional regulation of an initiation region functional in an expression host, and a transcriptional termination region; a cell containing an expression cassette as part of an extrachromosomal element in the genome of a host cell, and the cellular progeny of the host cell; a method for producing a P1 by growing a cell where the protein is expressed and isolating protein free of other proteins; a purified protein composition containing at least 50 wt.% of P1; and a monoclonal antibody binding to the peptide. The isolated nucleic acid is useful for diagnosing and analytical methods, such as hybridization-based assays or amplification-based assays. The protein may be used for diagnostic purposes, for its enzymatic or structural activity, or as a vaccine. (330pp)

L7 ANSWER 30 OF 30 BIOTECHDS COPYRIGHT 2002 DERWENT INFO AND ISI

ACCESSION NUMBER: 1998-05630 BIOTECHDS

TITLE: Treating **chlamydia** infections using a combination of agents directed against different phases; disease diagnosis by DNA amplification

AUTHOR: Mitchell W M; Stratton C W

PATENT ASSIGNEE: Univ.Vanderbilt

LOCATION: Nashville, TN, USA.

PATENT INFO: WO 9806435 19 Feb 1998

APPLICATION INFO: WO 1997-US14402 14 Aug 1997

PRIORITY INFO: US 1996-23921 14 Aug 1996

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 1998-159294 [14]

AB A new composition (A) comprises at least 2 antichlamydial agents (I) active against different phases in the **Chlamydia** sp. life cycle. Also new are: a method for identifying agents that inhibit **chlamydial** infection or are active against the cryptic forms of **Chlamydia** sp.; a method for identifying cells containing these cryptic forms; a method for activating macrophages and monocytes in which the ability to combat infection has been comprised by **chlamydial** infection; a method for detecting **chlamydial** elementary bodies in a sample, which involves treatment with a disulfide reducing agent prior to detecting **chlamydial** DNA by DNA amplification using the polymerase chain reaction; 12 specific peptides derived from various **Chlamydia** spp.; the therapeutic agents identified by the method; therapy of **Chlamydia** sp. infection; and determination of the status of a patient and monitoring treatment for **Chlamydia** sp. infection. (A) is used for therapy of **Chlamydia** pneumoniae disease and related diseases (autoimmune diseases, inflammation, and immunodeficiency conditions. **Chlamydia** spp. have been associated with multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, etc. (82pp)

FILE 'HOME' ENTERED AT 14:11:26 ON 26 MAR 2002

**THIS PAGE BLANK (USPTO)**

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:37:19 ; Search time 42.75 Seconds  
(without alignments)  
26.728 Million cell updates/sec

Title: US-09-709-201-97

Perfect score: 82  
Sequence: 1 CFGVKGTFTVNAELP 15

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 219241 seqs, 76174552 residues

Total number of hits satisfying chosen parameters: 219241

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR\_68:\*

- 1: pir1:\*
- 2: pir2:\*
- 3: pir3:\*
- 4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB ID	Description
1	73	89.0	389	A43587	major outer membra
2	73	89.0	389	D86577	major outer membra
3	69	84.1	389	I40739	major outer membra
4	61	74.4	389	I40864	N utilization subs
5	45	54.9	500	B81060	N utilization subs
6	45	54.9	505	H81816	cell division prot
7	44	53.7	744	H71643	major outer membra
8	42	51.2	389	MMCWP3	hypothetical prote
9	42	51.2	455	F96817	peptide transport
10	42	51.2	708	A56163	ribosomal protein
11	41	50.0	93	R5R223	ribosomal protein
12	41	50.0	93	R5ZM23	probable 9-cis-epo
13	41	50.0	93	R5WT23	nine-cis-epoxycaro
14	41	50.0	604	T51936	probable actin ygg
15	41	50.0	605	T07123	hypothetical 26.6k
16	40	48.8	246	D85948	conserved hypotet
17	40	48.8	246	A65077	DNA-binding protei
18	40	48.8	365	G64705	p-type cation tran
19	40	48.8	1235	Q0BEW4	2k12.7 protein -
20	40	48.8	1984	A44396	phosphoglycolate p
21	40	48.8	3343	S44887	histidine-contains
22	39	47.6	215	C84098	probable transcrip
23	39	47.6	216	G70044	hypothetical prote
24	39	47.6	295	E83302	tail protein pb5 -
25	39	47.6	335	E71520	hypothetical prote
26	39	47.6	640	ZYBPT5	galacturan 1,4-alp
27	39	47.6	773	T27382	cytochrome-c oxida
28	38.5	47.0	435	S74208	
29	38	46.3	168	T52480	

probable oxidoredu  
branched-chain ket  
vanH protein - Ent  
3-methyl-2-oxobuta  
hypothetical prote  
hypothetical prote  
transmembrane prot  
hypothetical prote  
phosphoglucosylase  
phosphoglucosylase  
Ca2+/calmodulin-de  
hypothetical prote  
outer layer protei  
hypothetical prote  
hypothetical prote  
probable helicase

ALIGNMENTS

RESULT 1

A43587  
major outer membrane protein, porin CP0051 precursor [imported] - Chlamydomophila pneum  
N: Alternate names: MOMP  
C: Species: Chlamydomophila pneumoniae, Chlamydia pneumoniae  
C: Date: 29-Jan-1993 #sequence revision 29-Jan-1993 #text\_change 11-May-2000  
C: Accession: A43587; A49751; A49216; G72044; F81619  
R: Perez-Melgosa, M.; Kuo, C.C.; Campbell, L.A.  
Infect. Immun. 59:2195-2199, 1991  
A: Title: Sequence analysis of the major outer membrane protein gene of Chlamydia pneu  
A: Reference number: A43587; MUID: 91244474  
A: Accession: A43587  
A: Molecule type: DNA  
A: Residues: 1-389 <PER>  
A: Cross-references: GB:M69230; NID: g144540; PIDN: AAA73071.i; PID: g144541  
R: Garter, M.W.; Al-Mahdawi, S.A.H.; Giles, I.G.; Trehan, J.D.; Ward, M.E.; Clarke,  
C.J. Gen. Microbiol. 137:465-475, 1991  
A: Title: Nucleotide sequence and taxonomic value of the major outer membrane protein  
A: Reference number: A49751; MUID: 91237311  
A: Accession: A49751  
A: Status: preliminary  
A: Molecule type: DNA  
A: Residues: 1-389 <CAR>  
A: Cross-references: GB:M64064; GB:M34942; NID: g144534; PIDN: AAA23143.1; PID: g144535  
A: Note: isolate IOL-207  
R: Garter, M.W.; Al-Mahdawi, S.A.H.; Giles, I.G.; Trehan, J.D.; Ward, M.E.; Clarke,  
C.J. Gen. Microbiol. 137:465-475, 1991  
A: Title: Similarity of Chlamydia pneumoniae strains in the variable domain IV region.  
A: Reference number: A49216; MUID: 93084388  
A: Accession: A49216  
A: Status: preliminary  
A: Molecule type: DNA  
A: Residues: 297-352 <GAY>  
A: Cross-references: GB:S50607; NID: g260372; PIDN: AAB24363.1; PID: g260373  
A: Note: sequence extracted from NCBI backbone (NCBI:120604, NCBIP:120605)  
R: Kalman, S.; Mitchell, W.; Marathe, R.; Lammel, C.; Fan, J.; Olinger, L.; Grimwood,  
N. Nature Genet. 21:385-389, 1999  
A: Title: Comparative genomes of Chlamydia pneumoniae and C. trachomatis.  
A: Reference number: A72000; MUID: 99206606  
A: Accession: G72044  
A: Molecule type: DNA  
A: Residues: 1-389 <ARN>  
A: Cross-references: GB:AE001652; GB:AE001363; NID: g4376997; PIDN: AAD18834.1; PID: g437  
A: Experimental source: strain CWL029  
R: Read, T.D.; Brunham, R.C.; Shen, C.; Gill, S.R.; Heidelberg, J.F.; White, O.; Hicke  
C.; Dodson, R.; Gwinn, M.; Nelson, W.; Deloy, R.; Kolonay, J.; McClarty, G.; Salzbe  
Nucleic Acids Res. 28, 1397-1406, 2000  
A: Title: Genome sequences of Chlamydia trachomatis MoPh and Chlamydia pneumoniae AR39  
A: Reference number: A81500; MUID: 20150255  
A: Accession: F81619  
A: Status: preliminary  
A: Molecule type: DNA

A:Residues: 1-389 <REA>

A:Cross-references: GB:AE002168; GB:AE002161; NID:g7188982; PIDN:AAF37944.1; PID:g718899

A:Experimental source: strain AR39, HL cells

C:Genetics:

A:Gene: ompA; CP0051

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-23/Domain: signal sequence #status predicted <SIG>

F:24-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 89.0%; Score 73; DB 2; Length 389;  
Best Local Similarity 100.0%; Pred. No. 3e-05;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FGKGTNNANELP 15

Db 158 FGKGTNNANELP 171

RESULT 2

major outer membrane protein [imported] - Chlamydia pneumoniae (strain J138)  
C:Species: Chlamydia pneumoniae, Chlamydia pneumoniae

C:Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 23-Mar-2001

C:Accession: D86577

R:Shirai, M.; Hirakawa, H.; Kimoto, M.; Tabuchi, M.; Kishi, F.; Ouchi, K.; Shiba, T.; Is

Nucleic Acids Res. 28, 2311-2314, 2000

A:Title: Comparison of whole genome sequences of chlamydia pneumoniae J138.

A:Reference number: A86491; MUID:20330349

A:Accession: D86577

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-389 <STO>

A:Cross-references: GB:BA000008; NID:g8979067; PIDN:BAA98902.1; GSPDB:GN00142

A:Experimental source: strain J138

C:Genetics:

A:Gene: ompA

C:Superfamily: Chlamydia major outer membrane protein

Query Match 89.0%; Score 73; DB 2; Length 389;

Best Local Similarity 100.0%; Pred. No. 3e-05;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FGKGTNNANELP 15

Db 158 FGKGTNNANELP 171

RESULT 3

major outer membrane protein precursor - Chlamydia pneumoniae (strain equine/N16)

C:Species: Chlamydia pneumoniae, Chlamydia pneumoniae

A:Variety: strain equine/N16

C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 20-Apr-2000

C:Accession: I40739

R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.

J. Gen. Microbiol. 139, 2621-2626, 1993

A:Title: Evidence for Chlamydia pneumoniae of non-human origin.

A:Reference number: I40739; MUID:94103736

A:Accession: I40739

A:Status: translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-389 <STO>

A:Cross-references: GB:L04982; NID:g289840; PIDN:AAAL7397.1; PID:g289841

C:Comment: On the basis of the major outer membrane protein the authors classified the

the sequence of the genome strain CWL029 and strain IOL-207. See PIR:A43587.

C:Genetics:

A:Gene: ompA

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-23/Domain: signal sequence #status predicted <SIG>

F:24-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 84.1%; Score 69; DB 2; Length 389;  
Best Local Similarity 92.9%; Pred. No. 0.00016;  
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2 FGKGTNNANELP 15

Db 158 FGKGTNNANELP 171

RESULT 4

140864

major outer membrane protein - Chlamydia psittaci

C:Species: Chlamydia psittaci, Chlamydia psittaci

C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 31-Mar-2000

C:Accession: I40864; S33465

R:Girjes, A.A.; Carrick, F.N.; Lavin, M.F.

Gene 138, 139-142, 1994

A:Title: Remarkable sequence relatedness in the DNA encoding the major outer membrane

A:Reference number: I40864; MUID:94117025

A:Accession: I40864

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-389 <RES>

A:Cross-references: EMBL:X72023; NID:g313844; PIDN:CAA50906.1; PID:g313845

C:Superfamily: Chlamydia major outer membrane protein

Query Match 74.4%; Score 61; DB 2; Length 389;

Best Local Similarity 85.7%; Pred. No. 0.0044;

Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 FGKGTNNANELP 15

Db 158 FGKGTNNANELP 171

RESULT 5

B81060

N utilization substance protein A NMBL642 [imported] - Neisseria meningitidis (strain

C:Species: Neisseria meningitidis

C:Date: 31-Mar-2000 #sequence\_revision 31-Mar-2000 #text\_change 19-Jan-2001

C:Accession: B81060

R:Tettelin, H.; Saunders, N.J.; Heidelberg, J.; Jeffries, A.C.; Nelson, K.E.; Eisen,

Hickey, E.K.; Haft, D.H.; Salzberg, S.L.; White, O.; Fleischmann, R.D.; Dougherty, B.

ri, H.; Qin, H.; Vamathevan, J.; Gill, J.; Scarlato, V.; Maignani, V.; Pizza, M.

Science 287, 1809-1815, 2000

A:Authors: Grandi, G.; Sun, L.; Smith, H.O.; Fraser, C.M.; Moxon, E.R.; Rappuoli, R.;

A:Title: Complete genome sequence of Neisseria meningitidis serogroup B strain MC58.

A:Reference number: A81000; MUID:20175755

A:Accession: B81060

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-500 <TET>

A:Cross-references: GB:AE002514; GB:AE002098; NID:g7226886; PIDN:AAF41991.1; PID:g722

A:Experimental source: serogroup B, strain MC58

C:Genetics:

A:Gene: NMB1642

C:Superfamily: Escherichia coli transcription factor nusA; transcription termination

Query Match 54.9%; Score 45; DB 2; Length 500;

Best Local Similarity 62.5%; Pred. No. 4.3;

Matches 10; Conservative 2; Mismatches 2; Indels 2; Gaps 1;

QY 1 CFGKGTNNANELP 14

Db 259 CIGVGRSVNAVSNEL 274

RESULT 6



Query Match	51.2%	Score 42;	DB 2;	Length 708;
Best Local Similarity	46.2%;	Pred. No. 22;		
Matches	6;	Conservative	5;	Mismatches
			2;	Indels
				Gaps

QY 3 FGKGTNNANL 15  
 Db 1524 GIKGFTISST 536

## RESULT 11

R5RZ23  
 Ribosomal protein L23 - rice chloroplast  
 C:Species: chloroplast Oryza sativa (rice)  
 C:Date: 31-Mar-1990 #sequence\_revision 31-Mar-1990 #text\_change 24-Sep-1999  
 C:Accession: J00271; S05151; JAO092  
 R:Shimada, H.; Whittier, R.F.; Hiratsuka, J.; Maeda, Y.; Hirai, A.; Sugiura, M.  
 submitted to JPIB, December 1989  
 A:Reference number: JQ0200  
 A:Accession: JQ0271  
 A:Molecule type: DNA  
 A:Residues: 1-93 <SHI>  
 A:Experimental source: cv. Nihonbare  
 R:Hiratsuka, J.; Shimada, H.; Whittier, R.; Ishibashi, T.; Sakamoto, M.; Mori, M.; Kond

Mol. Gen. Genet. 217, 185-194, 1989  
 A:Title: The complete sequence of the rice (Oryza sativa) chloroplast genome: intermoled  
 of the cereals.  
 A:Reference number: S05080; MUID:89364698  
 A:Accession: S05151  
 A>Status: nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-14, A', 16-93 <HIR>  
 A:Experimental source: cv. Nihonbare  
 R:Moore, E.; Wu, R.  
 Gene 706, 1-12, 1988  
 A:Title: Organization and nucleotide sequence of genes at both junctions between the two  
 A:Reference number: JAO092; MUID:89196901  
 A:Accession: JAO092  
 A:Molecule type: DNA  
 A:Residues: 1-14, A', 16-45, X', 47-93 <MOO>  
 A:Cross-references: GB:M22826; NID:9710564; PIDN:AAA84593.1; PID:g710565  
 A:Note: Genes located at the two inverted repeats (IRA and IRB) in the rice chloroplast  
 1 proteins L23 and L2 and S19, lies at the ends of the two IRS near the LSCR  
 C:Keywords: chloroplast; protein biosynthesis; ribosome

Query Match 50.0%; Score 41; DB 1; Length 93;  
 Best Local Similarity 57.1%; Pred. No. 3.7;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 32 FGKGTNNANL 15  
 Db 43 FGKVVAVNSHRLP 56

## RESULT 12

R5ZM23  
 Ribosomal protein L23 - maize chloroplast  
 C:Species: chloroplast Zea mays (maize)  
 C:Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 16-Jun-2000  
 C:Accession: S01396; S60127; S58536; S58638; S20058  
 R:McLaughlin, W.E.; Larinua, I.M.  
 Nucleic Acids Res. 16, 8183, 1988  
 A:Title: The sequence of the maize plastid encoded rpl23 locus.  
 A:Reference number: S01396; MUID:88335565  
 A:Accession: S01396  
 A:Molecule type: DNA  
 A:Residues: 1-93 <MCL>  
 A:Cross-references: EMBL:X07864; NID:g12417; PIDN:CAA30712.1; PID:g12418  
 A:Genetics: GEN1  
 A:Accession: S60127

Query Match 50.0%; Score 41; DB 1; Length 93;  
 Best Local Similarity 57.1%; Pred. No. 3.7;

A:Molecule type: DNA  
 A:Residues: 1-93 <MCW>  
 A:Cross-references: EMBL:X07864; NID:g12417; PIDN:CAA30712.1; PID:g12418  
 A:Genetics: GEN2  
 R:Maier, R.M.; Neckermann, K.; Igloi, G.L.; Koessel, H.  
 J. Mol. Biol. 251, 614-628, 1995  
 A:Title: Complete sequence of the maize chloroplast genome: gene content, hotspots of  
 A:Reference number: S58531; MUID:95395841  
 A:Accession: S58596  
 A>Status: nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-93 <MAI>  
 A:Cross-references: EMBL:X86563; NID:g902200; PIDN:CAA60330.1; PID:g902265  
 A:Genetics: GEN2  
 A:Note: the nucleotide sequence was submitted to the EMBL Data Library, April 1995  
 A:Accession: S58638  
 A:Molecule type: DNA  
 A:Residues: 1-93 <MAW>  
 A:Cross-references: EMBL:X86563; NID:g902200; PIDN:CAA60330.1; PID:g902265  
 A:Genetics: GEN1  
 A:Note: the nucleotide sequence was submitted to the EMBL Data Library, April 1995  
 R:Hoeh, B.; Maier, R.M.; Appel, K.; Igloi, G.L.; Koessel, H.  
 Nature 353, 178-180, 1991  
 A:Title: Editing of a chloroplast mRNA by creation of an initiation codon.  
 A:Reference number: S17874; MUID:91367263  
 A:Accession: S20058  
 A:Molecule type: mRNA  
 A:Residues: 81-93 <HOC>  
 A:Cross-references: EMBL:X62070; NID:g12463; PIDN:CAA43984.1; PID:g12465  
 C:Genetics: <GEN1>  
 A:Gene: rpl23  
 A:Map position: IR(A); IR(II)  
 A:Genome: chloroplast  
 C:Genetics: <GEN2>  
 A:Gene: rpl23  
 A:Map position: IR(B); IR(I)  
 A:Genome: chloroplast  
 C:Superfamily: Escherichia coli ribosomal protein L23  
 C:Keywords: chloroplast; protein biosynthesis; ribosome

Query Match 50.0%; Score 41; DB 1; Length 93;  
 Best Local Similarity 57.1%; Pred. No. 3.7;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 FGKGTNNANL 15  
 Db 43 FGKVVAVNSHRLP 56

## RESULT 13

R5WT23  
 Ribosomal protein L23 - wheat chloroplast  
 C:Species: chloroplast Triticum aestivum (common wheat)  
 C:Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 22-Jun-1999  
 C:Accession: S06026  
 R:Bowman, C.M.; Barker, R.F.; Dyer, T.A.  
 Curr. Genet. 14, 127-136, 1988  
 A:Title: In wheat tDNA, segments of ribosomal protein genes are dispersed repeats, p  
 A:Reference number: S06025; MUID:89028843  
 A:Accession: S06026  
 A:Molecule type: DNA  
 A:Residues: 1-93 <BOW>  
 A:Cross-references: EMBL:X12850; NID:g12369; PIDN:CAA31328.1; PID:g12370  
 C:Genetics:  
 A:Genome: chloroplast  
 C:Superfamily: Escherichia coli ribosomal protein L23  
 C:Keywords: chloroplast; protein biosynthesis; ribosome

Query Match 50.0%; Score 41; DB 1; Length 93;  
 Best Local Similarity 57.1%; Pred. No. 3.7;

Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;  
 QY 2 FGKGGTTVNANELP 15  
 |||||  
 Db 43 FGKVVAVNSHRLP 56

RESULT 14  
 T51936  
 probable 9-cis-epoxycarotenoid dioxygenase [imported] - potato  
 C;Species: Solanum tuberosum (potato)  
 C;Date: 20-Oct-2000 #sequence\_revision 20-Oct-2000 #text\_change 20-Oct-2000  
 C;Accession: T51936  
 R;Burbidge, A.; Taylor, I.B.; Thompson, A.  
 submitted to the EMBL Data Library, March 2000  
 A;Description: Potato putative 9-cis-epoxycarotenoid dioxygenase 1 cDNA.  
 A;Reference number: Z25874  
 A;Accession: T51936  
 A;Status: preliminary; translated from GB/EMBL/DBJ  
 A;Molecule type: mRNA  
 A;Residues: 1-604 <BUR>  
 A;Cross-references: EMBL:AJ276244; PIDN:CAB76920.1  
 C;Genetics:  
 A;Gene: nced1

Query Match 50.0%; Score 41; DB 2; Length 604;  
 Best Local Similarity 53.8%; Pred. No. 27;  
 Matches 7; Conservative 3; Mismatches 3; Indels 0; Gaps 0;  
 QY 2 FGKGGTTVNANEL 14  
 :| || :|||:  
 Db 588 YGFHGTFINANDL 600

RESULT 15  
 T07123  
 nine-cis-epoxycarotenoid dioxygenase - tomato  
 N;Alternate names: probable neoxanthin cleavage enzyme  
 C;Species: Lycopersicon esculentum (tomato)  
 C;Date: 30-Apr-1999 #sequence\_revision 30-Apr-1999 #text\_change 20-Jun-2000  
 C;Accession: T07123  
 R;Burbidge, A.  
 submitted to the EMBL Data Library, January 1998  
 A;Reference number: Z15934  
 A;Accession: T07123  
 A;Status: preliminary; translated from GB/EMBL/DBJ  
 A;Molecule type: mRNA  
 A;Residues: 1-605 <BUR>  
 A;Cross-references: EMBL:Z97215; PIDN:CAB10168.1

Query Match 50.0%; Score 41; DB 2; Length 605;  
 Best Local Similarity 53.8%; Pred. No. 28;  
 Matches 7; Conservative 3; Mismatches 3; Indels 0; Gaps 0;  
 QY 2 FGKGGTTVNANEL 14  
 :| || :|||:  
 Db 589 YGFHGTFINANDL 601

Search completed: March 26, 2002, 13:37:19  
 Job time: 53 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:13 ; Search time 79.01 Seconds  
(without alignments)  
27.770 Million cell updates/sec

Title: US-09-709-201-97  
Perfect score: 82  
Sequence: 1 CFGVKGTTVNANELP 15

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 473505 seqs, 146272329 residues

Total number of hits satisfying chosen parameters: 473505

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : SPTREMBL\_17:\*

- 1: sp\_archaea:\*
- 2: sp\_bacteria:\*
- 3: sp\_fungi:\*
- 4: sp\_human:\*
- 5: sp\_invertebrate:\*
- 6: sp\_mammal:\*
- 7: sp\_mhc:\*
- 8: sp\_organelle:\*
- 9: sp\_phase:\*
- 10: sp\_plant:\*
- 11: sp\_rodent:\*
- 12: sp\_virus:\*
- 13: sp\_vertebrate:\*
- 14: sp\_unclassified:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	73	89.0	223	2 Q9RB77	Q9rb77 chlamydia p
2	73	89.0	223	2 Q9RB76	Q9rb76 chlamydia p
3	61	74.4	389	2 Q08085	Q08085 chlamydia p
4	47	57.3	388	2 Q9AIK1	Q9aik1 chlamydia p
5	45	54.9	500	2 Q9JYD3	Q9jyd3 neisseria p
6	45	54.9	505	2 Q9JTB6	Q9jtb6 neisseria m
7	44	53.7	744	2 Q9ZCD4	Q9zcd4 rickettsia
8	44	53.7	1059	2 P95633	P95633 rickettsia
9	43	52.4	389	2 Q9APM4	Q9apm4 chlamydophi
10	42	51.2	318	3 Q9HEU6	Q9heu6 emericella
11	42	51.2	341	2 Q9X717	Q9x717 chlamydophi
12	42	51.2	352	2 Q69306	Q69306 chlamydia p
13	42	51.2	352	2 Q69307	Q69307 chlamydia p
14	42	51.2	352	2 Q70085	Q70085 chlamydia p
15	42	51.2	353	2 Q69305	Q69305 chlamydia p
16	42	51.2	455	10 Q9ZVA2	Q9zva2 arabidopsis
17	42	51.2	605	4 Q9BZ21	Q9bz21 homo sapien
18	42	51.2	708	4 Q43641	Q43641 homo sapien
19	42	51.2	743	5 Q9VK47	Q9vk47 drosophila

ALIGNMENTS

RESULT 1

Q9RB77 ID Q9RB77 PRELIMINARY; PRT; 223 AA.

AC Q9RB77

DT 01-MAY-2000 (TREMBLrel. 13, Created)

DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)

DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)

DE MUTANT MAJOR OUTER MEMBRANE PROTEIN (FRAGMENT).

GN MOMP.

OS Chlamydia pneumoniae (Chlamydophila pneumoniae).

OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.

ON NCBI\_TaxID=83558;

RX [1]

RP SEQUENCE FROM N.A.

RA Tharp A.C., Mitchell W.M., Stratton C.W., Ding L.-M.;

RT "Presence of viable Chlamydia pneumoniae in fetal calf serum and in epithelial-derived cell lines."

RL Submitted (FEB-1999) to the EMBL/GenBank/DBJ databases.

DR EMBL; AFI31230; AAD33511.1; -

DR InterPro; IPR000604; Chlamydia\_OMP.

DR Pfam; PF01308; Chlamydia\_OMP; 1.

DR ProDom; PD001717; Chlamydia\_OMP; 1.

FT NON\_TER 1

FT NON\_TER 223

SQ SEQUENCE 223 AA; 24171 MW; 6D19A6B4D8841496 CRC64;

Query Match 89.0%; Score 73; DB 2; Length 223;  
Best Local Similarity 100.0%; Pred. No. 6e-05;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FGKGGTTVNANELP 15  
Db 58 FGKGGTTVNANELP 71

RESULT 2

ID Q9RB76 PRELIMINARY; PRT; 223 AA.

AC Q9RB76

DT 01-MAY-2000 (TREMBLrel. 13, Created)

DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)

01-JUN-2001 (Tremblrel. 17, Last annotation update)  
MOMP.  
Chlamydia pneumoniae (Chlamydia pneumoniae).  
Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
NCBI\_TaxID=83558;

SEQUENCE FROM N.A.  
Tharp A.C., Mitchell W.M., Stratton C.W., Ding L.-M.;  
"Presence of viable Chlamydia pneumoniae in fetal calf serum and in  
epithelial-derived cell lines";  
Submitted (FEB-1999) to the EMBL/GenBank/DBJ databases.  
EMBL; AF131229; AAD33510.1;  
InterPro; IPR000604; Chlamydia\_OMP.  
Pfam; PF01308; Chlamydia\_OMP; 1.  
ProDom; PD001717; Chlamydia\_OMP; 1.  
FT NON\_TER 1 1  
FT VARIANT 6 6 A -> P.  
FT VARIANT 10 10 M -> K.  
FT VARIANT 161 161 V -> A.  
FT NON\_TER 223 223  
SQ SEQUENCE 223 AA; 4B676047B947C00F CRC64;

Query Match 89.0%; Score 73; DB 2; Length 223;  
Best Local Similarity 100.0%; Pred. No. 5e-05;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FGVKGTNNANL 15  
DB 158 FGVKGTNNANL 71

RESULT 3

ID Q08085 PRELIMINARY; PRT; 389 AA.  
AC Q08085;  
DT 01-NOV-1996 (Tremblrel. 01, Created)  
DT 01-NOV-1996 (Tremblrel. 01, Last sequence update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
OS Chlamydia psittaci (Chlamydia psittaci).  
Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-KOALA TYPE 1;  
RX MEDLINE=94171025; PubMed=8125292;  
RA Gillespie A., Carrick F.N., Lavin M.F.;  
"Remarkable sequence relatedness in the DNA encoding the major outer  
membrane protein of Chlamydia psittaci (koala type 1) and Chlamydia  
pneumoniae";  
Gene 338:339-342 (1993).

CC - FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
CC - SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
CC - SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
DR EMBL; X72023; CAA50906.1;  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR PROSITE; PR01334; CHLAMYDIA\_OMP.  
DR PRODOM; PD001717; Chlamydia\_OMP; 1.  
KW Outer membrane; Transmembrane; Porin; Signal.  
FT SIGNAL 1 23 BY SIMILARITY.  
FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 389 AA; 41579 MW; 5DC50E85A6F4E50F CRC64;

Query Match 74.4%; Score 61; DB 2; Length 389;  
Best Local Similarity 85.7%; Pred. No. 0.014;  
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 FGVKGTNNANL 15  
DB 158 FGVKGTNNANL 171

RESULT 4

ID Q9A1K1 PRELIMINARY; PRT; 388 AA.  
AC Q9A1K1;  
DT 01-JUN-2001 (Tremblrel. 17, Created)  
DT 01-JUN-2001 (Tremblrel. 17, Last sequence update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
GN OMPA.  
OS Chlamydia psittaci (Chlamydia psittaci).  
Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-VS225;  
RX MEDLINE=21078680; PubMed=11211261;  
RA Bush R.M., Everett K.D.;  
"Molecular evolution of the Chlamydiaceae";  
Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
DR EMBL; AF269259; AAK00240.1;  
KW Signal.  
FT NON\_TER 1 1 POTENTIAL.  
FT SIGNAL <1 19 MAJOR OUTER MEMBRANE PROTEIN.  
FT CHAIN 20 388  
SQ SEQUENCE 388 AA; 41573 MW; 8E232D22C9B9948D CRC64;

Query Match 57.3%; Score 47; DB 2; Length 388;  
Best Local Similarity 69.2%; Pred. No. 4;  
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3 GVKGTNNANL 15  
DB 156 GVKGTNNANL 168

RESULT 5

ID Q9JYD3 PRELIMINARY; PRT; 500 AA.  
AC Q9JYD3;  
DT 01-OCT-2000 (Tremblrel. 15, Created)  
DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)  
DE N UTILIZATION SUBSTANCE PROTEIN A.  
GN NMB1642.  
OS Neisseria meningitidis (serogroup B).  
Bacteria; Proteobacteria; beta subdivision; Neisseriaceae; Neisseria.  
NCBI\_TaxID=491;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-MC58 / SEROGROUP B;  
RX MEDLINE=20175755; PubMed=10710307;  
RA Tettelin H., Saunders N.J., Heidelberg J., Jeffries A.C., Nelson K.E.,  
Eisen J.A., Ketchum K.A., Hood D.W., Peden J.F., Dodson R.J.,  
Nelson W.C., Gwin M.L., DeBoy R., Peterson J.D., Hickey E.K.,  
Haft D.H., Salzberg S.L., White O., Fleischmann R.D., Dougherty B.A.,  
Mason T., Ciecko A., Parksey D.S., Blair E., Citterone H., Clark E.B.,  
Cotton M.D., Utterback T.R., Khouri H., Qin H., Vamathevan J.,  
Gill J., Scarlato V., Masignani V., Pizzo M., Grandi G., Sun L.,  
Smith H.O., Fraser C.M., Moxon E.R., Rappuoli R., Venter J.C.;  
"Complete genome sequence of Neisseria meningitidis serogroup B strain  
MC58";  
Science 287:1809-1815(2000).  
DR EMBL; AE002514; AAF41991.1;  
DR TIGR; NMB1642;  
DR InterPro; IPR000958; KH.  
DR InterPro; IPR003029; SI.

DR Pfam: PF00013; KH-domain; 1.  
 DR Pfam: PF00575; S1; 1.  
 DR SMART: SM00322; KH; 2.  
 DR SMART: SM00316; S1; 1.  
 DR Complete proteome.  
 SQ SEQUENCE 500 AA; 55751 MW; 753FA50DDEF5B774 CRC64;

Query Match 54.9%; Score 45; DB 2; Length 500;  
 Best Local Similarity 62.5%; Pred. No. 12;  
 Matches 10; Conservative 2; Mismatches 2; Indels 2; Gaps 1;

QY 1 CFGVGKGTVA--NEL 14  
 | | | | | | | | | |  
 Db 259 CIGVGRSRVNAVSNEL 274

RESULT 6

Q9JTB6 PRELIMINARY; PRT; 505 AA.  
 AC Q9JTB6;  
 DT 01-OCT-2000 (TrEMBLrel. 15, Created)  
 DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE N UTILISATION SUBSTANCE PROTEIN A.  
 GN NUSA OR NMA1896.  
 OS Neisseria meningitidis (serogroup A).  
 OC Bacteria; Proteobacteria; beta subdivision; Neisseriaceae; Neisseria.  
 OX NCBI\_TaxID=65699;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=22491 / SEROGROUP A / SEROTYPE 4A;  
 RX MEDLINE=20222556; PubMed=10761919;  
 RA Parkhill J., Achtman M., James K.D., Bentley S.D., Churcher C.,  
 RA Klee S.R., Morelli G., Basham D., Brown D., Chillingworth T.,  
 RA Davies R.M., Davis P., Devlin K., Feltwell T., Hamlin N., Holroyd S.,  
 RA Jagels K., Leather S., Moule S., Mungall K., Quail M.A.,  
 RA Rajandream M.A., Rutherford K.M., Simmonds M., Skelton J.,  
 RA Whitehead S., Spratt B.G., Barrell B.G.;  
 RT "Complete DNA sequence of a serogroup A strain of Neisseria  
 meningitidis 22491";  
 RL Nature 404:502-506(2000).  
 DR EMBL; AL162757; CAB85117.1;  
 DR InterPro; IPR000958; KH.  
 DR InterPro; IPR003029; S1.  
 DR Pfam; PF00013; KH-domain; 1.  
 DR Pfam; PF00575; S1; 1.  
 DR SMART: SM00322; KH; 2.  
 DR SMART: SM00316; S1; 1.  
 DR Complete proteome.  
 KW SEQUENCE 505 AA; 56418 MW; 5A0F080DCA99E5D7 CRC64;

Query Match 54.9%; Score 45; DB 2; Length 505;  
 Best Local Similarity 62.5%; Pred. No. 12;  
 Matches 10; Conservative 2; Mismatches 2; Indels 2; Gaps 1;

QY 1 CFGVGKGTVA--NEL 14  
 | | | | | | | | | |  
 Db 264 CIGVGRSRVNAVSNEL 279

RESULT 7

Q9ZCDA PRELIMINARY; PRT; 744 AA.  
 AC Q9ZCDA;  
 DT 01-MAY-1999 (TrEMBLrel. 10, Created)  
 DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE CELL DIVISION PROTEIN FTSK HOMOLOG (FTSK).  
 GN RP823.  
 OS Rickettsia prowazekii.  
 OC Bacteria; Proteobacteria; alpha subdivision; Rickettsiales;

OC Rickettsiaceae; Rickettsiae; Rickettsia.  
 OX NCBI\_TaxID=782;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=MADRID E;  
 RX MEDLINE=99039499; PubMed=9823893;  
 RA Andersson S.G.E., Zomorodipour A., Andersson J.O.,  
 RA Sacheritz-Ponten T., Alsmark U.C.M., Podowski R.M., Naeslund A.K.,  
 RA Eriksson A.-S., Winkler H.H., Kurland C.G.;  
 RT "The genome sequence of Rickettsia prowazekii and the origin of  
 mitochondria";  
 RL Nature 396:133-140(1998).  
 DR EMBL; AJ235273; CAAL5248.1;  
 DR InterPro; IPR002543; FtsK\_SpoIIIE.  
 DR Pfam; PF01580; FtsK\_SpoIIIE; 1.  
 DR Complete proteome.  
 KW SEQUENCE 744 AA; 82819 MW; C8208B0A9D9E42AC CRC64;

Query Match 53.7%; Score 44; DB 2; Length 744;  
 Best Local Similarity 57.1%; Pred. No. 27;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 FGKGGTTVNANELP 15  
 | | | | | : | | : |  
 Db 288 FGKGGTTVNANELP 301

RESULT 8

P95633 PRELIMINARY; PRT; 1055 AA.  
 AC P95633;  
 DT 01-MAY-1997 (TrEMBLrel. 03, Created)  
 DT 01-MAY-1997 (TrEMBLrel. 03, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE ROMPA (FRAGMENT).  
 GN OMPA.  
 OS Rickettsia montana.  
 OC Bacteria; Proteobacteria; alpha subdivision; Rickettsiales;  
 OC Rickettsiaceae; Rickettsiae; Rickettsia.  
 OX NCBI\_TaxID=33991;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=M5/6;  
 RA Raoult D., Fournier P.E., Roux V.;  
 RL Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; U83447; AAC35183.1;  
 DR InterPro; IPR003858; rOmpA\_rOmpB.  
 DR Pfam; PF02708; rOmpA\_rOmpB; 1.  
 DR NON\_TER 1  
 FT NON\_TER 1059 1059  
 SQ SEQUENCE 1059 AA; 110213 MW; DD9EECF128990632 CRC64;

Query Match 53.7%; Score 44; DB 2; Length 1059;  
 Best Local Similarity 61.5%; Pred. No. 40;  
 Matches 8; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 2 FGKGGTTVNANEL 14  
 | | | | | : | : | :  
 Db 301 FGKGGTTVNANEL 313

RESULT 9

Q9APM4 PRELIMINARY; PRT; 369 AA.  
 AC Q9APM4;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.  
 GN OMP1.  
 OS Chlamydomonas abortus.

```

OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=83555;
RN [1]
RC SEQUENCE FROM N.A.
RX STRAIN=LIG; PubMed=11119563;
RA Vreton E., Psarrou E., Kaisar M., Vilisidou I., Sali-Montesanto V.,
RA Longbottom D.;
RT "Identification of protective epitopes by sequencing of the major
RT outer membrane protein gene of a variant strain of Chlamydia psittaci
RT serotype 1.";
RL Infect. Immun. 69:607-612(2001).
RL EMBL; AF272945; AAG53881.1; -.
KW SIGNAL.
FT CHAIN 1 22 POTENTIAL.
FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.
SQ SEQUENCE 389 AA; 41897 MW; 20513C69C7DBAAF5 CRC64;

Query Match 52.4%; Score 43; DB 2; Length 389;
Best Local Similarity 61.5%; Pred. No. 20;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 3 GVKGTTVNANELP 15
Db 159 GVKGSVAADQLP 171
||||| |::|

RESULT 10
Q9HEU6 PRELIMINARY; PRT; 318 AA.
AC Q9HEU6;
DT 01-MAR-2001 (Tremblrel. 16; Created)
DT 01-MAR-2001 (Tremblrel. 16; Last sequence update)
DT 01-MAR-2001 (Tremblrel. 16; Last annotation update)
DE PTAC BETA (FRAGMENT).
GN PTAC.
OS Emericella nidulans (Aspergillus nidulans).
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eutiales; Trichocomaceae; Emericella.
OX NCBI_TaxID=5072;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=89218944; PubMed=2651886;
RA Arst H.N. Jr., Tollervey D., Caddick M.X.;
RT "A translocation associated, loss-of-function mutation in the nitrogen
RT metabolite repression regulatory gene of Aspergillus nidulans can
RT revert intracistronically.";
RL Mol. Gen. Genet. 215:364-367(1989).
RN [2]
RP SEQUENCE FROM N.A.
RA Conlon H.E., Zadra I., Haas H., Jones M.G., Arst H.N. Jr.,
RA Caddick M.X.;
RT "The Aspergillus nidulans GATA transcription factor gene areB encodes
RT at least three proteins and features three classes of mutation.";
RL Submitted (NOV-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF320980; AAG49360.1; -.
FT NON_TER 1
FT SEQUENCE 318 AA; 34750 MW; 1F2F8776D1C46A3D CRC64;

Query Match 51.2%; Score 42; DB 3; Length 318;
Best Local Similarity 46.7%; Pred. No. 25;
Matches 7; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

Qy 1 CFGVGKTTVNANELP 15
Db 237 CIGLSGQVNRNKP 251
| | | | | | | |
| | | | | | | |

RESULT 11
Q9X717 PRELIMINARY; PRT; 341 AA.
ID Q9X717

```

```

AC Q9X717;
DT 01-NOV-1999 (Tremblrel. 12; Created)
DT 01-NOV-1999 (Tremblrel. 12; Last sequence update)
DT 01-JUN-2001 (Tremblrel. 17; Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).
GN OMPA.
OS Chlamydia abortus.
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=83555;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=LW508;
RX MEDLINE=93123168; PubMed=8419295;
RA Kaltenboeck B., Kousoulas K.G., Storz J.;
RT "Structures of and allelic diversity and relationships among the major
RT outer membrane protein (ompA) genes of the four chlamydial species.";
RL J. Bacteriol. 175:487-502(1993).
DR EMBL; M73040; AAD29103.1; -.
DR InterPro; IPR000604; Chlamydia_OMP.
DR Pfam; PF01308; Chlamydia_OMP; 1.
DR ProDom; PD001717; Chlamydia_OMP; 1.
FT NON_TER 1
FT NON_TER 341
FT SEQUENCE 341 AA; 36762 MW; B5933C9BF6AAF171 CRC64;

Query Match 51.2%; Score 42; DB 2; Length 341;
Best Local Similarity 53.8%; Pred. No. 27;
Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 3 GVKGTTVNANELP 15
Db 123 GVKGSSTAADQLP 135
||||| |::|

RESULT 12
O69306 PRELIMINARY; PRT; 352 AA.
AC O69306;
DT 01-AUG-1998 (Tremblrel. 07; Created)
DT 01-AUG-1998 (Tremblrel. 07; Last sequence update)
DT 01-JUN-2001 (Tremblrel. 17; Last annotation update)
DE OMP1 PROTEIN (FRAGMENT).
GN OMP1.
OS Chlamydia psittaci (Chlamydia psittaci).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=83554;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=PM234;
RA Hoelzle L.E., Steinhilber G., Eggemann G., Schiller I.,
RA Wittenbrink M.M.;
RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ004874; CAA06183.1; -.
DR InterPro; IPR000604; Chlamydia_OMP.
DR Pfam; PF01308; Chlamydia_OMP; 1.
DR ProDom; PD001717; Chlamydia_OMP; 1.
FT NON_TER 352
FT SEQUENCE 352 AA; 37868 MW; 0AE99B1E099EED41 CRC64;

Query Match 51.2%; Score 42; DB 2; Length 352;
Best Local Similarity 53.8%; Pred. No. 28;
Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 3 GVKGTTVNANELP 15
Db 159 GVKGSSTAADQLP 171
||||| |::|

RESULT 13
O69307 PRELIMINARY; PRT; 352 AA.
ID O69307

```



AC O69307;  
 DT 01-AUG-1998 (TrEMBLrel. 07, Created)  
 DT 01-AUG-1998 (TrEMBLrel. 07, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE OMP1 PROTEIN (FRAGMENT).  
 GN OMP1.  
 OS Chlamydia psittaci (Chlamydomphila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomphila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=PM326;  
 RA Hoelzle L.E., Steinhäusen G., Eggemann G., Schiller I.,  
 RA Wittenbrink M.M.;  
 RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AJ004875; CAA06184.1; -  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 FT NON\_TER 352  
 SQ SEQUENCE 352 AA; 37854 MW; 33589C6D1137CCDB CRC64;

Query Match 51.2%; Score 42; DB 2; Length 352;  
 Best Local Similarity 53.8%; Pred. No. 28;  
 Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;  
 QY 3 GVKGTTVNANELP 15  
 |||:::|::|  
 Db 159 GVGSSIAADQLP 171

RESULT 14  
 O70085  
 ID O70085 PRELIMINARY; PRT; 352 AA.  
 AC O70085;  
 DT 01-AUG-1998 (TrEMBLrel. 07, Created)  
 DT 01-AUG-1998 (TrEMBLrel. 07, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE OMP1 (FRAGMENT).  
 GN OMP1.  
 OS Chlamydia psittaci (Chlamydomphila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomphila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=PM326;  
 RA Hoelzle L.E., Steinhäusen G., Eggemann G., Schiller I.,  
 RA Wittenbrink M.M.;  
 RL Submitted (APR-1998) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AJ005618; CAA06625.1; -  
 DR EMBL; AJ005617; CAA06624.1; -  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 FT NON\_TER 352  
 SQ SEQUENCE 352 AA; 37854 MW; 391914AD146072CB CRC64;

Query Match 51.2%; Score 42; DB 2; Length 352;  
 Best Local Similarity 53.8%; Pred. No. 28;  
 Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;  
 QY 3 GVKGTTVNANELP 15  
 |||:::|::|  
 Db 159 GVGSSIAADQLP 171

RESULT 15  
 O69305  
 ID O69305 PRELIMINARY; PRT; 353 AA.  
 AC O69305;  
 DT 01-AUG-1998 (TrEMBLrel. 07, Created)

DT 01-AUG-1998 (TrEMBLrel. 07, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE OMP1 PROTEIN (FRAGMENT).  
 GN OMP1.  
 OS Chlamydia psittaci (Chlamydomphila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomphila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=OCLH196;  
 RA Hoelzle L.E., Steinhäusen G., Eggemann G., Schiller I.,  
 RA Wittenbrink M.M.;  
 RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AJ004873; CAA06182.1; -  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 FT NON\_TER 353  
 SQ SEQUENCE 353 AA; 37933 MW; AC7D8FD9FA6E1728 CRC64;

Query Match 51.2%; Score 42; DB 2; Length 353;  
 Best Local Similarity 53.8%; Pred. No. 28;  
 Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;  
 QY 3 GVKGTTVNANELP 15  
 |||:::|::|  
 Db 159 GVGSSIAADQLP 171

Search completed: March 26, 2002, 13:40:14  
 Job time: 228 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:43 ; Search time 24.63 Seconds  
(without alignments)  
22.329 Million cell updates/sec

Title: US-09-709-201-97  
Perfect score: 82  
Sequence: 1 CFGVKGTTVNANELP 15

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 100059 seqs, 36664827 residues

Total number of hits satisfying chosen parameters: 100059

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_39:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	73	89.0	389	1	OMPI_CHLPN
2	69	84.1	389	1	OMIN_CHLPN
3	61	74.4	333	1	OM1K_CHLPN
4	42	51.2	389	1	OM1A_CHLPN
5	42	51.2	708	1	PETL_HUMAN
6	41	50.0	93	1	RK23_MAIZE
7	41	50.0	93	1	RK23_ORYZA
8	41	50.0	93	1	RK23_WHEAT
9	40	48.8	246	1	YGGE_ECOLI
10	40	48.8	1235	1	DNBI_HCMVA
11	40	48.8	1956	1	ATX1_PLAFA
12	40	48.8	3343	1	YOG7_CAEEL
13	39	47.6	640	1	TPB5_BPT5
14	38.5	47.0	435	1	PGLX_ASPTU
15	38	46.3	168	1	GLX2_THETH
16	38	46.3	223	1	CLIC_ARATH
17	38	46.3	229	1	NECL_NICPL
18	38	46.3	322	1	VANL_ENTFC
19	38	46.3	330	1	ODBA_BACSU
20	38	46.3	473	1	KCC4_HUMAN
21	38	46.3	776	1	VP4_ROT5
22	37	45.1	93	1	RK23_ARATH
23	37	45.1	93	1	RK23_TOBAC
24	37	45.1	222	1	PYRK_ARCFU
25	37	45.1	335	1	NAG2_XYLFA
26	37	45.1	395	1	NUSA_HELPJ
27	37	45.1	395	1	NUSA_HELPJ
28	37	45.1	2731	1	RRPB_CVMJH
29	36	43.9	202	1	YJ72_YEAST
30	36	43.9	246	1	PSA6_CAEEL
31	36	43.9	413	1	COBL_PSEDE
32	36	43.9	425	1	SYH_STREQ
33	36	43.9	474	1	LCND_LACLA

34 36 43.9 539 1 VLL\_HPVA5  
35 36 43.9 556 1 FTHS\_CLOCY  
36 36 43.9 916 1 CAD4\_HUMAN  
37 36 43.9 964 1 PMPE\_CHLTR  
38 36 43.9 976 1 PMPE\_CHLMU  
39 36 43.9 1178 1 YNI7\_YEAST  
40 36 43.9 1208 1 RCQA\_HUMAN  
41 36 43.9 1242 1 CY41\_TRYBB  
42 36 43.9 1271 1 Y338\_MYCGE  
43 36 43.9 2733 1 RRPB\_CVMA5  
44 35.5 43.3 215 1 HP27\_TAMAS  
45 35.5 43.3 238 1 Y097\_CAEEL

P36741 human papill  
Q07064 clostridium  
P55283 homo sapien  
O84877 chlamydia t  
Q9pi47 chlamydia m  
P48231 saccharomyc  
O94761 homo sapien  
Q99279 trypanosoma  
P47580 mycoplasma  
P16342 murine coro  
Q06577 tamias asia  
P41847 caenorhabdi

#### ALIGNMENTS

RESULT 1  
OMPI\_CHLPN  
ID OMPI\_CHLPN STANDARD; PRT; 389 AA.  
AC P27455: O9JOF6;  
DT 01-AUG-1992 (Rel. 23, Created)  
DT 01-AUG-1992 (Rel. 23, Last sequence update)  
DE 20-AUG-2001 (Rel. 40, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
GN OMPA OR OMPI OR CPN0695 OR CP0051.  
OS Chlamydia pneumoniae (Chlamydia pneumoniae).  
OC Bacteria; Chlamydiales; Chlamydiales; Chlamydiales.  
OX NCBI\_TaxID=83558;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=IOL-207;  
RX MEDLINE=91237311; PubMed=2033374;  
RA Carter M.W., Al-Mahdawi S.A.H., Giles I.G., Trehan J.D.,  
RA Ward M.E., Clarke I.N.;  
RA "Nucleotide sequence and taxonomic value of the major outer membrane  
RT protein gene of Chlamydia pneumoniae IOL-207";  
RL J. Gen. Microbiol. 137:465-475(1991).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=TWAR;  
RX MEDLINE=91244474; PubMed=1840574;  
RA Perez Melgosa M., Kuo C.-C., Campbell L.A.;  
RA "Sequence analysis of the major outer membrane protein gene of  
RT Chlamydia pneumoniae";  
RL Infect. Immun. 59:2195-2199(1991).  
RN [3]  
RP SEQUENCE FROM N.A.  
RA Mitchell W.M., Tharp A.C., Stratton C.W., Srinam S.;  
RL Submitted (FEB-1995) to the EMBL/GenBank/DBJ databases.  
RN [4]  
RP SEQUENCE FROM N.A.  
RC STRAIN=CWL029;  
RX MEDLINE=99206606; PubMed=10192388;  
RA Kalman S., Mitchell W., Marathe R., Lamell C., Fan J., Hyman R.W.,  
RA Olinger L., Grimwood J., Davis R.W., Stephens R.S.;  
RA "Comparative genomes of Chlamydia pneumoniae and C. trachomatis";  
RT Nat. Genet. 21:385-389(1999).  
RN [5]  
RP SEQUENCE FROM N.A.  
RC STRAIN=AR39;  
RX MEDLINE=20150255; PubMed=10684935;  
RA Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F., Bass S.,  
RA White O., Hickey E.K., Peterson J., Utterback T., Berry K., Dods R.,  
RA Linher K., Weidman J., Khouri H., Craven B., Bowman C., Dodson R.,  
RA Gwin M., Nelson J., DeBoy R., Kolonay J., McClarty G., Salzberg S.L.,  
RA Eisen J., Fraser C.M.;  
RT "Genome sequences of Chlamydia trachomatis MOPn and Chlamydia  
RT pneumoniae AR39";  
RL Nucleic Acids Res. 28:1397-1406(2000).  
RN [6]  
RP SEQUENCE FROM N.A.  
RC STRAIN=J138;

```

RX MEDLINE=20330349; PubMed=10871362;
RA Shirai M., Hirakawa H., Kimoto M., Tabuchi M., Kishi F., Ouchi K.,
RA Shiba T., Ishii K., Hattori M., Kuhara S., Nakazawa T.;
RT "Comparison of whole genome sequences of Chlamydia pneumoniae J138
RL from Japan and CWL029 from USA.";
RL Nucleic Acids Res. 28:2311-2314(2000).
RN [7]
RN SEQUENCE FROM N.A.
RC STRAIN=J138;
RC MEDLINE=20298986; PubMed=10839753;
RA Shirai M., Hirakawa H., Ouchi K., Tabuchi M., Kishi F., Kimoto M.,
RA Takeuchi H., Nishida J., Shibata K., Fujinaga R., Yoneda H.,
RA Matsushina H., Tanaka C., Furukawa S., Miura K., Nakazawa A.,
RA Ishii K., Shiba T., Hattori M., Kuhara S., Nakazawa T.;
RT "Comparison of outer membrane protein genes omp and pmp in the whole
RT genome sequences of Chlamydia pneumoniae isolates from Japan and the
RT United States.";
RL J. Infect. Dis. 181 Suppl 3:S524-S527(2000).
CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY
CC BODIES AND PORIN FORMING. PERMITTING DIFFUSION OF SOLUTES THROUGH
CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.
CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP
CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.
CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: M64064; AAA73071.1;
CC EMBL: M69230; AAA73071.1;
CC EMBL: AF131889; AAD22492.1;
CC EMBL: AE001652; AAD18834.1;
CC EMBL: AE002167; AAF37944.1;
CC EMBL: AP002547; BAA89802.1;
CC EMBL: AB033787; BAA85940.1;
CC PIR: A43587; A43587.
CC PIR: A49751; A49751.
CC TIGR: CP0051;
CC InterPro: IPR000604; Chlamydia_OMP.
CC Pfam: PF01308; Chlamydia_OMP; 1.
CC ProDom: PD001717; Chlamydia_OMP; 1.
CC Outer membrane; Transmembrane; Porin; Signal; Complete proteome.
FT SIGNAL 1 23
FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.
FT SEQUENCE 389 AA; 41620 MW; 15D984151E41F8F2 CRC64;
SQ
Query Match 89.08; Score 73; DB 1; Length 389;
Best Local Similarity 100.0%; Pred. No. 1.4e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2 FGKGGTTVNANELP 15
Db 158 FGKGGTTVNANELP 171
RESULT 2
OM1N_CHLPN STANDARD; PRT; 389 AA.
AC Q07430;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN (MOMP).
GN OMPA OR OMP1.
OS Chlamydia pneumoniae (Chlamydia pneumoniae).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
CC

```

```

OX NCBI_TaxID=83558;
RN [1]
RN SEQUENCE FROM N.A.
RC STRAIN=N16;
RC MEDLINE=94103736; PubMed=8277245;
RA Storey C., Lusher M., Yates P., Richmond S.;
RT "Evidence for Chlamydia pneumoniae of non-human origin.";
RL J. Gen. Microbiol. 139:2621-2626(1993).
CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY
CC BODIES AND PORIN FORMING. PERMITTING DIFFUSION OF SOLUTES THROUGH
CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.
CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP
CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.
CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: L04982; AAA17397.1;
CC InterPro: IPR000604; Chlamydia_OMP.
CC Pfam: PF01308; Chlamydia_OMP; 1.
CC ProDom: PD001717; Chlamydia_OMP; 1.
CC Outer membrane; Transmembrane; Porin; Signal.
FT SIGNAL 1 23 BY SIMILARITY.
FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.
FT SEQUENCE 389 AA; 41628 MW; 801622F05D841967 CRC64;
SQ
Query Match 84.1%; Score 69; DB 1; Length 389;
Best Local Similarity 92.9%; Pred. No. 7.2e-05;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 2 FGKGGTTVNANELP 15
Db 158 FGKGGTTVNANELP 171
RESULT 3
OM1K_CHLPN STANDARD; PRT; 333 AA.
AC Q9XB4;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN (MOMP) (FRAGMENT).
GN OMPA OR OMP1.
OS Chlamydia pneumoniae (Chlamydia pneumoniae).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
CC

```

CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; M73038; AAD38210.1; -  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin.  
 FT NON\_TER 333 333  
 FT NON\_TER 333 333  
 SQ SEQUENCE 333 AA; 35811 MW; 204604512C4C3B3F CRC64;

Query Match 74.48; Score 61; DB 1; Length 333;  
 Best Local Similarity 85.78; Pred. No. 0.0017;  
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Oy 2 FGKGTNNANLNP 15  
 |||||:|||||  
 Db 114 FGKGTNNANLNP 127

RESULT 4  
 OM1A\_CHLPS STANDARD; PRT; 389 AA.  
 AC P16567;  
 DT 01-AUG-1990 (Rel. 15, Created)  
 DT 01-AUG-1990 (Rel. 15, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
 GN OMPA OR OMP1.  
 OS Chlamydia psittaci (Chlamydia psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-OVINE ENZOOTIC ABORTION ISOLATE S26/3;  
 RA MEDLINE=90128177; PubMed=3612883;  
 RA Griffiths P.C., Plater J.M., Martin T.C., Hughes S.L.,  
 RA Hughes K.J., Hewinson R.G., Dawson M.;  
 RT "Epizootic bovine abortion in a dairy herd: characterization of a  
 RT Chlamydia psittaci isolate and antibody response.";  
 RL Br. Vet. J. 151:683-693(1995).  
 CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC EMBL; X51859; CAA36152.1; -  
 DR EMBL; L39020; AAB02850.1; -  
 DR PIR; S08770; MMCWP3.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal.  
 FT SIGNAL 1 22  
 FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41883 MW; 741B5A23ACDBB447 CRC64;

Query Match 51.28; Score 42; DB 1; Length 389;  
 Best Local Similarity 53.88; Pred. No. 5.1;  
 Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Oy 3 GVKGTNNANLNP 15  
 |||||:|:|:|  
 Db 159 GVKGTNNANLNP 171

RESULT 5  
 PET1\_HUMAN STANDARD; PRT; 708 AA.  
 AC P46059;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE OLIGOPEPTIDE TRANSPORTER, SMALL INTESTINE ISOFORM (PEPTIDE TRANSPORTER  
 DE 1) (INTESTINAL H+/PEPTIDE COTRANSPORTER) (SOLUTE CARRIER FAMILY 15,  
 DE MEMBER 1).  
 GN SLC15A1 OR PEPT1.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Intestine;  
 RX MEDLINE=95204429; PubMed=7896779;  
 RA Liang R., Fei Y.-J., Prasad P.D., Ramamoorthy S., Han H.,  
 RA Yang-Feng T.L., Hediger M.A., Ganapathy V., Leibach F.H.;  
 RT "Human intestinal H+/peptide cotransporter: Cloning, functional  
 RT expression, and chromosomal localization.";  
 RL J. Biol. Chem. 270:6456-6463(1995).  
 CC -1- FUNCTION: PROTON-COUPLED INTAKE OF OLIGOPEPTIDES OF 2 TO 4  
 CC AMINO ACIDS WITH A PREFERENCE FOR DIPEPTIDES. MAY CONSTITUTE  
 CC A MAJOR ROUTE FOR THE ABSORPTION OF PROTEIN DIGESTION END-  
 CC PRODUCTS.

CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.  
 CC -1- SIMILARITY: BELONGS TO THE PTR2 FAMILY OF TRANSPORTERS.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC EMBL; U13173; AAB61693.1; -  
 DR EMBL; U21936; AAA63797.1; -  
 DR MIM; 600544; -  
 DR InterPro; IPR00109; PTR2.  
 DR Pfam; PF00854; PTR2; 2.  
 DR PROSITE; PS01022; PTR2\_1; 1.  
 DR PROSITE; PS01023; PTR2\_2; 1.  
 KW Peptide transport; Transport; Transmembrane; Symport; Glycoprotein.  
 FT TRANSMEM 1 21 POTENTIAL.  
 FT DOMAIN 22 53 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 54 74 POTENTIAL.  
 FT DOMAIN 75 82 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 83 103 POTENTIAL.  
 FT DOMAIN 104 118 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 119 139 POTENTIAL.  
 FT DOMAIN 140 161 CYTOPLASMIC (POTENTIAL).



CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; X15901; CAA33938.1; -;  
 DR EMBL; X15901; CAA33923.1; -;  
 DR EMBL; M22826; AAB84593.1; -;  
 DR EMBL; L40578; AAD15253.1; -;  
 DR PIR; J00271; R5R223.  
 DR Mendel; 5010; ORYsa; rpl23; 2.  
 DR InterPro; IPR001014; Ribosomal\_L23.  
 DR Pfam; PF00276; Ribosomal\_L23; 1.  
 DR ProDom; PD001141; Ribosomal\_L23; 1.  
 DR PROSITE; PS00050; Ribosomal\_L23; 1.  
 KW Ribosomal protein; Chloroplast; rRNA-binding.  
 FT CONFLICT 15 15 R -> A (IN REF. 3).  
 SQ SEQUENCE 93 AA; 10764 MW; 721EBD893CF77566 CRC64;

Query Match 50.0%; Score 41; DB 1; Length 93;  
 Best Local Similarity 57.1%; Pred. No. 1.7;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;  
 QY 2 FGVKGTNNANLPL 15  
 DB 43 FGVKVVAVNSHRLP 56  
 ||||| ||::||

RESULT 8  
 RK23.WHEAT  
 ID RK23.WHEAT STANDARD; PRT; 93 AA.  
 AC P11535; P41097;  
 DT 01-OCT-1989 (Rel. 12, Created)  
 DT 01-OCT-1989 (Rel. 12, Last sequence update)  
 DT 01-FEB-1996 (Rel. 33, Last annotation update)  
 DE CHLOROPLAST 50S RIBOSOMAL PROTEIN L23.  
 GN RPL23.  
 OS Triticum aestivum (Wheat), and Hordeum vulgare (Barley).  
 OG Chloroplast.  
 OC Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;  
 OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
 OC Triticeae; Triticum.  
 OX NCBI\_TaxID=4565, 4513;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC SPECIES=T.aestivum;  
 RX MEDLINE=89028843; PubMed=3180271;  
 RA Bowman C.M., Barker R.F., Dyer T.A.;  
 RT "In wheat ctDNA, segments of ribosomal protein genes are dispersed  
 RT repeats, probably conserved by nonreciprocal recombination.";  
 RL Curr. Genet. 14:127-136(1988).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC SPECIES=H.vulgare; STRAIN=CV. HAISA;  
 RX MEDLINE=95086380; PubMed=7994178;  
 RA Hess W.R., Hoch B., Zeltz P., Huebschmann T., Koessel H.,  
 RA Boerner T.;  
 RT "Inefficient rpl2 splicing in barley mutants with ribosome-deficient  
 RT plastids.";  
 RL Plant Cell 6:1455-1465(1994).

CC -1- SIMILARITY: BELONGS TO THE L23P FAMILY OF RIBOSOMAL PROTEINS.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; X12850; CAA31328.1; -;  
 DR EMBL; X78185; CAA55027.1; -;  
 DR PIR; S06026; R5WT23.  
 DR InterPro; IPR001014; Ribosomal\_L23.  
 DR Pfam; PF00276; Ribosomal\_L23; 1.  
 DR ProDom; PD001141; Ribosomal\_L23; 1.  
 DR PROSITE; PS00050; Ribosomal\_L23; 1.  
 KW Ribosomal protein; Chloroplast; rRNA-binding.  
 SQ SEQUENCE 93 AA; 10746 MW; 1E747D893CF77562 CRC64;

Query Match 50.0%; Score 41; DB 1; Length 93;  
 Best Local Similarity 57.1%; Pred. No. 1.7;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;  
 QY 2 FGVKGTNNANLPL 15  
 DB 43 FGVKVVAVNSHRLP 56  
 ||||| ||::||

RESULT 9  
 YGGE.ECOLI  
 ID YGGE.ECOLI STANDARD; PRT; 246 AA.  
 AC P11668;  
 DT 01-OCT-1989 (Rel. 12, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE HYPOTHETICAL PROTEIN YGGE.  
 GN YGGE OR B2922 OR Z4259 OR ECS3793.  
 OS Escherichia coli, and  
 OS Escherichia coli O157:H7.  
 OC Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae;  
 OC Escherichia.  
 OX NCBI\_TaxID=562, 83334;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=K12 / MG1655;  
 RX MEDLINE=97426617; PubMed=9278503;  
 RA Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,  
 RA Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,  
 RA Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,  
 RA Mau B., Shao Y.;  
 RT "The complete genome sequence of Escherichia coli K-12.";  
 RL Science 277:1453-1474(1997).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=O157:H7 / EDL933 / ATCC 700927;  
 RX MEDLINE=21074935; PubMed=11206551;  
 RA Perna N.T., Plunkett G. III, Burland V., Mau B., Glasner J.D.,  
 RA Rose D.J., Mayhew G.F., Evans P.S., Gregor J., Kirkpatrick H.A.,  
 RA Postel G., Hackett J., Klink S., Boutin A., Shao Y., Miller L.,  
 RA Grobeck E.J., Davis N.W., Lim A., Dinalanta E.T., Potamoudis K.,  
 RA Apodaca T., Anantharaman T.S., Lin J., Yen G., Schwartz D.C.,  
 RA Welch R.A., Blattner F.R.;  
 RT "Genome sequence of enterohaemorrhagic Escherichia coli O157:H7.";  
 RL Nature 409:529-533(2001).

RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=O157:H7 / RIMD 0509952;  
 RX MEDLINE=21156231; PubMed=11258796;  
 RA Hayashi T., Makino K., Ohnishi M., Kurokawa K., Ishii K., Yokoyama K.,  
 RA Han C.-G., Ohnishi E., Nakayama K., Murata T., Tanaka M., Tohe T.,  
 RA Kida T., Takami H., Honda T., Sasaki C., Ogasawara N., Yasunaga T.,  
 RA Kuhara S., Shiba T., Hattori M., Shinagawa H.;  
 RT "Complete genome sequence of enterohaemorrhagic Escherichia coli  
 RT O157:H7 and genomic comparison with a laboratory strain K-12.";  
 RL DNA Res. 8:11-22(2001).  
 RN [4]  
 RP SEQUENCE OF 1-155 FROM N.A.  
 RC STRAIN=K12 / CS520;  
 RX MEDLINE=89313302; PubMed=2546007;  
 RA Alefounder P.R., Baldwin S.A., perham S.A., Short N.J.;  
 RT "Identification, molecular cloning and sequence analysis of a gene

RT cluster encoding the class II fructose 1,6-bisphosphate aldolase, 3-phosphoglycerate kinase and a putative second glyceraldehyde 3-phosphate dehydrogenase of *Escherichia coli*.";  
 RL Mol. Microbiol. 3:723-732(1989).  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; U28377; AAC69089.1;  
 DR EMBL; AF000375; AAC75959.1;  
 DR EMBL; AF005522; AAG58048.1;  
 DR EMBL; AP002563; BAB37216.1;  
 DR EMBL; X14436; CAA32608.1;  
 DR PIR; S04737; S04737.  
 DR EcoGene; EG11244; Y99E.  
 KW Hypothetical protein; Complete proteome.  
 SQ SEQUENCE 246 AA; 26635 MW; 92436CA0B3DFA891 CRC64;  
 CC -----  
 Query Match 48.8%; Score 40; DB 1; Length 246;  
 Best Local Similarity 53.8%; Pred. No. 7.3;  
 Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;  
 QY 3 GVKGTTVNANLP 15  
 | | | | |  
 DB 13 GISGMAAQANLP 25  
 -----  
 RESULT 10  
 DNBI\_HCMVA STANDARD; PRT; 1235 AA.  
 ID DNBI\_HCMVA  
 AC DNBI\_HCMVA  
 DT 01-AUG-1990 (Rel. 15, Created)  
 DT 01-AUG-1990 (Rel. 15, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR DNA-BINDING PROTEIN (MDBP).  
 GN 157 OR DBP.  
 OS Human cytomegalovirus (strain Ad169).  
 OC Viruses; GSDNA viruses, no RNA stage; Herpesviridae;  
 OC Betaherpesvirinae; Cytomegalovirus.  
 OX NCBI\_TaxID=10360;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=90269039; PubMed=2161319;  
 RA Chee M.S., Bankier A.T., Beck S., Bohni R., Brown C.M., Cerny R.,  
 RA Horsnell T., Hutchison C.A. III, Kouzarides T., Martignetti J.A.,  
 RA Reddick E., Satchwell S.C., Tomlinson P., Weston K.M., Barrell B.G.;  
 RT Analysis of the protein-coding content of the sequence of human  
 RT cytomegalovirus strain Ad169.";  
 RL Curr. Top. Microbiol. Immunol. 154:125-169(1990).  
 CC FUNCTION: SINGLE-STRAND DNA-BINDING PROTEIN REQUIRED FOR DNA  
 CC REPLICATION.  
 CC SUBCELLULAR LOCATION: NUCLEAR (PROBABLE).  
 CC SIMILARITY: BELONGS TO THE HERPESVIRUSES DNA-BINDING PROTEIN  
 CC FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; X17403; CAA35372.1;  
 DR PIR; S09820; Q0BEM4.  
 DR InterPro; IPR000635; Viral\_DNA\_bind.  
 DR Pfam; PF00747; Viral\_DNA\_bp. 1.

KW DNA-binding; DNA replication; Zinc-finger; Nuclear protein;  
 KW Early protein.  
 FT ZN\_FING 467 481 C2HC-TYPE.  
 SQ SEQUENCE 1235 AA; 133878 MW; 94E8D4F8D3BB2CB6 CRC64;  
 CC -----  
 Query Match 48.8%; Score 40; DB 1; Length 1235;  
 Best Local Similarity 52.6%; Pred. No. 40;  
 Matches 10; Conservative 0; Mismatches 3; Indels 6; Gaps 1;  
 QY 1 CFGVKVKT-----VNANE 13  
 | | | | |  
 DB 1191 CFGVPGTGGGFLVNAGE 1209  
 -----  
 RESULT 11  
 ATXL\_PLAFA STANDARD; PRT; 1956 AA.  
 ID ATXL\_PLAFA  
 AC Q04956;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE PROBABLE CATION-TRANSPORTING ATPASE 1 (EC 3.6.3.-).  
 OS Plasmodium falciparum.  
 OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.  
 OX NCBI\_TaxID=5833;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=T9/96;  
 RX MEDLINE=93132070; PubMed=8421054;  
 RA Krishna S., Cowan G., Meade J.C., Wells R.A., Stringer J.R.,  
 RA Robson K.J.;  
 RT "A family of cation ATPase-like molecules from Plasmodium  
 RT falciparum.";  
 RL J. Cell Biol. 120:385-398(1993).  
 CC CATALYTIC ACTIVITY: ATP + H(2)O = ADP + PHOSPHATE.  
 CC SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.  
 CC SIMILARITY: BELONGS TO THE CATION TRANSPORT ATPASES FAMILY (E1-E2  
 CC ATPASES). SUBFAMILY V.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; X65738; CAA46646.1;  
 DR InterPro; IPR001757; E1-E2\_ATPase.  
 DR Pfam; PF00122; E1-E2\_ATPase; 1.  
 DR PROSITE; PS00154; ATPASE\_E1\_E2; 1.  
 KW Hydrolase; Transmembrane; Phosphorylation; Magnesium; ATP-binding.  
 FT DOMAIN 1 35 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 36 58 EXTRACELLULAR (POTENTIAL).  
 FT DOMAIN 59 61 POTENTIAL.  
 FT TRANSMEM 62 80 POTENTIAL.  
 FT DOMAIN 81 407 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 408 427 POTENTIAL.  
 FT DOMAIN 428 440 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 441 462 POTENTIAL.  
 FT DOMAIN 463 1818 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 1819 1837 POTENTIAL.  
 FT DOMAIN 1838 1845 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 1846 1863 POTENTIAL.  
 FT DOMAIN 1864 1881 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 1882 1905 POTENTIAL.  
 FT DOMAIN 1906 1928 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 1929 1952 POTENTIAL.  
 FT DOMAIN 1953 1956 CYTOPLASMIC (POTENTIAL).  
 FT MOD\_RES 496 496 PHOSPHORYLATION (BY SIMILARITY).  
 FT METAL 1760 1760 MAGNESIUM (BY SIMILARITY).  
 FT METAL 1764 1764 MAGNESIUM (BY SIMILARITY).



FT DOMAIN 246 251 POLY-ASN.  
 FT DOMAIN 252 256 POLY-LYS.  
 FT DOMAIN 937 941 POLY-ASN.  
 FT DOMAIN 1344 1347 POLY-LYS.  
 FT DOMAIN 1363 1372 POLY-ASN.  
 FT DOMAIN 1680 1684 POLY-ASN.  
 SQ SEQUENCE 1956 AA; 230285 MW; AE708AAE99009335 CRC64;

Query Match 48.8%; Score 40; DB 1; Length 1956;  
 Best Local Similarity 53.8%; Pred. No. 65;  
 Matches 7; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 4 VKGTTVANEL 14  
 |||| :|:|:|  
 DB 263 VKGTIYNSDL 273

RESULT 12  
 YOG7\_CAEEL STANDARD; PRT; 3343 AA.  
 AC P34616;  
 DT 01-FEB-1994 (Rel. 28, Created)  
 DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE HYPOTHETICAL 375.7 KDA PROTEIN ZK112.7 IN CHROMOSOME III PRECURSOR.  
 GN ZK112.7.  
 OS Caenorhabditis elegans.  
 OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditidae;  
 OC Rhabditidae; Peloderinae; Caenorhabditis.  
 OX NCBI\_TaxID=6239;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=BRISTOL N2;  
 RX MEDLINE=94150718; PubMed=7906398;  
 RA Wilson R., Ainscough R., Anderson K., Baynes C., Berks M.,  
 RA Bonfield J., Burton J., Connell M., Copsey T., Cooper J., Coulson A.,  
 RA Craxton M., Dear S., Du Z., Durbin R., Favell A., Fraser A.,  
 RA Fulton L., Gardner A., Green P., Hawkins T., Hillier L., Jier M.,  
 RA Johnston L., Jones M., Kershaw J., Kirsten J., Laister N.,  
 RA Latreille P., Lightning J., Lloyd C., Mortimore B., O'Callaghan M.,  
 RA Parsons J., Percy C., Rifkin L., Roopra A., Saunders D., Showkeen R.,  
 RA Sims M., Smaldon N., Smith A., Smith M., Sonhammer E., Staden R.,  
 RA Sulston J., Thierry-Mieg J., Thomas K., Vaudin M., Vaughan K.,  
 RA Watson R., Watson A., Weinstock L., Wilkinson-Sproat J.,  
 RA Wohlsman P.;  
 RT \*2.2 Mb of contiguous nucleotide sequence from chromosome III of C.  
 RT elegans.;  
 RL Nature 368:32-38(1994).  
 CC -!- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN (POTENTIAL).  
 CC -!- SIMILARITY: CONTAINS 11 CADHERIN DOMAINS.  
 CC -!- SIMILARITY: CONTAINS 1 LAMININ G-LIKE DOMAIN.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: L14324; AAA28182.1;  
 DR PIR: S44887; S44887.  
 DR WormPep; ZK112.7; CE00378.  
 DR InterPro; IPR002126; Cadherin.  
 DR InterPro; IPR000561; EGF-like.  
 DR InterPro; IPR001791; Laminin.G.  
 DR Pfam; PF00028; cadherin; 11.  
 DR Pfam; PF00054; laminin.G; 1.  
 DR PRINTS; PR00205; CADHERIN.  
 DR SMART; SM00112; CA; 12.  
 DR SMART; SM00181; EGF; 1.  
 DR SMART; SM00282; LamG; 1.

DR PROSITE; PS00232; CADHERIN\_1; 8.  
 DR PROSITE; PS0268; CADHERIN\_2; 11.  
 DR PROSITE; PS01186; EGF\_2; UNKNOWN 1.  
 KW Hypothetical protein; Cell adhesion; Signal; Transmembrane;  
 KW Cytoskeleton; Glycoprotein; Calcium-binding; Repeat.  
 FT SIGNAL 1 26 POTENTIAL.  
 FT CHAIN 27 3343 HYPOTHETICAL PROTEIN ZK112.7.  
 FT DOMAIN 27 3228 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 3229 3250 POTENTIAL.  
 FT DOMAIN 3251 3343 CYTOPLASMIC (POTENTIAL).  
 FT DOMAIN 28 117 CADHERIN 1.  
 FT DOMAIN 118 229 CADHERIN 2.  
 FT DOMAIN 242 330 CADHERIN 3.  
 FT DOMAIN 632 738 CADHERIN 4.  
 FT DOMAIN 1279 1368 CADHERIN 5.  
 FT DOMAIN 1545 1648 CADHERIN 6.  
 FT DOMAIN 1676 1756 CADHERIN 7.  
 FT DOMAIN 1757 1857 CADHERIN 8.  
 FT DOMAIN 1954 2045 CADHERIN 9.  
 FT DOMAIN 2046 2145 CADHERIN 10.  
 FT DOMAIN 2146 2245 CADHERIN 11.  
 FT CARBOHYD 22 22 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 149 149 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 250 250 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 288 288 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 369 369 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 467 467 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 612 612 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 752 752 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 806 806 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 941 941 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 966 966 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 970 970 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 985 985 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1042 1042 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1335 1335 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1425 1425 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1429 1429 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1557 1557 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1563 1563 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1597 1597 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1624 1624 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1695 1695 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1702 1702 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1895 1895 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1900 1900 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2053 2053 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2129 2129 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2203 2203 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2382 2382 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2391 2391 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2410 2410 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2414 2414 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2431 2431 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2520 2520 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2530 2530 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2564 2564 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2621 2621 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2665 2665 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2712 2712 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2798 2798 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2809 2809 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2927 2927 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2976 2976 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 3045 3045 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 3222 3222 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 3225 3225 N-LINKED (GLCNAC... ) (POTENTIAL).  
 SQ SEQUENCE 3343 AA; 375745 MW; 063E6B17FCC15D18 CRC64;

Query Match 48.8%; Score 40; DB 1; Length 3343;  
 Best Local Similarity 50.0%; Pred. No. 11e+02;  
 Matches 7; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 2 FGKGTNNANL 15  
 ||:|:|:|:|:|  
 Db 229 FGIRSLTNWGLP 242

RESULT 13  
 TPB5\_BPT5 STANDARD; PRT; 640 AA.  
 AC P23207;  
 DT 01-NOV-1991 (Rel. 20, Created)  
 DT 01-NOV-1991 (Rel. 20, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE TAIL PROTEIN PB5.  
 GN OAD.  
 OS Bacteriophage T5.  
 OC Viruses; dsDNA viruses, no RNA stage; Tailed phages; Siphoviridae.  
 OX NCBI\_TaxID=10726;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=91123205; PubMed=1825083;  
 RA Krauel V., Heller K.J.;  
 RT "Cloning, sequencing, and recombinational analysis with bacteriophage  
 RT B23 of the bacteriophage T5 oad gene encoding the receptor-binding  
 RT protein.";  
 RL J. Bacteriol. 173:1287-1297(1991).  
 RN [2]  
 RP SEQUENCE OF 1-21 FROM N.A.  
 RX MEDLINE=94335651; PubMed=8057856;  
 RA Decker K., Krauel V., Meesmann A., Heller K.J.;  
 RT "Lytic conversion of Escherichia coli by bacteriophage T5: blocking  
 RT of the FhuA receptor protein by a lipoprotein expressed early during  
 RT infection.";  
 RL Mol. Microbiol. 12:321-332(1994).  
 CC -1- FUNCTION: STRUCTURAL COMPONENT OF THE TAIL. MEDIATES T5 BINDING TO  
 CC ITS HOST RECEPTOR, THE E-COLI FHUA PROTEIN.  
 CC -1- MISCELLANEOUS: ONLY SMALL REGIONS OF PB5 MAY BE INVOLVED IN  
 CC PROTEIN-PROTEIN INTERACTIONS IN THE TAIL STRUCTURE, THE MAJOR PART  
 CC BEING USED IN RECEPTOR BINDING.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC EMBL; M62847; AAA32559.1;  
 DR EMBL; X75922; CAA53526.1;  
 DR PIR; A38181; ZYBPT5.  
 KW Structural protein; Late protein.  
 SQ SEQUENCE 640 AA; 68756 MW; 7EE77F287D2C1DE3 CRC64;

Query Match 47.6%; Score 39; DB 1; Length 640;  
 Best Local Similarity 61.5%; Pred. No. 30;  
 Matches 8; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 2 FGKGTNNANL 14  
 |:|:|:|:|:|  
 Db 560 FTIRGTNNACKL 572

RESULT 14  
 PGLX\_ASPTU STANDARD; PRT; 435 AA.  
 AC Q00293;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE EXOPOLYGALACTURONASE PRECURSOR (EC 3.2.1.67) (EXOPG) (GALACTURAN 1,4-  
 DE ALPHA-GALACTURONIDASE) (POLY(1,4-ALPHA-D-

DE GALACTURONIDE)GALACTURONOHYDROLASE).  
 GN PGAX;  
 OS Aspergillus tubingensis.  
 OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;  
 OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.  
 OX NCBI\_TaxID=5068;  
 RN [1]  
 RP SEQUENCE FROM N.A., AND SEQUENCE OF 23-41; 172-191 AND 301-315.  
 RX MEDLINE=97008968; PubMed=8856078;  
 RA Kester H.C.M., Kusters-van Someren M.A., Mueller Y., Visser J.;  
 RT "Primary structure and characterization of an exopolysaccharuronase  
 RT from Aspergillus tubingensis.";  
 RL Eur. J. Biochem. 240:738-746(1996).  
 CC -1- FUNCTION: THE ACTIVITY OF THIS ENZYME IS OPTIMAL AT PH 4.2.  
 CC SPECIFIC IN HYDROLYZING THE TERMINAL GLYCOSIDIC BOND OF  
 CC POLYGALACTURONIC ACID AND OLIGOGALACTURONATES.  
 CC -1- CATALYTIC ACTIVITY: RANDOM HYDROLYSIS OF 1,4-ALPHA-D-  
 CC GALACTOSIDURONIC LINKAGES IN PECTATE AND OTHER GALACTURONANS.  
 CC -1- SUBCELLULAR LOCATION: SECRETED.  
 CC -1- SIMILARITY: BELONGS TO FAMILY 28 OF GLYCOSYL HYDROLASES  
 CC (POLYGALACTURONASES).  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC EMBL; X9795; CAA68128.1;  
 DR InterPro; IPR000743; Polygalacturonase.  
 DR Pfam; PF00295; Glyco\_hydro\_28; 1.  
 DR PROSITE; PS00502; POLYGALACTURONASE; 1.  
 KW Hydrolase; Glycosidase; Cell wall; Signal; Glycoprotein.  
 FT CHAIN 1 22  
 FT SIGNAL 23 435  
 FT ACT\_SITE 267 267  
 FT CARBOHYD 93 93  
 FT CARBOHYD 112 112  
 FT CARBOHYD 128 128  
 FT CARBOHYD 198 198  
 FT CARBOHYD 252 252  
 FT CARBOHYD 264 264  
 FT CARBOHYD 291 291  
 FT CARBOHYD 296 296  
 FT CARBOHYD 328 328  
 FT CARBOHYD 353 353  
 FT CARBOHYD 406 406  
 FT CARBOHYD 429 429  
 FT CONFLICT 25 25  
 FT CONFLICT 31 31  
 FT CONFLICT 41 41  
 FT SEQUENCE 435 AA; 47296 MW; C47CD97FCD1657C0 CRC64;  
 EXOPOLYGALACTURONASE.  
 PROBABLE.  
 N-LINKED (GLCNAC. .) (POTENTIAL).  
 N-LINKED (GLCNAC. .) (POTENTIAL).  
 N-LINKED (GLCNAC. .) (POTENTIAL).  
 N-LINKED (GLCNAC. .) (POTENTIAL).  
 N-LINKED (GLCNAC. .) (POTENTIAL).  
 N-LINKED (GLCNAC. .) (POTENTIAL).  
 N-LINKED (GLCNAC. .) (POTENTIAL).  
 N-LINKED (GLCNAC. .) (POTENTIAL).  
 N-LINKED (GLCNAC. .) (POTENTIAL).  
 N-LINKED (GLCNAC. .) (POTENTIAL).  
 N-LINKED (GLCNAC. .) (POTENTIAL).  
 R -> L (IN REF. 1; AA SEQUENCE).  
 C -> T (IN REF. 1; AA SEQUENCE).  
 P -> L (IN REF. 1; AA SEQUENCE).

Query Match 47.0%; Score 38.5; DB 1; Length 435;  
 Best Local Similarity 53.3%; Pred. No. 25;  
 Matches 8; Conservative 2; Mismatches 4; Indels 1; Gaps 1;

QY 1 CFGVKGITVNNANL 15  
 |:|:|:|:|:|  
 Db 348 CYGQKNTTL-CNEYP 361

RESULT 15  
 COX2\_THETH STANDARD; PRT; 168 AA.  
 ID COX2\_THETH  
 AC P98052;  
 DT 01-OCT-1996 (Rel. 34, Created)  
 DT 01-OCT-1996 (Rel. 34, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE CYTOCHROME C OXIDASE POLYPEPTIDE II (EC 1.9.3.1) (CYTOCHROME C BA(3)

Search completed: March 26, 2002, 13:40:44  
Job time: 258 sec

DE SUBUNIT II) (CYTOCHROME CBA3 SUBUNIT 2).  
GN CBAB OR CTAC.  
OS Thermus aquaticus (subsp. thermophilus).  
OC Bacteria; Thermus/Deinococcus group; Thermus group; Thermus.  
OX NCBI\_TaxID=274;  
RN [1]  
RP SEQUENCE FROM N.A., AND SEQUENCE OF 1-30.  
RC STRAIN=HB8 / ATCC 27634;  
RA MEDLINE=95386472; PubMed=7657607;  
RX Keightley J.A., Zimmermann B.H., Mather M.W., Springer P.,  
RA Pastuszyn A., Lawrence D.M., Fee J.A.;  
RT "Molecular genetic and protein chemical characterization of the  
cytochrome ba3 from Thermus thermophilus HB8.";  
RL J. Biol. Chem. 270:20345-20358(1995).  
RN [2]  
RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS).  
RX MEDLINE=99287095; PubMed=10360350;  
RA Williams P.A., Blackburn N.J., Sanders D., Bellamy H., Stura E.A.,  
RA Fee J.A., McRee D.E.;  
RT "The Cua domain of Thermus thermophilus ba3-type cytochrome c oxidase  
at 1.6-A resolution.";  
RL Nat. Struct. Biol. 6:509-516(1999).  
RN [3]  
RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).  
RC STRAIN=HB8 / ATCC 27634;  
RA MEDLINE=20237613; PubMed=10775261;  
RX Soulimane T., Buse G., Bourenkov G.P., Bartunik H.D., Huber R.,  
RA Than M.E.;  
RT "Structure and mechanism of the aberrant ba3-cytochrome c oxidase  
from Thermus thermophilus.";  
RL EMBO J. 19:1766-1776(2000).  
CC -1- FUNCTION: SUBUNIT I AND II FORM THE FUNCTIONAL CORE OF THE ENZYME  
COMPLEX. ELECTRONS ORIGINATING IN CYTOCHROME C ARE TRANSFERRED VIA  
HEME A AND CU(A) TO THE BINUCLEAR CENTER FORMED BY HEME A3 AND  
CU(B).  
CC -1- CATALYTIC ACTIVITY: 4 FERROCYTOCHROME C + O(2) = 2 H(2)O +  
4 FERRICYTOCHROME C.  
CC -1- SUBCELLULAR LOCATION: MEMBRANE-BOUND.  
CC -1- SIMILARITY: BELONGS TO THE CYTOCHROME C OXIDASE SUBUNIT 2 FAMILY.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; L09121; AAB00369.1; -  
DR PDB; 2CUA; 28-MAY-99.  
DR InterPro; IPR001505; COX2.  
DR ProDom; PD000131; COX2; 1.  
DR PROSITE; PS00078; COX2; 1.  
KW Oxidoreductase; Respiratory chain; Electron transport; Transmembrane;  
KW Copper; 3D-structure.  
FT DOMAIN 1 3 PERIPLASMIC (POTENTIAL).  
FT TRANSMEM 4 38  
FT DOMAIN 39 69 CYTOPLASMIC (POTENTIAL).  
FT METAL 114 114 COPPER A.  
FT METAL 149 149 COPPER A.  
FT METAL 153 153 COPPER A.  
FT METAL 157 157 COPPER A.  
SQ SEQUENCE 168 AA; 18563 MW; FE5689FB7672CF05 CRC64;

Query Match 46.3%; Score 38; DB 1; Length 168;  
Best Local Similarity 50.0%; Pred. No. 11;  
Matches 7; Conservative 2; Mismatches 5; Indels 0; Gaps 0;  
QY 2 FGVKGTNNANELP 15  
| | | | : | |  
DB 116 FHVEGTNNINVEVLP 129



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:38:46 ; Search time 81.51 Seconds  
(without alignments)  
13.631 Million cell updates/sec

Title: US-09-709-201-97

Perfect score: 82

Sequence: 1 CFGVGKGTIVNANELP 15

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A\_Geneseq\_1101.\*  
1: /SID88/gcgdata/geneseq/geneseq/AA1980.DAT.\*  
2: /SID88/gcgdata/geneseq/geneseq/AA1981.DAT.\*  
3: /SID88/gcgdata/geneseq/geneseq/AA1982.DAT.\*  
4: /SID88/gcgdata/geneseq/geneseq/AA1983.DAT.\*  
5: /SID88/gcgdata/geneseq/geneseq/AA1984.DAT.\*  
6: /SID88/gcgdata/geneseq/geneseq/AA1985.DAT.\*  
7: /SID88/gcgdata/geneseq/geneseq/AA1986.DAT.\*  
8: /SID88/gcgdata/geneseq/geneseq/AA1987.DAT.\*  
9: /SID88/gcgdata/geneseq/geneseq/AA1988.DAT.\*  
10: /SID88/gcgdata/geneseq/geneseq/AA1989.DAT.\*  
11: /SID88/gcgdata/geneseq/geneseq/AA1990.DAT.\*  
12: /SID88/gcgdata/geneseq/geneseq/AA1991.DAT.\*  
13: /SID88/gcgdata/geneseq/geneseq/AA1992.DAT.\*  
14: /SID88/gcgdata/geneseq/geneseq/AA1993.DAT.\*  
15: /SID88/gcgdata/geneseq/geneseq/AA1994.DAT.\*  
16: /SID88/gcgdata/geneseq/geneseq/AA1995.DAT.\*  
17: /SID88/gcgdata/geneseq/geneseq/AA1996.DAT.\*  
18: /SID88/gcgdata/geneseq/geneseq/AA1997.DAT.\*  
19: /SID88/gcgdata/geneseq/geneseq/AA1998.DAT.\*  
20: /SID88/gcgdata/geneseq/geneseq/AA1999.DAT.\*  
21: /SID88/gcgdata/geneseq/geneseq/AA2000.DAT.\*  
22: /SID88/gcgdata/geneseq/geneseq/AA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	82	100.0	15	AAW95324	Peptide fragment o
2	73	89.0	100	AAW95295	Chlamydia major o
3	73	89.0	343	AAV56771	C. trachomatis ser
4	67	81.7	391	AAV53119	Chlamydia pneumoni
5	61	74.4	20	AAW84463	Peptide Cp2A deriv
6	61	74.4	20	AAW84457	Peptide C.p.2A der
7	42	51.2	257	AAV30954	Arabidopsis thalia
8	42	51.2	365	AAV30953	Arabidopsis thalia
9	42	51.2	389	AAW98188	Chlamydia psittaci
10	42	51.2	455	AAV30952	Arabidopsis thalia
11	42	51.2	708	AAW74088	Human hPEPT1 prote

12	42	51.2	708	20	AAW74087	Gastro-intestinal
13	42	51.2	708	20	AAW83394	Human protein-coup
14	41	50.0	605	22	AAE04789	Lycopersicon escul
15	41	50.0	605	22	AAE72308	Neoxanthin cleavag
16	40	48.8	246	21	AAE15923	E. coli proliferat
17	39	47.6	352	20	AAV36781	Chlamydia trachoma
18	38.5	47.0	452	15	AAW59792	Aspergillus tubige
19	38	46.3	15	20	AAW95325	Peptide fragment o
20	38	46.3	146	22	AAV18041	Peptide #4475 enco
21	38	46.3	146	22	AAV30554	Peptide #4591 enco
22	38	46.3	146	22	AAW05680	Peptide #4362 enco
23	38	46.3	322	13	AAE24297	Glycopeptide resis
24	38	46.3	380	18	AAW09406	Transforming growt
25	38	46.3	395	20	AAV35621	Chlamydia pneumoni
26	38	46.3	989	20	AAV37242	Chlamydia trachoma
27	38	46.3	2408	13	AAE24307	Translation of ORF
28	37	45.1	89	18	AAW20662	H. pylori secreted
29	37	45.1	97	21	AAE16756	Bacteriophage Dp-1
30	37	45.1	98	18	AAW20457	H. pylori secreted
31	37	45.1	158	22	AAE76134	Human colon cancer
32	37	45.1	395	19	AAW98760	H. pylori GHPO 108
33	37	45.1	463	22	AAE90216	C glutamicum prote
34	37	45.1	469	12	AAE15510	Tomato ACC synthas
35	37	45.1	469	22	AAE00987	Tomato l-aminocycl
36	37	45.1	469	22	AAE59726	Tomato ACC synthas
37	37	45.1	583	22	AAE04782	Arabidopsis thalia
38	37	45.1	1073	21	AAE01837	Haemophilus influe
39	37	45.1	1079	21	AAE01836	Haemophilus influe
40	36.5	44.5	537	22	AAE05684	Arabidopsis thalia
41	36	43.9	54	13	AAE20077	Sequence encoded b
42	36	43.9	144	20	AAV08240	Human cadherin-4 p
43	36	43.9	144	21	AAE40800	zea mays protein f
44	36	43.9	147	21	AAE49588	Arabidopsis thalia
45	36	43.9	158	21	AAE49587	Arabidopsis thalia

#### ALIGNMENTS

RESULT 1  
AAW95324  
ID AAW95324 standard; Protein: 15 AA.  
XX  
AC AAW95324;  
XX  
DT 15-MAR-1999 (first entry)  
XX  
DE Peptide fragment of C. pneumoniae CPN1:8-171.  
XX  
KW Chlamydia; cryptic phase; elementary body phase; replicating; probenidicid;  
KW antiporphyrilic acid; immune response; infection; diagnostic; assay; MOMP;  
KW major outer membrane protein; autoimmune; inflammatory; porphyria;  
KW Epstein Barr virus; antioxidant.  
XX  
OS Chlamydia pneumoniae.  
XX  
PN WO9850074-A2.  
XX  
PD 12-NOV-1998.  
XX  
PF 06-MAY-1998; 98WO-US09237.  
XX  
PR 18-FEB-1998; 98US-0025521.  
XX  
PR 06-MAY-1997; 97US-0045889.  
XX  
PR 06-MAY-1997; 97US-0045739.  
XX  
PR 06-MAY-1997; 97US-0045779.  
XX  
PR 06-MAY-1997; 97US-0045780.  
XX  
PR 06-MAY-1997; 97US-0045784.  
XX  
PR 06-MAY-1997; 97US-0045787.  
XX  
PR 14-AUG-1997; 97US-0911593.  
XX  
PR 18-FEB-1998; 98US-0025174.  
XX  
PR 18-FEB-1998; 98US-0025176.

PA (UYVA-) UNIV VANDERBILT.  
 XX Mitchell WM, Stratton CW;  
 PI WPI; 1999-059653/05.  
 XX  
 XX Composition with two agents effective against different stages of  
 PT Chlamydial life cycle - comprises agent targetted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT probenicid and antiporphyrin  
 XX Claim 4; Fig 4; 138pp; English.  
 PS  
 XX The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targetted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targetted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targetted against replicating phase of chlamydial  
 CC life cycle; (d) probenicid, and (e) antiporphyrin acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Ebsstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AAW95324 to AAW95327 represent peptides  
 CC employed for the construction of peptide based ELISAs with species  
 CC specificity for variable domain 1 (VD1).  
 XX  
 SQ Sequence 15 AA;  
 Query Match 100.0%; Score 82; DB 20; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 2.7e-08;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CFGVKGTTVNANELP 15  
 Db 1 CFGVKGTTVNANELP 15  
 RESULT 2  
 AAW95295  
 ID AAW95295 standard; Protein: 100 AA.  
 AC AAW95295;  
 XX  
 XX 15-MAR-1999 (first entry)  
 DE Chlamydial major outer membrane protein (MOMP) PN fragment.  
 XX  
 XX Chlamydia; cryptic phase; elementary body phase; replicating; probenicid;  
 KW antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
 KW major outer membrane protein; autoimmune; inflammatory; porphyria,  
 KW Ebsstein Barr virus; antioxidant.  
 XX Chlamydia sp.  
 OS WO9850074-A2.  
 PN 12-NOV-1998.  
 PD 06-MAY-1998; 98WO-0509237.  
 PF

XX 18-FEB-1998; 98US-0025521.  
 PR 06-MAY-1997; 97US-0045689.  
 PR 06-MAY-1997; 97US-0045739.  
 PR 06-MAY-1997; 97US-0045779.  
 PR 06-MAY-1997; 97US-0045780.  
 PR 06-MAY-1997; 97US-0045784.  
 PR 06-MAY-1997; 97US-0045787.  
 PR 14-AUG-1997; 97US-0911593.  
 PR 18-FEB-1998; 98US-0025174.  
 PR 18-FEB-1998; 98US-0025176.  
 XX  
 PA (UYVA-) UNIV VANDERBILT.  
 XX Mitchell WM, Stratton CW;  
 PI WPI; 1999-059653/05.  
 XX  
 XX Composition with two agents effective against different stages of  
 PT Chlamydial life cycle - comprises agent targetted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT probenicid and antiporphyrin  
 XX Disclosure; Fig 1A; 138pp; English.  
 PS  
 XX The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targetted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targetted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targetted against replicating phase of chlamydial  
 CC life cycle; (d) probenicid, and (e) antiporphyrin acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Ebsstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AAW95272 to AAW95319 represent peptide  
 CC fragments of various Chlamydial MOMPs.  
 XX  
 SQ Sequence 100 AA;  
 Query Match 89.0%; Score 73; DB 20; Length 100;  
 Best Local Similarity 100.0%; Pred. No. 1e-05;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 2 FGKVGTTVNANELP 15  
 Db 62 FGKVGTTVNANELP 75  
 RESULT 3  
 AAY56771  
 ID AAY56771 standard; Protein: 343 AA.  
 AC AAY56771;  
 XX  
 XX 22-FEB-2000 (first entry)  
 DE C. trachomatis serovar HuPn MOMP sequence;  
 DE Major outer membrane protein; MOMP; Chlamydia; vaccine; immune response;  
 KW

KW cellular response; immunogen; Th1-like CD4 response; mucosal immunity.

OS Chlamydia trachomatis.

PN WO9951745-A2.

XX 14-OCT-1999.

XX 07-APR-1999; 99WO-CA00292.

XX 07-APR-1998; 98US-0055765.

XX (UYMA-) UNIV MANITOBA.

XX Bruhnam RC;

XX WPI; 1999-620205/53.

XX Non-replicating vector encoding fragments of the outer membrane protein  
PT of Chlamydia, useful in vaccines and as immunogen

XX Disclosure; Fig 10 A-F; 52pp; English.

XX The invention provides a non-replicating vector that comprises, linked  
CC to a promoter, a nucleotide sequence that encodes a region containing at  
CC least one of the conserved domains 2, 3 and 5 of a major outer membrane  
CC protein (MOMP) of a Chlamydia strain. The vector is used: (a) in  
CC vaccines to generate a protective immune response (mainly cellular)  
CC against MOMP, and (b) as immunogens to raise anti-MOMP antibodies, useful  
CC in standard immunoassays. Immunization with the vector induces a broad  
CC spectrum of immune responses, including Th1-like CD4 responses and  
CC mucosal immunity, providing significant protection against subsequent  
CC challenge. Sequences AAY56757-71 represent MOMP sequences from a variety  
CC of serovars of *C. trachomatis*.

XX Sequence 343 AA;

Query Match 89.0%; Score 73; DB 20; Length 343;

Best Local Similarity 100.0%; Pred. No. 4.1e-05;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FGVRGTTVNANELP 15

Db 158 fgvggtvnanelp 171

RESULT 4

AAAY35319  
ID AAY35319 standard; Protein; 391 AA.

XX AC AAY35319;

DT 13-SEP-1999 (first entry)

XX Chlamydia pneumoniae transmembrane protein sequence.

XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;  
KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis;  
KW vaccine; neutralising epitope.

XX Chlamydia pneumoniae.

XX WO9927105-A2.

XX 03-JUN-1999.

XX 20-NOV-1998; 98WO-IB01890.

XX 04-NOV-1998; 98US-0107078.

XX 21-NOV-1997; 97FR-0014673.

XX (GEST ) GENSET.

XX Griffais R;

XX WPI; 1999-357842/30.

XX Genome sequence of Chlamydia pneumoniae

XX Page 1130-1131; Disclosure; 1912pp; English.

XX AAY34584-Y35879 represent the proteins encoded by all the open reading  
CC frames in the complete genome (see AAX91990) of Chlamydia pneumoniae.  
CC C. pneumoniae causes respiratory disease such as pneumonia and  
CC bronchitis and is thought to be a contributing factor in heart  
CC disease, sarcoidosis, sinusitis, purulent otitis media, erythema  
CC nodosum or pharyngitis. The polypeptides encoded by the open reading  
CC frames of the C. pneumoniae genome (see AAY34584-Y35879) can be used in  
CC immunogenic compositions as vaccines. Vectors containing C. pneumoniae  
CC nucleotide sequences can also be used as immunogenic compositions,  
CC especially where the vector directs the expression of a neutralising  
CC epitope of C. pneumoniae.

XX Sequence 391 AA;

Query Match 81.7%; Score 67; DB 20; Length 391;

Best Local Similarity 92.9%; Pred. No. 0.00058;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 FGVRGTTVNANELP 15

Db 160 fgvggtvnanelp 173

RESULT 5

AAW84463  
ID AAW84463 standard; peptide; 20 AA.

XX AC AAW84463;

DT 23-MAR-1999 (first entry)

XX Peptide Cp2A derived from a major outer membrane protein.

XX Variable domain; major outer membrane protein; MOMP;

XX Chlamydia; detection; infection; vaccine.

XX Synthetic.

XX Chlamydia pneumoniae.

XX WO9857981-A2.

XX 23-DEC-1998.

XX 15-JUN-1998; 98WO-IL00277.

XX 19-JUN-1997; 97IL-0121114.

XX (SAVY-) SAVYON DIAGNOSTICS LTD.

XX Ohana B;

XX WPI; 1999-080945/07.

XX New peptides derived from Chlamydia pneumoniae MOMP protein - useful  
PT to detect C. pneumoniae infection

XX Claim 2; Page 53; 39pp; English.

XX The present peptide is derived from the variable domain of the  
CC major outer membrane protein (MOMP) of Chlamydia pneumoniae. The  
CC peptide is able to react with antibodies formed during C. pneumoniae  
CC infection and characterised by having essentially very low  
CC cross-reactivity towards antibodies against other Chlamydia species.

CC A mixture of such peptides (see also AAW84462-68) is used to detect  
 CC C. pneumoniae infection, and in the preparation of vaccines.

SQ Sequence 20 AA;

Query Match 74.4%; Score 61; DB 20; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 0.00024;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 VKGTTVNANELP 15  
 | | | | | | | | | |  
 Db 1 vkgttvanelp 12

RESULT 6

AAW84557  
 ID AAW84557 standard; peptide; 20 AA.

XX AC AAW84557;

XX DT 26-MAR-1999 (first entry)

XX DE Peptide C.p.2A derived from the major outer membrane protein.

XX KW Variable domain; immunodominant; major outer membrane protein; MOMP;  
 anti-MOMP antibody; Chlamydia; vaccine; C. trachomatis.

XX OS Chlamydia pneumoniae.

XX PN WO9900414-A1.

XX PD 07-JAN-1999.

XX PF 15-JUN-1998; 98WO-IL00276.

XX PR 19-JUN-1997; 97IL-0121115.

XX PA (SAVY-) SAVYON DIAGNOSTICS LTD.

XX PI Ohana B;

XX DR WPI; 1999-095677/08.

XX PT Chlamydia trachomatis specific peptides useful in diagnostic assays  
 PT - derived from major outer membrane protein variable domains and  
 PT useful in mixtures to detect infection with or immunise against all  
 PT serovars

XX PS Example 1; Page 24; 78pp; English.

XX CC The present sequence represents a peptide derived from variable  
 CC domain 2 (VDII) of the Chlamydia pneumoniae major outer membrane  
 CC protein (MOMP). The specification also describes C. trachomatis  
 CC MOMP derived peptides which have specificity only to C. trachomatis  
 CC anti-MOMP antibodies and are non-cross reactive with anti-MOMP  
 CC antibodies of other Chlamydia species. Such peptides are useful to  
 CC detect C. trachomatis infections in humans. Mixtures of MOMP peptide  
 CC mixtures allow detection of and vaccination against all C. trachomatis  
 CC serovars, which is not possible with existing MOMP-derived peptides  
 CC for C. trachomatis-specific detection.

XX SQ Sequence 20 AA;

Query Match 74.4%; Score 61; DB 20; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 0.00024;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 VKGTTVNANELP 15  
 | | | | | | | | | |  
 Db 1 vkgttvanelp 12

RESULT 7

AAG30954

ID AAG30954 standard; Protein; 257 AA.

XX AC AAG30954;

XX DT 17-OCT-2000 (first entry)

XX DE Arabidopsis thaliana protein fragment SEQ ID NO: 37095.

XX KW Protein identification; signal transduction pathway; metabolic pathway;  
 KW hybridisation assay; genetic mapping; gene expression control; promoter;  
 KW termination sequence.

XX OS Arabidopsis thaliana.

XX PN EP1033405-A2.

XX PD 06-SEP-2000.

XX PF 25-FEB-2000; 2000EP-0301439.

XX PR 25-FEB-1999; 99US-0121825.

XX PR 05-MAR-1999; 99US-0123180.

XX PR 09-MAR-1999; 99US-0123548.

XX PR 23-MAR-1999; 99US-0125788.

XX PR 25-MAR-1999; 99US-0126264.

XX PR 29-MAR-1999; 99US-0126785.

XX PR 01-APR-1999; 99US-0127462.

XX PR 06-APR-1999; 99US-0128234.

XX PR 08-APR-1999; 99US-0128714.

XX PR 16-APR-1999; 99US-0129845.

XX PR 19-APR-1999; 99US-0130077.

XX PR 21-APR-1999; 99US-0130449.

XX PR 23-APR-1999; 99US-0130510.

XX PR 28-APR-1999; 99US-0131449.

XX PR 30-APR-1999; 99US-0132048.

XX PR 30-APR-1999; 99US-0132407.

XX PR 04-MAY-1999; 99US-0132484.

XX PR 05-MAY-1999; 99US-0132485.

XX PR 06-MAY-1999; 99US-0132486.

XX PR 06-MAY-1999; 99US-0132487.

XX PR 07-MAY-1999; 99US-0132863.

XX PR 11-MAY-1999; 99US-0134256.

XX PR 14-MAY-1999; 99US-0134218.

XX PR 14-MAY-1999; 99US-0134219.

XX PR 14-MAY-1999; 99US-0134221.

XX PR 14-MAY-1999; 99US-0134370.

XX PR 18-MAY-1999; 99US-0134768.

XX PR 19-MAY-1999; 99US-0134941.

XX PR 20-MAY-1999; 99US-0135124.

XX PR 21-MAY-1999; 99US-0135353.

XX PR 24-MAY-1999; 99US-0135629.

XX PR 25-MAY-1999; 99US-0136021.

XX PR 27-MAY-1999; 99US-0136392.

XX PR 28-MAY-1999; 99US-0136782.

XX PR 01-JUN-1999; 99US-0137222.

XX PR 03-JUN-1999; 99US-0137528.

XX PR 04-JUN-1999; 99US-0137502.

XX PR 07-JUN-1999; 99US-0137724.

XX PR 08-JUN-1999; 99US-0138094.

XX PR 10-JUN-1999; 99US-0138540.

XX PR 10-JUN-1999; 99US-0138847.

XX PR 14-JUN-1999; 99US-0139119.

XX PR 16-JUN-1999; 99US-0139452.

XX PR 16-JUN-1999; 99US-0139453.

XX PR 17-JUN-1999; 99US-0139492.

XX PR 18-JUN-1999; 99US-0139454.

XX PR 18-JUN-1999; 99US-0139455.

XX PR 18-JUN-1999; 99US-0139456.

XX PR 18-JUN-1999; 99US-0139457.





DT	17-OCT-2000	(first entry)
XX	Arabidopsis thaliana	protein fragment SEQ ID NO: 37094.
DE	Protein identification; signal transduction pathway; metabolic pathway;	
XX	hybridisation assay; genetic mapping; gene expression control; promoter;	
KW	termination sequence.	
KW	Arabidopsis thaliana.	
XX	OS	
XX	EP1033405-A2.	
XX	06-SEP-2000.	
XX	25-FEB-2000;	2000EP-0301439.
XX	25-FEB-1999;	99US-0121825.
XX	05-MAR-1999;	99US-0123180.
XX	09-MAR-1999;	99US-0123548.
XX	23-MAR-1999;	99US-0125788.
XX	25-MAR-1999;	99US-0126264.
XX	29-MAR-1999;	99US-0126785.
XX	01-APR-1999;	99US-0127462.
XX	06-APR-1999;	99US-0128234.
XX	08-APR-1999;	99US-0128714.
XX	16-APR-1999;	99US-0129845.
XX	19-APR-1999;	99US-0130077.
XX	21-APR-1999;	99US-0130449.
XX	23-APR-1999;	99US-0130510.
XX	28-APR-1999;	99US-0130891.
XX	30-APR-1999;	99US-0131449.
XX	30-APR-1999;	99US-0132048.
XX	04-MAY-1999;	99US-0132407.
XX	05-MAY-1999;	99US-0132484.
XX	06-MAY-1999;	99US-0132485.
XX	07-MAY-1999;	99US-0132486.
XX	11-MAY-1999;	99US-0132863.
XX	16-MAY-1999;	99US-0134256.
XX	17-MAY-1999;	99US-0134218.
XX	18-MAY-1999;	99US-0134219.
XX	18-MAY-1999;	99US-0134221.
XX	18-MAY-1999;	99US-0134370.
XX	18-MAY-1999;	99US-0134768.
XX	19-MAY-1999;	99US-0134941.
XX	20-MAY-1999;	99US-0135124.
XX	21-MAY-1999;	99US-0135353.
XX	24-MAY-1999;	99US-0135629.
XX	25-MAY-1999;	99US-0136021.
XX	27-MAY-1999;	99US-0136392.
XX	28-MAY-1999;	99US-0136782.
XX	01-JUN-1999;	99US-0137222.
XX	03-JUN-1999;	99US-0137528.
XX	04-JUN-1999;	99US-0137502.
XX	07-JUN-1999;	99US-0137724.
XX	08-JUN-1999;	99US-0138094.
XX	10-JUN-1999;	99US-0138540.
XX	10-JUN-1999;	99US-0138847.
XX	14-JUN-1999;	99US-0139119.
XX	16-JUN-1999;	99US-0139452.
XX	16-JUN-1999;	99US-0139453.
XX	17-JUN-1999;	99US-0139492.
XX	18-JUN-1999;	99US-0139454.
XX	18-JUN-1999;	99US-0139455.
XX	18-JUN-1999;	99US-0139456.
XX	18-JUN-1999;	99US-0139457.
XX	18-JUN-1999;	99US-0139458.
XX	18-JUN-1999;	99US-0139459.
XX	18-JUN-1999;	99US-0139460.
XX	18-JUN-1999;	99US-0139461.
XX	18-JUN-1999;	99US-0139462.
XX	18-JUN-1999;	99US-0139463.
XX	18-JUN-1999;	99US-0139750.

PR 27-AUG-1999; 99US-0151066.  
PR 27-AUG-1999; 99US-0151080.  
PR 30-AUG-1999; 99US-0151303.  
PR 31-AUG-1999; 99US-0151438.  
PR 01-SEP-1999; 99US-0151930.  
PR 07-SEP-1999; 99US-0152363.  
PR 10-SEP-1999; 99US-0153070.  
PR 13-SEP-1999; 99US-0153758.  
PR 15-SEP-1999; 99US-0154018.  
PR 16-SEP-1999; 99US-0154039.  
PR 20-SEP-1999; 99US-0154779.  
PR 22-SEP-1999; 99US-0155139.  
PR 23-SEP-1999; 99US-0155486.  
PR 24-SEP-1999; 99US-0155659.  
PR 28-SEP-1999; 99US-0156458.  
PR 29-SEP-1999; 99US-0156596.  
PR 04-OCT-1999; 99US-0157117.  
PR 05-OCT-1999; 99US-0157753.  
PR 06-OCT-1999; 99US-0157865.  
PR 07-OCT-1999; 99US-0158029.  
PR 08-OCT-1999; 99US-0158232.  
PR 12-OCT-1999; 99US-0158369.  
PR 13-OCT-1999; 99US-0159293.  
PR 13-OCT-1999; 99US-0159294.  
PR 13-OCT-1999; 99US-0159295.  
PR 14-OCT-1999; 99US-0159329.  
PR 14-OCT-1999; 99US-0159330.  
PR 14-OCT-1999; 99US-0159331.  
PR 14-OCT-1999; 99US-0159637.  
PR 14-OCT-1999; 99US-0159638.  
PR 18-OCT-1999; 99US-0159584.  
PR 21-OCT-1999; 99US-0160741.  
PR 21-OCT-1999; 99US-0160767.  
PR 21-OCT-1999; 99US-0160768.  
PR 21-OCT-1999; 99US-0160770.  
PR 21-OCT-1999; 99US-0160814.  
PR 21-OCT-1999; 99US-0160815.  
PR 22-OCT-1999; 99US-0160980.  
PR 22-OCT-1999; 99US-0160981.  
PR 22-OCT-1999; 99US-0160989.  
PR 25-OCT-1999; 99US-0161404.  
PR 25-OCT-1999; 99US-0161405.  
PR 25-OCT-1999; 99US-0161406.  
PR 26-OCT-1999; 99US-0161359.  
PR 26-OCT-1999; 99US-0161360.  
PR 26-OCT-1999; 99US-0161361.  
PR 28-OCT-1999; 99US-0161920.  
PR 28-OCT-1999; 99US-0161922.  
PR 28-OCT-1999; 99US-0161993.  
PR 29-OCT-1999; 99US-0162142.

Query Match 51.2%; Score 42; DB 21; Length 365;  
Best Local Similarity 80.0%; Pred. No. 18;  
Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 CFGVKGTTVN 10  
| |||||  
Db 284 csqvkgtktn 293

RESULT 9  
AAW98188  
ID AAW98188 standard; Protein; 389 AA.  
XX  
AC AAW98188;

DT 05-JUL-1999 (first entry)  
XX  
XX Chlamydia psittaci major outer membrane protein.  
XX  
XX Major outer membrane protein; MOMP; psittacosis; infection;  
KW vaccine; genetic immunisation.  
XX

OS Chlamydia psittaci.  
XX  
PN WO9910005-A1.  
XX  
XX 04-MAR-1999.  
PD  
XX 28-AUG-1998; 98WO-US17943.  
XX  
XX 28-AUG-1997; 97US-0057147.  
XX  
XX (LOU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.  
XX  
XX Baghian A, Chouljenko VN, Kousoulas K3, Tully TN;  
XX  
XX WPI: 1999-254214/21.  
XX  
XX N-PSDB; AAX25047.  
XX  
XX A new vaccine for Chlamydia psittaci infections  
PT  
XX  
XX Disclosure; Page 60-61; 72pp; English.  
XX

XX The present sequence is the major outer membrane protein (MOMP)  
XX of Chlamydia psittaci strain B577. A claimed MOMP polypeptide (see  
XX AA98184) comprises regions VD3 and VD4 of B577 MOMP, i.e. it lacks  
XX regions VD1 and VD2. A claimed vaccine composition includes MOMP  
XX polypeptide lacking VD1 and VD2, optionally fused to a maltose  
XX binding protein. Also claimed are an isolated nucleic acid  
XX encoding the polypeptide, a vector, and a method of preventing C.  
XX psittaci infection by administering the vaccine containing the  
XX MOMP polypeptide. Vectors encoding MOMP polypeptides lacking the  
XX regions VD1 and VD2 are useful for genetic vaccination. The  
XX vaccines are used to prevent C. psittaci infection, especially in  
XX birds.  
XX

SQ Sequence 389 AA;

Query Match 51.2%; Score 42; DB 20; Length 389;  
Best Local Similarity 53.8%; Pred. No. 20;  
Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 3 GVKGTVMNANELP 15  
| |||::: |::|  
Db 159 gvkgsiaadqlp 171

RESULT 10  
AAG30952  
ID AAG30952 standard; Protein; 455 AA.  
XX  
XX AAG30952;

DT 17-OCT-2000 (first entry)  
XX  
XX Arabidopsis thaliana protein fragment 3EQ ID NO: 37093.

XX Protein identification; signal transduction pathway; metabolic pathway;  
KW hybridisation assay; genetic mapping; gene expression control; promoter;  
KW termination sequence.  
XX

OS Arabidopsis thaliana.  
XX  
XX EPI033405-A2.  
XX  
XX 06-SEP-2000.  
XX

XX 25-FEB-2000; 2000EP-0301439.  
XX  
XX 25-FEB-1999; 99US-0121825.  
PR 05-MAR-1999; 99US-0123180.  
PR 09-MAR-1999; 99US-0123548.  
PR 23-MAR-1999; 99US-0125788.  
PR 25-MAR-1999; 99US-0126264.

PR 29-MAR-1999; 99US-0126785.  
PR 01-APR-1999; 99US-0127462.  
PR 06-APR-1999; 99US-0128234.  
PR 08-APR-1999; 99US-0128714.  
PR 16-APR-1999; 99US-0129845.  
PR 19-APR-1999; 99US-0130077.  
PR 21-APR-1999; 99US-0130449.  
PR 23-APR-1999; 99US-0130510.  
PR 28-APR-1999; 99US-0130891.  
PR 30-APR-1999; 99US-0131449.  
PR 30-APR-1999; 99US-0132048.  
PR 04-MAY-1999; 99US-0132407.  
PR 05-MAY-1999; 99US-0132484.  
PR 06-MAY-1999; 99US-0132485.  
PR 07-MAY-1999; 99US-0132486.  
PR 11-MAY-1999; 99US-0132863.  
PR 14-MAY-1999; 99US-0134256.  
PR 14-MAY-1999; 99US-0134218.  
PR 14-MAY-1999; 99US-0134219.  
PR 14-MAY-1999; 99US-0134221.  
PR 16-MAY-1999; 99US-0134370.  
PR 16-MAY-1999; 99US-0134768.  
PR 16-MAY-1999; 99US-0134941.  
PR 20-MAY-1999; 99US-0135124.  
PR 20-MAY-1999; 99US-0135353.  
PR 20-MAY-1999; 99US-0135629.  
PR 25-MAY-1999; 99US-0136021.  
PR 27-MAY-1999; 99US-0136392.  
PR 28-MAY-1999; 99US-0136782.  
PR 01-JUN-1999; 99US-0137222.  
PR 03-JUN-1999; 99US-0137528.  
PR 04-JUN-1999; 99US-0137502.  
PR 07-JUN-1999; 99US-0137724.  
PR 08-JUN-1999; 99US-0138094.  
PR 10-JUN-1999; 99US-0138540.  
PR 10-JUN-1999; 99US-0138847.  
PR 14-JUN-1999; 99US-0139119.  
PR 16-JUN-1999; 99US-0139452.  
PR 16-JUN-1999; 99US-0139453.  
PR 17-JUN-1999; 99US-0139492.  
PR 18-JUN-1999; 99US-0139454.  
PR 18-JUN-1999; 99US-0139455.  
PR 18-JUN-1999; 99US-0139456.  
PR 18-JUN-1999; 99US-0139457.  
PR 18-JUN-1999; 99US-0139458.  
PR 18-JUN-1999; 99US-0139459.  
PR 18-JUN-1999; 99US-0139460.  
PR 18-JUN-1999; 99US-0139461.  
PR 18-JUN-1999; 99US-0139462.  
PR 18-JUN-1999; 99US-0139463.  
PR 18-JUN-1999; 99US-0139750.  
PR 18-JUN-1999; 99US-0139763.  
PR 20-JUN-1999; 99US-0139817.  
PR 22-JUN-1999; 99US-0139899.  
PR 23-JUN-1999; 99US-0140353.  
PR 23-JUN-1999; 99US-0140354.  
PR 24-JUN-1999; 99US-0140695.  
PR 26-JUN-1999; 99US-0140823.  
PR 26-JUN-1999; 99US-0140991.  
PR 30-JUN-1999; 99US-0141287.  
PR 01-JUL-1999; 99US-0141842.  
PR 01-JUL-1999; 99US-0142154.  
PR 02-JUL-1999; 99US-0142055.  
PR 06-JUL-1999; 99US-0142390.  
PR 08-JUL-1999; 99US-0142803.  
PR 09-JUL-1999; 99US-0142920.  
PR 12-JUL-1999; 99US-0142977.  
PR 13-JUL-1999; 99US-0143542.  
PR 14-JUL-1999; 99US-0143624.  
PR 15-JUL-1999; 99US-0144005.  
PR 16-JUL-1999; 99US-0144085.  
PR 16-JUL-1999; 99US-0144086.  
PR 19-JUL-1999; 99US-0144325.  
PR 19-JUL-1999; 99US-0144331.  
PR 19-JUL-1999; 99US-0144332.  
PR 19-JUL-1999; 99US-0144333.  
PR 19-JUL-1999; 99US-0144334.  
PR 19-JUL-1999; 99US-0144335.  
PR 20-JUL-1999; 99US-0144352.  
PR 20-JUL-1999; 99US-0144632.  
PR 20-JUL-1999; 99US-0144884.  
PR 21-JUL-1999; 99US-0144814.  
PR 21-JUL-1999; 99US-0145086.  
PR 21-JUL-1999; 99US-0145088.  
PR 22-JUL-1999; 99US-0145085.  
PR 22-JUL-1999; 99US-0145087.  
PR 22-JUL-1999; 99US-0145089.  
PR 22-JUL-1999; 99US-0145192.  
PR 23-JUL-1999; 99US-0145145.  
PR 23-JUL-1999; 99US-0145218.  
PR 23-JUL-1999; 99US-0145224.  
PR 26-JUL-1999; 99US-0145276.  
PR 27-JUL-1999; 99US-0145913.  
PR 27-JUL-1999; 99US-0145918.  
PR 27-JUL-1999; 99US-0145919.  
PR 28-JUL-1999; 99US-0145951.  
PR 02-AUG-1999; 99US-0146386.  
PR 02-AUG-1999; 99US-0146388.  
PR 02-AUG-1999; 99US-0146389.  
PR 03-AUG-1999; 99US-0147038.  
PR 04-AUG-1999; 99US-0147204.  
PR 04-AUG-1999; 99US-0147302.  
PR 05-AUG-1999; 99US-0147192.  
PR 05-AUG-1999; 99US-0147260.  
PR 06-AUG-1999; 99US-0147303.  
PR 06-AUG-1999; 99US-0147416.  
PR 09-AUG-1999; 99US-0147493.  
PR 09-AUG-1999; 99US-0147935.  
PR 10-AUG-1999; 99US-0148171.  
PR 11-AUG-1999; 99US-0148319.  
PR 12-AUG-1999; 99US-0148341.  
PR 13-AUG-1999; 99US-0148565.  
PR 13-AUG-1999; 99US-0148684.  
PR 16-AUG-1999; 99US-0149368.  
PR 17-AUG-1999; 99US-0149175.  
PR 18-AUG-1999; 99US-0149426.  
PR 20-AUG-1999; 99US-0149722.  
PR 20-AUG-1999; 99US-0149723.  
PR 23-AUG-1999; 99US-0149929.  
PR 23-AUG-1999; 99US-0149902.  
PR 25-AUG-1999; 99US-0149930.  
PR 26-AUG-1999; 99US-0150566.  
PR 27-AUG-1999; 99US-0150884.  
PR 27-AUG-1999; 99US-0151065.  
PR 27-AUG-1999; 99US-0151066.  
PR 27-AUG-1999; 99US-0151080.  
PR 30-AUG-1999; 99US-0151303.  
PR 31-AUG-1999; 99US-0151438.  
PR 01-SEP-1999; 99US-0151930.  
PR 07-SEP-1999; 99US-0153263.  
PR 10-SEP-1999; 99US-0153070.  
PR 13-SEP-1999; 99US-0153758.  
PR 15-SEP-1999; 99US-0154018.  
PR 16-SEP-1999; 99US-0154039.  
PR 20-SEP-1999; 99US-0154779.  
PR 22-SEP-1999; 99US-0155139.  
PR 23-SEP-1999; 99US-0155486.  
PR 24-SEP-1999; 99US-0155659.  
PR 28-SEP-1999; 99US-0156458.  
PR 29-SEP-1999; 99US-0156596.  
PR 04-OCT-1999; 99US-0157117.  
PR 05-OCT-1999; 99US-0157753.  
PR 06-OCT-1999; 99US-0157865.  
PR 07-OCT-1999; 99US-0158029.  
PR 08-OCT-1999; 99US-0158232.

PR 12-OCT-1999; 99US-0158369.  
 PR 13-OCT-1999; 99US-0159293.  
 PR 13-OCT-1999; 99US-0159294.  
 PR 13-OCT-1999; 99US-0159295.  
 PR 14-OCT-1999; 99US-0159329.  
 PR 14-OCT-1999; 99US-0159330.  
 PR 14-OCT-1999; 99US-0159331.  
 PR 14-OCT-1999; 99US-0159637.  
 PR 14-OCT-1999; 99US-0159638.  
 PR 18-OCT-1999; 99US-0159584.  
 PR 21-OCT-1999; 99US-0160741.  
 PR 21-OCT-1999; 99US-0160767.  
 PR 21-OCT-1999; 99US-0160768.  
 PR 21-OCT-1999; 99US-0160770.  
 PR 21-OCT-1999; 99US-0160814.  
 PR 21-OCT-1999; 99US-0160815.  
 PR 22-OCT-1999; 99US-0160980.  
 PR 22-OCT-1999; 99US-0160981.  
 PR 22-OCT-1999; 99US-0160989.  
 PR 25-OCT-1999; 99US-0161404.  
 PR 25-OCT-1999; 99US-0161405.  
 PR 25-OCT-1999; 99US-0161406.  
 PR 26-OCT-1999; 99US-0161359.  
 PR 26-OCT-1999; 99US-0161360.  
 PR 28-OCT-1999; 99US-0161361.  
 PR 28-OCT-1999; 99US-0161920.  
 PR 28-OCT-1999; 99US-0161992.  
 PR 28-OCT-1999; 99US-0161993.  
 PR 29-OCT-1999; 99US-0162142.

Query Match 51.2%; Score 42; DB 21; Length 455;  
 Best Local Similarity 80.0%; Pred. No. 23;  
 Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CFGVKGTNVN 10  
 | | | | | | | |  
 Db 374 csqvkgtvn 383

RESULT 11  
 AAW74088  
 ID AAW74088 standard; Protein; 708 AA.  
 AC AAW74088;  
 XX  
 XX 04-MAY-1999 (first entry)  
 DT  
 XX Human hPEPT1 protein.  
 DE

XX Gastro-intestinal transport receptor; binding protein; hSI; HPT1;  
 KW D2H; hPEPT1; human; GI tract receptor; sucrose-isomaltase complex;  
 KW intestinal peptide-associated transporter; hypertension; diabetes;  
 KW osteoporosis; haemophilia; anaemia; cancer; migraine; angina pectoris;  
 KW therapeutic agent delivery; therapy; probe.

XX Homo sapiens.  
 OS  
 XX WO9851325-A2.  
 PN  
 XX 19-NOV-1998.  
 PD  
 XX 15-MAY-1998; 98WO-US10088.  
 PF  
 XX 15-MAY-1997; 97US-0046595.  
 PR  
 XX (CYTO-) CYTOGEN CORP.  
 PA  
 XX (ELAN-) ELAN CORP PLC.

XX Alvarez VL, Belinka BA, Cagney GM, Carter JM, Lambkin IJ;  
 PI Omahony DJ, Patterson CA, Singleton J;  
 XX WPI; 1999-009568/01.  
 DR  
 XX

PT New proteins that bind specifically to receptors in the  
 PT gastro-intestinal tract and related nucleic acid - chimaeras and  
 PT antibodies, used to deliver therapeutic or diagnostic agents to, or  
 PT through, the gastrointestinal tract, e.g. insulin or leuprolide  
 XX  
 XX disclosure; Flg 1; 294pp; English.

XX This sequence is the human hPEPT1 protein. The invention relates to  
 CC purified proteins (I) that bind specifically to at least one of the  
 CC gastro-intestinal (GI) tract receptors human intestinal  
 CC peptide-associated transporter (HPT1), hPEPT1, D2H and human  
 CC sucrose-isomaltase complex (hSI). (I) provide active transport of  
 CC therapeutic agents through human and animal GI tissue (into the blood)  
 CC for in vivo delivery, particularly for treatment or prevention  
 CC of hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer,  
 CC migraine, or angina pectoris. Specifically they are used to deliver  
 CC insulin or leuprolide, but many other suitable therapeutic agents are  
 CC disclosed, including genes or inhibitory nucleic acid, imaging agents and  
 CC antigens. (I) may also provide targeting to the GI tract. Other uses of  
 CC (I) are: (i) to determine the level of specified receptors in a sample  
 CC (in a binding assay); and (ii) to screen for molecules that bind (I).  
 CC immunogenic analogues or derivatives of (I) are used to raise antibodies  
 CC and in immunoassays. The antibodies are used to locate, detect and  
 CC measure (I), e.g. for imaging, monitoring treatment, tissue analysis  
 CC etc., also for peptide purification and immobilisation.

XX Sequence 708 AA;

Query Match 51.2%; Score 42; DB 20; Length 708;  
 Best Local Similarity 46.2%; Pred. No. 39;  
 Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3 GVKGTNVNANELP 15  
 | | | | | | | | | |  
 Db 524 gikgftissteip 536

RESULT 12  
 AAW74087  
 ID AAW74087 standard; peptide; 708 AA.  
 XX  
 AC AAW74087;  
 XX  
 XX 04-MAY-1999 (first entry)  
 DT  
 XX Gastro-intestinal transport receptor binding protein.

XX Gastro-intestinal transport receptor; binding protein; hSI; HPT1;  
 KW D2H; hPEPT1; human; GI tract receptor; sucrose-isomaltase complex;  
 KW intestinal peptide-associated transporter; hypertension; diabetes;  
 KW osteoporosis; haemophilia; anaemia; cancer; migraine; angina pectoris;  
 KW therapeutic agent delivery; therapy.

XX Homo sapiens.  
 OS  
 XX WO9851325-A2.  
 PN  
 XX 19-NOV-1998.  
 PD  
 XX 15-MAY-1998; 98WO-US10088.  
 PF  
 XX 15-MAY-1997; 97US-0046595.  
 PR  
 XX (CYTO-) CYTOGEN CORP.  
 PA  
 XX (ELAN-) ELAN CORP PLC.

XX Alvarez VL, Belinka BA, Cagney GM, Carter JM, Lambkin IJ;  
 PI Omahony DJ, Patterson CA, Singleton J;  
 XX WPI; 1999-009568/01.  
 DR  
 XX

PT New proteins that bind specifically to receptors in the

gastro-intestinal tract and related nucleic acid - chimaeras and antibodies, used to deliver therapeutic or diagnostic agents to, or through, the gastrointestinal tract, e.g. insulin or leuprolide

Claim 48; Page 163-164; 294pp; English.

The invention relates to purified proteins (I) that bind specifically to at least one of the gastro-intestinal (GI) tract receptors human intestinal peptide-associated transporter (hPIT1), hPIT1, D2H and human sucrose-isomaltase complex (hSI). (I) provide active transport of therapeutic agents through human and animal GI tissue (into the blood) for in vivo delivery, particularly for treatment or prevention of hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, or angina pectoris. Specifically they are used to deliver insulin or leuprolide, but many other suitable therapeutic agents are disclosed, including genes or inhibitory nucleic acid, imaging agents and antigens. (I) may also provide targeting to the GI tract. Other uses of (I) are: (i) to determine the level of specified receptors in a sample (in a binding assay); and (ii) to screen for molecules that bind (I). Immunogenic analogues or derivatives of (I) are used to raise antibodies and in immunoassays. The antibodies are used to locate, detect and measure (I), e.g. for imaging, monitoring treatment, tissue analysis etc., also for peptide purification and immobilisation.

Note: This sequence is claimed as being a nucleotide sequence.

Sequence 708 AA;

Query Match 51.2%; Score 42; DB 20; Length 708;  
Best Local Similarity 46.2%; Pred. No. 39;  
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3 GVKGTTVNANELP 15  
I:|I| |::: |I|  
Db 524 gikgtfisstelp 536

#### RESULT 13

AAW83394  
ID AAW83394 standard; Protein; 708 AA.

AC AAW83394;

DT 23-FEB-1999 (first entry)

DE Human protein-coupled peptide transporter.

KW Human; protein-coupled peptide transporter; cell membrane;  
KW blood-brain barrier; transportation.

OS Homo sapiens.

PN US5849525-A.

PD 15-DEC-1998.

PF 21-DEC-1995; 95US-0576165.

PR 09-MAR-1994; 94US-0208645.

PR 21-DEC-1995; 95US-0576165.

PA (BGHM ) BRIGHAM & WOMENS HOSPITAL.

PI Hediger M;

DR WPI; 1999-069726/06.

DR N-PSDB; AAV72892.

XX Nucleic acid encoding proton-coupled peptide transporter - providing  
PT transport of peptides, their mimetics and drugs coupled to peptides  
PT across cell membranes, including the blood-brain barrier

XX Claim 2; Fig 2; 29pp; English.

XX

CC The present sequence represents human proton-coupled peptide transporter  
CC (PCPT). Transporting cells with a nucleic acid molecule encoding PCPT  
CC allows transport of peptides or their mimics across a cellular membrane.  
CC Any di- or tri-peptide (and structurally similar compounds such as  
CC beta-lactam antibiotics) can be transported into cells of the  
CC gastrointestinal tract, brain, the blood-brain barrier, kidney and  
CC liver. Chemicals (particularly therapeutic agents) can be coupled to  
CC the peptides for delivery across membranes (with subsequent release of  
CC active drug by enzymatic hydrolysis). Sequences antisense to the nucleic  
CC acid molecule encoding PCPT may be used to inhibit PCPT expression.

XX Sequence 708 AA;

Query Match 51.2%; Score 42; DB 20; Length 708;  
Best Local Similarity 46.2%; Pred. No. 39;  
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3 GVKGTTVNANELP 15  
I:|I| |::: |I|  
Db 524 gikgtfisstelp 536

#### RESULT 14

AAE04789  
ID AAE04789 standard; Protein; 605 AA.

AC AAE04789;

DT 10-SEP-2001 (first entry)

DE Lycopersicon esculentum neoxanthin cleavage enzyme, LENCED1.

XX Tomato; neoxanthin cleavage enzyme; LENCED1; abscisic acid; ABA;  
KW stress tolerance; transgenic plant; plant breeding; antisense-therapy;  
KW plant growth protectant; herbicide.

OS Lycopersicon esculentum.

PN EP1116794-A2.

PD 18-JUL-2001.

PF 11-JAN-2001; 2001EP-0300218.

PR 13-JAN-2000; 2000JP-0010056.

PR 11-JAN-2001; 2001JP-0003476.

XX (RIKE ) RIKEN KK.

PI Tuchi S, Kobayashi M, Shinozaki K;

DR WPI; 2001-400081/43.

DR N-PSDB; AAD09401.

XX A DNA encoding a protein with a neoxanthin cleavage activity for  
PT producing transgenic plants with improved or decreased stress tolerance

PS Claim 3; Fig 2; 101pp; English.

XX The invention relates to neoxanthin cleavage enzymes and their  
CC corresponding cDNA molecules. Neoxanthin cleavage enzyme plays a key  
CC role in endogenous abscisic acid (ABA) biosynthesis under drought stress.  
CC Neoxanthin cleavage enzyme is used for improving stress tolerance in a  
CC plant when expressed in a plant cell. The invention also relates to  
CC methods for increasing or decreasing stress tolerance in a plant by  
CC introducing the DNA into the plant, and a transgenic plant into which a  
CC neoxanthin cleavage enzyme is introduced. The improvement of stress  
CC tolerance in plants is useful, for example in plant breeding. Neoxanthin  
CC cleavage enzyme genes are useful for producing transgenic plants. An arid  
CC land can be improved by growing transformant weed for several years and

CC then removing the weed by specifically lowering stress tolerance in the  
 CC weed by inducing an inducible promoter. The present sequence is  
 CC Lycopersicon esculentum neoxanthin cleavage enzyme, LeNCEd1 protein  
 CC related to the invention.

XX SQ Sequence 605 AA;

Query Match 50.0%; Score 41; DB 22; Length 605;  
 Best Local Similarity 53.8%; Pred. No. 49;  
 Matches 7; Conservative 3; Mismatches 3; Indels 0; Gaps 0;  
 QY 2 FGKGGTTVNANEL 14  
 :| || :|||:  
 Db 589 ygfhtfinandl 601

# RESULT 15

AAB72308  
 ID AAB72308 standard; Protein; 605 AA.

AC AAB72308;

DT 16-MAY-2001 (first entry)

DE Neoxanthin cleavage enzyme-like protein amino acid sequence.

KW Defence-related signalling gene; sunflower; neoxanthin cleavage enzyme;  
 NCE; amino acid permease; AAP; glutamic acid rich protein; GRP;  
 KW pathogen resistance; abscisic acid metabolism.

XX Lycopersicon esculentum.

OS W0200112801-A2.

PN 22-FEB-2001.

XX 17-AUG-2000; 2000WO-US22961.

XX 18-AUG-1999; 99US-0149656.

PR 23-MAY-2000; 2000US-0206405.

XX (PION-) PIONEER HI-BRED INT INC.

PA (CURA-) CURAGEN CORP.

XX Bidney DL, Crasta OR, Hu X, Lu G;

XX WPI; 2001-211215/21.

XX Novel isolated defence-related signalling gene isolated from sunflower  
 PT encoding neoxanthin cleavage enzyme, amino acid permease or glutamic  
 PT acid-rich protein useful for increasing resistance of plant to a  
 PT pathogen

XX Disclosure; Fig 1; 135pp; English.

XX This invention relates to defence-related signalling genes isolated from  
 CC the sunflower (*Helianthus annuus*). The genes encode a neoxanthin cleavage  
 CC enzyme (NCE), an amino acid permease (AAP) and a glutamic acid rich  
 CC protein (GRP). The signalling gene is useful for increasing the  
 CC resistance of a plant to a pathogen such as fungus, virus, bacterium,  
 CC nematode or insect (e.g. European corn borer), preferably  
 CC *Sclerotinia* spp., *Phoma* spp. or *Phomopsis* spp. by stably incorporating a  
 CC construct containing the gene into the genome of the plant. The gene is  
 CC useful for regulating gene expression in a plant, in response to a  
 CC stimulus such as infection with a pathogen, damage from a pathogen,  
 CC hydrogen peroxide, jasmonic acid, methyl jasmonate, salicylic acid,  
 CC oxalic acid or expression of a gene encoding oxalic acid oxidase. The  
 CC genes are also useful for stem-preferred regulation of gene expression in  
 CC a plant. The genes are useful in agriculture, particularly in the  
 CC breeding of crop plants with improved agronomic traits, for modifying  
 CC abscisic acid (ABA) metabolism and for modifying amino acid transport and  
 CC content in plants. The present sequence represents a neoxanthin cleavage

CC enzyme-like protein from Lycopersicon esculentum used in the  
 CC characterisation of sunflower NCE.

XX SQ Sequence 605 AA;

Query Match 50.0%; Score 41; DB 22; Length 605;  
 Best Local Similarity 53.8%; Pred. No. 49;  
 Matches 7; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 2 FGKGGTTVNANEL 14  
 :| || :|||:  
 Db 589 ygfhtfinandl 601

Search completed: March 26, 2002, 13:38:47  
 Job time: 141 sec





GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:41:27 ; Search time 37.72 Seconds  
(without alignments)  
8.949 Million cell updates/sec

Title: US-09-709-201-97

Perfect score: 82  
Sequence: 1 CFGVKGTTVNANL 15

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 212252 seqs, 22503292 residues

Total number of hits satisfying chosen parameters: 212252

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued\_Patents\_AA:\*

- 1: /cgn2\_6/prodata/2/1aa/5A\_COMB.pep:\*
- 2: /cgn2\_6/prodata/2/1aa/5B\_COMB.pep:\*
- 3: /cgn2\_6/prodata/2/1aa/6A\_COMB.pep:\*
- 4: /cgn2\_6/prodata/2/1aa/6B\_COMB.pep:\*
- 5: /cgn2\_6/prodata/2/1aa/6C\_COMB.pep:\*
- 6: /cgn2\_6/prodata/2/1aa/backfiles1.pep:\*

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	42	51.2	708	US-08-576-165-2	Sequence 2, Appli
2	38.5	47.0	452	US-08-290-978A-5	Sequence 5, Appli
3	38.5	47.0	452	US-08-780-869-5	Sequence 5, Appli
4	38	46.3	322	US-08-286-819A-2	Sequence 2, Appli
5	38	46.3	322	US-08-980-357-2	Sequence 2, Appli
6	38	46.3	380	US-08-468-846-2	Sequence 2, Appli
7	38	46.3	380	US-08-915-096A-2	Sequence 2, Appli
8	38	46.3	2291	US-08-286-819A-29	Sequence 29, Appli
9	38	46.3	2291	US-08-980-357-29	Sequence 29, Appli
10	37	45.1	469	US-08-378-313-33	Sequence 33, Appli
11	36	43.9	916	US-08-188-228-48	Sequence 48, Appli
12	36	43.9	916	US-08-332-643-42	Sequence 42, Appli
13	36	43.9	916	US-08-332-638-48	Sequence 48, Appli
14	35.5	43.3	185	US-08-463-911-3	Sequence 3, Appli
15	35.5	43.3	236	US-09-140-804-6	Sequence 6, Appli
16	35	42.7	664	US-08-421-661-6	Sequence 1, Appli
17	35	42.7	992	US-08-890-865A-1	Sequence 2, Appli
18	34.5	42.1	200	US-09-282-146-2	Sequence 2, Appli
19	34	41.5	121	US-08-560-003-8	Sequence 8, Appli
20	34	41.5	121	US-09-418-540-8	Sequence 8, Appli
21	34	41.5	263	US-08-776-059-43	Sequence 43, Appli
22	34	41.5	264	US-08-776-059-33	Sequence 33, Appli
23	34	41.5	564	US-08-776-059-35	Sequence 35, Appli
24	34	41.5	953	US-08-500-857A-2	Sequence 2, Appli
25	34	41.5	1147	US-08-131-365B-38	Sequence 38, Appli
26	34	41.5	1147	US-08-668-123-38	Sequence 38, Appli
27	34	41.5	1297	US-09-540-245A-17	Sequence 17, Appli

28	34	41.5	2556	1	US-08-185-432-17	Sequence 17, Appli
29	34	41.5	2556	1	US-08-083-590A-20	Sequence 20, Appli
30	34	41.5	2556	3	US-08-532-384-20	Sequence 20, Appli
31	33.5	40.9	559	1	US-08-030-096-6	Sequence 6, Appli
32	33	40.2	31	2	US-08-023-980B-30	Sequence 30, Appli
33	33	40.2	31	2	US-08-486-933A-25	Sequence 25, Appli
34	33	40.2	79	1	US-08-154-916-12	Sequence 12, Appli
35	33	40.2	151	2	US-08-722-050-8	Sequence 8, Appli
36	33	40.2	237	4	US-08-861-774E-68	Sequence 68, Appli
37	33	40.2	317	6	5340934-11	Patent No. 5340934
38	33	40.2	369	1	US-07-854-596B-31	Sequence 31, Appli
39	33	40.2	385	2	US-08-892-715-2	Sequence 2, Appli
40	33	40.2	385	2	US-09-145-917-2	Sequence 2, Appli
41	33	40.2	403	2	US-08-533-659A-10	Sequence 10, Appli
42	33	40.2	403	2	US-08-607-509-2	Sequence 2, Appli
43	33	40.2	403	2	US-08-454-036-2	Sequence 2, Appli
44	33	40.2	403	2	US-08-634-612-2	Sequence 2, Appli
45	33	40.2	403	3	US-08-639-370-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1  
US-08-576-165-2  
; Sequence 2, Application US/08576165  
; Patent No. 5849525  
; GENERAL INFORMATION:  
; APPLICANT: HEDIGER, MATTHIAS  
; TITLE OF INVENTION: COMPOSITIONS CORRESPONDING TO A  
; TITLE OF INVENTION: PROTON-COUPLED PEPTIDE TRANSPORTER AND METHODS OF MAKING  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESSES:  
; ADDRESSEE: WOLF, GREENFIELD & SACKS, P.C.  
; STREET: 600 ATLANTIC AVENUE  
; CITY: BOSTON  
; STATE: MASSACHUSETTS  
; COUNTRY: USA  
; ZIP: 02210  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: IBM PC compatible  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/576,165  
; FILING DATE:  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/208,645  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: JANIUK, ANTHONY J.  
; REGISTRATION NUMBER: 29,809  
; REFERENCE/DOCKET NUMBER: B0801/7022  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-720-3500  
; TELEFAX: 617-720-2441  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 708 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-576-165-2

Query Match 51.2%; Score 42; DB 2; Length 708;  
Best Local Similarity 46.2%; Pred. No.: 11;  
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
QY 3 GVKGTTVNANL 15

Db 524 GIKGFTISSTEIP 536

## RESULT 2

US-08-290-978A-5  
; Sequence 5, Application US/08290978A  
; Patent No. 5624834  
; GENERAL INFORMATION:  
; APPLICANT: KUSTERS-VAN SOMEREN, MARGO A.  
; APPLICANT: MULLER, YVONNE  
; APPLICANT: KESTER, HERMANUS C.M.  
; APPLICANT: VISSER, JACOB  
; APPLICANT: VAN COYEN, ALBERT J.J.  
; APPLICANT: ROLIN, CLAUD  
; TITLE OF INVENTION: CLONING AND EXPRESSION OF THE  
; TITLE OF INVENTION: EXO-POLYGALACTURONASE GENE FROM ASPERGILLUS  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: MORRISON & FOERSTER  
; STREET: 2000 Pennsylvania Avenue N.W.  
; CITY: Washington  
; STATE: DC  
; COUNTRY: USA  
; ZIP: 20006-1812  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/290,978A  
; FILING DATE: 17-OCT-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 435  
; FILING DATE: 17-OCT-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: MURASHIGE, KATE H.  
; REGISTRATION NUMBER: 29,959  
; REFERENCE/DOCKET NUMBER: 4615-0044.00  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 887-1500  
; TELEFAX: (202) 887-0763  
; TELEX: 90-4030  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 452 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-290-978A-5

Query Match 47.0%; Score 38.5; DB 1; Length 452;  
Best Local Similarity 53.3%; Pred. No. 30;  
Matches 8; Conservative 2; Mismatches 4; Indels 1; Gaps 1;  
QY 1 CFGVKGTIVNANLP 15  
Db 365 CYGQKNTTL-CNEYP 378  
RESULT 3  
US-08-780-869-5  
; Sequence 5, Application US/08780869  
; Patent No. 5830737  
; GENERAL INFORMATION:  
; APPLICANT: KUSTERS-VAN SOMEREN, MARGO A.  
; APPLICANT: MULLER, YVONNE  
; APPLICANT: KESTER, HERMANUS C.M.  
; APPLICANT: VISSER, JACOB  
; APPLICANT: VAN COYEN, ALBERT J.J.  
; APPLICANT: ROLIN, CLAUD  
; TITLE OF INVENTION: CLONING AND EXPRESSION OF THE  
; TITLE OF INVENTION: EXO-POLYGALACTURONASE GENE FROM ASPERGILLUS

NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: MORRISON & FOERSTER  
; STREET: 2000 Pennsylvania Avenue N.W.  
; CITY: Washington  
; STATE: DC  
; COUNTRY: USA  
; ZIP: 20006-1812  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/780,869  
; FILING DATE: 24-JAN-1997  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/290,978  
; FILING DATE: 17-OCT-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: MURASHIGE, KATE H.  
; REGISTRATION NUMBER: 29,959  
; REFERENCE/DOCKET NUMBER: 4615-0044.00  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 887-1500  
; TELEFAX: (202) 887-0763  
; TELEX: 90-4030  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 452 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-780-869-5

Query Match 47.0%; Score 38.5; DB 2; Length 452;  
Best Local Similarity 53.3%; Pred. No. 30;  
Matches 8; Conservative 2; Mismatches 4; Indels 1; Gaps 1;  
QY 1 CFGVKGTIVNANLP 15  
Db 365 CYGQKNTTL-CNEYP 378  
RESULT 4  
US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; ADDRESSEE: P.C.  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; ADDRESSEE: P.C.  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; ADDRESSEE: P.C.  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; ADDRESSEE: P.C.  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; ADDRESSEE: P.C.  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; ADDRESSEE: P.C.  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; ADDRESSEE: P.C.  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/286,819A  
;; FILING DATE: 05-AUG-1994  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/174,682  
;; FILING DATE: 28-DEC-1993  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/917,146  
;; FILING DATE: 10-AUG-1992  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: PCT/FR/91/00855  
;; FILING DATE: 29-OCT-1991  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: FR 9013579  
;; FILING DATE: 31-OCT-1990  
;; CLASSIFICATION: 435  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Oblon, No. 5871910man F.  
;; REGISTRATION NUMBER: 24,618  
;; REFERENCE/DOCKET NUMBER: 560-060-0 PCT  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (703) 413-3000  
;; TELEFAX: (703) 413-2220  
;; TELEX: 248855 OPAT UR  
;; INFORMATION FOR SEQ ID NO: 2:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 322 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; US-08-286-819A-2

Query Match 46.3%; Score 38; DB 2; Length 322;  
Best Local Similarity 63.6%; Pred. No. 24;  
Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 2 FGVKGTTVNAN 12  
||| | :|||  
Db 26 FGVMTATINAN 36

RESULT 5  
US-08-980-357-2  
; Sequence 2, Application US/08980357  
; Patent No. 6013508  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPEPTIDES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; ADDRESSEE: P.C.  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:

;; APPLICATION NUMBER: US/08/980,357  
;; FILING DATE:  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/286,819  
;; FILING DATE: 05-AUG-1994  
;; APPLICATION NUMBER: US 08/174,682  
;; FILING DATE: 28-DEC-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/917,146  
;; FILING DATE: 10-AUG-1992  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: PCT/FR/91/00855  
;; FILING DATE: 29-OCT-1991  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: FR 9013579  
;; FILING DATE: 31-OCT-1990  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Oblon, No. 6013508man F.  
;; REGISTRATION NUMBER: 24,618  
;; REFERENCE/DOCKET NUMBER: 560-060-0 PCT  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (703) 413-3000  
;; TELEFAX: (703) 413-2220  
;; TELEX: 248855 OPAT UR  
;; INFORMATION FOR SEQ ID NO: 2:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 322 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; US-08-980-357-2

Query Match 46.3%; Score 38; DB 3; Length 322;  
Best Local Similarity 63.6%; Pred. No. 24;  
Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 2 FGVKGTTVNAN 12  
||| | :|||  
Db 26 FGVMTATINAN 36

RESULT 6  
US-08-468-846-2  
; Sequence 2, Application US/08468846  
; Patent No. 6074839  
; GENERAL INFORMATION:  
; APPLICANT: Meissner, Paul  
; APPLICANT: Fuldner, Rebecca  
; APPLICANT: Fel-wel, Ying  
; APPLICANT: Adams, Mark  
; TITLE OF INVENTION: TRANSFORMING GROWTH FACTOR ALPHA HI  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: CARELLA, BYRNE, BAIN, GUILFILLAN, CECCHI,  
; ADDRESSEE: STUART & OLSTEIN  
; STREET: 6 Becker Farm Road  
; CITY: Roseland  
; STATE: New Jersey  
; COUNTRY: USA  
; ZIP: 07068  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/468,846  
; FILING DATE: 06-JUN-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/208,008

FILING DATE: 08-MAR-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Ferraro, Gregory D.  
REGISTRATION NUMBER: 36,134  
REFERENCE/DOCKET NUMBER: 325800-465  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 201-994-1700  
TELEFAX: 201-994-1744  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 380 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-468-846-2

Query Match 46.38; Score 38; DB 3; Length 380;  
Best Local Similarity 50.08; Pred. No. 30;  
Matches 7; Conservative 3; Mismatches 4; Indels 0; Gaps 0;  
Qy 1 CFGVGKTTVNANEL 14  
| | | | : | : | : |  
Db 54 CPGGKGKSINCSL 67

RESULT 7  
US-08-915-096A-2  
Sequence 2, Application US/08915096A  
Patent No. 6265543  
GENERAL INFORMATION:  
APPLICANT: Meissner, Paul S.  
APPLICANT: Fuldner, Rebecca A.  
APPLICANT: Adams, Mark D.  
TITLE OF INVENTION: Transforming Growth Factor Alpha HI  
NUMBER OF SEQUENCES: 15  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Human Genome Sciences, Inc.  
STREET: 9410 Key West Avenue  
CITY: Rockville  
STATE: MD  
COUNTRY: USA  
ZIP: 20850  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/915,096A  
FILING DATE: 20-AUG-1997  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/468,846  
FILING DATE: 06-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/208,008  
FILING DATE: 08-MAR-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Brookes, A. Anders  
REGISTRATION NUMBER: 36,373  
REFERENCE/DOCKET NUMBER: PF110D1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 301-309-8504  
TELEX: 301-309-8439  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 380 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-915-096A-2

Query Match 46.38; Score 38; DB 4; Length 380;  
Best Local Similarity 50.08; Pred. No. 30;  
Matches 7; Conservative 3; Mismatches 4; Indels 0; Gaps 0;  
Qy 1 CFGVGKTTVNANEL 14  
| | | | : | : | : |  
Db 54 CPGGKGKSINCSL 67

RESULT 8  
US-08-286-819A-29  
Sequence 29, Application US/08286819A  
Patent No. 5871910  
GENERAL INFORMATION:  
APPLICANT: ARTHUR, MICHEL  
APPLICANT: DUKIA-MALEN, SYLVIE  
APPLICANT: MOLINAS, CATHERINE  
APPLICANT: COURVALIN, PATRICE  
TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPETIDES, IN PARTICULAR  
TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
NUMBER OF SEQUENCES: 54  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
ADDRESS: P.C.  
STREET: 1755 S. Jefferson Davis Highway, Suite 400  
CITY: Arlington  
STATE: Virginia  
COUNTRY: U.S.A.  
ZIP: 22202  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/286,819A  
FILING DATE: 05-AUG-1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/174,682  
FILING DATE: 28-DEC-1993  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/917,146  
FILING DATE: 10-AUG-1992  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/FR/91/00855  
FILING DATE: 29-OCT-1991  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: FR 9013579  
FILING DATE: 31-OCT-1990  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Oblon, No. 5871910man F.  
REGISTRATION NUMBER: 24,618  
REFERENCE/DOCKET NUMBER: 660-060-0 PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 413-3000  
TELEFAX: (703) 413-2220  
TELEX: 248855 OPAT UR  
INFORMATION FOR SEQ ID NO: 29:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 2291 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-286-819A-29

Query Match 46.3%; Score 38; DB 2; Length 2291;  
Best Local Similarity 63.6%; Pred. No. 2.6e+02;  
Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 2 FGVKGTNNAN 12  
| | | | : | | |  
Db 1138 FGVMTIINAN 1148

RESULT 9  
US-08-980-357-29  
; Sequence 29, Application US/08980357  
; Patent No. 6013508  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPETIDES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; ADDRESSEE: P.C.  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/980.357  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/286.819  
; FILING DATE: 05-AUG-1994  
; APPLICATION NUMBER: US 08/174.682  
; FILING DATE: 28-DEC-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/917.146  
; FILING DATE: 10-AUG-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/FR/91/00855  
; FILING DATE: 29-OCT-1991  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: FR 9013579  
; FILING DATE: 31-OCT-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Oblon, No. 6013508man F.  
; REGISTRATION NUMBER: 24,618  
; REFERENCE/DOCKET NUMBER: 660-060-0 PCT  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (703) 413-3000  
; TELEFAX: (703) 413-2220  
; TELEX: 248855 OPAT UR  
; INFORMATION FOR SEQ ID NO: 29:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 2291 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-980-357-29

Query Match 46.3%; Score 38; DB 3; Length 2291;  
Best Local Similarity 63.6%; Pred. No. 2.6e+02;

Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;  
Qy 2 FGVKGTNNAN 12  
| | | | : | | |  
Db 1138 FGVMTIINAN 1148

RESULT 10  
US-08-378-313-33  
; Sequence 33, Application US/08378313  
; Patent No. 6207881  
; GENERAL INFORMATION:  
; APPLICANT: THEOLOGIS, ATHANASIOS  
; APPLICANT: SATO, TAKAHIDO  
; TITLE OF INVENTION: CONTROL OF FRUIT RIPENING THROUGH  
; TITLE OF INVENTION: GENETIC CONTROL OF ACC SYNTHASE SYNTHESIS  
; NUMBER OF SEQUENCES: 34  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: MORRISON & FOERSTER  
; STREET: 755 Page Mill Road  
; CITY: Palo Alto  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94304-1018  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/378.313  
; FILING DATE:  
; CLASSIFICATION: 800  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/862.493  
; FILING DATE: 02-APR-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: MURASHIGE, KATE H.  
; REGISTRATION NUMBER: 29,959  
; REFERENCE/DOCKET NUMBER: 29190-20003.20  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 856-5600  
; TELEFAX: (415) 494-0792  
; TELEX: 706141  
; INFORMATION FOR SEQ ID NO: 33:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 469 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-378-313-33

Query Match 45.1%; Score 37; DB 4; Length 469;  
Best Local Similarity 77.8%; Pred. No. 59;  
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 6 GTTVNANEL 14  
| | | | : | | |  
Db 205 GTTLNREL 213

RESULT 11  
US-08-188-228-48  
; Sequence 48, Application US/08188228  
; Patent No. 5597725  
; GENERAL INFORMATION:  
; APPLICANT: Suzuki, Shintaro  
; TITLE OF INVENTION: CADHERIN MATERIALS AND METHODS  
; NUMBER OF SEQUENCES: 62  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &  
; ADDRESSEE: Borun

STREET: 6300 Sears Tower, 233 S. Wacker Drive  
CITY: Chicago  
STATE: Illinois  
COUNTRY: USA  
ZIP: 60606  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/188,228  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/049,460  
FILING DATE: 19 APR 1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/872,643  
FILING DATE: 17 APR 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: No. 559772sand, Greta E.  
REGISTRATION NUMBER: 35,302  
REFERENCE/DOCKET NUMBER: 31340  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 474-6300  
TELEFAX: (312) 474-0448  
TELEX: 25-3856  
INFORMATION FOR SEQ ID NO: 48:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 916 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-332-643-42

Query Match 43.9%; Score 36; DB 1; Length 916;  
Best Local Similarity 42.9%; Pred. No. 2e+02;  
Matches 6; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

Qy 1 CFGVKGTTVNANEL 14  
| | | | |  
Db 62 CVGTGQTQYETNSM 75

RESULT 12  
US-08-332-643-42  
Sequence 42, Application US/08332643  
Patent No. 5639634  
GENERAL INFORMATION:  
APPLICANT: Suzuki, Shintaro  
TITLE OF INVENTION: CADHERIN MATERIALS AND METHODS  
NUMBER OF SEQUENCES: 56  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &  
ADDRESSEE: Bicknell  
STREET: Two First National Plaza, 20 South Clark  
STREET: Street  
CITY: Chicago  
STATE: Illinois  
COUNTRY: USA  
ZIP: 60603  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/332,643  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/07/872,643  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: No. 5639634and, Greta E.  
REGISTRATION NUMBER: 35,302  
REFERENCE/DOCKET NUMBER: 27866/30795  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 346-5750  
TELEFAX: (312) 984-9740  
TELEX: 25-3856  
INFORMATION FOR SEQ ID NO: 42:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 916 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-332-643-42

Query Match 43.9%; Score 36; DB 1; Length 916;  
Best Local Similarity 42.9%; Pred. No. 2e+02;  
Matches 6; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

Qy 1 CFGVKGTTVNANEL 14  
| | | | |  
Db 62 CVGTGQTQYETNSM 75

RESULT 13  
US-08-332-638-48  
Sequence 48, Application US/08332638  
Patent No. 5646250  
GENERAL INFORMATION:  
APPLICANT: Suzuki, Shintaro  
TITLE OF INVENTION: CADHERIN MATERIALS AND METHODS  
NUMBER OF SEQUENCES: 62  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &  
ADDRESSEE: Borun  
STREET: 6300 Sears Tower, 233 S. Wacker Drive  
CITY: Chicago  
STATE: Illinois  
COUNTRY: USA  
ZIP: 60606  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/332,638  
FILING DATE: 01-NOV-1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/872,643  
FILING DATE: 17 APR 1992  
APPLICATION NUMBER: US/08/049,460  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: No. 5646250and, Greta E.  
REGISTRATION NUMBER: 35,302  
REFERENCE/DOCKET NUMBER: 31340  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 474-6300  
TELEFAX: (312) 474-0448  
TELEX: 25-3856  
INFORMATION FOR SEQ ID NO: 48:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 916 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-332-638-48

Query Match 43.9%; Score 36; DB 1; Length 916;  
Best Local Similarity 42.9%; Pred. No. 2e+02;  
Matches 6; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

QY 1 CFGVKGTTVNANEL 14  
| | | | |  
DB 62 CVGTRGTQYETNSM 75

## RESULT 14

US-08-463-911-3  
; Sequence 3, Application US/08463911  
; Patent No. 5869330  
; GENERAL INFORMATION:  
; APPLICANT: Scherer, Philipp E.  
; APPLICANT: Lodish, Harvey F.  
; TITLE OF INVENTION: A NOVEL SERUM PROTEIN PRODUCED  
; TITLE OF INVENTION: EXCLUSIVELY IN ADIPOCYTES  
; NUMBER OF SEQUENCES: 7  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
; STREET: Two Militia Drive  
; CITY: Lexington  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02173  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/463,911  
; FILING DATE:  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Granahan, Patricia  
; REGISTRATION NUMBER: 32,227  
; REFERENCE/DOCKET NUMBER: WHI95-05  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 861-6240  
; TELEFAX: (617) 861-9540  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 185 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)

US-08-463-911-3

Query Match 43.3%; Score 35.5; DB 2; Length 185;  
Best Local Similarity 64.3%; Pred. No. 37;  
Matches 9; Conservative 1; Mismatches 1; Indels 3; Gaps 1;

QY 5 KGTT---VNANELP 15  
| | | | |  
DB 57 KCTSAFAVKANELP 70

## RESULT 15

US-09-140-804-6  
; Sequence 6, Application US/09140804  
; Patent No. 6197930  
; GENERAL INFORMATION:  
; APPLICANT: Sheppard, Paul O.  
; APPLICANT: Humes, Jacqueline M.  
; TITLE OF INVENTION: ADIPOCYTE-SPECIFIC PROTEIN HOMOLOGS  
; FILE REFERENCE: 97-49  
; CURRENT APPLICATION NUMBER: US/09/140,804

; CURRENT FILING DATE: 1998-08-26  
; EARLIER APPLICATION NUMBER: 60/056,983  
; EARLIER FILING DATE: 1997-08-26  
; NUMBER OF SEQ ID NOS: 47  
; SOFTWARE: FastSEQ for Windows Version 3.0  
; SEQ ID NO 6  
; LENGTH: 236  
; TYPE: PRT  
; ORGANISM: Tamias sibiricus  
US-09-140-804-6

Query Match 43.3%; Score 35.5; DB 4; Length 236;  
Best Local Similarity 64.3%; Pred. No. 50;  
Matches 9; Conservative 1; Mismatches 1; Indels 3; Gaps 1;

QY 5 KGTT---VNANELP 15  
| | | | |  
DB 108 KCTSAFAVKANELP 121

Search completed: March 26, 2002, 13:41:28  
Job time: 302 sec





GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:36:26 ; Search time 81.51 Seconds  
(without alignments)  
15.449 Million cell updates/sec

Title: US-09-709-201-93

Perfect score: 91

Sequence: 1 CTGSAANYTTAVDRPN 17

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A\_Geneseq\_1101.\*

```

1: /SID88/gcgdata/geneseq/geneseq/AA1980.DAT.*
2: /SID88/gcgdata/geneseq/geneseq/AA1981.DAT.*
3: /SID88/gcgdata/geneseq/geneseq/AA1982.DAT.*
4: /SID88/gcgdata/geneseq/geneseq/AA1983.DAT.*
5: /SID88/gcgdata/geneseq/geneseq/AA1984.DAT.*
6: /SID88/gcgdata/geneseq/geneseq/AA1985.DAT.*
7: /SID88/gcgdata/geneseq/geneseq/AA1986.DAT.*
8: /SID88/gcgdata/geneseq/geneseq/AA1987.DAT.*
9: /SID88/gcgdata/geneseq/geneseq/AA1988.DAT.*
10: /SID88/gcgdata/geneseq/geneseq/AA1989.DAT.*
11: /SID88/gcgdata/geneseq/geneseq/AA1990.DAT.*
12: /SID88/gcgdata/geneseq/geneseq/AA1991.DAT.*
13: /SID88/gcgdata/geneseq/geneseq/AA1992.DAT.*
14: /SID88/gcgdata/geneseq/geneseq/AA1993.DAT.*
15: /SID88/gcgdata/geneseq/geneseq/AA1994.DAT.*
16: /SID88/gcgdata/geneseq/geneseq/AA1995.DAT.*
17: /SID88/gcgdata/geneseq/geneseq/AA1996.DAT.*
18: /SID88/gcgdata/geneseq/geneseq/AA1997.DAT.*
19: /SID88/gcgdata/geneseq/geneseq/AA1998.DAT.*
20: /SID88/gcgdata/geneseq/geneseq/AA1999.DAT.*
21: /SID88/gcgdata/geneseq/geneseq/AA2000.DAT.*
22: /SID88/gcgdata/geneseq/geneseq/AA2001.DAT.*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	91	100.0	17	20 AAW95320	Costant and variab
2	82	90.1	29	20 AAW84462	Peptide CplA deriv
3	82	90.1	29	20 AAW84556	Peptide C.p.IA der
4	82	90.1	343	20 AAY56771	C. trachomatis ser
5	82	90.1	391	20 AAY35319	Chlamydia pneumoni
6	69	75.8	23	20 AAW84468	Peptide CplAmp de
7	64	70.3	389	20 AAW98188	Chlamydia psittaci
8	55	60.4	10	20 AAW84466	Peptide CpVDI deri
9	55	60.4	10	20 AAW84553	Peptide C.pVDI deri
10	49	53.8	100	20 AAW95295	Chlamydial major o
11	48	52.7	1241	22 AAW25606	Human protein sequ

12	48	52.7	1330	22	AAW65630	Novel protein kina
13	47	51.6	343	20	AAV56769	C. trachomatis ser
14	43	47.3	17	20	AAW95323	Costant and variab
15	43	47.3	250	21	AAW06126	Arabidopsis thalia
16	43	47.3	250	21	AAW06126	Arabidopsis thalia
17	43	47.3	263	21	AAW06125	Arabidopsis thalia
18	43	47.3	263	21	AAW06125	Arabidopsis thalia
19	41	45.1	345	22	AAW85128	Carica cysteine pr
20	41	45.1	477	22	AAW70765	Human betal-adreno
21	41	45.1	1736	22	AAW36932	Hepatitis C virus
22	41	45.1	2813	19	AAW54347	Canine von Willebr
23	41	45.1	2813	21	AAW70557	Canine von Willebr
24	41	45.1	3910	14	AAW38470	ALL-1 protein. Ho
25	41	45.1	3910	16	AAW66462	ALL-1 (acute lymph
26	41	45.1	3969	15	AAW52971	Product of the cDN
27	40	44.0	3011	16	AAW67588	Hepatitis C virus
28	39	42.9	205	22	AAW92148	C glutamicum prote
29	39	42.9	217	22	AAW79574	Corynebacterium gl
30	39	42.9	356	22	AAW99749	Oryza sativa perox
31	39	42.9	375	20	AAW30532	A G protein-couple
32	39	42.9	375	21	AAW71298	Human orphan G pro
33	39	42.9	375	21	AAW02832	Human G protein co
34	39	42.9	377	20	AAW30536	A G protein-couple
35	39	42.9	411	19	AAW80938	Human kidney lecti
36	39	42.9	414	19	AAW80941	Human kidney lecti
37	39	42.9	444	19	AAW80943	Human kidney lecti
38	38	41.8	158	21	AAW78913	Androgen independe
39	38	41.8	272	13	AAW29871	HCY NS4-NS5 peptid
40	38	41.8	374	22	AAW90207	C glutamicum prote
41	38	41.8	422	21	AAW28827	Arabidopsis thalia
42	38	41.8	422	21	AAW32115	Arabidopsis thalia
43	38	41.8	438	21	AAW51345	Arabidopsis thalia
44	38	41.8	459	19	AAW38456	Schizosaccharomyce
45	38	41.8	643	22	AAW97666	Zea mays ZmEIN3-1

#### ALIGNMENTS

RESULT 1

AAW95320  
ID AAW95320 standard; Protein; 17 AA.

XX AC AAW95320;

XX DT 15-MAR-1999 (first entry)

XX DE Costant and variable domain sequence of C. pneumoniae CPN90-105.

XX DE Chlamydia; cryptic phase; elementary body phase; replicating; probedicid;  
KW antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
KW major outer membrane protein; autoimmunity; inflammatory; porphyria;  
KW Ebstein Bar virus; antioxidant.

XX OS Chlamydia pneumoniae.

XX PN WO9850074-A2.

XX PD 12-NOV-1998.

XX PF 06-MAY-1998; 98WO-US09237.

XX PR 18-FEB-1998; 98US-0025521.

XX PR 06-MAY-1997; 97US-0045689.

XX PR 06-MAY-1997; 97US-0045739.

XX PR 06-MAY-1997; 97US-0045779.

XX PR 06-MAY-1997; 97US-0045780.

XX PR 06-MAY-1997; 97US-0045784.

XX PR 06-MAY-1997; 97US-0045787.

XX PR 14-AUG-1997; 97US-0911593.

XX PR 18-FEB-1998; 98US-0025174.

XX PR 18-FEB-1998; 98US-0025176.



CC antibodies of other Chlamydia species. Such peptides are useful to  
 CC detect C. trachomatis infections in humans. Mixtures of MOMP peptide  
 CC mixtures allow detection of and vaccination against all C. trachomatis  
 CC serovars, which is not possible with existing MOMP-derived peptides  
 CC for C. trachomatis-specific detection.

XX Sequence 29 AA;

Query Match 90.1%; Score 82; DB 20; Length 29;  
 Best Local Similarity 100.0%; Pred. No. 8.2e-07;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
 |||||

Db 9 tgsaaanyttavdrpn 24

RESULT 4

AAV56771  
 ID AAV56771 standard; Protein; 343 AA.

XX

AC AAV56771;

XX 22-FEB-2000 (first entry)

DE C. trachomatis serovar HuPn MOMP sequence.

XX Major outer membrane protein; MOMP; Chlamydia; vaccine; immune response;  
 KW cellular response; immunogen; Th1-like CD4 response; mucosal immunity.

XX Chlamydia trachomatis.

XX WO9951745-A2.

XX 14-OCT-1999.

XX 07-APR-1999; 99WO-CA00292.

XX 07-APR-1998; 98US-0055765.

XX (UYMA-) UNIV MANITOBA.

XX Bruham RC;

XX WPI; 1999-620205/53.

XX Non-replicating vector encoding fragments of the outer membrane protein  
 PT of Chlamydia, useful in vaccines and as immunogen

PS Disclosure; Fig 10 A-F; 52pp; English.

XX The invention provides a non-replicating vector that comprises, linked  
 CC to a promoter, a nucleotide sequence that encodes a region containing at  
 CC least one of the conserved domains 2, 3 and 5 of a major outer membrane  
 CC protein (MOMP) of a Chlamydia strain. The vector is used: (a) in  
 CC vaccines to generate a protective immune response (mainly cellular)  
 CC against MOMP, and (b) as immunogens to raise anti-MOMP antibodies, useful  
 CC in standard immunoassays. Immunization with the vector induces a broad  
 CC spectrum of immune responses, including Th1-like CD4 responses and  
 CC mucosal immunity, providing significant protection against subsequent  
 CC challenge. Sequences AAV56757-71 represent MOMP sequences from a variety  
 CC of serovars of C. trachomatis.

XX Sequence 343 AA;

Query Match 90.1%; Score 82; DB 20; Length 343;  
 Best Local Similarity 100.0%; Pred. No. 1.1e-05;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
 |||||

Db 90 tgsaaanyttavdrpn 105

RESULT 5

AAV5319  
 ID AAV5319 standard; Protein; 391 AA.

XX AAV5319;

XX 13-SEP-1999 (first entry)

DE Chlamydia pneumoniae transmembrane protein sequence.

XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;  
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis;  
 KW vaccine; neutralising epitope.

XX Chlamydia pneumoniae.

XX WO9927105-A2.

XX 03-JUN-1999.

XX 20-NOV-1998; 98WO-IB01890.

XX 04-NOV-1998; 98US-0107078.

XX 21-NOV-1997; 97FR-0014673.

XX (GEST ) GENSET.

XX Griffais R;

XX WPI; 1999-357842/30.

XX Genome sequence of Chlamydia pneumoniae

XX Page 1130-1131; Disclosure; 1912pp; English.

XX AAY34584-Y35879 represent the proteins encoded by all the open reading  
 CC frames in the complete genome (see AAY34584-Y35879) of Chlamydia pneumoniae.  
 CC C. pneumoniae causes respiratory disease such as pneumonia and  
 CC bronchitis and is thought to be a contributing factor in heart  
 CC disease, sarcoidosis, sinusitis, purulent otitis media, erythema  
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading  
 CC frames of the C. pneumoniae genome (see AAY34584-Y35879) can be used in  
 CC immunogenic compositions as vaccines. Vectors containing C. pneumoniae  
 CC nucleotide sequences can also be used as immunogenic compositions,  
 CC especially where the vector directs the expression of a neutralising  
 CC epitope of C. pneumoniae.

XX Sequence 391 AA;

Query Match 90.1%; Score 82; DB 20; Length 391;  
 Best Local Similarity 100.0%; Pred. No. 1.2e-05;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
 |||||

Db 92 tgsaaanyttavdrpn 107

RESULT 6

AAW84468  
 ID AAW84468 standard; peptide; 23 AA.

XX AAW84468;

XX 23-MAR-1999 (first entry)

DE Peptide CpiAimp derived from a major outer membrane protein.

XX Variable domain; major outer membrane protein; MOMP;

KW Chlamydia; detection; infection; vaccine.

XX Synthetic.  
OS Chlamydia pneumoniae.

XX WO9857981-A2.

PD 23-DEC-1998.

PF 15-JUN-1998; 98WO-IL00277.

XX 19-JUN-1997; 97IL-0121114.

XX (SAVY-) SAVYON DIAGNOSTICS LTD.

XX Ohana B;

XX WPI; 1999-080945/07.

XX New peptides derived from Chlamydia pneumoniae MOMP protein - useful  
PT to detect C. pneumoniae infection

XX Claim 2; Page 54; 39pp; English.

XX The present peptide is derived from the variable domain of the  
CC major outer membrane protein (MOMP) of Chlamydia pneumoniae. The  
CC peptide is able to react with antibodies formed during C. pneumoniae  
CC infection and characterised by having essentially very low  
CC cross-reactivity towards antibodies against other Chlamydia species.  
CC A mixture of such peptides (see also AAW84462-68) is used to detect  
CC C. pneumoniae infection, and in the preparation of vaccines.

XX Sequence 23 AA;

Query Match 75.8%; Score 69; DB 20; Length 23;  
Best Local Similarity 100.0%; Pred. No. 9.3e-05;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDR 15  
Db (|||||)|||||

9 tgtaaanyttavdr 22

RESULT 7

AAW98188  
ID AAW98188 standard; Protein; 389 AA.

XX AAW98188;

XX 05-JUL-1999 (first entry);

XX Chlamydia psittaci major outer membrane protein.

XX Major outer membrane protein; MOMP; psittacosis; infection;  
KW vaccine; genetic immunisation.

XX Chlamydia psittaci.

XX WO9910005-A1.

XX 04-MAR-1999.

XX 28-AUG-1998; 98WO-US17943.

XX 28-AUG-1997; 97US-0057147.

XX (LOU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.

XX Baghian A, Chouljenko VN, Kousoulas KG, Tully TN;

XX WPI; 1999-254214/21.

DR N-PSDB; AAX25047.

XX A new vaccine for Chlamydia psittaci infections  
PT Disclosure; Page 60-61; 72pp; English.

XX The present sequence is the major outer membrane protein (MOMP)  
CC of Chlamydia psittaci strain B577. A claimed MOMP polypeptide (see  
CC AAW98184) comprises regions VD3 and VD4 of B577 MOMP, i.e. it lacks  
CC regions VD1 and VD2. A claimed vaccine composition includes MOMP  
CC polypeptide lacking VD1 and VD2, optionally fused to a maltose  
CC binding protein. Also claimed are an isolated nucleic acid  
CC encoding the polypeptide, a vector, and a method of preventing C.  
CC psittaci infection by administering the vaccine containing the  
CC MOMP polypeptide. Vectors encoding MOMP polypeptides lacking  
CC regions VD1 and VD2 are useful for genetic vaccination. The  
CC vaccines are used to prevent C. psittaci infection, especially in  
CC birds.

XX Sequence 389 AA;

Query Match 70.3%; Score 64; DB 20; Length 389;  
Best Local Similarity 75.0%; Pred. No. 0.012;  
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
Db (|||||)|||||

90 tgtaaanyktptdrpn 105

RESULT 8

AAW84466

ID AAW84466 standard; peptide; 10 AA.

XX AAW84466;

XX 23-MAR-1999 (first entry)

XX Peptide CpVDI derived from a major outer membrane protein.

XX Variable domain; major outer membrane protein; MOMP;  
KW Chlamydia; detection; infection; vaccine.

XX Synthetic.

OS Chlamydia pneumoniae.

XX WO9857981-A2.

XX 23-DEC-1999

XX 15-JUN-1998; 98WO-IL00277.

XX 19-JUN-1997; 97IL-0121114.

XX (SAVY-) SAVYON DIAGNOSTICS LTD.

XX Ohana B;

XX WPI; 1999-080945/07.

XX New peptides derived from Chlamydia pneumoniae MOMP protein - useful  
PT to detect C. pneumoniae infection

XX Claim 2; Page 53; 39pp; English.

XX The present peptide is derived from the variable domain of the  
CC major outer membrane protein (MOMP) of Chlamydia pneumoniae. The  
CC peptide is able to react with antibodies formed during C. pneumoniae  
CC infection and characterised by having essentially very low  
CC cross-reactivity towards antibodies against other Chlamydia species.  
CC A mixture of such peptides (see also AAW84462-68) is used to detect  
CC C. pneumoniae infection, and in the preparation of vaccines.

SQ Sequence 10 AA;

Query Match 60.4%; Score 55; DB 20; Length 10;  
 Best Local Similarity 100.0%; Pred. No. 0.0082;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 NYTTAVDRPN 17  
 |||||  
 Db 1 nyttavdrpn 10

RESULT 9  
 AAW84553  
 ID AAW84553 standard; peptide; 10 AA.  
 XX AC AAW84553;  
 XX DT 26-MAR-1999 (first entry)  
 XX PE Peptide C.pVDI derived from the major outer membrane protein.  
 DE Variable domain; immunodominant; major outer membrane protein; MOMP;  
 KW anti-MOMP antibody; Chlamydia; vaccine; C. trachomatis.  
 XX OS Chlamydia pneumoniae.  
 XX PN WO9900414-A1.  
 XX PD 07-JAN-1999.  
 XX PF 15-JUN-1998; 98WO-IL00276.  
 XX PR 19-JUN-1997; 97IL-0121115.  
 XX PA (SAVY-) SAVYON DIAGNOSTICS LTD.  
 XX PI Ohana B;  
 XX DR WPI; 1999-095677/08.  
 XX PT Chlamydia trachomatis specific peptides useful in diagnostic assays  
 PT - derived from major outer membrane protein variable domains and  
 PT useful in mixtures to detect infection with or immunise against all  
 PT serovars  
 XX PS Example 1; Page 21; 78pp; English.  
 XX CC The present sequence represents a peptide derived from variable  
 CC domain 1 (VDI) of the Chlamydia pneumoniae major outer membrane  
 CC protein (MOMP). The specification also describes C. trachomatis  
 CC MOMP derived peptides which have specificity only to C. trachomatis  
 CC anti-MOMP antibodies and are non-cross reactive with anti-MOMP  
 CC antibodies of other Chlamydia species. Such peptides are useful to  
 CC detect C. trachomatis infections in humans. Mixtures of MOMP peptide  
 CC mixtures allow detection of and vaccination against all C. trachomatis  
 CC serovars, which is not possible with existing MOMP-derived peptides  
 CC for C. trachomatis-specific detection.  
 XX SQ Sequence 10 AA;

Query Match 60.4%; Score 55; DB 20; Length 10;  
 Best Local Similarity 100.0%; Pred. No. 0.0082;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 NYTTAVDRPN 17  
 |||||  
 Db 1 nyttavdrpn 10

RESULT 10  
 AAW95295

ID AAW95295 standard; Protein; 100 AA.  
 XX AC AAW95295;  
 XX DT 15-MAR-1999 (first entry)  
 XX DE Chlamydial major outer membrane protein (MOMP) PN fragment.  
 XX KW Chlamydia; cryptic phase; elementary body phase; replicating; prohenicid;  
 KW antiporphyric acid; immune response; infection; diagnostic; assay; MOMP;  
 KW major outer membrane protein; autoimmune; inflammatory; porphyria;  
 KW Epstein Barr virus; antioxidant.  
 XX OS Chlamydia sp.  
 XX PN WO9850074-A2.  
 XX PD 12-NOV-1998.  
 XX PF 06-MAY-1998; 98WO-US09237.  
 XX PR 18-FEB-1998; 98US-0025521.  
 PR 06-MAY-1997; 97US-0045689.  
 PR 06-MAY-1997; 97US-0045739.  
 PR 06-MAY-1997; 97US-0045779.  
 PR 06-MAY-1997; 97US-0045780.  
 PR 06-MAY-1997; 97US-0045784.  
 PR 06-MAY-1997; 97US-0045787.  
 PR 14-AUG-1997; 97US-0911593.  
 PR 18-FEB-1998; 98US-0025174.  
 PR 18-FEB-1998; 98US-0025176.  
 XX (UYVA-) UNIV VANDERBILT.  
 XX PI Mitchell WM, Stratton CW;  
 XX DR WPI; 1999-059653/05.  
 XX PT Composition with two agents effective against different stages of  
 PT chlamydial life cycle - comprises agent targeted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT prohenicid and antiporphyric  
 XX PS Disclosure; Fig 1A; 138pp; English.  
 XX CC The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targeted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targeted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targeted against replicating phase of chlamydial  
 CC life cycle; (d) prohenicid, and (e) antiporphyric acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the cellular load of infectious  
 CC Epstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AAW95272 to AAW95319 represent peptide  
 CC fragments of various Chlamydial MOMPs.  
 XX SQ Sequence 100 AA;

Query Match 53.8%; Score 49; DB 20; Length 100;  
 Best Local Similarity 100.0%; Pred. No. 0.9;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 9 YTTAVDRPN 17  
 |||||  
 Db 1 yttavdrpn 9

RESULT 11  
 AAM25606  
 ID AAM25606 standard; Protein; 1241 AA.  
 XX AC AAM25606;  
 XX DT 16-OCT-2001 (first entry)  
 XX DE Human protein sequence SEQ ID NO:1121.  
 XX KW Human; cancer; ulcer; HIV infection; human immunodeficiency virus;  
 KW antinflammatory; antirheumatic; antiarthritic; immunosuppressive;  
 KW antibacterial; endocrine; cardiant; central nervous system; virucide;  
 KW anti-HIV; fungicide; antimutagen; cardiovascular; antianaemic; anaemia;  
 KW antiaggregant; haemostatic; vulnery; antiulcer; osteopathic; eczema;  
 KW dermatological; antiallergic; antiasthmatic; antidiabetic; cytostatic;  
 KW neuroprotective; antidepressant; nootropic; antiparkinsonian; infection;  
 KW immunostimulant; gene therapy; antisense therapy; vaccine; inflammation;  
 KW antianaphylactic; rheumatoid arthritis; septic shock; pancreatitis;  
 KW cardiac dysfunction; neuropathology; cardiac anaphylaxis; autoimmunity;  
 KW genetic disease; haematopoietic disorder; platelet disorder; asthma;  
 KW thrombocytopaenia; osteoporosis; severe combined immunodeficiency;  
 KW allergic rhinitis; diabetes; multiple sclerosis; depression;  
 KW Alzheimer's disease; Parkinson's disease; neurodegenerative disorder;  
 KW neurological disorder.  
 XX OS Homo sapiens.  
 XX WO200153455-A2.  
 XX 26-JUL-2001.  
 XX 22-DEC-2000; 2000WO-US35017.  
 XX 23-DEC-1999; 99US-0471275.  
 XX 21-JAN-2000; 2000US-0488725.  
 XX 25-APR-2000; 2000US-0552317.  
 XX (HYSE-) HYSEQ INC.  
 XX Tang YT, Liu C, Drmanac RT;  
 XX WPI; 2001-457603/49.  
 XX N-PSDB; AAH99547.  
 XX Isolated human polynucleotides encoding polypeptides, useful for the  
 XX treatment and diagnosis of e.g. cancer, ulcers and HIV infection.  
 XX Claim 20; Page 232; 1217pp; English.  
 XX AAH99166 to AAH99904 encode the human proteins given in AAM25225 to  
 XX AAM25963. The proteins can have activities based on the tissues and  
 XX cells they are expressed in, such as: antinflammatory; antirheumatic;  
 XX antiarthritic; immunosuppressive; antibacterial; endocrine; cardiant;  
 XX central nervous system; virucide; anti-HIV; fungicide; antimutagen;  
 XX cardiovascular; antianaemic; antiaggregant; haemostatic; vulnery;  
 XX antiulcer; osteopathic; dermatological; antiallergic; antiasthmatic;  
 XX antidiabetic; cytostatic; neuroprotective; antidepressant; nootropic;  
 XX antiparkinsonian; and immunostimulant. The proteins and polynucleotides  
 XX encoding them can be used in gene therapy, antisense therapy and vaccine  
 XX production. The proteins and polynucleotides are useful for screening for  
 XX agonists or antagonists of a protein and for the treatment and diagnosis  
 XX of disorders associated with the activity of a protein e.g. inflammation,  
 XX rheumatoid arthritis, septic shock, pancreatitis, cardiac dysfunction,

CC neuropathology, cardiac anaphylaxis, viral, bacterial, HIV and fungal  
 CC infections, autoimmunity, genetic diseases, haematopoietic disorders,  
 CC anaemia, platelet disorders, thrombocytopaenia, wounds, burns, ulcers,  
 CC osteoporosis, severe combined immunodeficiency, eczema, allergic  
 CC rhinitis, asthma, diabetes, cancer, multiple sclerosis, depression,  
 CC Alzheimer's disease, Parkinson's disease, neurodegenerative and  
 CC neurological disorders.  
 XX XX  
 SQ Sequence 1241 AA;

Query Match 52.7%; Score 48; DB 22; Length 1241;  
 Best Local Similarity 56.2%; Pred. No. 18;  
 Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDRP 16  
 |||||  
 Db 619 ctgssacyalatdp 634

RESULT 12  
 AAB65630  
 ID AAB65630 standard; Protein; 1330 AA.  
 XX AC AAB65630;  
 XX DT 27-MAR-2001 (first entry)  
 XX DE Novel protein kinase, SEQ ID NO: 156.  
 XX KW Human; mouse; protein kinase; antiarthritic; antisclerotic; osteopathic;  
 KW immunosuppressive; cardiant; renal; antinflammatory; antiasthmatic;  
 KW dermatological; antidiabetic; antiinfertility; gene therapy; vaccine;  
 KW immune disorder; cardiovascular disease; neurodegenerative disease;  
 KW cancer; autoimmune disorder; stroke; inflammatory bowel disease;  
 KW inflammatory pelvic disease; multiple sclerosis; psoriasis.  
 XX OS Homo sapiens.  
 XX WO200073469-A2.  
 XX 07-DEC-2000.  
 XX 26-MAY-2000; 2000WO-US14842.  
 XX 28-MAY-1999; 99US-0136503.  
 XX (SUGE-) SUGEN INC.  
 XX Plowman GD, Martinez R, Whyte D, Sudersanam S;  
 XX WPI; 2001-032161/04.  
 XX N-PSDB; AAF44656.  
 XX Nucleic acids encoding kinase polypeptides, useful for diagnosing and  
 XX treating immune-related diseases and disorders, cardiovascular disease,  
 XX neurodegenerative diseases and/or cancers -  
 XX Claim 10; Fig 1; 310pp; English.  
 XX The present sequence is a novel protein kinase. The novel protein kinases  
 XX and the nucleic acids that encode them may be used in the treatment and  
 XX diagnosis of diseases associated with inappropriate kinase expression  
 XX such as immune-related diseases and disorders, cardiovascular disease,  
 XX neurodegenerative diseases and/or cancers. The nucleic acids and  
 XX complementary sequences may also be used as DNA probes in diagnostic  
 XX assays. The kinase polypeptides may be used as antigens in the production  
 XX of antibodies of kinase expression and activity. Anti-kinase antibodies  
 XX and kinase antagonists may also be used to down regulate kinase  
 XX expression and activity. Diseases related to kinase expression and  
 XX activity include rheumatoid arthritis, atherosclerosis, autoimmune  
 XX disorders, complications of organ transplantation, myocardial infarction,  
 XX immune disorders, cardiomyopathies, strokes, renal failure,

CC oxidative-stress related disorders, chronic inflammatory bowel disease,  
 CC chronic inflammatory pelvic disease, multiple sclerosis, asthma,  
 CC osteoarthritis, psoriasis, rhinitis, autoimmunity, diabetes, cancers and  
 CC reproductive disorders.

XX Sequence 1330 AA;

Query Match 52.7%; Score 48; DB 22; Length 1330;  
 Best Local Similarity 56.2%; Pred. No. 20;  
 Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDRP 16  
 ||||:| | | |  
 Db 708 ctgssacacvalatd1p 723

# RESULT 13

AAV56769  
 ID AAV56769 standard; Protein; 343 AA.

XX AC

AAV56769;

XX DT 22-FEB-2000 (first entry)

XX DE C. trachomatis serovar GPIC MOMP sequence.

XX KW Major outer membrane protein; MOMP; Chlamydia; vaccine; immune response;  
 cellular response; immunogen; Th1-like CD4 response; mucosal immunity.

XX OS Chlamydia trachomatis.

XX PN W09951745-A2.

XX PD 14-OCT-1999.

XX PF 07-APR-1999; 99WO-CA00292.

XX PR 07-APR-1998; 98US-0055765.

XX PA (UYVA-) UNIV MANITOBA.

XX PI Bruham RC;

XX DR WPI; 1999-620205/53.

XX PT Non-replicating vector encoding fragments of the outer membrane protein  
 of Chlamydia, useful in vaccines and as immunogen

XX PS Disclosure; Fig 10 A-F; 52pp; English.

XX CC The invention provides a non-replicating vector that comprises, linked  
 to a promoter, a nucleotide sequence that encodes a region containing at  
 least one of the conserved domains 2, 3 and 5 of a major outer membrane  
 protein (MOMP) of a Chlamydia strain. The vector is used: (a) in  
 CC vaccines to generate a protective immune response (mainly cellular)  
 CC against MOMP, and (b) as immunogens to raise anti-MOMP antibodies, useful  
 CC in standard immunoassays. Immunization with the vector induces a broad  
 CC spectrum of immune responses, including Th1-like CD4 responses and  
 CC mucosal immunity, providing significant protection against subsequent  
 CC challenge. Sequences AAV56757-71 represent MOMP sequences from a variety  
 CC of serovars of C. trachomatis.

XX Sequence 343 AA;

Query Match 51.6%; Score 47; DB 20; Length 343;  
 Best Local Similarity 56.2%; Pred. No. 7;  
 Matches 9; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
 ||||:| | | |  
 Db 89 tgnaaadftvdrnn 104

## RESULT 14

AAW95323

ID AAW95323 standard; Protein; 17 AA.

XX AC

AAW95323;

XX DT 15-MAR-1999 (first entry)

XX DE Costant and variable domain sequence of C. psittaci CP592-106.

XX KW Chlamydia; cryptic phase; elementary body phase; replicating; probenicid;  
 KW antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
 KW major outer membrane protein; autoimmune; inflammatory; porphyria;  
 KW Epstein Barr virus; antioxidant.

XX OS Chlamydia psittaci.

XX PN W09850074-A2.

XX PD 12-NOV-1998.

XX PF 06-MAY-1998; 98WO-US09237.

XX PR 18-FEB-1998; 98US-0025521.

XX PR 06-MAY-1997; 97US-0045689.

XX PR 06-MAY-1997; 97US-0045739.

XX PR 06-MAY-1997; 97US-0045779.

XX PR 06-MAY-1997; 97US-0045780.

XX PR 06-MAY-1997; 97US-0045784.

XX PR 14-AUG-1997; 97US-0911593.

XX PR 18-FEB-1998; 98US-0025174.

XX PR 18-FEB-1998; 98US-0025176.

XX PA (UYVA-) UNIV VANDERBILT.

XX PI Mitchell Th. Stratton CW;

XX DR WPI; 1999-059653/05.

XX CC Composition with two agents effective against different stages of  
 Chlamydia life cycle - comprises agent targeted against cryptic  
 phase, against elementary body phase, against replicating phase,  
 probenicid and antiporphyrin

XX PS Claim 4; Fig 3; 138pp; English.

XX CC The invention relates to the diagnosis and management of infections by  
 Chlamydia species. The invention provides a composition that comprises  
 at least two agents, where each of the agents is effective against a  
 different phase of the chlamydial life cycle. The agents are selected  
 from: (a) agents targeted against cryptic phase of chlamydial life  
 cycle; (b) agents targeted against elementary body phase of chlamydial  
 life cycle; (c) agents targeted against replicating phase of chlamydial  
 life cycle; (d) probenicid, and (e) antiporphyrin acid. The composition  
 is used to elicit a protective immune response to Chlamydia infection in  
 an animal or human and is applied until the animal or human tests  
 negative for Chlamydia infection. It is also used to treat biological  
 material infected with Chlamydia. Diagnostic kits for antibody assays  
 against recombinant major outer membrane protein (MOMP), and for DNA  
 amplification assays for chlamydial genes, are used to diagnose disease,  
 e.g. autoimmune disease, an inflammatory disease or a disease that  
 occurs in an immuno-compromised individual, associated with Chlamydia  
 infection. The kits are used to detect chlamydial elementary bodies in a  
 sample. They are also used to monitor and/or modify the course of therapy  
 in a patient. The treatment reduces the cellular load of infectious  
 Epstein Barr virus. The method is also used to treat porphyria, by  
 reducing the number of elementary bodies and applying a drug, e.g.  
 cimetidine, and antioxidants, to reduce the adverse effects associated  
 with porphyria. Sequences AAW95320 to AAW95323 represent constant and  
 CC variable domain sequences of various Chlamydia species.

XX SQ Sequence 17 AA; 07-JUN-1999; 99US-0137724.  
PR 08-JUN-1999; 99US-0138094.  
PR 10-JUN-1999; 99US-0138540.  
PR 10-JUN-1999; 99US-0138847.  
PR 14-JUN-1999; 99US-0139119.  
PR 16-JUN-1999; 99US-0139452.  
PR 16-JUN-1999; 99US-0139453.  
PR 17-JUN-1999; 99US-0139492.  
PR 18-JUN-1999; 99US-0139454.  
PR 18-JUN-1999; 99US-0139455.  
PR 18-JUN-1999; 99US-0139456.  
PR 18-JUN-1999; 99US-0139457.  
PR 18-JUN-1999; 99US-0139458.  
PR 18-JUN-1999; 99US-0139459.  
PR 18-JUN-1999; 99US-0139460.  
PR 18-JUN-1999; 99US-0139461.  
PR 18-JUN-1999; 99US-0139462.  
PR 18-JUN-1999; 99US-0139463.  
PR 18-JUN-1999; 99US-0139750.  
PR 18-JUN-1999; 99US-0139763.  
PR 21-JUN-1999; 99US-0139817.  
PR 22-JUN-1999; 99US-0139899.  
PR 23-JUN-1999; 99US-0140353.  
PR 23-JUN-1999; 99US-0140354.  
PR 24-JUN-1999; 99US-0140695.  
PR 28-JUN-1999; 99US-0140823.  
PR 29-JUN-1999; 99US-0140991.  
PR 30-JUN-1999; 99US-0141287.  
PR 01-JUL-1999; 99US-0141842.  
PR 01-JUL-1999; 99US-0142154.  
PR 02-JUL-1999; 99US-0142055.  
PR 06-JUL-1999; 99US-0142390.  
PR 08-JUL-1999; 99US-0142803.  
PR 09-JUL-1999; 99US-0142920.  
PR 12-JUL-1999; 99US-0142977.  
PR 13-JUL-1999; 99US-0143542.  
PR 14-JUL-1999; 99US-0143624.  
PR 15-JUL-1999; 99US-0144005.  
PR 16-JUL-1999; 99US-0144085.  
PR 16-JUL-1999; 99US-0144086.  
PR 19-JUL-1999; 99US-0144325.  
PR 19-JUL-1999; 99US-0144331.  
PR 19-JUL-1999; 99US-0144332.  
PR 19-JUL-1999; 99US-0144333.  
PR 19-JUL-1999; 99US-0144334.  
PR 19-JUL-1999; 99US-0144335.  
PR 20-JUL-1999; 99US-0144352.  
PR 20-JUL-1999; 99US-0144632.  
PR 20-JUL-1999; 99US-0144884.  
PR 21-JUL-1999; 99US-0144814.  
PR 21-JUL-1999; 99US-0145086.  
PR 21-JUL-1999; 99US-0145088.  
PR 22-JUL-1999; 99US-0145085.  
PR 22-JUL-1999; 99US-0145087.  
PR 22-JUL-1999; 99US-0145089.  
PR 22-JUL-1999; 99US-0145192.  
PR 23-JUL-1999; 99US-0145145.  
PR 23-JUL-1999; 99US-0145218.  
PR 23-JUL-1999; 99US-0145224.  
PR 26-JUL-1999; 99US-0145276.  
PR 27-JUL-1999; 99US-0145913.  
PR 27-JUL-1999; 99US-0145918.  
PR 27-JUL-1999; 99US-0145919.  
PR 28-JUL-1999; 99US-0145951.  
PR 02-AUG-1999; 99US-0146386.  
PR 02-AUG-1999; 99US-0146388.  
PR 02-AUG-1999; 99US-0146389.  
PR 03-AUG-1999; 99US-0147038.  
PR 04-AUG-1999; 99US-0147204.  
PR 04-AUG-1999; 99US-0147302.  
PR 05-AUG-1999; 99US-0147192.  
PR 05-AUG-1999; 99US-0147260.  
PR 06-AUG-1999; 99US-0147303.

Query Match 47.38; Score 43; DB 20; Length 17;  
Best Local Similarity 47.18; Pred. No. 1.4;  
Matches 8; Conservative 1; Mismatches 8; Indels 0; Gaps 0;  
QY 1 CTGSAANYTTAVDRPN 17  
I : I : I : I : I : I : I : I :  
Db 1 casgtasnttvaadrns 17

RESULT C 15  
AAG06126  
ID AAG06126 standard; Protein; 250 AA.  
XX AC AAG06126;  
XX DT 17 OCT-2000 (first entry)  
XX DE Arabidopsis thaliana protein fragment SEQ ID NO: 2786.  
XX KW Protein identification; signal transduction pathway; metabolic pathway;  
KW hybridisation assay; genetic mapping; gene expression control; promoter;  
KW termination sequence.  
XX OS Arabidopsis thaliana.  
XX PN EPI033405-A2.  
XX PD 06 SEP-2000.  
XX PF 25 FEB-2000; 2000EP-0301439.  
XX PR 25 FEB-1999; 99US-0121825.  
PR 05 MAR-1999; 99US-0123180.  
PR 09 MAR-1999; 99US-0123548.  
PR 23 MAR-1999; 99US-0125788.  
PR 25 MAR-1999; 99US-0126264.  
PR 29 MAR-1999; 99US-0126785.  
PR 01 APR-1999; 99US-0127462.  
PR 06 APR-1999; 99US-0128234.  
PR 08 APR-1999; 99US-0128714.  
PR 16 APR-1999; 99US-0129845.  
PR 19 APR-1999; 99US-0130077.  
PR 21 APR-1999; 99US-0130449.  
PR 23 APR-1999; 99US-0130510.  
PR 28 APR-1999; 99US-0130891.  
PR 30 APR-1999; 99US-0131449.  
PR 30 APR-1999; 99US-0132048.  
PR 30 APR-1999; 99US-0132407.  
PR 04 MAY-1999; 99US-0132484.  
PR 05 MAY-1999; 99US-0132485.  
PR 06 MAY-1999; 99US-0132486.  
PR 06 MAY-1999; 99US-0132487.  
PR 07 MAY-1999; 99US-0132863.  
PR 11 MAY-1999; 99US-0134256.  
PR 14 MAY-1999; 99US-0134218.  
PR 14 MAY-1999; 99US-0134219.  
PR 14 MAY-1999; 99US-0134221.  
PR 14 MAY-1999; 99US-0134370.  
PR 18 MAY-1999; 99US-0134768.  
PR 19 MAY-1999; 99US-0134941.  
PR 20 MAY-1999; 99US-0135124.  
PR 21 MAY-1999; 99US-0135353.  
PR 24 MAY-1999; 99US-0135629.  
PR 25 MAY-1999; 99US-0136021.  
PR 27 MAY-1999; 99US-0136392.  
PR 28 MAY-1999; 99US-0136782.  
PR 01 JUN-1999; 99US-0137222.  
PR 03 JUN-1999; 99US-0137528.  
PR 04 JUN-1999; 99US-0137529.



PR 06-AUG-1999; 99US-0147416.  
PR 09-AUG-1999; 99US-0147493.  
PR 09-AUG-1999; 99US-0147935.  
PR 10-AUG-1999; 99US-0148171.  
PR 11-AUG-1999; 99US-0148319.  
PR 12-AUG-1999; 99US-0148341.  
PR 13-AUG-1999; 99US-0148565.  
PR 13-AUG-1999; 99US-0148684.  
PR 16-AUG-1999; 99US-0149368.  
PR 17-AUG-1999; 99US-0149175.  
PR 18-AUG-1999; 99US-0149426.  
PR 20-AUG-1999; 99US-0149722.  
PR 20-AUG-1999; 99US-0149723.  
PR 20-AUG-1999; 99US-0149929.  
PR 23-AUG-1999; 99US-0149902.  
PR 23-AUG-1999; 99US-0149930.  
PR 25-AUG-1999; 99US-0150566.  
PR 26-AUG-1999; 99US-0150884.  
PR 27-AUG-1999; 99US-0151065.  
PR 27-AUG-1999; 99US-0151066.  
PR 27-AUG-1999; 99US-0151080.  
PR 30-AUG-1999; 99US-0151303.  
PR 31-AUG-1999; 99US-0151438.  
PR 01-SEP-1999; 99US-0151930.  
PR 07-SEP-1999; 99US-0152363.  
PR 10-SEP-1999; 99US-0153070.  
PR 13-SEP-1999; 99US-0153758.  
PR 15-SEP-1999; 99US-0154018.  
PR 16-SEP-1999; 99US-0154039.  
PR 20-SEP-1999; 99US-0154779.  
PR 22-SEP-1999; 99US-0155139.  
PR 23-SEP-1999; 99US-0155486.  
PR 24-SEP-1999; 99US-0155659.  
PR 28-SEP-1999; 99US-0156458.  
PR 29-SEP-1999; 99US-0156596.  
PR 04-OCT-1999; 99US-0157117.  
PR 05-OCT-1999; 99US-0157753.  
PR 06-OCT-1999; 99US-0157865.  
PR 07-OCT-1999; 99US-0158029.  
PR 08-OCT-1999; 99US-0158232.  
PR 12-OCT-1999; 99US-0158369.  
PR 13-OCT-1999; 99US-0159293.  
PR 13-OCT-1999; 99US-0159294.  
PR 13-OCT-1999; 99US-0159295.  
PR 14-OCT-1999; 99US-0159329.  
PR 14-OCT-1999; 99US-0159330.  
PR 14-OCT-1999; 99US-0159331.  
PR 14-OCT-1999; 99US-0159637.  
PR 14-OCT-1999; 99US-0159638.  
PR 18-OCT-1999; 99US-0159584.  
PR 21-OCT-1999; 99US-0160741.  
PR 21-OCT-1999; 99US-0160767.  
PR 21-OCT-1999; 99US-0160768.  
PR 21-OCT-1999; 99US-0160770.  
PR 21-OCT-1999; 99US-0160814.  
PR 21-OCT-1999; 99US-0160815.  
PR 22-OCT-1999; 99US-0160980.  
PR 22-OCT-1999; 99US-0160981.  
PR 22-OCT-1999; 99US-0160981.  
PR 22-OCT-1999; 99US-0160989.  
PR 23-OCT-1999; 99US-0161404.  
PR 25-OCT-1999; 99US-0161405.  
PR 25-OCT-1999; 99US-0161406.  
PR 26-OCT-1999; 99US-0161359.  
PR 26-OCT-1999; 99US-0161360.  
PR 26-OCT-1999; 99US-0161361.  
PR 28-OCT-1999; 99US-0161920.  
PR 28-OCT-1999; 99US-0161992.  
PR 28-OCT-1999; 99US-0161993.  
PR 29-OCT-1999; 99US-0162142.

Query Match 47.3%; Score 43; DB 21; Length 250;  
Best Local Similarity 66.7%; Pred. No. 23;  
Matches 8; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 4 SAAANYTTAVDR 15  
| | | | | | | | | |  
Db 47 sralnystaird 58

Search completed: March 26, 2002, 13:38:45  
Job time: 139 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:36:26 ; Search time 37.72 Seconds  
(without alignments)  
10.142 Million cell updates/sec

Title: US-09-709-201-93

Perfect score: 91  
Sequence: 1 CTGSAANYTTAVDRPN 17

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 212252 seqs, 22503292 residues

Total number of hits satisfying chosen parameters: 212252

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued\_Patents\_AA.\*

- 1: /cgn2\_6/ptodata/2/iaa/5A-COMB.pep.\*
- 2: /cgn2\_6/ptodata/2/iaa/5B-COMB.pep.\*
- 3: /cgn2\_6/ptodata/2/iaa/6A-COMB.pep.\*
- 4: /cgn2\_6/ptodata/2/iaa/6B-COMB.pep.\*
- 5: /cgn2\_6/ptodata/2/iaa/PCTUS-COMB.pep.\*
- 6: /cgn2\_6/ptodata/2/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	41	45.1	345	3	US-09-120-365-73
2	41	45.1	345	4	US-09-515-039-73
3	41	45.1	345	4	US-08-827-171B-7
4	41	45.1	468	2	US-08-390-000A-7
5	41	45.1	477	1	US-08-444-734A-4
6	41	45.1	477	1	US-08-087-772A-16
7	41	45.1	2813	3	US-08-896-449A-2
8	41	45.1	2813	3	US-09-132-652-2
9	41	45.1	3969	4	US-08-061-376-5
10	40	44.0	472	1	US-08-194-338-6
11	38	41.8	459	2	US-08-870-518-4
12	38	41.8	918	4	US-09-041-886-11
13	37	40.7	505	4	US-09-382-256-8
14	37	40.7	505	4	US-09-395-115-8
15	37	40.7	997	1	US-08-324-977-50
16	37	40.7	997	2	US-08-384-616-50
17	37	40.7	997	2	US-08-904-686A-50
18	37	40.7	997	4	US-09-315-850-50
19	37	40.7	2620	1	US-08-324-977-32
20	37	40.7	2620	2	US-08-384-616-32
21	37	40.7	2620	2	US-08-904-686A-32
22	37	40.7	2620	4	US-09-315-850-32
23	37	40.7	2621	1	US-08-324-977-36
24	37	40.7	2621	2	US-08-384-616-36
25	37	40.7	2621	2	US-08-904-686A-36
26	37	40.7	2621	4	US-09-315-850-36
27	37	40.7	3010	1	US-08-324-977-2

28	37	40.7	3010	1	US-08-324-977-14	Sequence 14, Appl
29	37	40.7	3010	2	US-08-384-616-2	Sequence 2, Appl
30	37	40.7	3010	2	US-08-384-616-14	Sequence 14, Appl
31	37	40.7	3010	2	US-08-904-686A-2	Sequence 2, Appl
32	37	40.7	3010	2	US-08-904-686A-14	Sequence 14, Appl
33	37	40.7	3010	4	US-09-014-416-3	Sequence 3, Appl
34	37	40.7	3010	4	US-09-315-850-2	Sequence 2, Appl
35	37	40.7	3010	4	US-09-315-850-14	Sequence 14, Appl
36	36	39.6	120	1	US-08-539-304A-6	Sequence 6, Appl
37	36	39.6	304	4	US-09-088-651-2	Sequence 2, Appl
38	36	39.6	329	2	US-08-781-802-8	Sequence 8, Appl
39	36	39.6	329	4	US-08-694-078-8	Sequence 8, Appl
40	36	39.6	329	4	US-09-058-260-8	Sequence 8, Appl
41	36	39.6	366	3	US-08-945-056-6	Sequence 6, Appl
42	36	39.6	366	3	US-08-945-056-8	Sequence 8, Appl
43	36	39.6	374	2	US-08-915-107-2	Sequence 2, Appl
44	36	39.6	374	2	US-08-915-107-4	Sequence 4, Appl
45	36	39.6	374	4	US-09-273-C13-4	Sequence 4, Appl

#### ALIGNMENTS

RESULT 1  
US-09-120-365-73  
; Sequence 73, Application US/09120365  
; Patent No. 6103514  
; GENERAL INFORMATION:  
; APPLICANT: Natori, Shunji  
; TITLE OF INVENTION: NEW PROTEASE  
; FILE REFERENCE: 32290-144749  
; CURRENT APPLICATION NUMBER: US/09/120,365;  
; CURRENT FILING DATE: 1998-07-22  
; EARLIER APPLICATION NUMBER: JP 9-333 474  
; EARLIER FILING DATE: 1997-11-18  
; NUMBER OF SEQ ID NOS: 101  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 73  
; LENGTH: 345  
; TYPE: PRT  
; ORGANISM: Papain  
US-09-120-365-73

Query Match 45.1%; Score 41; DB 3; Length 345;  
Best Local Similarity 80.0%; Pred. No. 31;  
Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TGSAANYTT 11  
||| | |||  
Db 109 TGSAGNYTT 118

RESULT 2  
US-09-515-039-73  
; Sequence 73, Application US/09515039  
; Patent No. 6214599  
; GENERAL INFORMATION:  
; APPLICANT: Natori, Shunji  
; TITLE OF INVENTION: NEW PROTEASE  
; FILE REFERENCE: 32290-144749  
; CURRENT APPLICATION NUMBER: US/09/515,039  
; CURRENT FILING DATE: 2000-03-06  
; EARLIER APPLICATION NUMBER: JP 9-333 474  
; EARLIER FILING DATE: 1997-11-18  
; NUMBER OF SEQ ID NOS: 101  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 73  
; LENGTH: 345  
; TYPE: PRT  
; ORGANISM: Papain  
US-09-515-039-73

Query Match 45.1%; Score 41; DB 4; Length 345;  
 Best Local Similarity 80.0%; Pred. No. 31;  
 Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TGSAAANYTT 11  
 Db 109 TGSAGNYTT 118

RESULT 3  
 US-08-827-171B-7  
 ; Sequence 7, Application US/08827171B  
 ; Patent No. 6254869  
 ; GENERAL INFORMATION:  
 ; APPLICANT: CAROLYN PETERSEN  
 ; TITLE OF INVENTION: CRYPTOPOIN VACCINES, ANTIBODIES, PROTEINS,  
 ; TITLE OF INVENTION: PEPTIDES, DNA AND RNAs FOR PROPHYLAXIS,  
 ; TITLE OF INVENTION: TREATMENT, DIAGNOSIS AND  
 ; TITLE OF INVENTION: DETECTION OF  
 ; TITLE OF INVENTION: CRYPTOPOIDIDIUM PARVUM  
 ; NUMBER OF SEQUENCES: 16  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: PETERS, VERNY, JONES & BIK A  
 ; STREET: 385 Sherman Avenue, Suite 6  
 ; CITY: Palo Alto  
 ; STATE: California  
 ; COUNTRY: United States of America  
 ; ZIP: 94306-1840  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Kb storage  
 ; COMPUTER: PC  
 ; OPERATING SYSTEM: WINDOWS  
 ; SOFTWARE: Wordperfect 6.0a WINDOWS  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/827,171B  
 ; FILING DATE:  
 ; CLASSIFICATION: 536  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 60/014,233  
 ; FILING DATE: March 27, 1996  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Hana Verry  
 ; REGISTRATION NUMBER: 30,518  
 ; REFERENCE/DOCKET NUMBER: (HV)  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (415) 324-1677  
 ; TELEFAX: (415) 324-1678  
 ; INFORMATION FOR SEQ ID NO: 7:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 345 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: protein  
 ; ORGANISM: Carica  
 ; US-08-827-171B-7

Query Match 45.1%; Score 41; DB 2; Length 468;  
 Best Local Similarity 43.8%; Pred. No. 43;  
 Matches 7; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CTGSAANYTTAVDRP 16  
 Db 442 CNGGAADSDSLDEP 457

RESULT 5  
 US-08-444-734A-4  
 ; Sequence 4, Application US/08444734A  
 ; Patent No. 5610282  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Sibley, David R.  
 ; APPLICANT: Monsma, Frederick J.  
 ; APPLICANT: Mahan, Lawrence C.  
 ; APPLICANT: McVittie, Loris D.  
 ; TITLE OF INVENTION: cDNA encoding the rat D1 dopamine  
 ; TITLE OF INVENTION: receptor linked to adenylyl cyclase activation and  
 ; TITLE OF INVENTION: expression of the receptor protein in plasmid-transfected  
 ; TITLE OF INVENTION: cell lines  
 ; NUMBER OF SEQUENCES: 13  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Knobbe, Martens, Olson and Bear  
 ; STREET: 620 Newport Center Drive, Sixteenth Floor  
 ; CITY: Newport Beach  
 ; STATE: CA  
 ; COUNTRY: USA  
 ; ZIP: 92660  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS

Query Match 45.1%; Score 41; DB 4; Length 345;  
 Best Local Similarity 80.0%; Pred. No. 31;  
 Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TGSAAANYTT 11  
 Db 109 TGSAGNYTT 118

RESULT 4  
 US-08-390-000A-7  
 ; Sequence 7, Application US/08390000A

SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/444,734A  
FILING DATE:  
CLASSIFICATION: 530  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/029,917  
FILING DATE: 03-MAR-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/548,714  
FILING DATE: 06-JUL-1990  
ATTORNEY/AGENT INFORMATION:  
NAME: Altman, Daniel E.  
REGISTRATION NUMBER: 34,115  
REFERENCE/DOCKET NUMBER: NIH065.001FW1  
TELEPHONE: (714) 760-0404  
TELEFAX: (714) 760-9502  
INFORMATION FOR SEQ ID NO: 4:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 477 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
FRAGMENT TYPE: internal  
US-08-444-734A-4

Query Match 45.1%; Score 41; DB 1; Length 477;  
Best Local Similarity 43.8%; Pred. No. 44;  
Matches 7; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDRP 16  
| | | | | : : : : |  
Db 451 CNGGAAADSSSLDEP 466

RESULT 6  
US-08-087-772A-16  
Sequence 16, Application US/08087772A  
Patent No. 5691155  
GENERAL INFORMATION:  
APPLICANT: Nahmias, Clara  
APPLICANT: Emorine, Jean L.  
APPLICANT: Strosberg, Donny A.  
TITLE OF INVENTION: Nucleotide Sequences Encoding the Murine  
TITLE OF INVENTION: Beta3-Adrenergic Receptor and Their Applications  
NUMBER OF SEQUENCES: 17  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Bell, Seltzer, Park & Gibson  
STREET: Post Office Drawer 34009  
CITY: Charlotte  
STATE: No. 5691155th Carolina  
COUNTRY: USA  
ZIP: 28234  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/087,772A  
FILING DATE:  
CLASSIFICATION: 800  
ATTORNEY/AGENT INFORMATION:  
NAME: Linker, Raymond O.  
REGISTRATION NUMBER: 26,419  
REFERENCE/DOCKET NUMBER: 3339-195  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-881-3140

TELEFAX: 919-881-3175  
INFORMATION FOR SEQ ID NO: 16:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 477 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-087-772A-16

Query Match 45.1%; Score 41; DB 1; Length 477;  
Best Local Similarity 43.8%; Pred. No. 44;  
Matches 7; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDRP 16  
| | | | | : : : : |  
Db 451 CNGGAAADSSSLDEP 466

RESULT 7  
US-08-896-449A-2  
Sequence 2, Application US/08896449A  
Patent No. 6040143  
GENERAL INFORMATION:  
APPLICANT: Venta, Patrick J  
APPLICANT: Yuzbasiyan-Gurkan, Vilma  
APPLICANT: Schall, William D  
APPLICANT: Brewer, George J  
TITLE OF INVENTION: DNA ENCODING CANINE VON WILLEBRAND  
TITLE OF INVENTION: FACTOR AND METHODS OF USE  
NUMBER OF SEQUENCES: 11  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Harness, Dickey & Pierce, P.L.C.  
STREET: 5445 Corporate Drive  
CITY: Troy  
STATE: Michigan  
COUNTRY: USA  
ZIP: 48098  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/896,449A  
FILING DATE: 18-JUL-1997  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Smith, DeAnn F.  
REFERENCE/DOCKET NUMBER: 2115-001226  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 248-641-1600  
TELEFAX: 248-641-0270  
TELEX: 287637  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 2813 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-896-449A-2

Query Match 45.1%; Score 41; DB 3; Length 2813;  
Best Local Similarity 60.0%; Pred. No. 3.1e+02;  
Matches 9; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDR 15  
| | | | | : : : : |  
Db 621 CLCSAVANAAVAAR 635

```
RESULT 8
US-09-132-652-2
; Sequence 2, Application US/09132652
; Patent No. 6074832
; GENERAL INFORMATION:
; APPLICANT: Venta, Patrick J
; APPLICANT: Yuzbasiyan-Gurkan, Vilma
; APPLICANT: Schall, William D
; APPLICANT: Brewer, George J
; APPLICANT: Duffendeck, John
; TITLE OF INVENTION: DNA ENCODING CANINE VON WILLEBRAND FACTOR AND METHODS
; FILE REFERENCE: 2115S-001226CPB
; CURRENT APPLICATION NUMBER: US/09/132.652
; CURRENT FILING DATE: 1998-08-11
; EARLIER APPLICATION NUMBER: 08/896.449
; EARLIER FILING DATE: 1997-07-18
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 2813
; TYPE: PRT
; ORGANISM: Canis familiaris
US-09-132-652-2

Query Match 45.1%; Score 41; DB 3; Length 2813;
Best Local Similarity 60.0%; Pred. No. 3.1e+02;
Matches 9; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 1 CTGSAANYTTAVDR 15
| | | | | | | |
Db 621 CLCSAVANYAAVAR 635

RESULT 9
US-08-061-376-5
; Sequence 5, Application US/08061376
; Patent No. 6175000
; GENERAL INFORMATION:
; APPLICANT: Evans, Glen A.
; APPLICANT: Djabali, Malek
; APPLICANT: Selleri, Lucia
; APPLICANT: Parry, Pauline
; TITLE OF INVENTION: CHARACTERIZATION OF A CHROMOSOME 11Q23
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
; STREET: 444 South Flower Street, Suite 2000
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/061,376
; FILING DATE: 13-MAY-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Reiter, Stephen E.
; REGISTRATION NUMBER: 31,192
; REFERENCE/DOCKET NUMBER: P41 9387
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619)546-4737
; TELEFAX: (619)546-9392
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3969 amino acids
```

```
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
US-08-061-376-5

Query Match 45.1%; Score 41; DB 4; Length 3969;
Best Local Similarity 43.8%; Pred. No. 4.6e+02;
Matches 7; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

Qy 2 TGSAAANYTTAVDRPN 17
| | | | | | | |
Db 3475 SGQVSNFTQTVDPN 3490
| | | | | | | |

RESULT 10
US-08-194-338-6
; Sequence 6, Application US/08194338
; Patent No. 5474898
; GENERAL INFORMATION:
; APPLICANT: Venter, John C.
; APPLICANT: Fraser, Claire M.
; APPLICANT: McCombie, William R.
; TITLE OF INVENTION: OCTOPAMINE RECEPTOR
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson and Bear
; STREET: 620 Newport Center Drive, Sixteenth Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/194,338
; FILING DATE: 08-FEB-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/676,174
; FILING DATE: 28-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Israelsen, Ned A.
; REGISTRATION NUMBER: 29,655
; REFERENCE/DOCKET NUMBER: NIH101.001DV1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 235-8550
; TELEFAX: (619) 235-0176
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 472 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
US-08-194-338-6

Query Match 44.0%; Score 40; DB 1; Length 472;
Best Local Similarity 43.8%; Pred. No. 64;
Matches 7; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CTGSAANYTTAVDRP 16
| | | | | | | |
Db 446 CNGCAADSDSLDEP 461
```

## RESULT 11

US-08-870-518-4  
; Sequence 4, Application US/08870518  
; Patent No. 5925566  
; GENERAL INFORMATION:  
; APPLICANT: Davis, Roger J.  
; APPLICANT: Galcheva-Gargova, Zoya  
; TITLE OF INVENTION: NON-ACTIVATED RECEPTOR COMPLEX  
; TITLE OF INVENTION: PROTEINS AND USES THEREOF  
; NUMBER OF SEQUENCES: 35  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FASTSEQ for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/870,518  
; FILING DATE: 06-JUN-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/019,219  
; FILING DATE: 06-JUN-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Fasse, Peter J.  
; REGISTRATION NUMBER: 32,983  
; REFERENCE/DOCKET NUMBER: 04020/102001  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617/542-5070  
; TELEFAX: 617/542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 459 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-870-518-4

Query Match 41.8%; Score 38; DB 2; Length 459;  
Best Local Similarity 61.5%; Pred. No. 1.3e+02;  
Matches 8; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

## Qy

3 GSAANVTAVDR 15

## Db

14 GNAAQNVSTAEDR 26

## RESULT 12

US-09-041-886-11  
; Sequence 11, Application US/09041886  
; Patent No. 6235872  
; GENERAL INFORMATION:  
; APPLICANT: Bredesen, Dale E.  
; APPLICANT: Rabizadeh, Sharoz  
; TITLE OF INVENTION: Proapoptotic Peptides, Dependence  
; TITLE OF INVENTION: Polypeptides and Methods of Use  
; NUMBER OF SEQUENCES: 72  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Campbell & Flores LLP  
; STREET: 4370 La Jolla Village Drive, Suite 700  
; CITY: San Diego  
; STATE: California  
; COUNTRY: United States  
; ZIP: 92122  
; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/041,886  
; FILING DATE:  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Campbell, Cathryn A.  
; REGISTRATION NUMBER: 31,815  
; REFERENCE/DOCKET NUMBER: P-LJ 2626  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (619) 535-9001  
; TELEFAX: (619) 535-8949  
; INFORMATION FOR SEQ ID NO: 11:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 918 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-09-041-886-11

Query Match 41.8%; Score 38; DB 4; Length 918;  
Best Local Similarity 41.2%; Pred. No. 2.8e+02;  
Matches 7; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

## Qy

1 CTGSAANVTAVDRPN 17

## Db

321 CSGSAAAGSGTLELPS 337

## RESULT 13

US-09-382-256-8  
; Sequence 8, Application US/09382256A  
; Patent No. 6207814  
; GENERAL INFORMATION:  
; APPLICANT: MIYAZONO, Kohel  
; TEN DIJKE, Peter  
; FRANZEN, Petra  
; YAMASHITA, Hidetoshi  
; HELDIN, Carl-Henrik  
; TITLE OF INVENTION: ACTIVIN RECEPTOR LIKE KINASES, PROTEINS  
; HAVING SERINE THREONINE KINASE DOMAINS,  
; AND THEIR USE  
; NUMBER OF SEQUENCES: 29  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fulbright & Jaworski L.L.P.  
; STREET: 666 Fifth Avenue  
; CITY: New York City  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10103  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.25 inch, 1.44mb  
; COMPUTER: IBM PS/2  
; OPERATING SYSTEM: PC-DOS  
; SOFTWARE: Wordperfect  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/382,256A  
; FILING DATE: 24-Aug-1999  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/GB93/02367  
; FILING DATE: No. 6207814ember 17, 1993  
; APPLICATION NUMBER: GB 9224057.1  
; FILING DATE: No. 6207814ember 17, 1992  
; APPLICATION NUMBER: GB 9304677.9  
; FILING DATE: March 8, 1993  
; APPLICATION NUMBER: GB 9304680.3  
; FILING DATE: March 8, 1993  
; APPLICATION NUMBER: 9311047.6

; FILING DATE: May 28, 1993  
; APPLICATION NUMBER: 9313763.6  
; FILING DATE: July 2, 1993  
; APPLICATION NUMBER: 9316099.2  
; FILING DATE: August 3, 1993  
; APPLICATION NUMBER: 321344.5  
; FILING DATE: October 15, 1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: NO. 6207814man D. Hanson  
; REGISTRATION NUMBER: 30,946  
; REFERENCE/DOCKET NUMBER: LUD 5298.1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 318-3000  
; TELEFAX: (212) 752-5958  
; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 505 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:  
US-09-382-256-8

Query Match 40.7%; Score 37; DB 4; Length 505;  
Best Local Similarity 50.0%; Pred. No. 2.1e+02;  
Matches 7; Conservative 0; Mismatches 7; Indels 0; Gaps 0;  
QY 1 CTGSAANYTTAVD 14  
|| |||||  
Db 36 CTSCLOANYTCETD 49

RESULT 14  
US-09-395-115-8  
; Sequence 8, Application US/09395115  
; Patent No. 6271365  
; GENERAL INFORMATION:  
; APPLICANT: Miyazono, Kohei; Dijke, Peter Ten;  
; APPLICANT: Franzen, Petra; Yamashita, Hidetoshi; Heldin, Carl-Henrik  
; TITLE OF INVENTION: Activin Receptor-Like Kinase, Proteins  
; TITLE OF INVENTION: Having Serine Threonine Kinase Domains And Their Use  
; NUMBER OF SEQUENCES: 29  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Felfe & Lynch  
; STREET: 805 Third Avenue  
; CITY: New York City  
; STATE: New York  
; ZIP: 10022  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.5 inch, 360 kb storage  
; COMPUTER: IBM  
; OPERATING SYSTEM: PC-DOS  
; SOFTWARE: Wordperfect  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/395,115  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/436,265  
; FILING DATE: 30-October-1995  
; APPLICATION NUMBER: PCT/GB93/02367  
; FILING DATE: 17-No. 6271365ember-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9224057.1  
; FILING DATE: 17-No. 6271365ember-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9304677.9  
; FILING DATE: 8-March-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9304680.3  
; FILING DATE: 8-March-1993  
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 9311047.6  
; FILING DATE: 28-May-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9313763.6  
; FILING DATE: 2-July-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9136099.2  
; FILING DATE: 3-August-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9321344.5  
; FILING DATE: 15-October-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kohlei Vineet  
; REGISTRATION NUMBER: 37,003  
; REFERENCE/DOCKET NUMBER: LUD 5298  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 688-9200  
; TELEFAX: (212) 838-3884  
; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 505 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-09-395-115-8  
Query Match 40.7%; Score 37; DB 4; Length 505;  
Best Local Similarity 50.0%; Pred. No. 2.1e+02;  
Matches 7; Conservative 0; Mismatches 7; Indels 0; Gaps 0;  
QY 1 CTGSAANYTTAVD 14  
|| |||||  
Db 36 CTSCLOANYTCETD 49

RESULT 15  
US-08-324-977-50  
; Sequence 50, Application US/08324977  
; Patent No. 5747339  
; GENERAL INFORMATION:  
; APPLICANT: OKAYAMA, Hiroto  
; APPLICANT: FUKU, Isao  
; APPLICANT: MORI, Chisato  
; APPLICANT: TAKAMIZAWA, Akahisa  
; APPLICANT: YOSHIDA, Iwao  
; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC  
; TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE  
; NUMBER OF SEQUENCES: 50  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Armstrong, Westerman, Hattori, Mclelland &  
; ADDRESSEE: Naughton  
; STREET: 1725 K St. N.W. Suite 1000  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: U.S.A.  
; ZIP: 20006  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0  
; SOFTWARE: ASCII  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/324,977  
; FILING DATE: 18-OCT-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: JP 2-167466  
; FILING DATE: 25-JUN-1990  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: JP 2-230921  
; FILING DATE: 31-AUG-1990  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: JP 2-305605



;; FILING DATE: 09-NOV-1990  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/099,706  
;; FILING DATE: 30-JUL-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/769,996  
;; FILING DATE: 02-OCT-1991  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/635,451  
;; FILING DATE: 28-DEC-1990  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Stevens-Smith, Theresa M.  
;; REGISTRATION NUMBER: 36,281  
;; REFERENCE/DOCKET NUMBER: 900703D  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (202) 659-2930  
;; TELEFAX: (202) 887-0357  
;; TELEX: 440142  
;; INFORMATION FOR SEQ ID NO: 50:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 997 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
US-08-324-977-50

Query Match 40.7%; Score 37; DB 1; Length 997;  
Best Local Similarity 53.3%; Pred. No. 4.5e+02;  
Matches 8; Conservative 2; Mismatches 5; Indels 0; Gaps 0;  
QY 1 CTGSAANYTTAVDR 15  
Db 57 CTPSPAPNYSRALWR 71

Search completed: March 26, 2002, 13:41:27  
Job time: 301 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:36:26 ; Search time 42.75 Seconds  
(without alignments)  
30.292 Million cell updates/sec.

Title: US-09-709-201-93

Perfect score: 91

Sequence: 1 CTGSAANYYTTAVDRPN 17

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 219241 seqs, 76174552 residues

Total number of hits satisfying chosen parameters: 219241

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR\_68:\*  
1: pir1:\*  
2: pir2:\*  
3: pir3:\*  
4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	82	90.1	389	2 A43587	major outer membra
2	82	90.1	389	2 D86577	major outer membra
3	78	85.7	389	2 I40864	major outer membra
4	78	85.7	389	2 I40739	major outer membra
5	64	70.3	389	1 MMCWP3	major outer membra
6	48	52.7	662	2 T17211	hypothetical prote
7	47	51.6	56	2 D71349	probable ribosomal
8	47	51.6	389	2 A60109	major outer membra
9	46	50.5	168	2 A84156	single-strand DNA-
10	46	50.5	1325	2 T25753	hypothetical prote
11	45	49.5	3300	2 D70575	probable PPE prote
12	44	48.4	584	1 I39710	cellulose biosynth
13	43	47.3	429	2 T01009	hypothetical prote
14	42	46.2	306	2 S59540	heat shock transcr
15	42	46.2	422	2 D84403	dihydroorotase [lm
16	42	46.2	1005	2 C71513	hypothetical prote
17	41	45.1	229	2 E70978	hypothetical prote
18	41	45.1	273	2 G81952	Hemk protein NMA03
19	41	45.1	310	2 JC7275	acid nuclease Lel
20	41	45.1	345	1 PPPA	papain (EC 3.4.22.
21	41	45.1	423	2 E81010	hemk protein NMB20
22	41	45.1	431	2 JW0098	carbazole dioxygen
23	41	45.1	477	1 QRHUB1	beta-1-adrenergic
24	41	45.1	480	2 I53053	beta 1 adrenergic
25	41	45.1	693	2 JN0573	ubiquitin-like fus
26	41	45.1	3968	2 A44265	trithorax homolog
27	40	44.0	87	1 BXSNA6	antibacterial subs
28	40	44.0	280	2 G36808	hypothetical prote
29	40	44.0	337	2 B84335	hypothetical prote

ALIGNMENTS

RESULT 1

A43587

major outer membrane protein, porin CP0051 precursor [imported] - Chlamydomophila pneum  
N;Alternate names: MOMP  
C:Species: Chlamydomophila pneumoniae, Chlamydia pneumoniae  
C:Date: 29-Jan-1993 #sequence\_revision 29-Jan-1993 #text\_change 11-May-2000  
C:Accession: A43587; A49751; A49216; G72044; F81619  
R:Peretz Meigosa, M.; Kuo, C.C.; Campbell, L.A.  
A:Title: Sequence analysis of the major outer membrane protein gene of Chlamydia pneu  
A:Reference number: A43587; MUID:91244474  
A:Accession: A43587  
A:Molecule type: DNA  
A:Residues: 1-389 <PER>  
A:Cross-references: GB:M69230; NID:gl44540; PIDN:AAA75071.1; PID:gl44541  
R:Carter, M.W.; Al-Mahdawi, S.A.H.; Giles, I.G.; Trehan, J.D.; Ward, M.E.; Clarke,  
J. Gen. Microbiol. 137, 465-475, 1991  
A:Title: Nucleotide sequence and taxonomic value of the major outer membrane protein  
A:Reference number: A49751; MUID:91237311  
A:Accession: A49751  
A>Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-389 <CAR>  
A:Cross-references: GB:M64064; GB:M34942; NID:gl44534; PIDN:AAA23143.1; PID:gl44535  
A>Note: isolate IOL-207  
R:Gaydos, C.A.; Quinn, T.C.; Bobo, L.D.; Eiden, J.J.  
Infect. Immun. 60, 5319-5323, 1992  
A:Title: Similarity of Chlamydia pneumoniae strains in the variable domain IV region  
A:Reference number: A49216; MUID:93084388  
A:Accession: A49216  
A>Status: preliminary  
A:Molecule type: DNA  
A:Residues: 297-352 <GAY>  
A:Cross-references: GB:S50607; PIDN:AAB24363.1; PID:g260973  
A>Note: sequence extracted from NCBI backbone (NCBIN:120604, NCBIP:120605)  
R:Kalan, S.; Mitchell, W.; Marathe, R.; Lammel, C.; Fan, J.; Olinger, L.; Grimwood,  
Nature Genet. 21, 385-389, 1999  
A:Title: Comparative genomes of Chlamydia pneumoniae and C. trachomatis.  
A:Reference number: A72000; MUID:99206606  
A:Accession: G72044  
A:Molecule type: DNA  
A:Residues: 1-389 <ARN>  
A:Cross-references: GB:AE001652; GB:AE001365; NID:g4376997; PIDN:AAD18834.1; PID:g437  
R:Read, T.D.; Brunham, R.C.; Shen, C.; Gill, S.R.; Heidelberg, J.F.; White, O.; Hicke  
C.; Dodson, R.; Gwinn, M.; Nelson, W.; Deboy, R.; Kolonay, J.; McClarty, G.; Salzbe  
Nucleic Acids Res. 28, 1397-1406, 2000  
A:Title: Genome sequences of Chlamydia trachomatis Mopn and Chlamydia pneumoniae AR39  
A:Reference number: A81500; MUID:20150255  
A:Accession: F81619  
A>Status: preliminary  
A:Molecule type: DNA

hypothetical prote  
hypothetical prote  
hypothetical prote  
dihydrodipicolinat  
G-protein coupled  
hypothetical prote  
hypothetical-CoA syn  
probable lpg2 prot  
dihydroorotase (EC  
dihydroorotase - M  
hypothetical prote  
very hypothetical  
ferredoxin--NADP r

A:Residues: 1-389 <REA>  
A:Cross-references: GB:AE002169; GB:AE002161; NID:g7188982; PIDN:AAF37944.1; PID:g718898  
A:Experimental source: strain AR39, HL cells  
C:Genetics:  
A:Gene: ompA; CP0051  
C:Superfamily: Chlamydia major outer membrane protein  
C:Keywords: membrane protein  
F:1-23/Domain: signal sequence #status predicted <SIG>  
F:24-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 90.1%; Score 82; DB 2; Length 389;  
Best Local Similarity 100.0%; Pred. No. 4.1e-06;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
|||||  
Db 90 TGSAAANYTTAVDRPN 105

RESULT 2  
D86577  
major outer membrane protein [imported] - Chlamydia pneumoniae (strain J138)  
C:Species: Chlamydia pneumoniae, Chlamydia pneumoniae  
C:Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 23-Mar-2001  
C:Accession: D86577  
R:Shirai, M.; Hirakawa, H.; Kimoto, M.; Tabuchi, M.; Kishi, F.; Ouchi, K.; Shiba, T.; Ise  
Nucleic Acids Res. 28, 2311-2314, 2000  
A:Title: Comparison of whole genome sequences of chlamydia pneumoniae J138.  
A:Reference number: A86491; MUID:20330349  
A:Accession: D86577  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-389 <STO>  
A:Cross-references: GB:BA000008; NID:g8979067; PIDN:BAA98902.1; GSPDB:GN00142  
A:Experimental source: strain J138  
C:Genetics:  
A:Gene: ompA  
C:Superfamily: Chlamydia major outer membrane protein

Query Match 90.1%; Score 82; DB 2; Length 389;  
Best Local Similarity 100.0%; Pred. No. 4.1e-06;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
|||||  
Db 90 TGSAAANYTTAVDRPN 105

RESULT 3  
I40864  
major outer membrane protein - Chlamydia psittaci  
C:Species: Chlamydia psittaci, Chlamydia psittaci  
C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 31-Mar-2000  
C:Accession: I40864; S33465  
R:Girjes, A.A.; Carrick, F.N.; Lavin, M.F.  
Gene 139, 139-142, 1994  
A:Title: Remarkable sequence relatedness in the DNA encoding the major outer membrane pr  
A:Reference number: I40864; MUID:9411025  
A:Accession: I40864  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-389 <RES>  
A:Cross-references: EMBL:X72023; NID:g313844; PIDN:CAA50906.1; PID:g313845  
C:Superfamily: Chlamydia major outer membrane protein

Query Match 85.7%; Score 78; DB 2; Length 389;  
Best Local Similarity 93.8%; Pred. No. 1.9e-05;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
|||||

|||||  
Db 90 TGSATANYTTAVDRPN 105

RESULT 4  
I40739  
major outer membrane protein precursor - Chlamydia pneumoniae (strain equine/N16)  
C:Species: Chlamydia pneumoniae, Chlamydia pneumoniae  
A:Variety: strain equine/N16  
C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 20-Apr-2000  
C:Accession: I40739  
R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.  
J. Gen. Microbiol. 139, 2621-2626, 1993  
A:Title: Evidence for Chlamydia pneumoniae of non-human origin.  
A:Reference number: I40739; MUID:94103736  
A:Accession: I40739  
A:Status: translated from GB/EMBL/DDBJ  
A:Molecule type: DNA  
A:Residues: 1-389 <STO>  
A:Cross-references: GB:I04982; NID:g289840; PIDN:AAA17397.1; PID:g289841  
C:Comment: On the basis of the major outer membrane protein the authors classified th  
the sequence of the genome strain CWL029 and strain IOL-207. See PIR:A43587.  
C:Genetics:  
A:Gene: momp  
C:Superfamily: Chlamydia major outer membrane protein  
C:Keywords: membrane protein  
F:1-23/Domain: signal sequence #status predicted <SIG>  
F:24-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 85.7%; Score 78; DB 2; Length 389;  
Best Local Similarity 93.8%; Pred. No. 1.9e-05;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
|||||  
Db 90 TGSATANYTTAVDRPN 105

RESULT 5  
MWCWP3  
major outer membrane protein precursor - Chlamydia psittaci (strain S26/3)  
C:Species: Chlamydia psittaci, Chlamydia psittaci  
C:Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 31-Mar-2000  
C:Accession: S08770  
R:Herring, A.J.; Tan, T.W.; Baxter, S.; Inglis, N.F.; Dunbar, S.  
FEMS Microbiol. Lett. 65, 153-158, 1989  
A:Title: Sequence analysis of the major outer membrane protein gene of an ovine abort  
A:Reference number: S08770  
A:Accession: S08770  
A:Molecule type: DNA  
A:Residues: 1-389 <HER>  
A:Cross-references: EMBL:X51859; NID:g40600; PIDN:CAA36152.1; PID:g40601  
C:Superfamily: Chlamydia major outer membrane protein  
F:1-22/Domain: signal sequence #status predicted <SIG>  
F:23-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 70.3%; Score 64; DB 1; Length 389;  
Best Local Similarity 75.0%; Pred. No. 0.0044;  
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
|||||  
Db 90 TGSAAANYTTAVDRPN 105

RESULT 6  
T17211  
hypothetical protein DKFZp4340051.1 - human  
C:Species: Homo sapiens (man)  
C:Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 15-Oct-1999  
C:Accession: T17211

R.Poustka, A.; Klein, M.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.  
submitted to the Protein Sequence Database, September 1999  
A:Reference number: Z18723  
A:Accession: T17211  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-662 <POU>  
A:Cross-references: EMBL:AL117400  
A:Experimental source: adult testis; clone DKF2p4340051  
C:Genetics:  
A:Note: DKF2p4340051.1

Query Match 52.7%; Score 48; DB 2; Length 662;

Best Local Similarity 56.2%; Pred. No. 3.8;

Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANVTAVDRP 16

||||:| | | |

Db 251 CTGSSACVALATDLP 266

RESULT 7

D71349

probable ribosomal protein L33 (rpmG) - syphilis spirochete

C:Species: Treponema pallidum subsp. pallidum (syphilis spirochete)

C:Date: 24-Jul-1998 #sequence\_revision 24-Jul-1998 #text\_change 13-Aug-1999

C:Accession: D71349

R.Fraser, C.M.; Norris, S.J.; Weinstock, G.M.; White, O.; Sutton, G.G.; Dodson, R.; Gwin

son, J.; Khalak, H.; Richardson, D.; Howell, J.K.; Chidambaram, M.; Utterback, T.; McGo

they, L.; Weidman, J.; Smith, H.O.; Venter, J.C.

Science 281, 375-388, 1998

A:Title: Complete genome sequence of Treponema pallidum, the syphilis spirochete.

A:Reference number: A71250; MUID:98332770

A:Accession: D71349

A>Status: preliminary; nucleic acid sequence not shown; translation not shown

A:Molecule type: DNA

A:Residues: 1-56 <COL>

A:Cross-references: GB:AE001205; GB:AE000520; NID:g3322501; PID:g332250

A:Experimental source: strain Nichols

C:Genetics:

C:Superfamily: Escherichia coli ribosomal protein L33

Query Match

Best Local Similarity 51.6%; Score 47; DB 2; Length 56;

Matches 9; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 CTGSAANVTAVDRP 17

||||:| | | |

Db 14 CTGCKRRNTTSNRN 30

RESULT 8

A60109

major outer membrane protein precursor - Chlamydia psittaci (strain Guinea pig inclu

C:Species: Chlamydia psittaci, Chlamydia psittaci

C:Date: 10-Nov-1992 #sequence\_revision 10-Nov-1992 #text\_change 31-Mar-2000

C:Accession: A60109

R.Zhang, Y.X.; Morrison, S.G.; Caldwell, H.D.; Baehr, W.

Infect. Immun. 57, 1621-1625, 1989

A:Title: Cloning and sequence analysis of the major outer membrane protein genes of two

A:Reference number: A60109; MUID:89212917

A:Accession: A60109

A>Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-389 <ZHA>

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 51.6%; Score 47; DB 2; Length 389;

Best Local Similarity 56.2%; Pred. No. 3.2;

Matches 9; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRP 17

||||:| | | |

Db 89 TGNAAAEFTVADRN 104

RESULT 9

A84156

single-strand DNA-binding protein (phage-related protein) ssb [imported] - Bacillus h

C:Species: Bacillus halodurans

C:Date: 01-Dec-2000 #sequence\_revision 01-Dec-2000 #text\_change 08-Dec-2000

C:Accession: A84156

R.Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fujii, F.; H

Nucleic Acids Res. 28, 4317-4331, 2000

A:Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans a

A:Reference number: A83650; MUID:20263314

A:Accession: A84156

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-168 <STO>

A:Cross-references: GB:AP001520; GB:BA000004; NID:g10176401; PIDN:BAB07768.1; GSPDB:G

A:Experimental source: strain C-125

C:Genetics:

A:Gene: ssb

C:Superfamily: bacterial single-stranded DNA-binding protein; single-stranded DNA-bin

Query Match

Best Local Similarity 50.5%; Score 46; DB 2; Length 168;

Matches 9; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 3 GSAANVTAVDRP 16

||||:| | | |

Db 23 GVAVAFGLAVNRP 36

RESULT 10

T25753

hypothetical protein F45E4.3 - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C:Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 15-Oct-1999

C:Accession: T25753

R.Wilson, R.

submitted to the EMBL Data Library, September 1996

A:Description: The sequence of C. elegans cosmid F45E4.

A:Reference number: 220082

A:Accession: T25753

A>Status: preliminary; translated from GB/EM3L/DBDJ

A:Molecule type: DNA

A:Residues: 1-1325 <WIL>

A:Cross-references: EMBL:U70852; PIDN:AAB09134.1; GSPDB:GN00022; CESP:F45E4.3

A:Experimental source: strain Bristol N2; clone F45E4

C:Genetics:

A:Gene: CESP:F45E4.3

A:Map position: 4

A:Introns: 25/3; 859/1; 928/1; 966/1; 1002/2; 1106/2; 1167/1; 1255/1; 1274/2

Query Match

Best Local Similarity 50.5%; Score 46; DB 2; Length 1325;

Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 GSAANVTATA 12

||||:| | | |

Db 156 GSAASNYTTA 165

RESULT 11

D70575

probable PPE protein - Mycobacterium tuberculosis (strain H37RV)  
 C:Species: Mycobacterium tuberculosis  
 C>Date: 17-Jul-1998 #sequence\_revision 17-Jul-1998 #text\_change 22-Oct-1999  
 C:Accession: D70575  
 R:Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, S.; Squares, S.; Nature 393, 537-544, 1998  
 A:Authors: Squares, R.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G.  
 A:Title: Deciphering the biology of Mycobacterium tuberculosis from the complete genome  
 A:Reference number: A70500; MUID:98295987  
 A:Accession: D70575  
 A:Status: preliminary; nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-3300 <COL>  
 A:Cross-references: GB:Z95324; GB:AL123456; NID:g3261760; PIDN:CAB08587.1; PID:el299834  
 A:Experimental source: strain H37RV  
 C:Genetics:  
 A:Gene: PPE

Query Match 49.5%; Score 45; DB 2; Length 3300;  
 Best Local Similarity 57.1%; Pred. No. 61;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;  
 QY 3 GSAANYTTAVDRP 16  
 | | | | | : | |  
 Db 2792 GLLAANYTTIERP 2805

RESULT 12  
 I39710  
 cellulose biosynthesis protein celd - Agrobacterium tumefaciens  
 C:Species: Agrobacterium tumefaciens  
 C>Date: 03-Dec-1999 #sequence\_revision 03-Dec-1999 #text\_change 03-Dec-1999  
 C:Accession: I39710  
 R:Matthysse, A.G.; White, S.; Lightfoot, R.  
 J. Bacteriol. 177, 1069-1075, 1995  
 A:Title: Genes required for cellulose synthesis in Agrobacterium tumefaciens.  
 A:Reference number: I39709; MUID:95164506  
 A:Accession: I39710  
 A:Status: translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-584 <RES>  
 A:Cross-references: GB:I39609; NID:g710486; PIDN:AAC41431.1; PID:g710488  
 C:Comment: This protein is required for cellulose biosynthesis.  
 C:Genetics:  
 A:Gene: celd  
 C:Superfamily: Agrobacterium tumefaciens cellulose biosynthesis protein celd

Query Match 48.4%; Score 44; DB 1; Length 584;  
 Best Local Similarity 53.3%; Pred. No. 16;  
 Matches 8; Conservative 4; Mismatches 3; Indels 0; Gaps 0;  
 QY 3 GSAANYTTAVDRPN 17  
 | | | | | : | |  
 Db 89 GNAADYTGFSRPD 103

RESULT 13  
 T01009  
 hypothetical protein At2g39790 [imported] - Arabidopsis thaliana  
 N:Alternate names: hypothetical protein T517.9  
 C:Species: Arabidopsis thaliana (mouse-ear cress)  
 C>Date: 05-Feb-1999 #sequence\_revision 05-Feb-1999 #text\_change 23-Mar-2001  
 C:Accession: T01009; E84821  
 R:Rounsley, S.D.; Lin, X.; Ketchum, K.A.; Crosby, M.L.; Brandon, R.C.; Sykes, S.M.; Kaul  
 submitted to the EMBL Data Library, November 1997  
 A:Description: Arabidopsis thaliana chromosome II BAC T517 genomic sequence.  
 A:Reference number: Z14162  
 A:Accession: T01009  
 A:Status: translated from GB/EMBL/DBJ

A:Molecule type: DNA  
 A:Residues: 1-429 <ROU>  
 A:Cross-references: EMBL:AC003000; NID:g2642152; PID:g2642161  
 A:Experimental source: cultivar Columbia  
 R:Lin, X.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.; Fujii, C.Y.; M.; Koo, H.; Moffat, K.S.; Cronin, L.A.; Shen, M.; VanAken, S.E.; Umayam, L.; Tallon, E.; D.; Nierman, W.C.; White, O.; Eisen, J.A.; Salzberg, S.L.; Fraser, C.M.; Venter  
 Nature 402, 761-768, 1999  
 A:Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana.  
 A:Reference number: A84420; MUID:20083487  
 A:Accession: E84821  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-429 <STO>  
 A:Cross-references: GB:AE002093; NID:g2642161; PIDN:AAB87138.1; GSPDB:GNO0139  
 C:Genetics:  
 A:Gene: T517.9; At2g39790  
 A:Map position: 2  
 A:Introns: 82/3; 189/2; 263/3; 377/2

Query Match 47.3%; Score 43; DB 2; Length 429;  
 Best Local Similarity 66.7%; Pred. No. 17;  
 Matches 8; Conservative 2; Mismatches 2; Indels 0; Gaps 0;  
 QY 4 SAAANYTTAVDR 15  
 | | | | | : | |  
 Db 226 SRALNYSTAIDR 237

RESULT 14  
 S59540  
 heat shock transcription factor HSF31 - soybean (fragment)  
 C:Species: Glycine max (soybean)  
 C>Date: 15-Feb-1996 #sequence\_revision 01-Mar-1996 #text\_change 03-Nov-2000  
 C:Accession: S59540  
 R:Czarnecka-Verner, E.; Yuan, C.X.; Fox, P.C.; Gurley, W.B.  
 Plant Mol. Biol. 29, 37-51, 1995  
 A:Title: Isolation and characterization of six heat shock transcription factor cDNA c  
 A:Reference number: S59537; MUID:96017612  
 A:Accession: S59540  
 A:Status: nucleic acid sequence not shown  
 A:Molecule type: mRNA  
 A:Residues: 1-306 <CZA>  
 A:Cross-references: EMBL:Z46955; NID:g662926; PIDN:CAA87079.1; PID:g671867  
 A:Note: constitutively expressed  
 C:Genetics:  
 A:Gene: HSF31  
 C:Superfamily: tomato heat shock transcription factor HSF8; HSF DNA-binding domain ho  
 C:Keywords: DNA binding; leucine zipper; nucleus; transcription factor  
 F:1-63/Domain: HSF DNA-binding domain homology (fragment) <HSF>

Query Match 46.2%; Score 42; DB 2; Length 306;  
 Best Local Similarity 72.7%; Pred. No. 18;  
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 QY 3 GSAANYTTAV 13  
 | | | | | : | |  
 Db 122 GAAANYNTSV 132

RESULT 15  
 D84403  
 dihydroorotase [imported] - Halobacterium sp. NRC-1  
 C:Species: Halobacterium sp. NRC-1  
 C>Date: 02-Feb-2001 #sequence\_revision 02-Feb-2001 #text\_change 16-Feb-2001  
 C:Accession: D84403  
 R:Ng, W.V.; Kennedy, S.P.; Mahairas, G.G.; Berquist, B.; Pan, M.; Shukla, H.D.; Lasky  
 ; Leithausen, B.; Keller, K.; Cruz, R.; Danson, M.J.; Hough, D.W.; Maddocks, D.G.; Ja  
 Jung, K.H.; Alam, M.; Freitas, T.  
 Proc. Natl. Acad. Sci. U.S.A. 97, 12176-12181, 2000  
 A:Authors: Hou, S.; Daniels, C.J.; Dennis, P.P.; Omer, A.D.; Ebhardt, H.; Lowe, T.M.;

A;Title: Genome sequence of Halobacterium species NRC-1.  
A;Reference number: A84160; MUID:20504483  
A;Accession: D84403  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-422 <STO>  
A;Cross-references: GB:AE004437; NID:g10581925; PIDN:AAG20592.1; GSPDB:GN00138  
C;Genetics:  
A;Gene: pvrC  
C;Superfamily: Bacillus dihydroorotase; Bacillus dihydroorotase homology

Query Match 46.2%; Score 42; DB 2; Length 422;  
Best Local Similarity 57.1%; Pred. No. 24;  
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 4 SAANYTTAVDRPN 17  
:|:| | | | | | |  
Db 74 AAGGVTTVVDQPN 87

Search completed: March 26, 2002, 13:37:18  
Job time: 52 sec





GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:36:26 ; Search time 24.63 Seconds  
(without alignments)  
25.307 Million cell updates/sec

Title: US-09-709-201-93

Perfect score: 91

Sequence: 1 CTGSAANYTTAVDRPN 17

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 100059 seqs, 36664827 residues

Total number of hits satisfying chosen parameters: 100059

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : SwissProt\_39:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	82	90.1	389	1	OMPL_CHLPN
2	78	85.7	333	1	OMIK_CHLPN
3	78	85.7	389	1	OMIN_CHLPN
4	64	70.3	389	1	OMIA_CHLPN
5	47	51.6	56	1	RL33_TREPA
6	43	47.3	429	1	YB90_ARATH
7	42	46.2	1005	1	Y456_CHLTR
8	41	45.1	345	1	PAPA_CARPA
9	41	45.1	477	1	BIAR_HUMAN
10	41	45.1	480	1	BIAR_MACMU
11	41	45.1	3969	1	HRX_HUMAN
12	40	44.0	87	1	ANSA_STRCZ
13	40	44.0	280	1	VG27_HSVSA
14	40	44.0	722	1	PALY_CITLI
15	39.5	43.4	268	1	DAPB_PSEAE
16	39	42.9	375	1	GPRS_HUMAN
17	39	42.9	377	1	GPRS_RAT
18	39	42.9	379	1	GPRS_MOUSE
19	39	42.9	414	1	Y878_METJA
20	39	42.9	2037	1	FAS1_CANAL
21	38.5	42.3	454	1	PYRC_METHH
22	38	41.8	116	1	Y243_MYCGE
23	38	41.8	278	1	YFOL_STRTR
24	38	41.8	309	1	JILL_HCVWA
25	38	41.8	346	1	CRLI_CANAL
26	38	41.8	459	1	ZPRI_SCHPO
27	38	41.8	538	1	DAC_ACTSP
28	38	41.8	557	1	YP85_MYCTU
29	38	41.8	580	1	MEND_BACSU
30	38	41.8	713	1	CDGT_BACSP
31	38	41.8	895	1	ANDR_MACFA
32	38	41.8	895	1	ANDR_PAPHA
33	38	41.8	911	1	ANDR_PANTR

RESULT 1

ID	OMPL_CHLPN	STANDARD;	PRT;	369 AA.
AC	P27455; Q9JQF6;			
DT	01-AUG-1992 (Rel. 23, Created)			
DT	01-AUG-1992 (Rel. 23, Last sequence update)			
DT	20-AUG-2001 (Rel. 40, Last annotation update)			
DE	MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).			
GN	OMPA OR OMPI OR CPN0695 OR CP0051.			
OS	Chlamydia pneumoniae (Chlamydia pneumoniae).			
OC	Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.			
OX	NCBI_TaxID=83558;			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=IOL-207;			
RX	MEDLINE=91237311; PubMed=2033374;			
RA	Cartier M.W., Al-Mahdawi S.A.H., Giles I.G., Trehan J.D.,			
RA	Ward M.E., Clarke I.N.;			
RT	"Nucleotide sequence and taxonomic value of the major outer membrane			
RL	protein gene of Chlamydia pneumoniae IOL-207."			
RL	J. Gen. Microbiol. 137:465-475(1991).			
RN	[2]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=TWAR;			
RX	MEDLINE=91244474; PubMed=1840574;			
RA	Perez Melgosa M., Kuo C.-C., Campbell L.A.;			
RT	"Sequence analysis of the major outer membrane protein gene of			
RL	Chlamydia pneumoniae."			
RL	Infect. Immun. 59:2195-2199(1991).			
RN	[3]			
RP	SEQUENCE FROM N.A.			
RA	Mitchell W.M., Tharp A.C., Stratton C.N., Sriram S.;			
RL	Submitted (FEB-1999) to the EMBL/GenBank/DBJ databases.			
RN	[4]			
RP	SEQUENCE FROM N.A.			
RX	STRAIN=CWL029;			
RX	MEDLINE=99206606; PubMed=10192388;			
RA	Kalman S., Mitchell W., Marathe R., Laumel C., Fan J., Hyman R.W.,			
RA	Olinger L., Grimwood J., Davis R.W., Stephens R.S.;			
RT	"Comparative genomes of Chlamydia pneumoniae and C. trachomatis."			
RN	Nat. Genet. 21:385-389(1999).			
RN	[5]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=AR39;			
RX	MEDLINE=20150255; PubMed=10684935;			
RA	Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F., Bass S.,			
RA	White O., Hickey E.K., Peterson J., Utterback T., Berry K., Doudson R.,			
RA	Linher K., Weidman J., Khouri H., Cravan B., Bowman C., Dodson R.,			
RA	Gwin M., Nelson W., DeKoy R., Kolonay J., McClarty G., Salzberg S.L.,			
RA	Eisen J., Fraser C.M.;			
RT	"Genome sequences of Chlamydia trachomatis MOPN and Chlamydia			
RL	pneumoniae AR39."			
RL	Nucleic Acids Res. 28:1397-1406(2000).			
RN	[6]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=J138;			

34	38	41.8	919	1	ANDR_HUMAN
35	38	41.8	1318	1	VP14_EBV
36	38	41.8	1790	1	VIT_ANTGR
37	37.5	41.2	1142	1	ENAM_PIG
38	37	40.7	270	1	NUPI_PENCI
39	37	40.7	270	1	NUP3_PENSQ
40	37	40.7	280	1	YTZA_AGRVI
41	37	40.7	341	1	COA2_POVMK
42	37	40.7	505	1	KIR2_HUMAN
43	37	40.7	718	1	YSO2_CAEEL
44	37	40.7	754	1	SULX_YEAST
45	37	40.7	884	1	CADB_XENLA

ALIGNMENTS

RX MEDLINE-20330349; PubMed=10871362;  
 RA Shirai M., Hirakawa H., Kimoto M., Tabuchi M., Kishi F., Ouchi K.,  
 RA Shiba T., Ishii K., Hattori M., Kuhara S., Nakazawa T.,  
 RT "Comparison of whole genome sequences of Chlamydia pneumoniae J138  
 RL from Japan and CML029 from USA.",  
 Nucleic Acids Res. 28:2311-2314 (2000).  
 [7]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-J138;  
 RX MEDLINE-20298986; PubMed=10839753;  
 RA Shirai M., Hirakawa H., Ouchi K., Tabuchi M., Kishi F., Kimoto M.,  
 RA Takeuchi H., Nishida J., Shibata K., Fujinaga R., Yoneda H.,  
 RA Matsushima H., Tanaka C., Furukawa S., Miura K., Nakazawa A.,  
 RA Ishii K., Shiba T., Hattori M., Kuhara S., Nakazawa T.,  
 RT "Comparison of outer membrane protein genes omp and pmp in the whole  
 RT genome sequences of Chlamydia pneumoniae isolates from Japan and the  
 RT United States.",  
 J. Infect. Dis. 181 Suppl 3:S524-S527 (2000).  
 CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL: M64064; AAA23143.1;  
 DR EMBL: M69230; AAA73071.1;  
 DR EMBL: AF131889; AAD22492.1;  
 DR EMBL: AE001652; AAD18834.1;  
 DR EMBL: AE002167; AAF37944.1;  
 DR EMBL: AP002547; BAA98902.1;  
 DR EMBL: AB033787; BAA85940.1;  
 DR PIR: A43587; A43587.  
 DR PIR: A49751; A49751.  
 DR TIGR: CP0051;  
 DR InterPro: IPR000604; Chlamydia\_OMP.  
 DR Pfam: PF01308; Chlamydia\_OMP; 1.  
 DR ProDom: PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal; Complete proteome.  
 FT SIGNAL 1 23  
 FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.  
 FT SEQUENCE 389 AA; 41620 MW; 15D984151E41F8F2 CRC64;  
 CC  
 Query Match 90.1%; Score 82; DB 1; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 1.5e-06;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 2 TGSAAANYTTAVDRPN 17  
 Db 90 TGSAAANYTTAVDRPN 105  
 |||||  
 RESULT 2  
 OMIK\_CHLPN STANDARD; PRT; 333 AA.  
 AC Q9XB4;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN (MOMP) (FRAGMENT).  
 GN OMPA OR OMP1.  
 OS Chlamydia pneumoniae (Chlamydia pneumoniae).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.

OX NCBI\_TaxID=83558;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-KOALA TYPE I;  
 RX MEDLINE-93123168; PubMed=8419295;  
 RA Kaltenboeck B., Kousoulas K.G., Storz J.,  
 RT "Structures of and allelic diversity and relationships among the major  
 RL outer membrane protein (ompA) genes of the four chlamydial species.",  
 J. Bacteriol. 175:487-502 (1993).  
 CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL: M73038; AAD38210.1;  
 DR InterPro: IPR000604; Chlamydia\_OMP.  
 DR Pfam: PF01308; Chlamydia\_OMP; 1.  
 DR ProDom: PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin.  
 FT NON\_TER 1 1  
 FT NON\_TER 333 333  
 FT SEQUENCE 333 AA; 35811 MW; 204604512C4C3B3F CRC64;  
 CC  
 Query Match 85.7%; Score 78; DB 1; Length 333;  
 Best Local Similarity 93.8%; Pred. No. 6.2e-06;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Qy 2 TGSAAANYTTAVDRPN 17  
 Db 46 TGSAAANYTTAVDRPN 61  
 |||||  
 RESULT 3  
 OMIN\_CHLPN STANDARD; PRT; 389 AA.  
 AC Q07430;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
 GN OMPA OR OMP1.  
 OS Chlamydia pneumoniae (Chlamydia pneumoniae).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.  
 OX NCBI\_TaxID=83558;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-N16;  
 RX MEDLINE-94103736; PubMed=8277245;  
 RA Storey C., Lusher M., Yates P., Richmond S.,  
 RT "Evidence for Chlamydia pneumoniae of non-human origin.",  
 J. Gen. Microbiol. 139:2621-2626 (1993).  
 CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; L04982; AAA17397.1; -  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal.  
 FT SIGNAL 1 23 BY SIMILARITY.  
 FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41628 MW; 801622F05D841967 CRC64;

Query Match 85.7%; Score 78; DB 1; Length 389;  
 Best Local Similarity 93.8%; Pred. No. 7.3e-06;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 TGSAAANYTTTAVDRPN 17  
 ||| ||||| |||||  
 Db 90 TGSATANYTTTAVDRPN 105

## RESULT 4

OM1A\_CHLPS STANDARD; PRT; 389 AA.

AC P16567;  
 DT 01-AUG-1990 (Rel. 15, Created)  
 DT 01-AUG-1990 (Rel. 15, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
 GN OMPA OR OMP1.  
 OS Chlamydia psittaci (Chlamydophila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.  
 OX NCBI\_TaxID=83554;  
 RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN-OVINE ENZOOTIC ABORTION ISOLATE S26/3;

RX MEDLINE=90128177; PubMed=2612883;

RA Herring A.J., Tan T.W., Baxter S., Inglis N.F., Dunbar S.;

RT "Sequence analysis of the major outer membrane protein gene of an

ovine abortion strain of Chlamydia psittaci.";

RL FEMS Microbiol. Lett. 53:153-158(1989).

RN [2]

RP SEQUENCE FROM N.A.

RC STRAIN-BOVINE ABORTION ISOLATE BAL;

RX MEDLINE=96189695; PubMed=8605581;

RA Griffiths P.C., Plater J.M., Martin T.C., Hughes S.L.,

RA Hughes K.J., Hewinson R.G., Dawson M.;

RT "Epizootic bovine abortion in a dairy herd: characterization of a

Chlamydia psittaci isolate and antibody response.";

RL Br. Vet. J. 151:683-693(1995).

CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY

BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH

THE INTRACELLULAR RETICULATE BODY MEMBRANE.

CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP

MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.

CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.

CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; X51859; CAA36152.1; -

DR EMBL; L39020; AAB02850.1; -

DR PIR; S08770; MMCWP3.

DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal.  
 FT SIGNAL 1 22  
 FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41883 MW; 741B5A23ACDDB447 CRC64;

Query Match 70.3%; Score 64; DB 1; Length 389;  
 Best Local Similarity 75.0%; Pred. No. 0.0017;  
 Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 TGSAAANYTTTAVDRPN 17  
 ||| ||||| |||||  
 Db 90 TGTAAANYKTPTDRPN 105

## RESULT 5

RL33\_TREPA STANDARD; PRT; 56 AA.

ID RL33\_TREPA STANDARD; PRT; 56 AA.

AC O83262;

DT 15-DEC-1998 (Rel. 37, Created)

DT 15-DEC-1998 (Rel. 37, Last sequence update)

DT 20-AUG-2001 (Rel. 40, Last annotation update)

DE 50S RIBOSOMAL PROTEIN L33.

GN RPMG OR TP0234

OS Treponema pallidum.

OC Bacteria; Spirochaetales; Spirochaetaceae; Treponema.

OX NCBI\_TaxID=160;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=NICHOLS;

RX MEDLINE=98332770; PubMed=9665876;

RA Fraser C.M., Norris S.J., Weinstock G.K., White O., Sutton G.G.,

RA Dodson R., Gwinn M., Hickey E.K., Clayton R., Ketchum K.A.,

RA Sodergren E., Hardham J.M., McLeod M.P., Salzberg S., Peterson J.,

RA Khalak H., Richardson D., Howell J.K., Chidambaram M., Utterback T.,

RA McDonald L., Attiach P., Bowman C., Cotton M.D., Fujii C., Garland S.,

RA Hatch B., Horst K., Roberts K., Sandusky M., Weidman J., Smith H.O.,

RA Venter J.C.;

RT "Complete genome sequence of Treponema pallidum, the syphilis

agent Spirochete.";

RL Science 281:375-388(1998).

CC -1- SIMILARITY: BELONGS TO THE L33P FAMILY OF RIBOSOMAL PROTEINS.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; AE001205; AAC65222.1; -

DR TIGR; TP0234; -

DR InterPro; IPR001705; Ribosomal\_L33.

DR Pfam; PF004711; Ribosomal\_L33; 1.

DR ProDom; PD002595; Ribosomal\_L33; 1.

DR PROSITE; PS00582; RIBOSOMAL\_L33; 1.

KW Ribosomal protein; Complete proteome.

SQ SEQUENCE 56 AA; 6820 MW; 1636DC3500D1F4B1 CRC64;

Query Match 51.6%; Score 47; DB 1; Length 56;  
 Best Local Similarity 52.9%; Pred. No. 0.2;  
 Matches 9; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 CTGSAAANYTTTAVDRPN 17  
 ||| ||||| :||  
 Db 14 CTGCKRRNYTTSNRNRN 30

```

RESULT 6
YB90_ARATH
ID YB90_ARATH STANDARD; PRT; 429 AA.
AC O22286;
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE HYPOTHETICAL 47.9 KDA PROTEIN AT2G39790.
GN AT2G39790 OR T517.9.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eurosids II; Brassicales; Brassicaceae; Arabidopsids.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CV. COLUMBIA;
RX MEDLINE=20083487; PubMed=10617197;
RA Lin X., Kaul S., Rounsley S.D., Shea T.P., Benito M.-I., Town C.D.,
RA Fujii C.Y., Mason T.M., Bowman C.L., Barnstead M.E., Feldblum T.V.,
RA Buell C.R., Ketchum K.A., Lee J.J., Ronning C.M., Koo H.L.,
RA Moffat K.S., Cronin L.A., Shen M., VanAken S.E., Umayam L.,
RA Tallon L.J., Gill J.E., Adams M.D., Carrera A.J., Creasy T.H.,
RA Goodman H.M., Somerville C.R., Copenhaver G.P., Preuss D.,
RA Nierman W.C., White O., Eisen J.A., Salzberg S.L., Fraser C.M.,
RA Venter J.C.;
RT "Sequence and analysis of chromosome 2 of the plant Arabidopsis
RT thaliana.";
RT Nature 402:761-768(1999).
CC -1- SIMILARITY: DISTANTLY RELATED TO THE MAM33 FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: AC003000; AB87128.1;
DR InterPro: IPR003428; MAM33.
DR Pfam: PF02330; MAM33; 1.
DR Hypothetical protein.
KW SEQUENCE 429 AA; 47860 MW; FC5F0BD011CF0A83 CRC64;

Query Match 47.3%; Score 43; DB 1; Length 429;
Best Local Similarity 66.7%; Pred. No. 7;
Matches 8; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 4 SAAANYTTAVDR 15
DB 226 SRALNYSTAIRD 237
| | | | | | | |
| | | | | | | |

RESULT 7
Y456_CHLTR
ID Y456_CHLTR STANDARD; PRT; 1005 AA.
AC O84462;
DT 20-AUG-2001 (Rel. 40, Created)
DT 20-AUG-2001 (Rel. 40, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE HYPOTHETICAL PROTEIN CT456 PRECURSOR.
GN CT456.
OS Chlamydia trachomatis.
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=813;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=D/UV-3/CX;
RX MEDLINE=99000809; PubMed=9784136;
RA Stephens R.S., Kalman S., Lammel C.J., Fan J., Marathe R., Aravind L.,
RA Mitchell W.P., Olinger L., Tatusov R.L., Zhao Q., Koonin E.V.,

```

```

RA Davis R.W.;
RT "Genome sequence of an obligate intracellular pathogen of humans:
RT Chlamydia trachomatis.";
RL Science 282:754-759(1998).
CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL CPN0572/CT456/TC0741
CC FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: AE001319; AAC68056.1;
DR Hypothetical protein; Signal; Complete proteome.
FT SIGNAL 1 40 POTENTIAL.
FT CHAIN 41 1005 HYPOTHETICAL PROTEIN CT456.
SQ SEQUENCE 1005 AA; 102131 MW; EC47EC389851CD1E CRC64;

Query Match 46.2%; Score 42; DB 1; Length 1005;
Best Local Similarity 43.8%; Pred. No. 24;
Matches 7; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17
DB 60 TGETVVVNTNSASAPN 75
| | | | | |
| | | | | |

RESULT 8
PAPA_CARPA
ID PAPA_CARPA STANDARD; PRT; 345 AA.
AC P00784;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE PAPAIN PRECURSOR (EC 3.4.22.2) (PAPAYA PROTEINASE I) (PPI).
OS Carica papaya (papaya).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eurosids II; Brassicales; Caricaceae; Carica.
OX NCBI_TaxID=3649;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=87163525; PubMed=2881845;
RA Cohen L.W., Coghlan V.M., Dihel L.C.;
RT "Cloning and sequencing of papain-encoding cDNA.";
RL Gene 48:219-227(1986).
RN [2]
RP SEQUENCE OF 134-345.
RX MEDLINE=71007899; PubMed=5470818;
RA Mitchell R.E.J., Chaiken I.M., Smith E.L.;
RT "The complete amino acid sequence of papain. Additions and
RT corrections.";
RL J. Biol. Chem. 245:3485-3492(1970).
RN [3]
RP REVISION TO 197.
RX MEDLINE=70141125; PubMed=5435495;
RA Husain S.S., Lowe G.;
RT "A reinvestigation of residues 64-68 and 175 in papain. Evidence that
RT residues 64 and 175 are asparagine.";
RL Biochem. J. 116:689-692(1970).
RN [4]
RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS).
RX MEDLINE=6906973; PubMed=5681232;
RA Drenth J., Jansoni J.N., Koekoek R., Swen H.M., Wolthers B.G.;
RT "Structure of papain.";
RL Nature 218:929-932(1968).
RN [5]
RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS).
RX MEDLINE=85058190; PubMed=6502713;

```

RA Kamphuis I.G., Kalk K.H., Swarte M.B.A., Drenth J.;  
RT "Structure of papain refined at 1.65-A resolution.";  
RL J. Mol. Biol. 179:233-256(1984).  
RN [6]  
RX X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).  
RA MEDLINE-90269230; PubMed-2347312;  
RA Stubbs M.T., Laber B., Bode W., Huber R., Jerala R., Lenarcic B.,  
RA Turk V.;  
RT "The refined 2.4 A X-ray crystal structure of recombinant human  
RT stefin B in complex with the cysteine proteinase papain: a novel type  
RT of proteinase inhibitor interaction.";  
RL EMBO J. 9:1939-1947(1990).  
RN [7]  
RX X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS).  
RA MEDLINE-93075728; PubMed-1445868;  
RA Yamamoto A., Tomoo K., Doi M., Ohishi H., Inoue M., Ishida T.,  
RA Yamamoto D., Tsuboi S., Okamoto H., Okada Y.;  
RT "Crystal structure of  
RT papain-succinyl-Gln-Val-Ala-p-nitroanilide complex at 1.7-A  
RT resolution: noncovalent binding mode of a common sequence of  
RT endogenous thiol protease inhibitors.";  
RL Biochemistry 31:11305-11309(1992).  
RN [8]  
RX X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS).  
RA Pickersgill R.W., Harris G.W., Garman E.;  
RT "Structure of monoclinal papain at 1.60-A resolution.";  
RL Acta Crystallogr. B 48:59-67(1992).  
CC -|- CATALYTIC ACTIVITY: PREFERENTIAL CLEAVAGE: ARG-, LYS-, PHE-XAA-  
CC -|- SIMILARITY: BELONGS TO PEPTIDASE FAMILY C1; ALSO KNOWN AS THE  
CC PAPAIN FAMILY OF THIOL PROTEASES.  
CC -|- DATABASE: NAME=Worthington enzyme manual;  
CC WWW="http://www.worthington-biochem.com/manual/P/PAP.html".  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; M15203; AAB02650.1; -;  
DR PIR; A26466; PPPA.  
DR PDB; 1PAD; 17-FEB-84.  
DR PDB; 2PAD; 17-FEB-84.  
DR PDB; 4PAD; 04-MAR-85.  
DR PDB; 5PAD; 17-FEB-84.  
DR PDB; 6PAD; 17-FEB-84.  
DR PDB; 9PAD; 15-JAN-95.  
DR PDB; 1PE6; 15-APR-93.  
DR PDB; 1PIP; 31-OCT-93.  
DR PDB; 1POP; 02-JAN-85.  
DR PDB; 1PPD; 31-JAN-94.  
DR PDB; 1PPP; 31-JAN-94.  
DR PDB; 1STF; 31-JAN-94.  
DR MEROPS; C01.001; -;  
DR InterPro; IPR000668; Peptidase\_C1.  
DR InterPro; IPR000189; Thiolprot\_act\_site.  
DR Pfam; PF00112; Peptidase\_C1; 1.  
DR PRINTS; PR00705; PAPAIN.  
DR PROSITE; PS00139; THIOL\_PROTEASE\_CYS; 1.  
DR PROSITE; PS00639; THIOL\_PROTEASE\_HIS; 1.  
DR PROSITE; PS00640; THIOL\_PROTEASE\_ASN; 1.  
KW Hydrolase; Thiol protease; Zymogen; Signal; 3D-structure.  
FT SIGNAL 1 18  
FT PROPEP 19 133  
FT CHAIN 134 345  
FT ACT\_SITE 158 158  
FT ACT\_SITE 292 292  
FT ACT\_SITE 308 308  
FT ACT\_SITE 155 196  
FT DISULFID 189 228

FT DISULFID 286 333  
FT CONFLICT 180  
FT CONFLICT 219 220  
FT CONFLICT 251 251  
FT CONFLICT 268 268  
FT STRAND 138 139  
FT TURN 140 144  
FT STRAND 151 151  
FT TURN 153 154  
FT STRAND 156 156  
FT HELIX 158 175  
FT STRAND 181 181  
FT HELIX 183 189  
FT TURN 191 192  
FT TURN 195 196  
FT STRAND 197 197  
FT STRAND 199 199  
FT HELIX 201 210  
FT TURN 211 211  
FT STRAND 213 213  
FT STRAND 215 215  
FT TURN 216 218  
FT HELIX 231 233  
FT STRAND 238 238  
FT STRAND 242 245  
FT HELIX 251 260  
FT STRAND 263 267  
FT HELIX 272 276  
FT STRAND 281 282  
FT STRAND 292 299  
FT STRAND 303 307  
FT STRAND 310 310  
FT TURN 312 313  
FT TURN 315 315  
FT STRAND 316 316  
FT TURN 317 318  
FT STRAND 319 323  
FT HELIX 332 334  
FT TURN 335 336  
FT STRAND 340 343  
SQ SEQUENCE 345 AA; 38922 MW; 82D9FB35EDCAL2EF CRC64;  
  
Query Match 45.1%; Score 41; DB 1; Length 345;  
Best Local Similarity 80.0%; Pred. No. 12;  
Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 2 TGSAAANYTT 11  
||| |  
Db 109 TGSAGNYTT 118  
  
RESULT 9  
BIAR\_HUMAN  
ID BIAR\_HUMAN STANDARD; PRT; 477 AA.  
AC P08588; O9UGX8; O9UGX7;  
DT 01-AUG-1988 (Rel. 08, Created)  
DT 01-AUG-1988 (Rel. 08, Last sequence update)  
DT 20-AUG-2001 (Rel. 08, Last annotation update)  
DE BETA-1 ADRENERGIC RECEPTOR.  
GN ADRB1 OR ADRB1R OR BIAR.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Placenta;  
RX MEDLINE-88068509; PubMed-2825170;  
RA Frielle T., Collins S., Daniel K.W., Lefkowitz R.J.,  
RA Kobilka B.;  
RT "Cloning of the cDNA for the human beta 1-adrenergic receptor.";  
RL Proc. Natl. Acad. Sci. U.S.A. 84:7920-7924(1987).



FT DOMAIN 121 131 EXTRACELLULAR (POTENTIAL).  
 FT TRANSSEM 132 155 3 (POTENTIAL).  
 FT DOMAIN 156 175 CYTOPLASMIC (POTENTIAL).  
 FT TRANSSEM 176 199 4 (POTENTIAL).  
 FT DOMAIN 200 221 EXTRACELLULAR (POTENTIAL).  
 FT TRANSSEM 222 245 5 (POTENTIAL).  
 FT DOMAIN 246 328 CYTOPLASMIC (POTENTIAL).  
 FT TRANSSEM 329 352 6 (POTENTIAL).  
 FT DOMAIN 353 359 EXTRACELLULAR (POTENTIAL).  
 FT TRANSSEM 360 383 7 (POTENTIAL).  
 FT DOMAIN 384 480 CYTOPLASMIC (POTENTIAL).  
 FT CARBOHYD 15 15 N-LINKED (GLYCAC. . .) (PROBABLE).  
 FT DISULFID 131 209 BY SIMILARITY.  
 FT MOD\_RES 315 315 PHOSPHORYLATION (BY CAPK) (POTENTIAL).  
 FT MOD\_RES 415 415 PHOSPHORYLATION (BY CAPK) (POTENTIAL).  
 FT LIPID 395 395 PALMITATE (BY SIMILARITY).  
 SQ SEQUENCE 480 AA; 51608 MW; 25CB18FA03128084 CRC64;

Query Match 45.1%; Score 41; DB 1; Length 480;  
 Best Local Similarity 43.8%; Pred. No. 17;  
 Matches 7; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDRP 16  
 I I I I I : : : I I  
 Db 454 CNGGAADSDSLDEP 469

RESULT 11  
 HRX\_HUMAN STANDARD; PRT; 3969 AA.  
 ID AC Q03164; Q16364; Q13743; Q13744; Q9UMA3;  
 DT 01-OCT-1993 (Rel. 27, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE ZINC FINGER PROTEIN HRX (ALL-1) (TRITHORAX-LIKE PROTEIN).  
 GN MLL OR HRX OR ALL1 OR TRX1 OR HTRX.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP MEDLINE-93046667; PubMed-1423624;  
 RA Tkachuk D.C., Kohler S., Cleary M.L.;  
 RT Involvement of a homolog of Drosophila trithorax by 11q23  
 RT chromosomal translocations in acute leukemias.";  
 RL Cell 71:691-709(1992).  
 RN [2]  
 RP MEDLINE-96290553; PubMed-8703835;  
 RA Nilsson I., Loechner K., Slegler G., Greil J., Beck J.D., Fey G.H.,  
 RA Marschalek R.;  
 RT "Exon/intron structure of the human ALL-1 (MLL) gene involved in  
 RT translocations to chromosomal region 11q23 and acute leukemias.";  
 RL Br. J. Haematol. 93:966-972(1996).  
 RN [3]  
 RP SEQUENCE OF 1-1909 FROM N.A.  
 RX MEDLINE-93390935; PubMed-8378076;  
 RA Yamamoto K., Seto M., Komatsu H., Iida S., Akao Y., Kojima S.,  
 RA Kodera Y., Nakazawa S., Ariyoshi Y., Takahashi T., Ueda R.;  
 RT "Two distinct portions of LTR19/ENL at 19p13 are involved in t(11;19)  
 RT leukemia.";  
 RL Oncogene 8:2617-2625(1993).  
 RN [4]  
 RP SEQUENCE OF 1317-2328 FROM N.A.  
 RC TISSUE=Brain;  
 RX MEDLINE-93265134; PubMed-1303259;  
 RA Djabali M., Salleri L., Parry P., Bower M., Young B.D., Evans G.A.;  
 RT "A trithorax-like gene is interrupted by chromosome 11q23  
 RT translocations in acute leukemias.";  
 RL Nat. Genet. 2:113-118(1992).  
 RN [5]

RP SEQUENCE OF 1251-1538 FROM N.A.  
 RX MEDLINE-94215165; PubMed-8162575;  
 RA Gu Y., Alder H., Nakamura T., Schichman S.A., Prasad R., Canaani O.,  
 RA Saito H., Croce C.M., Canaani E.;  
 RT "Sequence analysis of the breakpoint cluster region in the ALL-1 gene  
 RT involved in acute leukemia.";  
 RL Cancer Res. 54:2326-2330(1994).  
 RN [6]  
 RP SEQUENCE OF 1251-1654 FROM N.A. (ISOFORM 14P-18B).  
 RX MEDLINE-95322025; PubMed-7598802;  
 RA Mankololo D., Burnett R., McCabe N., Thirman M., Gill H., Yu H.,  
 RA Rowley J.D., Diaz M.O.;  
 RT "The human MLL gene: nucleotide sequence, homology to the Drosophila  
 RT trz zinc-finger domain, and alternative splicing.";  
 RL DNA Cell Biol. 14:475-483(1995).  
 RN [7]  
 RP SEQUENCE OF 1212-1603 FROM N.A.  
 RX MEDLINE-95315013; PubMed-7794749;  
 RA Marschalek R., Greil J., Loechner K., Nilsson I., Slegler G.,  
 RA Zwickbrunner I., Beck J.D., Fey G.H.;  
 RT "Molecular analysis of the chromosomal breakpoint and fusion  
 RT transcripts in the acute lymphoblastic SEM cell line with chromosomal  
 RT translocation t(4;11).";  
 RL Br. J. Haematol. 90:308-320(1995).  
 RN [8]  
 RP SEQUENCE OF 1421-1540 FROM N.A.  
 RX MEDLINE-94020842; PubMed-8414518;  
 RA Forster A., Rabbitts T.H.;  
 RT "A method for identifying genes within yeast artificial chromosomes:  
 RT application to isolation of MLL fusion cDNAs from acute leukaemia  
 RT translocations.";  
 RL Oncogene 8:3157-3160(1993).  
 RN [9]  
 RP CHROMOSOMAL TRANSLOCATION WITH GAS7.  
 RX MEDLINE-20183971; PubMed-10706619;  
 RA Megonigal M.D., Cheung N.-K.V., Rappaport E.F., Nowell P.C.,  
 RA Willson R.B., Jones D.H., Addya K., Leonard D.G.B., Kushner B.H.,  
 RA Williams T.M., Lange B.J., Felix C.A.;  
 RT "Detection of leukemia-associated MLL-CAS7 translocation early during  
 RT chemotherapy with DNA topoisomerase II inhibitors.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 97:2814-2819(2000).  
 CC -1- FUNCTION: POSSIBLY ACTS AS A TRANSCRIPTIONAL REGULATORY FACTOR.  
 CC -1- SUBCELLULAR LOCATION: NUCLEAR.  
 CC -1- TISSUE SPECIFICITY: HEART, LUNG, BRAIN AND T AND B LYMPHOCYTES.  
 CC -1- DISEASE: INVOLVED IN ACUTE LEUKEMIAS BY CHROMOSOMAL TRANSLOCATIONS  
 CC T(11;19)(Q23;P13.3) THAT INVOLVES MLL AND MLLT1/ENL;  
 CC T(4;11)(Q21;Q23) THAT INVOLVES MLL AND MLLT2/AF4; T(9;11)(P22;Q23)  
 CC THAT INVOLVES MLL AND MLLT3/AF9; T(6;11)(Q27;Q23) THAT INVOLVES  
 CC MLL AND MLLT4/AF6; T(11;17)(Q23;Q21) THAT INVOLVES MLL AND  
 CC MLLT6/AF17; T(X;11)(Q13;Q23) THAT INVOLVES MLL AND MLLT7/AFX1;  
 CC T(10;11)(P12;Q23) THAT INVOLVES MLL AND MLLT10/AF10;  
 CC T(1;11)(Q21;Q23) THAT INVOLVES MLL AND AF1Q; T(11;19)(Q23;P13.3)  
 CC AND GAS7.  
 CC -1- SIMILARITY: BELONGS TO THE TRITHORAX FAMILY OF TRANSCRIPTION  
 CC FACTORS.  
 CC -1- SIMILARITY: CONTAINS 1 BROMODOMAIN.  
 CC -1- SIMILARITY: CONTAINS 1 SET DOMAIN.  
 CC -1- SIMILARITY: CONTAINS 3 PHD-TYPE ZINC FINGERS.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
 CC or send an email to license@sib-sib.ch).  
 CC -----  
 CC EMBL; L04284; AAA58669.1; -;  
 CC EMBL; Z69744; CAA93625.1; -;  
 CC EMBL; Z69745; CAA93625.1; JOINED.  
 CC EMBL; Z69746; CAA93625.1; JOINED.  
 CC EMBL; Z69747; CAA93625.1; JOINED.

DR EMBL; Z69748; CAA93625.1; JOINED.  
 DR EMBL; Z69749; CAA93625.1; JOINED.  
 DR EMBL; Z69750; CAA93625.1; JOINED.  
 DR EMBL; Z69751; CAA93625.1; JOINED.  
 DR EMBL; Z69752; CAA93625.1; JOINED.  
 DR EMBL; Z69753; CAA93625.1; JOINED.  
 DR EMBL; Z69754; CAA93625.1; JOINED.  
 DR EMBL; Z69755; CAA93625.1; JOINED.  
 DR EMBL; Z69756; CAA93625.1; JOINED.  
 DR EMBL; Z69757; CAA93625.1; JOINED.  
 DR EMBL; Z69758; CAA93625.1; JOINED.  
 DR EMBL; Z69759; CAA93625.1; JOINED.  
 DR EMBL; Z69760; CAA93625.1; JOINED.  
 DR EMBL; Z69761; CAA93625.1; JOINED.  
 DR EMBL; Z69762; CAA93625.1; JOINED.  
 DR EMBL; Z69763; CAA93625.1; JOINED.  
 DR EMBL; Z69764; CAA93625.1; JOINED.  
 DR EMBL; Z69765; CAA93625.1; JOINED.  
 DR EMBL; Z69766; CAA93625.1; JOINED.  
 DR EMBL; Z69767; CAA93625.1; JOINED.  
 DR EMBL; Z69768; CAA93625.1; JOINED.  
 DR EMBL; Z69769; CAA93625.1; JOINED.  
 DR EMBL; Z69770; CAA93625.1; JOINED.  
 DR EMBL; Z69771; CAA93625.1; JOINED.  
 DR EMBL; Z69772; CAA93625.1; JOINED.  
 DR EMBL; Z69773; CAA93625.1; JOINED.  
 DR EMBL; Z69774; CAA93625.1; JOINED.  
 DR EMBL; Z69775; CAA93625.1; JOINED.  
 DR EMBL; Z69776; CAA93625.1; JOINED.  
 DR EMBL; Z69777; CAA93625.1; JOINED.  
 DR EMBL; Z69778; CAA93625.1; JOINED.  
 DR EMBL; Z69779; CAA93625.1; JOINED.  
 DR EMBL; Z69780; CAA93625.1; JOINED.  
 DR EMBL; D14540; BAA03407.1; JOINED.  
 DR EMBL; L01986; AAA2511.1; JOINED.  
 DR EMBL; U04737; AAA1864.1; JOINED.  
 DR EMBL; S78570; AAB34770.1; JOINED.  
 DR EMBL; X83604; CAA58584.1; JOINED.  
 DR EMBL; S66432; AAB28545.1; JOINED.  
 DR EMBL; AF231998; AAG26332.2; ALT\_TERM.  
 DR TRANSFAC; T02337; -.  
 DR MIM; 159555; -.  
 DR InterPro; IPR001487; Bromodomain.  
 DR InterPro; IPR003889; Fyric\_C.  
 DR InterPro; IPR003888; Fyric\_N.  
 DR InterPro; IPR001965; PHD.  
 DR InterPro; IPR003616; PostSET.  
 DR InterPro; IPR001214; SET.  
 DR InterPro; IPR002857; Znf-CXXC.  
 DR Pfam; PF00628; PHD; 3.  
 DR Pfam; PF00856; SET; 1.  
 DR Pfam; PF02008; zf-CXXC; 1.  
 DR SMART; SM00297; BROMO; 1.  
 DR SMART; SM00542; FYRC; 1.  
 DR SMART; SM00541; FYRN; 1.  
 DR SMART; SM00249; PHD; 4.  
 DR SMART; SM00508; PostSET; 1.  
 DR SMART; SM00317; SET; 1.  
 DR PROSITE; PS0014; BROMODOMAIN\_2; 1.  
 DR PROSITE; PS0280; SET; 1.  
 KW P1; Poly-omogene; Chromosomal translocation; DNA-binding; Bromodomain;  
 KW Nuclear protein; Zinc-finger; Metal-binding; Transcription regulation;  
 KW Alternative splicing.  
 FT DOMAIN 17 102  
 FT DNASBIND 169 180  
 FT DNASBIND 217 227  
 FT DNASBIND 301 309  
 FT ZNFING 1431 1482  
 FT ZNFING 1484 1533  
 FT ZNFING 1566 1627  
 FT DOMAIN 1703 1748  
 FT DOMAIN 3840 3969  
 FT DOMAIN 137 143  
 FT DOMAIN 561 564

FT DOMAIN 568 571  
 FT SITE 1444 1445  
 FT VARSPLIC 1407 1444  
 FT CONFLICT 144 144  
 FT CONFLICT 317 379  
 FT CONFLICT 556 556  
 Query Match 45.1%; Score 41; DB 1; Length 3969;  
 Best Local Similarity 43.8%; Pred. No. 1.4e+02;  
 Matches 7; Conservative 3; Mismatches 6; Indels 0; Gaps 0;  
 QY 2 TGSAAAYTTAVDRPN 17  
 DB 3476 SGPOVSNETQIVDAPN 3491  
 RESULT 12  
 ANSA\_STRCZ STANDARD; PRT; 87 AA.  
 ID ANSA\_STRCZ  
 AC P01548;  
 DT 21-JUL-1986 (Rel. 01, Created)  
 DT 21-JUL-1986 (Rel. 01, Last sequence update)  
 DT 20-MAR-1987 (Rel. 04, Last annotation update)  
 DE ANTI-BACTERIAL SUBSTANCE A.  
 OS Streptomyces carzinostaticus.  
 OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;  
 OC Actinomycetales; Streptomycetaceae; Streptomyces.  
 OX NCBI\_TaxID=1897;  
 RN [ ]  
 RP SEQUENCE.  
 RC STRAIN=F41;  
 RX MEDLINE=700391118; PubMed=5353565;  
 RA Sato H., Tanimura T., Nakajima T., Tamura Z.;  
 RT "The total amino acid sequence of substance A produced by  
 FT Streptomyces carzinostaticus.";  
 RL Chem. Pharm. Bull. 17:2188-2191(1969).  
 KW Antibiotic.  
 FT DISULFID 42 50  
 SQ SEQUENCE 87 AA; 8477 MW; C9A114BE1534029B CRC64;  
 Query Match 44.0%; Score 40; DB 1; Length 87;  
 Best Local Similarity 66.7%; Pred. No. 4.7;  
 Matches 8; Conservative 1; Mismatches 3; Indels 0; Gaps 0;  
 QY 2 TGSAAAYTTAV 13  
 DB 8 TGCATATYSTAV 19  
 RESULT 13  
 VG27\_HSVSA  
 ID VG27\_HSVSA STANDARD; PRT; 280 AA.  
 AC Q00998;  
 DT 01-APR-1993 (Rel. 25, Created)  
 DT 01-APR-1993 (Rel. 25, Last sequence update)  
 DT 01-APR-1993 (Rel. 25, Last annotation update)  
 DE HYPOTHETICAL GENE 27 PROTEIN.  
 GN 27.  
 OS Herpesvirus saimiri (strain 11).  
 OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;  
 OC Gammaherpesvirinae; Rhadinovirus.  
 OX NCBI\_TaxID=10383;  
 RN [ ]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=92333688; PubMed=1321287;  
 RA Albrecht J.-C., Nicholas J., Biller D., Cameron K.R., Biesinger B.,



RA Newman C., Wittmann S., Craxton M.A., Coleman H., Fleckenstein B.,  
RA Honess R.W.;  
RT "Primary structure of the herpesvirus saimiri genome.";  
RL J. Virol. 66:5047-5058(1992).  
CC  
CC -1- SIMILARITY: LOW, TO EBV BDLF2.  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL: X64346; CAA45650.1; -  
DR PIR: G36808; G36808.  
DR Hypothetical protein.  
KW  
SQ SEQUENCE 280 AA; 32372 MW; 6B470950E93E9ABF CRC64;  
  
Query Match 44.0%; Score 40; DB 1; Length 280;  
Best Local Similarity 50.0%; Pred. No. 15;  
Matches 7; Conservative 4; Mismatches 3; Indels 0; Gaps 0;  
  
QY 2 TGSAAANYTTAVDR 15  
|| :||| |::|  
DB 146 TGSSANYKLALER 159  
  
RESULT 14  
PALLY\_CITLI  
ID PALLY\_CITLI STANDARD; PRT; 722 AA.  
AC Q42667;  
DT 15-JUL-1998 (Rel. 36, Created)  
DT 15-JUL-1998 (Rel. 36, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE PHENYLALANINE AMMONIA-LYASE (EC 4.3.1.5).  
GN PAL6.  
OS Citrus limon (Lemon).  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;  
OC eurosids II; Sapindales; Rutaceae; Citrus.  
OX NCBI\_TaxID=2708;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Seelenfreund D., Chiong M., Lobos S., Perez L.M.;  
RT "A full-length cDNA coding for phenylalanine ammonia-lyase from Citrus  
RT limon.";  
RL (in) Plant Gene Register PGR96-026.  
CC -1- FUNCTION: THIS IS A KEY ENZYME OF PLANT METABOLISM CATALYZING THE  
CC FIRST REACTION IN THE BIOSYNTHESIS FROM L-PHENYLALANINE OF A WIDE  
CC VARIETY OF NATURAL PRODUCTS BASED ON THE PHENYLPROPANE SKELETON.  
CC -1- CATALYTIC ACTIVITY: L-PHENYLALANINE + TRANS-CINNAMATE + NH(3).  
CC -1- PATHWAY: KEY ENZYME OF PHENYLPROPANOID METABOLISM.  
CC -1- SUBCELLULAR LOCATION: CYTOPLASMIC (PROBABLE).  
CC -1- PTM: CONTAINS AN ACTIVE SITE 4-METHYLIDENE-IMIDAZOLE-5-ONE (MIO),  
CC WHICH IS FORMED AUTOCATALYTICALLY BY CYCLIZATION AND DEHYDRATION  
CC OF RESIDUES ALA-SER-GLY (BY SIMILARITY).  
CC -1- SIMILARITY: BELONGS TO THE PAL / HISTIDASE FAMILY.  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL: U43338; AAB67733.1; -  
DR InterPro: IPR001106; PAL.  
DR Pfam: PF00221; PAL; 1.  
DR PROSITE: PS00488; PAL\_HISTIDASE; 1.  
KW Lyase; Phenylpropanoid metabolism; Multigene family.

FT SITE 206 208 MODIFIED TO FORM 4-METHYLIDENE-IMIDAZOLE-  
FT 5-ONE (BY SIMILARITY).  
SQ SEQUENCE 722 AA; 78490 MW; C96893196530D9E5 CRC64;  
  
Query Match 44.0%; Score 40; DB 1; Length 722;  
Best Local Similarity 50.0%; Pred. No. 38;  
Matches 7; Conservative 2; Mismatches 5; Indels 0; Gaps 0;  
  
QY 1 CTGSAANYTTAVD 14  
||| :||| |  
DB 25 CTGTDPLNWTVAAD 38  
  
RESULT 15  
DAPB\_PSEAE  
ID DAPB\_PSEAE STANDARD; PRT; 268 AA.  
AC P38103;  
DT 01-OCT-1994 (Rel. 30, Created)  
DT 20-AUG-2001 (Rel. 40, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE DIHYDRODIPICOLINATE REDUCTASE (EC 1.3.1.26) (DHPR).  
GN DAPB OR PA4759.  
OS Pseudomonas aeruginosa.  
OC Bacteria; Proteobacteria; gamma subdivision; Pseudomonadaceae;  
OC Pseudomonas.  
OX NCBI\_TaxID=287;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA STRAIN=ATCC 15692 / PA01;  
RX MEDLINE=20437337; PubMed=10984043;  
RA Stover C.K., Pham X.-Q.T., Erwin A.L., Mizoguchi S.D., Warren P.,  
RA Hickey M.J., Brinkman F.S.L., Hufnagle W.O., Kowalik D.J., Lagrou M.,  
RA Garber R.L., Goltzy L., Tolentino E., Westbrock-Wadman S., Yuan Y.,  
RA Brody L.L., Coulter S.N., Folger K.R., Kas A., Larbig K., Lim R.M.,  
RA Smith K.A., Spencer D.H., Wong G.K.-S., Wu Z., Paulsen I.T.,  
RA Reizer J., Sailer M.H., Hancock R.E.W., Lory S., Olson M.V.;  
RT "Complete genome sequence of Pseudomonas aeruginosa PA01, an  
RT opportunistic pathogen.";  
RL Nature 406:959-964(2000).  
RN [2]  
RP SEQUENCE OF 135-268 FROM N.A.  
RA STRAIN=ATCC 15692 / PA01;  
RX MEDLINE=94222830; PubMed=8169201;  
RA Kwon D.-H., Lu C.-D., Walthall D.A., Brown T.M., Houghton J.E.,  
RA Abdelal A.T.;  
RT "Structure and regulation of the carAB operon in Pseudomonas  
RT aeruginosa and Pseudomonas stutzeri: no untranslated region exists.";  
RL J. Bacteriol. 176:2532-2542(1994).  
CC -1- CATALYTIC ACTIVITY: 2,3,4,5-TETRAHYDRODIPICOLINATE + NAD(P)(+) -  
CC 2,3-DIHYDRODIPICOLINATE + NAD(P)H.  
CC -1- PATHWAY: BIOSYNTHESIS OF DIAMINOPIMELATE AND LYSINE FROM ASPARTATE  
CC SEMIALDEHYDE; SECOND STEP.  
CC -1- SUBCELLULAR LOCATION: CYTOPLASMIC (BY SIMILARITY).  
CC -1- SIMILARITY: BELONGS TO THE DIHYDRODIPICOLINATE REDUCTASE FAMILY.  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL: AE004889; AAG08145.1; -  
DR EMBL: U04992; AAA19045.1; -  
DR EMBL: U81259; AAB39249.1; -  
DR HSP: P04036; LDRV.  
DR InterPro: IPR000846; DapB.  
DR Pfam: PF01113; DapB; 1.  
DR ProDom: PD004105; DapB; 1.  
DR PROSITE: PS01298; DAPB; 1.  
KW Diaminopimelate biosynthesis; Lysine biosynthesis; Oxidoreductase;

SQ SEQUENCE 268 AA; 28324 MW; 0B37EAF688419254 CRC64;

Query Match 43.4%; Score 39.5; DB 1; Length 268;  
Best Local Similarity 62.5%; Pred. No. 17;  
Matches 10; Conservative 1; Mismatches 4; Indels 1; Gaps 1;

**QY**      2    TGSAAANYTTAVDRPN 17  
             || | | | | | |  
**Dbb**     24   TG-GAAGLTAADVDPD 38

Search completed: March 26, 2002, 13:40:42  
Job time: 256 sec

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

# OM protein - protein search, using sw model

Run on: March 26, 2002, 13:36:26 ; Search time 79.01 Seconds  
(without alignments)  
31.472 Million cell updates/sec

Title: US-09-709-201-93

Perfect score: 91

Sequence: 1 CTGSAANYTTAVDRPN 17

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 473505 seqs, 146272329 residues

Total number of hits satisfying chosen parameters: 473505

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

## Database :

SPTREMBL\_17.\*  
1: sp\_archaea.\*  
2: sp\_bacteria.\*  
3: sp\_fungi.\*  
4: sp\_human.\*  
5: sp\_invertebrate.\*  
6: sp\_mammal.\*  
7: sp\_mhc.\*  
8: sp\_organelle.\*  
9: sp\_phage.\*  
10: sp\_plant.\*  
11: sp\_rodent.\*  
12: sp\_virus.\*  
13: sp\_vertebrate.\*  
14: sp\_unclassified.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	78	85.7	389	2 Q08085	Q08085 chlamydia p
2	64	70.3	341	2 Q9X717	Q9X717 chlamydia p
3	64	70.3	352	2 Q69306	Q69306 chlamydia p
4	64	70.3	352	2 Q69307	Q69307 chlamydia p
5	64	70.3	352	2 Q70050	Q70050 chlamydia p
6	64	70.3	352	2 Q70085	Q70085 chlamydia p
7	64	70.3	353	2 Q69305	Q69305 chlamydia p
8	62	68.1	388	2 Q9AIK1	Q9AIK1 chlamydia p
9	59	64.8	389	2 Q9APM4	Q9APM4 chlamydia p
10	48	52.7	557	2 Q99V50	Q99V50 staphylococ
11	48	52.7	662	4 Q9URF7	Q9URF7 homo sapien
12	48	52.7	1241	4 Q14I48	Q14I48 homo sapien
13	47	51.6	326	2 Q9K5C5	Q9K5C5 chlamydia p
14	47	51.6	389	2 Q9AIH9	Q9AIH9 chlamydia p
15	46	50.5	168	2 Q9K5N9	Q9K5N9 bacillus ha
16	46	50.5	836	5 Q9B165	Q9B165 caenorhabdi
17	46	50.5	1231	5 Q9B166	Q9B166 caenorhabdi
18	45	49.5	3300	2 Q06304	Q06304 mycobacteri
19	44.5	48.9	356	2 Q52924	Q52924 chlamydia p

20	44.5	48.9	390	2 Q9AIJ5	Q9AIJ5 chlamydia p
21	44.5	48.9	392	2 Q9AIJ4	Q9AIJ4 chlamydia p
22	44	48.4	584	2 Q59152	Q59152 agrobacteri
23	43	47.3	1459	3 Q9HG03	Q9HG03 penicillium
24	42	46.2	306	10 Q43456	Q43456 glycine max
25	42	46.2	388	2 Q9AIK0	Q9AIK0 chlamydia p
26	42	46.2	391	2 Q46235	Q46235 chlamydia p
27	42	46.2	422	1 Q9HMH9	Q9HMH9 halobacteri
28	42	46.2	499	5 Q9VVM1	Q9VVM1 drosophila
29	42	46.2	618	2 Q9A9F7	Q9A9F7 caulobacter
30	42	46.2	1583	12 Q90304	Q90304 breva virus
31	41	45.1	218	2 Q34189	Q34189 neisseria g
32	41	45.1	229	2 P96873	P96873 mycobacteri
33	41	45.1	273	2 Q9JWH6	Q9JWH6 neisseria m
34	41	45.1	310	3 Q9P356	Q9P356 lentinula e
35	41	45.1	385	12 Q39888	Q39888 hepatitis b
36	41	45.1	423	2 Q9JXG1	Q9JXG1 neisseria m
37	41	45.1	431	2 Q85283	Q85283 sphingomona
38	41	45.1	589	3 Q9HE13	Q9HE13 schizosacch
39	41	45.1	626	2 Q45877	Q45877 clostridium
40	41	45.1	693	13 Q91889	Q91889 xenopus lae
41	41	45.1	834	3 Q9P978	Q9P978 neurospora
42	41	45.1	1682	5 Q9V693	Q9V693 drosophila
43	41	45.1	3010	12 Q9HJ3G2	Q9HJ3G2 hepatitis c
44	40	44.0	337	1 Q9HP24	Q9HP24 halobacteri
45	40	44.0	375	2 Q9HXE3	Q9HXE3 pseudomonas

## ALIGNMENTS

RESULT 1

Q08085 ID Q08085 PRELIMINARY: PRT: 383 AA.

AC Q08085;  
DT 01-NOV-1996 (TREMBLrel. 01, Created)  
DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)  
DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
OS Chlamydia psittaci (Chlamydia psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.   
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-KOALA TYPE 1;  
RX MEDLINE=94171025; Pubmed=8125292;  
RA Girjes A.A., Carrick F.N., Lavin M.F.;

RT "Remarkable sequence relatedness in the DNA encoding the major outer membrane protein of Chlamydia psittaci (koala type I) and Chlamydia pneumoniae.";  
RL Gene J38.139-142(1994).  
CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
DR EMBL: X72023; CAA50906.1;  
DR InterPro: IPR000604; Chlamydia\_OMP.  
DR Pfam: PF01308; Chlamydia\_OMP; 1.  
DR PRINTS: PR01334; CHLAMIDIAOMP.  
DR ProDom: PD001717; Chlamydia\_OMP; 1.  
KW Outer membrane; Transmembrane; Porin; Signal.  
FT SIGNAL 1 23 BY SIMILARITY.  
FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 389 AA; 41579 MW; 5DC50E8FA6F4E50F CRC64;

Query Match 85.7%; Score 78; DB 2; Length 389;  
Best Local Similarity 93.8%; Pred. No. 3.6e-05;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 TGSAANYTTAVDRPN 17

Db 90 TGSATANYTTAVDRPN 105  
|||||

RESULT 2  
Q9X717 ID Q9X717 PRELIMINARY; PRT; 341 AA.  
AC Q9X717;  
DT 01-NOV-1999 (Tremblrel. 12, Created)  
DT 01-NOV-1999 (Tremblrel. 12, Last sequence update)  
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
GN OMPA.  
OS Chlamydia abortus.  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia. 352  
OX NCBI\_TaxID=83555;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-LW508;  
RX MEDLINE=93123168; PubMed=8419295;  
RA Kaltenboeck B., Kousoulas K.G., Storz J.;  
RT "Structures of and allelic diversity and relationships among the major  
RT outer membrane protein (ompA) genes of the four chlamydial species";  
RL J. Bacteriol. 175:487-502(1993).  
DR EMBL; M73040; AAD29103.1; -;  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
FT NON\_TER 1 341  
SQ SEQUENCE 341 AA; 36762 MW; B5933C9BF6AAF171 CRC64;

Query Match 70.3%; Score 64; DB 2; Length 341;  
Best Local Similarity 75.0%; Pred. No. 0.0073;  
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;  
QY 2 TGSAAANYTTAVDRPN 17  
|||||

RESULT 3  
O69306 ID O69306 PRELIMINARY; PRT; 352 AA.  
AC O69306;  
DT 01-AUG-1998 (Tremblrel. 07, Created)  
DT 01-AUG-1998 (Tremblrel. 07, Last sequence update)  
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)  
DE OMP1 PROTEIN (FRAGMENT).  
GN OMP1.  
OS Chlamydia psittaci (Chlamydia psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia. 352  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-PW234;  
RX Hoelzle L.E., Steinhausen G., Eggemann G., Schiller I.,  
RA Wittenbrink M.M.;  
RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AJ004874; CAA06183.1; -;  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
FT NON\_TER 352 352  
SQ SEQUENCE 352 AA; 37868 MW; 0AE9B1E099EED41 CRC64;

Query Match 70.3%; Score 64; DB 2; Length 352;  
Best Local Similarity 75.0%; Pred. No. 0.0075;  
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;  
QY 2 TGSAAANYTTAVDRPN 17  
|||||

Db 90 TGTAAANYKTPTDRPN 105  
|||||

RESULT 4  
O69307 ID O69307 PRELIMINARY; PRT; 352 AA.  
AC O69307;  
DT 01-AUG-1998 (Tremblrel. 07, Created)  
DT 01-AUG-1998 (Tremblrel. 07, Last sequence update)  
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)  
DE OMP1 PROTEIN (FRAGMENT).  
GN OMP1.  
OS Chlamydia psittaci (Chlamydia psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia. 352  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-PW326;  
RX Hoelzle L.E., Steinhausen G., Eggemann G., Schiller I.,  
RA Wittenbrink M.M.;  
RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AJ004875; CAA06184.1; -;  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
FT NON\_TER 352 352  
SQ SEQUENCE 352 AA; 37854 MW; 33589C6D1137CCDB CRC64;

Query Match 70.3%; Score 64; DB 2; Length 352;  
Best Local Similarity 75.0%; Pred. No. 0.0075;  
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;  
QY 2 TGSAAANYTTAVDRPN 17  
|||||

RESULT 5  
O70050 ID O70050 PRELIMINARY; PRT; 352 AA.  
AC O70050;  
DT 01-AUG-1998 (Tremblrel. 07, Created)  
DT 01-AUG-1998 (Tremblrel. 07, Last sequence update)  
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)  
DE OMP1 PROTEIN (FRAGMENT).  
GN OMP1.  
OS Chlamydia psittaci (Chlamydia psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia. 352  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-PW623, PM112, PM364;  
RX Hoelzle L.E., Steinhausen G., Eggemann G., Schiller I.,  
RA Wittenbrink M.M.;  
RL Submitted (APR-1998) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AJ005615; CAA06622.1; -;  
DR EMBL; AJ005613; CAA06620.1; -;  
DR EMBL; AJ005614; CAA06621.1; -;  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
FT NON\_TER 352 352  
SQ SEQUENCE 352 AA; 37826 MW; 2F9D092492E462D4 CRC64;

Query Match 70.3%; Score 64; DB 2; Length 352;  
Best Local Similarity 75.0%; Pred. No. 0.0075;  
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;  
QY 2 TGSAAANYTTAVDRPN 17  
|||||

Db 90 TGTAAANYKTPTDRPN 105

RESULT 6  
ID 070085 PRELIMINARY; PRT; 352 AA.  
AC 070085;  
DT 01-AUG-1998 (TReMBLrel. 07, Created)  
DT 01-AUG-1998 (TReMBLrel. 07, Last sequence update)  
DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
DE OMP1 (FRAGMENT).  
GN OMP1.  
OS Chlamydia psittaci (Chlamydothila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydothila.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=PMSH1, PM225;  
RA Hoelzle L.E., Steinhausen G., Eggemann G., Schiller I.,  
RA Wittenbrink M.M.;  
RL Submitted (APR-1998) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AJ005618; CAA06625.1; -;  
DR EMBL: AJ005617; CAA06624.1; -;  
DR InterPro: IPR000604; Chlamydia\_OMP.  
DR Pfam: PF01308; Chlamydia\_OMP; 1.  
DR ProDom: PD001717; Chlamydia\_OMP; 1.  
FT NON\_TER 352 352  
SQ SEQUENCE 352 AA; 37854 MW; 391914AD146072CB CRC64;

Query Match 70.3%; Score 64; DB 2; Length 352;  
Best Local Similarity 75.0%; Pred. No. 0.0075;  
Matches 12; Conservative 1; Mismatches 3; Indels 3; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
II:IIIIII I IIII  
Db 90 TGTAAANYKTPTDRPN 105

RESULT 7  
ID 069305 PRELIMINARY; PRT; 353 AA.  
AC 069305;  
DT 01-AUG-1998 (TReMBLrel. 07, Created)  
DT 01-AUG-1998 (TReMBLrel. 07, Last sequence update)  
DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
DE OMP1 PROTEIN (FRAGMENT).  
GN OMP1.  
OS Chlamydia psittaci (Chlamydothila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydothila.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=OCLH196;  
RA Hoelzle L.E., Steinhausen G., Eggemann G., Schiller I.,  
RA Wittenbrink M.M.;  
RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AJ004873; CAA06182.1; -;  
DR InterPro: IPR000604; Chlamydia\_OMP.  
DR Pfam: PF01308; Chlamydia\_OMP; 1.  
DR ProDom: PD001717; Chlamydia\_OMP; 1.  
FT NON\_TER 353 353  
SQ SEQUENCE 353 AA; 37933 MW; AC7D8FD9FA6E1728 CRC64;

Query Match 70.3%; Score 64; DB 2; Length 353;  
Best Local Similarity 75.0%; Pred. No. 0.0076;  
Matches 12; Conservative 1; Mismatches 3; Indels 3; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
II:IIIIII I IIII  
Db 90 TGTAAANYKTPTDRPN 105

RESULT 8

ID 09AIK1 PRELIMINARY; PRT; 388 AA.  
AC 09AIK1;  
DT 01-JUN-2001 (TReMBLrel. 17, Created)  
DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
GN OMPA.  
OS Chlamydia psittaci (Chlamydothila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydothila.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=VS225;  
RA MEDLINE=21078680; PubMed=11211261;  
RA Bush R.M., Everett K.D.;  
RL "Molecular evolution of the Chlamydiaceae.";  
RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
DR EMBL: AF269259; AAK00240.1; -;  
KW Signal.  
FT NON\_TER 1 1  
FT SIGNAL <1 19 POTENTIAL.  
FT CHAIN 20 388 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 388 AA; 41573 MW; 8E232D22C9B9948D CRC64;

Query Match 68.1%; Score 62; DB 2; Length 388;  
Best Local Similarity 75.0%; Pred. No. 0.018;  
Matches 12; Conservative 1; Mismatches 3; Indels 3; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
IIIIII I IIII  
Db 87 TGSAAADYKTPTDRPN 102

RESULT 9

ID 09APM4 PRELIMINARY; PRT; 389 AA.  
AC 09APM4;  
DT 01-JUN-2001 (TReMBLrel. 17, Created)  
DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.  
GN OMP1.  
OS Chlamydothila abortus.  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydothila.  
OX NCBI\_TaxID=83555;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=LLG;  
RA MEDLINE=20569239; PubMed=11119563;  
RA Vretou E., Psarrou E., Kaisar M., Vlisidou I., Salti-Montesanto V.,  
RA Longbottom D.;  
RL "Identification of protective epitopes by sequencing of the major  
RL outer membrane protein gene of a variant strain of Chlamydia psittaci  
RL serotype 1.";  
RL Infect. Immun. 69:607-612(2001).  
DR EMBL: AF272945; AAG53881.1; -;  
KW Signal.  
FT SIGNAL 1 22 POTENTIAL.  
FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 389 AA; 41897 MW; 20513C65C7DBAAF5 CRC64;

Query Match 64.8%; Score 59; DB 2; Length 389;  
Best Local Similarity 68.8%; Pred. No. 0.059;  
Matches 11; Conservative 2; Mismatches 3; Indels 3; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
II:IIII I IIII  
Db 90 TGTAAADYKTPTDRPN 105

```

RESULT 10
Q99V50
ID Q99V50 PRELIMINARY; PRT; 557 AA.
AC Q99V50;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DE MENAQUINONE BIOSYNTHESIS PROTEIN.
GN MEND OR SA0896.
OS Staphylococcus aureus subsp. aureus N315.
OC Bacteria; Firmicutes; Bacillus/Clostridium group;
OC Bacillus/Staphylococcus group; Staphylococcus.
OX NCBI_TaxID=158879;
RN [1]
RP SEQUENCE FROM N.A.
RA Kuroda M., Ohta T., Uchiyama I., Baba T., Yuzawa H., Kobayashi I.,
RA Cui L., Oguchi A., Aoki K.I., Nagai Y., Lian J., Ito T., Kanamori M.,
RA Matsumaru H., Maruyama A., Murakami H., Hosoyama A., Mizutani-U I Y.,
RA Takahashi N.K., Sawano T., Inoue R.I., Kaito C., Sekimizu K.,
RA Hirakawa H., Kuhara S., Goto S., Yabuzaki J., Kanehisa M.,
RA Yamashita A., Oshima K., Furuya K., Yoshino C., Shiba T., Hattori M.,
RA Ogasawara N., Hayashi H., Hiramatsu K.;
RT "Whole genome sequencing of methicillin-resistant Staphylococcus
RT aureus.";
RL Lancet 357:1225-1240(2001).
DR EMBL; AP003132; BAB42141.1;
KW Complete proteome.
SQ SEQUENCE 557 AA; 63091 MW; B38C5DA274972483 CRC64;

Query Match 52.7%; Score 48; DB 2; Length 557;
Best Local Similarity 39.4%; Pred. No. 6.2;
Matches 13; Conservative 3; Mismatches 1; Indels 16; Gaps 2;

QY 1 CT-GSAAANYTTAV-----DRPN 17
|||:|||||:|
Db 78 CTGTAANYTPTAIAESQISRIPLVLTSDRPH 110
|||||:|

RESULT 11
Q99F7
ID Q99F7 PRELIMINARY; PRT; 662 AA.
AC Q99F7;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DE HYPOTHETICAL 71.0 KDA PROTEIN.
GN DKFZP4340051.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Poustka A., Klein M., Meves H.W., Gassenhuber J., Wiemann S.;
RA Submitted (SEP-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL117400; CAB55901.1;
DR InterPro; IPR000719; Euk_pkinase.
DR Pfam; PF00069; pkinase; 1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; UNKNOWN_1.
DR PROSITE; PS00111; PROTEIN_KINASE_DOM; 1.
KW ATP-binding; Hypothetical protein; Transferase.
SQ SEQUENCE 662 AA; 71003 MW; 8756E82919F6093D CRC64;

Query Match 52.7%; Score 48; DB 4; Length 662;
Best Local Similarity 56.2%; Pred. No. 7.4;
Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDRP 16
||||:|

```

```

||||:| | | |
Db 251 CTGSSSACYALATDLP 266

RESULT 12
Q14148
ID Q14148 PRELIMINARY; PRT; 1241 AA.
AC Q14148;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DE KIAA0135 PROTEIN (FRAGMENT).
GN KIAA0135.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA MEDLINE=96127530; PubMed=8590280;
RA Nagase T., Seki N., Tanaka A., Ishikawa K., Nomura N.;
RT "Prediction of the coding sequences of unidentified human genes. IV.
RT analysis of cDNA clones from human cell line KG-1.";
RL DNA Res. 2:167-174(1995).
RN [2]
RP SEQUENCE OF 1-54 FROM N.A.
RA Ceulemans H., Van Bynde A., Perez-Callejon E., Stalmans W., Bollen M.;
RT "Structure and splice products of the human gene encoding sds22, a
RT putative mitotic regulator of protein phosphatase-1.";
RL Submitted (MAY-1998) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: TO THE SER/THR FAMILY OF PROTEIN KINASES.
DR EMBL; D50925; BAA09484.1;
DR EMBL; AF067137; AAC23506.1;
DR InterPro; IPR000719; Euk_pkinase.
DR InterPro; IPR000014; PAS.
DR InterPro; IPR002290; Ser_thr_kin_actsite.
DR InterPro; IPR001245; Tyr_kin.
DR Pfam; PF00989; PAS; 3.
DR Pfam; PF00069; pkinase; 1.
DR PRINTS; P00109; TYRKINASE.
DR SMART; SM00091; PAS; 2.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; UNKNOWN_1.
DR PROSITE; PS00111; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
KW ATP-binding; Hypothetical protein; Serine/threonine-protein kinase;
KW Transferase.
FT NON_TER 1
SQ SEQUENCE 1241 AA; 134103 MW; B651937986664A84 CRC64;

Query Match 52.7%; Score 48; DB 4; Length 1241;
Best Local Similarity 56.2%; Pred. No. 14;
Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDRP 16
||||:| | | |
Db 619 CTGSSSACYALATDLP 634

RESULT 13
Q9K5C5
ID Q9K5C5 PRELIMINARY; PRT; 326 AA.
AC Q9K5C5;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DE OUTER MEMBRANE PROTEIN 1 (FRAGMENT).
GN OMPL.
OS Chlamydia psittaci (Chlamydophila psittaci).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.
OX NCBI_TaxID=83554;
RN [1]

```

RP SEQUENCE FROM N.A.

RC STRAIN-R54;  
RX PubMed-10919838;  
RA Herrmann B., Rahman R., Bergstrom S., Bonnedahl J., Olsen B.;  
RT "Chlamydomophila abortus in a Brown Skua (Catharacta antarctica  
lonnbergi) from a Subantarctic Island";  
RL Appl. Environ. Microbiol. 66:3654-3656(2000).  
DR EMBL; AJ243525; CAB96859.1; -;  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR PRINTS; PR01308; Chlamydia\_OMP; 1.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
FT NON\_TER 1 1  
FT CHAIN 326 326  
SQ SEQUENCE 326 AA; 35345 MW; 6C5A20C8913743C8 CRC64;

Query Match 51.6%; Score 47; DB 2; Length 326;  
Best Local Similarity 62.3%; Pred. No. 5.3;  
Matches 10; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
||||| : | | | |  
Db 36 TGSAAQDYKAAEDRAN 51

RESULT 14

Q9A1H9 PRELIMINARY; PRT; 389 AA.  
AC Q9A1H9;  
DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
DE 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.  
GN OMPA  
OS Chlamydomophila caviae.  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.  
OX NCBI\_TaxID=83557;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-GUINEA PIG INCLUSION CONJUNCTIVITIS, GPIC, ATCC VR813;  
RX MEDLINE-89212917; PubMed-2707861;  
RA Zhang Y.X., Morrison S.G., Caldwell H.D., Baehr W.;  
RT "Cloning and sequence analysis of the major outer membrane protein  
genes of two Chlamydia psittaci strains.";  
RL Infect. Immun. 57:1621-1625(1989).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN-GUINEA PIG INCLUSION CONJUNCTIVITIS, GPIC, ATCC VR813;  
RX MEDLINE-21078680; PubMed-11211261;  
RA Bush R.M., Everett K.D.;  
RT "Molecular evolution of the Chlamydiaceae";  
RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
DR EMBL; AF269282; AAK00263.1; -;  
KW SIGNAL.  
FT SIGNAL 1 22 POTENTIAL.  
FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 389 AA; 41932 MW; 2527A820C76F8310 CRC64;

Query Match 51.6%; Score 47; DB 2; Length 389;  
Best Local Similarity 56.2%; Pred. No. 6.3;  
Matches 9; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
||||| : | | | |  
Db 89 TGSAAADFKTVADRN 104

RESULT 15

Q9K5N9 PRELIMINARY; PRT; 168 AA.  
ID Q9K5N9  
AC Q9K5N9;

DT 01-OCT-2000 (TrEMBLrel. 15, Created)  
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)  
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
DE SINGLE-STRAND DNA-BINDING PROTEIN (PHAGE-RELATED PROTEIN).  
GN SSB OR BH4049.  
OS Bacillus halodurans.  
OC Bacteria; Firmicutes; Bacillus/Clostridium group;  
OC Bacillus/Staphylococcus group; Bacillus.  
OX NCBI\_TaxID=86665;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-C-125 / JCM 9153;  
RX MEDLINE-20512582; PubMed-11058132;  
RA Takami H., Nakasone K., Takaki Y., Maeno G., Sasaki R., Masui N.,  
Fuji F., Hiramata C., Nakamura Y., Ogasawara N., Kuhara S.,  
Horikoshi K.;  
RT "Complete genome sequence of the alkaliphilic bacterium Bacillus  
halodurans and genomic sequence comparison with Bacillus subtilis.";  
RL Nucleic Acids Res. 28:4317-4331(2000).  
DR EMBL; AF001520; BAB07768.1; -;  
DR InterPro; IPR000424; SSB.  
DR Pfam; PF00436; SSB; 1.  
DR PROSITE; PS00735; SSB\_1; 1.  
KW DNA-binding; Complete proteome.  
SQ SEQUENCE 168 AA; 18220 MW; 0D7C702E656232F6 CRC64;

Query Match 50.5%; Score 46; DB 2; Length 168;  
Best Local Similarity 64.3%; Pred. No. 3.9;  
Matches 9; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 3 GSAAANYTTAVDRP 16  
| | | | | | | | | |  
Db 23 GVAVANFTLAVNRP 36

Search completed: March 26, 2002, 13:40:11  
Job time: 225 sec





GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:38:45 ; Search time 81.51 Seconds  
(without alignments)  
15.449 Million cell updates/sec

Title: US-09-709-201-96

Perfect score: 85

Sequence: 1 CASOTASNTTVAADRSN 17

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A\_Geneseq\_1101.\*  
1: /SID88/gcgdata/geneseq/geneseq/AA1980.DAT.\*  
2: /SID88/gcgdata/geneseq/geneseq/AA1981.DAT.\*  
3: /SID88/gcgdata/geneseq/geneseq/AA1982.DAT.\*  
4: /SID88/gcgdata/geneseq/geneseq/AA1983.DAT.\*  
5: /SID88/gcgdata/geneseq/geneseq/AA1984.DAT.\*  
6: /SID88/gcgdata/geneseq/geneseq/AA1985.DAT.\*  
7: /SID88/gcgdata/geneseq/geneseq/AA1986.DAT.\*  
8: /SID88/gcgdata/geneseq/geneseq/AA1987.DAT.\*  
9: /SID88/gcgdata/geneseq/geneseq/AA1988.DAT.\*  
10: /SID88/gcgdata/geneseq/geneseq/AA1989.DAT.\*  
11: /SID88/gcgdata/geneseq/geneseq/AA1990.DAT.\*  
12: /SID88/gcgdata/geneseq/geneseq/AA1991.DAT.\*  
13: /SID88/gcgdata/geneseq/geneseq/AA1992.DAT.\*  
14: /SID88/gcgdata/geneseq/geneseq/AA1993.DAT.\*  
15: /SID88/gcgdata/geneseq/geneseq/AA1994.DAT.\*  
16: /SID88/gcgdata/geneseq/geneseq/AA1995.DAT.\*  
17: /SID88/gcgdata/geneseq/geneseq/AA1996.DAT.\*  
18: /SID88/gcgdata/geneseq/geneseq/AA1997.DAT.\*  
19: /SID88/gcgdata/geneseq/geneseq/AA1998.DAT.\*  
20: /SID88/gcgdata/geneseq/geneseq/AA1999.DAT.\*  
21: /SID88/gcgdata/geneseq/geneseq/AA2000.DAT.\*  
22: /SID88/gcgdata/geneseq/geneseq/AA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	85	100.0	17	AAW95323	Costant and variab
2	46	54.1	163	AA194712	Tumour necrosis fa
3	46	54.1	165	AAAB00014	Peptide fragment o
4	46	54.1	183	AAAT77421	BamTP delta53 nerv
5	46	54.1	198	AA194720	Human type 2 tumou
6	46	54.1	225	AA177463	Primate protein se
7	46	54.1	227	AAAB66981	Tnfr2 protein. Un
8	46	54.1	235	AAW59665	Human soluble tumo
9	46	54.1	235	AAW52270	Tumour necrosis fa
10	46	54.1	235	AAW89234	Tumour necrosis in
11	46	54.1	235	AA154440	Amino acid sequenc

12	46	54.1	235	21	AA154441	Amino acid sequenc
13	46	54.1	235	21	AA154442	A K108R/K120R muta
14	46	54.1	235	21	AA154443	Wild type N-termina
15	46	54.1	235	21	AA154444	Human 40 kDa TNF i
16	46	54.1	235	21	AA154445	Human 40 kDa TNF i
17	46	54.1	248	21	AA154446	Human type 2 tumou
18	46	54.1	392	12	AA111605	Human 75KD TNF-bin
19	46	54.1	392	20	AA111606	Human tumour necro
20	46	54.1	461	12	AA111001	40KD TNF inhibitor
21	46	54.1	461	12	AA111141	Human TNF-R deduce
22	46	54.1	461	14	AA111142	Fibroblast derived
23	46	54.1	461	16	AA111143	p75 Tumour Necrosi
24	46	54.1	461	21	AA111144	Human tumour necro
25	46	54.1	461	21	AA111145	A human tumour nec
26	46	54.1	461	21	AA111146	Death receptor. H
27	46	54.1	461	21	AA111147	Human TNF receptor
28	46	54.1	461	22	AA111148	Human tumour necro
29	46	54.1	461	22	AA111149	Human 40 kDa TNF i
30	46	54.1	485	13	AA111150	Fusion protein TNF
31	46	54.1	518	15	AA111151	Sequence of a reco
32	46	54.1	518	22	AA111152	STNFR(075):Fc fusi
33	46	54.1	518	22	AA111153	TNFR:Fc fusion pro
34	46	54.1	518	22	AA111154	Constant and variab
35	46	54.1	518	22	AA111155	Human protein sequ
36	46	54.1	518	22	AA111156	Human OREX ORF2871
37	46	54.1	518	22	AA111157	B. halodurans clon
38	46	54.1	518	22	AA111158	Rodent protein seq
39	46	54.1	518	22	AA111159	Rat TNFR (p80) ext
40	46	54.1	518	22	AA111160	TNFR-R deduced from
41	46	54.1	518	22	AA111161	TNFR:Fc fusion pro
42	46	54.1	518	22	AA111162	B. melitensis viru
43	46	54.1	518	22	AA111163	B. vulgaris NIM1 h
44	46	54.1	518	22	AA111164	TBP11-GBP 130 fusi
45	46	54.1	518	22	AA111165	TNFR-R-GBP 130 fusi
46	46	54.1	518	22	AA111166	Arabidopsis thalia

ALIGNMENTS

RESULT 1

AAW95323

ID AAW95323 standard; Protein; 17 AA.

AC AAW95323;

XX AAW95323;

DT 15-MAR-1999 (first entry)

XX Costant and variable domain sequence of C. psittaci CPS92-106.

DE Chlamydia; cryptic phase; elementary body phase; replicating; probedicid;

XX Chlamydia; cryptic phase; elementary body phase; replicating; probedicid;

KW antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;

KW major outer membrane protein; autoimmune; inflammatory; porphyria;

KW Ebstein Barr virus; antioxidant.

XX Chlamydia psittaci.

OS Chlamydia psittaci.

PN WO9850074-A2.

XX WO9850074-A2.

PD 12-NOV-1998.

XX 12-NOV-1998.

XX 06-MAY-1998; 98WO-US09237.

XX 18-FEB-1998; 98US-0025521.

PR 06-MAY-1997; 97US-0045689.

PR 06-MAY-1997; 97US-0045739.

PR 06-MAY-1997; 97US-0045779.

PR 06-MAY-1997; 97US-0045780.

PR 06-MAY-1997; 97US-0045784.

PR 06-MAY-1997; 97US-0045787.

PR 14-AUG-1997; 97US-0911593.

PR 18-FEB-1998; 98US-0025174.

PR 18-FEB-1998; 98US-0025176.

XX 18-FEB-1998; 98US-0025176.

XX 18-FEB-1998; 98US-0025176.

XX 18-FEB-1998; 98US-0025176.

XX 18-FEB-1998; 98US-0025176.

PA (UYVA-) UNIV VANDERBILT.  
 XX Mitchell WM, Stratton CW;  
 XX WPI; 1999-059653/05.  
 XX Composition with two agents effective against different stages of  
 PT chlamydial life cycle - comprises agent targetted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT probenicid and antiporphyrin  
 XX  
 PS Claim 4; Fig 3; 138pp; English.  
 XX  
 CC The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targetted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targetted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targetted against replicating phase of chlamydial  
 CC life cycle; (d) probenicid; and (e) antiporphyrin acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Ebsstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AA95320 to AA95323 represent constant and  
 CC variable domain sequences of various Chlamydia species.  
 XX  
 XX Sequence 17 AA;  
 XX  
 Query Match 100.0%; Score 85; DB 20; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.3e-07;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CASGTASNTTVAADRSN 17  
 Db 1 casgtasntttvaadrsn 17  
 |||||  
 RESULT 2  
 ID AAY94712  
 XX AAY94712 standard; Protein; 163 AA.  
 XX  
 XX AAY94712;  
 XX  
 XX 29-JAN-2001 (first entry)  
 XX  
 XX Tumour necrosis factor receptor (TNFR) domain of TNFR-II.  
 XX  
 XX Tumour necrosis factor-receptor related protein; TR2; human; cancer;  
 KW chromosome p36.2-p36.3; arthritis; inflammation; autoimmune disease;  
 KW immunodeficiency; metastasis; haemolytic anaemia; asthma; X-linked SCID;  
 KW severely combined immunodeficiency; apoptosis inhibition;  
 KW Alzheimer's disease; Parkinson's disease; Crohn's disease.  
 XX  
 OS Homo sapiens.  
 PN WO200056405-A2.  
 XX  
 PD 28-SEP-2000.  
 XX  
 XX 22-MAR-2000; 2000WO-US07521.  
 PF

XX 22-MAR-1999; 99US-0125683.  
 PR 26-MAR-1999; 99US-0126522.  
 PR 20-MAY-1999; 99US-0135169.  
 PR 06-AUG-1999; 99US-0147383.  
 XX  
 XX (NIJJ/) NI J.  
 PA (ROSE/) ROSEN C A.  
 PA (GENTZ/) GENTZ R L.  
 XX  
 PI Ni J, Rosen CA, Gentz RL;  
 XX  
 XX WPI; 2000-594519/56.  
 XX  
 CC Nucleic acid molecule encoding a human tumor necrosis factor receptor 2  
 CC and its two splice variants, useful for treating arthritis or  
 PT inflammation, cancer (such as follicular lymphomas) and  
 PT immunodeficiency disorders -  
 XX  
 PS Disclosure; Fig 16; 373pp; English.  
 XX  
 CC This invention relates to an isolated nucleic acid molecule encoding a  
 CC human tumour necrosis factor (TNF)-receptor related protein TR2. Included  
 CC in the invention are the two splice variants of TR2, TR2-SV1 and TR2-SV2.  
 CC The TR2 gene is located on chromosome 1 at position p36.2-p36.3. TR2 is a  
 CC member of the TNFR superfamily. The invention includes a method for the  
 CC treatment of arthritis or inflammation using an antibody directed against  
 CC a fragment of the TR2 protein. TR2 its agonists, antagonists and  
 CC antibodies exhibit cytostatic, dermatological, antianemic,  
 CC immunosuppressive, antiallergic, antarthritic, antiparkinsonian, and  
 CC antiinflammatory, neuroprotective, nootropic, antiparkinsonian, and  
 CC cerebroprotective activity. The methods are useful for treating arthritis  
 CC or inflammation, cancer (such as follicular lymphomas, carcinoma with p53  
 CC mutations, cardiac tumours, pancreatic, breast, or prostate cancer), an  
 CC immunodeficiency or for enhancing an in vivo leukocyte response to an  
 CC antigen. Anti-TR2 antibodies are useful for treating, inhibiting or  
 CC preventing autoimmune diseases (such as autoimmune haemolytic anaemia,  
 CC dermatitis, allergic encephalomyelitis, rheumatoid arthritis, asthma, and  
 CC inflammatory myopathies) and immunodeficiency disorders (such as severely  
 CC combined immunodeficiency (SCID)-X linked, B cell lymphoproliferative  
 CC disorder, or Nezelof syndrome-combined immunodeficiency with IgS). TR2,  
 CC TR2-SV1 and/or TR2-SV2 polynucleotides and polypeptides, agonists or  
 CC antagonists are useful for treating or preventing autoimmune diseases and  
 CC inhibit the growth, progression and/or metastasis of cancers. They are  
 CC also used to activate, differentiate or proliferate cancerous cells or  
 CC tissues, and can be used to treat diseases associated with increased cell  
 CC survival, or the inhibition of apoptosis, e.g. Alzheimer's disease,  
 CC Parkinson's disease, or Crohn's disease. The TR2 polypeptides are useful  
 CC as sources for generating antibodies, as molecular weight markers.  
 CC This sequence represents the tumour necrosis factor receptor (TNFR)  
 CC domain of the human TNFR-II protein. The sequence was used in the  
 CC characterisation of the TR2 receptor protein of the invention.  
 XX  
 XX Sequence 163 AA;  
 XX  
 Query Match 54.1%; Score 46; DB 21; Length 163;  
 Best Local Similarity 64.3%; Pred. No. 4.6;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 QY 1 CASGTASNTTVAAD 14  
 Db 126 capgtftsntssd 139  
 |||||  
 RESULT 3  
 ID AAB00014  
 XX AAB00014 standard; Peptide; 165 AA.  
 XX  
 AC AAB00014;  
 XX  
 XX 20-OCT-2000 (first entry)  
 XX

DE Peptide fragment of TNFR2.  
 XX Tumour necrosis factor receptor homologue; TRH1; TNF; arthritis;  
 KW transplant rejection; activation; proliferation; differentiation;  
 KW apoptosis; immunosuppression; antiinflammatory; immunostimulation;  
 KW probe; primer; human.  
 XX Homo sapiens.  
 OS  
 XX W0200034294-A2.  
 PN  
 XX 15-JUN-2000.  
 PD  
 XX 10-DEC-1999; 99WO-US29400.  
 XX 11-DEC-1998; 98US-0111826.  
 XX (BRIM ) BRISTOL-MYERS SQUIBB CO.  
 PA  
 XX Bowen MA, Siemers N;  
 PI  
 XX WPI; 2000-423364/36.  
 DR  
 XX Novel tumor necrosis factor receptor homologue-1 useful as a target for  
 PT immunosuppressive, antiinflammatory and/or immunostimulatory drug  
 PT development  
 XX  
 XX Disclosure; Fig 5; 42pp; English.  
 PS  
 XX The tumour necrosis factor receptor homologue TRH1 can be used for  
 CC treating a mammal e.g. a human, at risk for a disorder characterized  
 CC by an aberrant or unwanted level or biological activity of TRH1,  
 CC e.g. rheumatoid arthritis and transplant rejection. TRH1 may also be  
 CC useful to leach out or block a ligand which is found to bind to the  
 CC TRH1. TRH1 may be used in various drug screening techniques and to  
 CC identify fragments and analogs of a protein or peptide (agonist or  
 CC antagonist) which bind to TRH1. The TRH1 protein plays a role in  
 CC cellular function, cell activation, proliferation, differentiation,  
 CC and apoptosis. The interaction between the novel TNF protein of the  
 CC present invention and intracellular signaling molecules and/or its  
 CC potential co-receptor may serve as a novel target for  
 CC immunosuppressive, antiinflammatory and/or immunostimulatory drug  
 CC development. Gene constructs can also be used as part of a gene  
 CC therapy protocol to deliver nucleic acids encoding the TRH1, or an  
 CC agonist or antagonist form of a TRH1 protein or peptide. Antibody  
 CC directed against TRH1 can be used to reject TRH1 in tissues  
 CC and cells. They can also be used to make targeted antibody that  
 CC destroy TRH1 expressing cells. Fragments of the TRH1 gene can be  
 CC used as diagnostic probes or as PCR primers. Fragments of the full  
 CC length gene may be used as hybridization probes for a cDNA library to  
 CC isolate the full length gene and to isolate other genes which have a  
 CC high sequence similarity. The probes may be used to identify a cDNA  
 CC clone corresponding to a full length transcript and a genomic clone  
 CC or clones that contain the complete gene including regulatory and  
 CC promoter regions, exons, and introns. This peptide fragment  
 CC corresponds to amino acids 38-202 of TNFR2 was used in a  
 CC homology comparison with TRH1. This cysteine rich motif was aligned  
 CC with the extracellular region of TRH1 (See GENESEQ record AAB00012).  
 XX  
 SQ Sequence 165 AA;  
 Query Match 54.1%; Score 46; DB 21; Length 165;  
 Best Local Similarity 64.3%; Pred. No. 4.6;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 QY 1 CASGTASNTTVAAD 14  
 |||||  
 Db 127 capgtfsnttsstd 140  
 RESULT 4  
 AAR77421

ID AAR77421 standard; Protein; 183 AA.  
 XX  
 AC AAR77421;  
 XX  
 DT 10-FEB-1996 (first entry)  
 XX  
 DE BamTP delta53 nerve growth factor sequence.  
 XX  
 XX Nerve growth factor; neurotrophic factor; therapeutic;  
 KW protein refolding; NGF; plasmid pT3XI-2.  
 XX  
 OS Synthetic.  
 XX  
 XX W09530686-A1.  
 PN  
 XX 16-NOV-1995.  
 PD  
 XX 02-MAY-1995; 95WO-US05423.  
 XX  
 XX 27-JUN-1994; 94US-0266080.  
 PR  
 XX 09-MAY-1994; 94US-0240122.  
 XX  
 PA (SYNT ) SYNTAX-SYNERGEN NEUROSCIENCE JOINT VENTU.  
 XX  
 XX Bonam D, Kohno T, Lille J, Rosendahl MS;  
 PI  
 XX WPI; 1995-404080/51.  
 DR  
 XX N-PSDB; AAT05443.  
 DR  
 XX Process for bacterial expression of recombinant neurotrophic factor  
 PT - useful for promoting the survival and maintaining phenotypic  
 PT differentiation of nerve and glial cells.  
 XX  
 XX Example 1; Page 36-37; 57pp; English.  
 PS  
 XX The synthetic nerve growth factor (NGF) gene isolated from Bam TP  
 CC delta 53 plasmid pT3XI-2 is designed to optimize codons for  
 CC expression in Escherichia coli as well as create unique sites for  
 CC subsequent cloning steps. The recombinant protein is solubilized  
 CC and sulfonlated and allowed to refold in the presence of PEG and  
 CC urea. Biologically active NGF, used for promoting the survival of  
 CC and maintaining the phenotypic differentiation of nerve and glial  
 CC cells, is isolated and purified. This method breaks incorrectly  
 CC formed disulphide bonds and allows refolding of the factor into  
 CC the correct tertiary structure required for maximum yield of full  
 CC active protein.  
 XX  
 SQ Sequence 183 AA;  
 Query Match 54.1%; Score 46; DB 16; Length 183;  
 Best Local Similarity 64.3%; Pred. No. 5.2;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 QY 1 CASGTASNTTVAAD 14  
 |||||  
 Db 143 capgtfsnttsstd 156  
 RESULT 5  
 AAY94720  
 ID AAY94720 standard; Protein; 198 AA.  
 XX  
 AC AAY94720;  
 XX  
 DT 29-JAN-2001 (first entry)  
 XX  
 DE Human type 2 tumour necrosis factor receptor protein fragment.  
 XX  
 XX Tumour necrosis factor-receptor related protein; TR2; human; cancer;  
 KW chromosome p36.2-p36.3; arthritis; inflammation; autoimmune disease;  
 KW immunodeficiency; metastasis; haemolytic anaemia; asthma; X-linked SCID;  
 KW severely combined immunodeficiency; apoptosis inhibition;

KW Alzheimer's disease; Parkinson's disease; Crohn's disease.

XX Homo sapiens.

XX WO200056405-A2.

XX 28-SEP-2000.

XX 22-MAR-2000; 2000WO-US07521.

XX 22-MAR-1999; 99US-0125683.

XX 26-MAR-1999; 99US-0126522.

XX 20-MAY-1999; 99US-0135169.

XX 06-AUG-1999; 99US-0147383.

XX (NIJJ/) NI J.

XX (ROSE/) ROSEN C A.

XX (GENTZ/) GENTZ R L.

XX N1 J, Rosen CA, Gentz RL;

XX WPI; 2000-594519/56.

XX Nucleic acid molecule encoding a human tumor necrosis factor receptor 2  
XX and its two splice variants, useful for treating arthritis or  
XX inflammation, cancer (such as follicular lymphomas) and  
XX immunodeficiency disorders -

XX Disclosure; Fig 8; 373pp; English.

XX This invention relates to an isolated nucleic acid molecule encoding a  
XX human tumor necrosis factor(TNF)-receptor related protein TR2. Included  
XX in the invention are the two splice variants of TR2, TR2-SV1 and TR2-SV2.  
XX The TR2 gene is located on chromosome 1 at position p36.2-p36.3. TR2 is a  
XX member of the TNFR superfamily. The invention includes a method for the  
XX treatment of arthritis or inflammation using an antibody directed against  
XX a fragment of the TR2 protein. TR2 is its agonists, antagonists and  
XX antibodies exhibit cytostatic, dermatological, antineoplastic,  
XX immunosuppressive, antiallergic, antiarthritic, antiasthmatic,  
XX antiinflammatory, neuroprotective, neurotropic, antiparkinsonian, and  
XX cerebroprotective activity. The methods are useful for treating arthritis  
XX or inflammation, cancer (such as follicular lymphomas, carcinoma with p53  
XX mutations, cardiac tumors, pancreatic, breast, or prostate cancer), an  
XX immunodeficiency or for enhancing an in vivo leukocyte response to an  
XX antigen. Anti-TR2 antibodies are useful for treating, inhibiting or  
XX preventing autoimmune diseases (such as autoimmune haemolytic anaemia,  
XX dermatitis, allergic encephalomyelitis, rheumatoid arthritis, asthma, and  
XX inflammatory myopathies) and immunodeficiency disorders (such as severely  
XX combined immunodeficiency (SCID)-X linked, B cell lymphoproliferative  
XX disorder, or Nezelof syndrome-combined immunodeficiency with Igs). TR2,  
XX TR2-SV1 and/or TR2-SV2 polynucleotides and polypeptides, agonists or  
XX antagonists are useful for treating or preventing autoimmune diseases and  
XX inhibit the growth, progression and/or metastasis of cancers. They are  
XX also used to activate, differentiate or proliferate cancerous cells or  
XX tissues, and can be used to treat diseases associated with increased cell  
XX survival, or the inhibition of apoptosis, e.g. Alzheimer's disease,  
XX Parkinson's disease, or Crohn's disease. The TR2 polypeptides are useful  
XX as sources for generating antibodies, as molecular weight markers.  
XX This sequence represents a fragment of the type 2 human tumor necrosis  
XX factor receptor protein. The sequence is used in the characterisation of  
XX the TR2 receptor protein of the invention.

XX Sequence 198 AA;

Query Match 54.18; Score 46; DB 21; Length 198;

Best Local Similarity 64.39; Pred. No. 5.7;

Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14

|||||||

Db 164 capgfsntstsd 177

# RESULT 6

AA777463

ID AAY77463 standard; Protein: 225 AA.

XX AAY77463;

XX 05-JUN-2000 (first entry)

XX Primate protein sequence, SEQ ID NO:14.

XX Immune disorder; inflammation; allergy; immunosuppressant;  
XX antiarthritic; antirheumatoid; antiinflammatory; dermatological;  
XX antithyroid.

XX Primates.

XX WO200001817-A2.

XX 13-JAN-2000.

XX 06-JUL-1999; 99WO-US12366.

XX 06-JUL-1998; 98US-0110938.

XX 13-JUL-1998; 98US-0114466.

XX 23-JUL-1998; 98US-0093897.

XX 12-AUG-1998; 98US-0132968.

XX 18-AUG-1998; 98US-0136214.

XX 11-SEP-1998; 98US-0099999.

XX (SCHE ) SCHERING CORP.

XX Bates EEM, Lebecque SJE, Murphy EE, Mattson JD, Gorman DM;

XX Hedrick JA, Wang L, Zlotnik A, Murgolo NJ, Greene JR, Johnston JA;

XX Bazan JF, Mahony D, Lees EM;

XX WPI; 2000-171015/15.

XX New isolated mammalian genes, used to develop products for treating  
XX e.g. immune, inflammatory or allergic abnormalities, cancers or  
XX degenerative conditions -

XX Disclosure; Page 170-171; 218pp; English.

XX The invention relates to a number of primate and/or rodent proteins, and  
XX the genes which encode them. The invention encompasses human dendritic  
XX cell prostaglandin transporter (DC-PGT); the TNF (tumour necrosis  
XX factor) receptor family-related proteins HDTEA84, HSLJP37R and RANKL;  
XX human CC chemokine HCC5; human deubiquitinating proteins Dub11 and Dub  
XX 12; human MD-1 and human and murine MD-2 proteins, which exhibit the  
XX properties of ligands for proteins comprising a leucine-rich motif  
XX (LRR); human cyclin E2; cDNAs encoding these proteins; and antibodies  
XX against these proteins. The proteins can be used for modulating the  
XX physiology or development of a cell. They can be used to mediate uptake  
XX of substrates (e.g., prostaglandin-like molecules), to modulate or  
XX mediate cellular interactions (e.g., induce or prevent trafficking,  
XX proliferation, or differentiation of cells), or are intracellular  
XX proteins which are important in various cellular processes such as the  
XX deubiquitination of proteins or cell cycle regulation. The products can  
XX be used for treating medical conditions such as immune, inflammatory or  
XX allergic disorders, or abnormal cellular proliferation, for example,  
XX cancers or degenerative conditions. They can be used to modulate immune  
XX responses in disease states e.g., autoimmune disorders, including  
XX rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's  
XX autoimmune thyroiditis, as well as acute and chronic inflammatory  
XX responses in which T cell activation, expansion, and/or immunological T  
XX cell memory play an important role. Sequences AAY77463-Y77464,  
XX AAY77474-Y77475 and AAY77484 represent primate proteins of undefined  
XX function, AAY77462 and AAY77481 are rodent proteins of undefined  
XX function, and AAY77482 is an avian protein of undefined function. These  
XX sequences are given in the sequence listing but are not referred to in  
XX the remainder of the specification.

SQ Sequence 225 AA;

Query Match 54.1%; Score 46; DB 21; Length 225;  
 Best Local Similarity 64.3%; Pred. No. 6.6;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Caps 0;

QY 1 CASGTASNTTVAAD 14  
 || || || || || : |  
 Db 164 capgtfsnttsstd 177

RESULT 7

AAW59665  
 ID AAB66981 standard; Protein; 227 AA.

XX AC AAB66981;

XX DT 19-APR-2001 (first entry)

XX DE Tnfr2 protein.

XX KW Bone loss; osteoprotegerin; OPG; rheumatoid arthritis; hyperalgesia;  
 KW multiple sclerosis; osteoporosis; osteomyelitis; asthma; inflammation;  
 KW systemic lupus erythematosus; graft-versus-host disease; septic shock;  
 KW acute pancreatitis; Alzheimer's disease; anorexia; atherosclerosis; pain;  
 KW coronary condition; myocardial infarction; cancer; diabetes; psoriasis;  
 KW endometriosis; fever; glomerulonephritis; inflammatory bowel disease;  
 KW ischaemia; Parkinson's disease.

XX OS Unidentified.

XX PN W0200103719-A2.

XX PD 18-JAN-2001.

XX PF 07-JUL-2000; 2000WO-US18667.

XX PR 09-JUL-1999; 99US-0350670.

XX PR 09-DEC-1999; 99US-0457647.

XX PA (AMGE-) AMGEN INC.

XX PI Boyle WJ, Lacey DL, Calzone FJ, Chang M, Senaldi G;

XX PS WPI; 2001-103031/11.

XX PT Treating conditions leading to bone loss such as rheumatoid arthritis,  
 XX multiple sclerosis and asthma, comprises administering an  
 XX osteoprotegerin protein in conjunction with e.g. inhibitors of  
 XX interleukin and tumor necrosis factor alpha

XX PS Disclosure; Fig 2; 316pp; English.

XX CC The present invention relates to a method for treating conditions leading  
 XX to bone loss. The method comprises administering a purified and isolated  
 XX osteoprotegerin (OPG) protein (AAF57836-AAF57838 and AAB66974-AAB66976)  
 XX in conjunction with other substances such as tumour necrosis factor-alpha  
 XX (TNF-alpha) inhibitors, interleukin (IL)-6, -8 and -18 inhibitors, ICE  
 XX modulators, fibroblast growth factor (FGF)1-10 modulators and/or platelet  
 XX activating factor (PAF) antagonists. The method is useful for treating  
 XX conditions leading to bone loss such as rheumatoid arthritis, multiple  
 XX sclerosis, osteoporosis, osteomyelitis and asthma. The method is also  
 XX useful for treating inflammation, systemic lupus erythematosus (SLE) and  
 XX graft-versus-host disease (GVHD). Other diseases that can be treated  
 XX include acute pancreatitis, Alzheimer's disease, anorexia,  
 XX atherosclerosis, coronary conditions (e.g. myocardial infarction),  
 XX cancer, diabetes, endometriosis, fever, glomerulonephritis, hyperalgesia,  
 XX inflammatory bowel disease, ischaemia, pain, Parkinson's disease,  
 XX psoriasis and septic shock. The present sequence was used in a sequence  
 XX homology comparison.

XX SQ Sequence 227 AA;

Query Match 54.1%; Score 46; DB 22; Length 227;  
 Best Local Similarity 64.3%; Pred. No. 6.7;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Caps 0;

QY 1 CASGTASNTTVAAD 14  
 || || || || || : |  
 Db 164 capgtfsnttsstd 177

RESULT 8

AAW59665  
 ID AAW59665 standard; Protein; 235 AA.

XX AC AAW59665;

XX DT 28-SEP-1998 (first entry)

XX DE Human soluble tumour necrosis factor receptor type II.

XX KW Human; tumour necrosis factor; TNF; TNF receptor type II;  
 KW inflammatory disease; leukaemia; TNF binding protein;  
 KW anti-inflammatory drug; methotrexate.

XX OS Homo sapiens.

XX PN W09824463-A2.

XX PD 11-JUN-1998.

XX PF 08-DEC-1997; 97WO-US22733.

XX PR 09-JUL-1997; 97US-0052023.

XX PR 06-DEC-1996; 96US-0032587.

XX PR 23-JAN-1997; 97US-0036355.

XX PR 07-FEB-1997; 97US-0039315.

XX PA (AMGE-) AMGEN INC.

XX PI Bendele AM, Edwards CK, Sennello RM;

XX PS WPI; 1998-333039/29.

XX DR N-PSDB; AAV41549.

XX PT Treatment of acute or chronic inflammatory disease, e.g. leukaemia -  
 XX by administering tumour necrosis factor binding protein and at least  
 XX one additional anti-inflammatory drug, e.g. methotrexate

XX PS Disclosure; Fig 2; 104pp; English.

XX CC This is the amino acid sequence of the human tumour necrosis factor  
 XX receptor type II, used in the method of the invention involving the  
 XX treatment of acute or chronic inflammatory disease such as leukaemia  
 XX by administering tumour necrosis factor binding protein and at least  
 XX one additional anti-inflammatory drug, e.g. methotrexate.

XX SQ Sequence 235 AA;

Query Match 54.1%; Score 46; DB 19; Length 235;  
 Best Local Similarity 64.3%; Pred. No. 6.9;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Caps 0;

QY 1 CASGTASNTTVAAD 14  
 || || || || || : |  
 Db 142 capgtfsnttsstd 155

RESULT 9

AAW52270  
 ID AAW52270 standard; Protein; 235 AA.

XX

AC AAW52270;  
 XX  
 XX  
 DT 29-JUN-1998 (first entry)  
 XX  
 DE Tumour necrosis factor inhibitor.  
 XX  
 KW Soluble tumour necrosis factor receptor; sTNFR; TNF-mediated disease;  
 KW tumour necrosis factor binding protein; autoimmune disease; arthritis;  
 KW adult respiratory distress syndrome; cachexia/anorexia; cancer; therapy;  
 KW tumour necrosis factor inhibitor; Alzheimer's disease; TNBP.  
 XX  
 XX Homo sapiens.  
 OS  
 PN W09801555-A2.  
 XX  
 XX 15-JAN-1998.  
 PD  
 XX 09-JUL-1997; 97WO-US12244.  
 PF  
 XX 04-MAR-1997; 97US-0039792.  
 PR  
 XX 09-JUL-1996; 96US-0021443.  
 PR  
 XX 06-DEC-1996; 96US-0032534.  
 PR  
 XX 23-JAN-1997; 97US-0037737.  
 PR  
 XX 07-FEB-1997; 97US-0039314.  
 XX  
 XX (AMGE-) AMGEN INC.  
 PA  
 XX Edwards CK, Fisher EF, Kieft GL;  
 PI  
 XX WPI; 1998-101052/09.  
 DR  
 XX N-PSDB; AAV19802.  
 XX  
 PT Truncated and soluble forms of tumour necrosis factor receptor -  
 PT useful for treating diseases involving factor, e.g. arthritis and  
 PT adult respiratory distress syndrome  
 XX  
 XX Claim 3; Fig 8; 205pp; English.  
 PS  
 XX This sequence is the human tumour necrosis factor inhibitor. The protein  
 XX was used to make the truncated soluble tumour necrosis factor receptor  
 CC (sTNFR) proteins of the invention. The truncated sTNFR proteins and  
 CC tumour necrosis factor binding proteins (TNBP) are used to treat any  
 CC TNF-mediated disease, e.g. arthritis, adult respiratory distress  
 CC syndrome, cachexia/anorexia, cancer, chronic fatigue syndrome, graft  
 CC rejection, Alzheimer's disease and other autoimmune diseases. Cells  
 CC transformed with a vector containing DNA encoding the protein may be used  
 CC for production of recombinant sTNFR, which may also be used for measuring  
 CC the amount of sTNFR in samples and to raise antibodies against sTNFR.  
 CC TNBP may also be used in preparation of therapeutic compositions for  
 CC treating the above diseases. The sTNFR proteins are well suited to large  
 CC scale production (since they lack the deamidation site in region 111-126,  
 CC so are more stable in vivo); contain fewer disulphide bonds and fewer  
 CC epitopes, making them less antigenic than full-length proteins.  
 XX  
 XX Sequence 235 AA;  
 SQ  
 Query Match 54.1%; Score 46; DB 19; Length 235;  
 Best Local Similarity 64.3%; Pred. No. 6.9;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 Qy 1 CASGTASNTTVAAD 14  
 Db 142 capgftsnttsd 155  
 RESULT 10  
 AAW89234  
 ID AAW89234 standard; Protein; 235 AA.  
 XX  
 XX AAW89234;  
 AC  
 XX 04-MAR-1999 (first entry)  
 DT

XX Tumour necrosis inhibitor 40 kDa protein.  
 DE  
 XX  
 KW Tumour necrosis factor receptor 1; TNFR-1; inhibitor; osteoprotegerin;  
 KW OpG; chimeric; fusion; dimerisation domain; autoimmune disease;  
 KW inflammation; apoptosis.  
 XX  
 OS Homo sapiens.  
 XX  
 PN W09849305-A1.  
 XX  
 XX 05-NOV-1998.  
 PD  
 XX 29-APR-1998; 98WO-US08631.  
 PF  
 XX 01-MAY-1997; 97US-0850188.  
 PR  
 XX (AMGE-) AMGEN INC.  
 PA  
 XX Boyle WJ, Wooden S;  
 PI  
 XX WPI; 1999-034661/03.  
 DR  
 XX N-PSDB; AAV81733.  
 DR  
 XX New chimeric osteoprotegerin polypeptides - contain the  
 XX osteoprotegerin dimerisation domain and a heterologous sequence,  
 XX useful to treat TNF and TNFR-mediated disorders  
 PT  
 XX Disclosure; Fig 3; 92pp; English.  
 PS  
 XX The present invention describes a chimeric polypeptide (A1), comprising  
 XX an osteoprotegerin (OPG) dimerisation domain fused to a heterologous  
 CC amino acid sequence. Also described are: (1) a multimer polypeptide  
 CC comprising covalently associated A1 monomers; (2) an isolated nucleic  
 CC acid encoding A1; (3) an expression vector comprising the nucleic acid  
 CC sequence; and (4) a host cell transformed or transfected with the  
 CC expression vector so that the nucleic acid is expressible. The products  
 CC from the present invention are useful to treat a variety of disorders  
 CC including those related to receptor binding. Compositions comprising  
 CC tumour necrosis factor (TNF)/OPG and TNF receptor (TNFR)/OPG chimeras  
 CC are used to treat TNF and TNFR-mediated disorders such as inflammation,  
 CC autoimmune diseases and disorders related to excessive apoptosis. The  
 CC chimeras are also useful for detecting molecules which interact with  
 CC fused heterologous sequences to identify potential new receptors and  
 CC ligands. The present sequence represents the TNF inhibitor 40 kDa  
 CC protein.  
 XX  
 XX Sequence 235 AA;  
 SQ  
 Query Match 54.1%; Score 46; DB 20; Length 235;  
 Best Local Similarity 64.3%; Pred. No. 6.9;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 Qy 1 CASGTASNTTVAAD 14  
 Db 142 capgftsnttsd 155  
 RESULT 11  
 AAY54440  
 ID AAY54440 standard; Protein; 235 AA.  
 XX  
 XX AAY54440;  
 AC  
 XX 25-APR-2000 (first entry)  
 DT  
 XX Amino acid sequence of a K108R mutant of soluble p75 TNF receptor.  
 DE  
 XX p75 tumour necrosis factor receptor; mutant; PEG conjugated protein;  
 KW polyethylene glycol conjugation; PEG conjugation; protein activity.  
 KW  
 XX Homo sapiens.  
 OS

```

OS Synthetic.
XX Key Location/Qualifiers
FH Misc-difference 108
FT /note= "wild type Lys replaced with Arg"
XX
XX WO9967291-A2.
XX
XX 29-DEC-1999.
XX
XX 18-JUN-1999; 99WO-US13953.
XX
XX 22-JUN-1998; 98US-0102530.
XX
XX (IMMV ) IMMUNEX CORP.
XX
XX Pettit DK;
XX
XX WPI; 2000-160577/14.
XX
XX N-PSDB; AA245759.
XX
XX Novel methods for site-specific protein modification by mutagenesis by
XX replacing polyethylene glycol reacting sites
XX
XX Claim 17; Page 29; 36pp; English.
XX
XX The present sequence represents a N-terminal fragment of a mutant of
XX the soluble tumour necrosis factor (TNF) receptor, where the wild
XX type Lys residue at position 108 is replaced with Arg. Lys108 (and
XX Lys120) make contact between the p75 receptor and ligand. These
XX residues are also potential polyethylene glycol (PEG) conjugation
XX sites. The wild type p75 TNF receptor protein was mutated and conjugated
XX to PEG, using the method of the invention. The specification describes
XX a method for conjugating proteins with PEG to result in
XX PEG-conjugated proteins having little or no reduction in a desired
XX activity. Specifically, one or more amino acid residues that are
XX critical for protein bioactivity and which are capable of reacting
XX with PEG sites are deleted, prior to conjugation of the protein to PEG.
XX The methods provide PEG conjugated proteins that are more homogeneous
XX and present in higher yields. Conjugation does not take place at amino
XX acid residues that are critical to the proteins bioactivity, thus
XX maintaining the activity of the protein. The methods are used to
XX produce PEG conjugated proteins.
XX
XX Sequence 235 AA;

Query Match 54.1%; Score 46; DB 21; Length 235;
Best Local Similarity 64.3%; Pred. No. 6.9;
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14
Db 142 capgtfsnttsstd 155
|| || || || || : |

RESULT 12
AAV54441
ID AAY54441 standard; Protein; 235 AA.
XX
XX AAY54441;
XX
XX 25-APR-2000 (first entry)
XX
XX Amino acid sequence of a K120R mutant of soluble p75 TNF receptor.
XX
XX p75 tumour necrosis factor receptor; mutant; PEG conjugated protein;
XX polyethylene glycol conjugation; PEG conjugation; protein activity.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers

```

```

FT Misc-difference 120
FT /note= "wild type Lys replaced with Arg"
XX
XX WO9967291-A2.
XX
XX 29-DEC-1999.
XX
XX 18-JUN-1999; 99WO-US13953.
XX
XX 22-JUN-1998; 98US-0102530.
XX
XX (IMMV ) IMMUNEX CORP.
XX
XX Pettit DK;
XX
XX WPI; 2000-160577/14.
XX
XX N-PSDB; AA245760.
XX
XX Novel methods for site-specific protein modification by mutagenesis by
XX replacing polyethylene glycol reacting sites
XX
XX Claim 16; Page 31; 36pp; English.
XX
XX The present sequence represents a N-terminal fragment of a mutant of
XX the soluble tumour necrosis factor (TNF) receptor, where the wild
XX type Lys residue at position 120 is replaced with Arg. Lys120 (and
XX Lys108) make contact between the p75 receptor and ligand. These
XX residues are also potential polyethylene glycol (PEG) conjugation
XX sites. The wild type p75 TNF receptor protein was mutated and conjugated
XX to PEG, using the method of the invention. The specification describes
XX a method for conjugating proteins with PEG to result in
XX PEG-conjugated proteins having little or no reduction in a desired
XX activity. Specifically, one or more amino acid residues that are
XX critical for protein bioactivity and which are capable of reacting
XX with PEG sites are deleted, prior to conjugation of the protein to PEG.
XX The methods provide PEG conjugated proteins that are more homogeneous
XX and present in higher yields. Conjugation does not take place at amino
XX acid residues that are critical to the proteins bioactivity, thus
XX maintaining the activity of the protein. The methods are used to
XX produce PEG conjugated proteins.
XX
XX Sequence 235 AA;

Query Match 54.1%; Score 46; DB 21; Length 235;
Best Local Similarity 64.3%; Pred. No. 5.9;
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14
Db 142 capgtfsnttsstd 155
|| || || || || : |

RESULT 13
AAV54442
ID AAY54442 standard; Protein; 235 AA.
XX
XX AAY54442;
XX
XX 25-APR-2000 (first entry)
XX
XX A K108R/K120R mutant of soluble p75 TNF receptor.
XX
XX p75 tumour necrosis factor receptor; mutant; PEG conjugated protein;
XX polyethylene glycol conjugation; PEG conjugation; protein activity.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Misc-difference 108
FT /note= "wild type Lys replaced with Arg"
FT Misc-difference 120

```

/note= "wild type Lys replaced with Arg"

FT XX WO9967291-A2.  
 PN XX 29-DEC-1999.  
 PD XX  
 XX  
 PF XX 18-JUN-1999; 99WO-US13953.  
 XX  
 PR XX 22-JUN-1998; 98US-0102530.  
 XX  
 PA XX (IMMV ) IMMUNEX CORP.  
 XX  
 PI XX Pettit DK;  
 XX  
 DR XX WPI: 2000-160577/14.  
 DR XX N-PSDB; AA54761.  
 XX  
 PT Novel methods for site-specific protein modification by mutagenesis by  
 XX replacing polyethylene glycol reacting sites -  
 PS Claim 16; Page 33-34; 36pp; English.  
 XX  
 CC The present sequence represents a N-terminal fragment of a mutant of the  
 CC soluble tumour necrosis factor (TNF) receptor, where the wild type Lys  
 CC residues at positions 108 and 120 are replaced with Arg. Lys120 and  
 CC Lys108 make contact between the p75 receptor and ligand. These  
 CC residues are also potential polyethylene glycol (PEG) conjugation  
 CC sites. The wild type p75 TNF receptor protein was mutated and conjugated  
 CC to PEG, using the method of the invention. The specification describes  
 CC a method for conjugating proteins with PEG to result in  
 CC PEG-conjugated proteins having little or no reduction in a desired  
 CC activity. Specifically, one or more amino acid residues that are  
 CC critical for protein bioactivity and which are capable of reacting  
 CC with PEG sites are deleted, prior to conjugation of the protein to PEG.  
 CC The methods provide PEG conjugated proteins that are more homogeneous  
 CC and present in higher yields. Conjugation does not take place at amino  
 CC acid residues that are critical to the proteins bioactivity, thus  
 CC maintaining the activity of the protein. The methods are used to  
 CC produce PEG conjugated proteins.  
 XX  
 SQ Sequence 235 AA;

Query Match 54.1%; Score 46; DB 21; Length 235;  
 Best Local Similarity 64.3%; Pred. No. 6.9;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
 || || || || :  
 Db 142 capgtfsnttsstd 155

RESULT 14  
 AA54443  
 ID AAY54443 standard; Protein; 235 AA.  
 XX  
 AC AA54443;

DT 25-APR-2000 (first entry)  
 XX  
 DE Wild type N-terminal fragment of the soluble p75 TNF receptor.

XX p75 tumour necrosis factor receptor; mutant; PEG conjugated protein;  
 KW polyethylene glycol conjugation; PEG conjugation; protein activity.  
 XX  
 OS Homo sapiens.

XX WO9967291-A2.  
 PN  
 XX  
 XX 29-DEC-1999.  
 PD  
 XX  
 PF 18-JUN-1999; 99WO-US13953.  
 XX

PR XX 22-JUN-1998; 98US-0102530.  
 XX  
 PA XX (IMMV ) IMMUNEX CORP.  
 XX  
 PI XX Pettit DK;  
 XX  
 DR XX WPI: 2000-160577/14.  
 DR XX N-PSDB; AA245762.  
 XX  
 PT Novel methods for site-specific protein modification by mutagenesis by  
 XX replacing polyethylene glycol reacting sites -  
 PS Claim 16; Page 35-36; 36pp; English.  
 XX  
 CC The present sequence represents a N-terminal fragment of the soluble  
 CC tumour necrosis factor (TNF) receptor. The wild type Lys residues at  
 CC positions 108 and 120 are replaced with Arg (see AAY54441-42). Lys120  
 CC and Lys108 make contact between the p75 receptor and ligand. These  
 CC residues are also potential polyethylene glycol (PEG) conjugation  
 CC sites. The wild type p75 TNF receptor protein was mutated and conjugated  
 CC to PEG, using the method of the invention. The specification describes  
 CC a method for conjugating proteins with PEG to result in  
 CC PEG-conjugated proteins having little or no reduction in a desired  
 CC activity. Specifically, one or more amino acid residues that are  
 CC critical for protein bioactivity and which are capable of reacting  
 CC with PEG sites are deleted, prior to conjugation of the protein to PEG.  
 CC The methods provide PEG conjugated proteins that are more homogeneous  
 CC and present in higher yields. Conjugation does not take place at amino  
 CC acid residues that are critical to the proteins bioactivity, thus  
 CC maintaining the activity of the protein. The methods are used to  
 CC produce PEG conjugated proteins.  
 XX  
 SQ Sequence 235 AA;

Query Match 54.1%; Score 46; DB 21; Length 235;  
 Best Local Similarity 64.3%; Pred. No. 6.9;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
 || || || || :  
 Db 142 capgtfsnttsstd 155

RESULT 15  
 AAB37685  
 ID AAB37685 standard; Protein; 235 AA.  
 XX  
 AC AAB37685;

DT 02-MAR-2001 (first entry)  
 XX  
 DE Human 40 kDa TNF inhibitor.

XX TNF inhibitor; antiinflammatory; Tumour Necrosis Factor; Interleukin;  
 KW IL-1; inflammatory disease; degenerative disease; human; lymphotoxin.  
 XX  
 OS Homo sapiens.

XX US6143866-A.  
 PN  
 XX  
 XX 07-NOV-2000.

XX 19-JAN-1995; 95US-0375242.  
 XX  
 XX 19-JUL-1990; 90US-0555274.  
 PR 09-JUL-1993; 93US-0090366.  
 PR 18-JUL-1989; 89US-0381080.  
 PR 11-DEC-1989; 89US-0450329.  
 PR 07-FEB-1990; 90US-0479661.  
 XX  
 PA (AMGE-) AMGEN INC.  
 XX



PI Squires C, King MW, Hale KK, Brewer MT, Thompson RC;  
 PI Vanderslice RW, Vannice J, Kohno T;  
 XX WPI; 2001-006443/01.  
 DR  
 XX Novel 30 kDa tumor necrosis factor inhibitor analog comprising a  
 PT non-native cysteine residue cross-linked with polyethylene glycol,  
 PT useful for treating inflammatory and degenerative diseases mediated by  
 PT TNF -  
 XX  
 PS Example 12; Fig 38; 82pp; English.  
 XX  
 CC The present invention relates to Tumour Necrosis Factor (TNF) inhibitors  
 CC (see AAB37676 and AAB37685), which have TNF inhibitory activity. The  
 CC novel TNF inhibitors of the present invention are useful as therapeutic  
 CC agents for inhibiting the activity of TNF and interleukin (IL-1) and  
 CC for treating inflammatory and degenerative diseases mediated by TNF. The  
 CC present sequence is 40 kDa TNF inhibitor. The 40 kDa TNF inhibitor can  
 CC inhibit both TNF alpha and beta (lymphotoxin).  
 XX  
 SQ Sequence 235 AA;

Query Match 54.1%; Score 46; DB 22; Length 235;  
 Best Local Similarity 64.3%; Pred. No. 6.9;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 OY 1 CASGTASNTTVAAD 14  
 Db 142 capgtfsnttsstd 155  
 || || || || || : |

Search completed: March 26, 2002, 13:38:46  
 Job time: 140 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:41:27 ; Search time 37.72 Seconds  
(without alignments)  
10.142 Million cell updates/sec

Title: US-09-709-201-96

Perfect score: 85

Sequence: 1 CASGTASNTTVAADRSN 17

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 212252 seqs, 22503292 residues

Total number of hits satisfying chosen parameters: 212252

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- 1: /cgn2\_6/ptodata/2/iaa/5A.COMB.pep.\*
- 2: /cgn2\_6/ptodata/2/iaa/5B.COMB.pep.\*
- 3: /cgn2\_6/ptodata/2/iaa/6A.COMB.pep.\*
- 4: /cgn2\_6/ptodata/2/iaa/6B.COMB.pep.\*
- 5: /cgn2\_6/ptodata/2/iaa/PCTUS.COMB.pep.\*
- 6: /cgn2\_6/ptodata/2/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	46	54.1	39	1	US-08-050-319B-41
2	46	54.1	39	2	US-08-465-982-41
3	46	54.1	163	2	US-08-219-237B-5
4	46	54.1	163	4	US-08-477-347-13
5	46	54.1	163	4	US-08-476-862-4
6	46	54.1	163	4	US-08-468-560C-5
7	46	54.1	164	2	US-08-232-087A-9
8	46	54.1	227	3	US-08-974-022-48
9	46	54.1	227	4	US-08-795-445A-48
10	46	54.1	227	4	US-08-795-447A-48
11	46	54.1	227	4	US-08-974-186-48
12	46	54.1	227	4	US-08-795-446B-48
13	46	54.1	235	4	US-08-326-394-4
14	46	54.1	461	1	US-08-385-229-2
15	46	54.1	461	2	US-08-650-000-2
16	46	54.1	461	4	US-09-042-785A-7
17	46	54.1	461	4	US-08-477-347-3
18	46	54.1	461	4	US-09-006-353A-4
19	46	54.1	461	4	US-08-476-862-2
20	46	54.1	461	6	5395760-2
21	46	54.1	486	1	US-08-243-010-1
22	46	54.1	518	1	US-08-385-229-4
23	41	48.2	474	2	US-08-650-000-4
24	41	48.2	474	4	US-09-042-785A-8
25	41	48.2	474	6	5395760-4
26	40	47.1	223	1	US-08-278-091-13
27	40	47.1	223	1	US-08-483-859-13

28	40	47.1	223	1	US-08-472-173-13	Sequence 13, Appl
29	40	47.1	223	2	US-08-487-167-13	Sequence 13, Appl
30	40	47.1	223	2	US-08-482-316-13	Sequence 13, Appl
31	40	47.1	223	2	US-08-296-149-13	Sequence 13, Appl
32	40	47.1	223	2	US-08-801-199-13	Sequence 13, Appl
33	40	47.1	223	2	US-08-615-371-13	Sequence 13, Appl
34	40	47.1	223	3	US-09-074-659-13	Sequence 13, Appl
35	40	47.1	223	3	US-09-074-659-13	Sequence 13, Appl
36	40	47.1	223	3	US-09-106-468-13	Sequence 13, Appl
37	40	47.1	223	4	US-09-106-468A-13	Sequence 13, Appl
38	40	47.1	223	4	US-09-106-467-13	Sequence 13, Appl
39	39.5	46.5	1038	4	US-09-541-782-4	Sequence 4, Appl
40	39	45.9	1319	2	US-08-290-731C-2	Sequence 2, Appl
41	39	45.9	1336	6	US-08-290-731C-6	Sequence 6, Appl
42	38	44.7	327	1	US-08-240-049B-13	Sequence 13, Appl
43	38	44.7	327	1	US-08-240-049B-14	Sequence 14, Appl
44	38	44.7	327	1	US-08-259-148A-15	Sequence 15, Appl
45	38	44.7	327	1	US-08-259-148A-16	Sequence 16, Appl

ALIGNMENTS

RESULT 1  
US-08-050-319B-41  
; Sequence 41, Application US/08050319B  
; Patent No. 5633145  
; GENERAL INFORMATION:  
; APPLICANT: M.Feldmann, P.W. Gray,  
; APPLICANT: M.J.C. Turner, F.M Brennan  
; TITLE OF INVENTION: Modified human TNFalpha (Tumor  
; TITLE OF INVENTION: Necrosis Factor alpha) Receptor  
; NUMBER OF SEQUENCES: 57  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Reed & Robbins  
; STREET: 635 Bryant Street  
; CITY: Palo Alto  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94301  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/050,319B  
; FILING DATE: 10-May-1993  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Robbins, Roberta L.  
; REGISTRATION NUMBER: 33,208  
; REFERENCE/DOCKET NUMBER: 5150-0030  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 617-8999  
; TELEFAX: (415) 327-3231  
; INFORMATION FOR SEQ ID NO: 41:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 39 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-050-319B-41

Query Match 54.1%; Score 46; DB 1; Length 39;  
Best Local Similarity 64.3%; Pred. No. 0.45;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
QY 1 CASGTASNTTVAAD 14  
||| ||||| :  
Db 2 CAPGTFSTSTSTD 15

RESULT 2  
US-08-465-982-41  
; Sequence 41, Application US/08465982  
; Patent No. 5863786  
; GENERAL INFORMATION:  
; APPLICANT: M.Feldmann, P.W. Gray,  
; APPLICANT: M.J.C. Turner, F.M. Brennan  
; TITLE OF INVENTION: Modified human TNFalpha (Tumor  
; NUMBER OF SEQUENCES: 57  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Reed & Robbins  
; STREET: 635 Bryant Street  
; CITY: Palo Alto  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94301  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/465,982  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/050,319  
; FILING DATE: 10-May-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Robbins, Roberta L.  
; REGISTRATION NUMBER: 33,208  
; REFERENCE/DOCKET NUMBER: 5150-0030  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 617-8999  
; TELEFAX: (415) 327-3231  
; INFORMATION FOR SEQ ID NO: 41:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 39 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-465-982-41

Query Match 54.1%; Score 46; DB 2; Length 39;  
Best Local Similarity 64.3%; Pred. No. 0.45;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAAD 14  
||| ||||| :|  
Db 2 CAPGTFSTTSSTD 15

RESULT 3  
US-08-219-237B-5  
; Sequence 5, Application US/08219237B  
; Patent No. 5874546  
; GENERAL INFORMATION:  
; APPLICANT: NAGATA, Shigekazu  
; APPLICANT: ITOH, Naoto  
; APPLICANT: YONEHARA, Shin  
; TITLE OF INVENTION: DNA Coding for Human Cell Surface Antigen  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: James W. Hellwege  
; STREET: P.O. Box 2266 Eads Station  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: USA

ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/219,237B  
; FILING DATE: 28-MAR-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/872,129  
; FILING DATE: 22-APR-1992  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: James W. Hellwege  
; REGISTRATION NUMBER: 28,808  
; REFERENCE/DOCKET NUMBER: 516762  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 163 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-219-237B-5

Query Match 54.1%; Score 46; DB 2; Length 163;  
Best Local Similarity 64.3%; Pred. No. 2.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAAD 14  
||| ||||| :|  
Db 126 CAPGTFSTTSSTD 139

RESULT 4  
US-08-477-347-13  
; Sequence 13, Application US/08477347  
; Patent No. 6232446  
; GENERAL INFORMATION:  
; APPLICANT: WALLACH, David  
; APPLICANT: BIGDA, Jacek  
; APPLICANT: BELETSKY, Igor  
; APPLICANT: METT, Igor  
; TITLE OF INVENTION: TNF LIGANDS  
; NUMBER OF SEQUENCES: 17  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W.  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/477,347  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/115,685  
; FILING DATE:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: IL 106271  
; FILING DATE: 08-JUL-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Townsend, G. Kevin  
; REGISTRATION NUMBER: 34,033  
; REFERENCE/DOCKET NUMBER: WALLACH-10

TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
TELEX: 248633  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 163 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-477-347-13

Query Match 54.1% Score 46; DB 4; Length 163;  
Best Local Similarity 64.3% Pred. No. 2.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
||| ||||| :  
Db 126 CAPGTFNTSSTD 139

RESULT 5  
US-08-476-862-4  
; Sequence 4, Application US/08476862  
; Patent No. 6262239  
; GENERAL INFORMATION:  
; APPLICANT: WALLACH, David  
; APPLICANT: BIGDA, Jacek  
; APPLICANT: BELETSKY, Igor  
; APPLICANT: METT, Igor  
; APPLICANT: ENGELMANN, Hartmut  
; TITLE OF INVENTION: TNF INHIBITORS  
; NUMBER OF SEQUENCES: 8  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W.  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/476,862  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: IL 107267  
; FILING DATE: 12-OCT-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: IL 94039  
; FILING DATE: 06-APR-1990  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: IL 91229  
; FILING DATE: 06-AUG-1989  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: IL 90339  
; FILING DATE: 18-MAY-1989  
; ATTORNEY/AGENT INFORMATION:  
; NAME: BROWDY, Roger L.  
; REGISTRATION NUMBER: 25,618  
; REFERENCE/DOCKET NUMBER: WALLACH-12A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 163 amino acids

; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-476-862-4

Query Match 54.1% Score 46; DB 4; Length 163;  
Best Local Similarity 64.3% Pred. No. 2.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
||| ||||| :  
Db 126 CAPGTFNTSSTD 139

RESULT 6  
US-08-468-560C-5  
; Sequence 5, Application US/08468560C  
; Patent No. 6270998  
; GENERAL INFORMATION:  
; APPLICANT: NAGATA, Shigekazu  
; APPLICANT: ITOH, Naoto  
; APPLICANT: YONEHARA, Shin  
; TITLE OF INVENTION: DNA CODING FOR HUMAN CELL SURFACE  
; TITLE OF INVENTION: ANTIGEN  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BIRCH, STEWART, KOLASCH & BIRCH, LLP.  
; STREET: P.O. BOX 747  
; CITY: FALLS CHURCH  
; STATE: VA.  
; COUNTRY: USA  
; ZIP: 22040-0747  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/468,560C  
; FILING DATE: 06-JUN-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: MURPHY JR., GERLAD M.  
; REGISTRATION NUMBER: 28,977  
; REFERENCE/DOCKET NUMBER: 20-4393P  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-205-8000  
; TELEFAX: 703-205-8050  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 163 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-468-560C-5

Query Match 54.1% Score 46; DB 4; Length 163;  
Best Local Similarity 64.3% Pred. No. 2.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
||| ||||| :  
Db 126 CAPGTFNTSSTD 139

RESULT 7  
US-08-232-087A-9  
; Sequence 9, Application US/08232087A  
; Patent No. 5866372

GENERAL INFORMATION:  
APPLICANT: Stein, Harold  
APPLICANT: Drkop, Horst  
APPLICANT: Latza, Ute  
TITLE OF INVENTION: Lymphoid CD30-Antigen  
NUMBER OF SEQUENCES: 11  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Birch, Stewart, Kolasch & Birch, LLP  
STREET: 8110 Gatehouse Road, Suite 500 East  
CITY: Falls Church  
STATE: Virginia  
COUNTRY: U.S.A.  
ZIP: 22042

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/232,087A  
FILING DATE: 08-SEP-1994  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Murphy Jr., Gerald M.  
REGISTRATION NUMBER: 28,977  
REFERENCE/DOCKET NUMBER: 756-103P  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 205-8000  
TELEFAX: (703) 205-8050  
TELEX: 248345

INFORMATION FOR SEQ ID NO: 9:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 164 amino acids  
TYPE: amino acid  
STRANDEDNESS: not relevant  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
HYPOTHETICAL: NO  
FRAGMENT TYPE: internal  
FEATURE:  
NAME/KEY: Protein  
LOCATION: 1..164  
OTHER INFORMATION: /note= "TNFR2, see Fig. 5"

US-08-232-087A-9

Query Match 54.1%; Score 46; DB 2; Length 164;  
Best Local Similarity 64.3%; Pred. No. 2.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
||| |||||  
Db 227 CAPGTFSTSTSD 140

RESULT 8  
US-08-974-022-48  
Sequence 48, Application US/08974022  
Patent No. 6015938

GENERAL INFORMATION:  
APPLICANT: Boyle, William J.  
APPLICANT: Lacey, David L.  
APPLICANT: Calzone, Frank J.  
APPLICANT: Chang, Ming-Shi  
TITLE OF INVENTION: OSTEOPROTEGERIN  
NUMBER OF SEQUENCES: 53  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Amgen Inc.  
STREET: 1840 Dehavilland Drive  
CITY: Thousand Oaks  
STATE: California  
COUNTRY: USA  
ZIP: 91320-1789

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/974,022  
FILING DATE: 12-DEC-1995  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/577,788  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Winter, Robert B.  
REFERENCE/DOCKET NUMBER: A-378  
INFORMATION FOR SEQ ID NO: 48:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 227 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-974-022-48

Query Match 54.1%; Score 46; DB 3; Length 227;  
Best Local Similarity 64.3%; Pred. No. 3.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
||| |||||  
Db 164 CAPGTFSTSTSD 177

RESULT 9  
US-08-795-445A-48  
Sequence 48, Application US/08795445A  
Patent No. 6284485

GENERAL INFORMATION:  
APPLICANT: Boyle, William J.  
APPLICANT: Lacey, David L.  
APPLICANT: Calzone, Frank J.  
APPLICANT: Chang, Ming-Shi  
TITLE OF INVENTION: OSTEOPROTEGERIN  
NUMBER OF SEQUENCES: 53  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Amgen Inc.  
STREET: 1840 Dehavilland Drive  
CITY: Thousand Oaks  
STATE: California  
COUNTRY: USA  
ZIP: 91320-1789

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/795,445A  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/577,788  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Winter, Robert B.  
REFERENCE/DOCKET NUMBER: A-378  
INFORMATION FOR SEQ ID NO: 48:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 227 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear

MOLECULE TYPE: protein  
US-08-795-445A-48

Query Match 54.1%; Score 46; DB 4; Length 227;  
Best Local Similarity 64.3%; Pred. No. 3.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
|| || || || || : |  
Db 164 CAPGTFSTNTSSD 177

## RESULT 10

US-08-795-447A-48  
; Sequence 48, Application US/08795447A

; Patent No. 6284728

; GENERAL INFORMATION:

; APPLICANT: Boyle, William J.

; APPLICANT: Lacey, David L.

; APPLICANT: Calzone, Frank J.

; APPLICANT: Chang, Ming-Shi

; TITLE OF INVENTION: Osteoprotegerin

; NUMBER OF SEQUENCES: 53

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Amgen Inc.

; STREET: One Amgen Center Drive

; CITY: Thousand Oaks

; STATE: California

; COUNTRY: USA

; ZIP: 91362-1789

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patentin Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/795,447A

; FILING DATE:

; CLASSIFICATION: 514

; ATTORNEY/AGENT INFORMATION:

; NAME: Winter, Robert B.

; REFERENCE/DOCKET NUMBER: A-378D2

; INFORMATION FOR SEQ ID NO: 48:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 227 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: protein

US-08-795-447A-48

## Query Match

54.1%; Score 46; DB 4; Length 227;  
Best Local Similarity 64.3%; Pred. No. 3.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
|| || || || || : |  
Db 164 CAPGTFSTNTSSD 177

## RESULT 11

US-08-974-186-48

; Sequence 48, Application US/08974186

; Patent No. 6284740

; GENERAL INFORMATION:

; APPLICANT: Boyle, William J.

; APPLICANT: Lacey, David L.

; APPLICANT: Calzone, Frank J.

; APPLICANT: Chang, Ming-Shi

; TITLE OF INVENTION: OSTEOPTROGERIN

; NUMBER OF SEQUENCES: 53

CORRESPONDENCE ADDRESS:  
ADDRESSEE: Amgen Inc.  
STREET: 1840 Dehavilland Drive  
CITY: Thousand Oaks  
STATE: California  
COUNTRY: USA  
ZIP: 91320-1789  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/974,186  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/577,788  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Winter, Robert B.  
REFERENCE/DOCKET NUMBER: A-378  
INFORMATION FOR SEQ ID NO: 48:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 227 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-974-186-48

Query Match 54.1%; Score 46; DB 4; Length 227;  
Best Local Similarity 64.3%; Pred. No. 3.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
|| || || || || : |  
Db 164 CAPGTFSTNTSSD 177

## RESULT 12

US-08-795-446B-48

; Sequence 48, Application US/08795446B

; Patent No. 6288032

; GENERAL INFORMATION:

; APPLICANT: Boyle, William J.

; APPLICANT: Lacey, David L.

; APPLICANT: Calzone, Frank J.

; APPLICANT: Chang, Ming-Shi

; TITLE OF INVENTION: OSTEOPTROGERIN

; NUMBER OF SEQUENCES: 53

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Amgen Inc.

; STREET: 1840 Dehavilland Drive

; CITY: Thousand Oaks

; STATE: California

; COUNTRY: USA

; ZIP: 91320-1789

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patentin Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/795,446B

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/577,788

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Winter, Robert B.

REFERENCE/DOCKET NUMBER: A-378  
; INFORMATION FOR SEQ ID NO: 48:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 227 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-795-446B-48

Query Match 54.1%; Score 46; DB 4; Length 227;  
Best Local Similarity 64.3%; Pred. No. 3.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAAD 14  
|| || || || || : |  
Db 164 CAPGTFSTTSSTD 177

RESULT 13  
US-09-326-394-4  
; Sequence 4, Application US/09326394  
; Patent No. 6306820  
; GENERAL INFORMATION:  
; APPLICANT: Bendele, Alison M.  
; APPLICANT: Sennello, Regina M.  
; APPLICANT: Edwards, Carl K.  
; TITLE OF INVENTION: COMBINATION THERAPY USING A TNF BINDING  
; TITLE OF INVENTION: PROTEIN FOR TREATING TNF-MEDIATED DISEASES  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Amgen Inc.  
; STREET: 1840 DeHavilland Drive  
; CITY: Thousand Oaks  
; STATE: CA  
; COUNTRY: US  
; ZIP: 91320-1789  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/326,394  
; FILING DATE: 08-DEC-1997  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/032,587  
; FILING DATE: 06-DEC-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/036,355  
; FILING DATE: 23-JAN-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/039,315  
; FILING DATE: 07-FEB-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/052,023  
; FILING DATE: 09-JUL-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Zindrick, Thomas K.  
; REGISTRATION NUMBER: 32,185  
; REFERENCE/DOCKET NUMBER: A-430D  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 235 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-09-326-394-4

Query Match 54.1%; Score 46; DB 4; Length 235;

Best Local Similarity 64.3%; Pred. No. 3.4;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
Qy 1 CASGTASNTTVAAD 14  
|| || || || || : |  
Db 142 CAPGTFSTTSSTD 155

RESULT 14  
US-08-385-229-2  
; Sequence 2, Application US/08385229  
; Patent No. 5605690  
; GENERAL INFORMATION:  
; APPLICANT: Jacobs, Cindy A.  
; APPLICANT: Smith, Craig A.  
; TITLE OF INVENTION: Method of Treating TNF-Dependent  
; TITLE OF INVENTION: Inflammation Using Tumor Necrosis Factor Antagonists  
; NUMBER OF SEQUENCES: 5  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Immunex Corporation  
; STREET: 51 University Street  
; CITY: Seattle  
; STATE: Washington  
; COUNTRY: U.S.A.  
; ZIP: 98101  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/385,229  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/07/946,236  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Wight, Christopher L.  
; REGISTRATION NUMBER: 31,680  
; REFERENCE/DOCKET NUMBER: 2503  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (206) 587-0430  
; TELEFAX: (206) 587-0606  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 461 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-385-229-2

Query Match 54.1%; Score 46; DB 1; Length 461;  
Best Local Similarity 64.3%; Pred. No. 7.4;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAAD 14  
|| || || || || : |  
Db 164 CAPGTFSTTSSTD 177

RESULT 15  
US-08-650-000-2  
; Sequence 2, Application US/08650000  
; Patent No. 5945397  
; GENERAL INFORMATION:  
; APPLICANT: Smith, Craig A.  
; APPLICANT: Goodwin, Raymond G.  
; APPLICANT: Beckmann, M. Patricia  
; TITLE OF INVENTION: Tumor Necrosis Factor Receptors  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
US-08-650-000-2



ADDRESSEE: Immunex Corporation  
STREET: 51 University Street  
CITY: Seattle  
STATE: Washington  
COUNTRY: U.S.A.  
ZIP: 98101  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
OPERATING SYSTEM: IBM PC compatible  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/650,000  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/468,453  
FILING DATE:  
APPLICATION NUMBER: US/08/038,765  
FILING DATE:  
APPLICATION NUMBER: US 403,241  
FILING DATE: 05-SEP-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 405,370  
FILING DATE: 11-SEP-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 421,417  
FILING DATE: 13-OCT-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 523,635  
FILING DATE: 10-MAY-1990  
ATTORNEY/AGENT INFORMATION:  
NAME: Wight, Christopher L.  
REGISTRATION NUMBER: 31,680  
REFERENCE/DOCKET NUMBER: 2501-D  
TELEPHONE: (206) 587-0430  
TELEFAX: (206) 233-0644  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 461 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-650-000-2

Query Match 54.1%; Score 46; DB 2; Length 461;  
Best Local Similarity 64.3%; Pred. NO. 7.4;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

OY 1 CASGTASNTTVAAD 14  
Db 164 CAPGTFSTSTSD 177

Search completed: March 26, 2002, 13:41:27  
Job time: 301 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:37:18 ; Search time 42.75 Seconds  
(without alignments)  
30.292 Million cell updates/sec

Title: US-09-709-201-96  
Perfect score: 85  
Sequence: 1 CASGTASNTTVAADRSN 17

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 219241 seqs, 76174552 residues

Total number of hits satisfying chosen parameters: 219241

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR\_68:\*  
1: pir1:\*  
2: pir2:\*  
3: pir3:\*  
4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	76	89.4	392	2 A40371	major outer membra
2	46	54.1	461	1 A35356	tumor necrosis fac
3	46	54.1	1518	2 T28880	hypothetical prote
4	46	54.1	4753	1 A47437	IDL-receptor-relat
5	45	52.9	390	2 T25642	hypothetical prote
6	45	52.9	767	2 S55618	hypothetical prote
7	45	52.9	942	2 T13014	cytochrome b245 be
8	43	50.6	425	2 S41099	protein kinase (EC
9	43	50.6	427	2 T46265	hypothetical prote
10	43	50.6	1462	2 T06819	DNA topoisomerase
11	42	49.4	390	2 B84066	hypothetical prote
12	42	49.4	518	2 F70831	probable PPE prote
13	42	49.4	621	2 S35092	plakoglobin - mous
14	41	48.2	459	2 I48854	gene murine tumour
15	41	48.2	474	2 B38634	tumor necrosis fac
16	41	48.2	1237	2 H81660	DNA polymerase III
17	40	47.1	226	2 B41378	cytochrome c553i p
18	40	47.1	259	1 TRSMG	trypsin (EC 3.4.21
19	40	47.1	490	2 T49096	hypothetical prote
20	40	47.1	492	2 T47720	pyruvate kinase-II
21	40	47.1	510	2 T47704	pyruvate kinase-II
22	40	47.1	760	2 S18686	Sc/SvM protein --
23	39	45.9	202	2 JX0228	multicatalytic end
24	39	45.9	205	2 S17522	multicatalytic end
25	39	45.9	226	2 T40487	proteasome compone
26	39	45.9	239	2 B54589	proteasome subunit
27	39	45.9	323	2 B83757	sodium-dependent t
28	39	45.9	527	2 T04329	importin alpha - t
29	39	45.9	644	2 T37800	probable lysophosp

nitrate reductase  
myosin IC - sline  
hypothetical prote  
Ras guanine nucleo  
hemagglutinin/hemo  
hemagglutinin/hemo  
M protein precursor  
M protein precursor  
glycoprotein J . c  
Similar to blue co  
multicatalytic end  
probable transmem  
transporter NM8070  
GNSL/SUR4 family p  
centrosome-binding  
hypothetical prote

30 39 45.9 710 2 E69665  
31 39 45.9 1181 2 T30578  
32 39 45.9 1181 2 T19736  
33 39 45.9 1336 2 S25716  
34 39 45.9 1975 2 B81192  
35 39 45.9 1995 2 G81044  
36 38 44.7 85 2 S60856  
37 38 44.7 97 2 S60846  
38 38 44.7 117 1 J01745  
39 38 44.7 174 2 A86358  
40 38 44.7 215 2 S61337  
41 38 44.7 315 2 B81937  
42 38 44.7 315 2 B81168  
43 38 44.7 334 2 T50139  
44 38 44.7 335 2 S71796  
45 38 44.7 356 2 T27052

ALIGNMENTS

RESULT 1  
A40371.  
major outer membrane protein precursor - Chlamydia psittaci (strain Fpn/pring)  
C:Species: Chlamydia psittaci, Chlamydia psittaci  
C:Date: 27-Nov-1991 #sequence:revision 27-Nov-1991 #text\_change 31-Mar-2000  
C:Accession: I40859; A40371; S16137  
R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.  
J. Gen. Microbiol. 139, 2621-2626, 1993  
A:Title: Evidence for Chlamydia pneumoniae of non-human origin.  
A:Reference number: I40739; MUID:94103736  
A:Accession: I40859  
A:Status: nucleic acid sequence not shown; translation not shown; translated from GB/  
A:Molecule type: DNA  
A:Residues: 1-392 <RES>  
A:Cross-references: EMBL:X61096; NID:g40564; PIDN:CAA43409.1; PID:g40565  
A:Experimental source: strain Fpn  
C:Genetics:  
A:Gene: MOMP  
C:Superfamily: Chlamydia major outer membrane protein  
C:Keywords: membrane protein  
F:1-22/Domain: signal sequence #status predicted <SIG>  
F:23-392/Product: major outer membrane protein #status predicted <MAT>

Query Match 89.4%; Score 76; DB 2; Length 392;  
Best Local Similarity 100.0%; Pred. No. 7.5e-05;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 ASGTASNTTVAADRSN 17  
DB 92 ASGTASNTTVAADRSN 107

RESULT 2  
A35356  
tumor necrosis factor receptor 2 precursor [validated] - human  
N:Alternate names: 75K tumor necrosis factor receptor; TNF receptor type 2  
C:Species: Homo sapiens (man)  
C:Date: 10-Sep-1999 #sequence:revision 10-Sep-1999 #text\_change 08-Dec-2000  
C:Accession: A35356; A36475; A48416; A36007; A23666; B35010; I38094  
R:Smith, C.A.; Davis, T.; Anderson, D.; Solam, L.; Beckmann, M.P.; Jerzy, R.; Dover, Science 248, 1019-1023, 1990  
A:Title: A receptor for tumor necrosis factor defines an unusual family of cellular a  
A:Reference number: A35356; MUID:90260639  
A:Accession: A35356  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-461 <SMI>  
A:Cross-references: GB:M32315; NID:g189185; PIDN:AAA59929.1; PID:g189186  
R:Kohn, T.; Brewer, M.T.; Baker, S.L.; Schwartz, P.E.; King, M.W.; Hale, K.K.; Squir  
Proc. Natl. Acad. Sci. U.S.A. 87, 8331-8335, 1990  
A:Title: A second tumor necrosis factor receptor gene product can shed a naturally oc

Query Match 54.1%; Score 46; DB 1; Length 461;  
Best Local Similarity 64.3%; Pred. No. 6.8;  
Matches 9: Conservative 1: Mismatches 4: Indels 0: Gaps 0;



```
C;Species: Blastocladia emersonii
C;Date: 19-Mar-1997 #sequence_revision 06-Jun-1997 #text_change 28-May-1999
C;Accession: S41099; S77890
R;Franco de Oliveira, J.C.; Cantisani Borges, A.C.; do Valle Marques, M.; Lopes Gomes, S.
Eur. J. Biochem. 219, 555-562, 1994
A;Title: Cloning and characterization of the gene for the catalytic subunit of cAMP-dephosphorylase
A;Reference number: S41099; MUID:94139736
A;Accession: S41099
A;Molecule type: DNA
A;Residues: 1-425 <FRA>
A;Cross-references: GB:L17008; NID:g304272; PIDN:AAA20074.1; PID:g304273
A;Accession: S77889
A;Molecule type: mRNA
A;Residues: 22-425 <FRB>
A;Cross-references: GB:M81709; GB:L17038; NID:g507140; PIDN:AAAL94440.1; PID:g507141
A;Accession: S77890
A;Molecule type: protein
A;Residues: 2-16 <FRC>
C;Genetics:
A;Introns: 209/3; 243/3; 315/1
C;Superfamily: kinase-related transforming protein; protein kinase homology
C;Keywords: ATP; cAMP binding; magnesium; phosphoprotein; phosphotransferase; serine/threonine kinase
F;2-425/Product: protein kinase, cAMP-dependent, catalytic chain C #status experimental
F;114-370/Domain: protein kinase homology <KIN>
F;122-130/Region: protein kinase ATP-binding motif
F;127-128,194,200,243,256/Binding site: Mg-ATP (Phe, Gly, Glu, Thr) #status predicted
F;145,164,239,241/Active site: Lys, Glu, Asp, Lys #status predicted
F;244,257/Binding site: magnesium (Asn, Asp) #status predicted
F;270/Binding site: phosphate (Thr) (covalent) #status predicted

Query Match 50.6%; Score 43; DB 2; Length 425;
Best Local Similarity 62.5%; Pred. No. 19;
Matches 10; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 2 ASGTASNTTVAADRSN 17
|||:|||||
Db 40 ASSTASSTTTAAASGN 55

RESULT 9
T46265
hypothetical protein DKFzp761A052.1 - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 04-Feb-2000 #sequence_revision 04-Feb-2000 #text_change 04-Feb-2000
C;Accession: T46265
R;Ottewaelde, B.; Obermayer, B.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.
submitted to the Protein Sequence Database, January 2000
A;Reference number: Z23031
A;Accession: T46265
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-427 <AAA>
A;Cross-references: EMBL:AL137509
A;Experimental source: adult amygdala; clone DKFzp761A052
C;Genetics:
A;Note: DKFzp761A052.1

Query Match 50.6%; Score 43; DB 2; Length 427;
Best Local Similarity 50.0%; Pred. No. 20;
Matches 8; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRS 16
|||:|||||
Db 347 CAPGTSQFSAGADRA 362

RESULT 10
T06819
DNA topoisomerase (ATP-hydrolyzing) (EC 5.99.1.3) II - garden pea
C;Species: Pisum sativum (garden pea)
C;Date: 23-Apr-1999 #sequence_revision 23-Apr-1999 #text_change 20-Jun-2000

C;Accession: T06819
R;Reddy, M.K.; Nair, S.; Tewari, K.K.
submitted to the EMBL Data Library, August 1997
A;Reference number: Z15832
A;Accession: T06819
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-1462 <RED>
A;Cross-references: EMBL:Y14559; PIDN:CAA74891.1
C;Genetics:
A;Note: TOP11
C;Function:
A;Description: involved in DNA replication and chromosome condensation
C;Superfamily: eukaryotic type II DNA topoisomerase; phage T4 DNA topoisomerase (ATP-kinase)
C;Keywords: ATP; DNA binding; isomerase

Query Match 50.6%; Score 43; DB 2; Length 1462;
Best Local Similarity 50.0%; Pred. No. 64;
Matches 7; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14
|||:|||||
Db 1400 CSAGSASNTPLSD 1413

RESULT 11
E84066
hypothetical protein BH3333 [imported] - Bacillus halodurans (strain C-125)
C;Species: Bacillus halodurans
C;Date: 01-Dec-2000 #sequence_revision 01-Dec-2000 #text_change 31-Dec-2000
C;Accession: E84066
R;Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fujii, F.; H.
Nucleic Acids Res. 28, 4317-4331, 2000
A;Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans a
A;Reference number: A83650; MUID:20263314
A;Accession: E84066
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-390 <STO>
A;Cross-references: GB:AP001518; GB:BA000004; NID:g10175792; PIDN:BAB07052.1; GSPDB:G
A;Experimental source: strain C-125
C;Genetics:
A;Gene: BH3333

Query Match 49.4%; Score 42; DB 2; Length 390;
Best Local Similarity 61.5%; Pred. No. 26;
Matches 8; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 5 TASNTTVAADRSN 17
|||:|||||
Db 122 TVSNLTIDADRTN 134

RESULT 12
F70831
probable PPE protein - Mycobacterium tuberculosis (strain H37RV)
C;Species: Mycobacterium tuberculosis
C;Date: 17-Jul-1998 #sequence_revision 17-Jul-1998 #text_change 22-Oct-1999
C;Accession: F70831
R;Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon
; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd,
; Rajandream, M.A.; Rogers, R.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, S.; Squares, S.
Nature 393, 537-544, 1998
A;Authors: Squares, R.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G.
A;Title: Deciphering the biology of Mycobacterium tuberculosis from the complete geno
A;Reference number: A70500; MUID:98295987
A;Accession: F70831
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-518 <COL>
A;Cross-references: GB:AL021932; GB:AL123456; NID:g3261527; PIDN:CAA17410.1; PID:e125
```

A:Experimental source: strain H37Rv  
 C:Genetics:  
 A:Gene: PPE

Query Match 49.4%; Score 42; DB 2; Length 518;  
 Best Local Similarity 81.8%; Pred. No. 34;  
 Matches 9; Conservative 1; Mismatches 0; Gaps 0;

Qy 3 SGTASNTTVA 13  
 :|||||  
 Db 474 AGTASNTTVA 484

## RESULT 13

Plakoglobin - mouse (fragment)  
 C:Species: Mus musculus (house mouse)  
 C>Date: 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 17-Mar-1999  
 C:Accession: S35092  
 R:Butz, S.; Stappert, J.; Weissig, H.; Kemler, R.  
 Science 257, 1142-1144, 1992  
 A:Title: Plakoglobin and beta-catenin: distinct but closely related.  
 A:Reference number: S35091; MUID:92376536  
 A:Accession: S35092  
 A>Status: preliminary  
 A:Molecule type: mRNA  
 A:Residues: 1-621 <BUT>  
 A:Cross-references: EMBL:M90365  
 C:Keywords: cytoskeleton

Query Match 49.4%; Score 42; DB 2; Length 621;  
 Best Local Similarity 72.7%; Pred. No. 41;  
 Matches 8; Conservative 1; Mismatches 0; Gaps 0;

Qy 1 CASGTASNTTV 11  
 :|||  
 Db 286 CATGTLNRTV 296

## RESULT 14

gene murine tumour necrosis factor receptor 2 protein - mouse (fragment)  
 C:Species: Mus musculus (house mouse)  
 C>Date: 02-Jul-1996 #sequence\_revision 02-Jul-1996 #text\_change 23-Jul-1999  
 C:Accession: I48854  
 R:Powell, E.E.; Wicker, L.S.; Peterson, L.B.; Todd, J.A.  
 Mamm. Genome 5, 726-727, 1994  
 A:Title: Allelic variation of the type 2 tumor necrosis factor receptor gene.  
 A:Reference number: I48854; MUID:95178848  
 A:Accession: I48854  
 A>Status: preliminary; translated from GB/EMBL/DBJ  
 A:Molecule type: mRNA  
 A:Residues: 1-459 <RES>  
 A:Cross-references: EMBL:X76401; NID:9433830; PIDN:CAA53981.1; PID:9433831  
 C:Superfamily: tumor necrosis factor receptor type 2; NGF receptor repeat homology  
 F:151-188/Domain: NGF receptor repeat homology <NGF>

Query Match 48.2%; Score 41; DB 2; Length 459;  
 Best Local Similarity 57.1%; Pred. No. 44;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAAD 14  
 :|||  
 Db 151 CAPGTFSDTTSSTD 164

## RESULT 15

B38634  
 tumor necrosis factor receptor type 2 precursor - mouse  
 C:Species: Mus musculus (house mouse)

C>Date: 30-Jun-1992 #sequence\_revision 30-Jun-1992 #text\_change 23-Jul-1999  
 C:Accession: B38634; A40254; S54816  
 R:Lewis, M.; Tartaglia, L.A.; Lee, A.; Bennett, G.L.; Rice, G.C.; Wong, G.H.W.; Chen, Proc. Natl. Acad. Sci. U.S.A. 88, 2830-2834, 1991  
 A:Title: Cloning and expression of cDNAs for two distinct murine tumor necrosis facto

A:Reference number: A38634; MUID:91187885

A:Accession: B38634

A:Molecule type: mRNA

A:Residues: 1-474 <LEW>

A:Cross-references: GB:M60469; NID:9199827; PIDN:AAA39752.1; PID:9199828

R:Goodwin, R.G.; Anderson, D.; Jerzy, R.; Davis, T.; Brannan, C.L.; Copeland, N.G.; J Mol. Cell. Biol. 11, 3020-3026, 1991

A:Title: Molecular cloning and expression of the type 1 and type 2 murine receptors f

A:Reference number: A40254; MUID:91246168

A:Accession: A40254

A:Molecule type: mRNA

A:Residues: 1-474 <GOO>

A:Cross-references: GB:M60469; NID:9199827; PIDN:AAA39752.1; PID:9199828

R:Kisssnerghis, M.; Fellows, R.; Feldmann, M.; Chernaiovsky, Y.

submitted to the EMBL Data Library, May 1993

A:Description: Characterization of the promoter region of the murine p75-TNF receptor

A:Reference number: S54816

A:Accession: S54816

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-22 <KIS>

A:Cross-references: EMBL:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044

C:Superfamily: tumor necrosis factor receptor type 2; NGF receptor repeat homology

C:Keywords: cytokine receptor; transmembrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-474/Product: tumor necrosis factor receptor type 2 #status predicted <MAT>

F:40-77/Domain: NGF receptor repeat homology <NG1>

F:79-120/Domain: NGF receptor repeat homology <NG2>

F:166-203/Domain: NGF receptor repeat homology <NG4>

Query Match 48.2%; Score 41; DB 2; Length 474;  
 Best Local Similarity 57.1%; Pred. No. 46;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAAD 14  
 :|||  
 Db 166 CAPGTFSDTTSSTD 179

Search completed: March 26, 2002, 13:37:19  
 Job time: 53 sec







RESULT 2  
 TNR2\_HUMAN  
 ID TNR2\_HUMAN STANDARD; PRT; 461 AA.  
 AC P20333;  
 DT 01-FEB-1991 (Rel. 17, Created)  
 DT 01-AUG-1991 (Rel. 19, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE TUMOR NECROSIS FACTOR RECEPTOR 2 PRECURSOR (TUMOR NECROSIS FACTOR  
 DE BINDING PROTEIN 2) (TNF1) (P80) (TNF-R2) (P75) (CD120B) (ETANERCEPT).  
 GN TNFRSF1B OR TNFR2 OR TNFR.  
 GN Homo sapiens (human).  
 OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE-90260639; PubMed-2160731;  
 RA Smith C.A., Davis T., Anderson D., Solam L., Beckmann M.P., Jerzy R.,  
 RA Dower S.K., Cosman D., Goodwin R.G.;  
 RA "A receptor for tumor necrosis factor defines an unusual family of  
 RT cellular and viral proteins.";  
 RL Science 248:1019-1023(1990).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE-91045991; PubMed-2172983;  
 RA Kohno T., Brewer M.T., Baker S.L., Schwartz P.E., King M.W.,  
 RA Hale K.K., Squires C.H., Thompson R.C., Vannice J.L.;  
 RA "A second tumor necrosis factor receptor gene product can shed a  
 RT naturally occurring tumor necrosis factor inhibitor.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 87:8331-8335(1990).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE-96299745; PubMed-8661109;  
 RA Beltinger C.P., White P.S., Maris J.M., Sulman E.P., Jensen S.J.,  
 RA Lepaslier D., Stallard B.J., Goeddel D.V., Desauvage F.J.,  
 RA Brodeur G.M.;  
 RA "Physical mapping and genomic structure of the human TNFR2 gene.";  
 RL Genomics 35:94-100(1996).  
 RN [4]  
 RP SEQUENCE OF 116-461 FROM N.A., AND PARTIAL SEQUENCE.  
 RX MEDLINE-90349572; PubMed-2166946;  
 RA Heller R.A., Song K., Onasch M.A., Fischer W.H., Chang D.,  
 RA Ringold G.M.;  
 RA "Complementary DNA cloning of a receptor for tumor necrosis factor  
 RT and demonstration of a shed form of the receptor.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 87:6151-6155(1990).  
 RN [5]  
 RP SEQUENCE OF 27-31.  
 RX MEDLINE-90110215; PubMed-2153136;  
 RA Engelmann H., Novick D., Wallach D.;  
 RA "Two tumor necrosis factor-binding proteins purified from human  
 RT urine. Evidence for immunological cross-reactivity with cell surface  
 RT tumor necrosis factor receptors.";  
 RL J. Biol. Chem. 265:1531-1536(1990).  
 RN [6]  
 RP SEQUENCE OF 23-40; 65-69; 136-141; 300-306 AND 346-362.  
 RX MEDLINE-91056048; PubMed-2173696;  
 RA Loetscher H., Schlaeger E.J., Lahm H.-W., Pan Y.-C.E., Lesslauer W.,  
 RA Brockhaus M.;  
 RA "Purification and partial amino acid sequence analysis of two  
 RT distinct tumor necrosis factor receptors from HL60 cells.";  
 RL J. Biol. Chem. 265:20131-20138(1990).  
 RN [7]  
 RP CHARACTERIZATION.  
 RX MEDLINE-93016040; PubMed-1328224;  
 RA Pennica D., Lam V.T., Mize N.K., Weber R.F., Lewis M., Fendly B.M.,  
 RA Lipari M.T., Goeddel D.V.;  
 RA "Biochemical properties of the 75-kDa tumor necrosis factor receptor.  
 RT Characterization of ligand binding, internalization, and receptor  
 RT phosphorylation.";  
 RL J. Biol. Chem. 267:21172-21178(1992).  
 RN [8]  
 RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 419-428 IN TRAF2 COMPLEX.

RX MEDLINE-99221490; PubMed-10206649;  
 RA Park Y.C., Burkitt V., Villa A.R., Tong L., Wu H.;  
 RA "Structural basis for self-association and receptor recognition of  
 RT human TRAF2.";  
 RL Nature 398:533-538(1999).  
 CC -!- FUNCTION: RECEPTOR FOR TNF-ALPHA. HIGH AFFINITY FOR TNF-ALPHA AND  
 CC APPROXIMATELY 5-FOLD LOWER AFFINITY FOR TNF-BETA.  
 CC -!- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.  
 CC -!- PTM: PHOSPHORYLATED; MAINLY ON SERINE RESIDUES WITH A VERY LOW  
 CC LEVEL ON THREONINE RESIDUES.  
 CC -!- PHARMACEUTICAL: AVAILABLE UNDER THE NAME ENBREL (IMMUNEX AND  
 CC WYETH-AYERST). USED TO TREAT MODERATE TO SEVERE RHEUMATOID  
 CC ARTHRITIS (RA). ENBREL CONSIST OF THE EXTRACELLULAR LIGAND-BINDING  
 CC PORTION OF TNFR2 LINKED TO AN IMMUGLOBULIN FC CHAIN. IT BINDS TO  
 CC TNF-ALPHA AND BLOCKS ITS INTERACTIONS WITH RECEPTORS.  
 CC -!- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.  
 CC -!- DATABASE: NAMB-PROW; NOTE-CD guide CD120b entry;  
 CC WWW="http://www.ncbi.nlm.nih.gov/prov/cd/cd120b.htm".  
 CC -!- DATABASE: NAMB-Enbrel; NOTE-Clinical information on Enbrel;  
 CC WWW="http://www.enbrelinfo.com/".  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
 CC or send an email to license@sib-sib.ch).  
 CC -----  
 DR EMBL; M32315; AAA59929.1; -;  
 DR EMBL; M35857; AAC63262.1; -;  
 DR EMBL; U52165; AAC50622.1; -;  
 DR EMBL; U52157; AAC50622.1; JOINED.  
 DR EMBL; U52156; AAC50622.1; JOINED.  
 DR EMBL; U52158; AAC50622.1; JOINED.  
 DR EMBL; U52159; AAC50622.1; JOINED.  
 DR EMBL; U52160; AAC50622.1; JOINED.  
 DR EMBL; U52161; AAC50622.1; JOINED.  
 DR EMBL; U52162; AAC50622.1; JOINED.  
 DR EMBL; U52163; AAC50622.1; JOINED.  
 DR EMBL; U52164; AAC50622.1; JOINED.  
 DR EMBL; M55994; AAA36755.1; -;  
 DR PIR; A33356; A33356.  
 DR PIR; A36007; A36007.  
 DR PIR; A36475; A36475.  
 DR PIR; B35010; B35010.  
 DR PIR; A23666; A23666.  
 DR PDB; 1CA9; 12-APR-99.  
 DR MIM; 191191; -;  
 DR InterPro; IPR001368; TNFR\_c6.  
 DR Pfam; PF00020; TNFR\_c6; 4.  
 DR ProDom; PD000771; TNFR\_c6; 1.  
 DR SMART; SM00208; TNFR; 4.  
 DR PROSITE; PS00652; TNFR\_NGFR\_1; 2.  
 DR PROSITE; PSS0050; TNFR\_NGFR\_2; 4.  
 DR Receptor; Transmembrane; Glycoprotein; Repeat; Signal;  
 KW Phosphorylation; Pharmaceutical; 3D-structure.  
 FT SIGNAL 1 22  
 FT CHAIN 23 461 TUMOR NECROSIS FACTOR RECEPTOR 2.  
 FT DOMAIN 23 257 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 258 287 POTENTIAL.  
 FT DOMAIN 288 461 CYTOPLASMIC (POTENTIAL).  
 FT DOMAIN 39 201 4 X TNFR-CYS.  
 FT REPEAT 39 76 TNFR-CYS 1.  
 FT REPEAT 77 118 TNFR-CYS 2.  
 FT REPEAT 119 162 TNFR-CYS 3.  
 FT REPEAT 163 201 TNFR-CYS 4.  
 FT DISULFID 40 53 BY SIMILARITY.  
 FT DISULFID 54 67 BY SIMILARITY.  
 FT DISULFID 57 75 BY SIMILARITY.  
 FT DISULFID 78 93 BY SIMILARITY.  
 FT DISULFID 96 110 BY SIMILARITY.  
 FT DISULFID 100 118 BY SIMILARITY.

```
FT DISULFID 120 126 BY SIMILARITY.
FT FT DISULFID 134 143 BY SIMILARITY.
FT FT DISULFID 137 161 BY SIMILARITY.
FT FT DISULFID 164 179 BY SIMILARITY.
FT CARBOHYD 171 171 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 193 193 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CONFLICT 141 141 R -> P (IN REF. 4).
FT CONFLICT 196 196 R -> M (IN REF. 1 AND 3).
FT CONFLICT 363 363 A -> T (IN REF. 4).
SQ SEQUENCE 461 AA; 48316 MW; 503B580ECD67636F CRC64;

Query Match 54.1%; Score 46; DB 1; Length 461;
Best Local Similarity 64.3%; Pred. No. 3;
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14
    || || || || : |
Db 164 CARGTFSNTTSSD 177

RESULT 3
LRP_CAEEL STANDARD; PRT; 4753 AA.
ID LRP_CAEEL AC Q04833;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN PRECURSOR (LRP).
GN LRP OR F29D11.1.
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC Rhabditidae; Peloderinae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=93281621; PubMed=8506301;
RA Yochem J.; Greenwald I.;
RT "A gene for a low density lipoprotein receptor-related protein in the
RT nematode Caenorhabditis elegans."
RL Proc. Natl. Acad. Sci. U.S.A. 90:4572-4576(1993).
[2]
RN SEQUENCE FROM N.A.
RC STRAIN=BRISTOL N2;
RA Wilkinson J.;
RL Submitted (MAY-1996) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: MAY ACT AS A RECEPTOR FOR THE ENDOCYTOSIS OF
CC EXTRACELLULAR LIGANDS SUCH AS CHYLOMICRON REMNANTS, PROTEASE-
CC INHIBITOR COMPLEXES AND VITELLOGENIN.
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
CC -1- SIMILARITY: CONTAINS 35 LDL-RECEPTOR CLASS A DOMAINS.
CC -1- SIMILARITY: CONTAINS 17 EGF-LIKE DOMAINS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; M96150; AAA28105.1; -
CC HSP; P07204; IEGT.
CC Wormpep; F29D11.1; CE05765.
CC InterPro; IPR000152; Asx_hydroxyl.
CC InterPro; IPR000561; EGF-like.
CC InterPro; IPR001881; EGF_Ca.
CC InterPro; IPR002172; LDL_recept_A.
CC InterPro; IPR000033; ldl_rcptor_rep.
CC Pfam; PF00057; ldl_recept_a; 35.
CC Pfam; PF00058; ldl_recept_b; 26.
CC PRINTS; PR00261; LDLRECEPTOR.
DR SMART; SM00179; EGF_CA; 2.
DR SMART; SM00001; EGF_like; 15.
DR SMART; SM00192; LDLA; 34.
DR SMART; SM00135; LY; 30.
DR PROSITE; PS00010; ASX_HYDROXYL; 6.
DR PROSITE; PS00022; EGF_1; 1.
DR PROSITE; PS01186; EGF_2; 3.
DR PROSITE; PS01187; EGF_CA; 3.
DR PROSITE; PS01209; LDLFA_1; 27.
DR PROSITE; PS00088; LDLRA_2; 34.
KW Receptor; Transmembrane; Repeat; Endocytosis; Glycoprotein;
KW Signal; Calcium-binding; EGF-like domain; Coated pits.
FT SIGNAL 1 18 POTENTIAL.
FT CHAIN 19 4753 LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED
FT FT PROTEIN.
FT FT EXTRACELLULAR (POTENTIAL).
FT FT POTENTIAL.
FT FT CYTOPLASMIC (POTENTIAL).
FT FT LDL-RECEPTOR CLASS A 1.
FT FT LDL-RECEPTOR CLASS A 2.
FT FT LDL-RECEPTOR CLASS A 3.
FT FT LDL-RECEPTOR CLASS A 4.
FT FT LDL-RECEPTOR CLASS A 5.
FT FT LDL-RECEPTOR CLASS A 6.
FT FT EGF-LIKE 1.
FT FT EGF-LIKE 2. CALCIUM-BINDING (POTENTIAL).
FT FT EGF-LIKE 3.
FT FT EGF-LIKE 4.
FT FT LDL-RECEPTOR CLASS A 7.
FT FT LDL-RECEPTOR CLASS A 8.
FT FT LDL-RECEPTOR CLASS A 9.
FT FT LDL-RECEPTOR CLASS A 10.
FT FT LDL-RECEPTOR CLASS A 11.
FT FT LDL-RECEPTOR CLASS A 12.
FT FT LDL-RECEPTOR CLASS A 13.
FT FT LDL-RECEPTOR CLASS A 14.
FT FT EGF-LIKE 5.
FT FT EGF-LIKE 6.
FT FT EGF-LIKE 7.
FT FT EGF-LIKE 8.
FT FT EGF-LIKE 9.
FT FT EGF-LIKE 10.
FT FT LDL-RECEPTOR CLASS A 15.
FT FT LDL-RECEPTOR CLASS A 16.
FT FT LDL-RECEPTOR CLASS A 17.
FT FT LDL-RECEPTOR CLASS A 18.
FT FT LDL-RECEPTOR CLASS A 19.
FT FT LDL-RECEPTOR CLASS A 20.
FT FT LDL-RECEPTOR CLASS A 21.
FT FT LDL-RECEPTOR CLASS A 22.
FT FT LDL-RECEPTOR CLASS A 23.
FT FT LDL-RECEPTOR CLASS A 24.
FT FT EGF-LIKE 11.
FT FT CALCIUM-BINDING (POTENTIAL).
FT FT EGF-LIKE 12.
FT FT EGF-LIKE 13.
FT FT LDL-RECEPTOR CLASS A 25.
FT FT LDL-RECEPTOR CLASS A 26.
FT FT LDL-RECEPTOR CLASS A 27.
FT FT LDL-RECEPTOR CLASS A 28.
FT FT LDL-RECEPTOR CLASS A 29.
FT FT LDL-RECEPTOR CLASS A 30.
FT FT LDL-RECEPTOR CLASS A 31.
FT FT LDL-RECEPTOR CLASS A 32.
FT FT LDL-RECEPTOR CLASS A 33.
FT FT LDL-RECEPTOR CLASS A 34.
FT FT LDL-RECEPTOR CLASS A 35.
FT FT EGF-LIKE 14. CALCIUM-BINDING (POTENTIAL).
FT FT EGF-LIKE 15.
FT FT EGF-LIKE 16.
FT FT EGF-LIKE 17.
FT FT ENDOCYTOSIS SIGNAL (POTENTIAL).
FT FT CRITICAL FOR ENDOCYTOSIS (BY SIMILARITY).
FT SITE 4744 4744 BY SIMILARITY.
FT DISULFID 53 65
```

```
FT DISULFID 60 78 BY SIMILARITY.
FT DISULFID 72 87 BY SIMILARITY.
FT DISULFID 92 109 BY SIMILARITY.
FT DISULFID 99 122 BY SIMILARITY.
FT DISULFID 116 131 BY SIMILARITY.
FT DISULFID 138 152 BY SIMILARITY.
FT DISULFID 146 165 BY SIMILARITY.
FT DISULFID 159 175 BY SIMILARITY.
FT DISULFID 182 195 BY SIMILARITY.
FT DISULFID 189 208 BY SIMILARITY.
FT DISULFID 202 218 BY SIMILARITY.
FT DISULFID 223 235 BY SIMILARITY.
FT DISULFID 230 248 BY SIMILARITY.
FT DISULFID 242 257 BY SIMILARITY.
FT DISULFID 262 275 BY SIMILARITY.
FT DISULFID 269 288 BY SIMILARITY.
FT DISULFID 282 297 BY SIMILARITY.
FT DISULFID 302 311 BY SIMILARITY.
FT DISULFID 307 320 BY SIMILARITY.
FT DISULFID 322 336 BY SIMILARITY.
FT DISULFID 342 352 BY SIMILARITY.
FT DISULFID 348 361 BY SIMILARITY.
FT DISULFID 363 367 BY SIMILARITY.
FT DISULFID 673 682 BY SIMILARITY.
FT DISULFID 678 697 BY SIMILARITY.
FT DISULFID 699 711 BY SIMILARITY.
FT DISULFID 1001 1010 BY SIMILARITY.
FT DISULFID 1006 1026 BY SIMILARITY.
FT DISULFID 1028 1042 BY SIMILARITY.
FT DISULFID 1054 1068 BY SIMILARITY.
FT DISULFID 1063 1081 BY SIMILARITY.
FT DISULFID 1075 1095 BY SIMILARITY.
FT DISULFID 1101 1114 BY SIMILARITY.
FT DISULFID 1108 1127 BY SIMILARITY.
FT DISULFID 1121 1138 BY SIMILARITY.
FT DISULFID 1146 1158 BY SIMILARITY.
FT DISULFID 1153 1171 BY SIMILARITY.
FT DISULFID 1165 1182 BY SIMILARITY.
FT DISULFID 1187 1199 BY SIMILARITY.
FT DISULFID 1194 1212 BY SIMILARITY.
FT DISULFID 1206 1223 BY SIMILARITY.
FT DISULFID 1228 1241 BY SIMILARITY.
FT DISULFID 1235 1254 BY SIMILARITY.
FT DISULFID 1248 1263 BY SIMILARITY.
FT DISULFID 1270 1283 BY SIMILARITY.
FT DISULFID 1277 1296 BY SIMILARITY.
FT DISULFID 1290 1307 BY SIMILARITY.
FT DISULFID 1313 1325 BY SIMILARITY.
FT DISULFID 1320 1338 BY SIMILARITY.
FT DISULFID 1332 1350 BY SIMILARITY.
FT DISULFID 1359 1373 BY SIMILARITY.
FT DISULFID 1366 1386 BY SIMILARITY.
FT DISULFID 1380 1396 BY SIMILARITY.
FT DISULFID 1401 1412 BY SIMILARITY.
FT DISULFID 1408 1421 BY SIMILARITY.
FT DISULFID 1423 1435 BY SIMILARITY.
FT DISULFID 1441 1451 BY SIMILARITY.
FT DISULFID 1447 1460 BY SIMILARITY.
FT DISULFID 1462 1475 BY SIMILARITY.
FT DISULFID 1751 1760 BY SIMILARITY.
FT DISULFID 1756 1770 BY SIMILARITY.
FT DISULFID 1772 1785 BY SIMILARITY.
FT DISULFID 2084 2095 BY SIMILARITY.
FT DISULFID 2091 2105 BY SIMILARITY.
FT DISULFID 2107 2119 BY SIMILARITY.
FT DISULFID 2400 2415 BY SIMILARITY.
FT DISULFID 2411 2426 BY SIMILARITY.
FT DISULFID 2428 2438 BY SIMILARITY.
FT DISULFID 2732 2743 BY SIMILARITY.
FT DISULFID 2739 2759 BY SIMILARITY.
FT DISULFID 2761 2779 BY SIMILARITY.
FT DISULFID 2792 2805 BY SIMILARITY.
FT DISULFID 2800 2818 BY SIMILARITY.

Query Match 54.1% Score 46; DB 1: Length 4753;
Best Local Similarity 52.9%; Pred. No. 33;
Matches 9; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRSN 17
    ||:| | ||| ||:
Db 4056 CANGKCVNGTVACDRKD 4072

RESULT 4:
TOP2_PEA STANDARD; PRT: 1462 AA.
ID TOP2_PEA
AC 024308;
DT 15-DEC-1998 (Rel. 37, Created)
DT 15-DEC-1998 (Rel. 37, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE DNA TOPOISOMERASE II (EC 5.99.1.3).
GN TOP2 OR TOP11.
OS Pisum sativum (Garden pea).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eurosids I; Fabales; Fabaceae; Papilionoideae; Viciaeae; Pisum.
OX NCBI_TaxID=3888;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Leaf;
RA Reddy M.K., Nair S., Tewari K.K.;
RL Submitted (AUG-1997) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: CONTROL OF TOPOLOGICAL STATES OF DNA BY TRANSIENT
CC BREAKAGE AND SUBSEQUENT REJOINING OF DNA STRANDS. TOPOISOMERASE II
CC MAKES DOUBLE-STRAND BREAKS.
CC -1- CATALYTIC ACTIVITY: ATP-DEPENDENT BREAKAGE, PASSAGE AND REJOINING
CC OF DOUBLE-STRANDED DNA.
CC -1- SUBUNIT: HOMODIMER (BY SIMILARITY).
CC -1- MISCELLANEOUS: EUKARYOTIC TOPOISOMERASE I AND II CAN RELAX BOTH
CC NEGATIVE AND POSITIVE SUPERCOILS,
CC RELAX ONLY NEGATIVE SUPERCOILS.
CC -1- SIMILARITY: BELONGS TO THE TYPE II TOPOISOMERASE FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL: Y14559; CAA74891.1;
CC InterPro: IPR000947; CBFA_NFYB.
CC InterPro: IPR001241; DNA_topoisoiI.
CC InterPro: IPR002205; DNA_topoisoiV.
CC InterPro: IPR003594; HATPase_c.
CC Pfam: PF00204; DNA_topoisoiI; 1.
CC Pfam: PF00521; DNA_topoisoiV; 2.
CC Pfam: PF02518; HATPase_c; 1.
CC PRINTS; PR00418; TP12FAMILY.
CC PRINTS; PR00615; CCAATSUBUNTA.
CC PRINTS; PR01158; TOPISMRASEII.
CC ProDom; PD000616; DNA_topoisoiI; 1.
CC SMART; SM00433; TOP2c; 1.
CC SMART; SM00434; TOP4c; 1.
CC PROSITE; PS00177; TOPOISOMERASE_II; 1.
CC Isomerase; Topoisomerase; DNA-binding; ATP-binding.
CC NP_BIND 149 154 ATP (POTENTIAL).
CC ACT_SITE 761 761 DNA CLEAVAGE (BY SIMILARITY).
CC SEQUENCE 1462 AA; 164205 MW; D9212C54AE0F8B2E CRC64;
```

Query Match 50.6%; Score 43; DB 1; Length 1462;  
Best Local Similarity 50.0%; Pred. No. 31;  
Matches 7; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
|:::|:::|  
DB 1400 CSASASNTPLSD 1413

RESULT 5  
TNR2\_MOUSE STANDARD; PRT; 474 AA.  
ID TNR2\_MOUSE  
AC P25119; P97893;  
DT 01-MAY-1992 (Rel. 22, Created)  
DT 01-MAY-1992 (Rel. 22, Last sequence update)  
DT 15-JUL-1999 (Rel. 38, Last annotation update)  
DE TUMOR NECROSIS FACTOR RECEPTOR 2 PRECURSOR (TNF-R2) (P75).  
GN TNFRSF1B OR TNFR2 OR TNFR-2.  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
[1]  
SEQUENCE FROM N.A.  
RP MEDLINE=91187885; PubMed=1849278;  
RA Lewis M., Tartaglia L.A., Lee A., Bennett G.L., Rice G.C.,  
Wong G.H., Chen E.Y., Goeddel D.V.;  
RT "Cloning and expression of cDNAs for two distinct murine tumor  
necrosis factor receptors demonstrate one receptor is species  
specific."  
RL Proc. Natl. Acad. Sci. U.S.A. 88:2830-2834(1991).  
RN [2]  
SEQUENCE FROM N.A.  
RX MEDLINE=91246168; PubMed=1645445;  
RA Goodwin R.G., Anderson D., Jerzy R., Davis T., Brannan C.I.,  
Copeland N.G., Jenkins N.A., Smith C.A.;  
RT "Molecular cloning and expression of the type 1 and type 2 murine  
receptors for tumor necrosis factor."  
RL Mol. Cell. Biol. 11:3020-3026(1991).  
RN [3]  
SEQUENCE OF 1-26 FROM N.A.  
RC STRAIN=NOD;  
RA Jacob C.O., Liu J.;  
RL Submitted (JAN-1996) to the EMBL/GenBank/DBJ databases.  
RN [4]  
SEQUENCE OF 1-22 FROM N.A.  
RC TISSUE=Liver;  
RA Kissinger M., Fellowes R., Feldmann M., Chernajovsky Y.;  
RL Submitted (MAY-1995) to the EMBL/GenBank/DBJ databases.  
CC -1- FUNCTION: RECEPTOR FOR TNF-ALPHA.  
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.  
CC -1- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; M50469; AAA39752.1; -  
DR EMBL; M59378; AAA40463.1; -  
DR EMBL; U39488; AAA85021.1; -  
DR EMBL; X87128; CAA60618.1; -  
DR PIR; B38634; B38634.  
DR HSSP; P19438; 1NCF.  
DR MGD; MGI:1314883; Tnfrsf1b.  
DR InterPro; IPR001368; TNFR\_c6.  
DR Pfam; PF00020; TNFR\_c6; 4.  
DR ProDom; PD000771; TNFR\_c6; 1.  
DR SMART; SM00208; TNFR; 4.  
DR PROSITE; PS00652; TNFR\_NGFR\_1; 2.

DR PROSITE; PS00650; TNFR\_NGFR\_2; 3.  
KW Receptor; Transmembrane; Glycoprotein; Repeat; Signal.  
FT SIGNAL 1 22  
FT CHAIN 23 474 TUMOR NECROSIS FACTOR RECEPTOR 2.  
FT DOMAIN 23 258 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 259 288 POTENTIAL.  
FT DOMAIN 289 474 CYTOPLASMIC (POTENTIAL).  
FT DOMAIN 39 203 4 X TNFR-CYS.  
FT REPEAT 39 77 TNFR-CYS 3.  
FT REPEAT 78 119 TNFR-CYS 2.  
FT REPEAT 120 164 TNFR-CYS 3.  
FT REPEAT 165 203 TNFR-CYS 4.  
FT DISULFID 40 54 BY SIMILARITY.  
FT DISULFID 55 68 BY SIMILARITY.  
FT DISULFID 58 76 BY SIMILARITY.  
FT DISULFID 79 94 BY SIMILARITY.  
FT DISULFID 97 111 BY SIMILARITY.  
FT DISULFID 101 119 BY SIMILARITY.  
FT DISULFID 121 127 BY SIMILARITY.  
FT DISULFID 136 145 BY SIMILARITY.  
FT DISULFID 139 163 BY SIMILARITY.  
FT DISULFID 166 181 BY SIMILARITY.  
FT CARBOHYD 69 69 N-LINKED (GLCNAC... ) (POTENTIAL).  
FT CARBOHYD 195 195 N-LINKED (GLCNAC... ) (POTENTIAL).  
SQ SEQUENCE 474 AA; 50319 MW; 462EAE398C4D6563 CRC64;

Query Match 48.2%; Score 41; DB 1; Length 474;  
Best Local Similarity 57.1%; Pred. No. 21;  
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
|:::|:::|  
DB 166 CAPETSDTTSTSD 179

RESULT 6  
DP3A\_CHLMU  
ID DP3A\_CHLMU STANDARD; PRT; 1237 AA.  
AC G9PJU7;  
DT 20-AUG-2001 (Rel. 40, Created)  
DT 20-AUG-2001 (Rel. 40, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE DNA POLYMERASE III ALPHA SUBUNIT (EC 2.7.7.7).  
GN DNAE OR TC0832.  
OS Chlamydia muridarum.  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
OX NCBI\_TaxID=22560;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=M22; Nigg.  
RX MEDLINE=20150235; PubMed=10684935;  
RA Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F.,  
White O., Hickey E.K., Peterson J., Utterback T., Berry K., Bass S.,  
Linher K., Weidman J., Khouri H., Craven B., Bowman C., Dodson R.,  
Gwin M., Nelson W., DeBoy R., Kolonay J., McClarty G., Salzberg S.L.,  
Eisen J., Fraser C.M.;  
RT "Genome sequences of Chlamydia trachomatis MoPn and Chlamydia  
pneumoniae AR39."  
RL Nucleic Acids Res. 28:1397-1406(2000).  
CC -1- FUNCTION: DNA POLYMERASE III IS A COMPLEX, MULTICHAIN ENZYME  
RESPONSIBLE FOR MOST OF THE REPLICATIVE SYNTHESIS IN BACTERIA.  
CC THIS DNA POLYMERASE ALSO EXHIBITS 3' TO 5' EXONUCLEASE ACTIVITY.  
CC THE ALPHA CHAIN IS THE DNA POLYMERASE (BY SIMILARITY).  
CC -1- CATALYTIC ACTIVITY: N DEOXYNUCLEOSIDE TRIPHOSPHATE -  
N PYROPHOSPHATE + DNA(N).  
CC -1- SUBUNIT: CONTAINS A CORE (COMPOSED OF ALPHA, EPSILON, AND THETA  
CHAINS) THAT ASSOCIATES WITH A TAU SUBUNIT WHICH ALLOW THE CORE  
DIMERIZATION TO FORM THE POLIII' COMPLEX. POLIII' ASSOCIATES WITH  
THE GAMMA COMPLEX (COMPOSED OF CHAINS GAMMA, DELTA, DELTA', PSI,  
AND CHI) AND WITH THE BETA CHAIN (BY SIMILARITY).  
CC -1- SUBCELLULAR LOCATION: CYTOPLASMIC (BY SIMILARITY).  
CC -1- SIMILARITY: BELONGS TO DNA POLYMERASE TYPE-C FAMILY. DNAE

```

CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: AE002349; AAF39632.1;
DR TIGR: TC0832;
DR InterPro: IPR003141; PHP_N.
DR Pfam: PF02231; PHP_N; 1.
DR SMART: SM00481; POLIITAC; 1.
DR Transferrase; DNA-directed DNA polymerase; DNA replication;
KW Complete proteome.
SQ SEQUENCE 1237 AA; 139892 MW; 5839D4F98D4CA223 CRC64;

Query Match 48.2%; Score 41; DB 1; Length 1237;
Best Local Similarity 61.5%; Pred. No. 55;
Matches 8; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 5 TASNTTVAADRSN 17
   | | | | |
Db 289 TISNTLIVADRCN 301

RESULT 7
C553_PARDE STANDARD; PRT; 226 AA.
AC P29967;
DT 01-APR-1993 (Rel. 25, Created)
DT 01-APR-1993 (Rel. 25, Last sequence update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DE CYTOCHROME C-553I PRECURSOR (C553I).
GN CYCB.
OS Paracoccus denitrificans.
OC Bacteria; Proteobacteria; alpha subdivision; Rhodobacter group;
OC Paracoccus.
OX NCBI_TaxID=266;
RN [1]
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RC STRAIN=PD 1235;
RX MEDLINE=92041583; PubMed=1657873;
RA Ras J., Reijnders W.N.M., van Spanning R.J.M., Harms N., Oltmann L.F.,
RA Stouthamer A.H.;
RT "Isolation, sequencing, and mutagenesis of the gene encoding
RT cytochrome c553i of Paracoccus denitrificans and characterization of
RL J. Bacteriol. 173:6971-6979(1991).
CC -|- SUBCELLULAR LOCATION: PERIPLASMIC.
CC -|- INDUCTION: DURING GROWTH ON METHANOL.
CC -|- PTM: BINDS ONE HEME GROUP PER MOLECULE.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: M75583; AAA25575.1;
DR PIR: B41378; B41378.
DR InterPro: IPR000345; CytC_heme_bind.
DR InterPro: IPR003088; Cyt_C1.
DR Pfam: PF00034; cytochrome.c; 1.
DR PROSITE: PS00190; CYTOCHROME.C; FALSE_NEG.
KW Electron transport; Heme; Signal; Methanol utilization; Periplasmic.
FT SIGNAL 1 22 POTENTIAL.
FT CHAIN 23 226 CYTOCHROME C-553I.

```

```

FT BINDING 125 125 HEME (COVALENT) (BY SIMILARITY).
FT BINDING 128 128 HEME (COVALENT) (BY SIMILARITY).
FT METAL 129 129 IRON (HEME AXIAL LIGAND) (BY SIMILARITY).
FT METAL 173 173 IRON (HEME AXIAL LIGAND) (BY SIMILARITY).
FT DOMAIN 37 44 POLY-ALA.
FT DOMAIN 60 64 POLY-GLU.
SQ SEQUENCE 226 AA; 23879 MW; C1D5DAH03702AEC7 CRC64;

Query Match 47.1%; Score 40; DB 1; Length 226;
Best Local Similarity 41.2%; Pred. No. 14;
Matches 7; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRSN 17
   | | | | |
Db 16 CAASATAGTALCADRRN 32

RESULT 8
TRYP_STRGR STANDARD; PRT; 259 AA.
AC P00775;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-FEB-1994 (Rel. 28, Last sequence update)
DT 01-NOV-1995 (Rel. 32, Last annotation update)
DE TRYP SIN PRECURSOR (EC 3.4.21.4) (SGT).
GN SPRT.
OS Streptomyces griseus.
OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae.
OC Actinomycetales; Streptomyces; Streptomycetaceae; Streptomyces.
OX NCBI_TaxID=1911;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 10137;
RX MEDLINE=92095977; PubMed=1755852;
RA Kim J.C., Cha S.H., Jeong S.T., Oh S.K., Byun S.M.;
RT "Molecular cloning and nucleotide sequence of Streptomyces griseus
RT trypsin gene."
RT Biochem. Biophys. Res. Commun. 181:707-713(1991).
RN [2]
RP SEQUENCE OF 37-259.
RX MEDLINE=75127940; PubMed=804314;
RA Olafson R.W., Jurasek L., Carpenter M.R., Smillie L.B.;
RT "Amino acid sequence of Streptomyces griseus trypsin. Cyanogen
RT bromide fragments and complete sequence."
RL Biochemistry 14:1168-1177(1975).
RN [3]
RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
RX MEDLINE=88286735; PubMed=3135412;
RA Read R.J., James M.N.G.;
RT "Refined crystal structure of Streptomyces griseus trypsin at 1.7-A
RT resolution."
RL J. Mol. Biol. 200:523-551(1988).
CC -|- CATALYTIC ACTIVITY: PREFERENTIAL CLEAVAGE: ARG-, LYS-.
CC -|- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
CC TRYP SIN FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: M64471; AAA26820.1; ALT_SEQ.
DR PIR: A00962; TRSMG.
DR PIR: JQ1302; JQ1302.
DR PDB: 1SGT; 16-JUL-88.
DR MEROPS: S01.101.
DR InterPro: IPR001314; Chymotrypsin.
DR InterPro: IPR001254; Trypsin.
DR Pfam: PF00089; trypsin; 1.

```

DR PRINTS; PR00722; CHYMOTRYPSIN.  
DR SMART; SM00020; TRYP\_SPC; 1.  
DR PROSITE; PS02040; TRYPSIN\_DOM; 1.  
DR PROSITE; PS00134; TRYPSIN\_HIS; 1.  
DR PROSITE; PS00135; TRYPSIN\_SER; 1.  
KW Hydrolase; Serine protease; Zymogen; Signal; 3D-structure.  
FT SIGNAL 1 32  
FT PROPEP 33 36 ACTIVATION PEPTIDE.  
FT CHAIN 37 259 TRYPSIN.  
FT ACT\_SITE 73 73 CHARGE RELAY SYSTEM.  
FT ACT\_SITE 118 118 CHARGE RELAY SYSTEM.  
FT ACT\_SITE 208 208 CHARGE RELAY SYSTEM.  
FT DISULFID 58 74  
FT DISULFID 177 192  
FT DISULFID 204 233  
FT SITE 202 202 REQUIRED FOR SPECIFICITY.  
FT SITE 202 202 MISSING (IN REF. 2).  
FT CONFLICT 95 96  
FT STRAND 38 38  
FT TURN 39 39  
FT STRAND 41 42  
FT TURN 45 46  
FT TURN 49 50  
FT STRAND 51 54  
FT TURN 55 57  
FT STRAND 58 64  
FT TURN 65 66  
FT STRAND 67 70  
FT STRAND 72 74  
FT HELIX 79 80  
FT STRAND 85 88  
FT STRAND 92 92  
FT TURN 93 94  
FT TURN 96 97  
FT STRAND 99 108  
FT TURN 110 111  
FT STRAND 120 124  
FT STRAND 134 135  
FT TURN 140 141  
FT STRAND 145 150  
FT TURN 156 157  
FT STRAND 163 163  
FT STRAND 165 172  
FT HELIX 174 184  
FT TURN 187 189  
FT STRAND 190 193  
FT TURN 196 198  
FT STRAND 202 202  
FT TURN 205 206  
FT TURN 208 209  
FT STRAND 211 215  
FT TURN 217 218  
FT STRAND 221 229  
FT TURN 236 237  
FT STRAND 240 244  
FT HELIX 245 257  
FT TURN 258 258  
SQ SEQUENCE 259 AA; 26776 MW; 050233AFF1F64823 CRC64;

Query Match 47.1%; Score 40; DB 1; Length 259;  
Best Local Similarity 46.2%; Pred. No. 16;  
Matches 6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 CASGTASNTTVA 13  
Db 74 CVSGSGNNTSITA 86

RESULT 9  
PRCD\_RAT STANDARD; PRT; 237 AA.  
ID PRCD\_RAT  
AC P28073;  
DT 01-AUG-1992 (Rel. 23, Created)

DT 01-FEB-1994 (Rel. 28, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE PROTEASOME DELTA CHAIN PRECURSOR (EC 3.4.99.46) (MACROPAIN DELTA CHAIN) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX DELTA CHAIN) (PROTEASOME SUBUNIT Y) (PROTEASOME CHAIN 5) (FRAGMENT).  
GN PSMB6.  
OS Rattus norvegicus (Rat).  
OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Rattus.  
OX NCBI\_TaxID=10116;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=93147071; PubMed=1491007;  
RA Tamura T., Shimbara N., Aki M., Ishida N., Bey F., Scherrer K., Tanaka K., Ichihara A.;  
RT "Molecular cloning of cDNAs for rat proteasomes: deduced primary structures of four other subunits.",  
RL J. Biochem. 112:530-534(1992).  
RN [2]  
RP SEQUENCE OF 33-50.  
RX MEDLINE=90242957; PubMed=2335214;  
RA Lilley K.S., Davison M.D., Rivett A.J.;  
RT "N-terminal sequence similarities between components of the multicatalytic proteinase complex.",  
RL FEBS Lett. 262:327-329(1990).  
CC -1- FUNCTION: THE PROTEASOME IS A MULTICATALYTIC PROTEINASE COMPLEX WHICH IS CHARACTERIZED BY ITS ABILITY TO CLEAVE PEPTIDES WITH ARG, PHE, TYR, LEU, AND GLU ADJACENT TO THE LEAVING GROUP AT NEUTRAL OR SLIGHTLY BASIC PH. THE PROTEASOME HAS AN ATP-DEPENDENT PROTEOLYTIC ACTIVITY.  
CC -1- PATHWAY: INVOLVED IN AN ATP/UBIQUITIN-DEPENDENT NON-LYSOSOMAL PROTEOLYTIC PATHWAY.  
CC -1- SUBUNIT: THE PROTEASOME IS COMPOSED OF AT LEAST 15 NON IDENTICAL SUBUNITS WHICH FORM A HIGHLY ORDERED RING-SHAPED STRUCTURE.  
CC -1- SUBCELLULAR LOCATION: PROTEASOMES ARE FOUND IN THE CYTOPLASM AND ALSO IN THE NUCLEUS.  
CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY T1B; ALSO KNOWN AS THE PROTEASOME B-TYPE FAMILY. DELTA SUBFAMILY.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; D10754; BAA01586.1; ALT\_INIT.  
DR PIR; S09086; S09086.  
DR MEROPS; T01.010; -.  
DR InterPro; IPR001353; Proteasome.  
DR InterPro; IPR000243; Proteasome\_B.  
DR Pfam; PF00227; proteasome; 1.  
DR PROSITE; PS00854; PROTEASOME\_B; 1.  
DR Proteasome; Hydrolase; Protease; zymogen.  
FT NON\_TER 1 1  
FT PROPEP <1 32  
FT CHAIN 33 237 PROTEASOME DELTA CHAIN.  
SQ SEQUENCE 237 AA; 25158 MW; C215AC2A70D9AA5F CRC64;

Query Match 45.9%; Score 39; DB 1; Length 237;  
Best Local Similarity 50.0%; Pred. No. 21;  
Matches 7; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
Db 76 CRSGSAADTOAVAD 89

RESULT 10  
PRCD\_HUMAN STANDARD; PRT; 239 AA.  
ID PRCD\_HUMAN

```

1 34
PROPEP 1 34
CHAIN 35 239 PROTEASOME DELTA CHAIN.
CONFLICT 145 145 G -> V (IN REF. 2).
SEQUENCE 239 AA: 25315 MW; 66EEB9B6C685830D CRC64;

Query Match 45.9%; Score 39; DB 1; Length 239;
Best Local Similarity 50.0%; Pred. No. 22;
Matches 7; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14
DB 78 CRSGSAADTQAVAD 91

RESULT 11
YFOL_STRR STANDARD; PRT; 278 AA.
ID YFOL_STRR
AC P96051;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DE HYPOTHETICAL 23.9 KDA PROTEIN IN FOLD-PBP2B INTERGENIC REGION
DE (ORF1091).
OS Streptococcus thermophilus.
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Streptococcaceae;
OC Streptococcus.
OX NCBI_TaxID=1308;
OX [1]
RN SEQUENCE FROM N.A.
RP STRAIN=SF16;
RC MEDLINE=97084576; PubMed=8930919;
RA Stingle F., Mollet B.;
RX "Disruption of the gene encoding penicillin-binding protein 2b
RT (pbp2b) causes altered cell morphology and cease in exopolysaccharide
RT production in Streptococcus thermophilus Sf16.";
RL Mol. Microbiol. 22:357-366(1996).
CC 1- SIMILARITY: BELONGS TO THE UPF0031 FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announcement
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U58210; AAC44613.1; -
CC InterPro; IPR000631; UPF0031.
CC Pfam; PF01256; UPF0031; 1.
CC PROSITE; PS01049; UPF0031_1; 1.
CC DR PROSITE; PS01050; UPF0031_2; 1.
CC KW Hypothetical protein.
CC SEQUENCE 278 AA; 29912 MW; D392FBCB1BE70CD5 CRC64;

Query Match 45.9%; Score 39; DB 1; Length 278;
Best Local Similarity 47.1%; Pred. No. 25;
Matches 8; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRSN 17
DB 47 CVNSGAGLVTATDREN 63

RESULT 12
IMA_LYCES STANDARD; PRT; 527 AA.
ID IMA_LYCES
AC O22478;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-DEC-1998 (Rel. 37, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DT IWP0PTIN ALPHA SUBUNIT (KARYOPHERIN ALPHA SUBUNIT) (KAP ALPHA).

```



```

OS Lycopersicon esculentum ('Tomato').
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
OC Asteridae; euasterids I; Solanales; Solanaceae; Solanum.
OX NCBI_TaxID=4081;
RN [1]
RP SEQUENCE FROM N.A.
RA Kunik T., Mizrahy L., Citovsky V., Gafni Y.;
RL Submitted (JUN-1998) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: BINDS SPECIFICALLY AND DIRECTLY TO SUBSTRATES CONTAINING
CC EITHER A SIMPLE OR BIPARTITE NLS MOTIF. PROMOTES DOCKING OF IMPORT
CC SUBSTRATES TO THE NUCLEAR ENVELOPE. SEEMS TO ACT AS A CYTOSOLIC
CC RECEPTOR FOR BOTH SINGLE AND BIPARTITE NLS MOTIFS (BY SIMILARITY).
CC -1- SUBUNIT: FORMS A COMPLEX WITH IMPORTIN BETA-1 SUBUNIT (BY
CC SIMILARITY).
CC -1- SUBCELLULAR LOCATION: CYTOPLASMIC (BY SIMILARITY).
CC -1- SIMILARITY: BELONGS TO THE IMPORTIN ALPHA FAMILY.
CC -1- SIMILARITY: CONTAINS 8 ARM REPEATS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF017252; AAC23722.1; -.
DR InterPro; IPR000225; Armadillo.
DR Pfam; PF00514; Armadillo_seg; 8.
DR Pfam; PF01749; IBB; 1.
DR SMART; SM00185; ARM; 8.
DR PROSITE; PS00176; ARM_REPEAT; 5.
KW Transport; Protein transport; Repeat.
FT DOMAIN 12 51
FT REPEAT 109 151 ARM 1.
FT REPEAT 152 196 ARM 2.
FT REPEAT 197 234 ARM 3.
FT REPEAT 235 279 ARM 4.
FT REPEAT 280 319 ARM 5.
FT REPEAT 320 362 ARM 6.
FT REPEAT 363 403 ARM 7.
FT REPEAT 403 445 ARM 8.
FT DOMAIN 446 527 ASP/GLU-RICH (ACIDIC).
SQ SEQUENCE 527 AA; 58605 MW; 4A3F01691CE4817 CRC64;

Query Match 45.9%; Score 39; DB 1; Length 527;
Best Local Similarity 61.5%; Pred. No. 49;
Matches 8; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 2 ASGTASNTTVAAD 14
||||:| | |
Db 145 ASGTSNTKVVID 157

RESULT 13
NASC_BACSU
ID NASC_BACSU STANDARD; PRT; 710 AA.
AC P42434;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE ASSIMILATORY NITRATE REDUCTASE SUBUNIT (EC 1.7.99.4).
GN NASC OR NARB OR NASBB.
OS Bacillus subtilis.
OC Bacteria; Firmicutes; Bacillus/Clostridium group;
OC Bacillus/Staphylococcus group; Bacillus.
OX NCBI_TaxID=1423;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=168;

```

```

RX MEDLINE=97124189; PubMed=8969502;
RA Yamane K., Kumano M., Kurita K.;
RT "The 25 degrees-36 degrees region of the Bacillus subtilis
RT chromosome: determination of the sequence of a 146 kb segment and
RT identification of 113 genes.";
RL Microbiology 142:3047-3056(1996).
RN [2]
RP SEQUENCE OF 35-710 FROM N.A.
RC STRAIN=168;
RX MEDLINE=95173124; PubMed=7868621;
RA Ogawa K.-I., Akagawa E., Yamane K., Sun Z.-W., Lacelle M., Zuber P.,
RA Nakano M.M.;
RT "The nasB operon and nasA gene are required for nitrate/nitrite
RT assimilation in Bacillus subtilis.";
RL J. Bacteriol. 177:1409-1413(1995).
CC -1- FUNCTION: NITRATE REDUCTASE IS A KEY ENZYME INVOLVED IN THE FIRST
CC STEP OF NITRATE ASSIMILATION IN PLANTS, FUNGI AND BACTERIA.
CC -1- CATALYTIC ACTIVITY: NITRATE + ACCEPTOR -> NITRATE + REDUCED
CC ACCEPTOR.
CC -1- COFACTOR: MOLYBDENUM (MOLYBDOPTERIN); MAY BIND A 4FE-4S CLUSTER.
CC -1- PATHWAY: NITRATE ASSIMILATORY PATHWAY.
CC -1- SIMILARITY: BELONGS TO THE PROKARYOTIC MOLYBDOPTERIN-CONTAINING
CC OXIDOREDUCTASE FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; D50453; BAA08965.1; -.
DR EMBL; D30689; BAA06353.1; -.
DR EMBL; Z99105; CAB12125.1; -.
DR HSSP; P07658; IFDI.
DR Subtilist; BG11095; nasC.
DR InterPro; IPR001467; Molybdopterin.
DR Pfam; PF00384; molybdopterin; 1.
DR Pfam; PF01568; Molybdop_binding; 1.
DR PROSITE; PS00551; MOLYBDOPTERIN_PROK_1; 1.
DR PROSITE; PS00490; MOLYBDOPTERIN_PROK_2; 1.
DR PROSITE; PS00932; MOLYBDOPTERIN_PROK_3; FALSE_NEG.
KW Oxidoreductase; Molybdenum; Nitrate assimilation; Iron-sulfur; 4Fe-4S;
KW Complete proteome.
FT METAL 26 26 IRON-SULFUR (4FE-4S) (POTENTIAL).
FT METAL 29 29 IRON-SULFUR (4FE-4S) (POTENTIAL).
FT METAL 33 33 IRON-SULFUR (4FE-4S) (POTENTIAL).
FT METAL 63 63 IRON-SULFUR (4FE-4S) (POTENTIAL).
SQ SEQUENCE 710 AA; 78575 MW; 625E8864A1552AA2 CRC64;

Query Match 45.9%; Score 39; DB 1; Length 710;
Best Local Similarity 57.1%; Pred. No. 66;
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 2 ASGTASNTTVAADR 15
||||:| | |
Db 157 AAATANQTFGADR 170

RESULT 14
MYSC_DICDI
ID MYSC_DICDI STANDARD; PRT; 1181 AA.
AC P42522;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE MYOSIN IC HEAVY CHAIN.
GN MYOC OR DMIC.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyosteliida; Dictyostelium.
OX NCBI_TaxID=44689;

```

```

RN  SEQUENCE FROM N.A.
RP  STRAIN-AX2:
RX  MEDLINE-95348228; PubMed-762596;
RA  Peterson M.D., Novak K.D., Ready M.C., Ruman J.I., Titus M.A.;
RT  "Molecular genetic analysis of myoC, a Dictyostellium myosin I.";
RL  J. Cell Sci. 108:1093-1103(1995).
CC  -!- FUNCTION: MYOSIN IS A PROTEIN THAT BINDS TO ACTIN & HAS ATPASE
CC  ACTIVITY THAT IS ACTIVATED BY ACTIN.
CC  -!- SUBUNIT: MYOSIN I HEAVY CHAIN IS SINGLE-HEADED. DIMER OF A HEAVY
CC  AND A LIGHT CHAIN. INABILITY TO SELF-ASSEMBLE INTO FILAMENTS.
CC  -!- SIMILARITY: CONTAINS 1 MYOSIN-LIKE GLOBULAR HEAD DOMAIN.
CC  -!- SIMILARITY: CONTAINS 1 SH3 DOMAIN.
CC  -----
CC  This SWISS-PROT entry is copyright. It is produced through a collaboration
CC  between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC  the European Bioinformatics Institute. There are no restrictions on its
CC  use by non-profit institutions as long as its content is in no way
CC  modified and this statement is not removed. Usage by and for commercial
CC  entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC  or send an email to license@isb-sib.ch).
CC  -----
DR  EMBL: L35323; AAC37427.1;
DR  HSSP: P08799; LMND.
DR  DictyDb: DD01090; myoC.
DR  InterPro: IPR001452; SH3.
DR  InterPro: IPR001609; myosin_head.
DR  Pfam: PF00063; myosin_head; 2.
DR  Pfam: PF00018; SH3; 1.
DR  PRINTS: PR00193; MYOSINHEAVY.
DR  PRINTS: PR00452; SH3DOMAIN.
DR  ProDom: PD000355; myosin_head; 1.
DR  SMART: SM00242; MYSC; 1.
DR  SMART: SM00326; SH3; 1.
DR  PROSITE: PS00002; SH3; 1.
KW  Myosin; Actin-binding; ATP-binding; Chemotaxis; SH3 domain;
FT  DOMAIN 1 ? MYOSIN HEAD-LIKE.
FT  DOMAIN ? 1181 NON ALPHA-HELICAL, C-TERMINAL DOMAIN.
FT  NP_BIND 109 116 ATP (POTENTIAL).
FT  DOMAIN 1122 1181 SH3.
SQ  SEQUENCE 1181 AA; 132915 MW; 5B1EE47F0CA8803 CRC64;

Query Match 45.9%; Score 39; DB 1; Length 1181;
Best Local Similarity 56.2%; Pred. No. 1.1e+02;
Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY  2 ASGTASNTTVAADRSN 17
    ||| :||| | |
DB  951 ASGLPASTTVAKVRKN 966

RESULT 15
SOS1_MOUSE
ID  SOS1_MOUSE STANDARD; PRT; 1319 AA.
AC  O62245; O62244;
DT  15-JUL-1999 (Rel. 38, Created)
DT  15-JUL-1999 (Rel. 38, Last sequence update)
DT  30-MAY-2000 (Rel. 39, Last annotation update)
DE  SON OF SEVENLESS PROTEIN HOMOLOG 1 (SOS-1) (MSOS-1).
GN  SOS1.
OS  Mus musculus (Mouse).
OC  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX  NCBI_TaxID=10090;
RN  [1]
RP  SEQUENCE FROM N.A.
RX  STRAIN-SWISS: TISSUE-EYE;
RA  MEDLINE-9233328; PubMed-1631150;
RA  Bowtell D., Fu P., Simon M., Senior P.;
RT  "Identification of murine homologues of the Drosophila son of
RT  sevenless gene: potential activators of ras.";

```

```

Proc. Natl. Acad. Sci. U.S.A. 89:6511-6515(1992).
[2]
RP  STRUCTURE BY NMR OF 415-548.
RX  MEDLINE-97360234; PubMed-9217262;
RA  Koshiba S., Kigawa T., Kim J.-H., Shirouzu M., Bowtell D.,
RA  Yokoyama S.;
RT  "The solution structure of the pleckstrin homology domain of mouse
RT  Son-of-sevenless 1 (MSOS1).";
RL  J. Mol. Biol. 269:579-591(1997).
CC  -!- FUNCTION: PROMOTES THE EXCHANGE OF RAS-BOUND GDP BY GTP (BY
CC  SIMILARITY).
CC  -!- TISSUE SPECIFICITY: EXPRESSED IN MOST EMBRYONIC AND ADULT TISSUES.
CC  -!- SIMILARITY: CONTAINS 1 DBL-HOMOLOGY DOMAIN (DH).
CC  -!- SIMILARITY: CONTAINS 1 PH DOMAIN.
CC  -!- SIMILARITY: CONTAINS 1 RASGEF DOMAIN.
CC  -----
CC  This SWISS-PROT entry is copyright. It is produced through a collaboration
CC  between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC  the European Bioinformatics Institute. There are no restrictions on its
CC  use by non-profit institutions as long as its content is in no way
CC  modified and this statement is not removed. Usage by and for commercial
CC  entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC  or send an email to license@isb-sib.ch).
CC  -----
DR  EMBL: Z11574; CAA77662.1;
DR  EMBL: Z11578; CAA77665.1;
DR  PDB: 1PMS; 15-MAY-97.
DR  MGD: MGI:98354; Sosl.
DR  InterPro: IPR001166; Histone_core.
DR  InterPro: IPR001849; PH.
DR  InterPro: IPR000651; RasGEFN.
DR  InterPro: IPR001895; RasGRE_CDC25.
DR  InterPro: IPR000219; RhoGEF.
DR  Pfam: PF00169; PH; 1.
DR  Pfam: PF00617; RasGEF; 1.
DR  Pfam: PF00618; RasGEFN; 1.
DR  Pfam: PF00621; RhoGEF; 1.
DR  SMART: SM00233; PH; 1.
DR  SMART: SM00147; RasGEF; 1.
DR  SMART: SM00229; RasGEFN; 1.
DR  SMART: SM00325; RhoGEF; 1.
DR  PROSITE: PS00720; GDS_CDC25; 1.
DR  PROSITE: PS50003; PH_DOMAIN; 1.
KW  Guanine-nucleotide releasing factor; 3D-structure.
FT  DOMAIN 202 443 DH.
FT  DOMAIN 444 548 PH.
FT  DOMAIN 777 963 RASGEF.
FT  DOMAIN 1244 1247 POLY-PRO.
SQ  SEQUENCE 1319 AA; 150882 MW; 3286088A5BA04A6 CRC64;

Query Match 45.9%; Score 39; DB 1; Length 1319;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 8; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY  2 ASGTASNTTVA 13
    |||:| | |
DB  1092 ASGTSNTDVCS 1103

```

Search completed: March 26, 2002, 13:40:43  
Job time: 257 sec

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:11 ; Search time 79.01 Seconds  
(without alignments)  
31.472 Million cell updates/sec

Title: US-09-709-201-96

Perfect score: 85

Sequence: 1 CASGTASNTTVAADRSN 17

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 473505 seqs, 146272329 residues

Total number of hits satisfying chosen parameters: 473505

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- SPTREMBL\_17.\*
- 1: sp-archaea.\*
  - 2: sp-bacteria.\*
  - 3: sp-fungi.\*
  - 4: sp-human.\*
  - 5: sp-invertebrate.\*
  - 6: sp-mammal.\*
  - 7: sp-mhc.\*
  - 8: sp-organelle.\*
  - 9: sp-phage.\*
  - 10: sp-plant.\*
  - 11: sp-rodent.\*
  - 12: sp-virus.\*
  - 13: sp-vertebrate.\*
  - 14: sp-unclassified.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	76	89.4	392	2 Q99QB0	Q99qb0 chlamydia
2	54	63.5	356	2 O52924	O52924 chlamydia p
3	54	63.5	390	2 Q9AIJ5	Q9aij5 chlamydia p
4	54	63.5	392	2 Q9AIJ4	Q9aij4 chlamydia p
5	46	54.1	30	4 Q9UIH1	Q9uih1 homo sapien
6	46	54.1	425	4 Q16042	Q16042 homo sapien
7	46	54.1	1518	5 Q21850	Q21850 caenorhabdi
8	45	52.9	390	5 Q9GYJ3	Q9gyj3 caenorhabdi
9	45	52.9	767	12 Q66627	Q66627 equine herp
10	45	52.9	942	10 Q9SUT8	Q9sut8 arabidopsis
11	44	51.8	341	2 Q9X653	Q9x653 streptomyce
12	44	51.8	2911	5 Q9BLV4	Q9blv4 leishmania
13	44	51.8	3040	5 Q9GNV4	Q9gny4 leishmania
14	43	50.6	287	4 Q9H9U0	Q9h9u0 homo sapien
15	43	50.6	376	4 Q9H650	Q9h650 homo sapien
16	43	50.6	425	3 Q12741	Q12741 blastoclad
17	43	50.6	427	4 Q9NT65	Q9nt65 homo sapien
18	43	50.6	4899	5 Q9VR91	Q9vr91 drosophila
19	42	49.4	165	5 Q9N3E7	Q9n3e7 caenorhabdi

20	42	49.4	236	1 Q9HHV1	Q9hhv1 halobacteri
21	42	49.4	390	2 Q9K7M8	Q9k7m8 bacillus ha
22	42	49.4	518	2 O53738	O53738 mycobacteri
23	41.5	48.8	473	2 Q9RK75	Q9rk75 streptomyce
24	41	48.2	119	5 O61034	O61034 trypanosoma
25	41	48.2	175	11 Q9WUL4	Q9wul4 rattus norv
26	41	48.2	217	2 Q9X6X0	Q9x6x0 streptococc
27	41	48.2	338	5 Q9BLA4	Q9bla4 leishmania
28	41	48.2	459	11 Q62327	Q62327 mus musculu
29	41	48.2	482	11 O88734	O88734 mus musculu
30	41	48.2	3257	5 Q9V736	Q9v736 drosophila
31	40	47.1	226	2 Q51672	Q51672 paracoccus
32	40	47.1	259	2 Q54168	Q54168 streptomyce
33	40	47.1	355	10 Q9ATT5	Q9att5 coix lachry
34	40	47.1	490	10 Q9SUY8	Q9suy8 arabidopsis
35	40	47.1	492	10 Q9M044	Q9m044 arabidopsis
36	40	47.1	510	10 Q9M057	Q9m057 arabidopsis
37	40	47.1	760	2 Q47429	Q47429 escherichia
38	39	45.9	126	5 Q9CXD5	Q9cxd5 leishmania
39	39	45.9	166	11 Q9CV50	Q9cv50 mus musculu
40	39	45.9	190	11 Q9CV36	Q9cv36 mus musculu
41	39	45.9	202	5 Q9CZ03	Q9cz03 caenorhabdi
42	39	45.9	202	11 Q60692	Q60692 mus musculu
43	39	45.9	216	2 Q9X6H6	Q9x6h6 streptococc
44	39	45.9	226	3 O43063	O43063 schizosacch
45	39	45.9	231	13 O12992	O12992 lampetra ja

ALIGNMENTS

RESULT 1					
Q99QB0					
ID Q99QB0	PRELIMINARY;	PRT;	392 AA.		
AC Q99QB0					
DT 01-JUN-2001	(TREMBLrel. 17, Created)				
DT 01-JUN-2001	(TREMBLrel. 17, Last sequence update)				
DE 01-JUN-2001	(TREMBLrel. 17, Last annotation update)				
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.					
GN OMPA.					
OS Chlamydomonas reinhardtii					
OC Bacteria; Chlamydiales; Chlamydiales; Chlamydiales					
OX NCBI_TaxID=83556;					
RN [1]					
RP SEQUENCE FROM N.A.					
RC STRAIN-PP BAKER, ATCC VR120, AND PP CHLLO;					
RX MEDLINE=21078580; PubMed=11211261;					
RA Bush R.M., Everett K.D.;					
RT "Molecular evolution of the Chlamydiales";					
RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).					
DR EMBL; AF269257; AAK00238.1; -;					
DR EMBL; AF269258; AAK00239.1; -;					
KW Signal.					
FT SIGNAL	1	22	POTENTIAL.		
FT CHAIN	23	392	MAJOR OUTER MEMBRANE PROTEIN.		
SQ SEQUENCE	392 AA;	42051 MW;	88B3C09C1FEE26DB CRC64;		
Query Match	89.4%;	Score 76;	DB 2;	Length 392;	
Best Local Similarity	100.0%;	Pred. No. 0.0003;			
Matches	16;	Conservative	0;	Mismatches	0;
				Indels	0;
				Gaps	0;
QY 2 ASGTASNTTVAADRSN 17					
DB 92 ASGTASNTTVAADRSN 107					
RESULT 2					
O52924					
ID O52924	PRELIMINARY;	PRT;	356 AA.		
AC O52924					
DT 01-JUN-1998	(TREMBLrel. 06, Created)				
DT 01-JUN-1998	(TREMBLrel. 06, Last sequence update)				

DT 01-JUN-2001 (TRENBLrel. 17, Last annotation update)  
DE OUTER MEMBRANE PROTEIN 1 (FRAGMENT).  
GN OMP1.  
OS Chlamydia psittaci (Chlamydoiphila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydoiphila.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=92-1293, AVIAN SEROVAR D;  
RA Vanrompay D., Cox E., Goddeeris B.M., Volckaert G.;  
RL Submitted (FEB-1998) to the EMBL/GenBank/DBJ databases.  
DR EMBL; Y16562; CAA76286.1; -  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
KW Outer membrane.  
FT NON\_TER 356  
SQ SEQUENCE 356 AA; 38396 MW; D51DE06FB46EGF13 CRC64;

Query Match 63.5%; Score 54; DB 2; Length 356;  
Best Local Similarity 68.8%; Pred. No. 0.79; 3; Indels 0; Gaps 0;  
Matches 11; Conservative 2; Mismatches 3;

QY 2 ASGTASNTTVAADRSN 17  
I:||||| I I I I I  
Db 92 ATGTASATTAVDRTN 107

## RESULT 3

Q9AIJ5 PRELIMINARY; PRT; 390 AA.  
AC Q9AIJ5;  
DT 01-JUN-2001 (TRENBLrel. 17, Created)  
DT 01-JUN-2001 (TRENBLrel. 17, Last sequence update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
GN OMPA.  
OS Chlamydia psittaci (Chlamydoiphila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydoiphila.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=NEW JERSEY 1, NJ1;  
RX MEDLINE=21078680; PubMed=11211261;  
RA Bush R.M., Everett K.D.;  
RT "Molecular evolution of the Chlamydiaceae.";  
RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
DR EMBL; AF269266; AAK00247.1; -  
KW Signal.  
FT NON\_TER 1 1  
FT SIGNAL <1 20 POTENTIAL.  
FT CHAIN 21 390 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 390 AA; 42042 MW; B62858403DBFA4E6 CRC64;

Query Match 63.5%; Score 54; DB 2; Length 390;  
Best Local Similarity 68.8%; Pred. No. 0.85; 3; Indels 0; Gaps 0;  
Matches 11; Conservative 2; Mismatches 3;

QY 2 ASGTASNTTVAADRSN 17  
I:||||| I I I I I  
Db 90 ATGTASATTAVDRTN 105

## RESULT 4

Q9AIJ4 PRELIMINARY; PRT; 392 AA.  
AC Q9AIJ4;  
DT 01-JUN-2001 (TRENBLrel. 17, Created)  
DT 01-JUN-2001 (TRENBLrel. 17, Last sequence update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.

GN OMPA.  
OS Chlamydia psittaci (Chlamydoiphila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydoiphila.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=TEXAS TURKEY 3, TT3;  
RA MEDLINE=21078680; PubMed=11211261;  
RA Bush R.M., Everett K.D.;  
RT "Molecular evolution of the Chlamydiaceae.";  
RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
DR EMBL; AF269267; AAK00248.1; -  
KW Signal.  
FT SIGNAL 1 22 POTENTIAL.  
FT CHAIN 23 392 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 392 AA; 42293 MW; FC31FC051955246C CRC64;

Query Match 63.5%; Score 54; DB 2; Length 392;  
Best Local Similarity 68.8%; Pred. No. 0.86; 3; Indels 0; Gaps 0;  
Matches 11; Conservative 2; Mismatches 3;

QY 2 ASGTASNTTVAADRSN 17  
I:||||| I I I I I  
Db 92 ATGTASATTAVDRTN 107

## RESULT 5

Q9UIH1 PRELIMINARY; PRT; 30 AA.  
AC Q9UIH1;  
DT 01-MAY-2000 (TRENBLrel. 13, Created)  
DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)  
DE TUMOR NECROSIS FACTOR RECEPTOR 2 (FRAGMENT).  
GN TNFR2.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Komata T., Tsuchiya N., Matsushita M., Tokunaga K.;  
RT "New polymorphism within the extracellular region of TNFR2.";  
RL Submitted (AUG-1999) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AB030950; BAA89033.1; -  
KW Receptor.  
FT NON\_TER 1 1  
FT NON\_TER 30 30  
SQ SEQUENCE 30 AA; 3183 MW; 942C00239B909DF5 CRC64;

Query Match 54.1%; Score 46; DB 4; Length 30;  
Best Local Similarity 64.3%; Pred. No. 1.5; 4; Indels 0; Gaps 0;  
Matches 9; Conservative 1; Mismatches 4;

QY 1 CASGTASNTTVAAD 14  
I:||||| I I I I I  
Db 11 CAPGTFSTSTSD 24

## RESULT 6

Q16042 PRELIMINARY; PRT; 425 AA.  
AC Q16042;  
DT 01-NOV-1996 (TRENBLrel. 01, Created)  
DT 01-JUN-2001 (TRENBLrel. 17, Last sequence update)  
DT 01-JUN-2001 (TRENBLrel. 17, Last annotation update)  
DE TUMOR NECROSIS FACTOR RECEPTOR (FRAGMENT).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;

Query Match	54.1%	Score 46;	DB 5;	Length 1518;	
Best Local Similarity	52.9%	Pred. No. 53;			
Matches	9;	Conservative	1;	Mismatches	7; Indels 0; Gaps 0;

  

QY	1	CASGTASNTTVAADRSN 17			
Db	1275	CVYQSQNIKIAIDRSN 1291			

  

RESULT	8				
Q9GYJ3		PRELIMINARY;	PRT;	390 AA.	
ID	Q9GYJ3				
AC	Q9GYJ3;				
DT	01-MAR-2001 (TREMBlrel. 16, Created)				
DT	01-MAR-2001 (TREMBlrel. 16, Last sequence update)				
DT	01-JUN-2001 (TREMBlrel. 17, Last annotation update)				
DE	C46H11.8 PROTEIN.				
DE	C46H11.8.				
GN	Caenorhabditis elegans.				
OS	Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;				
OC	Rhabditidae; Peloderinae; Caenorhabditis.				
NCBI_TaxID=6239;					
RN	[1]				
RP	SEQUENCE FROM N.A.				
RC	STRAIN-BRISTOL N2;				
RX	MEDLINE=99069613; PubMed=9851916;				
RA	None;				
RT	"Genome sequence of the nematode C. elegans: a platform for				
RT	investigating biology. The C. elegans Sequencing Consortium.";				
RL	Science 282:2012-2018(1998).				
RN	[2]				
RP	SEQUENCE FROM N.A.				
RC	STRAIN-BRISTOL N2;				
RA	Miller N., Bradshaw H., Wamsley P.;				
RT	"The sequence of C. elegans cosmid C46H11.";				
RL	Submitted (FEB-1997) to the EMBL/GenBank/DBJ databases.				
RN	[3]				
RP	SEQUENCE FROM N.A.				
RC	STRAIN-BRISTOL N2;				
RA	Waterston R.;				
RL	Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.				
DR	EMBL; U88314; AAF99887.1; -.				
DR	InterPro; IPR002526; DUF18.				
DR	InterPro; IPR003582; SHKT.				
DR	Pfam; PF01549; DUF18; 1.				
DR	SMART; SM00254; SHKT; 5.				
SQ	SEQUENCE 390 AA; 40714 MW; 6158969H40CB161 CRC64;				

  

Query Match	52.9%	Score 45;	DB 5;	Length 390;	
Best Local Similarity	56.2%	Pred. No. 22;			
Matches	9;	Conservative	4;	Mismatches	3; Indels 0; Gaps 0;

  

QY	2	ASGTASNTTVAADRSN 17			
Db	182	SSTTSSSTTTCADRSN 197			

  

RESULT	9				
Q66627		PRELIMINARY;	PRT;	737 AA.	
ID	Q66627				
AC	Q66627;				
DT	01-NOV-1996 (TREMBlrel. 01, Created)				
DT	01-NOV-1996 (TREMBlrel. 01, Last sequence update)				
DT	01-MAR-2001 (TREMBlrel. 16, Last annotation update)				
DE	ORF 24.				
OS	Equine herpesvirus type 2 (strain 86/87).				
OC	Viruses; dsDNA viruses, no RNA stage; Herpesviridae;				
OC	Gammapherpesvirinae.				
NCBI_TaxID=82831;					
RN	[1]				
RP	SEQUENCE FROM N.A.				
RX	MEDLINE=95302501; PubMed=7783207;				

RA Telford E.A., Watson M.S., Aird H.C., Perry J., Davison A.J.;  
 RT "The DNA sequence of equine herpesvirus 2."  
 RL J. Mol. Biol. 249:520-528(1995).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RA Telford E.A.R.;  
 RL Submitted (FEB-1995) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; U20824; AAC13811.1; -  
 SQ SEQUENCE 767 AA; 84112 MW; 6DB41AA51B5B8EDA CRC64;

Query Match 52.9%; Score 45; DB 12; Length 767;  
 Best Local Similarity 57.1%; Pred. No. 41;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
 ||||| |::|  
 Db 511 CASGTAINMISGD 524

RESULT 10

ID Q9SUT8 PRELIMINARY; PRT; 942 AA.  
 AC Q9SUT8;  
 DT 01-MAY-2000 (TREMBLrel. 13, Created)  
 DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)  
 DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)  
 DE RESPIRATORY BURST OXIDASE HOMOLOG F-LIKE PROTEIN.  
 GN F8L21.20 OR AT4G11230.  
 OS Arabidopsis thaliana (Mouse-ear cress).  
 OC Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;  
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;  
 OC eurosids II; Brassicales; Brassicaceae; Arabidopsis.  
 OX NCBI\_TaxID=3702;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Bevan M., Peters S.A., van Staveren M., Dirkse W., Stiekema W.,  
 RA Bancroft I., Mewes H.W., Mayer K.F.X., Lemcke K., Schueller C.;  
 RL Submitted (JUL-1999) to the EMBL/GenBank/DBJ databases.  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RA EU Arabidopsis sequencing project;  
 RL Submitted (AUG-1999) to the EMBL/GenBank/DBJ databases.  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RA Peters S.A., van Staveren M., Dirkse W., Stiekema W., Mewes H.W.,  
 RA Lemcke K., Mayer K.F.X.;  
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RA EU Arabidopsis sequencing project;  
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AL095882; CAB51407.1; -  
 DR EMBL; AL161531; CAB81224.1; -  
 DR InterPro; IPR002916; Ferric\_reduct.  
 DR InterPro; IPR000778; GP91phox.  
 DR Pfam; PF01794; Ferric\_reduct; 1.  
 DR PRINTS; PR00466; GP91PHOX.  
 SQ SEQUENCE 942 AA; 107211 MW; 70672D6E2A9BCCD3 CRC64;

Query Match 52.9%; Score 45; DB 10; Length 942;  
 Best Local Similarity 43.8%; Pred. No. 49;  
 Matches 7; Conservative 5; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRS 16  
 | | | | | | | | | | | | | | | |  
 Db 769 CIGSCSNISSDHS 784

RESULT 11

Q9X653 PRELIMINARY; PRT; 341 AA.  
 ID Q9X653

AC Q9X653;  
 DT 01-NOV-1999 (TREMBLrel. 12, Created)  
 DT 01-NOV-1999 (TREMBLrel. 12, Last sequence update)  
 DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)  
 DE NAPG OXIDOREDUCTASE.  
 GN NAPG;  
 OS Streptomyces collinus.  
 OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;  
 OC Actinomycetales; Streptomycetaceae; Streptomycetaceae; Streptomycetes.  
 OX NCBI\_TaxID=42684;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=TU 1892;  
 MEDLINE=920203506; PubMed=10103039;  
 RA Chen S., von Bamberg D., Hale V., Breuer M., Hardt B., Mlier R.,  
 RA Floss H.G., Reynolds K.A., Leistner E.;  
 RT "Biosynthesis of ansatrienin (mycotrienin) and naphthomycin.  
 RT Identification and analysis of two separate biosynthetic gene clusters  
 RT in Streptomyces collinus Tu 1892."  
 RL Eur. J. Biochem. 261:98-107(1999).  
 DR EMBL; AF131877; AAD31829.1; -  
 DR InterPro; IPR000683; GFO\_IDH\_Moca.  
 DR InterPro; IPR002965; P\_rich\_extensn.  
 DR Pfam; PF01408; GFO\_IDH\_MOCA; 1.  
 DR PRINTS; PR01217; PRICHEXTENS.  
 SQ SEQUENCE 341 AA; 34598 MW; 8809EE179285291E CRC64;

Query Match 51.8%; Score 44; DB 2; Length 341;  
 Best Local Similarity 50.0%; Pred. No. 28;  
 Matches 8; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRS 16  
 | | | | | | | | | | | | | | | |  
 Db 97 CLSGTEADTLAAERA 112

RESULT 12

Q9BLV4 PRELIMINARY; PRT; 2911 AA.  
 ID Q9BLV4;  
 AC Q9BLV4;  
 DT 01-JUN-2001 (TREMBLrel. 17, Created)  
 DT 01-JUN-2001 (TREMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)  
 DE POSSIBLE HIGH MOLECULAR MASS NUCLEAR ANTIGEN (FRAGMENT).  
 GN L2230.01.  
 OS Leishmania major.  
 OC Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae; Leishmania.  
 OX NCBI\_TaxID=5664;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=FRIEDLIN;  
 RA Zimmermann W., Wambutt R., Ivens A.C., Quail M., Rajandream M.A.,  
 RA Barrell B.G.;  
 RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=FRIEDLIN;  
 RX MEDLINE=98146435; PubMed=9477341;  
 RA Ivens A.C., Lewis S.M., Bagherzadeh A., Zhang L., Chan H.M.,  
 RA Smith D.F.;  
 RT "A physical map of the Leishmania major Friedlin genome."  
 RL Genome Res. 8:135-145(1998).  
 DR EMBL; AL513062; CAC24680.1; -  
 FT NON\_TER 2911 2911  
 SQ SEQUENCE 2911 AA; 305079 MW; 45CD9DC05BC57091 CRC64;

Query Match 51.8%; Score 44; DB 5; Length 2911;  
 Best Local Similarity 60.0%; Pred. No. 2e+02;  
 Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 3 SGTASNTTVAADRSN 17

Db 939 TGSASSTAAAGRSN 953  
:|||||: || |||

## RESULT 13

Q9GNY4 PRELIMINARY; PRT: 3040 AA.  
AC Q9GNY4;  
DT 01-MAR-2001 (TREMBlrel. 16, Created)  
DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)  
DT 01-MAR-2001 (TREMBlrel. 16, Last annotation update)  
DE POSSIBLE KINETOPLAST-ASSOCIATED PROTEIN (FRAGMENT).  
GN L5852.01.  
OS Leishmania major.  
OC Eukaryota; Euzlenozoa; Kinetoplastida; Trypanosomatidae; Leishmania.  
OX NCBI\_TaxID=5664;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=FRIEDLIN;  
RA Reinhardt R., Klages S., Beck A., Ivens A.C., Murphy L., Quail M.,  
RA Rajandream M.A., Barrell B.G.;  
RL Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=FRIEDLIN;  
RX MEDLINE=98146435; PubMed=9477341;  
RA Ivens A.C., Lewis S.M., Bagherzadeh A., Zhang L., Chan H.M.,  
RA Smith D.F.;  
RT "A physical map of the Leishmania major Friedlin genome."  
RL Genome Res. 8:135-145(1998).  
DR EMBL; AL499614; CAC18858.1; -  
FT NON\_TER 1 1  
FT NON\_TER 3040 3040  
SQ SEQUENCE 3040 AA; 323433 MW; 8F2AD28D3C4021ED CRC64;

Query Match 51.8%; Score 44; DB 5; Length 3040;  
Best Local Similarity 60.0%; Pred. No. 2e+02;  
Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 3 SGTASNTTVAADRSN 17  
:|||||: || |||

Db 216 TGSASSTAAAGRSN 230

## RESULT 14

Q9H9U0 PRELIMINARY; PRT: 287 AA.  
AC Q9H9U0;  
DT 01-MAR-2001 (TREMBlrel. 16, Created)  
DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)  
DT 01-MAR-2001 (TREMBlrel. 16, Last annotation update)  
DE CDNA FLJ12550 FIS, CLONE NT2RM4000698.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Isogai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,  
RA Nishikawa T., Nagai K., Sugano S., Shiratori A., Sudo H.,  
RA Wagatsuma M., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,  
RA Takahashi M., Chiba Y., Ishida S., Murakawa K., Ono Y., Takiguchi S.,  
RA Watanabe S., Kimura K., Murakami K., Ishii S., Kawai Y., Saito K.,  
RA Yamamoto J., Wakamatsu A., Nakamura Y., Nagahari K., Masuho Y.,  
RA Ninomiya K., Iwayanagi T.;  
RT "NEDO human cDNA sequencing project."  
RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AK022612; BAB14131.1; -  
SQ SEQUENCE 287 AA; 31637 MW; 66A71B40BFC53F77 CRC64;

Query Match 50.6%; Score 43; DB 4; Length 287;

Best Local Similarity 50.0%; Pred. No. 35;  
Matches 8; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAADRS 16  
:|||||: || |||

Db 207 CAPGTSSQFSAGADRA 222

## RESULT 15

Q9H650 PRELIMINARY; PRT: 375 AA.  
AC Q9H650;  
DT 01-MAR-2001 (TREMBlrel. 16, Created)  
DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)  
DT 01-JUN-2001 (TREMBlrel. 17, Last annotation update)  
DE CDNA: FLJ22607 FIS, CLONE HSI04846.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=HUMAN SMALL INTESTINE;  
RA Watanabe K., Kumagai A., Itakura S., Yamazaki M., Tashiro H., Ota T.,  
RA Suzuki Y., Obayashi M., Nishi T., Shibahara T., Tanaka T.,  
RA Nakamura Y., Isogai T., Sugano S.;  
RT "NEDO human cDNA sequencing project."  
RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AK026260; BAB15416.1; -  
DR InterPro; IPR003323; OTU.  
DR Pfam; PF02338; OTU; 1.  
DR PROSITE; PS50802; OTU; 1.  
SQ SEQUENCE 375 AA; 42440 MW; 911A1020341BC66E CRC64;

Query Match 50.6%; Score 43; DB 4; Length 376;  
Best Local Similarity 50.0%; Pred. No. 44;  
Matches 8; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAADRS 16  
:|||||: || |||

Db 296 CAPGTSSQFSAGADRA 311

Search completed: March 26, 2002, 13:40:13  
Job time: 227 sec





GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

# OM protein - protein search, using sw model

Run on: March 26, 2002, 13:38:47 ; Search time 81.51 Seconds  
(without alignments)  
12.723 Million cell updates/sec

Title: US-09-709-201-100

Perfect score: 77

Sequence: 1 CIGLAGTDFANQRP 14

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

## Database :

A\_Geneseq\_1101.\*  
1: /SID88/gcgdata/geneseq/geneseq/AA1980.DAT.\*  
2: /SID88/gcgdata/geneseq/geneseq/AA1981.DAT.\*  
3: /SID88/gcgdata/geneseq/geneseq/AA1982.DAT.\*  
4: /SID88/gcgdata/geneseq/geneseq/AA1983.DAT.\*  
5: /SID88/gcgdata/geneseq/geneseq/AA1984.DAT.\*  
6: /SID88/gcgdata/geneseq/geneseq/AA1985.DAT.\*  
7: /SID88/gcgdata/geneseq/geneseq/AA1986.DAT.\*  
8: /SID88/gcgdata/geneseq/geneseq/AA1987.DAT.\*  
9: /SID88/gcgdata/geneseq/geneseq/AA1988.DAT.\*  
10: /SID88/gcgdata/geneseq/geneseq/AA1989.DAT.\*  
11: /SID88/gcgdata/geneseq/geneseq/AA1990.DAT.\*  
12: /SID88/gcgdata/geneseq/geneseq/AA1991.DAT.\*  
13: /SID88/gcgdata/geneseq/geneseq/AA1992.DAT.\*  
14: /SID88/gcgdata/geneseq/geneseq/AA1993.DAT.\*  
15: /SID88/gcgdata/geneseq/geneseq/AA1994.DAT.\*  
16: /SID88/gcgdata/geneseq/geneseq/AA1995.DAT.\*  
17: /SID88/gcgdata/geneseq/geneseq/AA1996.DAT.\*  
18: /SID88/gcgdata/geneseq/geneseq/AA1997.DAT.\*  
19: /SID88/gcgdata/geneseq/geneseq/AA1998.DAT.\*  
20: /SID88/gcgdata/geneseq/geneseq/AA1999.DAT.\*  
21: /SID88/gcgdata/geneseq/geneseq/AA2000.DAT.\*  
22: /SID88/gcgdata/geneseq/geneseq/AA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	77	100.0	14	20	AAW95327
2	41	53.2	112	20	AA148247
3	40	51.9	98	11	AAW06602
4	40	51.9	1096	21	AA192323
5	39	50.6	16	7	AA161750
6	39	50.6	99	16	AAW85208
7	39	50.6	126	17	AAW95230
8	39	50.6	201	17	AAW95232
9	39	50.6	320	21	AAW44529
10	39	50.6	348	21	AAW44528
11	39	50.6	351	21	AAW44527

12	39	50.6	355	21	AAV53884	A suppressor of cy
13	39	50.6	462	19	AAW73012	Cobra venom protea
14	39	50.6	496	22	AAW06222	Booroola sheep mut
15	39	50.6	502	13	AAW55374	Mouse Activin rece
16	39	50.6	502	16	AAW70238	Bone morphogenic p
17	39	50.6	502	16	AAW85209	Mouse ALK-6. Mus
18	39	50.6	502	17	AAW95226	Chick BMP type I r
19	39	50.6	502	17	AAW96202	Bone morphogenetic
20	39	50.6	502	20	AAV33307	Human ALK-6 clone
21	39	50.6	502	20	AAW86249	Mouse BMP receptor
22	39	50.6	502	22	AAW06221	Wild-type sheep BM
23	39	50.6	502	22	AAW06225	Human BMP1B recept
24	39	50.6	521	19	AAW73010	Cobra venom protea
25	39	50.6	592	19	AAW73011	Cobra venom protea
26	38	49.4	277	21	AAW10705	Arabidopsis thalia
27	38	49.4	290	21	AAW34779	Arabidopsis thalia
28	38	49.4	352	21	AAW10704	Arabidopsis thalia
29	38	49.4	356	21	AAW10703	Arabidopsis thalia
30	38	49.4	365	22	AAW01908	Arabidopsis thalia
31	38	49.4	365	21	AAW34778	Arabidopsis thalia
32	38	49.4	369	21	AAW34777	Arabidopsis thalia
33	37.5	48.7	288	18	AAW21776	Protein encoded by
34	37	48.1	135	18	AAW27804	Staphylococcus aur
35	36.5	47.4	319	10	AAW91951	Polypeptide with l
36	36.5	47.4	319	17	AAW09624	Pseudomonas glumae
37	36.5	47.4	319	17	AAW09625	Pseudomonas glumae
38	36.5	47.4	319	17	AAW88018	Mature Pseudomonas
39	36.5	47.4	319	17	AAW88010	Mature Pseudomonas
40	36.5	47.4	319	17	AAW88011	Mature Pseudomonas
41	36.5	47.4	319	17	AAW88012	Mature Pseudomonas
42	36.5	47.4	319	17	AAW88013	Mature Pseudomonas
43	36.5	47.4	319	17	AAW88014	Mature Pseudomonas
44	36.5	47.4	319	17	AAW88015	Mature Pseudomonas
45	36.5	47.4	319	17	AAW88016	Mature Pseudomonas

## ALIGNMENTS

### RESULT 1

AAW95327  
ID AAW95327 standard; Protein; 14 AA.  
XX  
AC AAW95327;  
XX  
DT 15-MAR-1999 (first entry)  
XX  
DE Peptide fragment of C. psittaci CPS160-172.  
XX  
KW Chlamydia: cryptic phase; elementary body phase; replicating; probenidicid;  
KW antiporphyrin acid; immune response; infection; diagnostic; assay; WOMP;  
KW major outer membrane protein; autolysins; inflammatory; porphyria;  
KW Epstein Barr virus; antioxidant.  
XX  
OS Chlamydia psittaci.  
XX  
PN WO9850074-A2.  
XX  
PD 12-NOV-1998.  
XX  
PF 06-MAY-1998; 98WO-US09237.  
XX  
PR 18-FEB-1998; 98US-0025521.  
PR 06-MAY-1997; 97US-0045689.  
PR 06-MAY-1997; 97US-0045739.  
PR 06-MAY-1997; 97US-0045779.  
PR 06-MAY-1997; 97US-0045780.  
PR 06-MAY-1997; 97US-0045784.  
PR 06-MAY-1997; 97US-0045787.  
PR 14-AUG-1997; 97US-0911593.  
PR 18-FEB-1998; 98US-0025174.  
PR 18-FEB-1998; 98US-0025176.  
XX



DR WPI; 1990-269480/36.  
 DR N-PSDB; AAQ05835.  
 XX  
 PT New DNA sequence for cytochrome C-552 of Hydrogenobacter  
 PT thermophilus - and heterologous recombinant expression systems,  
 PT useful e.g. for treating myocardial infarction and reducing  
 PT mutagenicity of foods  
 XX  
 XX Claim 1; Page 10; 25pp; English.  
 XX  
 CC The amino acid sequence of C-552 has been reported and from this  
 CC information oligonucleotides were synthesised (See AAQ06573-76).  
 CC The probes were used to isolate a 2.5 kb fragment from a  
 CC H. thermophilus digest. The C-552 gene was further localised  
 CC to a 1.1 kb fragment and this was subcloned in pUC14, forming  
 CC pHTC 135, and then sequenced. The sequence was inserted into a  
 CC yeast expression vector, and the recombinants used to transform  
 CC the yeast strain X8-39-2delta Cycl (deficient in iso-1  
 CC cytochrome C so unable to use lactic acid). The gene may also be  
 CC incorporated into E. coli.  
 CC The gene product is expected to be useful in treatment of  
 CC myocardial infarction and cerebrovascular diseases, and, compared  
 CC with equine cytochrome C, has lower mol. wt. and better stability.  
 CC It can also be used to reduce mutagenicity of food prods.  
 XX  
 XX Sequence 98 AA;  
 SQ  
 Query Match 51.9%; Score 40; DB 11; Length 98;  
 Best Local Similarity 58.3%; Pred. No. 3.9;  
 Matches 7; Conservative 3; Mismatches 2; Indels 0; Gaps 0;  
 QY 2 IGLAGTDFANOR 13  
 :||||| |||:  
 Db 10 vglagitfaneq 21  
 RESULT 4  
 AAY92323  
 ID AAY92323 standard; Protein; 1096 AA.  
 AC AAY92323;  
 XX  
 XX 10-AUG-2000 (first entry)  
 XX  
 XX Human alpha-2-delta-D polypeptide from splice variant 1.  
 XX  
 KW alpha-2-delta-D; calcium channel; 12p13.3; gabapentin; cytostatic;  
 KW anticonvulsant; antimigrane; antiparkinsonian; antidepressant;  
 KW splice variant.  
 XX  
 XX Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 310  
 FT /note= "encoded by RTT"  
 XX  
 XX WO200020450-A2.  
 XX  
 PD 13-APR-2000.  
 XX  
 XX 07-OCT-1999; 99WO-US23519.  
 XX  
 PR 07-OCT-1998; 98US-0103322.  
 PR 30-OCT-1998; 98US-0106473.  
 PR 29-DEC-1998; 98US-0114088.  
 XX  
 XX (WARN ) WARNER LAMBERT CO.  
 PA  
 XX Johns MA, Moldover B, Offord JD;  
 PI  
 XX WPI; 2000-303744/26.  
 DR  
 DR N-PSDB; AAA09278.

XX New human nucleic acids encoding the alpha2delta-C and alpha2delta-D  
 PT proteins, useful in the treatment of epilepsy, migraine, chronic pain,  
 PT anxiety, multiple sclerosis or cancer  
 XX  
 PS Example 3; Page 84; 88pp; English.  
 XX  
 CC The alpha-2-delta-D gene encodes a calcium channel subunit polypeptide.  
 CC The gene has been mapped to chromosome 12p13.1. This gene and the related  
 CC alpha-2-delta-C and -B genes are useful for protecting mammalian cells  
 CC from abnormal calcium flux by introducing expression vectors containing  
 CC the respective gene into mammalian cells. The antisense genes are also  
 CC useful for treating or preventing epilepsy. The alpha-delta-2-A protein  
 CC is a high-affinity binding target of the anti-convulsant drug gabapentin.  
 CC Therefore, alpha-delta-2 proteins may also be targeted to treat  
 CC seizure-related syndromes, migraine, ataxia, vestibular defects, chronic  
 CC pain, sleep interference, anxiety, amyotrophic lateral sclerosis (ALS),  
 CC multiple sclerosis, mania, tremor, parkinsonism, substance abuse or  
 CC addiction syndromes, mood, depression or cancer.  
 XX  
 SQ Sequence 1096 AA;  
 Query Match 51.9%; Score 40; DB 21; Length 1096;  
 Best Local Similarity 50.0%; Pred. No. 50;  
 Matches 7; Conservative 1; Mismatches 6; Indels 0; Gaps 0;  
 QY 1 CIGLAGTDFANORP 14  
 :|:||||| |||  
 Db 1013 clplggtllnqsp 1026  
 RESULT 5  
 AAP61750  
 ID AAP61750 standard; Protein; 16 AA.  
 XX  
 AC AAP61750;  
 XX  
 XX 11-JUL-1991 (first entry)  
 XX  
 XX Plasmid pSYC720 encoded penP mature protein fragment.  
 DE Large exopenicillinase; protein secretion.  
 KW  
 XX Bacillus licheniformis.  
 OS  
 PN ES8506800-A.  
 XX  
 XX 16-NOV-1985.  
 XX  
 XX 08-MAR-1984; 84ES-0530399.  
 XX  
 PR 02-MAR-1984; 84US-0583472.  
 PR 09-MAR-1983; 83US-0473820.  
 PR 22-AUG-1982; 89US-0407701.  
 XX  
 PA (CETU ) CETUS CORP.  
 XX  
 PI Shing C;  
 XX  
 DR WPI; 1986-057082/09.  
 DR N-PSDB; AAN60990.  
 XX  
 XX Recombinant plasmid vector prodn. - by combining single chain DNA  
 PT fragments of different lengths.  
 XX  
 PS Disclosure; Fig 6; 26pp; English.  
 XX  
 CC By removing the Cys residue from the gene product, the membrane  
 CC binding ability of the secretion signal is interfered with, whilst  
 CC the transport signal remains active. Thus the secretion of a  
 CC desired protein may be facilitated at increased levels by  
 CC attachment of the signal in a suitable host.

XX Sequence 16 AA;  
SQ

Query Match 50.6%; Score 39; DB 7; Length 16;  
Best Local Similarity 46.2%; Pred. No. 0.8;  
Matches 6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;  
QY 1 CIGLAGTDFANQR 13  
I: |||: ||: |  
Db 1 cvalagsafsnq 13

## RESULT 6

AAR85208  
ID -AAR85208 standard; Protein; 99 AA.

XX AC  
XX AAR85208;

DT 13-FEB-1996 (first entry)

XX Mouse ALK-6 extracellular domain.

DE ALK-3; OPI binding receptor; osteogenic protein 1; morphogenesis;  
KW morphogen; agonist; antagonist.

XX OS  
XX Mus sp.

XX WO9530003-A2.

PN 09-NOV-1995.

XX 28-APR-1995; 95WO-US05467.

XX 29-APR-1994; 94US-0236428.

XX (CREA-) CREATIVE BIOMOLECULES INC.  
PA (LUDW-) LUDWIG INST CANCER RES.

XX DiJke PT, Heldin C, Miyazano K, Sampath KT;

XX WPI; 1995-393076/50.

DR N-PSDB; AAT06032.

XX Identifying osteogenic protein-1 receptor-binding analogue - useful  
PT in the design of morphogen agonists and antagonists for therapeutic,  
PT diagnostic and experimental purposes

XX Claim 1; Page 73-74; 95pp; English.

XX The Type-I cell surface receptors ALK-2, ALK-3 and ALK-6 (given in  
CC AAR85206, AAR85207 and AAR85209) have specific binding affinity for  
CC osteogenic protein 1 (OPI) and OPI-related analogues. The  
CC receptors, and the extracellular domain of ALK-6 (AAR85208), are used  
CC to identify novel morphogen receptor binding analogues useful in  
CC drug design.

XX Sequence 99 AA;

Query Match 50.6%; Score 39; DB 16; Length 99;  
Best Local Similarity 66.7%; Pred. No. 6.2;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
I: ||| ||: ||  
Db 48 clglegsdf 56

## RESULT 7

AAR95230  
ID -AAR95230 standard; Protein; 126 AA.

XX

AC AAR95230;

XX 31-DEC-1996 (first entry)

XX Chick soluble BMP type I receptor kinase protein (BRK-2).

XX BMP type II receptor kinase-3; BRK-3; bone morphogenetic protein;  
KW BMP type I receptor kinase; BRK-2; BMP receptor.

XX Gallus sp.

XX WO9614579-A1.

XX 17-MAY-1996.

XX 30-OCT-1995; 95WO-US14027.

XX 05-JUN-1995; 95US-0462467.

XX 04-NOV-1994; 94US-0334178.

XX (PROC ) PROCTER & GAMBLE CO.

XX Rosenbaum JS;

XX WPI; 1996-251887/25.

DR N-PSDB; AAT28026.

XX Assays for bone morphogenetic protein activities - using complex of  
PT BMP type I receptor kinase protein and BMP receptor kinase protein  
PT BRK-3

XX Claim 9; Page 73-74; 101pp; English.

XX Chick soluble bone morphogenetic protein (BMP) type I receptor  
CC kinase protein-2 (BRK-2) (AAR95230) lacks the regions of the full-  
CC length receptor (AAR95226) not required for BMP binding. A BMP  
CC receptor kinase protein complex formed of full-length, incomplete  
CC or soluble BMP type I receptor kinase protein and full-length,  
CC incomplete or soluble BMP type II receptor kinase-3 (BRK-3) (see  
CC also AAR95222-29 and AAR95231-34) is useful for screening cpds. for BMP  
CC receptor affinity or for determining the concentration of a BMP  
CC receptor ligand in a clinical sample. The complex can be expressed  
CC by host cells co-transfected with vectors carrying the appropriate  
CC DNA sequences (see also AAT28018-30).

XX Sequence 126 AA;

Query Match 50.6%; Score 39; DB 17; Length 126;  
Best Local Similarity 66.7%; Pred. No. 8.2;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
I: ||| ||: ||  
Db 71 clglegsdf 79

## RESULT 8

AAR95232  
ID -AAR95232 standard; Protein; 201 AA.

XX AAR95232;

XX 31-DEC-1996 (first entry)

XX Chick incomplete BMP type I receptor kinase protein (BRK-2).

XX BMP type II receptor kinase-3; BRK-3; bone morphogenetic protein;  
KW BMP type I receptor kinase; BRK-2; BMP receptor.

XX Gallus sp.

XX WO9614579-A1.

XX 17-MAY-1996.  
 PD 30-OCT-1995; 95WO-US14027.  
 PF 05-JUN-1995; 95US-0462467.  
 XX 04-NOV-1994; 94US-0334178.  
 XX (PROC ) PROCTER & GAMBLE CO.  
 PA Rosenbaum JS;  
 XX WPI; 1996-251887/25.  
 PI N-PSDB; AAT28028.  
 DR Assays for bone morphogenetic protein activities - using complex of  
 PT BMP type I receptor kinase protein and BMP receptor kinase protein  
 PT BRK-3  
 XX Disclosure; Page 77; 101pp; English.  
 XX Chick incomplete bone morphogenetic protein (BMP) type I receptor  
 CC kinase protein-1 (BRK-1) (AAR95232) lacks the intracellular kinase  
 CC domain of the full-length receptor (AAR95226) and is incapable of  
 CC signal transduction. A BMP receptor kinase protein complex formed  
 CC of full-length, incomplete or soluble BMP type I receptor kinase  
 CC protein and full-length, incomplete or soluble BMP type II receptor  
 CC kinase-3 (BRK-3) (see also AAR95222-31 and AAR95233-34) is useful for  
 CC screening cpds. for BMP receptor affinity or for determining the  
 CC concentration of a BMP receptor ligand in a clinical sample. The  
 CC complex can be expressed by host cells co-transfected with vectors  
 CC carrying the appropriate DNA sequences (see also AAT28018-30).  
 XX Sequence 201 AA;  
 SQ

Query Match 50.6%; Score 39; DB 17; Length 201;  
 Best Local Similarity 66.7%; Pred. No. 14;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
 :|||:|:  
 Db 71 clglegsdff 79

RESULT 9  
 AAG44529  
 ID AAG44529 standard; Protein: 320 AA.  
 XX AAG44529;  
 AC 18-OCT-2000 (first entry)  
 XX  
 DT Arabidopsis thaliana protein fragment SEQ ID NO: 55790.  
 XX  
 DE Protein identification; signal transduction pathway; metabolic pathway;  
 KW hybridisation assay; genetic mapping; gene expression control; promoter;  
 KW termination sequence.  
 XX Arabidopsis thaliana.  
 OS EP1033405-A2.  
 XX  
 PN 06-SEP-2000.  
 PD  
 XX 25-FEB-2000; 2000EP-0301439.  
 PF  
 XX 25-FEB-1999; 99US-0121825.  
 PR 05-MAR-1999; 99US-0123180.  
 PR 09-MAR-1999; 99US-0123548.  
 PR 23-MAR-1999; 99US-0125788.  
 PR 25-MAR-1999; 99US-0126264.  
 PR 29-MAR-1999; 99US-0126785.

PR 01-APR-1999; 99US-0127462.  
 PR 06-APR-1999; 99US-0128234.  
 PR 08-APR-1999; 99US-0128714.  
 PR 16-APR-1999; 99US-0129845.  
 PR 19-APR-1999; 99US-0130077.  
 PR 21-APR-1999; 99US-0130449.  
 PR 23-APR-1999; 99US-0130510.  
 PR 23-APR-1999; 99US-0130891.  
 PR 28-APR-1999; 99US-0131449.  
 PR 30-APR-1999; 99US-0132048.  
 PR 30-APR-1999; 99US-0132407.  
 PR 04-MAY-1999; 99US-0132484.  
 PR 05-MAY-1999; 99US-0132485.  
 PR 06-MAY-1999; 99US-0132486.  
 PR 06-MAY-1999; 99US-0132487.  
 PR 07-MAY-1999; 99US-0132863.  
 PR 11-MAY-1999; 99US-0134256.  
 PR 14-MAY-1999; 99US-0134218.  
 PR 14-MAY-1999; 99US-0134219.  
 PR 14-MAY-1999; 99US-0134221.  
 PR 14-MAY-1999; 99US-0134370.  
 PR 18-MAY-1999; 99US-0134768.  
 PR 19-MAY-1999; 99US-0134941.  
 PR 20-MAY-1999; 99US-0135124.  
 PR 21-MAY-1999; 99US-0135353.  
 PR 24-MAY-1999; 99US-0135629.  
 PR 25-MAY-1999; 99US-0136021.  
 PR 27-MAY-1999; 99US-0136392.  
 PR 28-MAY-1999; 99US-0136782.  
 PR 01-JUN-1999; 99US-0137222.  
 PR 03-JUN-1999; 99US-0137528.  
 PR 04-JUN-1999; 99US-0137502.  
 PR 07-JUN-1999; 99US-0137724.  
 PR 08-JUN-1999; 99US-0138094.  
 PR 10-JUN-1999; 99US-0138540.  
 PR 10-JUN-1999; 99US-0138847.  
 PR 14-JUN-1999; 99US-0139119.  
 PR 16-JUN-1999; 99US-0139452.  
 PR 16-JUN-1999; 99US-0139453.  
 PR 17-JUN-1999; 99US-0139492.  
 PR 18-JUN-1999; 99US-0139454.  
 PR 18-JUN-1999; 99US-0139455.  
 PR 18-JUN-1999; 99US-0139456.  
 PR 18-JUN-1999; 99US-0139457.  
 PR 18-JUN-1999; 99US-0139458.  
 PR 18-JUN-1999; 99US-0139459.  
 PR 18-JUN-1999; 99US-0139460.  
 PR 18-JUN-1999; 99US-0139461.  
 PR 18-JUN-1999; 99US-0139462.  
 PR 18-JUN-1999; 99US-0139463.  
 PR 18-JUN-1999; 99US-0139750.  
 PR 18-JUN-1999; 99US-0139763.  
 PR 21-JUN-1999; 99US-0139817.  
 PR 22-JUN-1999; 99US-0139899.  
 PR 23-JUN-1999; 99US-0140353.  
 PR 23-JUN-1999; 99US-0140354.  
 PR 24-JUN-1999; 99US-0140595.  
 PR 28-JUN-1999; 99US-0140823.  
 PR 29-JUN-1999; 99US-0140991.  
 PR 30-JUN-1999; 99US-0141287.  
 PR 01-JUL-1999; 99US-0141842.  
 PR 01-JUL-1999; 99US-0142154.  
 PR 02-JUL-1999; 99US-0142055.  
 PR 06-JUL-1999; 99US-0142390.  
 PR 08-JUL-1999; 99US-0142803.  
 PR 09-JUL-1999; 99US-0142920.  
 PR 12-JUL-1999; 99US-0142977.  
 PR 13-JUL-1999; 99US-0143542.  
 PR 14-JUL-1999; 99US-0143824.  
 PR 15-JUL-1999; 99US-0144005.  
 PR 16-JUL-1999; 99US-0144085.  
 PR 16-JUL-1999; 99US-0144086.  
 PR 19-JUL-1999; 99US-0144325.

PR 19-JUL-1999; 99US-0144331.  
PR 19-JUL-1999; 99US-0144332.  
PR 19-JUL-1999; 99US-0144333.  
PR 19-JUL-1999; 99US-0144334.  
PR 19-JUL-1999; 99US-0144335.  
PR 20-JUL-1999; 99US-0144352.  
PR 20-JUL-1999; 99US-0144632.  
PR 20-JUL-1999; 99US-0144884.  
PR 21-JUL-1999; 99US-0144814.  
PR 21-JUL-1999; 99US-0145086.  
PR 21-JUL-1999; 99US-0145088.  
PR 22-JUL-1999; 99US-0145085.  
PR 22-JUL-1999; 99US-0145087.  
PR 22-JUL-1999; 99US-0145089.  
PR 22-JUL-1999; 99US-0145192.  
PR 23-JUL-1999; 99US-0145145.  
PR 23-JUL-1999; 99US-0145218.  
PR 23-JUL-1999; 99US-0145224.  
PR 26-JUL-1999; 99US-0145276.  
PR 27-JUL-1999; 99US-0145913.  
PR 27-JUL-1999; 99US-0145918.  
PR 27-JUL-1999; 99US-0145919.  
PR 28-JUL-1999; 99US-0145951.  
PR 02-AUG-1999; 99US-0146386.  
PR 02-AUG-1999; 99US-0146388.  
PR 02-AUG-1999; 99US-0146389.  
PR 03-AUG-1999; 99US-0147038.  
PR 04-AUG-1999; 99US-0147204.  
PR 04-AUG-1999; 99US-0147302.  
PR 05-AUG-1999; 99US-0147192.  
PR 05-AUG-1999; 99US-0147260.  
PR 06-AUG-1999; 99US-0147303.  
PR 06-AUG-1999; 99US-0147416.  
PR 06-AUG-1999; 99US-0147493.  
PR 08-AUG-1999; 99US-0147935.  
PR 10-AUG-1999; 99US-0148171.  
PR 11-AUG-1999; 99US-0148319.  
PR 12-AUG-1999; 99US-0148341.  
PR 13-AUG-1999; 99US-0148565.  
PR 13-AUG-1999; 99US-0148584.  
PR 16-AUG-1999; 99US-0149368.  
PR 17-AUG-1999; 99US-0149175.  
PR 18-AUG-1999; 99US-0149426.  
PR 20-AUG-1999; 99US-0149722.  
PR 20-AUG-1999; 99US-0149723.  
PR 20-AUG-1999; 99US-0149929.  
PR 23-AUG-1999; 99US-0149902.  
PR 23-AUG-1999; 99US-0149930.  
PR 23-AUG-1999; 99US-0150566.  
PR 26-AUG-1999; 99US-0150884.  
PR 27-AUG-1999; 99US-0151065.  
PR 27-AUG-1999; 99US-0151066.  
PR 27-AUG-1999; 99US-0151080.  
PR 30-AUG-1999; 99US-0151303.  
PR 31-AUG-1999; 99US-0151438.  
PR 01-SEP-1999; 99US-0151930.  
PR 07-SEP-1999; 99US-0152363.  
PR 10-SEP-1999; 99US-0153070.  
PR 13-SEP-1999; 99US-0153758.  
PR 15-SEP-1999; 99US-0154018.  
PR 16-SEP-1999; 99US-0154039.  
PR 20-SEP-1999; 99US-0154779.  
PR 22-SEP-1999; 99US-0155139.  
PR 23-SEP-1999; 99US-0155486.  
PR 24-SEP-1999; 99US-0155659.  
PR 28-SEP-1999; 99US-0156458.  
PR 29-SEP-1999; 99US-0156596.  
PR 01-OCT-1999; 99US-0157117.  
PR 05-OCT-1999; 99US-0157753.  
PR 06-OCT-1999; 99US-0157865.  
PR 07-OCT-1999; 99US-0158029.  
PR 08-OCT-1999; 99US-0158232.  
PR 12-OCT-1999; 99US-0158369.

PR 13-OCT-1999; 99US-0159293.  
PR 13-OCT-1999; 99US-0159294.  
PR 13-OCT-1999; 99US-0159295.  
PR 14-OCT-1999; 99US-0159329.  
PR 14-OCT-1999; 99US-0159330.  
PR 14-OCT-1999; 99US-0159331.  
PR 14-OCT-1999; 99US-0159637.  
PR 14-OCT-1999; 99US-0159638.  
PR 18-OCT-1999; 99US-0159584.  
PR 21-OCT-1999; 99US-0160741.  
PR 21-OCT-1999; 99US-0160767.  
PR 21-OCT-1999; 99US-0160768.  
PR 21-OCT-1999; 99US-0160770.  
PR 21-OCT-1999; 99US-0160814.  
PR 21-OCT-1999; 99US-0160815.  
PR 22-OCT-1999; 99US-0160980.  
PR 22-OCT-1999; 99US-0160981.  
PR 22-OCT-1999; 99US-0160989.  
PR 25-OCT-1999; 99US-0161404.  
PR 25-OCT-1999; 99US-0161405.  
PR 25-OCT-1999; 99US-0161406.  
PR 26-OCT-1999; 99US-0161359.  
PR 26-OCT-1999; 99US-0161360.  
PR 26-OCT-1999; 99US-0161361.  
PR 28-OCT-1999; 99US-0161920.  
PR 28-OCT-1999; 99US-0161992.  
PR 28-OCT-1999; 99US-0161993.  
PR 29-OCT-1999; 99US-0162142.

Query Match 50.6%; Score 39; DB 21; Length 320;  
Best Local Similarity 77.8%; Pred. No. 23;  
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GTDFANORP 14  
| | | | |  
Db 27 grdfndrp 35

## RESULT 10

AAG44528  
ID AAG44528 standard; Protein: 348 AA.

XX AAG44528;

XX 18-OCT-2000 (first entry)

DE Arabidopsis thaliana protein fragment SEQ ID NO: 55789.

XX Protein identification; signal transduction pathway; metabolic pathway;  
KW hybridisation assay; genetic mapping; gene expression control; promoter;  
KW termination sequence.

XX Arabidopsis thaliana.

XX EP1033405-A2.

XX 06-SEP-2000.

XX 25-FEB-2000; 2000EP-0301439.

XX 25-FEB-1999; 99US-0121825.

XX 05-MAR-1999; 99US-0123180.

XX 09-MAR-1999; 99US-0123548.

XX 23-MAR-1999; 99US-0125788.

XX 25-MAR-1999; 99US-0126264.

XX 29-MAR-1999; 99US-0126785.

XX 01-APR-1999; 99US-0127462.

XX 08-APR-1999; 99US-0128234.

XX 16-APR-1999; 99US-0129845.

XX 19-APR-1999; 99US-0130077.

XX 21-APR-1999; 99US-0130449.

XX 23-APR-1999; 99US-0130510.

PR 23-APR-1999;	99US-0130891.	PR 20-JUL-1999;	99US-0144884.
PR 28-APR-1999;	99US-0131449.	PR 21-JUL-1999;	99US-0144814.
PR 30-APR-1999;	99US-0132048.	PR 21-JUL-1999;	99US-0145086.
PR 30-APR-1999;	99US-0132407.	PR 21-JUL-1999;	99US-0145088.
PR 04-MAY-1999;	99US-0132484.	PR 22-JUL-1999;	99US-0145085.
PR 05-MAY-1999;	99US-0132485.	PR 22-JUL-1999;	99US-0145087.
PR 06-MAY-1999;	99US-0132486.	PR 22-JUL-1999;	99US-0145089.
PR 06-MAY-1999;	99US-0132487.	PR 22-JUL-1999;	99US-0145192.
PR 07-MAY-1999;	99US-0132863.	PR 23-JUL-1999;	99US-0145145.
PR 11-MAY-1999;	99US-0134256.	PR 23-JUL-1999;	99US-0145218.
PR 14-MAY-1999;	99US-0134218.	PR 23-JUL-1999;	99US-0145224.
PR 14-MAY-1999;	99US-0134219.	PR 26-JUL-1999;	99US-0145276.
PR 14-MAY-1999;	99US-0134221.	PR 27-JUL-1999;	99US-0145913.
PR 14-MAY-1999;	99US-0134370.	PR 27-JUL-1999;	99US-0145918.
PR 18-MAY-1999;	99US-0134768.	PR 27-JUL-1999;	99US-0145919.
PR 19-MAY-1999;	99US-0134941.	PR 28-JUL-1999;	99US-0145951.
PR 20-MAY-1999;	99US-0135124.	PR 02-AUG-1999;	99US-0146386.
PR 21-MAY-1999;	99US-0135353.	PR 02-AUG-1999;	99US-0146388.
PR 24-MAY-1999;	99US-0135629.	PR 02-AUG-1999;	99US-0146389.
PR 25-MAY-1999;	99US-0136021.	PR 03-AUG-1999;	99US-0147038.
PR 27-MAY-1999;	99US-0136392.	PR 04-AUG-1999;	99US-0147204.
PR 28-MAY-1999;	99US-0136782.	PR 04-AUG-1999;	99US-0147302.
PR 01-JUN-1999;	99US-0137222.	PR 05-AUG-1999;	99US-0147192.
PR 03-JUN-1999;	99US-0137528.	PR 05-AUG-1999;	99US-0147260.
PR 04-JUN-1999;	99US-0137502.	PR 06-AUG-1999;	99US-0147303.
PR 07-JUN-1999;	99US-0137724.	PR 06-AUG-1999;	99US-0147416.
PR 08-JUN-1999;	99US-0138094.	PR 09-AUG-1999;	99US-0147493.
PR 10-JUN-1999;	99US-0138540.	PR 09-AUG-1999;	99US-0147935.
PR 10-JUN-1999;	99US-0138847.	PR 10-AUG-1999;	99US-0148171.
PR 14-JUN-1999;	99US-0139119.	PR 11-AUG-1999;	99US-0148319.
PR 16-JUN-1999;	99US-0139452.	PR 12-AUG-1999;	99US-0148341.
PR 16-JUN-1999;	99US-0139453.	PR 13-AUG-1999;	99US-0148565.
PR 17-JUN-1999;	99US-0139453.	PR 13-AUG-1999;	99US-0148684.
PR 18-JUN-1999;	99US-0139454.	PR 16-AUG-1999;	99US-0149368.
PR 18-JUN-1999;	99US-0139455.	PR 17-AUG-1999;	99US-0149175.
PR 18-JUN-1999;	99US-0139456.	PR 18-AUG-1999;	99US-0149426.
PR 18-JUN-1999;	99US-0139457.	PR 20-AUG-1999;	99US-0149722.
PR 18-JUN-1999;	99US-0139458.	PR 20-AUG-1999;	99US-0149723.
PR 18-JUN-1999;	99US-0139459.	PR 20-AUG-1999;	99US-0149929.
PR 18-JUN-1999;	99US-0139460.	PR 23-AUG-1999;	99US-0149902.
PR 18-JUN-1999;	99US-0139461.	PR 23-AUG-1999;	99US-0149930.
PR 18-JUN-1999;	99US-0139462.	PR 25-AUG-1999;	99US-0150566.
PR 18-JUN-1999;	99US-0139463.	PR 26-AUG-1999;	99US-0150884.
PR 18-JUN-1999;	99US-0139750.	PR 27-AUG-1999;	99US-0151065.
PR 18-JUN-1999;	99US-0139763.	PR 27-AUG-1999;	99US-0151066.
PR 24-JUN-1999;	99US-0139817.	PR 27-AUG-1999;	99US-0151080.
PR 22-JUN-1999;	99US-0139899.	PR 30-AUG-1999;	99US-0151303.
PR 23-JUN-1999;	99US-0140353.	PR 31-AUG-1999;	99US-0151438.
PR 23-JUN-1999;	99US-0140354.	PR 01-SEP-1999;	99US-0151930.
PR 24-JUN-1999;	99US-0140695.	PR 07-SEP-1999;	99US-0152363.
PR 28-JUN-1999;	99US-0140823.	PR 10-SEP-1999;	99US-0153070.
PR 29-JUN-1999;	99US-0140991.	PR 13-SEP-1999;	99US-0153758.
PR 30-JUN-1999;	99US-0141287.	PR 15-SEP-1999;	99US-0154018.
PR 01-JUL-1999;	99US-0141842.	PR 16-SEP-1999;	99US-0154039.
PR 01-JUL-1999;	99US-0142154.	PR 20-SEP-1999;	99US-0154779.
PR 02-JUL-1999;	99US-0142055.	PR 22-SEP-1999;	99US-0155139.
PR 06-JUL-1999;	99US-0142390.	PR 23-SEP-1999;	99US-0155486.
PR 08-JUL-1999;	99US-0142803.	PR 24-SEP-1999;	99US-0155659.
PR 09-JUL-1999;	99US-0142920.	PR 28-SEP-1999;	99US-0156458.
PR 12-JUL-1999;	99US-0142977.	PR 29-SEP-1999;	99US-0156596.
PR 13-JUL-1999;	99US-0143342.	PR 04-OCT-1999;	99US-0157117.
PR 14-JUL-1999;	99US-0143624.	PR 05-OCT-1999;	99US-0157753.
PR 15-JUL-1999;	99US-0144005.	PR 06-OCT-1999;	99US-0157865.
PR 16-JUL-1999;	99US-0144085.	PR 07-OCT-1999;	99US-0158029.
PR 16-JUL-1999;	99US-0144086.	PR 08-OCT-1999;	99US-0158232.
PR 19-JUL-1999;	99US-0144325.	PR 12-OCT-1999;	99US-0158369.
PR 19-JUL-1999;	99US-0144331.	PR 13-OCT-1999;	99US-0159293.
PR 19-JUL-1999;	99US-0144332.	PR 13-OCT-1999;	99US-0159294.
PR 19-JUL-1999;	99US-0144333.	PR 13-OCT-1999;	99US-0159295.
PR 19-JUL-1999;	99US-0144334.	PR 14-OCT-1999;	99US-0159329.
PR 19-JUL-1999;	99US-0144335.	PR 14-OCT-1999;	99US-0159330.
PR 20-JUL-1999;	99US-0144352.	PR 14-OCT-1999;	99US-0159331.
PR 20-JUL-1999;	99US-0144632.	PR 14-OCT-1999;	99US-0159637.

PR 14-OCT-1999; 99US-0159638.  
PR 18-OCT-1999; 99US-0159584.  
PR 21-OCT-1999; 99US-0160741.  
PR 21-OCT-1999; 99US-0160767.  
PR 21-OCT-1999; 99US-0160768.  
PR 21-OCT-1999; 99US-0160770.  
PR 21-OCT-1999; 99US-0160814.  
PR 21-OCT-1999; 99US-0160815.  
PR 22-OCT-1999; 99US-0160980.  
PR 22-OCT-1999; 99US-0160981.  
PR 22-OCT-1999; 99US-0160989.  
PR 25-OCT-1999; 99US-0161404.  
PR 25-OCT-1999; 99US-0161405.  
PR 25-OCT-1999; 99US-0161406.  
PR 26-OCT-1999; 99US-0161359.  
PR 26-OCT-1999; 99US-0161360.  
PR 26-OCT-1999; 99US-0161361.  
PR 28-OCT-1999; 99US-0161920.  
PR 28-OCT-1999; 99US-0161992.  
PR 28-OCT-1999; 99US-0161993.  
PR 29-OCT-1999; 99US-0162142.  
Query Match 50.6%; Score 39; DB 21; Length 348;  
Best Local Similarity 77.8%; Pred. No. 26;  
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 6 GTDFANQRP 14  
| | | | |  
Db 55 grdfingrp 63  
RESULT 11  
AAG44527  
ID AAG44527 standard; Protein; 351 AA.  
XX AC AAG44527;  
XX DT 18-OCT-2000 (first entry)  
XX DE Arabidopsis thaliana protein fragment SEQ ID NO: 55788.  
XX KW Protein identification; signal transduction pathway; metabolic pathway;  
KW hybridisation assay; genetic mapping; gene expression control; promoter;  
KW termination sequence.  
XX OS Arabidopsis thaliana.  
XX PN EP1033405-A2.  
XX PD 06-SEP-2000.  
XX PF 25-FEB-2000; 2000EP-0301439.  
XX PR 25-FEB-1999; 99US-0121825.  
PR 05-MAR-1999; 99US-0123180.  
PR 09-MAR-1999; 99US-0123548.  
PR 23-MAR-1999; 99US-0125788.  
PR 25-MAR-1999; 99US-0126264.  
PR 29-MAR-1999; 99US-0126785.  
PR 01-APR-1999; 99US-0127462.  
PR 06-APR-1999; 99US-0128234.  
PR 08-APR-1999; 99US-0128714.  
PR 16-APR-1999; 99US-0129845.  
PR 19-APR-1999; 99US-0130077.  
PR 21-APR-1999; 99US-0130449.  
PR 23-APR-1999; 99US-0130510.  
PR 28-APR-1999; 99US-0130891.  
PR 30-APR-1999; 99US-0131449.  
PR 30-APR-1999; 99US-0132048.  
PR 04-MAY-1999; 99US-0132407.  
PR 05-MAY-1999; 99US-0132484.  
PR 06-MAY-1999; 99US-0132485.  
PR 06-MAY-1999; 99US-0132486.  
PR 06-MAY-1999; 99US-0132487.  
PR 07-MAY-1999; 99US-0132487.  
PR 11-MAY-1999; 99US-0134256.  
PR 14-MAY-1999; 99US-0134218.  
PR 14-MAY-1999; 99US-0134219.  
PR 14-MAY-1999; 99US-0134221.  
PR 14-MAY-1999; 99US-0134370.  
PR 18-MAY-1999; 99US-0134768.  
PR 19-MAY-1999; 99US-0134941.  
PR 20-MAY-1999; 99US-0135124.  
PR 21-MAY-1999; 99US-0135353.  
PR 24-MAY-1999; 99US-0135629.  
PR 25-MAY-1999; 99US-0136021.  
PR 27-MAY-1999; 99US-0136392.  
PR 28-MAY-1999; 99US-0136782.  
PR 01-JUN-1999; 99US-0137222.  
PR 03-JUN-1999; 99US-0137528.  
PR 04-JUN-1999; 99US-0137502.  
PR 07-JUN-1999; 99US-0137724.  
PR 08-JUN-1999; 99US-0138094.  
PR 10-JUN-1999; 99US-0138540.  
PR 10-JUN-1999; 99US-0138847.  
PR 14-JUN-1999; 99US-0139119.  
PR 16-JUN-1999; 99US-0139452.  
PR 16-JUN-1999; 99US-0139453.  
PR 17-JUN-1999; 99US-0139492.  
PR 18-JUN-1999; 99US-0139454.  
PR 18-JUN-1999; 99US-0139455.  
PR 18-JUN-1999; 99US-0139456.  
PR 18-JUN-1999; 99US-0139457.  
PR 18-JUN-1999; 99US-0139458.  
PR 18-JUN-1999; 99US-0139459.  
PR 18-JUN-1999; 99US-0139460.  
PR 18-JUN-1999; 99US-0139461.  
PR 18-JUN-1999; 99US-0139462.  
PR 18-JUN-1999; 99US-0139463.  
PR 18-JUN-1999; 99US-0139750.  
PR 21-JUN-1999; 99US-0139763.  
PR 21-JUN-1999; 99US-0139817.  
PR 23-JUN-1999; 99US-0139899.  
PR 23-JUN-1999; 99US-0140353.  
PR 23-JUN-1999; 99US-0140354.  
PR 24-JUN-1999; 99US-0140695.  
PR 28-JUN-1999; 99US-0140823.  
PR 29-JUN-1999; 99US-0140991.  
PR 30-JUN-1999; 99US-0141287.  
PR 01-JUL-1999; 99US-0141842.  
PR 01-JUL-1999; 99US-0142154.  
PR 02-JUL-1999; 99US-0142055.  
PR 06-JUL-1999; 99US-0142390.  
PR 08-JUL-1999; 99US-0142803.  
PR 09-JUL-1999; 99US-0142920.  
PR 12-JUL-1999; 99US-0142977.  
PR 13-JUL-1999; 99US-0143542.  
PR 14-JUL-1999; 99US-0143624.  
PR 15-JUL-1999; 99US-0144005.  
PR 16-JUL-1999; 99US-0144085.  
PR 16-JUL-1999; 99US-0144086.  
PR 19-JUL-1999; 99US-0144325.  
PR 19-JUL-1999; 99US-0144331.  
PR 19-JUL-1999; 99US-0144332.  
PR 19-JUL-1999; 99US-0144333.  
PR 19-JUL-1999; 99US-0144334.  
PR 19-JUL-1999; 99US-0144335.  
PR 20-JUL-1999; 99US-0144352.  
PR 20-JUL-1999; 99US-0144632.  
PR 20-JUL-1999; 99US-0144884.  
PR 21-JUL-1999; 99US-0144814.  
PR 21-JUL-1999; 99US-0145086.  
PR 21-JUL-1999; 99US-0145088.  
PR 22-JUL-1999; 99US-0145085.  
PR 22-JUL-1999; 99US-0145087.  
PR 22-JUL-1999; 99US-0145089.



```

PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.

Query Match 50.6%; Score 39; DB 21; Length 351;
Best Local Similarity 77.8%; Pred. No. 26;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GTDFANQRP 14
   | | | | |
Db 58 grdfnqrp 66

RESULT 12
AAY53884
ID AAY53884 standard; Protein; 355 AA.
XX
AC AAY53884;
XX
DT 13-MAR-2000 (first entry)
XX
DE A suppressor of cytokine signalling protein designated HSCOP-4.
XX
KW Human; suppressor of cytokine signalling protein; SOCS protein; HSCOP;
KW cancer; leukaemia; lymphoma; diabetes mellitus; Crohn's disease;
KW immune disorder; AIDS; allergy; atherosclerosis; inflammatory disorder;
KW rheumatoid arthritis; irritable bowel syndrome; multiple sclerosis;
KW ulcerative colitis; neurological disorder; Down's syndrome; amnesia;
KW cerebral neoplasm; Huntington's disease; viral infection; adenovirus;
KW acute respiratory disease; toga virus; rubella.
XX
OS Homo sapiens.
XX
FH Key
FT Modified-site 44
FT Modified-site 46 /note= "potential phosphorylation site"
FT Modified-site 48 /note= "potential phosphorylation site"
FT Modified-site 48 /note= "potential phosphorylation site"
FT Modified-site 69 /note= "potential phosphorylation site"
FT Modified-site 102 /note= "potential phosphorylation site"
FT Modified-site 111 /note= "potential phosphorylation site"
FT Modified-site 126 /note= "potential glycosylation site"
FT Modified-site 171 /note= "potential phosphorylation site"
FT Modified-site 211 /note= "potential phosphorylation site"
FT Modified-site 264 /note= "potential phosphorylation site"
FT Modified-site 340 /note= "potential phosphorylation site"
FT Modified-site 342 /note= "potential phosphorylation site"
FT /note= "potential phosphorylation site"
XX W09961614-A2.
XX
PD 02-DEC-1999.
```

XX PF 25-MAY-1999; 99WO-US11497.  
 XX PR 28-MAY-1998; 98US-0087104.  
 XX PR 17-DEC-1998; 98US-0216006.  
 XX XX  
 XX PA (INCY-) INCYTE PHARM INC.  
 XX XX  
 XX PI Lal P, Hillman JL, Gorgone G, Corley NC, Patterson C, Yue H;  
 XX PI Tang YT, Azimzai Y;  
 XX XX  
 XX DR WPI: 2000-072621/06.  
 XX DR N-PSDB; AAZ36828.  
 XX XX  
 XX PT New purified polypeptide encoding human suppressor of cytokine  
 XX PT signalling (SOCS) proteins useful for diagnosing, treating or preventing  
 XX PT disorders associated with human SOCS proteins  
 XX XX  
 XX PS Claim 1; Page 75-76; 90pp; English.  
 XX XX  
 XX CC The present sequence represents a human suppressor of cytokine signalling  
 XX CC (SOCS) protein, designated HSCOP-4. The protein is useful for treating  
 XX CC and/or preventing a disorder associated with decreased expression or  
 XX CC activity of HSCOP. The protein antagonist is useful for treating and/or  
 XX CC preventing a disorder associated with increased expression or activity  
 XX CC of HSCOP. The human SOCS proteins and polynucleotides encoding them are  
 XX CC useful in the diagnosis, treatment and prevention of cancer such as  
 XX CC leukaemia and lymphoma (especially e.g. cancers of the bone, heart and  
 XX CC skin), diabetes mellitus, Crohn's disease, immune disorders e.g. AIDS,  
 XX CC allergies and atherosclerosis, inflammatory disorders e.g. rheumatoid  
 XX CC arthritis, irritable bowel syndrome, multiple sclerosis and ulcerative  
 XX CC colitis, neurological disorders e.g. Down's syndrome, amnesia, cerebral  
 XX CC neoplasms and Huntington's disease and infectious diseases such as  
 XX CC those caused by viral infection e.g. adenoviruses (acute respiratory  
 XX CC disease) and toga viruses (rubella) as well as those caused by  
 XX CC bacterial, fungal, parasitic, protozoal and helminthic infections.  
 XX XX  
 XX SQ Sequence 355 AA;

Query Match 50.6%; Score 39; DB 21; Length 355;  
 Best Local Similarity 53.8%; Pred. No. 26;  
 Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANQR 13  
 |||:| | | |  
 Db 239 c|gvaatk|gnkr 251

RESULT 13  
 AAW73012  
 ID AAW73012 standard; Protein; 462 AA.  
 XX XX  
 XX AC AAW73012;  
 XX XX  
 XX DT 02-FEB-1999 (first entry)  
 XX XX  
 XX DE Cobra venom protease mocarhagin NM-3.  
 XX XX  
 XX KW Mocarhagin; snake venom; Mozambiquan spitting cobra; protease;  
 XX KW inflammation; myocardial infarction; thrombosis; infection;  
 XX KW metastasis; therapy; NM-3.  
 XX XX  
 XX OS Naja mossambica mossambica.  
 XX XX  
 XX FH Key Location/Qualifiers  
 XX FT Peptide 1..61  
 XX FT /label= Pro\_peptide  
 XX FT 62..462  
 XX FT /label= Mat\_protein  
 XX XX  
 XX PN W09846771-A2.  
 XX XX

PD 22-OCT-1998.  
 XX XX  
 XX PF 14-APR-1998; 98WO-US07998.  
 XX XX  
 XX PR 18-FEB-1998; 98US-0026001.  
 XX PR 15-APR-1997; 97US-0843373.  
 XX PR 23-JAN-1998; 98US-0012637.  
 XX XX  
 XX PA (GEMY ) GENETICS INST INC.  
 XX XX  
 XX PI Boodhoo A, Sako D, Seehra JS, Shaw G;  
 XX PI WPI: 1998-568735/48.  
 XX DR N-PSDB; AAV07900.  
 XX XX  
 XX PT Isolated mocarhagin cobra venom protease, and nucleic acids encoding  
 XX PT it - used to develop products for treating e.g. myocardial  
 XX PT infarction, thrombosis, bacterial or viral infection, metastatic  
 XX PT conditions or inflammatory disorders  
 XX XX  
 XX PS Claim 70; Page 61-63; 97pp; English.  
 XX XX  
 XX CC This is the amino acid sequence of mocarhagin NM-3, a highly  
 XX CC specific metalloproteinase from the venom of the Mozambiquan  
 XX CC spitting cobra. The invention provides mocarhagin polypeptides  
 XX CC (see AAW73007-13) and polynucleotides (see AAV07895-901) encoding them,  
 XX CC as well as host cells and methods of producing the (especially  
 XX CC mature) polypeptides. Mocarhagin proteins are capable of cleaving  
 XX CC anionic polypeptide containing sulphated tyrosine residues,  
 XX CC P-selectin glycoprotein (GP) ligand-1 (PSGL-1) and Gp1b-alpha  
 XX CC (claimed). They also inhibit neutrophil/HL60 binding, inhibit  
 XX CC platelet binding to von Willebrand Factor, require Ca2+ and Zn2+  
 XX CC ions for activity and have activity inhibited by excess EDTA or  
 XX CC high concentrations of DRP (claimed). They can be used to inhibit  
 XX CC selectin-mediated binding and to treat inflammatory disease  
 XX CC (claimed). In particular, they can be used to treat e.g. myocardial  
 XX CC infarction, vessel restenosis, thrombosis, bacterial or viral  
 XX CC infection, metastatic conditions, inflammatory disorders such as  
 XX CC arthritis, acute respiratory distress syndrome, asthma, emphysema,  
 XX CC delayed type hypersensitivity reaction, systemic lupus  
 XX CC erythematosus, thermal injury such as burns or frostbite,  
 XX CC autoimmune thyroiditis, experimental allergic encephalomyelitis,  
 XX CC multiple sclerosis, multiple organ injury syndrome secondary to  
 XX CC trauma, diabetes, Reynaud's syndrome, neutrophilic dermatosis  
 XX CC (Sweet's syndrome), inflammatory bowel disease, Grave's disease,  
 XX CC glomerulonephritis, gingivitis, periodontitis, haemolytic uremic  
 XX CC syndrome, ulcerative colitis, Crohn's disease, necrotising  
 XX CC enterocolitis, granulocyte transfusion associated syndrome,  
 XX CC cytokine-induced enterocolitis, granulocyte transfusion associated  
 XX CC syndrome, or cytokine-induced toxicity. Mocarhagin protein may  
 XX CC also be useful in organ transplantation, both to prepare organs for  
 XX CC transplantation and to quell organ transplant rejection, to treat  
 XX CC haemodialysis and leukophoresis patients, or as an inhibitor of P-  
 XX CC or E-selectin-mediated intercellular adhesion.

Sequence 462 AA;

Query Match 50.6%; Score 39; DB 19; Length 462;  
 Best Local Similarity 77.8%; Pred. No. 35;  
 Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
 || | |||  
 Db 369 cialmgtdf 377

RESULT 14  
 AAE06222  
 ID AAE06222 standard; Protein; 496 AA.  
 XX XX  
 XX AC AAE06222;  
 XX XX

DT 25-SEP-2001 (first entry)  
 XX Booroola sheep mutant BMP1B receptor.  
 XX  
 DE Bone morphogenetic protein 1B receptor; BMP1B receptor; ovulation;  
 KW FeCB; fecundity; fertility; Booroola; contraceptive; mutant; mutein;  
 KW transforming growth factor-beta family; chromosome 6; sheep.  
 KW  
 XX Ovis aries.  
 OS  
 XX  
 XX Key Location/Qualifiers  
 FH Domain 127..148  
 FT /label= Membrane\_spanning\_domain  
 FT Domain 203..496  
 FT /label= Intracellular\_kinase\_domain  
 FT Misc-difference 249  
 FT /note= "Wild type Gln is substituted with Arg"  
 XX  
 XX WO200148204-A1.  
 PN  
 XX  
 XX 05-JUL-2001.  
 PD  
 XX  
 XX 22-DEC-2000; 2000WO-NF00259.  
 PF  
 XX  
 XX 23-DEC-1999; 99NZ-0502058.  
 PR  
 XX (AGRE-) AGRESEARCH LTD.  
 PA  
 XX Wilson TM, Wu X;  
 PI  
 XX WPI; 2001-441717/47.  
 DR N-PSDB; AAD11872.  
 DR  
 XX Novel isolated bone morphogenetic protein 1B receptor polypeptide  
 PT useful for modulating the ovulation rate of a female vertebrate -  
 PT  
 XX  
 XX Claim 12; Page 50-52; 53pp; English.  
 PS  
 XX The invention relates to a bone morphogenetic protein 1B (BMP1B)  
 CC receptor polypeptide comprising a sequence which differs from that  
 CC of the wild type in that residue 249 is arginine and not glutamine,  
 CC or a sequence in which residue 249 is glutamine, but which is otherwise  
 CC different from the wild type BMP1B polypeptide sequence and which has  
 CC the ability to modulate ovulation in a female mammal. Mutation in  
 CC the BMP1B receptor gene is responsible for increased ovulation rate  
 CC in sheep derived from Booroola Merino strain that carry an autosomal  
 CC mutation in FeCB/Booroola gene. The FeCB gene is mapped to chromosome 6.  
 CC The BMP1B receptor of the invention and the polynucleotide encoding  
 CC it are useful for modulating the ovulation rate of a female vertebrate.  
 CC Identification of mutated BMP1B receptor nucleic acid molecule in a  
 CC vertebrate, is useful for assessing fecundity in vertebrate such as  
 CC humans and other commercially important mammals and birds including  
 CC sheep, cattle, horses, goats, deer, pigs, cats, dogs, possums, and  
 CC poultry. The polypeptide is useful to raise antibodies and for reducing  
 CC unwanted populations of feral vertebrates. The polynucleotide is useful  
 CC for identifying sequence variants in individual animals that are  
 CC associated with increased ovulation. The present sequence is mutant  
 CC BMP1B receptor from Booroola sheep. The BMP1B receptor is a  
 CC member of transforming growth factor-beta family.  
 XX  
 XX Sequence 496 AA;

Query Match 50.6%; Score 39; DB 22; Length 496;  
 Best Local Similarity 66.7%; Pred. No. 38;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 CIGLAGTDF 9  
 Db 71 c1glegsdf 79

RESULT 15

AAR55374  
 ID AAR55374 standard; Protein; 502 AA.  
 XX  
 AC AAR55374;  
 XX  
 DT 20-JAN-1995 (first entry)  
 XX  
 DE Mouse Activin receptor-like kinase 6 (mALK-6).  
 XX  
 XX serine threonine kinases; activin receptors; Act-R; superfamily;  
 KW transforming growth factor; TGF; diagnostics; detection; therapy;  
 KW rheumatoid arthritis; glomerular nephritis; fibrosis.  
 KW  
 XX Mus musculus.  
 OS  
 XX WO9411502-A.  
 PN  
 XX 26-MAY-1994.  
 PD  
 XX  
 XX 17-NOV-1993; 93WO-GB02367.  
 PF  
 XX  
 XX 17-NOV-1992; 92GB-0024057.  
 PR  
 XX 08-MAR-1993; 93GB-0004677.  
 PR  
 XX 08-MAR-1993; 93GB-0004680.  
 PR  
 XX 28-MAY-1993; 93GB-0011047.  
 PR  
 XX 02-JUL-1993; 93GB-0013763.  
 PR  
 XX 03-AUG-1993; 93GB-0016099.  
 PR  
 XX 15-OCT-1993; 93GB-0021344.  
 XX  
 XX (LUDW-) LUDWIG INST CANCER RES.  
 PA  
 XX  
 XX Dijke P, Franzen P, Heidin C, Miyazono K, Yamashita H;  
 PI  
 XX WPI; 1994-183503/22.  
 DR N-PSDB; AAQ66642.  
 DR  
 XX Activin receptor-like kinase(s) with serine/threonine kinase  
 PT domains - have activin/TGF beta-type I receptor function and can  
 PT be used in diagnosis or therapy of rheumatoid arthritis,  
 PT glomerular nephritis, fibrosis, etc.  
 XX  
 XX Claim 3; Page 75-77; 97pp; English.  
 PS  
 XX The inventors have identified a new family of receptor kinases  
 CC called activin receptor-like kinases (ALK). Their discovery was  
 CC based on the realisation that receptor serine/threonine kinases  
 CC form a new receptor family, which may include the type II receptors  
 CC for other proteins in the transforming growth factor(TGF) beta  
 CC superfamily. The activin receptor type II sequences from mouse and  
 CC the dafI gene product of C.elegans have high sequence similarity  
 CC and were used to design degenerate primers to clone related cDNA's  
 CC (see AA066643-49). Six distinct putative receptor serine/threonine  
 CC kinases were identified, called ALK (human ALK proteins are shown  
 CC in AAR55366-70, mouse ALK are shown in AAR55371-74). Products of the  
 CC invention can be used in therapy, eg. to modulate conditions  
 CC associated with activin or TGF beta activity. These conditions  
 CC include fibrosis, eg. liver cirrhosis and pulmonary fibrosis, cancer,  
 CC rheumatoid arthritis and glomeronephritis.  
 XX  
 XX Sequence 502 AA;

Query Match 50.6%; Score 39; DB 15; Length 502;  
 Best Local Similarity 66.7%; Pred. No. 39;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 CIGLAGTDF 9  
 Db 71 c1glegsdf 79

Search completed: March 26, 2002, 13:38:48

Job time: 142 sec

---

GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:41:28 ; Search time 37.72 Seconds  
(without alignments)  
8.352 Million cell updates/sec

Title: US-09-709-201-100  
Perfect score: 77  
Sequence: 1 CIGLAGTDFANORP 14

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 212252 seqs, 22503292 residues

Total number of hits satisfying chosen parameters: 212252

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued\_Patents\_AA:\*  
1: /cgn2\_6/ptodata/2/iaa/5A\_COMB.pep.\*  
2: /cgn2\_6/ptodata/2/iaa/5B\_COMB.pep.\*  
3: /cgn2\_6/ptodata/2/iaa/6A\_COMB.pep.\*  
4: /cgn2\_6/ptodata/2/iaa/6B\_COMB.pep.\*  
5: /cgn2\_6/ptodata/2/iaa/PCTUS\_COMB.pep.\*  
6: /cgn2\_6/ptodata/2/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	40	51.9	98	6	Patent No. 5459046
2	39	50.6	502	2	US-08-481-337A-8
3	39	50.6	502	4	US-09-382-256-18
4	39	50.6	502	4	US-09-395-115-18
5	39	50.6	502	4	US-08-123-934A-4
6	39	50.6	502	4	US-08-334-179A-14
7	39	50.6	502	5	PCT-US94-10080-4
8	39	50.6	502	5	PCT-US95-05467-8
9	36.5	47.4	358	1	US-08-034-650-10
10	36.5	47.4	358	1	US-08-449-015-10
11	36	46.8	309	2	US-08-849-480A-6
12	36	46.8	1580	2	US-08-804-227C-11
13	36	46.8	1580	2	US-08-804-198-5
14	35	45.5	672	1	US-07-841-651-2
15	35	45.5	672	1	US-07-841-651-3
16	35	45.5	1612	1	US-08-169-927-2
17	34	44.2	176	1	US-08-145-995A-3
18	34	44.2	176	2	US-08-451-747-3
19	34	44.2	176	3	US-09-134-852-3
20	34	44.2	269	4	US-09-028-366-6
21	34	44.2	570	2	US-08-484-993B-16
22	34	44.2	570	2	US-08-484-158B-16
23	34	44.2	570	2	US-08-484-596A-16
24	34	44.2	570	2	US-08-480-150A-16
25	34	44.2	570	3	US-08-458-731-16
26	34	44.2	570	3	US-08-149-223A-16
27	34	44.2	591	1	US-08-145-995A-21

28	34	44.2	591	2	US-08-451-747-21	Sequence 21, Appl
29	34	44.2	591	3	US-09-134-852-21	Sequence 21, Appl
30	34	44.2	659	4	US-09-189-462-4	Sequence 4, Appl
31	33	42.9	526	3	US-08-504-878A-2	Sequence 2, Appl
32	33	42.9	956	3	US-08-772-270A-8	Sequence 8, Appl
33	33	42.9	1127	4	US-08-937-195-3	Sequence 3, Appl
34	33	42.9	1127	4	US-08-915-152-3	Sequence 3, Appl
35	33	42.9	1127	5	PCT-US96-07627-3	Sequence 3, Appl
36	32	41.6	18	2	US-07-876-941A-29	Sequence 29, Appl
37	32	41.6	18	3	US-08-293-728-20	Sequence 20, Appl
38	32	41.6	18	4	US-09-421-868-20	Sequence 20, Appl
39	32	41.6	157	1	US-08-450-065-2	Sequence 2, Appl
40	32	41.6	157	1	US-08-450-595-2	Sequence 2, Appl
41	32	41.6	235	1	US-08-015-985-13	Sequence 13, Appl
42	32	41.6	252	2	US-08-685-992-33	Sequence 33, Appl
43	32	41.6	252	2	US-09-144-925-33	Sequence 33, Appl
44	32	41.6	255	1	US-08-459-264-4	Sequence 4, Appl
45	32	41.6	255	1	US-08-459-263-4	Sequence 4, Appl

ALIGNMENTS

RESULT 1  
5459046-6  
; Patent No. 5459046  
; APPLICANT: KODAMA, TOHRU;IGARASHI, YASUO  
; TITLE OF INVENTION: CYTOCHROME C GENE DERIVED FROM HYDROGEN  
; BACTERIUM  
; NUMBER OF SEQUENCES: 17  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/943,140  
; FILING DATE: 10-SEP-1992  
; PRIOR APPLICATION DATA:486,409  
; APPLICATION NUMBER: 28-FEB-1990  
; SEQ ID NO:6:  
; LENGTH: 98  
5459046-6

Query Match 51.9%; Score 40; DB 6; Length 98;  
Best Local Similarity 58.3%; Pred. No. 2.5;  
Matches 7; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2 IGLAGTDFANOR 13  
Db 10 VGLAGTDFANQ 21  
:|||||:|:|:|

RESULT 2  
US-08-481-337A-8  
; Sequence 8, Application US/08481337A  
; Patent No. 5863738  
; GENERAL INFORMATION:  
; APPLICANT: TEN DIJKE, Peter  
; APPLICANT: HELDIN, Carl-Henrik  
; APPLICANT: MIYAZONO, Kohei  
; APPLICANT: SAMPATH, Kuber T.  
; TITLE OF INVENTION: Morphogenic Protein-Specific Cell  
; TITLE OF INVENTION: Surface Receptors and Uses Therefor  
; NUMBER OF SEQUENCES: 18  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Testa, Hurwitz & Thibault  
; STREET: 125 High St.  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02110.  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30

;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/481,337A  
;; FILING DATE: 02-JUN-1995  
;; CLASSIFICATION: 435  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: MEYERS, Thomas C.  
;; REGISTRATION NUMBER: 36,989  
;; REFERENCE/DOCKET NUMBER: CRP-097CP2  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (617) 248-7000  
;; TELEFAX: (617) 248-7100  
;; INFORMATION FOR SEQ ID NO: 8:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 502 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; US-08-481-337A-8

Query Match 50.6%; Score 39; DB 2; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
I:|I| I:|I|  
Db 71 CLGLEGSDF 79

## RESULT 3

US-09-382-256-18  
; Sequence 18, Application US/09382256A  
; Patent No. 6207814  
; GENERAL INFORMATION:  
; APPLICANT: MIYAZONO, Kohei  
; TEN DIJKE, Peter  
; FRANZEN, Petra  
; YAMASHITA, Hidetoshi  
; HELDIN, Carl-Henrik  
; TITLE OF INVENTION: ACTIVIN RECEPTOR LIKE KINASES, PROTEINS  
; HAVING SERINE THREONINE KINASE DOMAINS,  
; AND THEIR USE  
; NUMBER OF SEQUENCES: 29  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fulbright & Jaworski L.L.P.  
; STREET: 666 Fifth Avenue  
; CITY: New York City  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10103  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.25 inch, 1.44mb  
; COMPUTER: IBM PS/2  
; OPERATING SYSTEM: PC-DOS  
; SOFTWARE: Wordperfect  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/382,256A  
; FILING DATE: 24-Aug-1999  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/GB93/02367  
; FILING DATE: No. 6207814ember 17, 1993  
; APPLICATION NUMBER: GB 9224057.1  
; FILING DATE: No. 6207814ember 17, 1992  
; APPLICATION NUMBER: GB 9304677.9  
; FILING DATE: March 8, 1993  
; APPLICATION NUMBER: GB 9304680.3  
; FILING DATE: March 8, 1993  
; APPLICATION NUMBER: 9311047.6  
; FILING DATE: May 28, 1993  
; APPLICATION NUMBER: 9313763.6  
; FILING DATE: July 2, 1993  
; APPLICATION NUMBER: 9316099.2

;; FILING DATE: August 3, 1993  
;; APPLICATION NUMBER: 321344.5  
;; FILING DATE: October 15, 1993  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: NO. 6207814man D. Hanson  
;; REGISTRATION NUMBER: 30,946  
;; REFERENCE/DOCKET NUMBER: LUD 5298.1  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (212) 318-3000  
;; TELEFAX: (212) 752-5958  
;; INFORMATION FOR SEQ ID NO: 18:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 502 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; SEQUENCE DESCRIPTION: SEQ ID NO: 18:  
;; US-09-382-256-18

Query Match 50.6%; Score 39; DB 4; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
I:|I| I:|I|  
Db 71 CLGLEGSDF 79

## RESULT 4

US-09-395-115-18  
; Sequence 18, Application US/09395115  
; Patent No. 6271365  
; GENERAL INFORMATION:  
; APPLICANT: Miyazono, Kohei; Dijke, Peter Ten;  
; APPLICANT: Franzen, Petra; Yamashita, Hidetoshi;  
; TITLE OF INVENTION: Activin Receptor-Like Kinase, Proteins  
; TITLE OF INVENTION: Having Serine Threonine Kinase Domains And Their Use  
; NUMBER OF SEQUENCES: 29  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Felfe & Lynch  
; STREET: 805 Third Avenue  
; CITY: New York City  
; STATE: New York  
; ZIP: 10022  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.5 inch, 360 kb storage  
; COMPUTER: IBM  
; OPERATING SYSTEM: PC-DOS  
; SOFTWARE: Wordperfect  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/395,115  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/436,265  
; FILING DATE: 30-October-1995  
; APPLICATION NUMBER: PCT/GB93/02367  
; FILING DATE: 17-No. 6271365ember-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9224057.1  
; FILING DATE: 17-No. 6271365ember-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9304677.9  
; FILING DATE: 8-March-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9304680.3  
; FILING DATE: 8-March-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9311047.6  
; FILING DATE: 28-May-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9313763.6

Query Match 50.6%; Score 39; DB 4; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
Db 71 CLGLEGSDF 79

RESULT 5  
US-08-123-934A-4  
; Sequence 4, Application US/08123934A  
; Patent No. 6291206  
; GENERAL INFORMATION:  
; APPLICANT: WOZNEY, John  
; APPLICANT: CELESTE, Anthony J.  
; APPLICANT: THIES, R. Scott  
; APPLICANT: YAMAJI, No. 6291206oru  
; TITLE OF INVENTION: RECEPTOR PROTEINS  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genetics Institute Inc. - Legal Affairs  
; STREET: 87 CambridgePark Drive  
; CITY: Cambridge  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02140  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/123,934A  
; FILING DATE: 17-SEP-1993  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: LAZAR, Steven R  
; REGISTRATION NUMBER: 32,618  
; REFERENCE/DOCKET NUMBER: 5203  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617 876 1170  
; TELEFAX: 617 876 5851  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 502 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-09-395-115-18

Query Match 50.6%; Score 39; DB 4; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
Db 71 CLGLEGSDF 79

RESULT 6  
US-08-334-179A-14  
; Sequence 14, Application US/08334179A  
; Patent No. 6306622  
; GENERAL INFORMATION:  
; APPLICANT: ROSENBAUM, JAN S.  
; APPLICANT: MOHNO, TSUTOMU  
; TITLE OF INVENTION: CDNA ENCODING A BMP TYPE II RECEPTOR  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: THE PROCTER AND GAMBLE COMPANY  
; STREET: 11810 EAST MIAMI RIVER ROAD  
; CITY: ROSS  
; STATE: OH  
; COUNTRY: US  
; ZIP: 45061  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.30, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/334,179A  
; FILING DATE: 04-NOV-1994  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: CORSTANJE, BRAHM J.  
; REGISTRATION NUMBER: 34,804  
; REFERENCE/DOCKET NUMBER: 5473  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 513-627-2858  
; TELEFAX: 513-627-0260  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 502 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-334-179A-14

Query Match 50.6%; Score 39; DB 4; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
Db 71 CLGLEGSDF 79

RESULT 7  
PCT-US94-10080-4  
; Sequence 4, Application PC/TUS9410080  
; GENERAL INFORMATION:  
; APPLICANT: GENETICS INSTITUTE, INC.  
; TITLE OF INVENTION: RECEPTOR PROTEINS  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genetics Institute Inc. - Legal Affairs  
; STREET: 87 CambridgePark Drive  
; CITY: Cambridge  
; STATE: MA

; COUNTRY: USA  
 ; ZIP: 02140  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: PCT/US94/10080  
 ; FILING DATE: HEREWITH  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/123,934  
 ; FILING DATE: 17-SEP-1993  
 ; CLASSIFICATION:  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: LAZAR, Steven R  
 ; REGISTRATION NUMBER: 32,618  
 ; REFERENCE/DOCKET NUMBER: 5203-PCT  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (617) 498-8260  
 ; TELEFAX: (617) 876-5851  
 ; INFORMATION FOR SEQ ID NO: 4:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 502 amino acids  
 ; TYPE: amino acid  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: protein  
 ; PCT-US94-10080-4

Query Match 50.6%; Score 39; DB 5; Length 502;  
 Best Local Similarity 66.7%; Pred. No. 24;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
 Db 71 CLGLEGSDF 79

RESULT 8  
 PCT-US95-05467-8  
 ; Sequence 8, Application PC/TUS9505467  
 ; GENERAL INFORMATION:  
 ; APPLICANT:  
 ; APPLICANT:  
 ; TITLE OF INVENTION: MORPHOGENIC PROTEIN-SPECIFIC CELL  
 ; SURFACE RECEPTORS AND USES THEREFOR  
 ; NUMBER OF SEQUENCES: 15  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: PATENT ADMINISTRATOR, TESTA, HURWITZ &  
 ; ADDRESS: THIBEAULT  
 ; STREET: 53 STATE STREET  
 ; CITY: BOSTON  
 ; STATE: MA  
 ; COUNTRY: USA  
 ; ZIP: 02109  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: PCT/US95/05467  
 ; FILING DATE:  
 ; CLASSIFICATION:  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: PITCHER, EDMUND R.  
 ; REGISTRATION NUMBER: 27,829  
 ; REFERENCE/DOCKET NUMBER: CRP-097PC  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (617) 248-7000  
 ; TELEFAX: (617) 248-7100

; INFORMATION FOR SEQ ID NO: 8:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 502 amino acids  
 ; TYPE: amino acid  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: protein  
 ; PCT-US95-05467-8

Query Match 50.6%; Score 39; DB 5; Length 502;  
 Best Local Similarity 66.7%; Pred. No. 24;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
 Db 71 CLGLEGSDF 79

RESULT 9  
 US-08-034-650-10  
 ; Sequence 10, Application US/08034650  
 ; Patent No. 5641671  
 ; GENERAL INFORMATION:  
 ; APPLICANT: BOS, Jannetje W.  
 ; APPLICANT: FRENKEN, Leon G.  
 ; APPLICANT: VERIPS, Cornelis T.  
 ; APPLICANT: VISSER, Christiaan  
 ; TITLE OF INVENTION: PRODUCTION OF ACTIVE PSEUDOMONAS GLUMAE  
 ; TITLE OF INVENTION: LIPASE IN HOMOLOGOUS OR HETEROLOGOUS HOSTS  
 ; NUMBER OF SEQUENCES: 13  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: CUSHMAN, DARBY & CUSHMAN  
 ; STREET: 1615 L. Street, N.W.  
 ; CITY: Washington  
 ; STATE: D.C.  
 ; COUNTRY: USA  
 ; ZIP: 20036-5601  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/034,650  
 ; FILING DATE:  
 ; CLASSIFICATION: 435  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 07/727,235  
 ; FILING DATE: 03-JUL-1991  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: KOKULLIS, Paul N.  
 ; REGISTRATION NUMBER: 16,773  
 ; REFERENCE/DOCKET NUMBER: PNK/5970/91731  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (202) 861-3000  
 ; TELEFAX: (202) 822-0944  
 ; TELEX: 6714627 CUSH  
 ; INFORMATION FOR SEQ ID NO: 10:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 358 amino acids  
 ; TYPE: amino acid  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: protein  
 ; US-08-034-650-10

Query Match 47.4%; Score 36.5; DB 1; Length 358;  
 Best Local Similarity 90.0%; Pred. No. 48;  
 Matches 9; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 3 GLAGTD-FAN 11  
 Db 55 GLAGTDKFN 64



RESULT 10  
US-08-449-015-10  
; Sequence 10, Application US/08449015  
; Patent No. 5804409  
; GENERAL INFORMATION:  
; APPLICANT: BOS, Jannetje W.  
; APPLICANT: FRENKEN, Leon G.  
; APPLICANT: VERRIPS, Cornelis T.  
; APPLICANT: VISSER, Christiaan  
; TITLE OF INVENTION: PRODUCTION OF ACTIVE PSEUDOMONAS GLUMAE  
; TITLE OF INVENTION: LIPASE IN HOMOLOGOUS OR HETEROLOGOUS HOSTS  
; NUMBER OF SEQUENCES: 13  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: CUSHMAN, DARBY & CUSHMAN  
; STREET: 1615 L. Street, N.W.  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20036-5601  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/449,015  
; FILING DATE: 24-MAY-1995  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/727,235  
; FILING DATE: 03-JUL-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: KOKULIS, Paul N.  
; REGISTRATION NUMBER: 16,773  
; REFERENCE/DOCKET NUMBER: PNK/5970/91731  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 861-3000  
; TELEFAX: (202) 822-0944  
; TELEX: 6714627 CUSH  
; INFORMATION FOR SEQ ID NO: 10:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 358 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-449-015-10

Query Match 47.4%; Score 36.5; DB 1; Length 358;  
Best Local Similarity 90.0%; Pred. No. 48;  
Matches 9; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 3 GLAGTD-FAN 11  
| | | | | | | |  
Db 55 GLAGTDKFN 64

RESULT 11  
US-08-849-480A-6  
; Sequence 6, Application US/08849480A  
; Patent No. 5981184  
; GENERAL INFORMATION:  
; APPLICANT: MELCHERS, Klaus  
; TITLE OF INVENTION: SCREENING MODEL  
; NUMBER OF SEQUENCES: 24  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: JACOBSON, PRICE, HOLMAN & STERN, PLLC  
; STREET: 400 - 7th Street, N. W.  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/849,480A  
; FILING DATE: 02-JUN-1997  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/EP95/04711  
; FILING DATE: 30-NOV-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: DE P4442970.3  
; FILING DATE: 02-DEC-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: DE 19505645.0  
; FILING DATE: 18-FEB-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AISENBERG, Irwin M.  
; REGISTRATION NUMBER: 19,007  
; REFERENCE/DOCKET NUMBER: 8125/P60984USO  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202/638-6666  
; TELEFAX: 202/393-5350  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 309 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; HYPOTHEICAL: YES  
; FRAGMENT TYPE: C-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: Helicobacter pylori  
; STRAIN: Helicobacter pylori 69A  
; INDIVIDUAL ISOLATE: Clinical isolate 69A  
; IMMEDIATE SOURCE:  
; LIBRARY: Helicobacter 69A - gene library in vector  
; LIBRARY: PRH160  
; CLONE: PRH948  
; US-08-849-480A-6

Query Match 46.8%; Score 36; DB 2; Length 309;  
Best Local Similarity 77.8%; Pred. No. 50;  
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3 GLAGTDKFN 11  
| | | | | | | |  
Db 52 GLAGADLAN 60

RESULT 12  
US-08-804-227C-11  
; Sequence 11, Application US/08804227C  
; Patent No. 5876991  
; GENERAL INFORMATION:  
; APPLICANT: DeHoff, Bradley S.  
; APPLICANT: Kubstoss, Stuart A.  
; APPLICANT: Rostock, Paul R., Jr.  
; APPLICANT: Sutton, Kimberly L.  
; TITLE OF INVENTION: POLYKETIDE SYNTHASE GENES  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: THOMAS G. PLANT 1501  
; STREET: LILLY CORPORATE CENTER  
; CITY: INDIANAPOLIS  
; STATE: IN  
; COUNTRY: USA  
; ZIP: 46285

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: MS-DOS  
SOFTWARE: ASCII(DOS) Text only  
CURRENT APPLICATION DATA:  
FILING DATE: February 21, 1997  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Plant, Thomas, G.  
REGISTRATION NUMBER: 35,784  
REFERENCE/DOCKET NUMBER: X-8231  
TELEPHONE: 317-276-2459  
INFORMATION FOR SEQ ID NO: 11:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1580 amino acids  
TYPE: amino acid  
TOPOLOGY: unknown  
MOLECULE TYPE: peptide  
US-08-804-227C-11

Query Match 46.8%; Score 36; DB 2; Length 1580;  
Best Local Similarity 63.6%; Pred. No. 3.1e+02;  
Matches 7; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 4 LAGTDFANQRP 14  
||| |||  
Db 752 LAGVDFAGHSP 762

RESULT 13  
US-08-804-198-5  
Sequence 5, Application US/08804198  
Patent No. 5945320  
GENERAL INFORMATION:  
APPLICANT: Burgett, Stanley G.  
APPLICANT: Kuhstoss, Stuart A.  
APPLICANT: Rao, Nagaraja R.  
APPLICANT: Richardson, Mark A.  
TITLE OF INVENTION: PLATENOLIDE SYNTHASE GENE  
NUMBER OF SEQUENCES: 6  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: PAUL R. CANTRELL 1138  
STREET: LILLY CORPORATE CENTER  
CITY: INDIANAPOLIS  
STATE: IN  
COUNTRY: USA  
ZIP: 46285

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: Macintosh  
OPERATING SYSTEM: Macintosh 7.0  
SOFTWARE: Microsoft Word 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/804,198  
FILING DATE:  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: CANTRELL, PAUL R.  
REGISTRATION NUMBER: 36,470  
REFERENCE/DOCKET NUMBER: P9113  
TELEPHONE: 317-276-3885  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1580 amino acids  
TYPE: amino acid  
TOPOLOGY: unknown  
MOLECULE TYPE: peptide

US-08-804-198-5

Query Match 46.8%; Score 36; DB 2; Length 1580;  
Best Local Similarity 63.6%; Pred. No. 3.1e+02;  
Matches 7; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 4 LAGTDFANQRP 14  
||| |||  
Db 752 LAGVDFAGHSP 762

RESULT 14  
US-07-841-651-2  
Sequence 2, Application US/07841651  
Patent No. 5410031  
GENERAL INFORMATION:  
APPLICANT: Pajor, Ana M  
APPLICANT: Wright, Ernest M  
TITLE OF INVENTION: Cloning and Functional Expression of a  
TITLE OF INVENTION: Mammalian Na+/Nucleoside Cotransporter: A Member of the  
TITLE OF INVENTION: SGLT Family  
NUMBER OF SEQUENCES: 4  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Sheldon & Mak  
STREET: 225 South Lake Avenue, Ninth Floor  
CITY: Pasadena  
STATE: California  
COUNTRY: USA  
ZIP: 91101

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/841,651  
FILING DATE: 19920224  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Mandel, Saralynn  
REGISTRATION NUMBER: 31,853  
REFERENCE/DOCKET NUMBER: 8772  
TELEPHONE: (818) 796-4000  
TELEFAX: (818) 795-6321  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 672 amino acids  
TYPE: AMINO ACID  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-07-841-651-2

Query Match 45.5%; Score 35; DB 1; Length 672;  
Best Local Similarity 70.0%; Pred. No. 1.8e+02;  
Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2 IGLAGTDFAN 11  
:|||||  
Db 82 VGLAGTGAAN 91

RESULT 15  
US-07-841-651-3  
Sequence 3, Application US/07841651  
Patent No. 5410031  
GENERAL INFORMATION:  
APPLICANT: Pajor, Ana M  
APPLICANT: Wright, Ernest M  
TITLE OF INVENTION: Cloning and Functional Expression of a  
TITLE OF INVENTION: Mammalian Na+/Nucleoside Cotransporter: A Member of the

;; TITLE OF INVENTION: SGLT Family  
;; NUMBER OF SEQUENCES: 4  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Sheldon & Mak  
;; STREET: 225 South Lake Avenue, Ninth Floor  
;; CITY: Pasadena  
;; STATE: California  
;; COUNTRY: USA  
;; ZIP: 91101  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.25  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/07/841,651  
;; FILING DATE: 19920224  
;; CLASSIFICATION: 435  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Mandel, Saralynn  
;; REGISTRATION NUMBER: 31,853  
;; REFERENCE/DOCKET NUMBER: 8772  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (818) 796-4000  
;; TELEFAX: (818) 795-6321  
;; INFORMATION FOR SEQ ID NO: 3:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 672 amino acids  
;; TYPE: AMINO ACID  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; HYPOTHETICAL: NO  
;; ORIGINAL SOURCE:  
;; ORGANISM: Oryctolagus cuniculus  
;; US-07-841-651-3

Query Match 45.5%; Score 35; DB 1; Length 672;  
Best Local Similarity 70.0%; Pred. No. 1.8e+02;  
Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 2 IGLAGTDFAN 11  
Db 82 VGLAGTGAAN 91

Search completed: March 26, 2002, 13:41:29  
Job time: 303 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:37:19 ; Search time 42.75 Seconds  
(without alignments)  
24.946 Million cell updates/sec

Title: US-09-709-201-100  
Perfect score: 77  
Sequence: 1 CIGLAGTDFANQRP 14

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 219241 seqs, 76174552 residues

Total number of hits satisfying chosen parameters: 219241

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR\_68: \*  
1: pir1: \*  
2: pir2: \*  
3: pir3: \*  
4: pir4: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	68	88.3	392	2 A40371	major outer membra
2	43	55.8	995	2 T50267	probable family 3i
3	41	53.2	1238	2 A64596	hypothetical prote
4	41	53.2	3194	2 D71917	toxin-like outer m
5	40	51.9	98	1 S32485	cytochrome c552 pr
6	39	50.6	289	2 S04407	phytoene synthase
7	39	50.6	324	2 C70785	probable carbohydr
8	39	50.6	377	3 JC7535	chitinase (EC 3.2
9	39	50.6	502	2 A56683	receptor protein k
10	39	50.6	502	2 A53444	activin receptor-1
11	39	50.6	502	2 JC2491	serine/threonine k
12	39	50.6	660	2 JW0067	chitinase (EC 3.2
13	39	50.6	743	2 G83726	assimilatory nitra
14	39	50.6	1785	2 T22595	hypothetical prote
15	38	49.4	356	2 F70636	probable ephA prot
16	38	49.4	365	2 T06615	hypothetical prote
17	37	48.1	141	2 JLO103	hypothetical 15.5k
18	37	48.1	276	2 S73410	hypothetical prote
19	37	48.1	547	2 S49814	transferrin-bindin
20	37	48.1	719	2 T33170	hypothetical prote
21	37	48.1	902	2 T49878	respiratory burst
22	37	48.1	926	2 E83375	probable glycosyl
23	37	48.1	1024	2 T46016	hypothetical prote
24	36.5	47.4	358	1 A48952	triacylglycerol li
25	36	46.8	155	2 D72696	riboflavin synthas
26	36	46.8	280	2 T24454	hypothetical prote
27	36	46.8	303	2 B70875	hypothetical prote
28	36	46.8	328	2 S74645	billiverdin reducta
29	36	46.8	354	2 A96596	hypothetical prote

30	36	46.8	371	2 T51695	cell division prot
31	36	46.8	416	2 S76310	hypothetical prote
32	36	46.8	464	2 B64970	hypothetical prote
33	36	46.8	464	2 C85830	hypothetical prote
34	36	46.8	467	2 S15297	hypothetical prote
35	36	46.8	513	2 T28933	hypothetical prote
36	36	46.8	616	2 S64624	alpha-glucosidase tr
37	36	46.8	632	2 D71941	ATP-dependent zinc
38	36	46.8	632	2 E64653	cell division prot
39	36	46.8	638	2 T47267	cell cycle protein
40	36	46.8	645	2 G81315	membrane bound zin
41	36	46.8	725	2 T27148	hypothetical prote
42	36	46.8	1050	2 T31853	hypothetical prote
43	36	46.8	1060	2 T31763	hypothetical prote
44	35	45.5	101	2 C31982	Ca2+-transporting
45	35	45.5	104	2 T44890	hypothetical prote

ALIGNMENTS

RESULT 1

A40371

major outer membrane protein precursor - Chlamydia psittaci (strain Fpn/pring)  
C:Species: Chlamydia psittaci, Chlamydia psittaci  
C:Date: 27-Nov-1991 #sequence\_revision 27-Nov-1991 #text\_change 31-Mar-2000  
C:Accession: I40859; A40371; S16137

R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.

J. Gen. Microbiol. 139, 2621-2626, 1993

A:Title: Evidence for Chlamydia pneumoniae of non-human origin.

A:Reference number: I40739; MUID:94103736

A:Accession: I40859

A:Status: nucleic acid sequence not shown; translation not shown; translated from GB/

A:Molecule type: DNA

A:Residues: 1-392 <RES>

A:Cross-references: EMBL:X61096; NID:g40564; PIDN:CAA43409.1; PID:g40565

A:Experimental source: strain Fpn

C:Genetics:

A:Gene: MOMP

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-392/Product: major outer membrane protein #status predicted <MAT>

Query Match 88.3%; Score 68; DB 2; Length 392;  
Best Local Similarity 100.0%; Pred. No. 0.00016;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQRP 14

|||||

Db 160 IGLAGTDFANQRP 172

RESULT 2

T50267

probable family 3i glucosidase [imported] - fission yeast (Schizosaccharomyces pombe)

C:Species: Schizosaccharomyces pombe

C:Date: 09-Jun-2000 #sequence\_revision 09-Jun-2000 #text\_change 21-Jul-2000

C:Accession: T50267

R:Hunt, C.; Aves, S.; McDougall, R.C.; Rajandream, M.A.; Barrell, B.G.

submitted to the EMBL Data Library, December 1999

A:Reference number: Z25031

A:Accession: T50267

A:Status: preliminary; translated from GB/EMBL/DDBJ

A:Molecule type: DNA

A:Residues: 1-995 <HUN>

A:Cross-references: EMBL:AL133522; PIDN:CA863549.1; GSPDB:GN00066; SPDB:SPAC922.02c

A:Experimental source: strain 972h(-); cosmid c922

C:Genetics:

A:Gene: SPAC1039.11c; SPDB:SPAC922.02c

A:Map position: 1

C:Superfamily: Schwannomyces glucan 1,4-alpha-glucosidase GAMI; sucrase/isomaltase h

Query Match 55.8%; Score 43; DB 2; Length 995;  
 Best Local Similarity 57.1%; Pred. No. 14;  
 Matches 8; Conservative 1; Mismatches 0; Gaps 0;

QY 1 CIGLAGTDFANORP 14  
 ||| ||| :||  
 Db 507 CIGSCGTDKLDQNP 520

RESULT 3  
 A64596  
 hypothetical protein HP0609 - Helicobacter pylori (strain 26695)  
 C:Species: Helicobacter pylori  
 C:Date: 09-Aug-1997 #sequence\_revision 09-Aug-1997 #text\_change 08-Oct-1999  
 C:Accession: A64596  
 R:Tomb, J.F.; White, O.; Kerlavage, A.R.; Clayton, R.A.; Sutton, G.G.; Fleischmann, R.D.; Peterson, S.; Loftus, B.; Richardson, D.; Dodson, R.; Khalak, H.G.; Glodek, A.; McKenna, J.D.; Kelley, J.M.; Cotton, M.D.; Weidman, J.M.; Fujii, C.; Bowman, C.; Watthey, L. Nature 388, 539-547, 1997  
 A:Authors: Wallin, E.; Hayes, W.S.; Borodovsky, M.; Karpk, P.D.; Smith, H.O.; Fraser, C.  
 A:Title: The complete genome sequence of the gastric pathogen Helicobacter pylori.  
 A:Reference number: A64520; MUID:97394467  
 A:Accession: A64596  
 A:Status: preliminary; nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-1238 <TOM>  
 A:Cross-references: GB:AE000575; GB:AE000511; NID:g2313730; PIDN:AAD07677.1; PID:g231373

Query Match 53.2%; Score 41; DB 2; Length 1238;  
 Best Local Similarity 53.8%; Pred. No. 39;  
 Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 2 IGLAGTDFANORP 14  
 : ||||| :||  
 Db 207 VNLNTDFGNQTP 219

RESULT 4  
 D71917  
 toxin-like outer membrane protein jhp0556 - Helicobacter pylori (strain J99)  
 C:Species: Helicobacter pylori  
 A:Variety: strain J99  
 C:Date: 12-Feb-1999 #sequence\_revision 12-Feb-1999 #text\_change 08-Oct-1999  
 C:Accession: D71917  
 R:Alm, R.A.; Ling, L.S.L.; Moir, D.T.; King, B.L.; Brown, E.D.; Doig, P.C.; Smith, D.R.; Ives, C.; Gibson, R.; Merberg, D.; Mills, S.D.; Jiang, Q.; Taylor, D.E.; Vovis, G.F.; Nature 397, 176-180, 1999  
 A:Title: Genomic sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori.  
 A:Reference number: A71800; MUID:99120557  
 A:Accession: D71917  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-3194 <ARN>  
 A:Cross-references: GB:AE001489; GB:AE001439; NID:g4155100; PIDN:AAD06134.1; PID:g4155100  
 A:Experimental source: strain J99  
 C:Genetics:  
 A:Gene: jhp0556

Query Match 53.2%; Score 41; DB 2; Length 3194;  
 Best Local Similarity 53.8%; Pred. No. 1e+02;  
 Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 2 IGLAGTDFANORP 14  
 : ||||| :||  
 Db 208 VNLNTDFGNQTP 220

RESULT 5  
 S32485

cytochrome c552 precursor - Hydrogenobacter thermophilus  
 C:Species: Hydrogenobacter thermophilus  
 C:Date: 06-Jan-1995 #sequence\_revision 27-Feb-1997 #text\_change 03-Mar-2000  
 C:Accession: S32485; A32226  
 R:Sanbongi, Y.; Yang, J.H.; Igarashi, Y.; Kodama, T. Eur. J. Biochem. 198, 7-12, 1991  
 A:Title: Cloning, nucleotide sequence and expression of the cytochrome c-552 gene from Hydrogenobacter thermophilus  
 A:Reference number: S32485; MUID:91249816  
 A:Accession: S32485  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-98 <SAN>  
 A:Cross-references: EMBL:X57735; NID:g43674; PIDN:CAA40902.1; PID:g43675  
 A:Experimental source: strain TK-6  
 R:Sanbongi, Y.; Ishii, M.; Igarashi, Y.; Kodama, T. J. Bacteriol. 171, 65-69, 1989  
 A:Title: Amino acid sequence of cytochrome c-552 from a thermophilic hydrogen-oxidizing bacterium  
 A:Reference number: A32226; MUID:89123087  
 A:Accession: A32226  
 A:Molecule type: protein  
 A:Residues: 15-98 <SA2>  
 A:Experimental source: strain TK-6  
 C:Function:  
 A:Description: primary electron acceptor for molecular hydrogen activated by hydrogenase  
 A:Pathway: hydrogen oxidation  
 C:Superfamily: cytochrome c6; cytochrome c6 homology  
 C:Keywords: chromoprotein; electron transfer; heme; iron; metalloprotein  
 F:1-18/Domain: signal sequence #status predicted <SIG>  
 F:17-94/Domain: cytochrome c6 homology <CYC>  
 F:19-98/Product: cytochrome c552 #status experimental <MAT>  
 F:28,31/Binding site: heme (Cys) (covalent) #status predicted  
 F:32,77/Binding site: heme iron (His, Met) (axial ligands) #status predicted

Query Match 51.9%; Score 40; DB 1; Length 98;  
 Best Local Similarity 58.3%; Pred. No. 4.7;  
 Matches 7; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2 IGLAGTDFANOR 13  
 : ||||| :||  
 Db 10 VLAGITFANEQ 21

RESULT 6  
 S04407  
 phycoene synthase - Rhodospirillum rubrum  
 C:Species: Rhodospirillum rubrum  
 C:Date: 28-Feb-1990 #sequence\_revision 28-Feb-1990 #text\_change 08-Oct-1999  
 C:Accession: S04407  
 R:Armstrong, G.A.; Alberti, M.; Leach, F.; Hearst, J.E. Mol. Gen. Genet. 216, 254-268, 1989  
 A:Title: Nucleotide sequence, organization, and nature of the protein products of the phycoene synthase gene from Rhodospirillum rubrum  
 A:Reference number: S04407  
 A:Accession: S04407  
 A:Molecule type: DNA  
 A:Residues: 1-289 <ARM>  
 A:Cross-references: EMBL:X52291; NID:g45996; PIDN:CAA36538.1; PID:g46003  
 C:Genetics:  
 A:Gene: crtE  
 C:Superfamily: geranyltransferase  
 C:Keywords: carotenoid biosynthesis

Query Match 50.6%; Score 39; DB 2; Length 289;  
 Best Local Similarity 70.0%; Pred. No. 21;  
 Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 5 AGTDFANORP 14  
 ||| ||| :||  
 Db 224 AGQDIANERP 233

RESULT 7

## C70785

probable carbohydrate kinase - Mycobacterium tuberculosis (strain H37RV)  
 C;Species: Mycobacterium tuberculosis  
 C;Date: 17-Jul-1998 #sequence\_revision 17-Jul-1998 #text\_change 20-Jun-2000  
 C;Accession: C70785  
 R;Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holtroyd, S.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, S.; Squares, S. Nature 393, 537-544, 1998  
 A;Authors: Soares, R.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G.  
 A;Title: Deciphering the biology of Mycobacterium tuberculosis from the complete genome  
 A;Reference number: A70500; MUID:98295987  
 A;Accession: C70785  
 A;Status: preliminary; nucleic acid sequence not shown; translation not shown  
 A;Molecule type: DNA  
 A;Residues: 1-324 <COL>  
 A;Cross-references: GB:270283; GB:AL123456; NID:g3261561; PIDN:CAA94245.1; PID:g1237055  
 A;Experimental source: strain H37RV  
 C;Genetics:  
 A;Gene: cbhK  
 C;Superfamily: probable ribokinase

Query Match 50.6%; Score 39; DB 2; Length 324;  
 Best Local Similarity 58.3%; Pred. No. 24;  
 Matches 7; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

## QY 2 IGLAGTDFANOR 13

Db 67 VGAAGADFADYR 78

## RESULT 8

JC7535  
 chitinase (EC 3.2.1.14) 35 - Streptomyces thermoviolaceus  
 C;Species: Streptomyces thermoviolaceus  
 C;Date: 31-Mar-2001 #sequence\_revision 31-Mar-2001 #text\_change 31-Mar-2001  
 C;Accession: JC7535  
 R;Tsujibo, H.; Okamoto, T.; Hatano, N.; Miyamoto, K.; Watanabe, T.; Mitsutomi, M.; Inanami, S. Biosci. Biotechnol. Biochem. 64, 2445-2453, 2000  
 A;Title: Family 19 chitinases from Streptomyces thermoviolaceus OPC-520: Molecular cloning  
 A;Reference number: JC7535; MUID:21036907  
 A;Accession: JC7535  
 A;Molecule type: DNA  
 A;Residues: 1-377 <TSU>  
 A;Cross-references: DDBJ:AB016842  
 A;Experimental source: strain OPC-520  
 C;Comment: This enzyme, a member of the family 19 chitinases, is involved in chitin degradation  
 C;Genetics:  
 A;Gene: ch135  
 C;Keywords: hydrolase; glycosidase

Query Match 50.6%; Score 39; DB 3; Length 377;  
 Best Local Similarity 50.0%; Pred. No. 27;  
 Matches 7; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

## QY 1 CIGLAGTDFANORP 14

Db 47 CLDVAGADSANGTP 60

## RESULT 9

A56683  
 receptor protein kinase RPK-1 precursor - chicken  
 C;Species: Gallus gallus (chicken)  
 C;Date: 08-Jul-1995 #sequence\_revision 03-Aug-1995 #text\_change 24-Sep-1999  
 C;Accession: A56683  
 R;Sumitomo, S.; Saito, T.; Nohno, T. DNA Seq. 3, 297-302, 1993  
 A;Title: A new receptor protein kinase from chick embryo related to type II receptor for  
 A;Reference number: A56683; MUID:94003400

## A;Accession: A56683

A;Status: preliminary  
 A;Molecule type: mRNA  
 A;Residues: 1-502 <SUM>  
 A;Cross-references: GB:DL13432; NID:g222862; PIDN:BAA02694.1; PID:dl1003199; PID:g22286  
 C;Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase hom  
 C;Keywords: ATP; phosphotransferase; transmembrane protein  
 F;202-498/Domain: protein kinase homology <KIN>  
 F;210-218/Region: protein kinase ATP-binding motif

Query Match 50.6%; Score 39; DB 2; Length 502;  
 Best Local Similarity 66.7%; Pred. No. 36;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

## QY 1 CIGLAGTDF 9

Db 71 CLGLEGSDF 79

## RESULT 10

A53444  
 activin receptor-like kinase 6 precursor - mouse  
 C;Species: Mus musculus (house mouse)  
 C;Date: 19-May-1994 #sequence\_revision 19-May-1994 #text\_change 24-Sep-1999  
 C;Accession: A53444; S40159  
 R;ten Dijke, P.; Yamashita, H.; Ichijo, H.; Franzen, P.; Laiho, M.; Miyazono, K.; Hei Science 264, 101-104, 1994  
 A;Title: Characterization of type I receptors for transforming growth factor-beta and  
 A;Reference number: A53444; MUID:94188705  
 A;Accession: A53444  
 A;Status: preliminary  
 A;Molecule type: mRNA  
 A;Residues: 1-502 <TEN>  
 A;Cross-references: GB:223143; NID:g437870; PIDN:CAA80674.1; PID:g437871  
 R;Miyazono, K.; Moren, A.; Grimsby, S.; Ichijo, H.; Heidlin, C.; ten Dijke, P. Submitted to the EMBL data Library, June 1993  
 A;Description: ALK-3 and ALK-6: the closely related members in the serine/threonine k  
 A;Reference number: S40158  
 A;Accession: S40159  
 A;Status: preliminary  
 A;Molecule type: mRNA  
 A;Residues: 1-502 <MTY>  
 A;Cross-references: EMBL:Z23143; NID:g437870; PIDN:CAA80674.1; PID:g437871  
 C;Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase hom  
 C;Keywords: ATP; serine/threonine-specific protein kinase; transmembrane protein  
 F;202-498/Domain: protein kinase homology <KIN>  
 F;210-218/Region: protein kinase ATP-binding motif

Query Match 50.6%; Score 39; DB 2; Length 502;  
 Best Local Similarity 66.7%; Pred. No. 36;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

## QY 1 CIGLAGTDF 9

Db 71 CLGLEGSDF 79

## RESULT 11

JC2491  
 serine/threonine kinase receptor - rat  
 C;Species: Rattus norvegicus (Norway rat)  
 C;Date: 22-Apr-1995 #sequence\_revision 26-May-1995 #text\_change 10-Sep-1997  
 C;Accession: JC2491  
 R;Yamaji, N.; Celeste, A.J.; Thies, R.S.; Song, J.J.; Bernier, S.M.; Goltzman, D.; Ly Biochem. Biophys. Res. Commun. 205, 1944-1951, 1994  
 A;Title: A mammalian serine/threonine kinase receptor specifically binds BMP-2 and BM  
 A;Reference number: JC2491; MUID:95110346  
 A;Accession: JC2491  
 A;Molecule type: mRNA  
 A;Residues: 1-502 <YAM>  
 C;Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase hom

C:Keywords: ATP; glycoprotein; transmembrane protein  
 F:127-148/Domain: transmembrane #status predicted <TM>  
 F:202-498/Domain: protein kinase homology <KIN>  
 F:210-218/Region: protein kinase ATP-binding motif  
 F:284,343,388/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 50.6%; Score 39; DB 2; Length 502;  
 Best Local Similarity 66.7%; Pred. No. 36;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
 ||| |||  
 Db 71 CLGLEGSDF 79

## RESULT 12

JW0067  
 chitinase (EC 3.2.1.14) A - Emericella nidulans  
 N:Alternate names: chIA  
 C:Species: Emericella nidulans, Aspergillus nidulans  
 C:Date: 13-Jun-1998 #sequence\_revision 10-Jul-1998 #text\_change 17-Mar-1999  
 C:Accession: JW0067  
 R:Takaya, N.; Yamazaki, D.; Horiuchi, H.; Ohta, A.; Takagi, M.  
 Biosci. Biotechnol. Biochem. 62, 60-65, 1998  
 A:Title: Cloning and characterization of a chitinase-encoding gene (chIA) from Aspergillus  
 A:Reference number: JW0067; MUID:98162139  
 A:Accession: JW0067  
 A:Molecule type: mRNA  
 A:Residues: 1-660 <TAK>  
 A:Cross-references: DDBJ:D87895; NID:g2821948; PID:d1025495; PID:g2828335  
 C:Comment: This enzyme hydrolyzes chitin at beta-1,4 bonds between N-acetylglucosamine  
 C:Genetics:  
 A:Gene: chIA  
 C:Keywords: glycosidase; hydrolase

Query Match 50.6%; Score 39; DB 2; Length 660;  
 Best Local Similarity 70.0%; Pred. No. 48;  
 Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3 GLAGTDFANQ 12  
 || ||| ||  
 Db 71 GLPGSDFGNQ 80

## RESULT 13

G83726  
 assimilatory nitrate reductase (catalytic subunit) nasC [imported] - Bacillus halodurans  
 C:Species: Bacillus halodurans  
 C:Date: 01-Dec-2000 #sequence\_revision 01-Dec-2000 #text\_change 08-Dec-2000  
 C:Accession: G83726  
 R:Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fujii, F.; Hira  
 Nucleic Acids Res. 28, 4317-4331, 2000  
 A:Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and  
 A:Reference number: A83650; MUID:20263314  
 A:Accession: G83726  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-743 <STO>  
 A:Cross-references: GB:AP001509; GB:BA000004; NID:g10173176; PIDN:BA04334.1; GSPDB:GNOC  
 A:Experimental source: strain C-125  
 C:Genetics:  
 A:Gene: nasC  
 C:Superfamily: formate dehydrogenase

Query Match 50.6%; Score 39; DB 2; Length 743;  
 Best Local Similarity 57.1%; Pred. No. 54;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANORP 14  
 || ||||| ||

Db 184 CIVLACTNLAEQOP 197

## RESULT 14

T22595  
 hypothetical protein F53H4.1 - Caenorhabditis elegans  
 C:Species: Caenorhabditis elegans  
 C:Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 18-Feb-2000  
 C:Accession: T22595  
 R:Dobson, R.  
 submitted to the EMBL Data Library, October 1996  
 A:Reference number: Z19587  
 A:Accession: T22595  
 A:Status: preliminary; translated from GB/EMBL/DDBJ  
 A:Molecule type: DNA  
 A:Residues: 1-1785 <WIL>  
 A:Cross-references: EMBL:281089; PIDN:CAB03135.1; GSPDB:GN00028; CESP:F53H4.1  
 A:Experimental source: clone F53H4  
 C:Genetics:  
 A:Gene: CESP:F53H4.1  
 A:Map position: X  
 A:Introns: 42/2; 196/2; 245/2; 454/3; 562/2; 658/2; 730/3; 790/2; 844/3; 953/1; 1007/

Query Match 50.6%; Score 39; DB 2; Length 1785;  
 Best Local Similarity 50.0%; Pred. No. 1.3e+02;  
 Matches 7; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANORP 14

||| ||| ||  
 Db 565 CVSLTGADSAARP 578

## RESULT 15

F70636  
 probable ephB protein - Mycobacterium tuberculosis (strain H37RV)  
 C:Species: Mycobacterium tuberculosis  
 C:Date: 17-Jul-1998 #sequence\_revision 17-Jul-1998 #text\_change 20-Jun-2000  
 C:Accession: F70636  
 R:Coles, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon  
 ; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd,  
 Rajandream, M.A.; Rogers, R.; Rutter, S.; Seeger, K.; Skelton, S.; Squares, S.  
 Nature 393, 537-544, 1998  
 A:Authors: Squares, R.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G.  
 A:Title: Deciphering the biology of Mycobacterium tuberculosis from the complete geno  
 A:Reference number: A70500; MUID:98295987  
 A:Accession: F70636  
 A:Status: preliminary; nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-356 <COL>  
 A:Cross-references: GB:284498; GB:AL123456; NID:g3261701; PIDN:CAB06523.1; PID:g18062  
 A:Experimental source: strain H37RV  
 C:Genetics:  
 A:Gene: ephB  
 C:Superfamily: tropinesterase

Query Match 49.4%; Score 38; DB 2; Length 356;  
 Best Local Similarity 53.8%; Pred. No. 39;  
 Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 IGLAGTDFANORP 14

||| ||| ||  
 Db 137 IGLPGSPFGERRP 149

Search completed: March 26, 2002, 13:37:21  
 Job time: 55 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:44 ; Search time 24.63 seconds  
(without alignments)  
20.841 Million cell updates/sec

Title: US-09-709-201-100  
Perfect score: 77  
Sequence: 1 CIGLAGTDFANQRP 14

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 100059 seqs, 36664827 residues

Total number of hits satisfying chosen parameters: 100059

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : SwissProt\_39:\*

pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	68	88.3	392	1 OM1P_CHLPS	Q00087 chlamydia p
2	40	51.9	98	1 C552_HYDTH	P15452 hydrogenoba
3	39	50.6	289	1 CRTE_RHOCA	P17060 rhodobacter
4	39	50.6	324	1 YM02_MYCTU	Q10391 mycobacteri
5	39	50.6	502	1 BMRE_CHICK	Q05438 gallus gall
6	39	50.6	502	1 BMRE_HUMAN	Q00238 homo sapien
7	39	50.6	502	1 BMRE_MOUSE	P36898 mus musculu
8	37	48.1	141	1 MBOB_METCA	P18797 methylococc
9	37	48.1	276	1 Y056_MYCPN	P75046 mycoplasma
10	36.5	47.4	358	1 LIP_PSEGL	Q05489 pseudomonas
11	36	46.8	155	1 RISC_AERPE	Q9Y4C5 aeropyrum p
12	36	46.8	300	1 YGAF_SHIFL	P37775 shigella fl
13	36	46.8	426	1 GLTA_MYCLE	Q9x794 mycobacteri
14	36	46.8	464	1 WCAM_ECOLI	P71244 escherichia
15	36	46.8	467	1 WCAM_SALTY	P26389 salmonella
16	36	46.8	616	1 AGT1_YEAST	P53048 saccharomyc
17	36	46.8	632	1 FTSH_HELPJ	Q9ZM66 helicobacte
18	36	46.8	632	1 FTSH_HELPY	P71408 helicobacte
19	36	46.8	638	1 FTSH_HELPF	Q32617 helicobacte
20	35	45.5	118	1 GLBN_NOSSN	P52335 nostoc sp.
21	35	45.5	241	1 PSB1_YEAST	P23724 saccharomyc
22	35	45.5	273	1 ALKB_SCHPO	O60066 schizosacch
23	35	45.5	314	1 IUNH_CRIFA	Q27546 crithidia f
24	35	45.5	350	1 ADHL_CANAL	P43067 candida alb
25	35	45.5	390	1 IADA_ECOLI	P39377 escherichia
26	35	45.5	440	1 YHRI_YEAST	P38820 saccharomyc
27	35	45.5	496	1 SWA1_SALTY	P37594 salmonella
28	35	45.5	601	1 MAON_SALTU	P37225 solanum tub
29	35	45.5	628	1 YZ68_PSEAE	P28812 pseudomonas
30	35	45.5	672	1 SL52_RABIT	P26430 oryctolagus
31	35	45.5	718	1 CTPC_MYCTU	P96875 mycobacteri
32	35	45.5	725	1 CTPC_MYCLE	Q9cc11 mycobacteri
33	35	45.5	1112	1 ATB2_OREMO	P58165 oreochromis

34	35	45.5	1198	1 ATB2_MOUSE	Q9R0K7 mus musculu
35	35	45.5	1203	1 ATB4_RAT	Q64542 rattus norv
36	35	45.5	1220	1 ATB1_PIG	P23220 sus scrofa
37	35	45.5	1220	1 ATB3_HUMAN	Q16720 homo sapien
38	35	45.5	1241	1 ATB4_HUMAN	P23634 homo sapien
39	35	45.5	1243	1 ATB2_HUMAN	Q01814 homo sapien
40	35	45.5	1243	1 ATB2_RAT	P11506 rattus norv
41	35	45.5	1249	1 ATB1_RABIT	Q00804 oryctolagus
42	35	45.5	1258	1 ATB1_HUMAN	P20020 homo sapien
43	35	45.5	1258	1 ATB1_RAT	P11505 rattus norv
44	35	45.5	1258	1 ATB3_RAT	Q64568 rattus norv
45	35	45.5	1643	1 OMPB_RICPR	Q53020 r outer mem

ALIGNMENTS

RESULT 1  
OM1P\_CHLPS STANDARD; PRT; 392 AA.  
ID AC Q00087;  
DT 01-DEC-1992 (Rel. 24, Created)  
DT 01-DEC-1992 (Rel. 24, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
GN OMPA OR OMPI.  
OS Chlamydia psittaci (Chlamydophila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.  
OX NCBI\_Taxid=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX STRAIN=FPN/PRING;  
RX MEDLINE=94103736; PubMed=8277245;  
RA Storey C., Lusher M., Yates P., Richmond S.;  
RT "Evidence for Chlamydia pneumoniae of non-human origin.";  
RL J. Gen. Microbiol. 139:2621-2626(1993).  
CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/  
CC or send an email to license@isb-sib.ch).  
CC -----  
CC EMBL; X61096; CAA43409.1;  
CC PIR; A40371; A40371.  
CC PIR; S16137; S16137.  
CC InterPro: IPR000604; Chlamydia\_OMP.  
CC Pfam: PF01308; Chlamydia\_OMP; 1.  
CC ProDom: PD001717; Chlamydia\_OMP; 1.  
CC Outer membrane; Transmembrane; Porin; Signal.  
CC SIGNAL 1 22  
CC CHAIN 23 392 MAJOR OUTER MEMBRANE PROTEIN.  
CC SEQUENCE 392 AA; 42069 MW; 88B3C5D90BBA26DB CRC64;

Query Match 88.3%; Score 68; DB 1; Length 392;  
Best Local Similarity 100.0%; Pred. No. 7.5e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQRP 14  
| | | | | | | | | | | | | | | |  
DB 160 IGLAGTDFANQRP 172

Tue Mar 26 15:55:31 2002

```
RESULT 2
C552_HYDTH STANDARD; PRT; 98 AA.
AC P13452;
DT 01-APR-1990 (Rel. 14, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE CYTOCHROME C-552 PRECURSOR (C552).
OS Hydrogenobacter thermophilus.
OC Bacteria; Aquificales; Aquificaceae; Hydrogenobacter.
OX NCBI_TaxID=940;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=TK-6;
RX MEDLINE=91249816; PubMed=1645652;
RA Sambongi Y., Yang J.H., Igarashi Y., Kodama T.;
RT "Cloning, nucleotide sequence and expression of the cytochrome c-552
RT gene from Hydrogenobacter thermophilus.";
RL Eur. J. Biochem. 198;7-12(1991).
RN [2]
RP SEQUENCE OF 19-98.
RX STRAIN=TK-6;
RX MEDLINE=89123087; PubMed=2336668;
RA Sambongi Y., Ishii M., Igarashi Y., Kodama T.;
RT "Amino acid sequence of cytochrome c-552 from a thermophilic
RT hydrogen-oxidizing bacterium, Hydrogenobacter thermophilus.";
RL J. Bacteriol. 171;65-69(1989).
RN [3]
RP THERMOSTABILITY.
RX MEDLINE=90122832; PubMed=2558725;
RA Sambongi Y., Igarashi Y., Kodama T.;
RT "Thermostability of cytochrome c-552 from the thermophilic hydrogen-
RT oxidizing bacterium Hydrogenobacter thermophilus.";
RL Biochemistry 28;9574-9578(1989).
RN [4]
RP STRUCTURE BY NMR.
RX STRAIN=TK-6;
RX MEDLINE=98322065; PubMed=9657676;
RA Hasegawa J., Yoshida T., Yamazaki T., Sambongi Y., Yu Y., Igarashi Y.,
RA Kodama T., Yamazaki K., Kyogoku Y., Kobayashi Y.;
RT "Solution structure of the thermostable cytochrome c-552 from
RT Hydrogenobacter thermophilus determined by 1H-NMR spectroscopy.";
RL Biochemistry 37;9641-9649(1998).
CC -!- FUNCTION: REACTS WITH HYDROGENASE.
CC -!- PTM: BINDS ONE HEME GROUP PER MOLECULE.
CC -!- SIMILARITY: 56% WITH P.AERUGINOSA C551.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; X57735; CAA40902.1; -
CC PIR; A32226; A32226.
CC PIR; S32485; S32485.
CC PDB; 1AYG; 13-JAN-99.
CC InterPro: IPR000345; CytC_heme_bind.
CC InterPro: IPR003088; Cyt-C1.
CC InterPro: IPR002324; Cyt_CID.
CC Pfam; PF00034; cytochrome_c; 1.
CC PRINTS; PR00606; CYTOCHROME_C1.
CC PROSITE; PS00190; CYTOCHROME_C; 1.
CC Electron transport; Heme; Signal; 3D-structure.
CC SIGNAL
CC CHAIN 1 18 CYTOCHROME C-552.
CC BINDING 28 28 HEME (COVALENT).
CC BINDING 31 31 HEME (COVALENT).
CC METAL 32 32 IRON (HEME AXIAL LIGAND).
CC METAL 77 77 IRON (HEME AXIAL LIGAND).
CC SEQUENCE 98 AA; 10431 MW; F49713D829DDE927 CRC64;
CC -----
Query Match 51.9%; Score 40; DB 1; Length 98;
Best Local Similarity 58.3%; Pred. No. 2;
Matches 7; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 2 IGLAGTDFANOR 13
DB 10 VGLAGITFANEQ 21
RESULT 3
CRTE_RHOCA STANDARD; PRT; 289 AA.
ID CRTE_RHOCA
AC P17060;
DT 01-AUG-1990 (Rel. 15, Created)
DT 01-AUG-1990 (Rel. 15, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE GERANYLGERANYL PYROPHOSPHATE SYNTHETASE (EC 2.5.1.29) (GGPP
DE SYNTHETASE) (FARNESYLTRANSFERASE).
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=SB1003; AND BEC404;
RX MEDLINE=89313663; PubMed=2747617;
RA Armstrong G.A., Alberti M., Leach F., Hearst J.E.;
RT "Nucleotide sequence, organization, and nature of the protein
RT products of the carotenoid biosynthesis gene cluster of Rhodobacter
RT capsulatus.";
RL Mol. Gen. Genet. 216;254-268(1989).
CC -!- CATALYTIC ACTIVITY: TRANS-TRANS-FARNESYL DIPHOSPHATE + ISOPENTENYL
CC DIPHOSPHATE = PYROPHOSPHATE + GERANYLGERANYL DIPHOSPHATE.
CC -!- PATHWAY: CAROTENOID AND CHLOROPHYLL BIOSYNTHESIS.
CC -!- SIMILARITY: BELONGS TO THE FPP/GGPP SYNTHETASES FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; X52291; CAA36538.1; -
CC EMBL; Z11165; CAA77545.1; -
CC PIR; S04407; S04407.
CC InterPro: IPR000092; Polyprenyl_synth.
CC Pfam; PF00348; polyprenyl_synth; 1.
CC PROSITE; PS00444; POLYPRENYL_SYNTHET_2; 1.
CC PROSITE; PS00723; POLYPRENYL_SYNTHET_1; 1.
CC Photosynthesis; Chlorophyll biosynthesis; Carotenoid biosynthesis;
CC Isoprene biosynthesis; Transferase.
CC SEQUENCE 289 AA; 30043 MW; CF483A26EAC9C859 CRC64;
CC -----
Query Match 50.6%; Score 39; DB 1; Length 289;
Best Local Similarity 70.0%; Pred. No. 9.9;
Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 5 AGTDFANORP 14
DB 224 AGQDIANERP 233
RESULT 4
YMO2_MYCTU STANDARD; PRT; 324 AA.
ID YMO2_MYCTU
AC Q10391;
DT 01-OCT-1996 (Rel. 34, Created)
```

DT 01-OCT-1996 (Rel. 34, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE HYPOTHETICAL SUGAR KINASE RV2202C.  
 GN RV2202C OR MT2258 OR MTCV190.13C.  
 OS Mycobacterium tuberculosis.  
 OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;  
 OC Actinomycetales; Corynebacterineae; Mycobacteriaceae; Mycobacterium.  
 OX NCBI\_TaxID=1773;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=H37RV;  
 RX MEDLINE=98295987; PubMed=9634230;  
 RA Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D.,  
 RA Gordon S.V., Eiglmeier K., Gas S., Barry C.E. III, Tekala F.,  
 RA Badcock K., Basham D., Brown D., Chillingworth T., Connor R.,  
 RA Davies R., Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S.,  
 RA Hornsby T., Jagels K., Krogh A., McLean J., Moule S., Murphy L.,  
 RA Oliver S., Osborne J., Quail M.A., Rajandream M.A., Rogers J.,  
 RA Rutter S., Seeger K., Skelton S., Squares S., Squares R.,  
 RA Sulston J.E., Taylor K., Whitehead S., Barrell B.G.;  
 RT "Deciphering the biology of Mycobacterium tuberculosis from the  
 complete genome sequence";  
 RL Nature 393:537-544 (1998).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=CDC 1551 / Oshkosh;  
 RA Fleischmann R.D., Alland D., Eisen J.A., Carpenter L., White O.,  
 RA Peterson J., DeBoy R., Dodson R., Gwinn M.L., Haft D., Hickey E.,  
 RA Kolonay J.F., Nelson W.C., Umayam L.A., Emdolava M.D., Salzberg S.L.,  
 RA Delcher A., Utterback T., Weidman J., Khouri H., Gill J., Mikula A.,  
 RA Bishai W.;  
 RT "Whole genome comparison of Mycobacterium tuberculosis clinical and  
 laboratory strains";  
 RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.  
 CC -1- SIMILARITY: BELONGS TO THE PFKB FAMILY OF CARBOHYDRATE KINASES.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: Z70283; CAA94245.1; -;  
 CC EMBL: AE007071; AAK46544.1; -;  
 CC TIGR: MT2258; -;  
 CC TubercuList: RV2202c; -;  
 CC InterPro: IPR002173; pfkb.  
 CC Pfam: PF00294; pfkb; 1.  
 CC PROSITE: PS00583; PFKB\_KINASES\_1; 1.  
 CC PROSITE: PS00584; PFKB\_KINASES\_2; FALSE\_NEG.  
 CC Hypothetical protein; Transferase; Kinase; Complete proteome.  
 KW SEQUENCE 324 AA; 34472 MW; 0C072206A3210A1D CRC64;  
 SQ

Query Match 50.6%; Score 39; DB 1; Length 324;  
 Best Local Similarity 58.3%; Pred. No. 11;  
 Matches 7; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

OY 2 IGLAGTDFANOR 13  
 : | | | | :  
 Db 67 VGAAGADFADYR 78

RESULT 5  
 BMRB\_CHICK STANDARD; PRT; 502 AA.  
 ID BMRB\_CHICK  
 AC Q05438;  
 DT 01-OCT-1996 (Rel. 34, Created)  
 DT 01-OCT-1996 (Rel. 34, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE IB PRECURSOR (EC 2.7.1.37)

DE (SERINE/THREONINE-PROTEIN KINASE RECEPTOR R6) (SKR6) (ACTIVIN  
 GN RECEPTOR-LIKE KINASE 6) (ALK-6) (RPK-1).  
 GN BMPRII.  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus.  
 OX NCBI\_TaxID=9031;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=94003400; PubMed=8400359;  
 RA Yamazaki Y., Saito T., Nohno T.;  
 RT "A new receptor protein kinase from chick embryo related to type II  
 RT receptor for TGF-beta";  
 RL DNA Seq. 3:297-302(1993).  
 CC -1- CATALYTIC ACTIVITY: ATP + A PROTEIN - ADP + A PHOSPHOPROTEIN.  
 CC -1- SUBUNIT: HETERODIMERIZE WITH A TYPE-II RECEPTOR (BY SIMILARITY).  
 CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.  
 CC -1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.  
 CC TGFβ RECEPTOR SUBFAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: D13432; BAA02694.1; -;  
 CC HSSP: P00523; 2PTK.  
 CC InterPro: IPR000472; Activin\_rec.  
 CC InterPro: IPR000719; Euk\_pkinase.  
 CC InterPro: IPR003605; GS.  
 CC InterPro: IPR002290; Ser\_thr\_kin\_actsite.  
 CC Pfam: PF01064; Activin\_rec; 1.  
 CC Pfam: PF00059; pkinase; 1.  
 CC SMART: SM00467; GS; 1.  
 CC PROSITE: PS00107; PROTEIN\_KINASE\_ATP; 1.  
 CC PROSITE: PS00108; PROTEIN\_KINASE\_ST; 1.  
 CC PROSITE: PS00011; PROTEIN\_KINASE\_DOM; 1.  
 CC Receptor; Transferase; Serine/threonine-protein kinase; ATP-binding;  
 KW Transmembrane; Glycoprotein; Signal.  
 FT SIGNAL 1 13  
 FT CHAIN 14 502 BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE  
 FT IB.  
 FT DOMAIN 14 126 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 127 148 POTENTIAL.  
 FT DOMAIN 149 502 CYTOPLASMIC (POTENTIAL).  
 FT DOMAIN 204 494 PROTEIN KINASE.  
 FT NP\_BIND 210 218 ATP (BY SIMILARITY).  
 FT BINDING 231 231 ATP (BY SIMILARITY).  
 FT ACT\_SITE 332 332 BY SIMILARITY.  
 FT CARBOHYD 44 44 N-LINKED (GLCNAC...) (POTENTIAL).  
 SQ SEQUENCE 502 AA; 56766 MW; D5D93CCEBF2A068C CRC64;

Query Match 50.6%; Score 39; DB 1; Length 502;  
 Best Local Similarity 66.7%; Pred. No. 18;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 1 CIGLAGTDF 9  
 : | | | | :  
 Db 71 CLGLEGSDF 79

RESULT 6  
 BMRB\_HUMAN STANDARD; PRT; 502 AA.  
 ID BMRB\_HUMAN  
 AC Q00238; P78366;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)



```

Query Match          50.6%; Score 39; DB 1; Length 502;
Best Local Similarity 66.7%; Pred. No. 18;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9
   :||| :|||
Db 71 CLGLEGSDF 79

RESULT 8
MNOB_METCA STANDARD; PRT; 141 AA.
AC P18797;
DT 01-NOV-1990 (Rel. 16, Created)
DT 01-NOV-1990 (Rel. 16, Last sequence update)
DT 01-AUG-1991 (Rel. 19, Last annotation update)
DE METHANE MONOOXYGENASE REGULATORY PROTEIN B.
GN MNOB.
OS Methylococcus capsulatus.
OC Bacteria; Proteobacteria; gamma subdivision; Methylococcaceae;
OC Methylococcus.
OX NCBI_TaxID=414;
RN [1]
RP STRAIN=BATH;
RX MEDLINE=89373399; PubMed=2505721;
RA Stainthorpe A.C., Murrell J.C., Salmund G.P.C., Dalton H., Lees V.;
RT "Molecular analysis of methane monooxygenase from Methylococcus
RT capsulatus (Bath).";
RL Arch. Microbiol. 152:154-159(1989).
RN [2]
RP IDENTIFICATION OF PROTEIN, AND SEQUENCE OF 3-19.
RA Pilkington S.J., Salmund G.P.C., Murrell J.C., Dalton H.;
RT "Identification of the gene encoding the regulatory protein B of
RT soluble methane monooxygenase.";
RL FEMS Microbiol. Lett. 72:345-348(1990).
CC -1- FUNCTION: THE B PROTEIN ACTS AS A REGULATOR OF ELECTRON FLOW
CC THROUGH THE SOLUBLE MMO COMPLEX, SWITCHING THE ENZYME FROM AN
CC OXIDASE TO A HYDROXYLASE IN THE PRESENCE OF THE SUBSTRATE.
CC -1- SUBUNIT: M.CAPSULATUS HAS TWO FORMS OF METHANE MONOOXYGENASE,
CC A SOLUBLE AND A MEMBRANE-BOUND TYPE. THE SOLUBLE TYPE CONSISTS
CC OF THREE COMPONENTS (A, B AND C).
PR: JLO103; JLO103.
DR InterPro: IPR003454; MmoB_DmpM.
DR Pfam: PF02406; MmoB_DmpM; 1.
KW Oxidoreductase; Monooxygenase.
SQ SEQUENCE 141 AA; 16018 MW; 45A42A61D6C58406 CRC64;

Query Match          48.1%; Score 37; DB 1; Length 141;
Best Local Similarity 63.8%; Pred. No. 11;
Matches 7; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQ 12
   :||| :|||
Db 13 MGLKGKDFADQ 23

RESULT 9
Y056_MYCPN STANDARD; PRT; 276 AA.
AC P75046;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE HYPOTHETICAL PROTEIN MG056 HOMOLOG (D09_ORF276).
GN MPN071 OR MPN084.
OS Mycoplasma pneumoniae.
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Mollicutes;
OC Mycoplasmataceae; Mycoplasma.
OX NCBI_TaxID=2104;

```

---

```

[1]
RN SEQUENCE FROM N.A.
RP STRAIN=ATCC 29342 / M129;
RX MEDLINE=97105885; PubMed=8948633;
RA Himmelfreich R., Hilbert H., Plagens H., Pirkel E., Li B.-C.,
RA Herrmann R.;
RT "Complete sequence analysis of the genome of the bacterium Mycoplasma
RT pneumoniae.";
RL Nucleic Acids Res. 24:4420-4449(1996).
CC -1- SIMILARITY: BELONGS TO THE UPF0011 FAMILY.
CC -----
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; AE000010; AAB95732.1;
DR InterPro: IPR000878; Corrin_porph_mthyltrnf.
DR InterPro: IPR000578; UPF0011.
DR Pfam: PF00590; TP_methylase; 1.
DR PRODom: PD007098; UPF0011; 1.
DR PROSITE: PS01296; UPF0011; 1.
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 276 AA; 31062 MW; 2A071E7A17FCD0CD CRC64;

Query Match          48.1%; Score 37; DB 1; Length 276;
Best Local Similarity 50.0%; Pred. No. 22;
Matches 6; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQR 13
   :||| :|||
Db 43 LGLLGIDFSNQ 54

RESULT 10
LIP_PSEGL STANDARD; PRT; 353 AA.
AC Q05489;
DT 01-OCT-1994 (Rel. 30, Created)
DT 01-OCT-1994 (Rel. 30, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE LIPASE PRECURSOR (EC 3.1.1.3) (TRIACYLGLYCEROL LIPASE).
GN LIPA.
OS Pseudomonas glumae, and Chromobacterium viscosum.
OC Bacteria; Proteobacteria; beta subdivision; Burkholderia group;
OC Burkholderia.
OX NCBI_TaxID=337; 42739;
RN [1]
RP SEQUENCE FROM N.A., SEQUENCE OF 40-61, AND MUTAGENESIS.
RC SPECIES=P. glumae; STRAIN=PG1 / CBS 322.89;
RX MEDLINE=93119130; PubMed=1476423;
RA Frenken L.G.J., Egmond M.R., Batenburg A.M., Bos J.W., Visser C.,
RA Verrips C.T.;
RT "Cloning of the Pseudomonas glumae lipase gene and determination of
RT the active site residues.";
RL Appl. Environ. Microbiol. 58:3787-3791(1992).
RN [2]
RP SEQUENCE OF 40-54, AND CHARACTERIZATION.
RC SPECIES=C. viscosum;
RX MEDLINE=95306500; PubMed=7786905;
RA Taipa M.A., Liebeton K., Costa J.V., Cabral J.M.S., Jaeger K.-E.;
RT "Lipase from Chromobacterium viscosum: biochemical characterization
RT indicating homology to the lipase from Pseudomonas glumae.";
RL Biochim. Biophys. Acta 1256:396-402(1995).
RN [3]
RP X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RC SPECIES=P. glumae;
RX MEDLINE=94009622; PubMed=8405390;
RA Noble M.E.M., Cleasby A., Johnson L.N., Egmond M.R., Frenken L.G.J.;

```

RT "The crystal structure of triacylglycerol lipase from *Pseudomonas*  
 RL glumae reveals a partially redundant catalytic aspartate.";  
 RN [4]  
 RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS).  
 RC SPECIES=C.viscosum; STRAIN=ATCC 6918;  
 RX MEDLINE=96275656; PubMed=8683577;  
 RA Lang D., Hofmann B., Haack L., Hecht H.-J., Spener F., Schmid R.D.,  
 RA Schomburg D.;  
 RT "Crystal structure of a bacterial lipase from *Chromobacterium*  
 RT viscosum ATCC 6918 refined at 1.6-A resolution.";  
 RL J. Mol. Biol. 259:704-717(1996).  
 CC -1- FUNCTION: HYDROLYSIS OF TRIGLYCERIDES.  
 CC -1- CATALYTIC ACTIVITY: TRIACYLGLYCEROL + H(2)O = DIACYLGLYCEROL +  
 CC A FATTY ACID ANION.  
 CC -1- SUBUNIT: REQUIRES CALCIUM.  
 CC -1- SUBUNIT: MONOMER.  
 CC -1- SUBCELLULAR LOCATION: SECRETED.  
 CC -1- SIMILARITY: STRONG TO OTHER PSEUDOMONAS LIPASES.  
 CC -1- SIMILARITY: PARTIAL WITH OTHER LIPASES (PANCREATIC, GASTRIC,  
 CC HEPATIC, LINGUAL, LIPOPROTEIN, BACTERIAL, ETC.).  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
 CC or send an email to license@isb-sib.ch).  
 CC -----  
 CC EMBL: X70354; CAA019812.1; -;  
 CC EMBL: A16323; CAA01279.1; -;  
 CC EMBL: A32021; CAA02073.1; -;  
 CC PIR: A48952; A48952.  
 CC PIR: S37291; S37291.  
 CC PDB: 1TAH; 3I-MAY-94.  
 CC InterPro: IPR000073; Abhydrolase.  
 CC InterPro: IPR000379; Est\_lip\_thioest\_actsite.  
 CC Pfam: PF00561; abhydrolase; 1.  
 CC PROSITE: PS00120; LIPASE\_SER; 1.  
 KW Hydrolase; Lipid degradation; Signal; Calcium; 3D-structure.  
 FT SIGNAL 1 39  
 FT CHAIN 40 358 LIPASE.  
 FT ACT\_SITE 126 126 CHARGE RELAY SYSTEM.  
 FT ACT\_SITE 302 302 CHARGE RELAY SYSTEM.  
 FT ACT\_SITE 324 324 CHARGE RELAY SYSTEM.  
 FT DISULFID 229 308  
 FT MUTAGEN 54 54 H->A: NO LOSS OF ACTIVITY.  
 FT MUTAGEN 126 126 S->A: COMPLETE LOSS OF ACTIVITY.  
 FT MUTAGEN 160 160 D->E: NO LOSS OF ACTIVITY.  
 FT MUTAGEN 160 160 D->A: NO LOSS OF ACTIVITY.  
 FT MUTAGEN 280 280 D->E: NO LOSS OF ACTIVITY.  
 FT MUTAGEN 280 280 D->A: COMPLETE LOSS OF ACTIVITY.  
 FT MUTAGEN 302 302 D->E: NO LOSS OF ACTIVITY.  
 FT MUTAGEN 302 302 D->A: 75% LOSS OF ACTIVITY.  
 FT MUTAGEN 324 324 H->A: COMPLETE LOSS OF ACTIVITY.  
 FT CONFLICT 40 40 A -> W (IN REF. 2).  
 SQ SEQUENCE 358 AA; 36928 MW; FE7B5D7A22EC6B4B CRC64;  
 Query Match 47.4%; Score 36.5; DB 1; Length 358;  
 Best Local Similarity 90.0%; Pred. No. 36;  
 Matches 9; Conservative 0; Mismatches 0; Indels 1; Gaps 1;  
 QY 3 GLAGTD-FAN 11  
 Db 55 GLAGTDKFN 64  
 RESULT 11  
 RISC\_AERPE STANDARD; PRT; 155 AA.  
 ID

AC Q9YDC5;  
 DT 20-AUG-2001 (Rel. 40, Created)  
 DT 20-AUG-2001 (Rel. 40, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE RIBOFLAVIN SYNTHASE (EC 2.5.1.9).  
 GN RIBC OR APE0988.  
 OS Aeropyrum pernix.  
 OC Archaea; Crenarchaeota; Desulfurococcales; Desulfurococcaceae;  
 OC Aeropyrum.  
 OX NCBI\_TaxID=56636;  
 RN [1]  
 RN SEQUENCE FROM N.A.  
 RP STRAIN=KI.  
 RC MEDLINE=99310339; PubMed=10382966;  
 RA Kawaiabayashi Y., Hino Y., Horikawa H., Yamazaki S., Halkawa Y.,  
 RA Jin-no K., Takahashi M., Sekine M., Baba S.-I., Anka A., Kosugi H.,  
 RA Hosoyama A., Fukui S., Nagai Y., Nishijima K., Nakazawa H.,  
 RA Takamiya M., Masuda S., Funahashi T., Tanaka T., Kudoh Y.,  
 RA Yamazaki J., Kishida N., Oguchi A., Aoki K.-I., Kubota K.,  
 RA Nakamura Y., Nomura N., Sako Y., Kikuchi H.;  
 RT "Complete genome sequence of an aerobic hyper-thermophilic  
 RT crenarchaeon, *Aeropyrum pernix* KI.";  
 RL DNA Res. 6:83-101(1999).  
 CC -1- CATALYTIC ACTIVITY: 2 6,7-DIMETHYL-8-(1-D-RIBITYL) LUMAZINE -  
 CC RIBOFLAVIN + 4-(1-D-RIBITYLAMINO)-5-AMINO-2,6-DIHYDROXYPYRIMIDINE.  
 CC -1- COFACTOR: FLAVOPROTEIN (BY SIMILARITY).  
 CC -1- PATHWAY: FINAL STEP OF RIBOFLAVIN SYNTHESIS.  
 CC -1- SIMILARITY: BELONGS TO THE DMRL SYNTHASE FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
 CC or send an email to license@isb-sib.ch).  
 CC -----  
 CC EMBL: AP000060; BAA79972.1; -;  
 CC Riboflavin biosynthesis; Transferase; Flavoprotein; Complete proteome.  
 KW SEQUENCE 155 AA; 16576 MW; 644B7A1BD313A4F3 CRC64;  
 Query Match 46.8%; Score 36; DB 1; Length 155;  
 Best Local Similarity 60.0%; Pred. No. 18;  
 Matches 6; Conservative 2; Mismatches 2; Indels 0; Gaps 0;  
 QY 1 CIGLAGTDFA 10  
 Db 4 CVGVADTTFA 13  
 RESULT 12  
 YGAF\_SHIFL STANDARD; PRT; 300 AA.  
 ID YGAF\_SHIFL  
 AC P37775;  
 DT 01-OCT-1994 (Rel. 30, Created)  
 DT 01-OCT-1994 (Rel. 30, Last sequence update)  
 DT 01-OCT-1994 (Rel. 30, Last annotation update)  
 DE HYPOTHETICAL PROTEIN IN GALF 5'REGION (ORF1X3) (FRAGMENT).  
 OS Shigella flexneri.  
 OC Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae;  
 OC Shigella.  
 OX NCBI\_TaxID=623;  
 RN [1]  
 RN SEQUENCE FROM N.A.  
 RP STRAIN=SEROTYPE 2A;  
 RX MEDLINE=94131953; PubMed=7507920;  
 RA Morona R., Mavris M., Fallarino A., Manning P.A.;  
 RT "Characterization of the rfc region of *Shigella flexneri*.";  
 RL J. Bacteriol. 176:733-747(1994).  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -

CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC -----  
 DR EMBL; X71970; CAA50765.1; -  
 KW Hypothetical protein.  
 FT NON\_TER 1  
 SQ SEQUENCE 300 AA; 33367 MW; 4735B2EF93E21325 CRC64;

Query Match 46.8%; Score 36; DB 1; Length 300;  
 Best Local Similarity 53.8%; Pred. No. 36;  
 Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQRP 14  
 |||||:| |  
 DB 73 IGLAGTGYDNNYP 85

RESULT 13  
 GLYA\_MYCLE STANDARD; PRT; 426 AA.  
 ID GLYA\_MYCLE  
 AC Q9X794;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE SERINE HYDROXYMETHYLTRANSFERASE (EC 2.1.2.1) (SERINE METHYLASE)  
 DE (SHMT).  
 GN GLYA OR ML1953 OR MLCB1222.22.  
 OS Mycobacterium leprae.  
 OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;  
 OC Actinomycetales; Corynebacterineae; Mycobacteriaceae; Mycobacterium.  
 OX NCBI\_TaxID=1769;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=TN;  
 RX MEDLINE=21128732; PubMed=11234002;  
 RA Cole S.T., Eiglmeyer K., Parkhill J., James K.D., Thomson N.R.,  
 Wheeler P.R., Honore N., Garnier T., Churcher C., Harris D.,  
 Mungall K., Basham D., Brown D., Chillingworth T., Connor R.,  
 Davies R.M., Devlin K., Duthoy S., Feltwell T., Fraser A., Hamlin N.,  
 Holroyd S., Hornsby T., Jagels K., Lacroix C., Maclean J., Moule S.,  
 Murphy L., Oliver K., Quail M.A., Rajandream M.A., Rutherford K.M.,  
 Rutter S., Seeger K., Simon S., Simmonds M., Skelton J., Squares R.,  
 Squares S., Stevens K., Taylor K., Whitehead S., Woodward J.R.,  
 Bartell B.G.;  
 RT "Massive gene decay in the leprosy bacillus";  
 RL Nature 409:1007-1011(2001).  
 CC -!- FUNCTION: INTERCONVERSION OF SERINE AND GLYCINE.  
 CC -!- CATALYTIC ACTIVITY: 5,10-METHYLENETETRAHYDROFOLATE + GLYCINE +  
 CC H(2)O = TETRAHYDROFOLATE + L-SERINE.  
 CC -!- COFACTOR: PYRIDOXAL PHOSPHATE (BY SIMILARITY).  
 CC -!- PATHWAY: KEY ENZYME IN THE BIOSYNTHESIS OF PURINES, LIPIDS,  
 CC HORMONES AND OTHER COMPONENTS.  
 CC -!- SUBUNIT: HOMOTETRAMER (BY SIMILARITY).  
 CC -!- SUBCELLULAR LOCATION: CYTOPLASMIC (BY SIMILARITY).  
 CC -!- SIMILARITY: BELONGS TO THE SHMT FAMILY.

CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC EMBL; AL049491; CAB39828.1; -  
 DR EMBL; AL583923; CAC30908.1; -  
 DR Leproma; ML1953; -  
 DR InterPro; IPR001085; SHMT.  
 DR Pfam; PF00464; SHMT; 1.

DR PROSITE; PS00096; SHMT; FALSE\_NEG.  
 KW Transferase; Pyridoxal phosphate; One-carbon metabolism;  
 KW Complete proteome. 227 PYRIDOXAL PHOSPHATE (BY SIMILARITY).  
 FT BINDING 227  
 SQ SEQUENCE 426 AA; 45224 MW; 27783E2328AF2C98 CRC64;

Query Match 46.8%; Score 36; DB 1; Length 426;  
 Best Local Similarity 63.6%; Pred. No. 33;  
 Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 4 LAGTDFANQRP 14  
 | | | | | : |  
 DB 82 LFGADFANVQP 92

RESULT 14  
 WCAM\_ECOLI STANDARD; PRT; 464 AA.  
 ID WCAM\_ECOLI  
 AC P71244; P76378;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE COLANIC ACID BIOSYNTHESIS PROTEIN WCAM.  
 GN WCAM OR B2043.  
 OS Escherichia coli.  
 OC Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae;  
 OC Escherichia.  
 OX NCBI\_TaxID=562;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=K12;  
 RX MEDLINE=96326333; PubMed=8759852;  
 RA Stevenson G., Andrianopoulos K., Hobbs M., Reeves P.R.;  
 RT "Organization of the Escherichia coli K-12 gene cluster responsible  
 RL J. Bacteriol. 178:4885-4893(1996).  
 RN [2]  
 RP REVISIONS.  
 RC STRAIN=K12;  
 RA Reeves P.R.;  
 RL Submitted (APR-1998) to the EMBL/GenBank/DBJ databases.  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=K12 / MCL655;  
 RX MEDLINE=97426617; PubMed=9278503;  
 RA Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,  
 Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,  
 Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,  
 Mau B., Shao Y.;  
 RT "The complete genome sequence of Escherichia coli K-12";  
 RL Science 277:1232-1244(1999).  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=K12;  
 RX MEDLINE=97251358; PubMed=9097040;  
 RA Itoh T., Alba H., Baba T., Fujita K., Hayashi K., Inada T.,  
 Isono K., Kasai H., Kimura S., Kitakawa M., Kitagawa M.,  
 Makino K., Miki T., Mizobuchi K., Mori H., Mori T., Motomura K.,  
 Nakade S., Nakamura Y., Nishimoto H., Nishio Y., Oshima T.,  
 Saito N., Sampei G., Seki Y., Sivasubramanian S., Tagami H.,  
 Takeda J., Takemoto K., Wada C., Yamamoto Y., Horiuchi T.;  
 RT "A 450-Kb DNA sequence of the Escherichia coli K-12 genome  
 RL corresponding to the 40.1-50.0 min region on the linkage map";  
 CC DNA Res. 3:379-392(1996).  
 CC -!- PATHWAY: INVOLVED IN THE BIOSYNTHESIS OF THE SLIME POLYSACCHARIDE  
 CC COLANIC ACID.

CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----

DR EMBL; U38473; AAC77852.1; -

DR EMBL; AE000295; AAC75104.1; -

DR EMBL; D90842; BAA15897.1; -

DR EcoGene; EGI2651; wcam.

KW Lipopolysaccharide biosynthesis; Complete proteome.

SQ SEQUENCE 464 AA; 51315 MW; 72A7655DC07368BE CRC64;

Query Match 46.8%; Score 36; DB 1; Length 464;

Best Local Similarity 53.8%; Pred. No. 58;

Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQRP 14

||||: :| |

Db 228 IGLAGSTYDNNYP 240

RESULT 15

WCAM\_SALTY STANDARD; PRT; 467 AA.

ID WCAM\_SALTY

AC P26389;

DT 01-AUG-1992 (Rel. 23, Created)

DT 01-AUG-1992 (Rel. 23, Last sequence update)

DT 01-NOV-1997 (Rel. 35, Last annotation update)

DE COLANIC ACID BIOSYNTHESIS PROTEIN WCAM.

GN WCAM.

OS Salmonella typhimurium.

OC Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae;

OC Salmonella.

OX NCBI\_TaxID=602;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=LT2;

RX MEDLINE=91260454; PubMed=1710759;

RA Jiang X.-M., Neal B., Santiago F., Lee S.J., Romana L.K., Reeves P.R.;

RT "Structure and sequence of the rfb (O antigen) gene cluster of

RT Salmonella serovar typhimurium (strain LT2).";

RL Mol. Microbiol. 5:695-713(1991).

CC -1- PATHWAY: INVOLVED IN THE BIOSYNTHESIS OF THE SLIME POLYSACCHARIDE

COLANIC ACID.

-----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----

DR EMBL; X56793; CAA40113.1; -

DR PIR; S15297; S15297.

DR StyGene; SG10448; wcam.

KW Lipopolysaccharide biosynthesis.

SQ SEQUENCE 467 AA; 50958 MW; 9DCCFD551218E6E8 CRC64;

Query Match 46.8%; Score 36; DB 1; Length 467;

Best Local Similarity 53.8%; Pred. No. 58;

Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQRP 14

||||: :| |

Db 231 IGLAGSTYDNNYP 243

Search completed: March 26, 2002, 13:40:45

Job time: 259 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:14 ; Search time 79.01 Seconds  
(without alignments)  
25.918 Million cell updates/sec

Title: US-09-709-201-100  
Perfect score: 77  
Sequence: 1 CIGLAGTDFANQRP 14

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 473505 seqs, 146272329 residues

Total number of hits satisfying chosen parameters: 473505

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 45 summaries

Database :

SPTREMBL\_17:\*  
1: sp\_archaea:\*  
2: sp\_bacteria:\*  
3: sp\_fungi:\*  
4: sp\_human:\*  
5: sp\_invertebrate:\*  
6: sp\_mammal:\*  
7: sp\_mhc:\*  
8: sp\_organelle:\*  
9: sp\_phase:\*  
10: sp\_plant:\*  
11: sp\_rodent:\*  
12: sp\_virus:\*  
13: sp\_vertebrate:\*  
14: sp\_unclassified:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	68	88.3	392	Q99QB0	Q99qb0 chlamydoghi
2	50	64.9	356	Q52924	Q52924 chlamydia p
3	50	64.9	390	Q9AIJ5	Q9aij5 chlamydia p
4	50	64.9	392	Q9AIJ4	Q9aij4 chlamydia p
5	43	55.8	188	Q9HFA9	Q9hfa9 trichosporo
6	43	55.8	995	Q9URX4	Q9urx4 schizosacch
7	41	53.2	1238	Q25330	Q25330 helicobacte
8	41	53.2	2546	Q9AI30	Q9ai30 burkholderi
9	41	53.2	3194	Q92LM3	Q92lm3 helicobacte
10	39	50.6	377	Q9RHU5	Q9rhu5 streptomyce
11	39	50.6	382	Q9AI11	Q9ai11 streptococc
12	39	50.6	502	Q9BDI4	Q9bdi4 ovis aries
13	39	50.6	502	Q9QVT7	Q9qvt7 rattus sp.
14	39	50.6	502	Q9PUF4	Q9puf4 cornuix co
15	39	50.6	743	Q9KF71	Q9kf71 bacillus ha
16	39	50.6	961	Q92223	Q92223 emericeila
17	39	50.6	1785	Q93781	Q93781 caenorhabdi
18	38	49.4	356	Q95276	Q95276 mycobacteri
19	38	49.4	365	Q9SZ73	Q9sz73 arabidopsis

20	38	49.4	388	3	Q9HDZ5	Q9hdz5 schizosacch
21	38	49.4	543	13	Q9W645	Q9w645 gallus gall
22	38	49.4	564	2	Q9F4V4	Q9f4v4 photorhabdu
23	38	49.4	614	10	Q9LV47	Q9lv47 arabidopsis
24	38	49.4	640	5	O61604	O61604 drosophila
25	37	48.1	141	2	Q9ICT7	Q9ict7 methylococc
26	37	48.1	144	2	Q9ACSI	Q9acsi streptomyce
27	37	48.1	270	13	Q9I9C0	Q9i9c0 trachemys s
28	37	48.1	293	2	Q9ZJ02	Q9zj02 streptococc
29	37	48.1	479	2	Q9KZE9	Q9kze9 streptomyce
30	37	48.1	500	5	Q9VPK7	Q9vpk7 drosophila
31	37	48.1	539	4	Q9NY99	Q9ny99 homo sapien
32	37	48.1	547	2	Q44167	Q44167 actinobacil
33	37	48.1	553	2	Q99SS5	Q99ss5 staphylococ
34	37	48.1	619	5	P91944	P91944 drosophila
35	37	48.1	719	5	O61862	O61862 caenorhabdi
36	37	48.1	719	5	Q9W4B8	Q9w4b8 drosophila
37	37	48.1	902	10	O81209	O81209 arabidopsis
38	37	48.1	902	10	Q9LY21	Q9ly21 arabidopsis
39	37	48.1	926	2	Q911V3	Q911v3 pseudomonas
40	37	48.1	1024	10	Q9M2Q4	Q9m2q4 arabidopsis
41	36.5	47.4	687	5	Q9VMJ5	Q9vmj5 drosophila
42	36	46.8	187	4	Q9H4Z9	Q9h4z9 homo sapien
43	36	46.8	187	12	Q66033	Q66033 cercopitheci
44	36	46.8	205	2	Q9FA16	Q9fa16 acetobacter
45	36	46.8	263	5	Q9GS30	Q9gs30 drosophila

## ALIGNMENTS

```

RESULT 1
Q99QB0 ID Q99QB0 PRELIMINARY; PRT; 392 AA.
AC Q99QB0;
DT 01-JUN-2001 (TREMblrel. 17, Created)
DT 01-JUN-2001 (TREMblrel. 17, Last sequence update)
DT 01-JUN-2001 (TREMblrel. 17, Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.
GN OMPA.
OS Chlamydoghila felis.
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydoghila.
OX NCBI_TaxID=83556;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=FP BAKER, ATCC VR120, AND FP CELLO;
RX MEDLINE=21078680; PubMed=11211261;
RA Bush R.M., Everett K.D.;
RT "Molecular evolution of the Chlamydiaceae.";
RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).
DR EMBL; AF269257; AAK00238.1; -.
DR EMBL; AF269258; AAK00239.1; -.
KW Signal.
FT SIGNAL 1 22 POTENTIAL.
FT CHAIN 23 392 MAJOR OUTER MEMBRANE PROTEIN.
SQ SEQUENCE 392 AA; 42051 MW; 88B3C09C1FEE26DB CRC64;

```

Query Match 88.3%; Score 68; DB 2; Length 392;  
Best Local Similarity 100.0%; Pred. No. 0.00059;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 2 IGLAGTDFANQRP 14
      |||||
DB 160 IGLAGTDFANQRP 172

```

```

RESULT 2
O52924 ID O52924 PRELIMINARY; PRT; 356 AA.
AC O52924;
DT 01-JUN-1998 (TREMblrel. 06, Created)
DT 01-JUN-1998 (TREMblrel. 06, Last sequence update)

```

DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE OUTER MEMBRANE PROTEIN 1 (FRAGMENT).  
 GN OMP1.  
 OS Chlamydia psittaci (Chlamydophila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=92-1293, AVIAN SEROVAR D;  
 RA Vanrompay D., Cox E., Goddeeris B.M., Volckaert G.;  
 RL Submitted (FEB-1998) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; Y16562; CAA76286.1;  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane.  
 FT NON\_TER 356  
 SQ SEQUENCE 356 AA; 38396 MW; D51DE06FB46E6F13 CRC64;

Query Match 64.9%; Score 50; DB 2; Length 356;  
 Best Local Similarity 76.9%; Pred. No. 0.8;  
 Matches 10; Conservative 0; Mismatches 3; Indels 3; Gaps 0;

QY 2 IGLAGTDFANQRP 14  
 III IIII III  
 Db 160 IGLKGTDFNNQLP 172

RESULT 3  
 Q9AIJ5 PRELIMINARY; PRT; 390 AA.  
 ID Q9AIJ5  
 AC Q9AIJ5  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DE 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia psittaci (Chlamydophila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=NEW JERSEY 1, NJ1;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269266; AAK00247.1;  
 KW Signal.  
 FT NON\_TER 1  
 FT SIGNAL <1 20 POTENTIAL.  
 FT CHAIN 21 390 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 390 AA; 42042 MW; B62858403DBFA4E6 CRC64;

Query Match 64.9%; Score 50; DB 2; Length 390;  
 Best Local Similarity 76.9%; Pred. No. 0.88;  
 Matches 10; Conservative 0; Mismatches 3; Indels 3; Gaps 0;

QY 2 IGLAGTDFANQRP 14  
 III IIII III  
 Db 158 IGLKGTDFNNQLP 170

RESULT 4  
 Q9AIJ4 PRELIMINARY; PRT; 392 AA.  
 ID Q9AIJ4  
 AC Q9AIJ4  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DE 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.

GN OMPA.  
 OS Chlamydia psittaci (Chlamydophila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=TEXAS TURKEY 3, TT3;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269267; AAK00248.1;  
 KW Signal.  
 FT SIGNAL 1 22 POTENTIAL.  
 FT CHAIN 23 392 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 392 AA; 42293 MW; FC31FC051955246C CRC64;

Query Match 64.9%; Score 50; DB 2; Length 392;  
 Best Local Similarity 76.9%; Pred. No. 0.88;  
 Matches 10; Conservative 0; Mismatches 3; Indels 3; Gaps 0;

QY 2 IGLAGTDFANQRP 14  
 III IIII III  
 Db 160 IGLKGTDFNNQLP 172

RESULT 5  
 Q9HFA9 PRELIMINARY; PRT; 188 AA.  
 ID Q9HFA9  
 AC Q9HFA9  
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
 DE 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE 20 KDA PROTEIN HAVING G-X-X-Q-X-W-MOTIF PRECURSOR.  
 OS Trichosporon mucoides.  
 OC Eukaryota; Fungi; Basidiomycota; Hymenomycetes; Tremellomycetidae;  
 OC Trichosporonales; Trichosporon.  
 OX NCBI\_TaxID=82522;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=TIMM 1573;  
 RA Usui Y., Matsunaga Y.;  
 RT "20 kDa protein having G-X-X-Q-X-W motif.";  
 RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AB036375; BAB20766.1;  
 DR InterPro; IPR000772; Ricin\_B\_lectin.  
 DR Pfam; PF00652; Ricin\_B\_lectin; 3.  
 DR SMART; SM00458; RICIN; 1.  
 KW Signal.  
 FT SIGNAL 1 16 POTENTIAL.  
 SQ SEQUENCE 188 AA; 19751 MW; A391173C35A547B1 CRC64;

Query Match 55.8%; Score 43; DB 3; Length 188;  
 Best Local Similarity 50.0%; Pred. No. 7;  
 Matches 7; Conservative 3; Mismatches 4; Indels 4; Gaps 0;

QY 1 CIGLAGTDFANQRP 14  
 I: :II :III I  
 Db 57 CVDVAGANFANGTP 70

RESULT 6  
 Q9URX4 PRELIMINARY; PRT; 995 AA.  
 ID Q9URX4  
 AC Q9URX4  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DE 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE PUTATIVE FAMILY 31 GLUCOSIDASE.  
 GN SPAC922.02C.  
 OS Schizosaccharomyces pombe (Fission yeast).

OC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;  
 OC Schizosaccharomycetales; Schizosaccharomycetaceae;  
 OX Schizosaccharomycetes;  
 RN NCBI\_TaxID=4896;  
 [1]

RP SEQUENCE FROM N.A.  
 RC STRAIN=972H-;  
 RA Hunt C., Aves S., McDougall R.C., Rajandream M.A., Barrell B.G.;

RL Submitted (DEC-1999) to the EMBL/GenBank/DBJ databases.  
 DR EMBL: AL133522; CAB63549.1; -;  
 DR InterPro: IPR000322; Glyco\_hydro\_31.  
 DR InterPro: IPR001680; WD40.  
 DR Pfam: PF01055; Glyco\_hydro\_31; 1.  
 DR PROSITE: PS00129; GLYCOSYL\_HYDROL\_F31\_1; 1.  
 DR PROSITE: PS00707; GLYCOSYL\_HYDROL\_F31\_2; 1.  
 DR PROSITE: PS00678; WD\_REPEATS\_1; UNKNOWN\_1.  
 SQ SEQUENCE 995 AA; 112713 MW; 1EC1D292DC30DBA8 CRC64;

Query Match 55.8%; Score 43; DB 3; Length 995;  
 Best Local Similarity 57.1%; Pred. No. 40;  
 Matches 8; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CIGLAGTDFANQRP 14

Db 507 CIGSCGTDKLDQNP 520

RESULT 7  
 O25330

ID O25330 PRELIMINARY; PRT; 1238 AA.

AC O25330;

DT 01-JAN-1998 (TEMBLrel. 05, Created)

DT 01-JAN-1998 (TEMBLrel. 05, Last sequence update)

DT 01-JUN-2000 (TEMBLrel. 14, Last annotation update)

DE HYPOTHETICAL 135.1 KDA PROTEIN.

GN HP0609.

OS Helicobacter pylori (Campylobacter pylori).

OC Bacteria; Proteobacteria; epsilon subdivision; Helicobacter group;

OC Helicobacter

OX NCBI\_TaxID=210;

[1]

RN SEQUENCE FROM N.A.

RC STRAIN=26695 / ATCC 700392;

RX MEDLINE=97394467; PubMed=9252185;

RA Tomb J.-F., White O., Kerlavage A.R., Clayton R.A., Sutton G.G.,

RA Fleischmann R.D., Ketchum K.A., Klenk H.-P., Gill S., Dougherty B.A.,

RA Nelson K., Quackenbush J., Zhou L., Kirkness E.F., Peterson S.,

RA Loftus B., Richardson D., Dodson R., Khalak H.G., Glodek A.,

RA McKenney K., Fitzgerald L.M., Lee N., Adams M.D., Hickey E.K.,

RA Berg D.E., Gocayne J.D., Utterback T.R., Peterson J.D., Kelley J.M.,

RA Cotton M.D., Weidman J.M., Fujii C., Bowman C., Watthey L., Wallin E.,

RA Hayes W.S., Borodovsky M., Karp P.D., Smith H.O., Fraser C.M.,

RA Venter J.C.;

RT "The complete genome sequence of the gastric pathogen Helicobacter

pylori.";

RL Nature 388:539-547(1997).

DR EMBL: AE000575; AAD07677.1; -;

DR TIGR: HP0609; -;

KW Hypothetical protein; Complete proteome.

SQ SEQUENCE 1238 AA; 135062 MW; 66DF754EB1BFB173 CRC64;

Query Match 53.2%; Score 41; DB 2; Length 1238;

Best Local Similarity 53.8%; Pred. No. 1.1e+02;

Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 2 IGLAGTDFANQRP 14

Db 207 VNLNTDFGNQTP 219

RESULT 8

Q9AI30

ID Q9AI30 PRELIMINARY; PRT; 2546 AA.

AC Q9AI30;

DT 01-JUN-2001 (TEMBLrel. 17, Created)

DT 01-JUN-2001 (TEMBLrel. 17, Last sequence update)

DT 01-JUN-2001 (TEMBLrel. 17, Last annotation update)

DE PUTATIVE TYPE I POLYKETIDE SYNTHASE WCBR.

GN WCBR.

OS Burkholderia mallei (Pseudomonas mallei).

OC Bacteria; Proteobacteria; beta subdivision; Burkholderia group;

OC Burkholderia.

OX NCBI\_TaxID=13373;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=ATCC23344;

RA DeShazer D., Waag D.M., Fritz D.L., Woods D.E.;

RT "Identification of a Burkholderia mallei polysaccharide gene cluster

by subtractive hybridization and demonstration that the encoded

capsule is an essential virulence determinant.";

RL Microb. Pathog. 0:0-0(2001).

DR EMBL: AF285636; AAK26474.1; -;

SQ SEQUENCE 2546 AA; 267597 MW; 55DFD9BC44A5F9BA CRC64;

Query Match 53.2%; Score 41; DB 2; Length 2546;

Best Local Similarity 54.5%; Pred. No. 2.4e+02;

Matches 6; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2 IGLAGTDFANQ 12

Db 123 VGVAGTDYGNR 133

RESULT 9  
 Q9ZLM3

ID Q9ZLM3 PRELIMINARY; PRT; 3194 AA.

AC Q9ZLM3;

DT 01-MAY-1999 (TEMBLrel. 10, Created)

DT 01-MAY-1999 (TEMBLrel. 10, Last sequence update)

DT 01-JUN-2001 (TEMBLrel. 17, Last annotation update)

DE PUTATIVE VACUOLATING CYTOTOXIN (VACA) PARALOG.

GN JHP0556.

OS Helicobacter pylori J99 (Campylobacter pylori J99).

OC Bacteria; Proteobacteria; epsilon subdivision; Helicobacter group;

OC Helicobacter

OX NCBI\_TaxID=85963;

[1]

RN SEQUENCE FROM N.A.

RC MEDLINE=99120557; PubMed=9923682;

RX Alm R.A., Ling L.-S.L., Moir D.T., King B.L., Brown E.D., Dolg P.C.,

RA Smith D.R., Noonan B., Guild B.C., deJonge B.L., Carmel G.,

RA Tummino P.J., Caruso A., Uribe-Nickelsen M., Mills D.M., Ives C.,

RA Gibson R., Merberg D., Mills S.D., Jiang Q., Taylor D.E., Vovis G.F.,

RA Trust T.J.;

RT "Genomic sequence comparison of two unrelated isolates of the human

gastric pathogen Helicobacter pylori.";

RL Nature 397:176-180(1999).

DR EMBL: AE001488; AAD06134.1; -;

DR InterPro: IPR001589; Actinin\_act\_bind.

DR PROSITE: PS00019; ACTININ\_1; UNKNOWN\_1.

KW Complete proteome.

SQ SEQUENCE 3194 AA; 348350 MW; 26D60C492DBECF0E CRC64;

Query Match 53.2%; Score 41; DB 2; Length 3194;

Best Local Similarity 53.8%; Pred. No. 3e+02;

Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 2 IGLAGTDFANQRP 14

Db 208 VNLNTDFGNQTP 220

```
RESULT 10
Q9RHU5 PRELIMINARY; PRT; 377 AA.
AC Q9RHU5;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DE 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE CHI35 PROTEIN.
GN CHI35.
OS Streptomyces thermoviolaceus.
OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
OC Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomycetes.
OX NCBI_TaxID=1952;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-OPC-520;
RC Tsujibo H.;
RT "Chitinase.";
RL Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB016842; BAA88833.1; -
DR HSSP; P23951; 2BAA.
DR InterPro; IPR000726; Glyco_hydro_19.
DR InterPro; IPR000772; Ricin_B_lectin.
DR Pfam; PF00182; Glyco_hydro_19; 1.
DR Pfam; PF00652; Ricin_B_lectin; 1.
DR ProDom; PD000574; Glyco_hydro_19; 1.
DR SMART; SM00458; RICIN; 1.
SQ SEQUENCE 377 AA; 39763 MW; 14267B344738562B CRC64;

Query Match 50.6%; Score 39; DB 2; Length 377;
Best Local Similarity 50.0%; Pred. No. 74;
Matches 7; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANQRP 14
   |: || | | | |
Db 47 CLDVAGADSANGTP 60

RESULT 11
Q9A111 PRELIMINARY; PRT; 382 AA.
AC Q9A111;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE PUTATIVE ACETYL-COA C-ACETYLTRANSFERASE (EC 2.3.1.).
GN SPY0524.
OS Streptococcus pyogenes.
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Streptococcaceae;
OC Streptococcus.
OX NCBI_TaxID=1314;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-SF370;
RC MEDLINE=21192684; PubMed=11296296;
RA Ferretti J.J., McShan W.M., Ajdic D.J., Savic D.J., Savic G., Lyon K.,
RA Primeaux C., Sezate S., Suvorov A.N., Kenton S., Lai H.S., Lin S.P.,
RA Qian Y., Jia H.G., Najjar F.Z., Ren Q., Zhu H., Song L., White J.,
RA Yuan X., Clifton S.W., Roe B.A., McLaughlin R.;
RT "Complete genome sequence of an M1 strain of Streptococcus pyogenes.";
RL Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663(2001).
DR EMBL; AE006510; AAK33520.1; -
KW Transferase; Acyltransferase; Complete proteome.
SQ SEQUENCE 382 AA; 40746 MW; 67755D330D73C2D4 CRC64;

Query Match 50.6%; Score 39; DB 2; Length 382;
Best Local Similarity 53.8%; Pred. No. 75;
Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQRP 14
   ||| | | | | |
Db 2 CLDVAGADSANGTP 60
```

```
Db 14 IGLVCKQFAKEQP 26

RESULT 12
Q9BDI4 PRELIMINARY; PRT; 502 AA.
AC Q9BDI4;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE IB.
GN BMPR-IB.
OS Ovis aries (Sheep).
OC Eukaryota; Metazoa; Chordata; Cranialata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Caprinae; Ovis.
OX NCBI_TaxID=9940;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE-OVARY;
RA Souza C.J.H., MacDougall C.N., Campbell B.K., McNeilly A.S.,
RA Baird D.T.;
RT "The Booroola (FecB) phenotype is associated with a mutation in the
RT bone morphogenetic receptor type IB (BMPRII) gene.";
RL J. Endocrinol. 0:0-0(2001).
KW EMBL; AF357007; AAK30296.1; -
KW Receptor.
SQ SEQUENCE 502 AA; 56907 MW; 6552124A0A24F35C CRC64;

Query Match 50.6%; Score 39; DB 6; Length 502;
Best Local Similarity 66.7%; Pred. No. 99;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9
   |: || | | | |
Db 71 CLGLEGSDF 79

RESULT 13
Q9QVT7 PRELIMINARY; PRT; 502 AA.
AC Q9QVT7;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE CFK-43A-BONE MORPHOGENETIC PROTEIN BINDING SERINE/THREONINE KINASE
DE RECEPTOR.
OS Rattus sp.
OC Eukaryota; Metazoa; Chordata; Cranialata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10118;
RN [1]
RP SEQUENCE FROM N.A.
RC MEDLINE=95110346; PubMed=7811286;
RA Yamaji N., Celeste A.J., Thies R.S., Song J.J., Bernier S.M.,
RA Goldtman D., Lyons K.M., Nove J., Rosen V., Wozney J.M.;
RT "A mammalian serine/threonine kinase receptor specifically binds BMP-2
RT and BMP-4.";
RL Biochem. Biophys. Res. Commun. 205:1944-1951(1994).
CC -I- SIMILARITY: TO THE SER/THR FAMILY OF PROTEIN KINASES.
DR InterPro; IPR000333; ActivinII_receptor.
DR InterPro; IPR000472; Activin_rec.
DR InterPro; IPR000719; Euk_pkinase.
DR InterPro; IPR003605; GS.
DR InterPro; IPR002290; Ser_thr_kin_actsite.
DR InterPro; IPR001245; Tyr_kin.
DR Pfam; PF01064; Activin_rec; 1.
DR Pfam; PF00069; pkinase; 1.
DR PRINTS; PR00653; ACTIVIN2R.
DR PRINTS; PR00109; TYRKINASE.
DR SMART; SM00467; GS; 1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
```

DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
KW ATP-binding; Serine/threonine-protein kinase; Transferase.  
SQ SEQUENCE 502 AA; 56870 MW; E147D1B4477F7573 CRC64;

Query Match 50.6%; Score 39; DB 11; Length 502;  
Best Local Similarity 66.7%; Pred. No. 99;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
|:|:| |:  
Db 71 CLGLEGSDF 79

## RESULT 14

Q9PUF4 PRELIMINARY; PRT; 502 AA.  
AC Q9PUF4;  
DT 01-MAY-2000 (Tremblrel. 13, Created)  
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)  
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)  
DE BONE MORPHOGENETIC PROTEIN RECEPTOR IB.  
GN BMPR-IB.  
OS Coturnix coturnix (common quail).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae;  
OC Coturnix.  
OX NCBI\_TaxID=9091;  
RN [1]  
RP McPherson C.N.A.  
RA McPherson C.E., Varley J.E., Maxwell G.D.;  
RT "Expression and Regulation of the Type I BMP Receptors during Avian  
RL Neural Crest Development";  
RL Submitted (SEP-1999) to the EMBL/GenBank/DBJ databases.  
CC -1- SIMILARITY: TO THE SER/THR FAMILY OF PROTEIN KINASES.  
DR EMBL; AF189778; AAF04583.1;  
DR HSSP; P36897; 1TBI.  
DR InterPro; IPR000333; ActivinII\_receptor.  
DR InterPro; IPR000472; Activin\_rec.  
DR InterPro; IPR000719; Euk\_pkinase.  
DR InterPro; IPR003605; GS.  
DR InterPro; IPR002290; Ser\_thr\_kin\_actsite.  
DR InterPro; IPR001245; Tyr\_kin.  
DR Pfam; PF01064; Activin\_rec; 1.  
DR Pfam; PF00069; pkinase; 1.  
DR PRINTS; PR00653; ACTIVIN2R.  
DR PRINTS; PR00109; TYRKINASE.  
DR SMART; SM00467; GS; 1.  
DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.  
DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
KW ATP-binding; Receptor; Serine/threonine-protein kinase; Transferase.  
SQ SEQUENCE 502 AA; 56886 MW; 6819265085F28422 CRC64;

Query Match 50.6%; Score 39; DB 13; Length 502;  
Best Local Similarity 66.7%; Pred. No. 99;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
|:|:| |:  
Db 71 CLGLEGSDF 79

## RESULT 15

Q9KF71 PRELIMINARY; PRT; 743 AA.  
AC Q9KF71;  
DT 01-OCT-2000 (Tremblrel. 15, Created)  
DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)  
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)  
DE ASSIMILATORY NITRATE REDUCTASE (CATALYTIC SUBUNIT).

GN NASC OR BH0615.  
OS Bacillus halodurans.  
OC Bacteria; Firmicutes; Bacillus/Clostridium group;  
OC Bacillus/Staphylococcus group; Bacillus.  
OX NCBI\_TaxID=86665;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=C-125 / JCM 9153;  
RX MEDLINE=20512582; PubMed=11058132;  
RA Takami H., Nakasone K., Takaki Y., Maeno G., Sasaki R., Masui N.,  
RA Fuji F., Hirama C., Nakamura Y., Ogasawara N., Kuhara S.,  
RA Horikoshi K.;  
RT "Complete genome sequence of the alkaliphilic bacterium Bacillus  
halodurans and genomic sequence comparison with Bacillus subtilis.";  
RL Nucleic Acids Res. 28:4317-4331(2000).  
DR EMBL; AP001509; BAB04334.1; -;  
DR InterPro; IPR001467; Molybdopterin.  
DR Pfam; PF00384; molybdopterin; 1.  
DR Pfam; PF01568; Molydop\_binding; 1.  
DR PROSITE; PS00551; MOLYBDOPTERIN\_PROK\_1; UNKNOWN\_1.  
DR PROSITE; PS00490; MOLYBDOPTERIN\_PROK\_2; 1.  
KW Complete proteome.  
SQ SEQUENCE 743 AA; 82692 MW; C7221E52CB270E1A CRC64;

Query Match 50.6%; Score 39; DB 2; Length 743;  
Best Local Similarity 57.1%; Pred. No. 1.5e+02;  
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANQRP 14  
|:|:|:|:  
Db 184 CIVLAGTNLAFCQP 197

Search completed: March 26, 2002, 13:40:15  
Job time: 229 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:38:48 ; Search time 81.51 Seconds  
(without alignments)  
11.814 Million cell updates/sec

Title: US-09-709-201-101

Perfect score: 73

Sequence: 1 CQINKFSRKACG 13

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A\_Geneseq\_1101.\*

1: /SID88/gcgdata/geneseq/geneseq/AA1980.DAT.\*  
2: /SID88/gcgdata/geneseq/geneseq/AA1981.DAT.\*  
3: /SID88/gcgdata/geneseq/geneseq/AA1982.DAT.\*  
4: /SID88/gcgdata/geneseq/geneseq/AA1983.DAT.\*  
5: /SID88/gcgdata/geneseq/geneseq/AA1984.DAT.\*  
6: /SID88/gcgdata/geneseq/geneseq/AA1985.DAT.\*  
7: /SID88/gcgdata/geneseq/geneseq/AA1986.DAT.\*  
8: /SID88/gcgdata/geneseq/geneseq/AA1987.DAT.\*  
9: /SID88/gcgdata/geneseq/geneseq/AA1988.DAT.\*  
10: /SID88/gcgdata/geneseq/geneseq/AA1989.DAT.\*  
11: /SID88/gcgdata/geneseq/geneseq/AA1990.DAT.\*  
12: /SID88/gcgdata/geneseq/geneseq/AA1991.DAT.\*  
13: /SID88/gcgdata/geneseq/geneseq/AA1992.DAT.\*  
14: /SID88/gcgdata/geneseq/geneseq/AA1993.DAT.\*  
15: /SID88/gcgdata/geneseq/geneseq/AA1994.DAT.\*  
16: /SID88/gcgdata/geneseq/geneseq/AA1995.DAT.\*  
17: /SID88/gcgdata/geneseq/geneseq/AA1996.DAT.\*  
18: /SID88/gcgdata/geneseq/geneseq/AA1997.DAT.\*  
19: /SID88/gcgdata/geneseq/geneseq/AA1998.DAT.\*  
20: /SID88/gcgdata/geneseq/geneseq/AA1999.DAT.\*  
21: /SID88/gcgdata/geneseq/geneseq/AA2000.DAT.\*  
22: /SID88/gcgdata/geneseq/geneseq/AA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	ID	Description
1	73	100.0	13	Peptide fragment o
2	73	100.0	343	C. trachomatis ser
3	73	100.0	391	Chlamydia pneumoni
4	67	91.8	93	Chlamydia major o
5	65	89.0	13	Peptide fragment o
6	65	89.0	13	Peptide fragment o
7	59	80.8	13	Peptide fragment o
8	58	79.5	215	Chlamydia psittaci
9	58	79.5	222	Chlamydia psittaci
10	58	79.5	225	Chlamydia psittaci
11	58	79.5	228	Chlamydia psittaci

12	58	79.5	343	20	AAW56769	C. trachomatis ser
13	58	79.5	356	20	AAW56770	C. trachomatis ser
14	58	79.5	389	20	AAW98188	Chlamydia psittaci
15	58	79.5	402	20	AAW98189	Chlamydia psittaci
16	58	79.5	402	20	AAW98187	Chlamydia psittaci
17	58	79.5	525	21	AAW13645	C. pneumoniae sero
18	58	79.5	525	22	AAW83213	Protein encoded by
19	53	72.6	94	20	AAW95308	Chlamydia major o
20	53	72.6	94	20	AAW95310	Chlamydia major o
21	53	72.6	94	20	AAW95311	Chlamydia major o
22	53	72.6	94	20	AAW95312	Chlamydia major o
23	53	72.6	94	20	AAW95315	Chlamydia major o
24	53	72.6	94	20	AAW95316	Chlamydia major o
25	53	72.6	95	20	AAW95313	Chlamydia major o
26	53	72.6	95	20	AAW95314	Chlamydia major o
27	53	72.6	95	20	AAW95317	Chlamydia major o
28	53	72.6	277	21	AAW82393	C. trachomatis MOM
29	53	72.6	349	21	AAW82392	C. trachomatis MOM
30	53	72.6	372	19	AAW76365	C. trachomatis JM1
31	53	72.6	373	19	AAW76362	C. trachomatis JM1
32	53	72.6	374	19	AAW76364	C. trachomatis JM1
33	53	72.6	376	19	AAW76363	C. trachomatis JM1
34	53	72.6	376	19	AAW76366	C. trachomatis JM1
35	53	72.6	387	20	AAW56767	C. trachomatis ser
36	53	72.6	392	20	AAW56760	C. trachomatis ser
37	53	72.6	393	20	AAW56757	C. trachomatis ser
38	53	72.6	393	20	AAW56759	C. trachomatis ser
39	53	72.6	393	22	AAW60646	Chlamydia trachoma
40	53	72.6	394	7	AAW60004	Sequence of a major
41	53	72.6	394	18	AAW15149	Chlamydia trachoma
42	53	72.6	394	19	AAW73141	Chlamydia trachoma
43	53	72.6	394	19	AAW57775	Chlamydia trachoma
44	53	72.6	394	20	AAW56758	C. trachomatis ser
45	53	72.6	394	21	AAW81268	Chlamydia trachoma

#### ALIGNMENTS

RESULT 1  
AAW95328  
ID AAW95328 standard; Protein; 13 AA.  
XX AC  
XX AC  
XX AC  
DT 15-MAR-1999 (first entry)  
XX  
DE Peptide fragment of C. pneumoniae CPN342-354.

Chlamydia; cryptic phase; elementary body phase; replicating; probenicid;  
antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
major outer membrane protein; autoimmuna; inflammatory; porphyria;  
Estein Barr virus; antioxidant.

Chlamydia pneumoniae.

OS WC9850074-A2.

PN WC9850074-A2.

PD 12-NOV-1998.

PF 06-MAY-1998;

PP 98WO-US09237.

XX 18-FEB-1998;

XX 98US-0025521.

XX 06-MAY-1997;

XX 97US-0045889.

XX 06-MAY-1997;

XX 97US-0045739.

XX 06-MAY-1997;

XX 97US-0045779.

XX 06-MAY-1997;

XX 97US-0045780.

XX 06-MAY-1997;

XX 97US-0045784.

XX 06-MAY-1997;

XX 97US-0045787.

XX 14-AUG-1997;

XX 97US-0911593.

XX 18-FEB-1998;

XX 98US-0025174.

XX 18-FEB-1998;

XX 98US-0025176.

PA (UYVA-) UNIV VANDERBILT.  
 XX Mitchell WM, Stratton CW;  
 PI WPI: 1999-059653/05.  
 XX  
 DR Composition with two agents effective against different stages of  
 XX Chlamydial life cycle - comprises agent targetted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT probenicid and antiporphyric  
 XX  
 PS Claim 4; Fig 5; 138pp; English.  
 XX  
 CC The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targetted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targetted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targetted against replicating phase of chlamydial  
 CC life cycle; (d) probenicid, and (e) antiporphyric acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Chlamydia virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AAY95328 to AAY95331 represent peptides  
 CC employed for the construction of peptide based ELISAs with species  
 CC specificity for variable domain 2 (VD2).  
 XX  
 SQ Sequence 13 AA;

Query Match 100.0%; Score 73; DB 20; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 5.3e-06;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CQINKFKSRKACG 13  
 Db 1 cqinkfksrkacg 13  
 |||||

RESULT 2  
 AAY56771  
 ID AAY56771 standard; Protein; 343 AA.  
 AC AAY56771;  
 XX  
 XX  
 DT 22-FEB-2000 (first entry)  
 DE C. trachomatis serovar HuPn MOMP sequence.  
 XX Major outer membrane protein; MOMP; Chlamydia; vaccine; immune response;  
 KW cellular response; immunogen; Th1-like CD4 response; mucosal immunity.  
 XX Chlamydia trachomatis.  
 OS WO9951745-A2.  
 XX  
 PN 14-OCT-1999.  
 XX  
 PD 07-APR-1999; 99WO-CA00292.  
 PF 07-APR-1998; 98US-0055765.  
 PR

XX (UYMA-) UNIV MANITOBA.  
 XX Bruhnam RC;  
 PI WPI: 1999-620205/53.  
 XX  
 DR Non-replicating vector encoding fragments of the outer membrane protein  
 XX of Chlamydia, useful in vaccines and as immunogen  
 PT  
 XX Disclosure: Fig 10 A-F; 52pp; English.  
 XX  
 CC The invention provides a non-replicating vector that comprises, linked  
 CC to a promoter, a nucleotide sequence that encodes a region containing at  
 CC least one of the conserved domains 2, 3 and 5 of a major outer membrane  
 CC protein (MOMP) of a Chlamydia strain. The vector is used: (a) in  
 CC vaccines to generate a protective immune response (mainly cellular)  
 CC against MOMP, and (b) as immunogens to raise anti-MOMP antibodies, useful  
 CC in standard immunoassays. Immunization with the vector induces a broad  
 CC spectrum of immune responses, including Th1-like CD4 responses and  
 CC mucosal immunity, providing significant protection against subsequent  
 CC challenge. Sequences AAY56757-71 represent MOMP sequences from a variety  
 CC of serovars of C. trachomatis.  
 XX  
 SQ Sequence 343 AA;

Query Match 100.0%; Score 73; DB 20; Length 343;  
 Best Local Similarity 100.0%; Pred. No. 0.00012;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CQINKFKSRKACG 13  
 Db 296 cqinkfksrkacg 308  
 |||||

RESULT 3  
 AAY35319  
 ID AAY35319 standard; Protein; 391 AA.  
 XX  
 AC AAY35319;  
 XX  
 DT 13-SEP-1999 (first entry)  
 XX Chlamydia pneumoniae transmembrane protein sequence.  
 DE  
 XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;  
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis;  
 KW vaccine; neutralising epitope.  
 XX Chlamydia pneumoniae.  
 OS WO9927105-A2.  
 XX  
 PN 03-JUN-1999.  
 PD  
 XX 20-NOV-1998; 98WO-IB01890.  
 PF  
 XX 04-NOV-1998; 98US-0107078.  
 PR 21-NOV-1997; 97FR-0014673.  
 XX (GEST) GENSET.  
 PA Griffais R;  
 XX  
 PI WPI: 1999-357842/30.  
 XX  
 DR Genome sequence of Chlamydia pneumoniae  
 PT  
 XX Page 1130-1131; Disclosure: 1912pp; English.  
 PS AAY34584-Y35879 represent the proteins encoded by all the open reading  
 XX frames in the complete genome (see AAY91990) of Chlamydia pneumoniae.  
 CC



CC C. pneumoniae causes respiratory disease such as pneumonia and  
 CC bronchitis and is thought to be a contributing factor in heart  
 CC disease, sarcoidosis, sinusitis, purulent otitis media, erythema  
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading  
 CC frames of the C. pneumoniae genome (see AAY34584-Y35879) can be used in  
 CC immunogenic compositions as vaccines. Vectors containing C. pneumoniae  
 CC nucleotide sequences can also be used as immunogenic compositions,  
 CC especially where the vector directs the expression of a neutralising  
 CC epitope of C. pneumoniae.  
 XX  
 SQ Sequence 391 AA;

Query Match 100.0%; Score 73; DB 20; Length 391;  
 Best Local Similarity 100.0%; Pred. No. 0.00014;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CQINKFKSRKACG 13  
 |||||  
 Db 344 cqinkfkkrkacg 356

RESULT 4  
 AAW95319  
 ID AAW95319 standard; Protein; 93 AA.  
 XX  
 AC AAW95319;

DT 15-MAR-1999 (first entry)

DE Chlamydia major outer membrane protein (MOMP) PN fragment.

XX Chlamydia; cryptic phase; elementary body phase; replicating; probenicid;  
 KW antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
 KW major outer membrane protein; autoimmune; inflammatory; porphyria;  
 KW Ebstein Barr virus; antioxidant.

XX Chlamydia sp.

XX WO9850074-A2.

XX 12-NOV-1998.

XX 06-MAY-1998; 98WO-US09237.

XX 18-FEB-1998; 98US-0025521.

XX 06-MAY-1997; 97US-0045689.

XX 06-MAY-1997; 97US-0045739.

XX 06-MAY-1997; 97US-0045779.

XX 06-MAY-1997; 97US-0045780.

XX 06-MAY-1997; 97US-0045784.

XX 06-MAY-1997; 97US-0045787.

XX 14-AUG-1997; 97US-0911593.

XX 18-FEB-1998; 98US-0025174.

XX 18-FEB-1998; 98US-0025176.

XX (UYVA-) UNIV VANDERBILT.

XX Mitchell WM, Stratton CW;

XX WPI; 1999-059653/05.

XX Composition with two agents effective against different stages of

PT chlamydial life cycle - comprises agent targeted against cryptic

PT phase, against elementary body phase, against replicating phase,

PT probenicid and antiporphyrin

XX Disclosure; Fig 1A; 138pp; English.

CC from: (a) agents targeted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targeted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targeted against replicating phase of chlamydial  
 CC life cycle; (d) probenicid, and (e) antiporphyrin acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Ebstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AAW95272 to AAW95319 represent peptide  
 CC fragments of various Chlamydial MOMPs.  
 XX  
 SQ Sequence 93 AA;

Query Match 91.8%; Score 67; DB 20; Length 93;  
 Best Local Similarity 100.0%; Pred. No. 0.00037;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CQINKFKSRKAC 12

Db 46 cqinkfkkrkac 57

|||||

RESULT 5

AAW95330

ID AAW95330 standard; Protein; 13 AA.

XX AAW95330;

XX 15-MAR-1999 (first entry)

XX Peptide fragment of C. trachomatis CTL342-354.

XX Chlamydia; cryptic phase; elementary body phase; replicating; probenicid;  
 KW antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
 KW major outer membrane protein; autoimmune; inflammatory; porphyria;  
 KW Ebstein Barr virus; antioxidant.

XX Chlamydia trachomatis.

XX WO9850074-A2.

XX 12-NOV-1998.

XX 06-MAY-1998; 98WO-US09237.

XX 18-FEB-1998; 98US-0025521.

XX 06-MAY-1997; 97US-0045689.

XX 06-MAY-1997; 97US-0045739.

XX 06-MAY-1997; 97US-0045779.

XX 06-MAY-1997; 97US-0045780.

XX 06-MAY-1997; 97US-0045784.

XX 06-MAY-1997; 97US-0045787.

XX 14-AUG-1997; 97US-0911593.

XX 18-FEB-1998; 98US-0025174.

XX 18-FEB-1998; 98US-0025176.

XX (UYVA-) UNIV VANDERBILT.

XX Mitchell WM, Stratton CW;

XX WPI; 1999-059653/05.

Composition with two agents effective against different stages of chlamydial life cycle - comprises agent targetted against cryptic phase, against elementary body phase, against replicating phase, probenicid and antiporphyric

Claim 4; Fig 5; 138pp; English.

The invention relates to the diagnosis and management of infections by Chlamydia species. The invention provides a composition that comprises at least two agents, where each of the agents is effective against a different phase of the chlamydial life cycle. The agents are selected from: (a) agents targetted against cryptic phase of chlamydial life cycle; (b) agents targetted against elementary body phase of chlamydial life cycle; (c) agents targetted against replicating phase of chlamydial life cycle; (d) probenicid, and (e) antiporphyric acid. The composition is used to elicit a protective immune response to Chlamydia infection in an animal or human and is applied until the animal or human tests negative for Chlamydia infection. It is also used to treat biological material infected with Chlamydia. Diagnostic kits for antibody assays against recombinant major outer membrane protein (MOMP), and for DNA amplification assays for chlamydial genes, are used to diagnose disease, e.g. autoimmune disease, an inflammatory disease or a disease that occurs in an immuno-compromised individual, associated with Chlamydia infection. The kits are used to detect chlamydial elementary bodies in a sample. They are also used to monitor and/or modify the course of therapy in a patient. The treatment reduces the acellular load of infectious Ebsstein Barr virus. The method is also used to treat porphyria, by reducing the number of elementary bodies and applying a drug, e.g. cimetidine, and antioxidants, to reduce the adverse effects associated with porphyria. Sequences AAW95328 to AAW95331 represent peptides employed for the construction of peptide based ELISAs with species specificity for variable domain 2 (VD2).

Sequence 13 AA;

Query Match 89.0%; Score 65; DB 20; Length 13;  
Best Local Similarity 84.6%; Pred. No. 0.00012;  
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 CQINKFKSRKACG 13  
|||:| |||||  
Db 1 cqinkfksrkacg 13

RESULT 6  
AAW95331

ID AAW95331 standard; Protein; 13 AA.

AC AAW95331;

DT 15-MAR-1999 (first entry)

DE Peptide fragment of C. psittaci CPS342-354.

Chlamydia; cryptic phase; elementary body phase; replicating; probenicid; antiporphyric acid; immune response; infection; diagnostic; assay; MOMP; major outer membrane protein; autoimmune; inflammatory; porphyria; Ebsstein Barr virus; antioxidant.

OS Chlamydia psittaci.

XX WO9850074-A2.

PN 12-NOV-1998.

XX 06-MAY-1998; 98WO-0509237.

XX 18-FEB-1998; 98US-0025521.

PR 06-MAY-1997; 97US-0045689.

PR 06-MAY-1997; 97US-0045739.

PR 06-MAY-1997; 97US-0045779.

PR 06-MAY-1997; 97US-0045780.

PR 06-MAY-1997; 97US-0045784.  
PR 06-MAY-1997; 97US-0045787.  
PR 14-AUG-1997; 97US-0011593.  
PR 18-FEB-1998; 98US-0025174.  
PR 18-FEB-1998; 98US-0025176.  
XX  
PA (UYVA-) UNIV VANDERBILT.

XX Mitchell WM, Stratton CW;

PI  
XX  
DR WPI; 1999-059653/05.

Composition with two agents effective against different stages of chlamydial life cycle - comprises agent targetted against cryptic phase, against elementary body phase, against replicating phase, probenicid and antiporphyric

Claim 4; Fig 5; 138pp; English.

The invention relates to the diagnosis and management of infections by Chlamydia species. The invention provides a composition that comprises at least two agents, where each of the agents is effective against a different phase of the chlamydial life cycle. The agents are selected from: (a) agents targetted against cryptic phase of chlamydial life cycle; (b) agents targetted against elementary body phase of chlamydial life cycle; (c) agents targetted against replicating phase of chlamydial life cycle; (d) probenicid, and (e) antiporphyric acid. The composition is used to elicit a protective immune response to Chlamydia infection in an animal or human and is applied until the animal or human tests negative for Chlamydia infection. It is also used to treat biological material infected with Chlamydia. Diagnostic kits for antibody assays against recombinant major outer membrane protein (MOMP), and for DNA amplification assays for chlamydial genes, are used to diagnose disease, e.g. autoimmune disease, an inflammatory disease or a disease that occurs in an immuno-compromised individual, associated with Chlamydia infection. The kits are used to detect chlamydial elementary bodies in a sample. They are also used to monitor and/or modify the course of therapy in a patient. The treatment reduces the acellular load of infectious Ebsstein Barr virus. The method is also used to treat porphyria, by reducing the number of elementary bodies and applying a drug, e.g. cimetidine, and antioxidants, to reduce the adverse effects associated with porphyria. Sequences AAW95328 to AAW95331 represent peptides employed for the construction of peptide based ELISAs with species specificity for variable domain 2 (VD2).

Sequence 13 AA;

Query Match 89.0%; Score 65; DB 20; Length 13;  
Best Local Similarity 92.3%; Pred. No. 0.00012;  
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CQINKFKSRKACG 13  
||||||| |||  
Db 1 cqinkfksrkacg 13

RESULT 7

AAW95329

ID AAW95329 standard; Protein; 13 AA.

AC AAW95329;

XX 15-MAR-1999 (first entry)

DE Peptide fragment of C. trachomatis CTP342-354.

Chlamydia; cryptic phase; elementary body phase; replicating; probenicid; antiporphyric acid; immune response; infection; diagnostic; assay; MOMP; major outer membrane protein; autoimmune; inflammatory; porphyria; Ebsstein Barr virus; antioxidant.

OS Chlamydia trachomatis.

XX WO9850074-A2.  
 PN 12-NOV-1998.  
 XX  
 PD  
 XX  
 PF 06-MAY-1998; 98WO-US09237.  
 XX  
 PR 18-FEB-1998; 98US-0025521.  
 PR 06-MAY-1997; 97US-0045689.  
 PR 06-MAY-1997; 97US-0045739.  
 PR 06-MAY-1997; 97US-0045779.  
 PR 06-MAY-1997; 97US-0045780.  
 PR 06-MAY-1997; 97US-0045784.  
 PR 06-MAY-1997; 97US-0045787.  
 PR 14-AUG-1997; 97US-0911593.  
 PR 18-FEB-1998; 98US-0025174.  
 PR 18-FEB-1998; 98US-0025176.  
 XX  
 PA (UYVA-) UNIV VANDERBILT.  
 XX  
 PI Mitchell WM, Stratton CW;  
 XX  
 DR WPI; 1999-059653/05.  
 XX  
 PT Composition with two agents effective against different stages of  
 PT chlamydial life cycle - comprises agent targetted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT probenidicid and antiporphyric  
 XX  
 PS Claim 4; Fig 5; 138pp; English.  
 XX  
 CC The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targetted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targetted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targetted against replicating phase of chlamydial  
 CC life cycle; (d) probenidicid, and (e) antiporphyric acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Epstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC clometidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AAW95328 to AAW95331 represent peptides  
 CC employed for the construction of peptide based ELISAs with species  
 CC specificity for variable domain 2 (VD2).  
 XX  
 SQ Sequence 13 AA;

Query Match 80.8%; Score 59; DB 20; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 0.0013;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CQINKFKSRKACG 13  
 Db 1 CQINKFKSRKACG 13  
 IIIII III III  
 RESULT 8  
 AAW98185  
 ID AAW98185 standard; Protein; 215 AA.  
 XX

AC AAW98185;  
 XX  
 DT 05-JUL-1999 (first entry)  
 XX  
 DE Chlamydia psittaci MOMP (minus VD1 and VD2 region).  
 XX  
 KW Major outer membrane protein; MOMP; psittacosis; infection;  
 KW vaccine; genetic immunisation.  
 XX  
 OS Chlamydia psittaci.  
 XX  
 PN WO9910005-A1.  
 XX  
 PD 04-MAR-1999.  
 XX  
 PF 28-AUG-1998; 98WO-US17943.  
 XX  
 PR 28-AUG-1997; 97US-0057147.  
 XX  
 PA (LOUU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.  
 XX  
 PI Baghian A, Chouljenko VN, Kousoulas KS, Tully TN;  
 XX  
 DR WPI; 1999-254214/21.  
 XX  
 PT A new vaccine for Chlamydia psittaci infections  
 XX  
 PS Claim 28; Page 51; 72pp; English.  
 XX  
 CC The present sequence is a major outer membrane protein (MOMP)  
 CC polypeptide of the cockatiel isolate LSJWTKC of Chlamydia psittaci  
 CC (the MOMP gene sequence of this isolate is identical to that of C.  
 CC psittaci Avian Type C). The MOMP polypeptide comprises regions VD3  
 CC and VD4 of native MOMP (see also AAW98137, i.e. it lacks regions VD1  
 CC and VD2 of MOMP. A claimed method of preventing a C. psittaci  
 CC infection in a subject comprises administering an immunising  
 CC amount of an expression vector comprising a eukaryotic promoter  
 CC functionally linked to a nucleic acid encoding a C. psittaci  
 CC MOMP polypeptide lacking regions VD1 and VD2, preferably the  
 CC present sequence or a polypeptide (see also AAW98186) from C.  
 CC psittaci strain B577.  
 XX  
 SQ Sequence 215 AA;

Query Match 79.5%; Score 58; DB 20; Length 215;  
 Best Local Similarity 91.7%; Pred. No. 0.027;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 Db 169 qinkmksrkacg 180  
 IIIII IIIIIII  
 RESULT 9  
 AAW98183  
 ID AAW98183 standard; Protein; 222 AA.  
 XX  
 AC AAW98183;  
 XX  
 DT 05-JUL-1999 (first entry)  
 XX  
 DE Chlamydia psittaci MOMP (minus VD1 and VD2 region).  
 XX  
 KW Major outer membrane protein; MOMP; psittacosis; infection;  
 KW vaccine; genetic immunisation.  
 XX  
 OS Chlamydia psittaci.  
 XX  
 PN WO9910005-A1.  
 XX  
 PD 04-MAR-1999.  
 XX

PF 28-AUG-1998; 98WO-US17943.  
 XX  
 PR 28-AUG-1997; 97US-0057147.  
 XX  
 PA (LOUU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.  
 XX  
 PI Baghian A, Chouljenko VN, Kousoulas KG, Tully TN;  
 XX  
 XX WPI; 1999-254214/21.  
 DR N-PSDB; AAX25044.  
 XX  
 PT A new vaccine for Chlamydia psittaci infections  
 XX  
 PS Claim 6; Page 41-42; 72pp; English.  
 XX  
 CC The present sequence is a major outer membrane protein (MOMP)  
 CC polypeptide of Chlamydia psittaci strain LSUTCK, a cockatiel  
 CC isolate (the MOMP gene sequence of this isolate is identical to  
 CC that of C. psittaci Avian Type C). The polypeptide comprises  
 CC regions VD3 and VD4 of native MOMP (see also AAW98187), i.e. it lacks  
 CC regions VD1 and VD2 of MOMP. A claimed vaccine composition includes  
 CC the MOMP polypeptide, optionally fused to a maltose binding protein.  
 CC Also claimed are an isolated nucleic acid (see AAX25044) encoding the  
 CC polypeptide, a vector, and a method of preventing C. psittaci  
 CC infection by administering the vaccine containing the MOMP  
 CC polypeptide. Vectors encoding MOMP polypeptides lacking regions  
 CC VD1 and VD2 are useful for genetic (naked nucleic acid) vaccination.  
 CC The vaccines are used to prevent C. psittaci infection, especially  
 CC in birds.  
 XX  
 SQ Sequence 222 AA;

Query Match 79.5%; Score 58; DB 20; Length 222;  
 Best Local Similarity 91.7%; Pred. No. 0.028;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 IIIIIIIIIII  
 Db 176 qinkmksrkacg 187

RESULT 10  
 AAW98186  
 ID AAW98186 standard; Protein; 225 AA.  
 XX  
 AC AAW98186;  
 XX  
 DT 05-JUL-1999 (first entry)  
 XX  
 DE Chlamydia psittaci MOMP (minus VD1 and VD2 region).  
 XX  
 KW Major outer membrane protein; MOMP; psittacosis; infection;  
 KW vaccine; genetic immunisation.  
 XX  
 OS Chlamydia psittaci.  
 XX  
 PN WO9910005-A1.  
 XX  
 PD 04-MAR-1999.  
 XX  
 PF 28-AUG-1998; 98WO-US17943.  
 XX  
 PR 28-AUG-1997; 97US-0057147.  
 XX  
 PA (LOUU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.  
 XX  
 PI Baghian A, Chouljenko VN, Kousoulas KG, Tully TN;  
 XX  
 XX WPI; 1999-254214/21.  
 DR N-PSDB; AAX25045.  
 XX  
 PT A new vaccine for Chlamydia psittaci infections  
 XX  
 PS Claim 6; Page 42-43; 72pp; English.  
 XX  
 CC The present sequence is a major outer membrane protein (MOMP)  
 CC polypeptide of Chlamydia psittaci strain B577. The polypeptide  
 CC comprises regions VD3 and VD4 of the native protein (see also  
 CC AAW98187), but lacks regions VD1 and VD2. A claimed vaccine  
 CC composition includes this MOMP polypeptide, optionally fused to a  
 CC maltose binding protein. Also claimed are an isolated nucleic  
 CC acid (see AAX25045) encoding the polypeptide, a vector, and a method  
 CC of preventing C. psittaci infection by administering the vaccine  
 CC containing the MOMP polypeptide. Vectors encoding MOMP polypeptides  
 CC lacking regions VD1 and VD2 are useful for genetic (naked nucleic  
 CC acid) vaccination. The vaccines are used to prevent C. psittaci  
 CC infection, especially in birds.  
 XX  
 SQ Sequence 228 AA;

Query Match 79.5%; Score 58; DB 20; Length 225;  
 Best Local Similarity 91.7%; Pred. No. 0.029;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 IIIIIIIIIII  
 Db 179 qinkmksrkacg 190

RESULT 11  
 AAW98184  
 ID AAW98184 standard; Protein; 228 AA.  
 XX  
 AC AAW98184;  
 XX  
 DT 05-JUL-1999 (first entry)  
 XX  
 DE Chlamydia psittaci MOMP (minus VD1 and VD2 region).  
 XX  
 KW Major outer membrane protein; MOMP; psittacosis; infection;  
 KW vaccine; genetic immunisation.  
 XX  
 OS Chlamydia psittaci.  
 XX  
 PN WO9910005-A1.  
 XX  
 PD 04-MAR-1999.  
 XX  
 PF 28-AUG-1998; 98WO-US17943.  
 XX  
 PR 28-AUG-1997; 97US-0057147.  
 XX  
 PA (LOUU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.  
 XX  
 PI Baghian A, Chouljenko VN, Kousoulas KG, Tully TN;  
 XX  
 XX WPI; 1999-254214/21.  
 DR N-PSDB; AAX25045.  
 XX  
 PT A new vaccine for Chlamydia psittaci infections  
 XX  
 PS Claim 6; Page 42-43; 72pp; English.  
 XX  
 CC The present sequence is a major outer membrane protein (MOMP)  
 CC polypeptide of Chlamydia psittaci strain B577. The polypeptide  
 CC comprises regions VD3 and VD4 of the native protein (see also  
 CC AAW98187), but lacks regions VD1 and VD2. A claimed vaccine  
 CC composition includes this MOMP polypeptide, optionally fused to a  
 CC maltose binding protein. Also claimed are an isolated nucleic  
 CC acid (see AAX25045) encoding the polypeptide, a vector, and a method  
 CC of preventing C. psittaci infection by administering the vaccine  
 CC containing the MOMP polypeptide. Vectors encoding MOMP polypeptides  
 CC lacking regions VD1 and VD2 are useful for genetic (naked nucleic  
 CC acid) vaccination. The vaccines are used to prevent C. psittaci  
 CC infection, especially in birds.  
 XX  
 SQ Sequence 228 AA;

Query Match 79.5%; Score 58; DB 20; Length 228;  
 Best Local Similarity 91.7%; Pred. No. 0.029; Mismatches 0; Indels 0; Gaps 0;

OY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 182 qinkmksrkacg 193

## RESULT 12

AAV56769  
 ID AAY56769 standard; Protein; 343 AA.

XX AC AAY56769;

XX DT 22-FEB-2000 (first entry)

XX DE C. trachomatis serovar GPIC MOMP sequence.

XX KW Major outer membrane protein; MOMP; Chlamydia; vaccine; immune response;  
 XX KW cellular response; immunogen; Th1-like CD4 response; mucosal immunity.

XX OS Chlamydia trachomatis.

XX PN WO9951745-A2.

XX PD 14-OCT-1999.

XX PF 07-APR-1999; 99WO-CA00292.

XX PR 07-APR-1998; 98US-0055765.

XX PA (UYMA-) UNIV MANITOBA.

XX PI Bruhnam RC;

XX DR WPI; 1999-620205/53.

XX PT Non-replicating vector encoding fragments of the outer membrane protein  
 of Chlamydia, useful in vaccines and as immunogen

XX PS Disclosure; Fig 10 A-F; 52pp; English.

XX CC The invention provides a non-replicating vector that comprises, linked  
 to a promoter, a nucleotide sequence that encodes a region containing at  
 least one of the conserved domains 2, 3 and 5 of a major outer membrane  
 protein (MOMP) of a Chlamydia strain. The vector is used: (a) in  
 vaccines to generate a protective immune response (mainly cellular)  
 against MOMP, and (b) as immunogens to raise anti-MOMP antibodies, useful  
 in standard immunoassays. Immunization with the vector induces a broad  
 spectrum of immune responses, including Th1-like CD4 responses and  
 mucosal immunity, providing significant protection against subsequent  
 challenge. Sequences AAY56757-71 represent MOMP sequences from a variety  
 of serovars of C. trachomatis.

XX SQ Sequence 343 AA;

Query Match 79.5%; Score 58; DB 20; Length 343;  
 Best Local Similarity 91.7%; Pred. No. 0.043; Mismatches 0; Indels 0; Gaps 0;

OY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 297 qinkmksrkacg 308

## RESULT 13

AAV56770  
 ID AAY56770 standard; Protein; 356 AA.

XX

## AAV56770:

XX DT 22-FEB-2000 (first entry)

XX DE C. trachomatis serovar Mn MOMP sequence.

XX KW Major outer membrane protein; MOMP; Chlamydia; vaccine; immune response;  
 XX KW cellular response; immunogen; Th1-like CD4 response; mucosal immunity.

XX OS Chlamydia trachomatis.

XX PN WO9951745-A2.

XX PD 14-OCT-1999.

XX PF 07-APR-1999; 99WO-CA00292.

XX PR 07-APR-1998; 98US-0055765.

XX PA (UYMA-) UNIV MANITOBA.

XX PI Bruhnam RC;

XX DR WPI; 1999-620205/53.

XX PT Non-replicating vector encoding fragments of the outer membrane protein  
 of Chlamydia, useful in vaccines and as immunogen

XX PS Disclosure; Fig 10 A-F; 52pp; English.

XX CC The invention provides a non-replicating vector that comprises, linked  
 to a promoter, a nucleotide sequence that encodes a region containing at  
 least one of the conserved domains 2, 3 and 5 of a major outer membrane  
 protein (MOMP) of a Chlamydia strain. The vector is used: (a) in  
 vaccines to generate a protective immune response (mainly cellular)  
 against MOMP, and (b) as immunogens to raise anti-MOMP antibodies, useful  
 in standard immunoassays. Immunization with the vector induces a broad  
 spectrum of immune responses, including Th1-like CD4 responses and  
 mucosal immunity, providing significant protection against subsequent  
 challenge. Sequences AAY56757-71 represent MOMP sequences from a variety  
 of serovars of C. trachomatis.

XX SQ Sequence 356 AA;

Query Match 79.5%; Score 58; DB 20; Length 356;  
 Best Local Similarity 91.7%; Pred. No. 0.045; Mismatches 1; Indels 0; Gaps 0;

OY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 310 qinkmksrkacg 321

## RESULT 14

AAV98188  
 ID AAW98188 standard; Protein; 389 AA.

XX AC AAW98188;

XX DT 05-JUL-1999 (first entry)

XX DE Chlamydia psittaci major outer membrane protein.

XX KW Major outer membrane protein; MOMP; psittacosis; infection;  
 XX KW vaccine; genetic immunisation.

XX OS Chlamydia psittaci.

XX PN WO9910005-A1.

XX PD 04-MAR-1999.

XX



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:41:29 ; Search time 37.72 seconds  
(without alignments)  
7.756 Million cell updates/sec

Title: US-09-709-201-101  
Perfect score: 73  
Sequence: 1 CQINKFKSRKACG 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 212252 seqs, 22503292 residues

Total number of hits satisfying chosen parameters: 212252

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued\_Patents\_AA:\*  
1: /cgn2\_6/ptodata/2/iaa/5A\_COMB.pep.\*  
2: /cgn2\_6/ptodata/2/iaa/5B\_COMB.pep.\*  
3: /cgn2\_6/ptodata/2/iaa/6A\_COMB.pep.\*  
4: /cgn2\_6/ptodata/2/iaa/6B\_COMB.pep.\*  
5: /cgn2\_6/ptodata/2/iaa/PCRUS\_COMB.pep.\*  
6: /cgn2\_6/ptodata/2/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	40	54.8	58	1	US-08-334-773A-2
2	38	52.1	824	1	US-08-221-750A-3
3	37.5	51.4	19	2	US-08-764-640-158
4	37.5	51.4	19	3	US-08-973-225-158
5	37.5	51.4	19	3	US-09-244-298A-158
6	37.5	51.4	19	4	US-09-516-704-158
7	36	49.3	42	4	US-08-974-549A-141
8	36	49.3	562	3	US-08-851-843A-5
9	36	49.3	562	4	US-08-854-050-5
10	35	47.9	19	2	US-08-764-640-164
11	35	47.9	19	3	US-08-973-225-164
12	35	47.9	19	3	US-09-244-298A-164
13	35	47.9	19	4	US-09-516-704-164
14	35	47.9	68	1	US-07-972-387-40
15	35	47.9	68	1	US-08-431-412-40
16	35	47.9	68	1	US-08-057-971-40
17	35	47.9	68	1	US-08-358-160-125
18	35	47.9	70	1	US-07-791-213D-5
19	35	47.9	70	1	US-08-293-150A-5
20	35	47.9	89	1	US-07-972-387-8
21	35	47.9	89	1	US-07-972-387-10
22	35	47.9	89	1	US-07-972-387-16
23	35	47.9	89	1	US-08-431-412-8
24	35	47.9	89	1	US-08-431-412-10
25	35	47.9	89	1	US-08-431-412-16
26	35	47.9	89	1	US-08-057-971-8
27	35	47.9	89	1	US-08-057-971-10

28	35	47.9	89	1	US-08-057-971-16	Sequence 16, Appl
29	35	47.9	91	1	US-07-791-213D-89	Sequence 89, Appl
30	35	47.9	91	1	US-07-972-387-2	Sequence 2, Appl
31	35	47.9	91	1	US-08-431-412-2	Sequence 2, Appl
32	35	47.9	91	1	US-08-057-971-2	Sequence 2, Appl
33	35	47.9	91	1	US-08-293-150A-89	Sequence 89, Appl
34	35	47.9	101	1	US-07-972-387-28	Sequence 28, Appl
35	35	47.9	101	1	US-08-431-412-28	Sequence 28, Appl
36	35	47.9	101	1	US-08-057-971-28	Sequence 28, Appl
37	35	47.9	540	4	US-09-011-074-4	Sequence 4, Appl
38	35	47.9	595	4	US-08-842-079-6	Sequence 6, Appl
39	35	47.9	595	4	US-08-842-079-17	Sequence 17, Appl
40	34	46.6	58	1	US-08-334-773A-1	Sequence 1, Appl
41	34	46.6	205	1	US-08-450-944-5	Sequence 5, Appl
42	34	46.6	205	5	PCT-US96-07709-5	Sequence 5, Appl
43	34	46.6	221	1	US-08-450-944-2	Sequence 2, Appl
44	34	46.6	221	5	PCT-US96-07709-2	Sequence 2, Appl
45	34	46.6	595	4	US-08-842-079-18	Sequence 18, Appl

ALIGNMENTS

RESULT 1  
US-08-334-773A-2  
; Sequence 2, Application US/08334773A  
; Patent No. 5629176  
; GENERAL INFORMATION:  
; APPLICANT: No. 5629176ris, Fanny  
; APPLICANT: No. 5629176ris, Kjeld  
; APPLICANT: Bjorn, Soren Erik  
; APPLICANT: Petersen, Lars Christian  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: A Human Kunitz-Type Protease Inhibitor  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESSES:  
; ADDRESSEE: No. 56291760 No. 5629176disk of No. 5629176th America, Inc.  
; STREET: 405 Lexington Avenue, Suite 5400  
; CITY: New York  
; STATE: New York  
; COUNTRY: U.S.A.  
; ZIP: 10174-6400  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/334,773A  
; FILING DATE: 04-NOV-1994  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Agris, Cheryl H.  
; REGISTRATION NUMBER: 34,086  
; REFERENCE/DOCKET NUMBER: 3695.210-US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 212 867 0123  
; TELEFAX: 212 878 9655  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 58 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; ORIGINAL SOURCE:  
; ORGANISM: synthetic  
; US-08-334-773A-2

Query Match 54.8%; Score 40; DB 1; Length 58;  
Best Local Similarity 77.8%; Pred. No. 5.4;  
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 4 NKFKSRKAC 12  
 Db 43 NKFKSQREC 51

RESULT 2  
 US-08-221-750A-3  
 ; Sequence 3, Application US/08221750A  
 ; Patent No. 5643747  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Baker, Steven M.  
 ; APPLICANT: Deich, Robert A.  
 ; TITLE OF INVENTION: Genes for the Export of Pertussis  
 ; TITLE OF INVENTION: Holotoxin  
 ; NUMBER OF SEQUENCES: 13  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
 ; STREET: Two Militia Drive  
 ; CITY: Lexington  
 ; STATE: MA  
 ; COUNTRY: USA  
 ; ZIP: 02173  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/221,750A  
 ; FILING DATE: 31-MAR-1994  
 ; CLASSIFICATION: 435  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/031,619  
 ; FILING DATE: 15-MAR-1993  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Carroll, Alice O.  
 ; REGISTRATION NUMBER: 33,542  
 ; REFERENCE/DOCKET NUMBER: ACC93-01A  
 ; TELEPHONE: (617) 861-6240  
 ; TELEFAX: (617) 861-9540  
 ; INFORMATION FOR SEQ ID NO: 3:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 824 amino acids  
 ; TYPE: amino acid  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: protein  
 ; US-08-221-750A-3

Query Match 52.1%; Score 38; DB 1; Length 824;  
 Best Local Similarity 53.8%; Pred. No. 1.3e+02;  
 Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 COINKFKSRKAC 13  
 Db 471 COLQKFRSADAG 483

RESULT 3  
 US-08-764-640-158  
 ; Sequence 158, Application US/08764640  
 ; Patent No. 5869451  
 ; Patent No. 5869451 5837683  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Dower, William J.  
 ; APPLICANT: Barrett, Ronald W.  
 ; APPLICANT: Cwirla, Steven E.  
 ; APPLICANT: Gates, Christian  
 ; APPLICANT: Schatz, Peter J.  
 ; APPLICANT: Balasubramanian, Palaniappan  
 ; APPLICANT: Wagstrom, Christopher R.

; APPLICANT: Hendren, Richard W.  
 ; APPLICANT: Deprience, Randolph B.  
 ; APPLICANT: Podduturi, Surekha  
 ; APPLICANT: Yin, Qun  
 ; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
 ; TITLE OF INVENTION: RECEPTOR  
 ; NUMBER OF SEQUENCES: 244  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Glaxo Wellcome  
 ; STREET: Five Moore Drive, P.O. Box 13398  
 ; CITY: Research Triangle Park  
 ; STATE: NC  
 ; COUNTRY: USA  
 ; ZIP: 27709  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/764,640  
 ; FILING DATE: 11-DEC-1996  
 ; CLASSIFICATION: 514  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Hrubiec, Robert T.  
 ; REGISTRATION NUMBER: 36,392  
 ; REFERENCE/DOCKET NUMBER: PK3281  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 919-248-1000  
 ; INFORMATION FOR SEQ ID NO: 158:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 19 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS:  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: peptide  
 ; US-08-764-640-158

Query Match 51.4%; Score 37.5; DB 2; Length 19;  
 Best Local Similarity 61.5%; Pred. No. 4.9;  
 Matches 8; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 1 COINKFKSRKAC 13  
 Db 5 CTLNGFKSRH-CG 16

RESULT 4  
 US-08-973-225-158  
 ; Sequence 158, Application US/08973225A  
 ; Patent No. 6083913  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Dower, William J.  
 ; APPLICANT: Barrett, Ronald W.  
 ; APPLICANT: Cwirla, Steven E.  
 ; APPLICANT: Duffin, David J.  
 ; APPLICANT: Gates, Christian  
 ; APPLICANT: Haselden, Sherril S.  
 ; APPLICANT: Mattheakis, Larry C.  
 ; APPLICANT: Schatz, Peter J.  
 ; APPLICANT: Wagstrom, Christopher R.  
 ; APPLICANT: Wrighton, Nicholas C.  
 ; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
 ; TITLE OF INVENTION: THROMBOPOIETIN RECEPTOR  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Glaxo Wellcome  
 ; STREET: Five Moore Drive, P.O. Box 13398  
 ; CITY: Research Triangle Park  
 ; STATE: NC  
 ; COUNTRY: USA  
 ; ZIP: 27709



COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/973,225A  
FILING DATE: 04-Dec-1997

ATTORNEY/AGENT INFORMATION:  
NAME: Hrubiec, Robert T.  
REGISTRATION NUMBER: 36,392  
REFERENCE/DOCKET NUMBER: PK3065USW

TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-248-1000  
INFORMATION FOR SEQ ID NO: 158:

SEQUENCE CHARACTERISTICS:  
LENGTH: 19 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear

MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 158:

US-08-973-225-158

Query Match 51.4%; Score 37.5; DB 3; Length 19;  
Best Local Similarity 61.5%; Pred. No. 4.9;  
Matches 8; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 1 COINKFKSRKACG 13  
| : | | | | | |  
Db 5 CTLNGFKSRH-CG 16

## RESULT 5

US-09-244-298A-158  
Sequence 158, Application US/09244298A  
Patent No. 6121238

GENERAL INFORMATION:  
APPLICANT: Dower, William J.  
APPLICANT: Barrett, Ronald W.

APPLICANT: Cwiria, Steven E.  
APPLICANT: Gates, Christian  
APPLICANT: Schatz, Peter J.

APPLICANT: Balasubramanian, Palaniappan  
APPLICANT: Wagstrom, Christopher R.  
APPLICANT: Hendren, Richard W.

APPLICANT: Deprience, Randolph B.  
APPLICANT: Podduturi, Surekha  
APPLICANT: Yin, Qun

TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
TITLE OF INVENTION: RECEPTOR  
NUMBER OF SEQUENCES: 244

CORRESPONDENCE ADDRESS:

ADDRESSEE: Glaxo Wellcome  
STREET: Five Moore Drive, P.O. Box 13398  
CITY: Research Triangle Park

STATE: NC  
COUNTRY: USA  
ZIP: 27709

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/244,298A

FILING DATE: 11-DEC-1996  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:

NAME: Hrubiec, Robert T.  
REGISTRATION NUMBER: 36,392  
REFERENCE/DOCKET NUMBER: PK3281

TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-248-1000  
INFORMATION FOR SEQ ID NO: 158:

SEQUENCE CHARACTERISTICS:  
LENGTH: 19 amino acids  
TYPE: amino acid  
STRANDEDNESS:

TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-09-244-298A-158

Query Match 51.4%; Score 37.5; DB 3; Length 19;  
Best Local Similarity 61.5%; Pred. No. 4.9;  
Matches 8; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 1 COINKFKSRKACG 13  
| : | | | | | |  
Db 5 CTLNGFKSRH-CG 16

## RESULT 6

US-09-516-704-158  
Sequence 158, Application US/09516704  
Patent No. 6251864

GENERAL INFORMATION:  
APPLICANT: Dower, William J.  
APPLICANT: Barrett, Ronald W.

APPLICANT: Cwiria, Steven E.  
APPLICANT: Schatz, Peter J.  
APPLICANT: Balasubramanian, Palaniappan

APPLICANT: Wagstrom, Christopher R.  
APPLICANT: Hendren, Richard W.  
APPLICANT: Deprience, Randolph B.

APPLICANT: Podduturi, Surekha  
APPLICANT: RECEPTOR  
TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A

NUMBER OF SEQUENCES: 244

CORRESPONDENCE ADDRESS:

ADDRESSEE: Glaxo Wellcome  
STREET: Five Moore Drive, P.O. Box 13398  
CITY: Research Triangle Park

STATE: NC  
COUNTRY: USA  
ZIP: 27709

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/516,704

FILING DATE: 01-Mar-2000  
CLASSIFICATION: <Unknown>  
ATTORNEY/AGENT INFORMATION:

NAME: Hrubiec, Robert T.  
REGISTRATION NUMBER: 36,392  
REFERENCE/DOCKET NUMBER: PK3281

TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-248-1000  
INFORMATION FOR SEQ ID NO: 158:

SEQUENCE CHARACTERISTICS:  
LENGTH: 19 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>

TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 158:

US-09-516-704-158

Query Match

51.4%; Score 37.5; DB 4; Length 19;

Best Local Similarity 61.5%; Pred. No. 4.9;  
Matches 8; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 1 COINPKSRKACG 13  
Db 5 CTLNGFKSRH-CG 16

## RESULT 7

US-08-974-549A-141  
; Sequence 141, Application US/08974549A  
; Patent No. 6166178

## GENERAL INFORMATION:

APPLICANT: Cech, Thomas R.  
APPLICANT: Lingner, Joachim  
APPLICANT: Nakamura, Toru  
APPLICANT: Chapman, Karen B.  
APPLICANT: Morin, Gregg B.  
APPLICANT: Harley, Calvin B.  
APPLICANT: Andrews, William H.  
TITLE OF INVENTION: Human Telomerase Catalytic Subunit  
NUMBER OF SEQUENCES: 727  
CORRESPONDENCE ADDRESS:

ADDRESSEE: Townsend and Townsend and Crew LLP  
STREET: Two Embarcadero Center, Eighth Floor  
CITY: San Francisco  
STATE: California  
COUNTRY: USA  
ZIP: 94111-3834

## COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/974,549A  
FILING DATE: 19-NOV-1997  
CLASSIFICATION: 536

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/724,643  
FILING DATE: 01-OCT-1996

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/844,419  
FILING DATE: 18-APR-1997

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/846,017  
FILING DATE: 25-APR-1997

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/851,843  
FILING DATE: 06-MAY-1997

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/854,050  
FILING DATE: 09-MAY-1997

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/911,312  
FILING DATE: 14-AUG-1997

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/912,951  
FILING DATE: 14-AUG-1997

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/915,503  
FILING DATE: 14-AUG-1997

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: WO PCT/US97/17618  
FILING DATE: 01-OCT-1997

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: WO PCT/US97/17885  
FILING DATE: 01-OCT-1997

ATTORNEY/AGENT INFORMATION:  
NAME: Apple, Randolph Ted  
REGISTRATION NUMBER: 36,429  
REFERENCE/DOCKET NUMBER: 015389-002610US  
TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 576-0200  
TELEFAX: (415) 576-0300  
INFORMATION FOR SEQ ID NO: 141:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 42 amino acids  
TYPE: amino acid  
STRANDEDNESS:  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-974-549A-141

Query Match 49.3%; Score 36; DB 4; Length 42;  
Best Local Similarity 60.0%; Pred. No. 17;  
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 4 NKPKSRKACG 13  
Db 8 NPYKRRKNCG 17

## RESULT 8

US-08-851-843A-5  
; Sequence 5, Application US/08851843A  
; Patent No. 6093809

## GENERAL INFORMATION:

APPLICANT: Cech, Thomas R.  
APPLICANT: Lingner, Joachim  
APPLICANT: Nakamura, Toru  
APPLICANT: Chapman, Karen B.  
APPLICANT: Morin, Gregg B.  
APPLICANT: Harley, Calvin  
APPLICANT: Andrews, William H.  
TITLE OF INVENTION: No. 6093809el Telomerase  
NUMBER OF SEQUENCES: 225  
CORRESPONDENCE ADDRESS:

ADDRESSEE: Townsend and Townsend and Crew LLP  
STREET: Two Embarcadero Center, 8th Floor  
CITY: San Francisco  
STATE: California  
COUNTRY: United States of America  
ZIP: 94111

## COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/851,843A  
FILING DATE: 06-MAY-1997

## CLASSIFICATION:

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/846,017  
FILING DATE: 25-APR-1997

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/844,419  
FILING DATE: 18-APR-1997

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/724,643  
FILING DATE: 01-OCT-1996

ATTORNEY/AGENT INFORMATION:  
NAME: Apple, Randolph T.  
REGISTRATION NUMBER: 36,429  
REFERENCE/DOCKET NUMBER: 015389-002930US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 576-0200  
TELEFAX: (415) 576-0300

INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 562 amino acids

;  
; TYPE: amino acid  
; STRANDEDNESS: not relevant  
; TOPOLOGY: not relevant  
; MOLECULE TYPE: protein  
US-08-851-843A-5

Query Match 49.3%; Score 36; DB 3; Length 562;  
Best Local Similarity 60.0%; Pred. No. 1.8e+02;  
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 4 NKFPSRKACG 13  
| : | | | |  
DB 8 NPYKKRKNCG 17

RESULT 9  
US-08-854-050-5  
; Sequence 5, Application US/08854050  
; Patent No. 6261836  
; GENERAL INFORMATION:  
; APPLICANT: Cech, Thomas R.  
; APPLICANT: Lingner, Joachim  
; APPLICANT: Nakamura, Toru  
; APPLICANT: Chapman, Karen B.  
; APPLICANT: Morin, Gregg B.  
; APPLICANT: Harley, Calvin  
; APPLICANT: Andrews, William H.  
; TITLE OF INVENTION: No. 6261836el Telomerase  
; NUMBER OF SEQUENCES: 225  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend and Crew LLP  
; STREET: Two Embarcadero Center, 8th Floor  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: United States of America  
; ZIP: 94111  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/854,050  
; FILING DATE: 09-MAY-1997  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/851,843  
; FILING DATE: 06-MAY-1997  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/846,017  
; FILING DATE: 25-APR-1997  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/844,419  
; FILING DATE: 18-APR-1997  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/724,643  
; FILING DATE: 01-OCT-1996  
; CLASSIFICATION: 536  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Apple, Randolph T.  
; REGISTRATION NUMBER: 36,429  
; REFERENCE/DOCKET NUMBER: 015389-002930US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 576-0200  
; TELEFAX: (415) 576-0300  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 562 amino acids  
; TYPE: amino acid

;  
; STRANDEDNESS: not relevant  
; TOPOLOGY: not relevant  
; MOLECULE TYPE: protein  
US-08-854-050-5

Query Match 49.3%; Score 36; DB 4; Length 562;  
Best Local Similarity 60.0%; Pred. No. 1.8e+02;  
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 4 NKFPSRKACG 13  
| : | | | |  
DB 8 NPYKKRKNCG 17

RESULT 10  
US-08-764-640-164  
; Sequence 164, Application US/08764640  
; Patent No. 5869451  
; Patent No. 5869451 5837683  
; GENERAL INFORMATION:  
; APPLICANT: Dower, William J.  
; APPLICANT: Barrett, Ronald W.  
; APPLICANT: Cwirla, Steven E.  
; APPLICANT: Gates, Christian  
; APPLICANT: Schatz, Peter J.  
; APPLICANT: Balasubramanian, Palaniappan  
; APPLICANT: Wegstrom, Christopher R.  
; APPLICANT: Hendren, Richard W.  
; APPLICANT: Deprence, Randolph B.  
; APPLICANT: Podduturi, Surekha  
; APPLICANT: Yin, Qun  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
; TITLE OF INVENTION: RECEPTOR  
; NUMBER OF SEQUENCES: 244  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Glaxo Wellcome  
; STREET: Five Moore Drive, P.O. Box 13398  
; CITY: Research Triangle Park  
; STATE: NC  
; COUNTRY: USA  
; ZIP: 27709  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/764,640  
; FILING DATE: 11-DEC-1996  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hrubiec, Robert T.  
; REGISTRATION NUMBER: 36,392  
; REFERENCE/DOCKET NUMBER: PK3281  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 919-248-1000  
; INFORMATION FOR SEQ ID NO: 164:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 19 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-764-640-164

Query Match 47.9%; Score 35; DB 2; Length 19;  
Best Local Similarity 46.2%; Pred. No. 12;  
Matches 6; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 CQINKFKSRKACG 13  
| : | | | |

Db 5 CSLAKLKGACG 17

## RESULT 11

US-08-973-225-164  
; Sequence 164, Application US/08973225A  
; Patent No. 6083913

## GENERAL INFORMATION:

APPLICANT: Dower, William J.  
; Barrett, Ronald W.  
; Cwiria, Steven E.  
; Duffin, David J.  
; Gates, Christian  
; Haselden, Sherril S.  
; Mattheakis, Larry C.  
; Schatz, Peter J.  
; Wagstrom, Christopher R.  
; Wrighton, Nicholas C.

TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
THROMBOPOIETIN RECEPTOR

NUMBER OF SEQUENCES: 232

CORRESPONDENCE ADDRESS:

ADDRESSEE: Glaxo Wellcome  
STREET: Five Moore Drive, P.O. Box 13398  
CITY: Research Triangle Park  
STATE: NC  
COUNTRY: USA

ZIP: 27709

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/973,225A  
FILING DATE: 04-Dec-1997

ATTORNEY/AGENT INFORMATION:

NAME: Hrubiec, Robert T.  
REGISTRATION NUMBER: 36,392  
REFERENCE/DOCKET NUMBER: PK3065USW  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-248-1000

INFORMATION FOR SEQ ID NO: 164:

SEQUENCE CHARACTERISTICS:  
LENGTH: 19 amino acids  
TYPE: amino acid  
STRANDEDNESS: <unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 164:

US-08-973-225-164

Query Match 47.9%; Score 35; DB 3; Length 19;  
Best Local Similarity 46.2%; Pred. No. 12;  
Matches 6; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 CQINKFKSRKACG 13

Db 5 CSLAKLKGACG 17

## RESULT 12

US-09-244-298A-164  
; Sequence 164, Application US/09244298A  
; Patent No. 6121238

## GENERAL INFORMATION:

APPLICANT: Dower, William J.  
; Barrett, Ronald W.  
; Cwiria, Steven E.  
; Gates, Christian  
; Schatz, Peter J.  
; Balasubramanian, Palaniappan

APPLICANT: Wagstrom, Christopher R.  
; Hendren, Richard W.  
; Deprence, Randolph B.  
; Podduturi, Surekha  
; Yin, Qun  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
RECEPTOR  
NUMBER OF SEQUENCES: 244  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Glaxo Wellcome  
STREET: Five Moore Drive, P.O. Box 13398  
CITY: Research Triangle Park  
STATE: NC  
COUNTRY: USA

ZIP: 27709

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/244,298A  
FILING DATE: 11-DEC-1996  
CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:

NAME: Hrubiec, Robert T.  
REGISTRATION NUMBER: 36,392  
REFERENCE/DOCKET NUMBER: PK3281  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-248-1000

INFORMATION FOR SEQ ID NO: 164:

SEQUENCE CHARACTERISTICS:  
LENGTH: 19 amino acids  
TYPE: amino acid  
STRANDEDNESS:  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-09-244-298A-164

Query Match 47.9%; Score 35; DB 3; Length 19;  
Best Local Similarity 46.2%; Pred. No. 12;  
Matches 6; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 CQINKFKSRKACG 13

Db 5 CSLAKLKGACG 17

## RESULT 13

US-09-516-704-164  
; Sequence 164, Application US/09516704  
; Patent No. 6251864

## GENERAL INFORMATION:

APPLICANT: Dower, William J.  
; Barrett, Ronald W.  
; Cwiria, Steven E.  
; Gates, Christian  
; Schatz, Peter J.  
; Balasubramanian, Palaniappan  
; Wagstrom, Christopher R.  
; Hendren, Richard W.  
; Deprence, Randolph B.  
; Podduturi, Surekha

TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
RECEPTOR

NUMBER OF SEQUENCES: 244

CORRESPONDENCE ADDRESS:

ADDRESSEE: Glaxo Wellcome  
STREET: Five Moore Drive, P.O. Box 13398  
CITY: Research Triangle Park  
STATE: NC  
COUNTRY: USA



Query Match 47.9%; Score 35; DB 1; Length 68;  
Best Local Similarity 66.7%; Pred. No. 39;  
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 4 NKFKSRKAC 12  
|||:| |  
Db 41 NAFSEKEC 49

Search completed: March 26, 2002, 13:41:30  
Job time: 304 sec

GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:37:21 ; Search time 42.75 seconds  
(without alignments)  
23.164 Million cell updates/sec

Title: US-09-709-201-101

Perfect score: 73

Sequence: 1 CQINKFKSRKACG 13

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 219241 seqs, 76174552 residues

Total number of hits satisfying chosen parameters: 219241

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR\_68.\*

1: pir1.\*

2: pir2.\*

3: pir3.\*

4: pir4.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	% Match	Length	DB ID	Description
1	73	100.0	389	2 A43587	major outer membra
2	73	100.0	389	2 I40864	major outer membra
3	73	100.0	389	2 I40739	major outer membra
4	73	100.0	389	2 D86577	major outer membra
5	58	79.5	389	1 MMCWP3	major outer membra
6	58	79.5	389	2 A60109	major outer membra
7	58	79.5	392	2 A40371	major outer membra
8	58	79.5	402	1 MMCWPM	major outer membra
9	58	79.5	402	2 A60341	major outer membra
10	58	79.5	402	2 B60109	major outer membra
11	58	79.5	402	2 I40740	major outer membra
12	53	72.6	372	2 S11009	major outer membra
13	53	72.6	372	2 B60756	major outer membra
14	53	72.6	374	2 S11006	major outer membra
15	53	72.6	375	2 S11007	major outer membra
16	53	72.6	387	2 J10947	mouse pneumonitis
17	53	72.6	387	2 S16034	major outer membra
18	53	72.6	387	2 C81747	major outer membra
19	53	72.6	393	1 MMCWPE	major outer membra
20	53	72.6	393	2 T01645	major outer membra
21	53	72.6	393	2 S06259	major outer membra
22	53	72.6	393	2 JC1432	major outer membra
23	53	72.6	393	2 H71484	probable major out
24	53	72.6	394	1 MMCWTB	major outer membra
25	53	72.6	394	2 S11012	major outer membra
26	53	72.6	395	1 MMCWTF	major outer membra
27	53	72.6	396	2 S12799	major outer membra
28	53	72.6	397	1 MMCWTH	major outer membra
29	53	72.6	397	1 MMCWTC	major outer membra

major outer membra  
major outer membra  
hypothetical prote  
diacylglycerol kin  
ORF MSV229 leucine  
aldehyde dehydroge  
alcohol dehydrogen  
NADH dehydrogenase  
VIB4 homolog - Bo  
hypothetical prote  
retrotransposable  
transposase tnpA [  
transposase - Lept  
alpha-1-microglobu  
hypothetical prote  
NADH-ubiquinone ox

30 53 72.6 397 2 JE0413  
31 53 72.6 404 2 I40741  
32 43 58.9 265 2 D81402  
33 41 56.2 1154 2 T18523  
34 40 54.8 182 2 T28390  
35 39 53.4 862 1 A49346  
36 38 53.4 894 2 D82127  
37 38 52.1 444 2 D84948  
38 38 52.1 824 2 B47301  
39 38 52.1 1330 2 A36373  
40 38 52.1 1333 2 T38401  
41 37 50.7 235 2 T44466  
42 37 50.7 364 2 S43117  
43 37 50.7 372 2 JC2556  
44 37 50.7 408 2 T16601  
45 37 50.7 444 2 H82821

#### ALIGNMENTS

RESULT 1  
A43587.  
major outer membrane protein, porin CP0051 precursor [imported] - Chlamydomophila pneum  
N:Alternate names: MOMP  
C:Species: Chlamydomophila pneumoniae, Chlamydia pneumoniae  
C:Date: 29-Jan-1993 #sequence-revision 29-Jan-1993 #text\_change 11-May-2000  
C:Accession: A43587; A49751; A49216; G72044; F81619  
R:Perez Melgosa, M.; Kuo, C.C.; Campbell, L.A.  
Infect. Immun. 59, 2195-2199, 1991  
A:Title: Sequence analysis of the major outer membrane protein gene of Chlamydia pneu  
A:Reference number: A43587; MUID:91244474  
A:Accession: A43587  
A:Molecule type: DNA  
A:Residues: 1-389 <PER>  
A:Cross-references: GB:M69230; NID:gl44540; PIDN:AAA73071.1; PID:gl44541  
R:Carter, M.W.; Al-Mahdawi, S.A.H.; Giles, I.G.; Treharne, J.D.; Ward, M.E.; Clarke, J. Gen. Microbiol. 137, 465-475, 1991  
A:Title: Nucleotide sequence and taxonomic value of the major outer membrane protein  
A:Reference number: A49751; MUID:91237311  
A:Accession: A49751  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-389 <CAR>  
A:Cross-references: GB:M64064; GB:M34942; NID:gl44534; PIDN:AAA23143.1; PID:gl44535  
A:Note: Isolate 101-207  
R:Gaydos, C.A.; Quinn, T.C.; Bobo, L.D.; Eiden, J.J.  
Infect. Immun. 60, 5319-5323, 1992  
A:Title: Similarity of Chlamydia pneumoniae strains in the variable domain IV region  
A:Reference number: A49216; MUID:93084388  
A:Accession: A49216  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 297-352 <GAY>  
A:Cross-references: GB:S50607; NID:g260972; PIDN:AAB24363.1; PID:g260973  
A:Note: sequence extracted from NCBI backbone (NCBIN:120604, NCBI:120605)  
R:Kelman, S.; Mitchell, W.; Marathe, R.; Lammel, C.; Fan, J.; Olinger, L.; Grimwood, Nature Genet. 21, 385-389, 1999  
A:Title: Comparative genomes of Clamydia pneumoniae and C. trachomatis.  
A:Reference number: A72000; MUID:99206606  
A:Accession: G72044  
A:Molecule type: DNA  
A:Residues: 1-389 <ARN>  
A:Cross-references: GB:AE001652; GB:AE001363; NID:g4376997; PIDN:AAD18834.1; PID:g437  
R:Read, T.D.; Brumham, R.C.; Shen, C.; Gill, S.R.; Heidelberg, J.F.; White, O.; Hicke  
C.; Dodson, R.; Gwinn, M.; Nelson, W.; DeBoy, R.; Kolonay, J.; McClarty, G.; Salzbe  
Nucleic Acids Res. 28, 1397-1406, 2000  
A:Title: Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39  
A:Reference number: A81500; MUID:20150255  
A:Accession: F81619  
A:Status: preliminary  
A:Molecule type: DNA

A:Residues: 1-389 <REA>  
 A:Cross-references: GB:AE002161; NID:g718982; PIDN:AAF37944.1; PID:g718899  
 A:Experimental source: strain AR39, HL cells  
 C:Genetics:

A:Gene: ompA; cp0051  
 C:Superfamily: Chlamydia major outer membrane protein  
 C:Keywords: membrane protein  
 F:1-23/Domain: signal sequence  
 F:24-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 100.0%; Score 73; DB 2; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-05;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 COINKFSRKACG 13  
 |||||

Db 342 COINKFSRKACG 354

## RESULT 2

major outer membrane protein - Chlamydia psittaci  
 C:Species: Chlamydia psittaci, Chlamydia psittaci  
 C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 31-Mar-2000  
 C:Accession: I40864; S33465  
 R:Girjes, A.A.; Carrick, F.N.; Lavin, M.F.  
 Gene 138, 139-142, 1994  
 A:Title: Remarkable sequence relatedness in the DNA encoding the major outer membrane protein  
 A:Reference number: I40864; MUID:94171025  
 A:Accession: I40864  
 A:Status: preliminary; translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-389 <RES>

A:Cross-references: EMBL:X72023; NID:g313844; PIDN:CAA50906.1; PID:g313845  
 C:Superfamily: Chlamydia major outer membrane protein

Query Match 100.0%; Score 73; DB 2; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-05;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 COINKFSRKACG 13  
 |||||

Db 342 COINKFSRKACG 354

## RESULT 3

major outer membrane protein precursor - Chlamydia pneumoniae (strain equine/N16)  
 C:Species: Chlamydia pneumoniae, Chlamydia pneumoniae  
 A:Variety: strain equine/N16  
 C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 20-Apr-2000  
 C:Accession: I40739  
 R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.  
 J. Gen. Microbiol. 139, 2621-2626, 1993  
 A:Title: Evidence for Chlamydia pneumoniae of non-human origin.  
 A:Reference number: I40739; MUID:94103736  
 A:Accession: I40739

A:Status: translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-389 <STO>

A:Cross-references: GB:L04982; NID:g289840; PIDN:AAAL7397.1; PID:g289841  
 C:Comment: On the basis of the major outer membrane protein the authors classified the e the sequence of the genome strain CWL029 and strain strain IOL-207. See PIR:A43587.  
 C:Genetics:

A:Gene: ompA  
 C:Superfamily: Chlamydia major outer membrane protein  
 C:Keywords: membrane protein  
 F:1-23/Domain: signal sequence  
 F:24-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 100.0%; Score 73; DB 2; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-05;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 COINKFSRKACG 13  
 |||||

Db 342 COINKFSRKACG 354

## RESULT 4

major outer membrane protein [imported] - Chlamydia pneumoniae (strain J138)  
 C:Species: Chlamydia pneumoniae, Chlamydia pneumoniae  
 C:Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 23-Mar-2001  
 C:Accession: D86577  
 R:Shirai, M.; Hirakawa, H.; Kimoto, M.; Tabuchi, M.; Kishi, F.; Ouchi, K.; Shiba, T.; Nucleic Acids Res. 28, 2311-2314, 2000  
 A:Title: Comparison of whole genome sequences of chlamydia pneumoniae J138.  
 A:Reference number: A86491; MUID:20330349  
 A:Accession: D86577  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-389 <STO>

A:Cross-references: GB:BA000008; NID:g8979067; PIDN:BAA98902.1; GSPDB:GN00142  
 A:Experimental source: strain J138  
 C:Genetics:  
 A:Gene: ompA  
 C:Superfamily: Chlamydia major outer membrane protein

Query Match 100.0%; Score 73; DB 2; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-05;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 COINKFSRKACG 13  
 |||||

Db 342 COINKFSRKACG 354

## RESULT 5

major outer membrane protein precursor - Chlamydia psittaci (strain S26/3)  
 C:Species: Chlamydia psittaci, Chlamydia psittaci  
 C:Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 31-Mar-2000  
 C:Accession: S08770  
 R:Herring, A.J.; Tan, T.W.; Baxter, S.; Inglis, N.F.; Dunbar, S.  
 FEMS Microbiol. Lett. 65, 153-158, 1989  
 A:Title: Sequence analysis of the major outer membrane protein gene of an ovine abort  
 A:Reference number: S08770  
 A:Accession: S08770  
 A:Molecule type: DNA  
 A:Residues: 1-389 <HER>

A:Cross-references: EMBL:X51859; NID:g40600; PIDN:CAA36152.1; PID:g40601  
 C:Superfamily: Chlamydia major outer membrane protein  
 F:1-22/Domain: signal sequence #status predicted <SIG>  
 F:23-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 79.5%; Score 58; DB 1; Length 389;  
 Best Local Similarity 91.7%; Pred. No. 0.011;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 OINKFSRKACG 13  
 |||||

Db 343 OINKFSRKACG 354

## RESULT 6

major outer membrane protein precursor - Chlamydia psittaci (strain Guinea pig in  
 C:Species: Chlamydia psittaci, Chlamydia psittaci  
 C:Date: 10-Nov-1992 #sequence\_revision 10-Nov-1992 #text\_change 31-Mar-2000  
 C:Accession: A60109



R:Zhang, Y.X.; Morrison, S.G.; Caldwell, H.D.; Baehr, W.  
Infect. Immun. 57, 1621-1625, 1989

A:Title: Cloning and sequence analysis of the major outer membrane protein genes of two

A:Reference number: A60109; MUID:89212917

A:Accession: A60109

A>Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-389 <ZHA>

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 79.5%; Score 58; DB 2; Length 389;

Best Local Similarity 91.7%; Pred. No. 0.011;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13

||||| |||||

Db 343 QINKMKSRKACG 354

RESULT 7

A40371

major outer membrane protein precursor - Chlamydomphila psittaci (strain Fpn/pring)

C:Species: Chlamydomphila psittaci, Chlamydia psittaci

C:Date: 27-Nov-1991 #sequence\_revision 27-Nov-1991 #text\_change 31-Mar-2000

C:Accession: I40859; A40371; S16137

R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.

J. Gen. Microbiol. 139, 2621-2626, 1993

A:Title: Evidence for Chlamydia pneumoniae of non-human origin.

A:Reference number: I40739; MUID:94103736

A:Accession: I40859

A>Status: nucleic acid sequence not shown; translation not shown; translated from GB/EMBL

A:Molecule type: DNA

A:Residues: 1-392 <RES>

A:Cross-references: EMBL:X61096; NID:g40564; PIDN:CAA43409.1; PID:g40565

A:Experimental source: strain Fpn

C:Genetics:

A:Gene: MOMP

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-392/Product: major outer membrane protein #status predicted <MAT>

Query Match 79.5%; Score 58; DB 2; Length 392;

Best Local Similarity 91.7%; Pred. No. 0.011;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13

||||| |||||

Db 346 QINKMKSRKACG 357

RESULT 8

M40CPM

major outer membrane protein precursor - Chlamydomphila psittaci (strain A22/W)

C:Species: Chlamydomphila psittaci, Chlamydia psittaci

C:Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 31-Mar-2000

C:Accession: S05954

R:Pickett, M.A.; Everson, J.S.; Clarke, I.N.

FEMS Microbiol. Lett. 55, 229-234, 1988

A:Title: Chlamydia psittaci ewe abortion agent: complete nucleotide sequence of the major

A:Reference number: S05954

A:Accession: S05954

A:Molecule type: DNA

A:Residues: 1-402 <PIC>

A:Cross-references: EMBL:X12647; NID:g40604; PIDN:CAA31177.1; PID:g40605

C:Superfamily: Chlamydia major outer membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-402/Product: major outer membrane protein #status predicted <MAT>

Query Match 79.5%; Score 58; DB 1; Length 402;

Best Local Similarity 91.7%; Pred. No. 0.011;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13

||||| |||||

Db 356 QINKMKSRKACG 367

RESULT 9

A60341

major outer membrane protein precursor - Chlamydomphila psittaci (strain 68C)

C:Species: Chlamydomphila psittaci, Chlamydia psittaci

C:Date: 11-Dec-1992 #sequence\_revision 24-Feb-1994 #text\_change 31-Mar-2000

C:Accession: A44565; A60341; B60341

R:Everett, K.D.E.

submitted to the EMBL Data Library, December 1990

A:Reference number: A44565

A:Accession: A44565

A:Molecule type: DNA

A:Residues: 1-402 <EVE>

A:Cross-references: GB:X56980; NID:g40568; PIDN:CAA40300.1; PID:g40569

R:Everett, K.D.E.; Andersen, A.A.; Plaunt, M.; Hatch, T.P.

Infect. Immun. 59, 2853-2855, 1991

A:Title: Cloning and sequence analysis of the major outer membrane protein gene of Ch

A:Reference number: A60341; MUID:91310346

A:Accession: A60341

A:Molecule type: protein

A:Residues: 23-35 <EV2>

A:Accession: B60341

A>Status: nucleic acid sequence not shown

A:Molecule type: DNA

A:Residues: 112-232;317-349 <EV3>

A:Cross-references: GB:X56980

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-402/Product: major outer membrane protein #status experimental <MAT>

Query Match 79.5%; Score 58; DB 2; Length 402;

Best Local Similarity 91.7%; Pred. No. 0.011;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13

||||| |||||

Db 356 QINKMKSRKACG 367

RESULT 10

B60109

major outer membrane protein precursor - Chlamydomphila psittaci (strain meningopneumo

C:Species: Chlamydomphila psittaci, Chlamydia psittaci

C:Date: 10-Nov-1992 #sequence\_revision 10-Nov-1992 #text\_change 31-Mar-2000

C:Accession: B60109

R:Zhang, Y.X.; Morrison, S.G.; Caldwell, H.D.; Baehr, W.

Infect. Immun. 57, 1621-1625, 1989

A:Title: Cloning and sequence analysis of the major outer membrane protein genes of t

A:Reference number: A60109; MUID:89212917

A:Accession: B60109

A>Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-402 <ZHA>

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 79.5%; Score 58; DB 2; Length 402;

Best Local Similarity 91.7%; Pred. No. 0.011;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 356 QINKMKSRKACG 367

## RESULT: 11

I40740  
 major outer membrane protein - Chlamydomophila psittaci (strain N352)

C:Species: Chlamydomophila psittaci, Chlamydia psittaci  
 C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 31-Mar-2000  
 C:Accession: I40740

R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.

J. Gen. Microbiol. 139, 2621-2626, 1993

A:Title: Evidence for Chlamydia pneumoniae of non-human origin.

A:Reference number: I40739; MUID:94103736

A:Accession: I40740

A:Status: nucleic acid sequence not shown; translation not shown; translated from GB/EHE

A:Molecule type: DNA

A:Residues: 1-402 <RES>

A:CrossReferences: GB:L04980; NID:g144544; PIDN:AAA17396.1; PID:g144545

C:Genetics:

A:Gene: momp

C:Superfamily: Chlamydia major outer membrane protein

Query Match 79.5%; Score 58; DB 2; Length 402;

Best Local Similarity 91.7%; Pred. No. 0.011;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 356 QINKMKSRKACG 367

## RESULT: 12

I11009  
 major outer membrane protein - Chlamydia trachomatis (serotype B)

C:Species: Chlamydia trachomatis

A:Variant: serotype B

C:Date: 30-Jun-1991 #sequence\_revision 30-Jun-1991 #text\_change 30-Apr-1999

R:Baehr, W.; Zhang, Y.X.; Joseph, T.; Su, H.; Nano, F.E.; Everett, K.D.E.; Caldwell, H.H.

Proc. Natl. Acad. Sci. U.S.A. 85, 4000-4004, 1988

A:Title: Mapping antigenic domains expressed by Chlamydia trachomatis major outer membra

A:Reference number: S11006; MUID:88234546

A:Accession: S11009

A:Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-372 <BAE>

A:Experimental source: serovar B

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-372/Product: major outer membrane protein #status predicted <MAT>

Query Match 72.6%; Score 53; DB 2; Length 372;

Best Local Similarity 75.0%; Pred. No. 0.082;

Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 326 QLNKMKSRKSCG 337

## RESULT: 13

B60756  
 major outer membrane protein - Chlamydia trachomatis (serotype B)

C:Species: Chlamydia trachomatis

C:Date: 03-Jun-1993 #sequence\_revision 24-Feb-1994 #text\_change 07-May-1999

C:Accession: B60756

R:Hayes, E.J.; Pickett, M.A.; Conlan, J.W.; Ferris, S.; Everson, J.S.; Ward, M.E.; Clark

J. Gen. Microbiol. 136, 1559-1566, 1990  
 A:Title: The major outer-membrane proteins of Chlamydia trachomatis serovars A and B:  
 9 domains.

A:Reference number: A60756; MUID:91086917

A:Accession: B60756

A:Status: nucleic acid sequence not shown; not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-372 <HAY>

A:Experimental source: strain B/Jali-20/OT

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

Query Match 72.6%; Score 53; DB 2; Length 372;

Best Local Similarity 75.0%; Pred. No. 0.082;

Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 326 QLNKMKSRKSCG 337

## RESULT: 14

S11006

major outer membrane protein - Chlamydia trachomatis (serotype A)

C:Species: Chlamydia trachomatis

C:Date: 30-Jun-1991 #sequence\_revision 30-Jun-1991 #text\_change 18-Jun-1993

C:Accession: S11006

R:Baehr, W.; Zhang, Y.X.; Joseph, T.; Su, H.; Nano, F.E.; Everett, K.D.E.; Caldwell,

Proc. Natl. Acad. Sci. U.S.A. 85, 4000-4004, 1988

A:Title: Mapping antigenic domains expressed by Chlamydia trachomatis major outer mem

A:Reference number: S11006; MUID:88234546

A:Accession: S11006

A:Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-374 <BAE>

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-374/Product: major outer membrane protein #status predicted <MAT>

Query Match 72.6%; Score 53; DB 2; Length 374;

Best Local Similarity 75.0%; Pred. No. 0.082;

Matches 19; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 328 QLNKMKSRKSCG 339

## RESULT: 15

S11007

major outer membrane protein - Chlamydia trachomatis (serotype C)

C:Species: Chlamydia trachomatis

C:Date: 30-Jun-1991 #sequence\_revision 30-Jun-1991 #text\_change 18-Jun-1993

C:Accession: S11007

R:Baehr, W.; Zhang, Y.X.; Joseph, T.; Su, H.; Nano, F.E.; Everett, K.D.E.; Caldwell,

Proc. Natl. Acad. Sci. U.S.A. 85, 4000-4004, 1988

A:Title: Mapping antigenic domains expressed by Chlamydia trachomatis major outer mem

A:Reference number: S11006; MUID:88234546

A:Accession: S11007

A:Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-375 <BAE>

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-375/Product: major outer membrane protein #status predicted <MAT>

Query Match 72.6%; Score 53; DB 2; Length 375;

Best Local Similarity 75.0%; Pred. No. 0.082;

Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2 QLNKFSRKACG 13  
|:| | | | |  
Db 329 QLNKFSRKSCG 340

Search completed: March 26, 2002, 13:37:21  
Job time: 55 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:45 ; Search time 24.63 Seconds  
(without alignments)  
19.352 Million cell updates/sec

Title: US-09-709-201-101  
Perfect score: 73  
Sequence: 1 CQINFKSRKACG 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 100059 seqs, 36664827 residues

Total number of hits satisfying chosen parameters: 100059

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_39:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	73	100.0	333	1 OM1K_CHLPN	Q8xbf4 chlamydia p
2	73	100.0	389	1 OM1N_CHLPN	Q07430 chlamydia p
3	73	100.0	389	1 OM1L_CHLPN	P27455 chlamydia p
4	58	79.5	389	1 OM1A_CHLPS	P16567 chlamydia p
5	58	79.5	392	1 OM1P_CHLPS	Q00087 chlamydia p
6	58	79.5	402	1 OM1E_CHLPS	P10332 chlamydia p
7	53	72.6	387	1 OM1L_CHLMU	P75024 chlamydia p
8	53	72.6	393	1 OM1D_CHLTR	Q46409 chlamydia t
9	53	72.6	393	1 OM1E_CHLTR	P17451 chlamydia t
10	53	72.6	393	1 OM1L_CHLTR	P19542 chlamydia t
11	53	72.6	394	1 OM1B_CHLTR	P23421 chlamydia t
12	53	72.6	394	1 OM1M_CHLTR	P06597 chlamydia t
13	53	72.6	395	1 OM1F_CHLTR	P16155 chlamydia t
14	53	72.6	396	1 OM1A_CHLTR	P23732 chlamydia t
15	53	72.6	397	1 OM1H_CHLTR	P08780 chlamydia t
16	53	72.6	397	1 OM1G_CHLTR	P13467 chlamydia t
17	53	72.6	397	1 OM1N_CHLTR	P23114 chlamydia t
18	41	56.2	1154	1 KDGD_MESAU	Q64398 mesocricetu
19	41	56.2	1195	1 KDGD_HUMAN	Q16760 homo sapien
20	39	53.4	862	1 ADHE_CLOAB	P33744 clostridium
21	38	52.1	444	1 NUOF_BUCAI	P57256 buchnera ap
22	38	52.1	1333	1 RDPO_SCHPO	Q05654 schizosacch
23	37	50.7	1075	1 PST2_SCHPO	O13919 schizosacch
24	37	50.7	1419	1 LYS2_SCHPO	P40976 schizosacch
25	37	50.7	1507	1 CADE_DROME	Q42498 drosophila
26	36	49.3	165	1 YSEA_STACA	P47995 staphylococ
27	36	49.3	419	1 CG2B_ORYSA	Q40671 oryza sativ
28	35.5	48.6	139	1 RS12_DROME	P80455 drosophila
29	35	47.9	141	1 LCA_PIG	P18137 sus scrofa
30	35	47.9	172	1 R172_HORVU	P35267 hordeum vul
31	35	47.9	300	1 TFP1_RABIT	P19761 oryctolagus
32	35	47.9	331	1 CATV_NPVBS	Q9ywk4 buzura supp
33	35	47.9	557	1 TKT2_HUMAN	P51854 homo sapien

34	35	47.9	595	1	P2X7_MOUSE	Q92lm0 mus musculu
35	35	47.9	595	1	P2X7_RAT	Q64663 rattus norv
36	35	47.9	704	1	TRFL_PIG	P14632 sus scrofa
37	35	47.9	884	1	RPOL_BPT3	P07659 bacterioph
38	35	47.9	2264	1	POLI_TBRSV	P18522 tomato blac
39	34.5	47.3	373	1	EGON_DROME	P15370 drosophila
40	34.5	47.3	512	1	DNB2_ADE04	P06500 human adeno
41	34.5	47.3	517	1	DNB2_ADE07	P04497 human adeno
42	34	46.6	36	1	TXAM_METSE	P11495 metridium s
43	34	46.6	146	1	AP4A_HUMAN	P50583 homo sapien
44	34	46.6	146	1	AP4A_MOUSE	P36380 mus musculu
45	34	46.6	146	1	AP4A_PIG	P50584 sus scrofa

ALIGNMENTS

RESULT 1  
OM1K\_CHLPN STANDARD; PRT: 333 AA.  
AC Q8XBFA:  
DT 30-MAY-2000 (Rel. 39, Created)  
DT 30-MAY-2000 (Rel. 39, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN (MOMP) (FRAGMENT).  
GN OMPA OR OMP1.  
OS Chlamydia pneumoniae (Chlamydia pneumoniae).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.   
OX NCBI\_TaxID=83558;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=KOALA TYPE 1;  
RX MEDLINE=93123168; PubMed=8419295;  
RA Kaltenboeck B., Kousoulas K.G., Storz J.;  
RT "Structures of and allelic diversity and relationships among the major  
outer membrane protein (ompA) genes of the four chlamydial species.";  
RL J. Bacteriol. 175:487-502(1993).  
CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
BODIES AND PORIN FORMING. PERMITTING DIFFUSION OF SOLUTES THROUGH  
THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
CC EMBL; M73038; AAD38210.1; -  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
KW Outer membrane; Transmembrane; Porin.  
FT NON\_TER 1  
FT 333 333  
SQ SEQUENCE 333 AA; 35811 MW; 204604512C4C3B3F CRC64;

Query Match 100.0%; Score 73; DB 1; Length 333;  
Best Local Similarity 100.0%; Pred. No. 1e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CQINFKSRKACG 13  
|||||  
DB 298 CQINFKSRKACG 310

RESULT 2

Tue Mar 26 15:55:34 2002

```

OMIN_CHLPN
ID OM1N_CHLPN STANDARD; PRT; 389 AA.
AC Q07430;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).
GN OMPA OR OMP1.
OS Chlamydia pneumoniae (Chlamydophila pneumoniae).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.
OX NCBI_TaxID=83358;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=N16;
RX MEDLINE=94103736; PubMed=8277245;
RA Storey C., Lusher M., Yates P., Richmond S.;
RL "Evidence for Chlamydia pneumoniae of non-human origin.";
RL J. Gen. Microbiol. 139:2621-2626(1993).
CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY
CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH
CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.
CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP
CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.
CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; L04982; AAA17397.1;
DR InterPro; IPR000604; Chlamydia_OMP.
DR Pfam; PF01308; Chlamydia_OMP; 1.
DR ProDom; PD001717; Chlamydia_OMP; 1.
DR Outer membrane; Transmembrane; Porin; Signal.
KW SIGNAL 1 23 BY SIMILARITY.
FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.
FT SEQUENCE 389 AA; 41628 MW; 801622F05D841967 CRC64;
SQ
Query Match 100.0%; Score 73; DB 1; Length 389;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CQINKFSRKACG 13
| | | | | | | | | | | | | | | | | |
DB 342 CQINKFSRKACG 354
RESULT 3
OMP1_CHLPN STANDARD; PRT; 389 AA.
AC P27455; O9J0F6;
DT 01-AUG-1992 (Rel. 23, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).
GN OMPA OR OMP1 OR CPN0695 OR CPN051.
OS Chlamydia pneumoniae (Chlamydophila pneumoniae).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.
OX NCBI_TaxID=83358;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=IOL-207;
RX MEDLINE=91237311; PubMed=2033374;
RA Carter M.W., Al-Mahdawi S.A.H., Giles I.G., Treharne J.D.,
RA Ward M.E., Clarke I.N.;
RL "Nucleotide sequence and taxonomic value of the major outer membrane
RT protein gene of Chlamydia pneumoniae IOL-207.";

```

```

J. Gen. Microbiol. 137:465-475(1991).
RL [2]
RN SEQUENCE FROM N.A.
RP STRAIN=TWAR;
RX MEDLINE=91244474; PubMed=1840574;
RA Perez Melgosa M., Kuo C.-C., Campbell L.A.;
RT "Sequence analysis of the major outer membrane protein gene of
RT Chlamydia pneumoniae.";
RL Infect. Immun. 59:2195-2199(1991).
RN [3]
RN SEQUENCE FROM N.A.
RP Mitchell W.M., Tharp A.C., Stratton C.W., Stram S.;
RA Submitted (FEB-1999) to the EMBL/GenBank/DBJ databases.
RL [4]
RN SEQUENCE FROM N.A.
RP STRAIN=CWL029;
RX MEDLINE=99206606; PubMed=10192388;
RA Kalman S., Mitchell W., Marathe R., Lammel C., Fan J., Hyman R.W.,
RA Olinger L., Grimwood J., Davis R.W., Stephens R.S.;
RT "Comparative genomes of Chlamydia pneumoniae and C. trachomatis.";
RN Nat. Genet. 21:385-389(1999).
RN [5]
RN SEQUENCE FROM N.A.
RP STRAIN=AR39;
RX MEDLINE=20150255; PubMed=10684935;
RA Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F.,
RA White O., Hickey E.K., Peterson J., Utterback T., Berry K., Bass S.,
RA Linher K., Weidman J., Khouri H., Craven B., Bowman C., Dodson R.,
RA Gwin M., Nelson W., DeBoy R., Kolonay J., McClarty G., Salzberg S.L.,
RA Eisen J., Fraser C.M.;
RT "Genome sequences of Chlamydia trachomatis MoPn and Chlamydia
RT pneumoniae AR39.";
RN Nucleic Acids Res. 28:1397-1406(2000).
RN [6]
RN SEQUENCE FROM N.A.
RP STRAIN=J138;
RX MEDLINE=20330349; PubMed=10871362;
RA Shirai M., Hirakawa H., Kimoto M., Tabuchi M., Kishi F., Ouchi K.,
RA Shirai T., Ishii K., Hattori M., Kuhara S., Nakazawa T.;
RT "Comparison of whole genome sequences of Chlamydia pneumoniae J138
RT from Japan and CWL029 from USA.";
RN Nucleic Acids Res. 28:2311-2314(2000).
RN [7]
RN SEQUENCE FROM N.A.
RP STRAIN=J138;
RX MEDLINE=20298986; PubMed=10839753;
RA Shirai M., Hirakawa H., Ouchi K., Tabuchi M., Kishi F., Kimoto M.,
RA Takeuchi H., Nishida J., Shibata K., Fujinaga R., Yoneda H.,
RA Matsushima H., Tanaka C., Furukawa S., Miura K., Nakazawa A.,
RA Ishii K., Shiba T., Hattori M., Kuhara S., Nakazawa T.;
RT "Comparison of outer membrane protein genes omp and pmp in the whole
RT genome sequences of Chlamydia pneumoniae isolates from Japan and the
RT United States.";
RN J. Infect. Dis. 181 Suppl 3:S524-S527(2000).
RN [8]
RN FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY
RN BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH
RN THE INTRACELLULAR RETICULATE BODY MEMBRANE.
RN -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP
RN MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.
RN -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.
RN -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.
RN -----
RN This SWISS-PROT entry is copyright. It is produced through a collaboration
RN between the Swiss Institute of Bioinformatics and the EMBL outstation -
RN the European Bioinformatics Institute. There are no restrictions on its
RN use by non-profit institutions as long as its content is in no way
RN modified and this statement is not removed. Usage by and for commercial
RN entities requires a license agreement (See http://www.isb-sib.ch/announce/
RN or send an email to license@isb-sib.ch).
RN -----
DR EMBL; M64064; AAA23143.1;
DR EMBL; M69230; AAA73071.1;
DR EMBL; AF131889; AAD22492.1;

```



```

RESULT 6
OMIE_CHLPS STANDARD; PRT; 402 AA.
ID OMIE_CHLPS
AC P10332;
DT 01-MAR-1989 (Rel. 10, Created)
DT 01-MAR-1989 (Rel. 10, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).
GN OMPA OR OMP1.
OS Chlamydia psittaci (Chlamydia psittaci).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=83554;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=EAE A22/M;
RA Pickett M.A., Everson S.J., Clarke I.N.;
RT "Chlamydia psittaci ewe abortion agent: complete nucleotide sequence
of the major outer membrane protein gene.";
RL FEMS Microbiol. Lett. 55:229-234(1988).
CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY
THE INTRACELLULAR RETICULATE BODY MEMBRANE.
CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH
CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.
CC -2- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP
MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.
CC -3- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.
CC -4- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.
CC -----
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation
at the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC -----
DR ENBL; X12647; CAA31177.1;
DR ENBL; M36703; AAA23146.1;
DR PIR; S05954; MMCWPM.
DR InterPro; IPR000604; Chlamydia_OMP.
DR Pfam; PF01308; Chlamydia_Omp; 1.
DR ProDom; PD001717; Chlamydia_Omp; 1.
KW Outer membrane; Transmembrane; Porin; Signal.
FT SIGNAL 1 22
FT CHAIN 23 402 MAJOR OUTER MEMBRANE PROTEIN.
SQ SEQUENCE 402 AA; 43277 MW; E6CF00D9DFEE87A CRC64;

Query Match 79.5%; Score 58; DB 1; Length 402;
Best Local Similarity 91.7%; Pred. No. 0.0052;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 42 QINKFKSRKACG 13
Db 356 QINKMKSRKACG 367
|||||
|||||

RESULT 7
OMPL_CHLMU STANDARD; PRT; 387 AA.
ID OMPL_CHLMU
AC P75024; Q04063; Q9X718;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).
GN OMPA OR OMP1 OR TC0052.
OS Chlamydia muridarum.
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=83560;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=MOPN;
RA MEDLINE=92039057; PubMed=1937036;

```

```

RA Fielder T.J., Pal S., Peterson E.M., la Maza L.M.;
RT "Sequence of the gene encoding the major outer membrane protein of the
mouse pneumonitis biovar of Chlamydia trachomatis.";
RL Gene 106:137-138(1991).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=MOPN;
RA MEDLINE=94104488; PubMed=8277858;
RA Zhang Y.X., Fox J.G., Ho Y., Zhang L., Stills H.F., Smith T.F.;
RT "Comparison of the major outer-membrane protein (MOMP) gene of mouse
pneumonitis (Mopn) and hamster SPFD strains of Chlamydia trachomatis
with other Chlamydia strains.";
RL Mol. Biol. Evol. 10:1327-1342(1993).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=SSP.BV.MOUSE / NIGG II;
RA Carter M.W., Giles I., Everson J.S., Clarke I.N.;
RT "Chlamydia trachomatis mouse biovar: major outer membrane protein
gene.";
RL (In) Marsh P.A., la Placa M., Ward M. (eds.);
Proceedings of the European society for chlamydia research and the
second international symposium of Uppsala university centre for std
research, pp.38-38, University of Uppsala, Uppsala (1992).
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=MOPN / NIGG;
RA MEDLINE=20150255; PubMed=10684935;
RA Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F.,
White O., Hickey E.K., Peterson J., Utterback T., Berry K.,
Bass S., Linher K., Weidman J., Khouri H., Craven B., Bowman C.,
Dodson R., Gwinn M., Nelson W., DeBoy R., Kolonay J., McClarty G.,
Salzberg S.L., Eisen J., Fraser C.M.;
RT "Genome sequences of Chlamydia trachomatis Mopn and Chlamydia
pneumoniae AR39.";
RL Nucleic Acids Res. 28:1397-1406(2000).
RN [5]
RP SEQUENCE OF 37-375 FROM N.A.
RC STRAIN=MOPN;
RA MEDLINE=93123168; PubMed=8419295;
RA Kallenboeck B., Kousoulas K.G., Storz J.;
RT "Structures of and allelic diversity and relationships among the major
outer membrane protein (ompA) genes of the four chlamydial species.";
RL J. Bacteriol. 175:487-502(1993).
CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY
BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH
CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.
CC -2- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP
MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.
CC -3- SUBCELLULAR LOCATION: CELL WALL SURFACE.
CC -4- MISCELLANEOUS: MOMP IS RESPONSIBLE FOR THE STRUCTURAL INTEGRITY OF
THE EXTRA-CELLULAR INFECTIOUS ELEMENTARY BODY & THE DEVELOPMENTAL
CONVERSION TO THE PLASTIC AND FRAGILE INTRACELLULAR RETICULATE
BODY.
CC -5- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.
CC -----
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation
at the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC -----
DR ENBL; M64171; AAA23144.1;
DR ENBL; U60196; AAB07068.1;
DR ENBL; X63409; CAA45006.1;
DR ENBL; AE002272; AAF38941.1;
DR ENBL; M73044; AAD29101.1;
DR TIGR; TC0052;
DR InterPro; IPR000604; Chlamydia_Omp.
DR Pfam; PF01308; Chlamydia_Omp; 1.
DR ProDom; PD001717; Chlamydia_Omp; 1.
KW Outer membrane; Transmembrane; Porin; Signal; Complete proteome.

```



FT SIGNAL 1 22 BY SIMILARITY.  
FT CHAIN 23 387 MAJOR OUTER MEMBRANE PROTEIN.  
FT CONFLICT 118 118 F -> Y (IN REF. 5).  
FT CONFLICT 123 123 Y -> F (IN REF. 5).  
FT CONFLICT 198 198 L -> F (IN REF. 1).  
FT CONFLICT 204 204 A -> P (IN REF. 1).  
SQ SEQUENCE 387 AA; 42009 MW; 4FD6DC23248E0A2 CRC64;

Query Match 72.6%; Score 53; DB 1; Length 387;  
Best Local Similarity 75.0%; Pred. No. 0.038;  
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 2 QINKFKSRKACG 13  
I:| | | | | | | | | |  
Db 341 QLNKMKSRKSCG 352

RESULT 8  
OMID\_CHLTR STANDARD; PRT; 393 AA.  
AC Q46409;  
DT 30-MAY-2000 (Rel. 39, Created)  
DT 30-MAY-2000 (Rel. 39, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN, SEROVAR D PRECURSOR (MOMP).  
GN OMPA OR OMP1 OR CT681.  
OS Chlamydia trachomatis.  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
OX NCBI\_TaxID=813;  
[1]  
RN SEQUENCE FROM N.A.  
RP STRAIN=D/B-120;  
RX MEDLINE=93013014; PubMed=1398119;  
RA Sayada C., Denamur E., Elion J.;  
RT "Complete sequence of the major outer membrane protein-encoding gene  
of Chlamydia trachomatis serovar Da.";  
RL Gene 120:129-130(1992).  
[2]  
RN SEQUENCE FROM N.A.  
RP STRAIN=D/IU-71960;  
RX MEDLINE=98339860; PubMed=9673241;  
RA Scothard D.R., Boguslawski G., Jones R.B.;  
RT "Phylogenetic analysis of the Chlamydia trachomatis major outer  
membrane protein and examination of potential pathogenic  
determinants.";  
RL Infect. Immun. 66:3618-3625(1998).  
[3]  
RN SEQUENCE FROM N.A.  
RP STRAIN=D/UW-3/CX;  
RX MEDLINE=99000809; PubMed=9784136;  
RA Stephens R.S., Kalman S., Lammel C.J., Fan J., Marathe R., Aravind L.,  
RA Mitchell W.P., Olinger L., Tatusov R.L., Zhao Q., Koonin E.V.,  
RA Davis R.W.;  
RT "Genome sequence of an obligate intracellular pathogen of humans:  
Chlamydia trachomatis.";  
RL Science 282:754-759(1998).  
[4]  
RN FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
-----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
-----

DR EMBL: X62918; CA44701.1; -;  
DR EMBL: AF063195; AAC31436.2; -;  
DR EMBL: AE001338; AAC68276.1; -;  
DR InterPro: IPR000604; Chlamydia\_OMP.  
DR Pfam: PF01308; Chlamydia\_OMP; 1.  
DR ProDom: PD001717; Chlamydia\_OMP; 1.  
KW Outer membrane; Transmembrane; Porin; Signal; Complete proteome.  
FT SIGNAL 1 22 BY SIMILARITY.  
FT CHAIN 23 393 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR D.  
SQ SEQUENCE 393 AA; 42438 MW; 8CD692FD3EFFF21D6 CRC64;

Query Match 72.6%; Score 53; DB 1; Length 393;  
Best Local Similarity 75.0%; Pred. No. 0.039;  
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 2 QINKFKSRKACG 13  
I:| | | | | | | | | |  
Db 347 QLNKMKSRKSCG 358

RESULT 9  
OMIE\_CHLTR STANDARD; PRT; 393 AA.  
AC P17451;  
DT 01-AUG-1990 (Rel. 15, Created)  
DT 01-AUG-1990 (Rel. 15, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN, SEROVAR E PRECURSOR (MOMP).  
GN OMPA OR OMP1E.  
OS Chlamydia trachomatis.  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
OX NCBI\_TaxID=813;  
[1]  
RN SEQUENCE FROM N.A.  
RP STRAIN=BOUR / SEROVAR E;  
RX MEDLINE=90287737; PubMed=2356137;  
RA Peterson E.M., Markoff B.A., de la Maza L.M.;  
RT "The major outer membrane protein nucleotide sequence of Chlamydia  
trachomatis, serovar E.";  
RL Nucleic Acids Res. 18:3414-3414(1990).  
CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
-----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
-----  
CC EMBL: X52557; CAA36791.1; -;  
DR PIR: S10201; MWCWTE.  
DR InterPro: IPR000604; Chlamydia\_OMP.  
DR Pfam: PF01308; Chlamydia\_OMP; 1.  
DR ProDom: PD001717; Chlamydia\_OMP; 1.  
KW Outer membrane; Transmembrane; Porin; Signal.  
FT SIGNAL 1 22  
FT CHAIN 23 393 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR E.  
SQ SEQUENCE 393 AA; 42424 MW; AB2B82D16027B361 CRC64;

Query Match 72.6%; Score 53; DB 1; Length 393;  
Best Local Similarity 75.0%; Pred. No. 0.039;  
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 2 QINKFKSRKACG 13

Db 347 QLNKMKSRKSCG 358  
 :||| ||||:|

RESULT 10  
 OMIM\_CHLTR  
 ID OMIM\_CHLTR STANDARD; PRT: 393 AA.  
 AC P19542;  
 DT 01-FEB-1991 (Rel. 17, Created)  
 DT 01-FEB-1991 (Rel. 17, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN, SEROVAR L1 PRECURSOR (MOMP).  
 GN OMPA OR OMP11.  
 OS Chlamydia trachomatis.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
 OX NCBI\_TaxID=813;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Pickett M.A., Ward M.E., Clarke I.N.;  
 RT "Complete nucleotide sequence of the major outer membrane protein  
 RT gene from Chlamydia trachomatis serovar L1.";  
 RL FEMS Microbiol. Lett. 42:185-190(1987).  
 CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: M36533; AAA23142.1;  
 CC PIR: S06259; S06259.  
 CC InterPro: IPR000604; Chlamydia\_OMP.  
 CC Pfam: PF01308; Chlamydia\_OMP; 1.  
 CC ProDom: PD001717; Chlamydia\_OMP; 1.  
 CC Outer membrane; Transmembrane; Porin; Signal.  
 FT SIGNAL 1 22  
 FT CHAIN 23 393 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR L1.  
 FT CHAIN 23 393 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR L1.  
 SQ SEQUENCE 393 AA; 42543 MW; 7A952839408EE2DF CRC64;

Query Match 72.6%; Score 53; DB 1; Length 393;  
 Best Local Similarity 75.0%; Pred. No. 0.039;  
 Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 QINKFKSRKACG 13  
 :||| ||||:|  
 Db 347 QLNKMKSRKSCG 358

RESULT 11  
 OMIB\_CHLTR  
 ID OMIB\_CHLTR STANDARD; PRT: 394 AA.  
 AC P23421;  
 DT 01-NOV-1991 (Rel. 20, Created)  
 DT 01-NOV-1991 (Rel. 20, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN, SEROVAR B PRECURSOR (MOMP).  
 GN OMPA OR OMP1B.  
 OS Chlamydia trachomatis.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
 OX NCBI\_TaxID=813;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Bini L., Santucci A., Magl B., Marzocchi B., Sanchez-Campillo M.,  
 RA Comanducci M., Christensen G., Birkelund S., Vretou E., Ratti G.,  
 RA MEDLINE=87307955; PubMed=3040664;

RA Stephens R.S., Sanchez-Pescador R., Wagar E.A., Inouye C., Urdea M.S.;  
 RT "Diversity of Chlamydia trachomatis major outer membrane protein  
 RT genes.";  
 RL J. Bacteriol. 169:3879-3885(1987).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=B/Tw-5/OT;  
 RA Dean D.A.;  
 RT "Sequence analysis of the major outer membrane protein gene (ompA) of  
 RT Chlamydia trachomatis.";  
 RL Submitted (SEP-2000) to the EMBL/GenBank/DBJ databases.  
 CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: M17342; NOT\_ANNOTATED\_CDS.  
 CC EMBL: AF304856; AAG41414.1;  
 CC PIR: S11010; MMCWTB.  
 CC InterPro: IPR000604; Chlamydia\_OMP.  
 CC Pfam: PF01308; Chlamydia\_OMP; 1.  
 CC ProDom: PD001717; Chlamydia\_OMP; 1.  
 CC Outer membrane; Transmembrane; Porin; Signal.  
 FT SIGNAL 1 22  
 FT CHAIN 23 394 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR B.  
 FT CHAIN 23 394 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR B.  
 SQ SEQUENCE 394 AA; 42528 MW; C36423145A69301 CRC64;

Query Match 72.6%; Score 53; DB 1; Length 394;  
 Best Local Similarity 75.0%; Pred. No. 0.039;  
 Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 QINKFKSRKACG 13  
 :||| ||||:|  
 Db 348 QLNKMKSRKSCG 359

RESULT 12  
 OMIM\_CHLTR  
 ID OMIM\_CHLTR STANDARD; PRT: 394 AA.  
 AC P06597;  
 DT 01-JAN-1988 (Rel. 06, Created)  
 DT 01-JAN-1988 (Rel. 06, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN, SEROVAR L2 PRECURSOR (MOMP).  
 GN OMPA OR OMP1L2.  
 OS Chlamydia trachomatis.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
 OX NCBI\_TaxID=813;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA MEDLINE=87057033; PubMed=2946665;  
 RA Stephens R.S., Mullenbach G., Sanchez-Pescador R., Agabian N.;  
 RT "Sequence analysis of the major outer membrane protein gene from  
 RT Chlamydia trachomatis serovar L2.";  
 RL J. Bacteriol. 168:1277-1282(1986).  
 RN [2]  
 RP SEQUENCE OF 23-27.  
 RC STRAIN=L2/434/B0;  
 RA Bini L., Santucci A., Magl B., Marzocchi B., Sanchez-Campillo M.,  
 RA Comanducci M., Christensen G., Birkelund S., Vretou E., Ratti G.,  
 RA Pallini V.;

RL Submitted (SEP-1994) to the SWISS-PROT data bank.  
CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN, OUTER MEMBRANE.  
CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; M14738; AAA23151.1; - -  
DR PIR; S11012; S11012.  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
KW Outer membrane; Transmembrane; Porin; Signal.  
FT SIGNAL 1 22  
FT CHAIN 23 394 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR L2.  
SQ SEQUENCE 394 AA; 42550 MW; BB5B7B80EB289CA5 CRC64;  
  
Query Match 72.6%; Score 53; DB 1; Length 394;  
Best Local Similarity 75.0%; Pred. No. 0.039;  
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
  
QY 2 QINFKSRKACG 13  
Db 348 QLNKMKSRKSCG 359  
I: || |||||: ||  
- - - - -  
RESULT 13  
OM1F\_CHLTR STANDARD; PRT; 395 AA.  
AC P1615;  
DT 01-APR-1990 (Rel. 14, Created)  
DT 01-APR-1990 (Rel. 14, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN, SEROVAR F PRECURSOR (MOMP).  
GN OMPA OR OMP1F.  
OS Chlamydia trachomatis.  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
OX NCBI\_TaxID=813;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-IC-CAL3 / SEROVAR F;  
RX MEDLINE=50192102; PubMed=2315025;  
RA Zhang Y.X., Morrison S.G., Caldwell H.D.;  
RT "The nucleotide sequence of major outer membrane protein gene of  
Chlamydia trachomatis serovar F.";  
RL Nucleic Acids Res. 18:1061-1061(1990).  
CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN, OUTER MEMBRANE.  
CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----

DR EMBL; X52080; CAA36299.1; - -  
DR PIR; S08463; MMCWTF.  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
KW Outer membrane; Transmembrane; Porin; Signal.  
FT SIGNAL 1 22  
FT CHAIN 23 395 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR F.  
SQ SEQUENCE 395 AA; 42586 MW; 7F90FFDEEC264ACF CRC64;  
  
Query Match 72.6%; Score 53; DB 1; Length 395;  
Best Local Similarity 75.0%; Pred. No. 0.039;  
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
  
QY 2 QINFKSRKACG 13  
Db 349 QLNKMKSRKSCG 360  
I: || |||||: ||  
- - - - -  
RESULT 14  
OM1A\_CHLTR STANDARD; PRT; 396 AA.  
AC P23732;  
DT 01-NOV-1991 (Rel. 20, Created)  
DT 01-NOV-1991 (Rel. 20, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN, SEROVAR A PRECURSOR (MOMP).  
GN OMPA OR OMP1A.  
OS Chlamydia trachomatis.  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
OX NCBI\_TaxID=813;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-SAL/OT / SEROVAR A;  
RX MEDLINE=91045080; PubMed=2235504;  
RA Hayes L.J., Clarke I.N.;  
RT "Nucleotide sequence of the major outer membrane protein gene of  
Chlamydia trachomatis strain A/SAL/OT.";  
RL Nucleic Acids Res. 18:6136-6136(1990).  
CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN, OUTER MEMBRANE.  
CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; M58938; AAA23141.1; - -  
DR PIR; S12799; S12799.  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
KW Outer membrane; Transmembrane; Porin; Signal.  
FT SIGNAL 1 22  
FT CHAIN 23 396 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR A.  
SQ SEQUENCE 396 AA; 42877 MW; 2F9D3B0CE2D08162 CRC64;  
  
Query Match 72.6%; Score 53; DB 1; Length 396;  
Best Local Similarity 75.0%; Pred. No. 0.039;  
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
  
QY 2 QINFKSRKACG 13

Tue Mar 26 15:55:34 2002

Db 350 QLNKMKSRKSCG 361

```

RESULT 15
OMIC_CHLTR STANDARD; PRT; 397 AA.
AC P08780;
DT 01-NOV-1988 (Rel. 09, Created)
DT 01-NOV-1988 (Rel. 09, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN, SEROVAR C PRECURSOR (MOMP).
GN OMPA OR OMP1 OR OMP1C.
OS Chlamydia trachomatis.
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=813;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=87307955; PubMed=3040664;
RA Stephens R.S., Sanchez-Pescador R., Wagar E.A., Inouye C., Urdea M.S.;
RT "Diversity of Chlamydia trachomatis major outer membrane protein
genes."
RL J. Bacteriol. 169:3879-3885(1987).
RN [2]
RP SEQUENCE FROM N.A.
RX STRAIN=C/TW3;
RX MEDLINE=20407420; PubMed=10950788;
RA Dean D., Suchland R.J., Stamm W.E.;
RT "Evidence for long-term cervical persistence of Chlamydia trachomatis
by omp1 genotyping."
RL J. Infect. Dis. 182:909-916(2000).
CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY
BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH
THE INTRACELLULAR RETICULATE BODY MEMBRANE.
CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP
MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.
CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC -----
CC EMBL: M17343; AAA23156.1; -.
CC EMBL: AF20455; AAG09443.1; -.
CC PIR: S11011; MMCWTC.
CC InterPro: IPR000604; Chlamydia_OMP.
CC Pfam: PF01308; Chlamydia_OMP; 1.
CC ProDom: PD001717; Chlamydia_OMP; 1.
KW Outer membrane; Transmembrane; Porin; Signal.
FT SIGNAL 1
FT CHAIN 23 397 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR C.
SQ SEQUENCE 397 AA; 42892 MW; 0047BCDB108E5309 CRC64;

```

Query Match 72.6%; Score 53; DB 1; Length 397;  
 Best Local Similarity 75.0%; Pred. No. 0.039; 1; Indels 0; Gaps 0;  
 Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 2 QLNKMKSRKACG 13  
 I: I I I I I I I I I I  
 Db 351 QLNKMKSRKSCG 362

Search completed: March 26, 2002, 13:40:46  
 Job time: 260 sec

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:15 ; Search time 79.01 Seconds  
(without alignments)  
24.067 Million cell updates/sec

Title: US-09-709-201-101  
Perfect score: 73  
Sequence: 1 CQINKFSRRKACG 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 473505 seqs, 146272329 residues

Total number of hits satisfying chosen parameters: 473505

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

#### Database :

SPTREMBL\_17.\*  
1: sp\_archaea.\*  
2: sp\_bacteria.\*  
3: sp\_fungi.\*  
4: sp\_human.\*  
5: sp\_invertebrate.\*  
6: sp\_mammal.\*  
7: sp\_mhc.\*  
8: sp\_organelle.\*  
9: sp\_phase.\*  
10: sp\_plant.\*  
11: sp\_rodent.\*  
12: sp\_virus.\*  
13: sp\_vertebrate.\*  
14: sp\_unclassified.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query %	Match	Length	DB ID	Description
1	73	100.0	389	2	Q08085	Q08085 chlamydia p
2	67	91.8	336	2	Q9XB5	Q9XB5 chlamydia p
3	58	79.5	326	2	Q9K5C5	Q9K5C5 chlamydia p
4	58	79.5	330	2	Q9XB3	Q9XB3 chlamydia p
5	58	79.5	337	2	Q9XB6	Q9XB6 chlamydia p
6	58	79.5	340	2	Q9XB7	Q9XB7 chlamydia p
7	58	79.5	341	2	Q9X717	Q9X717 chlamydia p
8	58	79.5	380	2	Q9A111	Q9A111 chlamydia p
9	58	79.5	381	2	Q9A112	Q9A112 chlamydia p
10	58	79.5	382	2	Q9A1J9	Q9A1J9 chlamydia p
11	58	79.5	388	2	Q9A1K1	Q9A1K1 chlamydia p
12	58	79.5	388	2	Q9A1K0	Q9A1K0 chlamydia p
13	58	79.5	389	2	Q9APM4	Q9APM4 chlamydia p
14	58	79.5	389	2	Q9A1H9	Q9A1H9 chlamydia p
15	58	79.5	390	2	Q9A1J5	Q9A1J5 chlamydia p
16	58	79.5	391	2	Q46235	Q46235 chlamydia p
17	58	79.5	391	2	Q9A1J2	Q9A1J2 chlamydia p
18	58	79.5	392	2	Q9A1J4	Q9A1J4 chlamydia p
19	58	79.5	392	2	Q99QB0	Q99QB0 chlamydia p

20	58	79.5	395	2	Q9A1J7	Q9A1J7 chlamydia p
21	58	79.5	397	2	Q9A1J8	Q9A1J8 chlamydia p
22	58	79.5	402	2	Q46203	Q46203 chlamydia p
23	58	79.5	402	2	Q46236	Q46236 chlamydia p
24	58	79.5	402	2	Q46193	Q46193 chlamydia p
25	58	79.5	402	2	Q9A1I0	Q9A1I0 chlamydia p
26	55	75.3	322	2	Q9XB1	Q9XB1 chlamydia s
27	55	75.3	376	2	Q9A1I9	Q9A1I9 chlamydia s
28	55	75.3	385	2	Q9A1I7	Q9A1I7 chlamydia s
29	55	75.3	385	2	Q9A1I6	Q9A1I6 chlamydia s
30	55	75.3	386	2	Q9A1I5	Q9A1I5 chlamydia s
31	55	75.3	387	2	Q9A1J1	Q9A1J1 chlamydia s
32	55	75.3	387	2	Q9A1J0	Q9A1J0 chlamydia s
33	55	75.3	389	2	Q9A1I4	Q9A1I4 chlamydia s
34	55	75.3	391	2	Q9A1I3	Q9A1I3 chlamydia s
35	55	75.3	396	2	Q9A1I8	Q9A1I8 chlamydia s
36	55	75.3	402	2	Q9A1J6	Q9A1J6 chlamydia p
37	55	75.3	402	2	Q9A1J3	Q9A1J3 chlamydia p
38	53	72.6	103	2	Q9S6E6	Q9S6E6 chlamydia t
39	53	72.6	106	2	Q9S6E9	Q9S6E9 chlamydia t
40	53	72.6	107	2	Q9S6E7	Q9S6E7 chlamydia t
41	53	72.6	108	2	Q9X4V8	Q9X4V8 chlamydia t
42	53	72.6	108	2	Q9S6F2	Q9S6F2 chlamydia t
43	53	72.6	108	2	Q9S6E8	Q9S6E8 chlamydia t
44	53	72.6	108	2	Q9S6E1	Q9S6E1 chlamydia t
45	53	72.6	109	2	Q9ZFE8	Q9ZFE8 chlamydia t

#### ALIGNMENTS

RESULT 1

Q08085 ID Q08085 PRELIMINARY; PRT; 389 AA.

AC Q08085; DT 01-NOV-1996 (TREMREL. 01, Created)  
DT 01-NOV-1996 (TREMREL. 01, Last sequence update)  
DE 01-JUN-2001 (TREMREL. 17, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
OS Chlamydia psittaci (Chlamydia psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=KOALA TYPE 1;  
RX MEDLINE=94:71025; PubMed=8125292;  
RA Girjes A.A., Carrick F.N., Lavin M.F.;

RT Remarkable sequence relatedness in the DNA encoding the major outer membrane protein of Chlamydia psittaci (koala type I) and Chlamydia pneumoniae.  
RL Gene 138:139-142(1994).  
CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH THE INTRACELLULAR RETICULATE BODY MEMBRANE.

CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.

CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE. EMBL; X72023; CAA50906.1; -

DR InterPro; IPR000604; Chlamydia\_OMP.

DR Pfam; PF01308; Chlamydia\_OMP; 1.

DR PRINTS; PR01334; CHLAMIDIAOMP.

DR ProDom; PD001717; Chlamydia\_OMP; 1.

KW Outer membrane; Transmembrane; Porin; Signal.

FT SIGNAL 1 23 BY SIMILARITY.

FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.

SQ SEQUENCE 389 AA; 41579 MW; 5DC50E85A6F4E50F CRC64;

Query Match 100.0%; Score 73; DB 2; Length 389;

Best Local Similarity 100.0%; Pred. No. 8e-06;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CQINKFSRRKACG 13

Query Match 79.5%; Score 58; DB 2; Length 337;

Best Local Similarity 91.7%; Pred. No. 0.0047; Mismatches 0; Gaps 0; Indels 1; Length 341;

Matches 11; Conservative 0; Mismatches 1; Indels 1; Gaps 0; Length 341;

QY 2 QINKFKSRKACG 13  
 DB 303 QINKLKSRRKACG 314

## RESULT 6

Q9XBF2 PRELIMINARY; PRT; 340 AA.  
 AC Q9XBF2;  
 DT 01-NOV-1999 (TReMBLrel. 12, Created)  
 DT 01-NOV-1999 (TReMBLrel. 12, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE OUTER MEMBRANE PROTEIN (FRAGMENT).  
 OS Chlamydia abortus.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydiaophila.  
 OX NCBI\_TaxID=85991;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=LW613;  
 RX MEDLINE=93123168; PubMed=8419295;  
 RA Kaltenboeck B., Kousoulas K.G., Storz J.;  
 RT "Structures of and allelic diversity and relationships among the major  
 RT outer membrane protein (ompA) genes of the four chlamydial species.";  
 RL J. Bacteriol. 175:487-502(1993).  
 DR EMBL; W73042; AAD29103.1;  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 FT NON\_TER 1  
 FT NON\_TER 340  
 FT NON\_TER 340  
 SQ SEQUENCE 340 AA; 36968 MW; F571E822DIDE0AA3 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 340;

Best Local Similarity 91.7%; Pred. No. 0.0047; Mismatches 0; Gaps 0; Indels 1; Length 340;

Matches 11; Conservative 0; Mismatches 1; Indels 1; Gaps 0; Length 340;

QY 2 QINKFKSRKACG 13  
 DB 306 QINKLKSRRKACG 317

## RESULT 7

Q9X717 PRELIMINARY; PRT; 341 AA.  
 AC Q9X717;  
 DT 01-NOV-1999 (TReMBLrel. 12, Created)  
 DT 01-NOV-1999 (TReMBLrel. 12, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia abortus.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydiaophila.  
 OX NCBI\_TaxID=83555;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=LW508;  
 RX MEDLINE=93123168; PubMed=8419295;  
 RA Kaltenboeck B., Kousoulas K.G., Storz J.;  
 RT "Structures of and allelic diversity and relationships among the major  
 RT outer membrane protein (ompA) genes of the four chlamydial species.";  
 RL J. Bacteriol. 175:487-502(1993).  
 DR EMBL; W73040; AAD29103.1;  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 FT NON\_TER 1  
 FT NON\_TER 341  
 FT NON\_TER 341  
 SQ SEQUENCE 341 AA; 36762 MW; B5933C9BF6AAFI71 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 341;

Best Local Similarity 91.7%; Pred. No. 0.0048; Mismatches 0; Gaps 0; Indels 1; Length 341;

Matches 11; Conservative 0; Mismatches 1; Indels 1; Gaps 0; Length 341;

QY 2 QINKFKSRKACG 13  
 DB 307 QINKMKSRRKACG 318

## RESULT 8

Q9AII1 PRELIMINARY; PRT; 380 AA.  
 AC Q9AII1;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia abortus.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydiaophila.  
 OX NCBI\_TaxID=85991;  
 RN [1]  
 RP SEQUENCE OF 40-352 FROM N.A.  
 RC STRAIN=L71;  
 RX MEDLINE=93123168; PubMed=8419295;  
 RA Kaltenboeck B., Kousoulas K.G., Storz J.;  
 RT "Structures of and allelic diversity and relationships among the major  
 RT outer membrane protein (ompA) genes of the four chlamydial species.";  
 RL J. Bacteriol. 175:487-502(1993).  
 DR EMBL; W73042; AAD29103.1;  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 FT NON\_TER 1  
 FT NON\_TER 340  
 FT NON\_TER 340  
 SQ SEQUENCE FROM N.A.

Query Match 79.5%; Score 58; DB 2; Length 380;

Best Local Similarity 91.7%; Pred. No. 0.0052; Mismatches 0; Gaps 0; Indels 1; Length 380;

Matches 11; Conservative 0; Mismatches 1; Indels 1; Gaps 0; Length 380;

QY 2 QINKFKSRKACG 13

DB 334 QINKLKSRRKACG 345

## RESULT 9

Q9AII2 PRELIMINARY; PRT; 381 AA.  
 AC Q9AII2;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia abortus.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydiaophila.  
 OX NCBI\_TaxID=85991;  
 RN [1]  
 RP SEQUENCE OF 34-369 FROM N.A.

Query Match 79.5%; Score 58; DB 2; Length 380;

Best Local Similarity 91.7%; Pred. No. 0.0052; Mismatches 0; Gaps 0; Indels 1; Length 380;

Matches 11; Conservative 0; Mismatches 1; Indels 1; Gaps 0; Length 380;

QY 2 QINKFKSRKACG 13

DB 334 QINKLKSRRKACG 345

RC STRAIN=1710S;  
 RX MEDLINE=93123168; PubMed=8419295;  
 RA Kaltenboeck B., Kousoulas K.G., Storz J.;  
 RT "Structures of and allelic diversity and relationships among the major  
 RT outer membrane protein (ompA) genes of the four chlamydial species.";  
 RL J. Bacteriol. 175:487-502(1993).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=1710S;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=1710S;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Everett K.D.E., Hambly W.A., Andersen A.A.;  
 RT Submitted (MAY-2000) to the EMBL/GenBank/DBSJ databases.  
 DR EMBL; AF269279; AAK00260.1; -;  
 KW Signal.  
 FT NON\_TER 1 1  
 FT SIGNAL <1 15 POTENTIAL.  
 FT CHAIN 16 381 MAJOR OUTER MEMBRANE PROTEIN.  
 FT SEQUENCE 381 AA; 41332 MW; 29406725CF9D3512 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 381;  
 Best Local Similarity 91.7%; Pred. No. 0.0052;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 QINKFKSRKACG 13  
 DB 335 QINKLKSRRKACG 346  
 ||||| |||||

RESULT 10  
 Q9AIJ9 PRELIMINARY; PRT; 382 AA.  
 AC Q9AIJ9;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia psittaci (Chlamydia phila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=MENINGOPNEUMONITIS, MN, ATCC VR122;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269262; AAK00243.1; -;  
 KW Signal.  
 FT NON\_TER 1 1  
 FT SIGNAL <1 2 POTENTIAL.  
 FT CHAIN 3 382 MAJOR OUTER MEMBRANE PROTEIN.  
 FT SEQUENCE 382 AA; 41231 MW; 6917171A9A69303B CRC64;

Query Match 79.5%; Score 58; DB 2; Length 382;  
 Best Local Similarity 91.7%; Pred. No. 0.0053;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 QINKFKSRKACG 13  
 DB 336 QINKMKSRKACG 347  
 ||||| |||||

RESULT 11  
 Q9AIK1 PRELIMINARY; PRT; 389 AA.

ID Q9AIK1 PRELIMINARY; PRT; 388 AA.  
 AC Q9AIK1;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia psittaci (Chlamydia phila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=VS225;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269259; AAK00240.1; -;  
 KW Signal.  
 FT NON\_TER 1 1  
 FT SIGNAL <1 19 POTENTIAL.  
 FT CHAIN 20 388 MAJOR OUTER MEMBRANE PROTEIN.  
 FT SEQUENCE 388 AA; 41573 MW; 8E232D22C9B9948D CRC64;

Query Match 79.5%; Score 58; DB 2; Length 388;  
 Best Local Similarity 91.7%; Pred. No. 0.0053;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 QINKFKSRKACG 13  
 DB 342 QINKMKSRKACG 353  
 ||||| |||||

RESULT 12  
 Q9AIK0 PRELIMINARY; PRT; 388 AA.  
 AC Q9AIK0;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia psittaci (Chlamydia phila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=CALIFORNIA TURKEY 1, CTL;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269260; AAK00241.1; -;  
 KW Signal.  
 FT NON\_TER 1 1  
 FT SIGNAL <1 19 POTENTIAL.  
 FT CHAIN 20 388 MAJOR OUTER MEMBRANE PROTEIN.  
 FT SEQUENCE 388 AA; 42053 MW; 96E675B3F69F708B CRC64;

Query Match 79.5%; Score 58; DB 2; Length 388;  
 Best Local Similarity 91.7%; Pred. No. 0.0053;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 QINKFKSRKACG 13  
 DB 342 QINKMKSRKACG 353  
 ||||| |||||

RESULT 13  
 Q9APM4 PRELIMINARY; PRT; 389 AA.



Q9APM4;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.  
 GN OMPL.  
 OS Chlamydomophila abortus.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.  
 OX NCBI\_TaxID=83355;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=LLG;  
 RX MEDLINE=20569239; PubMed=111119563;  
 RA Vretou E., Psarrou E., Kaisar M., Vlisidou I., Salti-Montesanto V.,  
 RA Longbottom D.;  
 RT "Identification of protective epitopes by sequencing of the major  
 RT outer membrane protein gene of a variant strain of Chlamydia psittaci  
 RT serotype 1.";  
 RL Infect. Immun. 69:607-612(2001).  
 DR EMBL; AF272945; AAG53881.1; -.  
 KW Signal.  
 FT SIGNAL 1 22 POTENTIAL.  
 FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41897 MW; 20513C69C7DBAAF5 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 389;  
 Best Local Similarity 91.7%; Pred. No. 0.0053;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 IIII IIIIIII  
 Db 343 QINKMKSRKACG 354

RESULT 14  
 Q9AIH9  
 ID Q9AIH9 PRELIMINARY; PRT; 389 AA.  
 AC Q9AIH9;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.  
 GN OMPA.  
 OS Chlamydomophila caviae.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.  
 OX NCBI\_TaxID=833557;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=GUINEA PIG INCLUSION CONJUNCTIVITIS, GPIC, ATCC VR813;  
 RX MEDLINE=89212917; PubMed=2707861;  
 RA Zhang Y.X., Morrison S.G., Caldwell H.D., Baehr W.;  
 RT "Cloning and sequence analysis of the major outer membrane protein  
 RT genes of two Chlamydia psittaci strains.";  
 RL Infect. Immun. 57:1621-1625(1989).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=GUINEA PIG INCLUSION CONJUNCTIVITIS, GPIC, ATCC VR813;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269282; AAK00263.1; -.  
 KW Signal.  
 FT SIGNAL 1 22 POTENTIAL.  
 FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41932 MW; 2527A820C76F8310 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 389;  
 Best Local Similarity 91.7%; Pred. No. 0.0053;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 IIII IIIIIII  
 Db 343 QINKMKSRKACG 354

RESULT 15  
 Q9AIJ5  
 ID Q9AIJ5 PRELIMINARY; PRT; 390 AA.  
 AC Q9AIJ5;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia psittaci (Chlamydomophila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.  
 OX NCBI\_TaxID=833554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=NEW JERSEY 1, NJ1;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269266; AAK00247.1; -.  
 KW Signal.  
 FT NON\_TER 1 1  
 FT SIGNAL <1 20 POTENTIAL.  
 FT CHAIN 21 390 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 390 AA; 42042 MW; B62858403DBFA4E6 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 390;  
 Best Local Similarity 91.7%; Pred. No. 0.0054;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 IIII IIIIIII  
 Db 344 QINKMKSRKACG 355

Search completed: March 26, 2002, 13:40:16  
 Job time: 230 sec

